WO2020070249A1 - Cleaning compositions - Google Patents

Cleaning compositions

Info

Publication number
WO2020070249A1
WO2020070249A1 PCT/EP2019/076825 EP2019076825W WO2020070249A1 WO 2020070249 A1 WO2020070249 A1 WO 2020070249A1 EP 2019076825 W EP2019076825 W EP 2019076825W WO 2020070249 A1 WO2020070249 A1 WO 2020070249A1
Authority
WO
WIPO (PCT)
Prior art keywords
seq
polypeptide
sequence identity
dnase
cleaning composition
Prior art date
Application number
PCT/EP2019/076825
Other languages
French (fr)
Inventor
Lilian Eva Tang Baltsen
Rebecca Munk VEJBORG
Klaus GORI
Original Assignee
Novozymes A/S
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novozymes A/S filed Critical Novozymes A/S
Publication of WO2020070249A1 publication Critical patent/WO2020070249A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01109—Endogalactosaminidase (3.2.1.109)
    • C—CHEMISTRY; METALLURGY
    • C11—ANIMAL OR VEGETABLE OILS, FATS, FATTY SUBSTANCES OR WAXES; FATTY ACIDS THEREFROM; DETERGENTS; CANDLES
    • C11D—DETERGENT COMPOSITIONS; USE OF SINGLE SUBSTANCES AS DETERGENTS; SOAP OR SOAP-MAKING; RESIN SOAPS; RECOVERY OF GLYCEROL
    • C11D3/00—Other compounding ingredients of detergent compositions covered in group C11D1/00
    • C11D3/16—Organic compounds
    • C11D3/38—Products with no well-defined composition, e.g. natural products
    • C11D3/386—Preparations containing enzymes, e.g. protease or amylase
    • C—CHEMISTRY; METALLURGY
    • C11—ANIMAL OR VEGETABLE OILS, FATS, FATTY SUBSTANCES OR WAXES; FATTY ACIDS THEREFROM; DETERGENTS; CANDLES
    • C11D—DETERGENT COMPOSITIONS; USE OF SINGLE SUBSTANCES AS DETERGENTS; SOAP OR SOAP-MAKING; RESIN SOAPS; RECOVERY OF GLYCEROL
    • C11D3/00—Other compounding ingredients of detergent compositions covered in group C11D1/00
    • C11D3/16—Organic compounds
    • C11D3/38—Products with no well-defined composition, e.g. natural products
    • C11D3/386—Preparations containing enzymes, e.g. protease or amylase
    • C11D3/38636—Preparations containing enzymes, e.g. protease or amylase containing enzymes other than protease, amylase, lipase, cellulase, oxidase or reductase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01052—Beta-N-acetylhexosaminidase (3.2.1.52)

Definitions

  • the present invention relates to cleaning compositions comprising a mix of enzymes.
  • the invention further relates to use of compositions comprising such enzymes in cleaning processes and/or for deep cleaning of biofilm soiling, and methods for removal or reduction of biofilm related soiling.
  • Enzymes have been used in detergents for decades. Usually a cocktail of various enzymes is added to detergent compositions.
  • the enzyme cocktail often comprises various enzymes, wherein each enzyme targets a specific substrate, e.g. amylases are active towards starch stains, proteases towards protein stains and so forth.
  • Textile surface and hard surfaces such as dishes or the inner space of a laundry machine enduring a number of wash cycles, become soiled with many different types of soiling which may compose of proteins, grease, starch etc.
  • One type of soiling may be organic matter, such as biofilm, extracellular polymeric substances (EPS), etc.
  • Organic matter comprises different molecules such as polysaccharides, extracellular DNA (eDNA) and proteins.
  • Some organic matter forms an extracellular polymeric matrix, which may be sticky or gluing, and which when present on textiles attracts soils and may cause redeposition or backstaining of soils, resulting in greying of the textile. Additionally, organic matter such as biofilms often cause malodor, as various malodor molecules can be adhered by the polysaccharides, extracellular eDNA and proteins in the complex extracellular matrix and be slowly released so as to result in noticeable malodor.
  • the cleaning compositions of the present invention are useful in cleaning compositions and are effective in deep cleaning of surfaces such as fabrics, for example for reducing or removing biofilm.
  • Biofilm is an extracellular matrix produced by various microorganisms that is typically composed of polysaccharides, extracellular RNA, DNA and proteins.
  • the cleaning compositions of the invention are also useful for prevention, reduction or removal of malodor, for prevention or reduction of redeposition of soils, and for improving whiteness.
  • the present invention thus relates to a cleaning composition
  • a cleaning composition comprising at least two cleaning enzymes selected from the group consisting of nucleases, hexosaminidases and glycosyl hydrolases and at least two detergent enzymes selected from the group consisting of proteases, amylases, lipases, mannanases, pectate lyases and cellulases.
  • the nuclease is in particular a DNase or an RNase
  • the glycosyl hydrolase is in particular a Glyco_hydro_1 14, GH39 or GHL13 glycosyl hydrolase.
  • the invention relates to use of the cleaning composition for cleaning an item such as a textile, for example for preventing, reducing or removing biofilm and/or body secretions such as dead cells, sebum or sweat from an item, and for a method of cleaning an item such as a textile with the cleaning composition.
  • SEQ ID NO: 1 mature DNase polypeptide obtained from Bacillus cibi
  • SEQ ID NO: 2 mature DNase polypeptide obtained from Bacillus licheniformis
  • SEQ ID NO: 7 mature Glyco_hydro_1 14 polypeptide obtained from Burkholderia sp.
  • SEQ ID NO: 10 mature GH39 polypeptide obtained from Pseudomonas fluorescens
  • SEQ ID NO: 1 mature GH39 polypeptide obtained from Pseudomonas sp.
  • SEQ ID NO: 14 mature GHL13 polypeptide obtained from Escherichia coli
  • SEQ ID NO: 18 mature RNase polypeptide obtained from Fusarium solani
  • SEQ ID NO: 19 mature hexosaminidase polypeptide obtained from Terribacillus saccharophilus
  • SEQ ID NO: 20 mature hexosaminidase polypeptide obtained from Terribacillus saccharophilus
  • SEQ ID NO: 21 mature hexosaminidase polypeptide obtained from Terribacillus saccharophilus
  • SEQ ID NO: 22 mature hexosaminidase polypeptide obtained from Aggregatibacter actinomycetemcomitans
  • SEQ ID NO: 23 mature hexosaminidase polypeptide obtained from Actinobacillus equuli subsp. equuli
  • SEQ ID NO: 24 mature protease polypeptide obtained from Bacillus lentus
  • SEQ ID NO: 25 mature protease polypeptide obtained from Bacillus amyloliquefaciens
  • SEQ ID NO: 26 mature protease polypeptide obtained from Bacillus sp. TY145
  • SEQ ID NO: 27 mature amylase polypeptide obtained from Bacillus sp.
  • SEQ ID NO: 28 mature amylase polypeptide obtained from Bacillus sp.
  • SEQ ID NO: 31 mature lipase polypeptide obtained from Thermomyces lanuginosus
  • SEQ ID NO: 32 mature mannanase polypeptide obtained from Bacillus bogoriensis
  • SEQ ID NO: 34 mature cellulase polypeptide obtained from Bacillus subtilis
  • Biofilm A biofilm is organic matter produced by any group of microorganisms in which cells stick to each other or stick to a surface, such as a textile, dishware or hard surface or another kind of surface. These adherent cells are frequently embedded within a self-produced matrix of extracellular polymeric substance (EPS).
  • EPS extracellular polymeric substance
  • Biofilm EPS is a polymeric conglomeration generally composed of extracellular DNA, proteins and polysaccharides. Biofilms may form on living or non-living surfaces.
  • the microbial cells growing in a biofilm are physiologically distinct from planktonic cells of the same organism, which, by contrast, are single-cells that may float or swim in a liquid medium.
  • EPS is the construction material of bacterial settlements and either remain attached to the cells’ outer surface, or is secreted into its growth medium.
  • organic matters such as EPS contained in many biofilms constitute a challenging type of soiling due to their complex nature. Detergents that are currently commercially available cannot effectively remove or reduce EPS- related soiling.
  • biofilm or EPS-producing bacteria can be found e.g. among the following species: Acinetobacter sp., Aeromicrobium sp., Brevundimonas sp., Microbacterium sp., Micrococcus luteus, Pseudomonas sp., Staphylococcus epidermidis, and Stenotrophomonas sp.
  • the biofilm-producing strain may e.g. be a species of Pseudomonas, for example Pseudomonas aeruginosa, Pseudomonas alcaliphila or Pseudomonas fluorescens.
  • the biofilm is caused by microorganisms or a group of microorganisms which produce Pel.
  • the biofilm produces a polysaccharide that is degradable by the Glyco_hydro_1 14 glycosyl hydrolases of the invention.
  • the biofilm is caused by microorganisms or a group of microorganisms which produce Psl.
  • the biofilm produces a polysaccharide that is degradable by the GH39 glycosyl hydrolases of the invention.
  • the biofilm may be caused by microorganisms that produce the linear exopolysaccharide poly-3-(1 ,6)-N-acetyl-D-glucosamine (PNAG).
  • PNAG linear exopolysaccharide poly-3-(1 ,6)-N-acetyl-D-glucosamine
  • This exopolymer is found in biofilms of both Gram-positive bacteria, e.g. Staphylococcus species, where it is referred to as polysaccharide intercellular adhesion (PIA), and Gram-negative bacteria, e.g. Escherichia coli, where it is referred to as PGA, and species of Bordetella, where it is referred to as Bps.
  • PIA polysaccharide intercellular adhesion
  • PGA species of Bordetella
  • the biofilm that may be formed on the surface of a material such as a textile may be caused by any microorganism or group of microorganisms that forms biofilm, for example a PelA- dependent biofilm, a PsIG-dependent biofilm or a PgaB-dependent biofilm.
  • microorganisms include but are not limited to Acinetobacter sp., Aeromicrobium sp., Brevundimonas sp., Microbacterium sp., Micrococcus luteus, Staphylococcus epidermidis, Staphylococcus aureus, Pseudomonas sp., Pseudomonas aeruginosa, Pseudomonas alcaliphila, Pseudomonas fluorescens, Stenotrophomonas sp., Paraburkholderia, Burkolderia sp., Candida sp., Bordetella pertussis Yersinia pestis, Escherichia coli and Aspergillus sp.
  • Catalytic domain means the region of an enzyme containing the catalytic machinery of the enzyme.
  • a clade is a group of polypeptides clustered together on the basis of homologous features traced to a common ancestor. Polypeptide clades can be visualized as phylogenetic trees and a clade is a group of polypeptides that consists of a common ancestor and all its lineal descendants.
  • Cleaning enzyme refers to an enzyme selected from the group consisting of nucleases, in particular DNases and RNases, hexosaminidases, in particular dispersins, and glycosyl hydrolases, in particular Glyco_hydro_1 14, GH39 and GHL13 glycosyl hydrolases.
  • cDNA means a DNA molecule that can be prepared by reverse transcription from a mature, spliced, mRNA molecule obtained from a eukaryotic or prokaryotic cell. cDNA lacks intron sequences that may be present in the corresponding genomic DNA.
  • the initial, primary RNA transcript is a precursor to mRNA that is processed through a series of steps, including splicing, before appearing as mature spliced mRNA.
  • Coding sequence means a polynucleotide, which directly specifies the amino acid sequence of a polypeptide.
  • the boundaries of the coding sequence are generally determined by an open reading frame, which begins with a start codon such as ATG, GTG, or TTG and ends with a stop codon such as TAA, TAG, or TGA.
  • the coding sequence may be a genomic DNA, cDNA, synthetic DNA, or a combination thereof.
  • control sequences means nucleic acid sequences necessary for expression of a polynucleotide encoding a mature polypeptide of the present invention.
  • Each control sequence may be native (/ ' .e., from the same gene) or foreign (/ ' .e., from a different gene) to the polynucleotide encoding the polypeptide or native or foreign to each other.
  • control sequences include, but are not limited to, a leader, polyadenylation sequence, propeptide sequence, promoter, signal peptide sequence, and transcription terminator.
  • the control sequences include a promoter, and transcriptional and translational stop signals.
  • the control sequences may be provided with linkers for the purpose of introducing specific restriction sites facilitating ligation of the control sequences with the coding region of the polynucleotide encoding a polypeptide.
  • the cleaning component e.g. a detergent adjunct ingredient
  • a detergent adjunct ingredient is different from the polypeptides (enzymes) of this invention.
  • the precise nature of these additional cleaning or adjunct components, and levels of incorporation thereof, will depend on the physical form of the composition and the nature of the operation for which it is to be used.
  • Suitable cleaning components include, but are not limited to the components described below such as surfactants, builders, flocculating aid, chelating agents, dye transfer inhibitors, other enzymes, enzyme stabilizers, enzyme inhibitors, catalytic materials, bleach activators, hydrogen peroxide, sources of hydrogen peroxide, preformed peracids, polymeric agents, clay soil removal/anti- redeposition agents, brighteners, suds suppressors, dyes, perfumes, structure elasticizing agents, fabric softeners, carriers, hydrotropes, builders and co-builders, fabric hueing agents, anti-foaming agents, dispersants, processing aids, and/or pigments.
  • surfactants such as surfactants, builders, flocculating aid, chelating agents, dye transfer inhibitors, other enzymes, enzyme stabilizers, enzyme inhibitors, catalytic materials, bleach activators, hydrogen peroxide, sources of hydrogen peroxide, preformed peracids, polymeric agents, clay soil removal/anti- redeposition agents, brighteners, suds suppress
  • cleaning composition includes “detergent composition” and refers to compositions that find use in the removal of undesired compounds from items to be cleaned, such as textiles.
  • the detergent composition may be used to e.g. clean textiles for both household cleaning and industrial cleaning.
  • the term encompasses any materials/compounds selected for the particular type of cleaning composition desired and the form of the product (e.g., liquid, gel, powder, granulate, paste, or spray compositions) and includes, but is not limited to, detergent compositions (e.g., liquid and/or solid laundry detergents and fine fabric detergents; fabric fresheners; fabric softeners; and textile and laundry pre- spotters/pretreatment).
  • the detergent formulation may contain one or more detergent adjunct ingredients such as surfactants, builders, chelators or chelating agents, bleach system or bleach components, polymers, fabric conditioners, foam boosters, suds suppressors, dyes, perfume, tannish inhibitors, optical brighteners, bactericides, fungicides, soil suspending agents, anti-corrosion agents, enzyme inhibitors or stabilizers, enzyme activators, transferase(s), hydrolytic enzymes, oxido reductases, bluing agents and fluorescent dyes, antioxidants, and solubilizers.
  • detergent adjunct ingredients such as surfactants, builders, chelators or chelating agents, bleach system or bleach components, polymers, fabric conditioners, foam boosters, suds suppressors, dyes, perfume, tannish inhibitors, optical brighteners, bactericides, fungicides, soil suspending agents, anti-corrosion agents, enzyme inhibitors or stabilizers, enzyme activators, transferase(s), hydrolytic enzymes, oxido reduct
  • Deep cleaning means disruption, reduction or removal of organic components such as polysaccharides such as Pel or PNAG, proteins, RNA, DNA, soil or other components present in organic matter such as biofilm.
  • Detergent enzyme refers to enzymes that are not encompassed by the term“cleaning enzyme” as defined above (i.e. enzymes that are not a DNase, an RNase, a hexosaminidase, a Glyco_hydro_1 14 glycosyl hydrolase, a GH39 glycosyl hydrolase or a GHL13 glycosyl hydrolase).
  • the term “detergent enzyme” includes enzymes traditionally used in detergent compositions, including but not limited to proteases, amylases, lipases, mannanases, pectate lyases and cellulases. Other detergent enzymes may e.g.
  • an enzyme such as a mannanase is considered to be a“detergent enzyme”.
  • Enzyme detergency benefit is defined herein as the advantageous effect an enzyme may add to a detergent compared to the same detergent without the enzyme.
  • Important detergency benefits which can be provided by enzymes are stain removal with no or very little visible soils after washing and/or cleaning, prevention or reduction of redeposition of soils released in the washing process (an effect that also is termed anti- redeposition), restoring fully or partly the whiteness of textiles which originally were white but after repeated use and wash have obtained a greyish or yellowish appearance (an effect that also is termed whitening).
  • Textile care benefits which are not directly related to catalytic stain removal or prevention of redeposition of soils, are also important for enzyme detergency benefits.
  • Examples of such textile care benefits are prevention or reduction of dye transfer from one fabric to another fabric or another part of the same fabric (an effect that is also termed dye transfer inhibition or anti-backstaining), removal of protruding or broken fibers from a fabric surface to decrease pilling tendencies or remove already existing pills or fuzz (an effect that also is termed anti-pilling), improvement of the fabric-softness, colour clarification of the fabric and removal of particulate soils which are trapped in the fibers of the fabric or garment.
  • Enzymatic bleaching is a further enzyme detergency benefit where the catalytic activity generally is used to catalyze the formation of bleaching components such as hydrogen peroxide or other peroxides.
  • expression includes any step involved in the production of a polypeptide including, but not limited to, transcription, post-transcriptional modification, translation, post-translational modification, and secretion.
  • Expression vector means a linear or circular DNA molecule that comprises a polynucleotide encoding a polypeptide and is operably linked to control sequences that provide for its expression.
  • fragment means a polypeptide or a catalytic domain having one or more amino acids absent from the amino and/or carboxyl terminus of a mature polypeptide or domain; wherein the fragment has activity.
  • host cell means any cell type that is susceptible to transformation, transfection, transduction, or the like with a nucleic acid construct or expression vector comprising a polynucleotide of the present invention.
  • host cell encompasses any progeny of a parent cell that is not identical to the parent cell due to mutations that occur during replication.
  • Isolated means a substance in a form or environment that does not occur in nature.
  • isolated substances include (1 ) any non-naturally occurring substance, (2) any substance including, but not limited to, any enzyme, variant, nucleic acid, protein, peptide or cofactor, that is at least partially removed from one or more or all of the naturally occurring constituents with which it is associated in nature; (3) any substance modified by the hand of man relative to that substance found in nature; or (4) any substance modified by increasing the amount of the substance relative to other components with which it is naturally associated (e.g., recombinant production in a host cell; multiple copies of a gene encoding the substance; and use of a stronger promoter than the promoter naturally associated with the gene encoding the substance).
  • An isolated substance may be present in a fermentation broth sample; e.g. a host cell may be genetically modified to express the polypeptide of the invention. The fermentation broth from that host cell will comprise the isolated polypeptide.
  • Improved wash performance is defined herein as an enzyme displaying an increased wash performance in a detergent composition relative to the wash performance of same detergent composition without the enzyme e.g. by increased stain removal or less re-deposition.
  • improved wash performance includes wash performance in laundry.
  • Laundering relates to both household laundering and industrial laundering and means the process of treating textiles with a solution containing a cleaning or detergent composition of the present invention.
  • the laundering process can for example be carried out using e.g. a household or an industrial washing machine or can be carried out by hand.
  • malodor By the term“malodor” is meant an odor which is not desired on clean items.
  • the cleaned item should smell fresh and clean without malodors adhered to the item.
  • malodor is compounds with an unpleasant smell, which may be produced by microorganisms.
  • unpleasant smells can be sweat or body odor adhered to an item which has been in contact with human or animal.
  • malodor can be the odor from spices which sticks to items, for example curry or other spices with a strong smell.
  • Mature polypeptide means a polypeptide in its final form following translation and any post-translational modifications, such as N-terminal processing, C-terminal truncation, glycosylation, phosphorylation, etc.
  • a host cell may produce a mixture of two of more different mature polypeptides (/ ' .e., with a different C-terminal and/or N-terminal amino acid) expressed by the same polynucleotide. It is also known in the art that different host cells process polypeptides differently, and thus, one host cell expressing a polynucleotide may produce a different mature polypeptide (e.g., having a different C-terminal and/or N-terminal amino acid) as compared to another host cell expressing the same polynucleotide.
  • Mature polypeptide coding sequence means a polynucleotide that encodes a mature polypeptide having activity.
  • nucleic acid construct means a nucleic acid molecule, either single- or double-stranded, which is isolated from a naturally occurring gene or is modified to contain segments of nucleic acids in a manner that would not otherwise exist in nature or which is synthetic, which comprises one or more control sequences.
  • operbly linked means a configuration in which a control sequence is placed at an appropriate position relative to the coding sequence of a polynucleotide such that the control sequence directs expression of the coding sequence.
  • Sequence identity The relatedness between two amino acid sequences or between two nucleotide sequences is described by the parameter“sequence identity”.
  • the sequence identity between two amino acid sequences is determined using the Needleman-Wunsch algorithm (Needleman and Wunsch, 1970, J. Mol. Biol. 48: 443-453) as implemented in the Needle program of the EMBOSS package (EMBOSS: The European Molecular Biology Open Software Suite, Rice et al., 2000, Trends Genet. 16: 276-277), preferably version 5.0.0 or later.
  • the parameters used are gap open penalty of 10, gap extension penalty of 0.5, and the EBLOSUM62 (EMBOSS version of BLOSUM62) substitution matrix.
  • the output of Needle labeled“longest identity” (obtained using the -nobrief option) is used as the percent identity and is calculated as follows:
  • variant means a polypeptide having a given enzymatic activity comprising an alteration, i.e., a substitution, insertion and/or deletion, at one or more positions.
  • a substitution means replacement of the amino acid occupying a position with a different amino acid;
  • a deletion means removal of the amino acid occupying a position; and
  • an insertion means adding an amino acid adjacent to and immediately following the amino acid occupying a position.
  • the nomenclature“E/Q” means that the amino acid at a given position may be a glutamic acid (Glu, E) or a glutamine (Gin, Q).
  • the nomenclature“V/G/A l” means that the amino acid at this position may be a valine (Val, V), glycine (Gly, G), alanine (Ala, A) or isoleucine (lie, I), and so forth for other combinations as described herein.
  • the amino acid X is defined such that it may be any of the 20 natural amino acids.
  • substitutions are typically indicated with the original amino acid, the position number, and the replacement amino acid.
  • A226V indicates that the original alanine residue in position 226 has been replaced by a valine residue.
  • G184 * indicates that the original glycine residue in position 184 has been deleted.
  • Insertions are indicated by listing the original amino acid, the position number, the original amino acid and the inserted amino acid. For example, S97SD indicates that an aspartic acid residue has been inserted after the serine residue in position 97.
  • the present invention relates to cleaning compositions comprising at least two cleaning enzymes selected from the group consisting of nucleases, hexosaminidases and glycosyl hydrolases and at least two detergent enzymes selected from the group consisting of proteases, amylases, lipases, mannanases, pectate lyases and cellulases, where the nuclease is a DNase or an RNase, the hexosaminidase is a dispersin, and the glycosyl hydrolase is a Glyco_hydro_1 14, GH39 or GHL13 glycosyl hydrolase.
  • the cleaning compositions will typically contain additional components that are commonly used in detergent or cleaning compositions, typically at least one surfactant and optionally at least one additional cleaning component selected from builders and bleach components. Such additional cleaning components are also described in detail further below.
  • the cleaning composition may comprise both a DNase and an RNase, more than one type of glycosyl hydrolase, more than one protease, more than one cellulase, etc.
  • DNase means a nuclease polypeptide having DNase activity that catalyzes the hydrolytic cleavage of phosphodiester linkages in a DNA backbone, thus degrading DNA.
  • DNase activity may be determined according to the procedure described in the Assay 1 or 2 herein.
  • X 1 , 2, 3, 4, 5, 6, 7, 8 or 9 e.g. Deoxyribonuclease I, Deoxyribonuclease IV, Type I site-specific deoxyribonuclease, Type II site-specific deoxyribonuclease, Type III site-specific deoxyribonuclea
  • Y 1 , 2, 4 or 5, e.g. Deoxyribonuclease II, Aspergillus deoxyribonuclease K(1 ), Crossover junction endo- deoxyribonuclease, or Deoxyribonuclease X.
  • the DNase activity is obtained from a microorganism, and the DNase is a microbial enzyme.
  • the DNase is preferably of fungal or bacterial origin.
  • the DNase may be obtained from a bacterium, e.g. Bacillus, such as Bacillus licheniformis, Bacillus subtilis, Bacillus sp., Bacillus ho koshii, Bacillus horneckiae, Bacillus cibi, Bacillus idriensis, Bacillus algicola, Bacillus vietnamensis, Bacillus hwajinpoensis, Bacillus indicus, Bacillus marisflavi, Bacillus luciferensis, or Bacillus sp. SA2-6.
  • Bacillus such as Bacillus licheniformis, Bacillus subtilis, Bacillus sp., Bacillus ho koshii, Bacillus horneckiae, Bacillus cibi, Bacillus idriensis, Bacillus algicola, Bacillus vietnamensis, Bacillus hwajinpoensis, Bacillus
  • the DNase may also be obtained from any of the following: Pyrenochaetopsis sp., Vibrissea flavovirens, Setosphaeria rostrate, Endophragmiella valdina, Corynespora cassiicola, Paraphoma sp., Monilinia fructicola, Curvularia lunata, Penicillium reticulisporum, Penicillium quercetorum, Setophaeosphaeria sp., Alternaria, Alternaria sp., Trichoderma reesei, Chaetomium thermophilum, Scytalidium thermophilum, Metapochonia suchlasporia, Daldinia fissa, Acremonium sp., Acremonium dichromosporum, Sarocladium sp., Metarhizium sp.
  • HNA15-2 Isaria tenuipes Scytalidium circinatum, Metarhizium lepidiotae, Thermobispora bispora, Sporormia fimetaria, Pycnidiophora cf. dispera, Clavicipitaceae sp., Westerdykella sp., Humicolopsis cephalosporioides, Neosartorya massa, Roussoella intermedia, Pleosporales, Phaeosphaeria or Didymosphaeria futilis.
  • the polypeptides having DNase activity are polypeptides comprising the PFAM domain DUF1524 ((http://pfam.xfam.org/), “The Pfam protein families database: towards a more sustainable future”, R.D. Finn, et.al. Nucleic Acids Research (2016) Database Issue 44:D279-D285”).
  • the DUF1524 domain contains a conserved HXXP sequence (where H is the amino acid histidine, P is the amino acid proline, and X is any amino acid motif) commonly found in nucleases (M.A. Machnicka, et al.
  • DUF stands for domain of unknown function, and the polypeptide families comprising, e.g., DUF have been collected together in the Pfam database, which provides sequence alignments and hidden Markov models that define the collected protein domains.
  • the polypeptides having DNase activity in the composition of the invention comprise the DUF1524 domain.
  • DNases comprising the DUF1524 domain see WO 2017/060475, which is hereby incorporated by reference.
  • the DNase is a NUC1 or NUC1_A DNase.
  • a NUC1 DNase is a DNase comprising a domain termed NUC1 , and polypeptides with this domain are in addition to having DNase activity characterized by comprising certain motifs.
  • a NUC1 sub-domain had been identified, termed the NUC1_A domain, which also is characterized by comprising certain motifs.
  • the NUC1 and NUC1_A DNases are described in WO 2017/060475 and WO 2018/184873, which are hereby incorporated by reference.
  • the preparation of the polypeptide having DNase activity as described herein can e.g. be performed as described in WO 2017/059802, in particular in the sections Nucleic Acid Construct, Expression Vectors, Host Cells, Methods of Production and Fermentation Broth Formulations.
  • the cleaning composition of the invention comprises a polypeptide having DNase activity and a sequence identity to the polypeptide shown in SEQ ID NO: 1 of at least 60%, e.g., at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100%.
  • the polypeptide has an amino acid sequence that comprises or consists of SEQ ID NO: 1.
  • the cleaning composition of the invention comprises a polypeptide having DNase activity and a sequence identity to the polypeptide shown in SEQ ID NO: 2 of at least 60%, e.g., at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100%.
  • the polypeptide has an amino acid sequence that comprises or consists of SEQ ID NO: 2.
  • the cleaning composition of the invention comprises a polypeptide having DNase activity and a sequence identity to the polypeptide shown in SEQ ID NO: 3 of at least 60%, e.g., at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100%.
  • the polypeptide has an amino acid sequence that comprises or consists of SEQ ID NO: 3.
  • the cleaning composition of the invention comprises a polypeptide having DNase activity and a sequence identity to the polypeptide shown in SEQ ID NO: 4 of at least 60%, e.g., at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100%.
  • the polypeptide has an amino acid sequence that comprises or consists of SEQ ID NO: 4.
  • the cleaning composition of the invention comprises a polypeptide having DNase activity and a sequence identity to the polypeptide shown in SEQ ID NO: 5 of at least 60%, e.g., at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100%.
  • the polypeptide has an amino acid sequence that comprises or consists of SEQ ID NO: 5.
  • the cleaning composition of the invention may comprise any of the DNase polypeptides disclosed in WO 2017/059802, WO 2017/060475, WO 2018/185285 or WO 2018/184873, the contents of which are incorporated herein by reference.
  • the DNase polypeptide When present in a cleaning composition of the invention, the DNase polypeptide will typically be present in an amount of from 0.01 to 1000 ppm, from 0.1 to 1000 ppm, from 1 ppm to 1000 ppm, from 10 ppm to 1000 ppm, from 50 ppm to 1000 ppm, from 100 ppm to 1000 ppm, from 150 ppm to 1000 ppm, from 200 ppm to 1000 ppm, from 250 ppm to 1000 ppm, from 250 ppm to 750 ppm, or from 250 ppm to 500 ppm, based on active protein.
  • the DNases above may be combined with one or more other cleaning enzyme in the composition, e.g. a hexosaminidase and/or a glycosyl hydrolase, to form a blend to be added to the wash liquor solution according to the invention.
  • a hexosaminidase and/or a glycosyl hydrolase e.g. a hexosaminidase and/or a glycosyl hydrolase
  • the concentration of the DNase in the wash liquor solution is typically in the range of from 0.00001 ppm to 10 ppm, from 0.00002 ppm to 10 ppm, from 0.0001 ppm to 10 ppm, from 0.0002 ppm to 10 ppm, from 0.001 ppm to 10 ppm s from 0.002 ppm to 10 ppm, from 0.01 ppm to 10 ppm, from 0.02 ppm to 10 ppm, from 0.1 ppm to 10 ppm, from 0.2ppm to 10 ppm, or from 0.5 ppm to 5 ppm.
  • RNase means a nuclease polypeptide having RNase activity (EC 3.1 .2.7) that catalyzes the degradation of RNA into smaller components. Ribonucleases can be divided into endoribonucleases and exoribonucleases. The present invention relates especially to endoribonucleases. For purposes of the present invention, RNase activity may be determined according to the procedure described in Assay 3 herein.
  • the polypeptides of the invention having RNase activity preferably comprise a domain from the RNase Barnase (UniProt P00648 (RNBR_BACAM), PF00545 family).
  • a phylogenetic tree has been constructed with polypeptide sequences containing a Barnase domain, as defined in PFAM (PF000545, Pfam version 30.0 Finn (2016), Nucleic Acids Research, Database Issue 44 D279-D285).
  • the phylogenetic tree was constructed from a multiple alignment of mature polypeptide sequences containing at least one Barnase domain. The sequences were aligned using the MUSCLE algorithm version 3.8.31 (Edgar, 2004. Nucleic Acids Research 32(5): 1792-1797), and the trees were constructed using FastTree version 2.1 .8 (Price et al., 2010, PloS one 5(3)) and visualized using iTOL (Letunic & Bork, 2007.
  • Bioinformatics 23(1 ): 127-128) Polypeptides comprising the barnase domain can be separated into multiple distinct sub-clusters, or clades, which can be defined in terms of distinct motifs for each clade. See WO 2018/178061 for further information.
  • the RNase barnase from the PF00545 family of ribonucleases catalyzes hydrolysis at diribonucleotide GpN sites. Cleavage occurs in two steps using a general acid-base mechanism: a cyclic intermediate is formed during the first transesterification step, which is then hydrolysed to release the cleaved RNA.
  • the two most important residues involved in catalysis are Glu73 and His102, which are both believed to be essential for enzymatic activity. Glu73 is the general base whilst His102 is the general acid.
  • Barnase has no disulfide bonds, nor does it require divalent cations or non-peptide components to fold.
  • a polypeptide having RNase activity of the present invention may be obtained from microorganisms of any genus.
  • the term“obtained from” as used herein about a given source shall mean that the polypeptide encoded by a polynucleotide is produced by the source or by a strain in which the polynucleotide from the source has been inserted.
  • the polypeptide obtained from a given source is secreted extracellularly.
  • the RNase is preferably a microbial RNase, preferably obtained from a bacterium or a fungus.
  • the polypeptide is a Paenibacillus polypeptide.
  • One embodiment of this aspect is e.g. a polypeptide obtained from Paenibacillus sp..
  • Another embodiment of this aspect is a polypeptide obtained from Paenibacillus tundrae.
  • the polypeptide is an Amycolatopsis polypeptide, e.g., a polypeptide obtained from Amycolatopsis azurea.
  • the polypeptide is an Acremonium polypeptide, e.g., a polypeptide obtained from Acremonium alcalophilum.
  • the polypeptide is a Stenotrophomonas polypeptide, e.g., a polypeptide obtained from Stenotrophomonas rhizophila.
  • the polypeptide is an Erwinia polypeptide, e.g., a polypeptide obtained from Erwinia persicina.
  • the polypeptide is a Saccharothrix polypeptide, e.g., a polypeptide obtained from Saccharothrix sp.
  • the polypeptide is a Saccharopolyspora polypeptide, e.g., a polypeptide obtained from Saccharopolyspora endophytica.
  • the polypeptide is an Amycolatopsis polypeptide, e.g., a polypeptide obtained from Amycolatopsis circi.
  • the polypeptide is an Alkalimonas polypeptide, e.g., a polypeptide obtained from Alkalimonas sp.
  • the polypeptide is a Nonomuraea polypeptide, e.g., a polypeptide obtained from Nonomuraea dietziae.
  • the polypeptide is a Trichoderma polypeptide, e.g., a polypeptide obtained from Trichoderma harzianum.
  • the polypeptide is a Fusarium polypeptide, e.g., a polypeptide obtained from Fusarium solani.
  • the invention encompasses both the perfect and imperfect states, and other taxonomic equivalents, e.g., anamorphs, regardless of the species name by which they are known. Those skilled in the art will readily recognize the identity of appropriate equivalents.
  • ATCC American Type Culture Collection
  • DSMZ Deutsche Sammlung von Mikroorganismen und Zellkulturen GmbH
  • CBS Centraalbureau Voor Schimmelcultures
  • NRRL Northern Regional Research Center
  • the cleaning composition of the invention comprises a polypeptide having RNase activity and a sequence identity to the polypeptide shown in SEQ ID NO: 16 of at least 60%, e.g., at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100%.
  • the polypeptide has an amino acid sequence that comprises or consists of SEQ ID NO: 16.
  • the cleaning composition of the invention comprises a polypeptide having RNase activity and a sequence identity to the polypeptide shown in SEQ ID NO: 17 of at least 60%, e.g., at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100%.
  • the polypeptide has an amino acid sequence that comprises or consists of SEQ ID NO: 17.
  • the cleaning composition of the invention comprises a polypeptide having RNase activity and a sequence identity to the polypeptide shown in SEQ ID NO: 18 of at least 60%, e.g., at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100%.
  • the polypeptide has an amino acid sequence that comprises or consists of SEQ ID NO: 18.
  • the cleaning composition of the invention may comprise any of the RNase polypeptides disclosed in WO 2018/178061 , the contents of which are incorporated herein by reference.
  • the RNase polypeptide When present in a cleaning composition of the invention, the RNase polypeptide will typically be present in an amount of from 0.01 to 1000 ppm, from 0.1 to 1000 ppm, from 1 ppm to 1000 ppm, from 10 ppm to 1000 ppm, from 50 ppm to 1000 ppm, from 100 ppm to 1000 ppm, from 150 ppm to 1000 ppm, from 200 ppm to 1000 ppm, from 250 ppm to 1000 ppm, from 250 ppm to 750 ppm, or from 250 ppm to 500 ppm, based on active protein.
  • the RNases above may be combined with one or more other cleaning enzyme in the composition, e.g. a hexosaminidase and/or a glycosyl hydrolase, to form a blend to be added to the wash liquor solution according to the invention.
  • a hexosaminidase and/or a glycosyl hydrolase e.g. a hexosaminidase and/or a glycosyl hydrolase
  • the concentration of the RNase in the wash liquor solution is typically in the range of from 0.00001 ppm to 10 ppm, from 0.00002 ppm to 10 ppm, from 0.0001 ppm to 10 ppm, from 0.0002 ppm to 10 ppm, from 0.001 ppm to 10 ppm s from 0.002 ppm to 10 ppm, from 0.01 ppm to 10 ppm, from 0.02 ppm to 10 ppm, from 0.1 ppm to 10 ppm, from 0.2ppm to 10 ppm, or from 0.5 ppm to 5 ppm.
  • hexosaminidase including“dispersin’’ and the abbreviation“Dsp”, means a polypeptide having hexosaminidase activity, EC 3.2.1., that catalyzes the hydrolysis of b-1 ,6- glycosidic linkages of N-acetyl-glucosamine polymers found e.g. in biofilm.
  • the term hexosaminidase includes polypeptides having N-acetylglucosaminidase activity and b-N- acetylglucosaminidase activity.
  • Enzymes having hexosaminidase activity include dispersins such as dispersin B (DspB), which is a b-N-acetylglucosaminidase belonging to the Glycoside Hydrolase 20 family.
  • DspB dispersin B
  • polypeptide having hexosaminidase activity may be used interchangeably with the term “hexosaminidase”, and similarly the term “polypeptide having b-N- acetylglucosaminidase activity” may be used interchangeably with the term “b-N- acetylglucosaminidases”.
  • the polypeptide having hexosaminidase activity is a b-N-acetylglucosaminidase targeting poly-b-1 ,6-N-acetylglucosamine, preferably a dispersin.
  • hexosaminidase activity may be determined according to the procedure described in Assay 4 or 5 herein.
  • a polypeptide having hexosaminidase activity may be obtained from a microorganism of any genus.
  • the hexosaminidase or the b-N-acetylglucosaminidase targeting poly-b- 1 ,6-N-acetylglucosamine e.g. a dispersin is obtained from Terribacillus, Curtobacterium, Aggregatibacter, Haemophilus or Actinobacillus, preferably Terribacillus.
  • the cleaning composition of the invention comprises a polypeptide having hexosaminidase activity and a sequence identity to the polypeptide shown in SEQ ID NO: 19 of at least 60%, e.g., at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100%.
  • the polypeptide has an amino acid sequence that comprises or consists of SEQ ID NO: 19.
  • the cleaning composition of the invention comprises a polypeptide having hexosaminidase activity and a sequence identity to the polypeptide shown in SEQ ID NO: 20 of at least 60%, e.g., at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100%.
  • the polypeptide has an amino acid sequence that comprises or consists of SEQ ID NO: 20.
  • the cleaning composition of the invention comprises a polypeptide having hexosaminidase activity and a sequence identity to the polypeptide shown in SEQ ID NO: 21 of at least 60%, e.g., at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100%.
  • the polypeptide has an amino acid sequence that comprises or consists of SEQ ID NO: 21 .
  • the cleaning composition of the invention comprises a polypeptide having hexosaminidase activity and a sequence identity to the polypeptide shown in SEQ ID NO: 22 of at least 60%, e.g., at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100%.
  • the polypeptide has an amino acid sequence that comprises or consists of SEQ ID NO: 22.
  • the cleaning composition of the invention comprises a polypeptide having hexosaminidase activity and a sequence identity to the polypeptide shown in SEQ ID NO: 23 of at least 60%, e.g., at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100%.
  • the polypeptide has an amino acid sequence that comprises or consists of SEQ ID NO: 23.
  • the cleaning composition of the invention may comprise any of the hexosaminidase polypeptides disclosed in WO 2017/186936, WO 2017/186937, WO 2017/186943 or WO 2018/184873, the contents of which are incorporated herein by reference.
  • the hexosaminidase polypeptide When present in a cleaning composition of the invention, the hexosaminidase polypeptide will typically be present in an amount of from 0.01 to 1000 ppm, from 0.1 to 1000 ppm, from 1 ppm to 1000 ppm, from 10 ppm to 1000 ppm, from 50 ppm to 1000 ppm, from 100 ppm to 1000 ppm, from 150 ppm to 1000 ppm, from 200 ppm to 1000 ppm, from 250 ppm to 1000 ppm, from 250 ppm to 750 ppm, or from 250 ppm to 500 ppm, based on active protein.
  • hexosaminidases above may be combined with one or more other cleaning enzyme in the composition, e.g. a nuclease and/or a glycosyl hydrolase, to form a blend to be added to the wash liquor solution according to the invention.
  • a nuclease and/or a glycosyl hydrolase e.g. a nuclease and/or a glycosyl hydrolase
  • the concentration of the hexosaminidase in the wash liquor solution is typically in the range of from 0.00001 ppm to 10 ppm, from 0.00002 ppm to 10 ppm, from 0.0001 ppm to 10 ppm, from 0.0002 ppm to 10 ppm, from 0.001 ppm to 10 ppm s from 0.002 ppm to 10 ppm, from 0.01 ppm to 10 ppm, from 0.02 ppm to 10 ppm, from 0.1 ppm to 10 ppm, from 0.2ppm to 10 ppm, or from 0.5 ppm to 5 ppm.
  • the present invention relates to cleaning compositions comprising glycosyl hydrolases (EC 3.2.1.-), which are a widespread group of enzymes that hydrolyze the glyosidic bond between two or more carbohydrates or between a carbohydrate and a non-carbohydrate moiety.
  • glycosyl hydrolases EC 3.2.1.-
  • a classification of glycoside hydrolases in families based on amino acid sequence similarities has been proposed.
  • the glycosyl hydrolase polypeptides of the invention comprise at least one glycosyl hydrolase domain.
  • glycosyl hydrolase domain comprised in such polypeptides may for purposes of the present invention be classified into one of three groups: 1 ) Glyco_hydro_1 14 glycosyl hydrolases, 2) GH39 glycosyl hydrolases, and 3) GHL13 glycosyl hydrolases.
  • a Glyco_hydro_1 14 glycosyl hydrolase is in the context of the present invention a glycosyl hydrolase comprising glycosyl hydrolase domain (DUF297), which here is termed Glyco_hydro_1 14 (Pfam domain id PF03537, Pfam version 31.0 Finn (2016) Nucleic Acids Research, Database Issue 44:D279-D285).
  • These polypeptides may further comprise a polysaccharide deacetylase domain (CE4).
  • the polypeptides of the invention are endo-alpha-1 ,4-polygalactosaminidases.
  • the polypeptides of the invention have at least hydrolytic activity on glyosidic bonds and may also have deacetylase activity.
  • the Glyco_hydro_1 14 glycosyl hydrolase is in particular a PelA enzyme, which is active towards the polysaccharide Pel that is present in many biofilms.
  • the pellicle (Pel) polysaccharide is synthesized e.g. by Pseudomonas aeruginosa and is an important biofilm constituent critical for bacterial virulence and persistence.
  • Pel is a cationic polymer composed of partially acetylated 1 4 glycosidic linkages of N-acetylgalactosamine and N-acetylglucosamine that promote cell-cell interactions within the biofilm matrix through electrostatic interactions with extracellular DNA (Jennings et al. PNAS Sept 2015, vol.1 12, no36, 1 1353-1 1358; Marmont et al. J Biol Chem. 2017 Nov 24;292(47):1941 1 -19422. 2017).
  • Glyco_hydro_1 14 glycosyl hydrolase activity may be determined according to the procedure described in Assay 6 herein.
  • the Glyco_hydro_114 polypeptides of the invention comprise a domain termed here as a CE4_PelA_like domain, which is represented by a protein PelA that is encoded by a gene in the pelA-G gene cluster for pellicle production and biofilm formation in Pseudomonas aeruginosa.
  • PelA and most of the family members contain a domain of unknown function, DUF297 (PF03537), in the N-terminus and a C-terminal domain that shows high sequence similarity to the catalytic domain of the six-stranded barrel rhizobial NodB-like proteins, which remove N-linked or O-linked acetyl groups from cell wall polysaccharides and belong to the larger carbohydrate esterase 4 (CE4) superfamily.
  • CE4 carbohydrate esterase 4
  • the cleaning composition of the invention comprises a polypeptide having Glyco_hydro_114 glycosyl hydrolase activity and a sequence identity to the polypeptide shown in SEQ ID NO: 6 of at least 60%, e.g., at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100%.
  • the polypeptide has an amino acid sequence that comprises or consists of SEQ ID NO: 6.
  • the cleaning composition of the invention comprises a polypeptide having Glyco_hydro_114 glycosyl hydrolase activity and a sequence identity to the polypeptide shown in SEQ ID NO: 7 of at least 60%, e.g., at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100%.
  • the polypeptide has an amino acid sequence that comprises or consists of SEQ ID NO: 7.
  • the cleaning composition of the invention comprises a polypeptide having Glyco_hydro_114 glycosyl hydrolase activity and a sequence identity to the polypeptide shown in SEQ ID NO: 8 of at least 60%, e.g., at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100%.
  • the polypeptide has an amino acid sequence that comprises or consists of SEQ ID NO: 8.
  • the cleaning composition of the invention comprises a polypeptide having Glyco_hydro_114 glycosyl hydrolase activity and a sequence identity to the polypeptide shown in SEQ ID NO: 9 of at least 60%, e.g., at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100%.
  • the polypeptide has an amino acid sequence that comprises or consists of SEQ ID NO: 9.
  • the cleaning composition of the invention may comprise any of the Glyco_hydro_1 14 glycosyl hydrolase polypeptides disclosed in WO 2018/185181 , the contents of which are incorporated herein by reference.
  • the Glyco_hydro_1 14 glycosyl hydrolase polypeptide When present in a cleaning composition of the invention, the Glyco_hydro_1 14 glycosyl hydrolase polypeptide will typically be present in an amount of from 0.01 to 1000 ppm, from 0.1 to 1000 ppm, from 1 ppm to 1000 ppm, from 10 ppm to 1000 ppm, from 50 ppm to 1000 ppm, from 100 ppm to 1000 ppm, from 150 ppm to 1000 ppm, from 200 ppm to 1000 ppm, from 250 ppm to 1000 ppm, from 250 ppm to 750 ppm, or from 250 ppm to 500 ppm, based on active protein.
  • the Glyco_hydro_1 14 glycosyl hydrolases above may be combined with one or more other cleaning enzyme in the composition, e.g. a hexosaminidase and/or a nuclease, to form a blend to be added to the wash liquor solution according to the invention.
  • one or more other cleaning enzyme in the composition e.g. a hexosaminidase and/or a nuclease
  • the concentration of the Glyco_hydro_1 14 glycosyl hydrolase in the wash liquor solution is typically in the range of from 0.00001 ppm to 10 ppm, from 0.00002 ppm to 10 ppm, from 0.0001 ppm to 10 ppm, from 0.0002 ppm to 10 ppm, from 0.001 ppm to 10 ppm, from 0.002 ppm to 10 ppm, from 0.01 ppm to 10 ppm, from 0.02 ppm to 10 ppm, from 0.1 ppm to 10 ppm, from 0.2ppm to 10 ppm, or from 0.5 ppm to 5 ppm.
  • the glycosyl hydrolase in cleaning compositions of the invention may be a GH39 glycosyl hydrolase that comprises the CAZY database domain GH39 (GH, CAZY database http://www.cazy.org/ (Coutinho & Henrissat, 1999).
  • the domain is a functional domain providing hydrolytic activity to the polypeptide.
  • the GH39 glycoside hydrolase family contains two known enzyme activities: b-xylosidase and a-L-iduronidase. Both enzyme activities cleave equatorial glycosidic bonds. The most highly conserved regions in these enzymes are located in their N- terminal sections (Henrissat et al. (1995). "Conserved catalytic machinery and the prediction of a common fold for several families of glycosyl hydrolases". Proc. Natl. Acad. Sci. U.S.A. 92 (15): 7090-7094).
  • the polypeptides of the invention comprising a GH39 domain are homologues of PsIG enzymes, which are proteins that degrade the exopolysaccharide Psl.
  • Psl is a pentasaccharide comprising D-glucose, L-rhamnose and D-mannose, which acts as a glue in e.g. bacteria surface interactions.
  • PsIG is a protein involved in the synthesis of the biofilm matrix exopolysaccharide Psl in Pseudomonas aeruginosa.
  • the polypeptides in GH39 can be separated into distinct sub- clusters defined by particular motifs.
  • the cleaning composition of the invention comprises a polypeptide having GH39 glycosyl hydrolase activity and a sequence identity to the polypeptide shown in SEQ ID NO: 10 of at least 60%, e.g., at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100%.
  • the polypeptide has an amino acid sequence that comprises or consists of SEQ ID NO: 10.
  • the cleaning composition of the invention comprises a polypeptide having GH39 glycosyl hydrolase activity and a sequence identity to the polypeptide shown in SEQ ID NO: 1 1 of at least 60%, e.g., at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100%.
  • the polypeptide has an amino acid sequence that comprises or consists of SEQ ID NO: 1 1.
  • the cleaning composition of the invention comprises a polypeptide having GH39 glycosyl hydrolase activity and a sequence identity to the polypeptide shown in SEQ ID NO: 12 of at least 60%, e.g., at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100%.
  • the polypeptide has an amino acid sequence that comprises or consists of SEQ ID NO: 12.
  • the cleaning composition of the invention may comprise any of the GH39 glycosyl hydrolase polypeptides disclosed in WO 2018/185150, the contents of which are incorporated herein by reference.
  • the GH39 glycosyl hydrolase polypeptide When present in a cleaning composition of the invention, the GH39 glycosyl hydrolase polypeptide will typically be present in an amount of from 0.01 to 1000 ppm, from 0.1 to 1000 ppm, from 1 ppm to 1000 ppm, from 10 ppm to 1000 ppm, from 50 ppm to 1000 ppm, from 100 ppm to 1000 ppm, from 150 ppm to 1000 ppm, from 200 ppm to 1000 ppm, from 250 ppm to 1000 ppm, from 250 ppm to 750 ppm, or from 250 ppm to 500 ppm, based on active protein.
  • the GH39 glycosyl hydrolases above may be combined with one or more other cleaning enzyme in the composition, e.g. a hexosaminidase and/or a nuclease, to form a blend to be added to the wash liquor solution according to the invention.
  • one or more other cleaning enzyme in the composition e.g. a hexosaminidase and/or a nuclease
  • the concentration of the GH39 glycosyl hydrolase in the wash liquor solution is typically in the range of from 0.00001 ppm to 10 ppm, from 0.00002 ppm to 10 ppm, from 0.0001 ppm to 10 ppm, from 0.0002 ppm to 10 ppm, from 0.001 ppm to 10 ppm, from 0.002 ppm to 10 ppm, from 0.01 ppm to 10 ppm, from 0.02 ppm to 10 ppm, from 0.1 ppm to 10 ppm, from 0.2ppm to 10 ppm, or from 0.5 ppm to 5 ppm.
  • the GHL13 glycosyl hydrolase polypeptides in cleaning compositions of the invention are BpsB and PgaB homologs comprising a GHL13 domain and with activity on the PNAG substrate. Some GHL13 glycosyl hydrolases also comprise the CE4 domain. Provided here are thus PgaA/BpsB homologs comprising a C-terminus glycosyl hydrolase domain (GHL13) and optionally a N-terminus deacetylase domain (CE4).
  • GHL13 glycosyl hydrolase activity may be determined according to the procedure described in Assay 7 herein.
  • the glycosyl hydrolase polypeptides comprise the Pfam database domain GHL13 (PFAM domain id PF14883, Pfam version 31.0 Finn (2016). Nucleic Acids Research, Database Issue 44:D279-D285), where this domain is a functional domain providing hydrolytic activity to the polypeptide.
  • the polypeptides preferably in addition to the GHL13 domain also comprise the CE4 domain (CE, CAZY database http://www.cazy.org/ (Coutinho & Henrissat, 1999) and have deacetylase activity.
  • the cleaning composition of the invention comprises a polypeptide having GHL13 glycosyl hydrolase activity and a sequence identity to the polypeptide shown in SEQ ID NO: 13 of at least 60%, e.g., at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100%.
  • the polypeptide has an amino acid sequence that comprises or consists of SEQ ID NO: 13.
  • the cleaning composition of the invention comprises a polypeptide having GHL13 glycosyl hydrolase activity and a sequence identity to the polypeptide shown in SEQ ID NO: 14 of at least 60%, e.g., at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100%.
  • the polypeptide has an amino acid sequence that comprises or consists of SEQ ID NO: 14.
  • the cleaning composition of the invention comprises a polypeptide having GHL13 glycosyl hydrolase activity and a sequence identity to the polypeptide shown in SEQ ID NO: 15 of at least 60%, e.g., at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100%.
  • the polypeptide has an amino acid sequence that comprises or consists of SEQ ID NO: 15.
  • the cleaning composition of the invention may comprise any of the GH39 glycosyl hydrolase polypeptides disclosed in WO 2018/185152, the contents of which are incorporated herein by reference.
  • the GHL13 glycosyl hydrolase polypeptide When present in a cleaning composition of the invention, the GHL13 glycosyl hydrolase polypeptide will typically be present in an amount of from 0.01 to 1000 ppm, from 0.1 to 1000 ppm, from 1 ppm to 1000 ppm, from 10 ppm to 1000 ppm, from 50 ppm to 1000 ppm, from 100 ppm to 1000 ppm, from 150 ppm to 1000 ppm, from 200 ppm to 1000 ppm, from 250 ppm to 1000 ppm, from 250 ppm to 750 ppm, or from 250 ppm to 500 ppm, based on active protein.
  • the GHL13 glycosyl hydrolase above may be combined with one or more other cleaning enzyme in the composition, e.g. a hexosaminidase and/or a nuclease, to form a blend to be added to the wash liquor solution according to the invention.
  • one or more other cleaning enzyme in the composition e.g. a hexosaminidase and/or a nuclease
  • the concentration of the GHL13 glycosyl hydrolase in the wash liquor solution is typically in the range of from 0.00001 ppm to 10 ppm, from 0.00002 ppm to 10 ppm, from 0.0001 ppm to 10 ppm, from 0.0002 ppm to 10 ppm, from 0.001 ppm to 10 ppm, from 0.002 ppm to 10 ppm, from 0.01 ppm to 10 ppm, from 0.02 ppm to 10 ppm, from 0.1 ppm to 10 ppm, from 0.2ppm to 10 ppm, or from 0.5 ppm to 5 ppm.
  • the cleaning compositions of the invention include at least two detergent enzymes selected from the group consisting of proteases, amylases, lipases, mannanases, pectate lyases and cellulases. These detergent enzymes are described in more detail below.
  • compositions will typically comprise at least a protease, for example a protease and an amylase.
  • the cleaning composition may comprise three, four, five or more detergent enzymes.
  • the cleaning composition comprises at least one protease, at least one amylase, at least one lipase, at least one mannanase, at least on pectate lyase, and at least one cellulase.
  • the composition may optionally include two or more different enzymes of one type, for example two proteases or two cellulases.
  • the composition may also contain one or more further enzymes such as a carbohydrase, a pectinase, an arabinase, a galactanase, a xylanase or an oxidase, e.g. a laccase and/or peroxidase.
  • a carbohydrase such as a carbohydrase, a pectinase, an arabinase, a galactanase, a xylanase or an oxidase, e.g. a laccase and/or peroxidase.
  • Suitable proteases for the compositions of the invention include those of bacterial, fungal, plant, viral or animal origin, although those of microbial origin are preferred, including chemically modified or protein engineered variants.
  • the protease may be an alkaline protease, such as a serine protease or a metalloprotease.
  • a serine protease may for example be of the S1 family, such as trypsin, or the S8 family such as subtilisin.
  • a metalloprotease may for example be a thermolysin from e.g. family M4 or another metalloprotease such as those from the M5, M7 or M8 families.
  • subtilase proteases are those derived from Bacillus such as Bacillus lentus, Bacillus alkalophilus, Bacillus subtilis, Bacillus amyloliquefaciens, Bacillus pumilus and Bacillus gibsonii, described in e.g. US 7262042 and WO 2009/021867, Subtilisin lentus, Subtilisin Novo, subtilisin Carlsberg, Bacillus licheniformis, subtilisin BPN’, subtilisin 309, subtilisin 147 and subtilisin 168, and e.g. protease PD138 (described in WO 93/18140).
  • Other useful proteases include e.g.
  • trypsin-like proteases are trypsin (e.g. of porcine or bovine origin), the Fusarium protease described in WO 94/25583 and WO 2005/040372, and the chymotrypsin proteases derived from Cellumonas described in WO 2005/052161 and WO 2005/052146.
  • protease is the alkaline protease from Bacillus lentus DSM 5483, as described for example in WO 95/23221 , and variants thereof which are described in e.g. WO 92/21760, WO 95/23221 , EP 1921 147 and EP 1921 148.
  • metalloproteases are the neutral metalloprotease as described in WO 2007/044993 such as those derived from Bacillus amyloliquefaciens.
  • proteases are the variants described in: WO 89/06279, WO 92/19729, WO 96/034946, WO 98/201 15, WO 98/201 16, WO 99/01 1768, WO 01/44452, WO 03/006602, WO 2004/03186, WO 2004/041979, WO 2007/006305, WO 201 1/036263, WO 201 1/036264, WO 2014/207227 and WO 2016/087617, especially variants with substitutions in one or more of the following positions: 3, 4, 9, 15, 24, 27, 42, 55, 59, 60, 66, 74, 85, 96, 97, 98, 99, 100, 101 , 102, 104, 1 16, 1 18, 121 , 126, 127, 128, 154, 156, 157, 158, 161 , 164, 176, 179, 182, 185, 188, 189, 193, 198, 199, 200,
  • the protease variants may comprise one or more of the mutations selected from the group consisting of: S3T, V4I, S9R, S9E, A15T, S24G, S24R, K27R, N42R, S55P, G59E, G59D, N60D, N60E, V66A, N74D, S85R, A96S, S97G, S97D, S97A, S97SD, S99E, S99D, S99G, S99M, S99N, S99R, S99H, S101A, V102I, V102Y, V102N, S104A, G1 16V, G1 16R, H1 18D, H1 18N, A120S, S126L, P127Q, S128A, S154D, A156E, G157D, G157P, G157P, S158E, Y161A,
  • protease variants are preferably variants of the Bacillus lentus protease (Savinase®) shown in SEQ ID NO: 24 or the Bacillus amyloliquefaciens protease (BPN’) shown in SEQ ID NO: 25, preferably variants having at least 80% sequence identity to one of these two sequences.
  • protease is the TY145 protease of SEQ ID NO: 26 or a variant thereof.
  • Preferred variants of this protease are those comprising a substitution at one or more positions corresponding to positions 171 , 173, 175, 179 or 180 of SEQ ID NO: 26, wherein the variant has a sequence identity of at least 75% to SEQ ID NO: 26.
  • Suitable variants of SEQ ID NO: 26 are disclosed e.g. in WO 2015/014790, WO 2016/097350, WO 2016/097352, WO 2016/097357 and WO 2016/097354, the contents of which are incorporated herein by reference.
  • Suitable commercially available protease enzymes include those sold under the trade names Alcalase®, Duralase Tm , Durazyrn Tm , Relase®, Relase® Ultra, Savinase®, Savinase® Ultra, Primase®, Polarzyme®, Kannase®, Liquanase®, Liquanase® Ultra, Ovozyme®, Coronase®, Coronase® Ultra, Blaze®, Blaze Evity® 100T, Blaze Evity® 125T, Blaze Evity® 150T, Neutrase®, Everlase®, Esperase®, Progress® Uno, Progress® Excel and Progress® In (Novozymes A/S), those sold under the tradename Maxatase®, Maxacal®, Maxapem®, Purafect Ox®, Purafect OxP®, Puramax®, FN2®, FN3®, FN4®, Excellase®, Excellenz P1000TM, Excellenz P
  • Preferred proteases for use in the cleaning compositions of the present invention include a) variants of the polypeptide of SEQ ID NO: 24 having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97% or at least 98% sequence identity to SEQ ID NO: 24; b) variants of the polypeptide of SEQ ID NO: 26 having at least 80%, at least 85%, at least 90%, or at least 95% sequence identity to SEQ ID NO: 26; and c) variants of the polypeptide of SEQ ID NO: 37 having at least 90%, at least 95%, at least 96%, at least 97% or at least 98% sequence identity to SEQ ID NO: 37.
  • One preferred protease for use in the cleaning compositions of the present invention is a variant of the polypeptide of SEQ ID NO: 24 with the substitutions Y161A, R164S and A188P.
  • Another preferred protease for use in the cleaning compositions of the present invention is a variant of the polypeptide of SEQ ID NO: 24 with the substitutions S9E, N42R, N74D, V199I, Q200L, Y203W, S253D, N255W and L256E.
  • Another preferred protease for use in the cleaning compositions of the present invention is a variant of the polypeptide of SEQ ID NO: 26 with the substitutions S27K, N109K, S1 1 1 E, S171 E, S173P, G174K, S175P, F180Y, G182A, L184F, Q198E, N199K and T297P, corresponding to the polypeptide of SEQ ID NO: 37.
  • amylases include alpha-amylases and/or glucoamylases and may be of bacterial orfungal origin. Chemically modified or protein engineered mutants are included. Amylases include, for example, alpha-amylases obtained from Bacillus, e.g., a special strain of Bacillus licheniformis, described in more detail in GB 1 ,296,839.
  • Suitable amylases include amylases having SEQ ID NO: 2 in WO 95/10603 or variants having 90% sequence identity to SEQ ID NO: 3 thereof. Preferred variants are described in WO 94/02597, WO 94/18314, WO 97/43424 and SEQ ID NO: 4 of WO 99/019467, such as variants with substitutions in one or more of the following positions: 15, 23, 105, 106, 124, 128, 133, 154, 156, 178, 179, 181 , 188, 190, 197, 201 , 202, 207, 208, 209, 21 1 , 243, 264, 304, 305, 391 , 408, and 444.
  • amylases having SEQ ID NO: 6 in WO 02/010355 or variants thereof having 90% sequence identity to SEQ ID NO: 6.
  • Preferred variants of SEQ ID NO: 6 are those having a deletion in positions 181 and 182 and a substitution in position 193.
  • amylases which are suitable are hybrid alpha-amylase comprising residues 1-33 of the alpha-amylase derived from B. amyloliquefaciens shown in SEQ ID NO: 6 of WO 2006/066594 and residues 36-483 of the B. licheniformis alpha-amylase shown in SEQ ID NO: 4 of WO 2006/066594 or variants having 90% sequence identity thereof.
  • Preferred variants of this hybrid alpha-amylase are those having a substitution, a deletion or an insertion in one of more of the following positions: G48, T49, G107, H156, A181 , N190, M197, 1201 , A209 and Q264.
  • hybrid alpha-amylase comprising residues 1 -33 of the alpha-amylase derived from B. amyloliquefaciens shown in SEQ ID NO: 6 of WO 2006/066594 and residues 36- 483 of SEQ ID NO: 4 are those having the substitutions:
  • amylases which are suitable are amylases having SEQ ID NO: 6 in WO 99/019467 or variants thereof having 90% sequence identity to SEQ ID NO: 6.
  • Preferred variants of SEQ ID NO: 6 are those having a substitution, a deletion or an insertion in one or more of the following positions: R181 , G182, H183, G184, N195, I206, E212, E216 and K269.
  • Particularly preferred amylases are those having deletion in positions R181 and G182, or positions H183 and G184.
  • Additional amylases which can be used are those having SEQ ID NO: 1 , SEQ ID NO: 3, SEQ ID NO: 2 or SEQ ID NO: 7 of WO 96/023873 or variants thereof having 90% sequence identity to SEQ ID NO: 1 , SEQ ID NO: 2, SEQ ID NO: 3 or SEQ ID NO: 7.
  • Preferred variants of SEQ ID NO: 1 , SEQ ID NO: 2, SEQ ID NO: 3 or SEQ ID NO: 7 are those having a substitution, a deletion or an insertion in one or more of the following positions: 140, 181 , 182, 183, 184, 195, 206, 212, 243, 260, 269, 304 and 476, using SEQ ID 2 of WO 96/023873 for numbering. More preferred variants are those having a deletion in two positions selected from 181 , 182, 183 and 184, such as 181 and 182, 182 and 183, or positions 183 and 184.
  • Most preferred amylase variants of SEQ ID NO: 1 , SEQ ID NO: 2 or SEQ ID NO: 7 are those having a deletion in positions 183 and 184 and a substitution in one or more of positions 140, 195, 206, 243, 260, 304 and 476.
  • amylases which can be used are amylases having SEQ ID NO: 2 of WO 08/153815, SEQ ID NO: 10 in WO 01/66712 or variants thereof having 90% sequence identity to SEQ ID NO: 2 of WO 08/153815 or 90% sequence identity to SEQ ID NO: 10 in WO 01/66712.
  • Preferred variants of SEQ ID NO: 10 in WO 01/66712 are those having a substitution, a deletion or an insertion in one of more of the following positions: 176, 177, 178, 179, 190, 201 , 207, 21 1 and 264.
  • amylases having SEQ ID NO: 2 of WO 09/061380 or variants having 90% sequence identity to SEQ ID NO: 2 thereof.
  • Preferred variants of SEQ ID NO: 2 are those having a truncation of the C-terminus and/or a substitution, a deletion or an insertion in one of more of the following positions: Q87, Q98, S125, N128, T131 , T165, K178, R180, S181 , T182, G183, M201 , F202, N225, S243, N272, N282, Y305, R309, D319, Q320, Q359, K444 and G475.
  • More preferred variants of SEQ ID NO: 2 are those having the substitution in one of more of the following positions: Q87E,R, Q98R, S125A, N128C, T131 I, T165I, K178L, T182G, M201 L, F202Y, N225E,R, N272E,R, S243Q,A,E,D, Y305R, R309A, Q320R, Q359E, K444E and G475K and/or deletion in position R180 and/or S181 or of T182 and/or G183.
  • Most preferred amylase variants of SEQ ID NO: 2 are those having the substitutions:
  • variants are C- terminally truncated and optionally further comprises a substitution at position 243 and/or a deletion at position 180 and/or position 181 .
  • amylases having SEQ ID NO: 1 of W013184577 or variants having 90% sequence identity to SEQ ID NO: 1 thereof.
  • Preferred variants of SEQ ID NO: 1 are those having a substitution, a deletion or an insertion in one of more of the following positions: K176, R178, G179, T180, G181 , E187, N192, M199, I203, S241 , R458, T459, D460, G476 and G477.
  • More preferred variants of SEQ ID NO: 1 are those having the substitution in one of more of the following positions: K176L, E187P, N192FYH, M199L, I203YF, S241 QADN, R458N, T459S, D460T, G476K and G477K and/or deletion in position R178 and/or S179 or of T180 and/or G181.
  • Most preferred amylase variants of SEQ ID NO: 1 are those having the substitutions:
  • variants optionally further comprise a substitution at position 241 and/or a deletion at position 178 and/or position 179.
  • amylases having SEQ ID NO: 1 of W010104675 or variants having 90% sequence identity to SEQ ID NO: 1 thereof.
  • Preferred variants of SEQ ID NO: 1 are those having a substitution, a deletion or an insertion in one of more of the following positions: N21 , D97, V128 K177, R179, S180, 1181 , G182, M200, L204, E242, G477 and G478.
  • SEQ ID NO: 1 More preferred variants of SEQ ID NO: 1 are those having the substitution in one of more of the following positions: N21 D, D97N, V128I K177L, M200L, L204YF, E242QA, G477K and G478K and/or deletion in position R179 and/or S180 or of 1181 and/or G182. Most preferred amylase variants of SEQ ID NO: 1 are those having the substitutions:
  • variants optionally further comprise a substitution at position 200 and/or a deletion at position 180 and/or position 181.
  • suitable amylases are the alpha-amylase having SEQ ID NO: 12 in WO01/66712 or a variant having at least 90% sequence identity to SEQ ID NO: 12.
  • Preferred amylase variants are those having a substitution, a deletion or an insertion in one of more of the following positions of SEQ ID NO: 12 in WO01/66712: R28, R118, N174; R181 , G182, D183, G184, G186, W189, N195, M202, Y298, N299, K302, S303, N306, R310, N314; R320, H324, E345, Y396, R400, W439, R444, N445, K446, Q449, R458, N471 , N484.
  • Preferred amylases include variants having a deletion of D183 and G184 and having the substitutions R1 18K, N195F, R320K and R458K, and a variant additionally having substitutions in one or more position selected from the group: M9, G149, G182, G186, M202, T257, Y295, N299, M323, E345 and A339, most preferred a variant that additionally has substitutions in all these positions.
  • amylase variants such as those described in WO201 1/098531 , WO2013/001078 and WO2013/001087.
  • amylases are DuramylTM, TermamylTM, FungamylTM, StainzymeTM, Stainzyme PlusTM, NatalaseTM, Liquozyme X, BANTM, Amplify® and Amplify® Prime (from Novozymes A/S), and RapidaseTM, PurastarTM/EffectenzTM, Powerase, Preferenz S1000, Preferenz S100 and Preferenz S1 10 (from Genencor International Inc./DuPont).
  • the cleaning composition of the invention comprises an amylase which is a variant of the polypeptide of SEQ ID NO: 27 with the mutations W140Y, N195F, D183 * , G184 * , V206Y, Y243F, E260G, G304R and G476K.
  • the cleaning composition of the invention comprises an amylase which is a variant of the polypeptide of SEQ ID NO: 27 with the mutations H 1 * , G7A, G109A, W140Y, N195F, D183 * , G184 * , V206Y, Y243F, E260G, N280S, G304R, E391A and G476K.
  • the cleaning composition of the invention comprises an amylase which is a variant of the polypeptide of SEQ ID NO: 28 with the mutations M9L, G149A, R1 18K, G182T, D183 * , G184 * , G186A, N195F, T246V, T257I, Y295F, N299Y, M323T, A339S and E345R.
  • the cleaning composition of the invention comprises an amylase which is a variant of the polypeptide of SEQ ID NO: 28 with the mutations R1 18K, D183 * , G184 * , N195F, R320K and R458K.
  • the cleaning composition of the invention comprises an amylase which is a variant of the polypeptide of SEQ ID NO: 28 with the mutations M9L, G149A, R1 18K, G182T, D183 * , G184 * , G186A, N195F, M202L, T257I, Y295F, N299Y, M323T, A339S and E345R.
  • the cleaning composition of the invention comprises an amylase which is a variant of the polypeptide of SEQ ID NO: 29 with the mutations H1 * , N54S, V56T, K72R, G109A, F1 13Q, R1 16Q, W167F, Q172G, A174S, G182 * , D183 * , G184T, N195F, V206L, K391A, P473R and G476K.
  • the cleaning composition of the invention comprises an amylase which is a variant of the polypeptide of SEQ ID NO: 30 with the mutations H183 * , G184 * , I405L, A421 H, A422P and A428T.
  • Suitable lipases include those of bacterial or fungal origin. Chemically modified or protein engineered mutant enzymes are included. Examples include lipase from Thermomyces, e.g. from T. lanuginosus (previously named Humicola lanuginosa) as described in EP258068 and EP305216, cutinase from Humicola, e.g. H. insolens (WO96/13580), lipase from strains of Pseudomonas (some of these now renamed to Burkholderia), e.g. P. alcaligenes or P. pseudoalcaligenes (EP218272), P. cepacia (EP331376), P. sp.
  • Thermomyces e.g. from T. lanuginosus (previously named Humicola lanuginosa) as described in EP258068 and EP305216
  • cutinase from Humicola e.g. H. insolens
  • strain SD705 (W095/06720 & W096/27002), P. wisconsinensis (WO96/12012), GDSL-type Streptomyces lipases (W010/065455), lipase from Thermobifida fusca (W01 1/084412), Geobacillus stearothermophilus lipase (W01 1/084417), lipase from Bacillus subtilis (W01 1/084599), and lipase from Streptomyces griseus (W01 1/150157) and S. pristinaespiralis (W012/137147).
  • lipase variants such as those described in EP407225, WO92/05249, WO94/01541 , W094/25578, W095/14783, WO95/30744, W095/35381 , W095/22615,
  • Preferred commercial lipase products include LipolaseTM, LipexTM, LipolexTM and LipocleanTM (Novozymes A/S), Lumafast (originally from Genencor) and Lipomax (originally from Gist-Brocades).
  • lipases sometimes referred to as acyltransferases or perhydrolases, e.g. acyltransferases with homology to Candida antarctica lipase A (W010/11 1 143), acyltransferase from Mycobacterium smegmatis (WO05/56782), perhydrolases from the CE 7 family (WO09/67279), and variants of the M. smegmatis perhydrolase in particular the S54V variant used in the commercial product Gentle Power Bleach from Huntsman Textile Effects Pte Ltd (W010/100028).
  • the cleaning composition of the invention comprises a lipase which is a variant of the polypeptide of SEQ ID NO: 31.
  • the cleaning composition of the invention comprises a lipase which is a variant of the polypeptide of SEQ ID NO: 31 with the mutations T231 R and N233R.
  • the cleaning composition of the invention comprises a lipase which is a variant of the polypeptide of SEQ ID NO: 31 with the mutations N33Q, G91 Q, E210Q, T231 R, N233R and I255A.
  • the cleaning composition of the invention comprises a lipase which is a variant of the polypeptide of SEQ ID NO: 31 with the mutations E1 C, D27R, G38A, F51V, D96E, K98I, D1 1 1A, G163K, H198S, Y220F, T231 R, N233C, D254S and P256T.
  • the cleaning composition of the invention comprises a lipase which is a variant of the polypeptide of SEQ ID NO: 31 with the mutations D27R, G38A, D96E, D1 1 1A, G163K, T231 R, N233R, D254S and P256T.
  • Suitable mannanases include those of bacterial or fungal origin. Chemically or genetically modified mutants are included.
  • the mannanase may be an alkaline mannanase of Family 5 or 26. It may be a wild-type from Bacillus or Humicola, particularly B. agaradhaerens, B. licheniformis, B. halodurans, B. clausii, or H. insolens.
  • Suitable mannanases are described e.g. in WO 1999/064619. A commercially available mannanase is Mannaway® (Novozymes A/S).
  • the cleaning composition of the invention comprises a mannanase with the amino acid sequence of SEQ ID NO: 32.
  • a pectate lyase is an enzyme that catalyzes the random cleavage of alpha-1 ,4- glycosidic linkages in pectic acid, also known as polygalacturonic acid, by transelimination.
  • Pectate lyases include the enzyme class polygalacturonate lyase (EC 4.2.2.2) (PGL), also known as poly(1 ,4-alpha-D-galacturonide) lyase.
  • Suitable pectate lyases include those of bacterial or fungal origin. Chemically or genetically modified pectate lyase are included. Pectate lyases have been cloned from different bacterial genera such as Erwinia, Pseudomonas, Klebsiella and Xanthomonas. Also from Bacillus subtilis (Nasser et al. (1993) FEBS 335:319-326) and Bacillus sp. YA-14 (Kim et al. (1994) Biosci. Biotech. Biochem. 58:947-949) cloning of a pectate lyase has been described. Variants of a pectate lyase from Bacillus subtilis have been disclosed in WO 2002/092741 and WO 2003/095638.
  • pectate lyases include Xpect® (Novozymes, A/S), Pectawash® (Novozymes, A/S) and Pectaway® (Novozymes, A/S).
  • the cleaning composition of the invention comprises a pectate lyase with the amino acid sequence of SEQ ID NO: 33.
  • Suitable cellulases include those of bacterial or fungal origin. Chemically modified or protein engineered mutants are included. Suitable cellulases include those from the genera Bacillus, Pseudomonas, Humicola, Fusarium, Thielavia, or Acremonium, e.g., the fungal cellulases produced from Humicola insolens, Myceliophthora thermophila and Fusarium oxysporum disclosed in US 4,435,307, US 5,648,263, US 5,691 ,178, US 5,776,757 and WO 89/09259.
  • cellulases are the alkaline or neutral cellulases having colour care benefits.
  • Examples of such cellulases are those described in EP 0 495 257, EP 0 531 372, WO 96/1 1262, WO 96/29397, WO 98/08940.
  • Other examples are cellulase variants such as those described in WO 94/07998, EP 0 531 315, US 5,457,046, US 5,686,593, US 5,763,254, WO 95/24471 , WO 98/12307 and W099/001544.
  • cellulases are e.g. an endo-beta-1 ,4-glucanase enzyme having a sequence of at least 97% identity to the amino acid sequence of positions 1-773 of SEQ ID NO:2 of WO 02/099091 or a family 44 xyloglucanase, which a xyloglucanase enzyme having a sequence of at least 60% identity to positions 40-559 of SEQ ID NO: 2 of WO 01/062903.
  • cellulases include CelluzymeTM, and CarezymeTM (Novozymes A/S) Carezyme PremiumTM (Novozymes A/S), CellucleanTM (Novozymes A/S), Celluclean ClassicTM (Novozymes A/S), CellusoftTM (Novozymes A/S), WhitezymeTM (Novozymes A/S), ClazinaseTM, and Puradax HATM (Genencor International Inc.), and KAC-500(B)TM (Kao Corporation).
  • the cleaning composition of the invention comprises a cellulase with the amino acid sequence of SEQ ID NO: 34.
  • the cleaning composition of the invention comprises a cellulase with the amino acid sequence of SEQ ID NO: 35.
  • the cleaning composition of the invention comprises two cellulases, in particular a cellulase with the amino acid sequence of SEQ ID NO: 34 and a cellulase with the amino acid sequence of SEQ ID NO: 35.
  • the cleaning composition of the invention comprises a xyloglucanase with the amino acid sequence of SEQ ID NO: 36.
  • Suitable peroxidases/oxidases include those of plant, bacterial or fungal origin. Chemically modified or protein engineered mutants are included.
  • a suitable peroxidase is a peroxidase enzyme comprised by the enzyme classification EC 1.1 1.1.7, as set out by the Nomenclature Committee of the International Union of Biochemistry and Molecular Biology (IUBMB), or any fragment derived therefrom, exhibiting peroxidase activity.
  • peroxidases examples include peroxidases from Coprinus, e.g., from C. cinereus, and variants thereof as those described in WO 93/24618, WO 95/10602, and WO 98/15257.
  • Commercially available peroxidases include GuardzymeTM (Novozymes A/S).
  • haloperoxidase enzymes such as chloroperoxidase, bromoperoxidase and compounds exhibiting chloroperoxidase or bromoperoxidase activity.
  • Haloperoxidases are classified according to their specificity for halide ions. Chloroperoxidases (E.C. 1.1 1.1.10) catalyze formation of hypochlorite from chloride ions.
  • the haloperoxidase is a vanadium haloperoxidase, i.e., a vanadate-containing haloperoxidase.
  • Haloperoxidases have been isolated from many different fungi, in particular from the fungus group dematiaceous hyphomycetes, such as Caldariomyces, e.g., C. fumago, Alternaria, Curvularia, e.g., C. verruculosa and C. inaequalis, Drechslera, Ulocladium and Botrytis.
  • Caldariomyces e.g., C. fumago
  • Alternaria Curvularia
  • Curvularia e.g., C. verruculosa and C. inaequalis
  • Drechslera Ulocladium and Botrytis.
  • Haloperoxidases have also been isolated from bacteria such as Pseudomonas, e.g., P. pyrrocinia and Streptomyces, e.g., S. aureofaciens.
  • a suitable oxidase also includes any laccase enzyme comprised by the enzyme classification EC 1.10.3.2, or any fragment derived therefrom exhibiting laccase activity, or a compound exhibiting a similar activity, such as a catechol oxidase (EC 1.10.3.1 ), an o-aminophenol oxidase (EC 1.10.3.4), or a bilirubin oxidase (EC 1.3.3.5).
  • Preferred laccase enzymes are enzymes of microbial origin. The enzymes may be derived from plants, bacteria or fungi (including filamentous fungi and yeasts). Suitable examples from fungi include a laccase derivable from a strain of Aspergillus, Neurospora, e.g., N.
  • crassa Podospora, Botrytis, Collybia, Fomes, Lentinus, Pleurotus, Trametes, e.g., T. villosa and T. versicolor, Rhizoctonia, e.g., R. solani, Coprinopsis, e.g., C. cinerea, C. comatus, C. friesii, and C. plicatilis, Psathyrella, e.g., P. condelleana, Panaeolus, e.g., P. papilionaceus, Myceliophthora, e.g., M. thermophila, Schytalidium, e.g., S.
  • thermophilum Polyporus, e.g., P. pinsitus, Phlebia, e.g., P. radiata (WO 92/01046), or Coriolus, e.g., C. hirsutus (JP 2238885).
  • Suitable examples from bacteria include a laccase derivable from a strain ot Bacillus.
  • a laccase derived from Coprinopsis or Myceliophthora is preferred; in particular, a laccase derived from Coprinopsis cinerea, as disclosed in WO 97/08325; or from Myceliophthora thermophila, as disclosed in WO 95/33836.
  • the cleaning composition of the invention in its broadest aspect comprises at least two cleaning enzymes selected from the group consisting of nucleases, hexosaminidases and glycosyl hydrolases and at least two detergent enzymes selected from the group consisting of proteases, amylases, lipases, mannanases, pectate lyases and cellulases.
  • the invention relates to a cleaning composition
  • a cleaning composition comprising 1 ) at least two cleaning enzymes selected from the group consisting of nucleases, hexosaminidases and glycosyl hydrolases, wherein the nuclease is a DNase or an RNase, and the glycosyl hydrolase is a Glyco_hydro_1 14, GH39 or GHL13 glycosyl hydrolase; and 2) at least two detergent enzymes selected from the group consisting of proteases, amylases, lipases, mannanases, pectate lyases and cellulases.
  • compositions of the invention will typically comprise a cleaning enzyme selected from at least two of the categories nucleases, hexosaminidases and glycosyl hydrolases.
  • the compositions will typically comprise one of the following combinations: a) at least one nuclease and at least one hexosaminidase; b) at least one nuclease and at least one glycosyl hydrolase; or c) at least one hexosaminidase and at least one glycosyl hydrolase.
  • the compositions may of course comprise one or more enzymes from each of these groups, i.e. at least one nuclease, at least one hexosaminidase and at least one glycosyl hydrolase.
  • compositions comprising a DNase and a Glvco hydro 114 polypeptide
  • One aspect of the invention relates to a cleaning composition
  • a cleaning composition comprising at least a DNase and a Glyco_hydro_1 14 glycosyl hydrolase as the cleaning enzymes. Exemplary embodiments of this aspect of the invention are described below.
  • the composition comprises:
  • a DNase that comprises or consists of SEQ ID NO: 1 , or which is a variant thereof having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity to SEQ ID NO: 1 ;
  • Glyco_hydro_1 14 polypeptide that comprises or consists of SEQ ID NO: 6, or which is a variant thereof having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity to SEQ ID NO: 6;
  • a protease selected from: a) a polypeptide that comprises or consists of SEQ ID NO: 24 or SEQ ID NO: 26, or a variant thereof having at least 80%, at least 85%, at least 90% or at least 95% sequence identity to SEQ ID NO: 24 or SEQ ID NO: 26; b) a polypeptide that comprises SEQ ID NO: 24 with the substitutions Y161A, R164S and A188P; c) a polypeptide that comprises SEQ ID NO: 24 with the substitutions S9E, N42R, N74D, V199I, Q200L, Y203W, S253D, N255W and L256E; and d) a polypeptide that comprises SEQ ID NO: 37; and
  • At least one enzyme selected from the group consisting of amylases, lipases, mannanases, pectate lyases and cellulases.
  • the composition comprises:
  • a DNase that comprises or consists of SEQ ID NO: 1 ;
  • o the amylase comprises SEQ ID NO: 30 with the mutations H183 * , G184 * , I405L, A421 H, A422P and A428T; o the lipase comprises SEQ ID NO: 31 with the mutations D27R, G38A, D96E, D11 1A, G163K, T231 R, N233R, D254S and P256T; o the mannanase comprises SEQ ID NO: 32;
  • o the pectate lyase comprises SEQ ID NO: 33;
  • the cellulase comprises SEQ ID NO: 34 or SEQ ID NO: 35.
  • the composition comprises:
  • a DNase that comprises or consists of SEQ ID NO: 1 ;
  • a protease that comprises SEQ ID NO: 24 with the substitutions S9E, N42R, N74D, V199I, Q200L, Y203W, S253D, N255W and L256E;
  • o the amylase comprises SEQ ID NO: 29 with the mutations H 1 * , N54S, V56T, K72R, G109A, F113Q, R116Q, W167F, Q172G, A174S, G182 * , D183 * , G184T, N195F, V206L, K391A, P473R and G476K; and o the cellulase comprises SEQ ID NO: 34.
  • the composition comprises:
  • a DNase that comprises or consists of SEQ ID NO: 1 , or which is a variant thereof having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity to SEQ ID NO: 1 ;
  • Glyco_hydro_1 14 polypeptide that comprises or consists of SEQ ID NO: 7, or which is a variant thereof having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity to SEQ ID NO: 7;
  • a protease selected from: a) a polypeptide that comprises or consists of SEQ ID NO: 24 or SEQ ID NO: 26, or a variant thereof having at least 80%, at least 85%, at least 90% or at least 95% sequence identity to SEQ ID NO: 24 or SEQ ID NO: 26; b) a polypeptide that comprises SEQ ID NO: 24 with the substitutions Y161A, R164S and A188P; c) a polypeptide that comprises SEQ ID NO: 24 with the substitutions S9E, N42R, N74D, V199I, Q200L, Y203W, S253D, N255W and L256E; and d) a polypeptide that comprises SEQ ID NO: 37; and
  • At least one enzyme selected from the group consisting of amylases, lipases, mannanases, pectate lyases and cellulases.
  • the composition comprises:
  • a DNase that comprises or consists of SEQ ID NO: 1 ;
  • amylase comprises SEQ ID NO: 30 with the mutations H183 * , G184 * , I405L, A421 H, A422P and A428T;
  • o the lipase comprises SEQ ID NO: 31 with the mutations D27R, G38A, D96E, D11 1A, G163K, T231 R, N233R, D254S and P256T; o the mannanase comprises SEQ ID NO: 32;
  • o the pectate lyase comprises SEQ ID NO: 33;
  • the cellulase comprises SEQ ID NO: 34 or SEQ ID NO: 35.
  • the composition comprises:
  • a DNase that comprises or consists of SEQ ID NO: 1 ;
  • a protease that comprises SEQ ID NO: 24 with the substitutions S9E, N42R, N74D, V199I, Q200L, Y203W, S253D, N255W and L256E;
  • o the amylase comprises SEQ ID NO: 29 with the mutations H 1 * , N54S, V56T, K72R, G109A, F113Q, R116Q, W167F, Q172G, A174S, G182 * , D183 * , G184T, N195F, V206L, K391A, P473R and G476K; and o the cellulase comprises SEQ ID NO: 34.
  • the composition comprises:
  • a DNase that comprises or consists of SEQ I D NO: 1 , or which is a variant thereof having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity to SEQ ID NO: 1 ;
  • Glyco_hydro_1 14 polypeptide that comprises or consists of SEQ ID NO: 8, or which is a variant thereof having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity to SEQ ID NO: 8;
  • a protease selected from: a) a polypeptide that comprises or consists of SEQ ID NO: 24 or SEQ ID NO: 26, or a variant thereof having at least 80%, at least 85%, at least 90% or at least 95% sequence identity to SEQ ID NO: 24 or SEQ ID NO: 26; b) a polypeptide that comprises SEQ ID NO: 24 with the substitutions Y161A, R164S and A188P; c) a polypeptide that comprises SEQ ID NO: 24 with the substitutions S9E, N42R, N74D, V199I, Q200L, Y203W, S253D, N255W and L256E; and d) a polypeptide that comprises SEQ ID NO: 37; and
  • At least one enzyme selected from the group consisting of amylases, lipases, mannanases, pectate lyases and cellulases.
  • the composition comprises:
  • a DNase that comprises or consists of SEQ ID NO: 1 ;
  • amylase comprises SEQ ID NO: 30 with the mutations H183 * , G184 * , I405L, A421 H, A422P and A428T;
  • o the lipase comprises SEQ ID NO: 31 with the mutations D27R, G38A, D96E, D11 1A, G163K, T231 R, N233R, D254S and P256T; o the mannanase comprises SEQ ID NO: 32;
  • o the pectate lyase comprises SEQ ID NO: 33;
  • the cellulase comprises SEQ ID NO: 34 or SEQ ID NO: 35.
  • the composition comprises:
  • a DNase that comprises or consists of SEQ ID NO: 1 ;
  • a protease that comprises SEQ ID NO: 24 with the substitutions S9E, N42R, N74D, V199I, Q200L, Y203W, S253D, N255W and L256E;
  • o the amylase comprises SEQ ID NO: 29 with the mutations H 1 * , N54S, V56T, K72R, G109A, F113Q, R116Q, W167F, Q172G, A174S, G182 * , D183 * , G184T, N195F, V206L, K391A, P473R and G476K; and o the cellulase comprises SEQ ID NO: 34.
  • the composition comprises:
  • a DNase that comprises or consists of SEQ ID NO: 1 , or which is a variant thereof having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity to SEQ ID NO: 1 ;
  • Glyco_hydro_1 14 polypeptide that comprises or consists of SEQ ID NO: 9, or which is a variant thereof having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity to SEQ ID NO: 9;
  • a protease selected from: a) a polypeptide that comprises or consists of SEQ ID NO: 24 or SEQ ID NO: 26, or a variant thereof having at least 80%, at least 85%, at least 90% or at least 95% sequence identity to SEQ ID NO: 24 or SEQ ID NO: 26; b) a polypeptide that comprises SEQ ID NO: 24 with the substitutions Y161A, R164S and A188P; c) a polypeptide that comprises SEQ ID NO: 24 with the substitutions S9E, N42R, N74D, V199I, Q200L, Y203W, S253D, N255W and L256E; and d) a polypeptide that comprises SEQ ID NO: 37; and
  • At least one enzyme selected from the group consisting of amylases, lipases, mannanases, pectate lyases and cellulases.
  • the composition comprises:
  • a DNase that comprises or consists of SEQ ID NO: 1 ;
  • amylase comprises SEQ ID NO: 30 with the mutations H183 * , G184 * , I405L, A421 H, A422P and A428T;
  • o the lipase comprises SEQ ID NO: 31 with the mutations D27R, G38A, D96E, D11 1A, G163K, T231 R, N233R, D254S and P256T; o the mannanase comprises SEQ ID NO: 32;
  • o the pectate lyase comprises SEQ ID NO: 33;
  • the cellulase comprises SEQ ID NO: 34 or SEQ ID NO: 35.
  • the composition comprises:
  • a DNase that comprises or consists of SEQ ID NO: 1 ;
  • a protease that comprises SEQ ID NO: 24 with the substitutions S9E, N42R, N74D, V199I, Q200L, Y203W, S253D, N255W and L256E;
  • the amylase comprises SEQ ID NO: 29 with the mutations H 1 * , N54S, V56T, K72R, G109A, F113Q, R116Q, W167F, Q172G, A174S, G182 * , D183 * , G184T, N195F, V206L, K391A, P473R and G476K; and o the cellulase comprises SEQ ID NO: 34.
  • the composition comprises:
  • a DNase that comprises or consists of SEQ ID NO: 2, or which is a variant thereof having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity to SEQ ID NO: 2;
  • Glyco_hydro_1 14 polypeptide that comprises or consists of SEQ ID NO: 6, or which is a variant thereof having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity to SEQ ID NO: 6;
  • a protease selected from: a) a polypeptide that comprises or consists of SEQ ID NO: 24 or SEQ ID NO: 26, or a variant thereof having at least 80%, at least 85%, at least 90% or at least 95% sequence identity to SEQ ID NO: 24 or SEQ ID NO: 26; b) a polypeptide that comprises SEQ ID NO: 24 with the substitutions Y161A, R164S and A188P; c) a polypeptide that comprises SEQ ID NO: 24 with the substitutions S9E, N42R, N74D, V199I, Q200L, Y203W, S253D, N255W and L256E; and d) a polypeptide that comprises SEQ ID NO: 37; and
  • At least one enzyme selected from the group consisting of amylases, lipases, mannanases, pectate lyases and cellulases.
  • the composition comprises:
  • amylase comprises SEQ ID NO: 30 with the mutations H183 * , G184 * , I405L, A421 H, A422P and A428T;
  • o the lipase comprises SEQ ID NO: 31 with the mutations D27R, G38A, D96E, D11 1A, G163K, T231 R, N233R, D254S and P256T; o the mannanase comprises SEQ ID NO: 32;
  • o the pectate lyase comprises SEQ ID NO: 33;
  • the cellulase comprises SEQ ID NO: 34 or SEQ ID NO: 35.
  • the composition comprises:
  • a protease that comprises SEQ ID NO: 24 with the substitutions S9E, N42R, N74D, V199I, Q200L, Y203W, S253D, N255W and L256E; and • at least one enzyme selected from the group consisting of amylases and cellulases; wherein:
  • o the amylase comprises SEQ ID NO: 29 with the mutations H 1 * , N54S, V56T, K72R, G109A, F113Q, R116Q, W167F, Q172G, A174S, G182 * , D183 * , G184T, N195F, V206L, K391A, P473R and G476K; and o the cellulase comprises SEQ ID NO: 34.
  • the composition comprises:
  • a DNase that comprises or consists of SEQ ID NO: 2, or which is a variant thereof having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity to SEQ ID NO: 2;
  • Glyco_hydro_1 14 polypeptide that comprises or consists of SEQ ID NO: 7, or which is a variant thereof having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity to SEQ ID NO: 7;
  • a protease selected from: a) a polypeptide that comprises or consists of SEQ ID NO: 24 or SEQ ID NO: 26, or a variant thereof having at least 80%, at least 85%, at least 90% or at least 95% sequence identity to SEQ ID NO: 24 or SEQ ID NO: 26; b) a polypeptide that comprises SEQ ID NO: 24 with the substitutions Y161A, R164S and A188P; c) a polypeptide that comprises SEQ ID NO: 24 with the substitutions S9E, N42R, N74D, V199I, Q200L, Y203W, S253D, N255W and L256E; and d) a polypeptide that comprises SEQ ID NO: 37; and
  • At least one enzyme selected from the group consisting of amylases, lipases, mannanases, pectate lyases and cellulases.
  • the composition comprises:
  • amylase comprises SEQ ID NO: 30 with the mutations H183 * , G184 * , I405L, A421 H, A422P and A428T;
  • o the lipase comprises SEQ ID NO: 31 with the mutations D27R, G38A, D96E, D11 1A, G163K, T231 R, N233R, D254S and P256T; o the mannanase comprises SEQ ID NO: 32;
  • o the pectate lyase comprises SEQ ID NO: 33; and o the cellulase comprises SEQ ID NO: 34 or SEQ ID NO: 35.
  • the composition comprises:
  • a protease that comprises SEQ ID NO: 24 with the substitutions S9E, N42R, N74D, V199I, Q200L, Y203W, S253D, N255W and L256E;
  • o the amylase comprises SEQ ID NO: 29 with the mutations H 1 * , N54S, V56T, K72R, G109A, F113Q, R116Q, W167F, Q172G, A174S, G182 * , D183 * , G184T, N195F, V206L, K391A, P473R and G476K; and o the cellulase comprises SEQ ID NO: 34.
  • the composition comprises:
  • a DNase that comprises or consists of SEQ ID NO: 2, or which is a variant thereof having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity to SEQ ID NO: 2;
  • Glyco_hydro_1 14 polypeptide that comprises or consists of SEQ ID NO: 8, or which is a variant thereof having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity to SEQ ID NO: 8;
  • a protease selected from: a) a polypeptide that comprises or consists of SEQ ID NO: 24 or SEQ ID NO: 26, or a variant thereof having at least 80%, at least 85%, at least 90% or at least 95% sequence identity to SEQ ID NO: 24 or SEQ ID NO: 26; b) a polypeptide that comprises SEQ ID NO: 24 with the substitutions Y161A, R164S and A188P; c) a polypeptide that comprises SEQ ID NO: 24 with the substitutions S9E, N42R, N74D, V199I, Q200L, Y203W, S253D, N255W and L256E; and d) a polypeptide that comprises SEQ ID NO: 37; and
  • At least one enzyme selected from the group consisting of amylases, lipases, mannanases, pectate lyases and cellulases.
  • the composition comprises:
  • amylases • at least one enzyme selected from the group consisting of amylases, lipases, mannanases, pectate lyases and cellulases; wherein: o the amylase comprises SEQ ID NO: 30 with the mutations H183 * , G184 * , I405L, A421 H, A422P and A428T;
  • o the lipase comprises SEQ ID NO: 31 with the mutations D27R, G38A, D96E, D11 1A, G163K, T231 R, N233R, D254S and P256T; o the mannanase comprises SEQ ID NO: 32;
  • o the pectate lyase comprises SEQ ID NO: 33;
  • the cellulase comprises SEQ ID NO: 34 or SEQ ID NO: 35.
  • the composition comprises:
  • a protease that comprises SEQ ID NO: 24 with the substitutions S9E, N42R, N74D, V199I, Q200L, Y203W, S253D, N255W and L256E;
  • o the amylase comprises SEQ ID NO: 29 with the mutations H 1 * , N54S, V56T, K72R, G109A, F113Q, R116Q, W167F, Q172G, A174S, G182 * , D183 * , G184T, N195F, V206L, K391A, P473R and G476K; and o the cellulase comprises SEQ ID NO: 34.
  • the composition comprises:
  • a DNase that comprises or consists of SEQ ID NO: 2, or which is a variant thereof having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity to SEQ ID NO: 2;
  • Glyco_hydro_1 14 polypeptide that comprises or consists of SEQ ID NO: 9, or which is a variant thereof having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity to SEQ ID NO: 9;
  • a protease selected from: a) a polypeptide that comprises or consists of SEQ ID NO: 24 or SEQ ID NO: 26, or a variant thereof having at least 80%, at least 85%, at least 90% or at least 95% sequence identity to SEQ ID NO: 24 or SEQ ID NO: 26; b) a polypeptide that comprises SEQ ID NO: 24 with the substitutions Y161A, R164S and A188P; c) a polypeptide that comprises SEQ ID NO: 24 with the substitutions S9E, N42R, N74D, V199I, Q200L, Y203W, S253D, N255W and L256E; and d) a polypeptide that comprises SEQ ID NO: 37; and
  • At least one enzyme selected from the group consisting of amylases, lipases, mannanases, pectate lyases and cellulases.
  • the composition comprises: • a DNase that comprises or consists of SEQ ID NO: 2;
  • amylase comprises SEQ ID NO: 30 with the mutations H183 * , G184 * , I405L, A421 H, A422P and A428T;
  • o the lipase comprises SEQ ID NO: 31 with the mutations D27R, G38A, D96E, D11 1A, G163K, T231 R, N233R, D254S and P256T; o the mannanase comprises SEQ ID NO: 32;
  • o the pectate lyase comprises SEQ ID NO: 33;
  • the cellulase comprises SEQ ID NO: 34 or SEQ ID NO: 35.
  • the composition comprises:
  • a protease that comprises SEQ ID NO: 24 with the substitutions S9E, N42R, N74D, V199I, Q200L, Y203W, S253D, N255W and L256E;
  • o the amylase comprises SEQ ID NO: 29 with the mutations H 1 * , N54S, V56T, K72R, G109A, F113Q, R116Q, W167F, Q172G, A174S, G182 * , D183 * , G184T, N195F, V206L, K391A, P473R and G476K; and o the cellulase comprises SEQ ID NO: 34.
  • the composition comprises:
  • a DNase that comprises or consists of SEQ ID NO: 3, or which is a variant thereof having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity to SEQ ID NO: 3;
  • Glyco_hydro_1 14 polypeptide that comprises or consists of SEQ ID NO: 6, or which is a variant thereof having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity to SEQ ID NO: 6;
  • a protease selected from: a) a polypeptide that comprises or consists of SEQ ID NO: 24 or SEQ ID NO: 26, or a variant thereof having at least 80%, at least 85%, at least 90% or at least 95% sequence identity to SEQ ID NO: 24 or SEQ ID NO: 26; b) a polypeptide that comprises SEQ ID NO: 24 with the substitutions Y161A, R164S and A188P; c) a polypeptide that comprises SEQ ID NO: 24 with the substitutions S9E, N42R, N74D, V199I, Q200L, Y203W, S253D, N255W and L256E; and d) a polypeptide that comprises SEQ ID NO: 37; and
  • At least one enzyme selected from the group consisting of amylases, lipases, mannanases, pectate lyases and cellulases.
  • the composition comprises:
  • amylase comprises SEQ ID NO: 30 with the mutations H183 * , G184 * , I405L, A421 H, A422P and A428T;
  • o the lipase comprises SEQ ID NO: 31 with the mutations D27R, G38A, D96E, D11 1A, G163K, T231 R, N233R, D254S and P256T; o the mannanase comprises SEQ ID NO: 32;
  • o the pectate lyase comprises SEQ ID NO: 33;
  • the cellulase comprises SEQ ID NO: 34 or SEQ ID NO: 35.
  • the composition comprises:
  • a protease that comprises SEQ ID NO: 24 with the substitutions S9E, N42R, N74D, V199I, Q200L, Y203W, S253D, N255W and L256E;
  • o the amylase comprises SEQ ID NO: 29 with the mutations H 1 * , N54S, V56T, K72R, G109A, F113Q, R116Q, W167F, Q172G, A174S, G182 * , D183 * , G184T, N195F, V206L, K391A, P473R and G476K; and o the cellulase comprises SEQ ID NO: 34.
  • the composition comprises:
  • a DNase that comprises or consists of SEQ ID NO: 3, or which is a variant thereof having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity to SEQ ID NO: 3;
  • Glyco_hydro_1 14 polypeptide that comprises or consists of SEQ ID NO: 7, or which is a variant thereof having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity to SEQ ID NO: 7;
  • a protease selected from: a) a polypeptide that comprises or consists of SEQ ID NO: 24 or SEQ ID NO: 26, or a variant thereof having at least 80%, at least 85%, at least 90% or at least 95% sequence identity to SEQ ID NO: 24 or SEQ ID NO: 26; b) a polypeptide that comprises SEQ ID NO: 24 with the substitutions Y161A, R164S and A188P; c) a polypeptide that comprises SEQ ID NO: 24 with the substitutions S9E, N42R, N74D, V199I, Q200L, Y203W, S253D, N255W and L256E; and d) a polypeptide that comprises SEQ ID NO: 37; and
  • At least one enzyme selected from the group consisting of amylases, lipases, mannanases, pectate lyases and cellulases.
  • the composition comprises:
  • amylase comprises SEQ ID NO: 30 with the mutations H183 * , G184 * , I405L, A421 H, A422P and A428T;
  • o the lipase comprises SEQ ID NO: 31 with the mutations D27R, G38A, D96E, D11 1A, G163K, T231 R, N233R, D254S and P256T; o the mannanase comprises SEQ ID NO: 32;
  • o the pectate lyase comprises SEQ ID NO: 33;
  • the cellulase comprises SEQ ID NO: 34 or SEQ ID NO: 35.
  • the composition comprises:
  • a protease that comprises SEQ ID NO: 24 with the substitutions S9E, N42R, N74D, V199I, Q200L, Y203W, S253D, N255W and L256E;
  • the amylase comprises SEQ ID NO: 29 with the mutations H 1 * , N54S, V56T, K72R, G109A, F113Q, R116Q, W167F, Q172G, A174S, G182 * , D183 * , G184T, N195F, V206L, K391A, P473R and G476K; and o the cellulase comprises SEQ ID NO: 34.
  • the composition comprises:
  • a DNase that comprises or consists of SEQ ID NO: 3, or which is a variant thereof having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity to SEQ ID NO: 3;
  • Glyco_hydro_1 14 polypeptide that comprises or consists of SEQ ID NO: 8, or which is a variant thereof having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity to SEQ ID NO: 8;
  • a protease selected from: a) a polypeptide that comprises or consists of SEQ ID NO: 24 or SEQ ID NO: 26, or a variant thereof having at least 80%, at least 85%, at least 90% or at least 95% sequence identity to SEQ ID NO: 24 or SEQ ID NO: 26; b) a polypeptide that comprises SEQ ID NO: 24 with the substitutions Y161A, R164S and A188P; c) a polypeptide that comprises SEQ ID NO: 24 with the substitutions S9E, N42R, N74D, V199I, Q200L, Y203W, S253D, N255W and L256E; and d) a polypeptide that comprises SEQ ID NO: 37; and
  • At least one enzyme selected from the group consisting of amylases, lipases, mannanases, pectate lyases and cellulases.
  • the composition comprises:
  • amylase comprises SEQ ID NO: 30 with the mutations H183 * , G184 * , I405L, A421 H, A422P and A428T;
  • o the lipase comprises SEQ ID NO: 31 with the mutations D27R, G38A, D96E, D11 1A, G163K, T231 R, N233R, D254S and P256T; o the mannanase comprises SEQ ID NO: 32;
  • o the pectate lyase comprises SEQ ID NO: 33;
  • the cellulase comprises SEQ ID NO: 34 or SEQ ID NO: 35.
  • the composition comprises:
  • a protease that comprises SEQ ID NO: 24 with the substitutions S9E, N42R, N74D, V199I, Q200L, Y203W, S253D, N255W and L256E; and • at least one enzyme selected from the group consisting of amylases and cellulases; wherein:
  • o the amylase comprises SEQ ID NO: 29 with the mutations H 1 * , N54S, V56T, K72R, G109A, F113Q, R116Q, W167F, Q172G, A174S, G182 * , D183 * , G184T, N195F, V206L, K391A, P473R and G476K; and o the cellulase comprises SEQ ID NO: 34.
  • the composition comprises:
  • a DNase that comprises or consists of SEQ ID NO: 3, or which is a variant thereof having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity to SEQ ID NO: 3;
  • Glyco_hydro_1 14 polypeptide that comprises or consists of SEQ ID NO: 9, or which is a variant thereof having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity to SEQ ID NO: 9;
  • a protease selected from: a) a polypeptide that comprises or consists of SEQ ID NO: 24 or SEQ ID NO: 26, or a variant thereof having at least 80%, at least 85%, at least 90% or at least 95% sequence identity to SEQ ID NO: 24 or SEQ ID NO: 26; b) a polypeptide that comprises SEQ ID NO: 24 with the substitutions Y161A, R164S and A188P; c) a polypeptide that comprises SEQ ID NO: 24 with the substitutions S9E, N42R, N74D, V199I, Q200L, Y203W, S253D, N255W and L256E; and d) a polypeptide that comprises SEQ ID NO: 37; and
  • At least one enzyme selected from the group consisting of amylases, lipases, mannanases, pectate lyases and cellulases.
  • the composition comprises:
  • amylase comprises SEQ ID NO: 30 with the mutations H183 * , G184 * , I405L, A421 H, A422P and A428T;
  • o the lipase comprises SEQ ID NO: 31 with the mutations D27R, G38A, D96E, D11 1A, G163K, T231 R, N233R, D254S and P256T; o the mannanase comprises SEQ ID NO: 32;
  • o the pectate lyase comprises SEQ ID NO: 33; and o the cellulase comprises SEQ ID NO: 34 or SEQ ID NO: 35.
  • the composition comprises:
  • a protease that comprises SEQ ID NO: 24 with the substitutions S9E, N42R, N74D, V199I, Q200L, Y203W, S253D, N255W and L256E;
  • o the amylase comprises SEQ ID NO: 29 with the mutations H 1 * , N54S, V56T, K72R, G109A, F113Q, R116Q, W167F, Q172G, A174S, G182 * , D183 * , G184T, N195F, V206L, K391A, P473R and G476K; and o the cellulase comprises SEQ ID NO: 34.
  • the composition comprises:
  • a DNase that comprises or consists of SEQ ID NO: 4, or which is a variant thereof having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity to SEQ ID NO: 4;
  • Glyco_hydro_1 14 polypeptide that comprises or consists of SEQ ID NO: 6, or which is a variant thereof having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity to SEQ ID NO: 6;
  • a protease selected from: a) a polypeptide that comprises or consists of SEQ ID NO: 24 or SEQ ID NO: 26, or a variant thereof having at least 80%, at least 85%, at least 90% or at least 95% sequence identity to SEQ ID NO: 24 or SEQ ID NO: 26; b) a polypeptide that comprises SEQ ID NO: 24 with the substitutions Y161A, R164S and A188P; c) a polypeptide that comprises SEQ ID NO: 24 with the substitutions S9E, N42R, N74D, V199I, Q200L, Y203W, S253D, N255W and L256E; and d) a polypeptide that comprises SEQ ID NO: 37; and
  • At least one enzyme selected from the group consisting of amylases, lipases, mannanases, pectate lyases and cellulases.
  • the composition comprises:
  • amylases • at least one enzyme selected from the group consisting of amylases, lipases, mannanases, pectate lyases and cellulases; wherein: o the amylase comprises SEQ ID NO: 30 with the mutations H183 * , G184 * , I405L, A421 H, A422P and A428T;
  • o the lipase comprises SEQ ID NO: 31 with the mutations D27R, G38A, D96E, D11 1A, G163K, T231 R, N233R, D254S and P256T; o the mannanase comprises SEQ ID NO: 32;
  • o the pectate lyase comprises SEQ ID NO: 33;
  • the cellulase comprises SEQ ID NO: 34 or SEQ ID NO: 35.
  • the composition comprises:
  • a protease that comprises SEQ ID NO: 24 with the substitutions S9E, N42R, N74D, V199I, Q200L, Y203W, S253D, N255W and L256E;
  • o the amylase comprises SEQ ID NO: 29 with the mutations H 1 * , N54S, V56T, K72R, G109A, F113Q, R116Q, W167F, Q172G, A174S, G182 * , D183 * , G184T, N195F, V206L, K391A, P473R and G476K; and o the cellulase comprises SEQ ID NO: 34.
  • the composition comprises:
  • a DNase that comprises or consists of SEQ ID NO: 4, or which is a variant thereof having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity to SEQ ID NO: 4;
  • Glyco_hydro_114 polypeptide that comprises or consists of SEQ ID NO: 7, or which is a variant thereof having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity to SEQ ID NO: 7;
  • a protease selected from: a) a polypeptide that comprises or consists of SEQ ID NO: 24 or SEQ ID NO: 26, or a variant thereof having at least 80%, at least 85%, at least 90% or at least 95% sequence identity to SEQ ID NO: 24 or SEQ ID NO: 26; b) a polypeptide that comprises SEQ ID NO: 24 with the substitutions Y161A, R164S and A188P; c) a polypeptide that comprises SEQ ID NO: 24 with the substitutions S9E, N42R, N74D, V199I, Q200L, Y203W, S253D, N255W and L256E; and d) a polypeptide that comprises SEQ ID NO: 37; and
  • At least one enzyme selected from the group consisting of amylases, lipases, mannanases, pectate lyases and cellulases.
  • the composition comprises: • a DNase that comprises or consists of SEQ ID NO: 4;
  • amylase comprises SEQ ID NO: 30 with the mutations H183 * , G184 * , I405L, A421 H, A422P and A428T;
  • o the lipase comprises SEQ ID NO: 31 with the mutations D27R, G38A, D96E, D11 1A, G163K, T231 R, N233R, D254S and P256T; o the mannanase comprises SEQ ID NO: 32;
  • o the pectate lyase comprises SEQ ID NO: 33;
  • the cellulase comprises SEQ ID NO: 34 or SEQ ID NO: 35.
  • the composition comprises:
  • a protease that comprises SEQ ID NO: 24 with the substitutions S9E, N42R, N74D, V199I, Q200L, Y203W, S253D, N255W and L256E;
  • o the amylase comprises SEQ ID NO: 29 with the mutations H 1 * , N54S, V56T, K72R, G109A, F113Q, R116Q, W167F, Q172G, A174S, G182 * , D183 * , G184T, N195F, V206L, K391A, P473R and G476K; and o the cellulase comprises SEQ ID NO: 34.
  • the composition comprises:
  • a DNase that comprises or consists of SEQ ID NO: 4, or which is a variant thereof having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity to SEQ ID NO: 4;
  • Glyco_hydro_1 14 polypeptide that comprises or consists of SEQ ID NO: 8, or which is a variant thereof having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity to SEQ ID NO: 8;
  • a protease selected from: a) a polypeptide that comprises or consists of SEQ ID NO: 24 or SEQ ID NO: 26, or a variant thereof having at least 80%, at least 85%, at least 90% or at least 95% sequence identity to SEQ ID NO: 24 or SEQ ID NO: 26; b) a polypeptide that comprises SEQ ID NO: 24 with the substitutions Y161A, R164S and A188P; c) a polypeptide that comprises SEQ ID NO: 24 with the substitutions S9E, N42R, N74D, V199I, Q200L, Y203W, S253D, N255W and L256E; and d) a polypeptide that comprises SEQ ID NO: 37; and
  • At least one enzyme selected from the group consisting of amylases, lipases, mannanases, pectate lyases and cellulases.
  • the composition comprises:
  • amylase comprises SEQ ID NO: 30 with the mutations H183 * , G184 * , I405L, A421 H, A422P and A428T;
  • o the lipase comprises SEQ ID NO: 31 with the mutations D27R, G38A, D96E, D11 1A, G163K, T231 R, N233R, D254S and P256T; o the mannanase comprises SEQ ID NO: 32;
  • o the pectate lyase comprises SEQ ID NO: 33;
  • the cellulase comprises SEQ ID NO: 34 or SEQ ID NO: 35.
  • the composition comprises:
  • a protease that comprises SEQ ID NO: 24 with the substitutions S9E, N42R, N74D, V199I, Q200L, Y203W, S253D, N255W and L256E;
  • o the amylase comprises SEQ ID NO: 29 with the mutations H 1 * , N54S, V56T, K72R, G109A, F113Q, R116Q, W167F, Q172G, A174S, G182 * , D183 * , G184T, N195F, V206L, K391A, P473R and G476K; and o the cellulase comprises SEQ ID NO: 34.
  • the composition comprises:
  • a DNase that comprises or consists of SEQ ID NO: 4, or which is a variant thereof having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity to SEQ ID NO: 4;
  • Glyco_hydro_1 14 polypeptide that comprises or consists of SEQ ID NO: 9, or which is a variant thereof having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity to SEQ ID NO: 9;
  • a protease selected from: a) a polypeptide that comprises or consists of SEQ ID NO: 24 or SEQ ID NO: 26, or a variant thereof having at least 80%, at least 85%, at least 90% or at least 95% sequence identity to SEQ ID NO: 24 or SEQ ID NO: 26; b) a polypeptide that comprises SEQ ID NO: 24 with the substitutions Y161A, R164S and A188P; c) a polypeptide that comprises SEQ ID NO: 24 with the substitutions S9E, N42R, N74D, V199I, Q200L, Y203W, S253D, N255W and L256E; and d) a polypeptide that comprises SEQ ID NO: 37; and
  • At least one enzyme selected from the group consisting of amylases, lipases, mannanases, pectate lyases and cellulases.
  • the composition comprises:
  • amylase comprises SEQ ID NO: 30 with the mutations H183 * , G184 * , I405L, A421 H, A422P and A428T;
  • o the lipase comprises SEQ ID NO: 31 with the mutations D27R, G38A, D96E, D11 1A, G163K, T231 R, N233R, D254S and P256T; o the mannanase comprises SEQ ID NO: 32;
  • o the pectate lyase comprises SEQ ID NO: 33;
  • the cellulase comprises SEQ ID NO: 34 or SEQ ID NO: 35.
  • the composition comprises:
  • a protease that comprises SEQ ID NO: 24 with the substitutions S9E, N42R, N74D, V199I, Q200L, Y203W, S253D, N255W and L256E;
  • the amylase comprises SEQ ID NO: 29 with the mutations H 1 * , N54S, V56T, K72R, G109A, F113Q, R116Q, W167F, Q172G, A174S, G182 * , D183 * , G184T, N195F, V206L, K391A, P473R and G476K; and o the cellulase comprises SEQ ID NO: 34.
  • the composition comprises:
  • a DNase that comprises or consists of SEQ ID NO: 5, or which is a variant thereof having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity to SEQ ID NO: 5;
  • Glyco_hydro_1 14 polypeptide that comprises or consists of SEQ ID NO: 6, or which is a variant thereof having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity to SEQ ID NO: 6;
  • a protease selected from: a) a polypeptide that comprises or consists of SEQ ID NO: 24 or SEQ ID NO: 26, or a variant thereof having at least 80%, at least 85%, at least 90% or at least 95% sequence identity to SEQ ID NO: 24 or SEQ ID NO: 26; b) a polypeptide that comprises SEQ ID NO: 24 with the substitutions Y161A, R164S and A188P; c) a polypeptide that comprises SEQ ID NO: 24 with the substitutions S9E, N42R, N74D, V199I, Q200L, Y203W, S253D, N255W and L256E; and d) a polypeptide that comprises SEQ ID NO: 37; and
  • At least one enzyme selected from the group consisting of amylases, lipases, mannanases, pectate lyases and cellulases.
  • the composition comprises:
  • amylase comprises SEQ ID NO: 30 with the mutations H183 * , G184 * , I405L, A421 H, A422P and A428T;
  • o the lipase comprises SEQ ID NO: 31 with the mutations D27R, G38A, D96E, D11 1A, G163K, T231 R, N233R, D254S and P256T; o the mannanase comprises SEQ ID NO: 32;
  • o the pectate lyase comprises SEQ ID NO: 33;
  • the cellulase comprises SEQ ID NO: 34 or SEQ ID NO: 35.
  • the composition comprises:
  • a protease that comprises SEQ ID NO: 24 with the substitutions S9E, N42R, N74D, V199I, Q200L, Y203W, S253D, N255W and L256E; and • at least one enzyme selected from the group consisting of amylases and cellulases; wherein:
  • o the amylase comprises SEQ ID NO: 29 with the mutations H 1 * , N54S, V56T, K72R, G109A, F113Q, R116Q, W167F, Q172G, A174S, G182 * , D183 * , G184T, N195F, V206L, K391A, P473R and G476K; and o the cellulase comprises SEQ ID NO: 34.
  • the composition comprises:
  • a DNase that comprises or consists of SEQ ID NO: 5, or which is a variant thereof having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity to SEQ ID NO: 5;
  • Glyco_hydro_1 14 polypeptide that comprises or consists of SEQ ID NO: 7, or which is a variant thereof having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity to SEQ ID NO: 7;
  • a protease selected from: a) a polypeptide that comprises or consists of SEQ ID NO: 24 or SEQ ID NO: 26, or a variant thereof having at least 80%, at least 85%, at least 90% or at least 95% sequence identity to SEQ ID NO: 24 or SEQ ID NO: 26; b) a polypeptide that comprises SEQ ID NO: 24 with the substitutions Y161A, R164S and A188P; c) a polypeptide that comprises SEQ ID NO: 24 with the substitutions S9E, N42R, N74D, V199I, Q200L, Y203W, S253D, N255W and L256E; and d) a polypeptide that comprises SEQ ID NO: 37; and
  • At least one enzyme selected from the group consisting of amylases, lipases, mannanases, pectate lyases and cellulases.
  • the composition comprises:
  • amylase comprises SEQ ID NO: 30 with the mutations H183 * , G184 * , I405L, A421 H, A422P and A428T;
  • o the lipase comprises SEQ ID NO: 31 with the mutations D27R, G38A, D96E, D11 1A, G163K, T231 R, N233R, D254S and P256T; o the mannanase comprises SEQ ID NO: 32;
  • o the pectate lyase comprises SEQ ID NO: 33; and o the cellulase comprises SEQ ID NO: 34 or SEQ ID NO: 35.
  • the composition comprises:
  • a protease that comprises SEQ ID NO: 24 with the substitutions S9E, N42R, N74D, V199I, Q200L, Y203W, S253D, N255W and L256E;
  • o the amylase comprises SEQ ID NO: 29 with the mutations H 1 * , N54S, V56T, K72R, G109A, F113Q, R116Q, W167F, Q172G, A174S, G182 * , D183 * , G184T, N195F, V206L, K391A, P473R and G476K; and o the cellulase comprises SEQ ID NO: 34.
  • the composition comprises:
  • a DNase that comprises or consists of SEQ ID NO: 5, or which is a variant thereof having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity to SEQ ID NO: 5;
  • Glyco_hydro_1 14 polypeptide that comprises or consists of SEQ ID NO: 8, or which is a variant thereof having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity to SEQ ID NO: 8;
  • a protease selected from: a) a polypeptide that comprises or consists of SEQ ID NO: 24 or SEQ ID NO: 26, or a variant thereof having at least 80%, at least 85%, at least 90% or at least 95% sequence identity to SEQ ID NO: 24 or SEQ ID NO: 26; b) a polypeptide that comprises SEQ ID NO: 24 with the substitutions Y161A, R164S and A188P; c) a polypeptide that comprises SEQ ID NO: 24 with the substitutions S9E, N42R, N74D, V199I, Q200L, Y203W, S253D, N255W and L256E; and d) a polypeptide that comprises SEQ ID NO: 37; and
  • At least one enzyme selected from the group consisting of amylases, lipases, mannanases, pectate lyases and cellulases.
  • the composition comprises:
  • amylases • at least one enzyme selected from the group consisting of amylases, lipases, mannanases, pectate lyases and cellulases; wherein: o the amylase comprises SEQ ID NO: 30 with the mutations H183 * , G184 * , I405L, A421 H, A422P and A428T;
  • o the lipase comprises SEQ ID NO: 31 with the mutations D27R, G38A, D96E, D11 1A, G163K, T231 R, N233R, D254S and P256T; o the mannanase comprises SEQ ID NO: 32;
  • o the pectate lyase comprises SEQ ID NO: 33;
  • the cellulase comprises SEQ ID NO: 34 or SEQ ID NO: 35.
  • the composition comprises:
  • a protease that comprises SEQ ID NO: 24 with the substitutions S9E, N42R, N74D, V199I, Q200L, Y203W, S253D, N255W and L256E;
  • o the amylase comprises SEQ ID NO: 29 with the mutations H 1 * , N54S, V56T, K72R, G109A, F113Q, R116Q, W167F, Q172G, A174S, G182 * , D183 * , G184T, N195F, V206L, K391A, P473R and G476K; and o the cellulase comprises SEQ ID NO: 34.
  • the composition comprises:
  • a DNase that comprises or consists of SEQ ID NO: 5, or which is a variant thereof having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity to SEQ ID NO: 5;
  • Glyco_hydro_1 14 polypeptide that comprises or consists of SEQ ID NO: 9, or which is a variant thereof having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity to SEQ ID NO: 9;
  • a protease selected from: a) a polypeptide that comprises or consists of SEQ ID NO: 24 or SEQ ID NO: 26, or a variant thereof having at least 80%, at least 85%, at least 90% or at least 95% sequence identity to SEQ ID NO: 24 or SEQ ID NO: 26; b) a polypeptide that comprises SEQ ID NO: 24 with the substitutions Y161A, R164S and A188P; c) a polypeptide that comprises SEQ ID NO: 24 with the substitutions S9E, N42R, N74D, V199I, Q200L, Y203W, S253D, N255W and L256E; and d) a polypeptide that comprises SEQ ID NO: 37; and
  • At least one enzyme selected from the group consisting of amylases, lipases, mannanases, pectate lyases and cellulases.
  • the composition comprises: • a DNase that comprises or consists of SEQ ID NO: 5;
  • amylase comprises SEQ ID NO: 30 with the mutations H183 * , G184 * , I405L, A421 H, A422P and A428T;
  • o the lipase comprises SEQ ID NO: 31 with the mutations D27R, G38A, D96E, D1 1 1A, G163K, T231 R, N233R, D254S and P256T;
  • o the mannanase comprises SEQ ID NO: 32;
  • o the pectate lyase comprises SEQ ID NO: 33;
  • the cellulase comprises SEQ ID NO: 34 or SEQ ID NO: 35.
  • the composition comprises:
  • a protease that comprises SEQ ID NO: 24 with the substitutions S9E, N42R, N74D, V199I, Q200L, Y203W, S253D, N255W and L256E;
  • o the amylase comprises SEQ ID NO: 29 with the mutations H 1 * , N54S, V56T, K72R, G109A, F1 13Q, R1 16Q, W167F, Q172G, A174S, G182 * , D183 * , G184T, N 195F, V206L, K391A, P473R and G476K; and o the cellulase comprises SEQ ID NO: 34.
  • the cleaning composition may optionally comprise one or more of any of the other cleaning enzymes described herein. Any of these compositions may thus comprise one or more of an RNase, a GH39 glycosyl hydrolase, a GHL13 glycosyl hydrolase or a hexosaminidase.
  • compositions comprising a DNase and a GH39 polypeptide
  • One aspect of the invention relates to a cleaning composition
  • a cleaning composition comprising at least a DNase and a GH39 glycosyl hydrolase as the cleaning enzymes. Exemplary embodiments of this aspect of the invention are described below.
  • the composition comprises: • a DNase that comprises or consists of SEQ ID NO: 1 , or which is a variant thereof having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity to SEQ ID NO: 1 ;
  • a GH39 polypeptide that comprises or consists of SEQ ID NO: 10, or which is a variant thereof having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity to SEQ ID NO: 10;
  • a protease selected from: a) a polypeptide that comprises or consists of SEQ ID NO: 24 or SEQ ID NO: 26, or a variant thereof having at least 80%, at least 85%, at least 90% or at least 95% sequence identity to SEQ ID NO: 24 or SEQ ID NO: 26; b) a polypeptide that comprises SEQ ID NO: 24 with the substitutions Y161A, R164S and A188P; c) a polypeptide that comprises SEQ ID NO: 24 with the substitutions S9E, N42R, N74D, V199I, Q200L, Y203W, S253D, N255W and L256E; and d) a polypeptide that comprises SEQ ID NO: 37; and
  • At least one enzyme selected from the group consisting of amylases, lipases, mannanases, pectate lyases and cellulases.
  • the composition comprises:
  • a DNase that comprises or consists of SEQ ID NO: 1 ;
  • a GH39 polypeptide that comprises or consists of SEQ ID NO: 10;
  • amylase comprises SEQ ID NO: 30 with the mutations H183 * , G184 * , I405L, A421 H, A422P and A428T;
  • o the lipase comprises SEQ ID NO: 31 with the mutations D27R, G38A, D96E, D11 1A, G163K, T231 R, N233R, D254S and P256T; o the mannanase comprises SEQ ID NO: 32;
  • o the pectate lyase comprises SEQ ID NO: 33;
  • the cellulase comprises SEQ ID NO: 34 or SEQ ID NO: 35.
  • the composition comprises:
  • a DNase that comprises or consists of SEQ ID NO: 1 ;
  • a GH39 polypeptide that comprises or consists of SEQ ID NO: 10;
  • a protease that comprises SEQ ID NO: 24 with the substitutions S9E, N42R, N74D, V199I, Q200L, Y203W, S253D, N255W and L256E;
  • amylases and cellulases • at least one enzyme selected from the group consisting of amylases and cellulases; wherein: o the amylase comprises SEQ ID NO: 29 with the mutations H 1 * , N54S, V56T, K72R, G109A, F113Q, R116Q, W167F, Q172G, A174S, G182 * , D183 * , G184T, N195F, V206L, K391A, P473R and G476K; and o the cellulase comprises SEQ ID NO: 34.
  • the composition comprises:
  • a DNase that comprises or consists of SEQ ID NO: 1 , or which is a variant thereof having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity to SEQ ID NO: 1 ;
  • a GH39 polypeptide that comprises or consists of SEQ ID NO: 11 , or which is a variant thereof having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity to SEQ ID NO: 1 1 ;
  • a protease selected from: a) a polypeptide that comprises or consists of SEQ ID NO: 24 or SEQ ID NO: 26, or a variant thereof having at least 80%, at least 85%, at least 90% or at least 95% sequence identity to SEQ ID NO: 24 or SEQ ID NO: 26; b) a polypeptide that comprises SEQ ID NO: 24 with the substitutions Y161A, R164S and A188P; c) a polypeptide that comprises SEQ ID NO: 24 with the substitutions S9E, N42R, N74D, V199I, Q200L, Y203W, S253D, N255W and L256E; and d) a polypeptide that comprises SEQ ID NO: 37; and
  • At least one enzyme selected from the group consisting of amylases, lipases, mannanases, pectate lyases and cellulases.
  • the composition comprises:
  • a DNase that comprises or consists of SEQ ID NO: 1 ;
  • a GH39 polypeptide that comprises or consists of SEQ ID NO: 11 ;
  • amylase comprises SEQ ID NO: 30 with the mutations H183 * , G184 * , I405L, A421 H, A422P and A428T;
  • o the lipase comprises SEQ ID NO: 31 with the mutations D27R, G38A, D96E, D11 1A, G163K, T231 R, N233R, D254S and P256T; o the mannanase comprises SEQ ID NO: 32;
  • o the pectate lyase comprises SEQ ID NO: 33;
  • the cellulase comprises SEQ ID NO: 34 or SEQ ID NO: 35.
  • the composition comprises: • a DNase that comprises or consists of SEQ ID NO: 1 ;
  • a GH39 polypeptide that comprises or consists of SEQ ID NO: 11 ;
  • a protease that comprises SEQ ID NO: 24 with the substitutions S9E, N42R, N74D, V199I, Q200L, Y203W, S253D, N255W and L256E;
  • o the amylase comprises SEQ ID NO: 29 with the mutations H 1 * , N54S, V56T, K72R, G109A, F113Q, R116Q, W167F, Q172G, A174S, G182 * , D183 * , G184T, N195F, V206L, K391A, P473R and G476K; and o the cellulase comprises SEQ ID NO: 34.
  • the composition comprises:
  • a DNase that comprises or consists of SEQ ID NO: 1 , or which is a variant thereof having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity to SEQ ID NO: 1 ;
  • a GH39 polypeptide that comprises or consists of SEQ ID NO: 12, or which is a variant thereof having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity to SEQ ID NO: 12;
  • a protease selected from: a) a polypeptide that comprises or consists of SEQ ID NO: 24 or SEQ ID NO: 26, or a variant thereof having at least 80%, at least 85%, at least 90% or at least 95% sequence identity to SEQ ID NO: 24 or SEQ ID NO: 26; b) a polypeptide that comprises SEQ ID NO: 24 with the substitutions Y161A, R164S and A188P; c) a polypeptide that comprises SEQ ID NO: 24 with the substitutions S9E, N42R, N74D, V199I, Q200L, Y203W, S253D, N255W and L256E; and d) a polypeptide that comprises SEQ ID NO: 37; and
  • At least one enzyme selected from the group consisting of amylases, lipases, mannanases, pectate lyases and cellulases.
  • the composition comprises:
  • a DNase that comprises or consists of SEQ ID NO: 1 ;
  • a GH39 polypeptide that comprises or consists of SEQ ID NO: 12;
  • o the amylase comprises SEQ ID NO: 30 with the mutations H183 * , G184 * , I405L, A421 H, A422P and A428T; o the lipase comprises SEQ ID NO: 31 with the mutations D27R, G38A, D96E, D11 1A, G163K, T231 R, N233R, D254S and P256T; o the mannanase comprises SEQ ID NO: 32;
  • o the pectate lyase comprises SEQ ID NO: 33;
  • the cellulase comprises SEQ ID NO: 34 or SEQ ID NO: 35.
  • the composition comprises:
  • a DNase that comprises or consists of SEQ ID NO: 1 ;
  • a GH39 polypeptide that comprises or consists of SEQ ID NO: 12;
  • a protease that comprises SEQ ID NO: 24 with the substitutions S9E, N42R, N74D, V199I, Q200L, Y203W, S253D, N255W and L256E;
  • o the amylase comprises SEQ ID NO: 29 with the mutations H 1 * , N54S, V56T, K72R, G109A, F113Q, R116Q, W167F, Q172G, A174S, G182 * , D183 * , G184T, N195F, V206L, K391A, P473R and G476K; and o the cellulase comprises SEQ ID NO: 34.
  • the composition comprises:
  • a DNase that comprises or consists of SEQ ID NO: 2, or which is a variant thereof having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity to SEQ ID NO: 2;
  • a GH39 polypeptide that comprises or consists of SEQ ID NO: 10, or which is a variant thereof having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity to SEQ ID NO: 10;
  • a protease selected from: a) a polypeptide that comprises or consists of SEQ ID NO: 24 or SEQ ID NO: 26, or a variant thereof having at least 80%, at least 85%, at least 90% or at least 95% sequence identity to SEQ ID NO: 24 or SEQ ID NO: 26; b) a polypeptide that comprises SEQ ID NO: 24 with the substitutions Y161A, R164S and A188P; c) a polypeptide that comprises SEQ ID NO: 24 with the substitutions S9E, N42R, N74D, V199I, Q200L, Y203W, S253D, N255W and L256E; and d) a polypeptide that comprises SEQ ID NO: 37; and
  • At least one enzyme selected from the group consisting of amylases, lipases, mannanases, pectate lyases and cellulases.
  • the composition comprises:
  • a GH39 polypeptide that comprises or consists of SEQ ID NO: 10
  • a protease that comprises SEQ ID NO: 24 with the substitutions Y161A, R164S and A188P, or that comprises SEQ ID NO: 37;
  • amylase comprises SEQ ID NO: 30 with the mutations H183 * , G184 * , I405L, A421 H, A422P and A428T;
  • o the lipase comprises SEQ ID NO: 31 with the mutations D27R, G38A, D96E, D11 1A, G163K, T231 R, N233R, D254S and P256T; o the mannanase comprises SEQ ID NO: 32;
  • o the pectate lyase comprises SEQ ID NO: 33;
  • the cellulase comprises SEQ ID NO: 34 or SEQ ID NO: 35.
  • the composition comprises:
  • a GH39 polypeptide that comprises or consists of SEQ ID NO: 10;
  • a protease that comprises SEQ ID NO: 24 with the substitutions S9E, N42R, N74D, V199I, Q200L, Y203W, S253D, N255W and L256E;
  • o the amylase comprises SEQ ID NO: 29 with the mutations H 1 * , N54S, V56T, K72R, G109A, F113Q, R116Q, W167F, Q172G, A174S, G182 * , D183 * , G184T, N195F, V206L, K391A, P473R and G476K; and o the cellulase comprises SEQ ID NO: 34.
  • the composition comprises:
  • a DNase that comprises or consists of SEQ ID NO: 2, or which is a variant thereof having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity to SEQ ID NO: 2;
  • a GH39 polypeptide that comprises or consists of SEQ ID NO: 11 , or which is a variant thereof having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity to SEQ ID NO: 1 1 ;
  • a protease selected from: a) a polypeptide that comprises or consists of SEQ ID NO: 24 or SEQ ID NO: 26, or a variant thereof having at least 80%, at least 85%, at least 90% or at least 95% sequence identity to SEQ ID NO: 24 or SEQ ID NO: 26; b) a polypeptide that comprises SEQ ID NO: 24 with the substitutions Y161A, R164S and A188P; c) a polypeptide that comprises SEQ ID NO: 24 with the substitutions S9E, N42R, N74D, V199I, Q200L, Y203W, S253D, N255W and L256E; and d) a polypeptide that comprises SEQ ID NO: 37; and
  • At least one enzyme selected from the group consisting of amylases, lipases, mannanases, pectate lyases and cellulases.
  • the composition comprises:
  • a GH39 polypeptide that comprises or consists of SEQ ID NO: 11 ;
  • amylase comprises SEQ ID NO: 30 with the mutations H183 * , G184 * , I405L, A421 H, A422P and A428T;
  • o the lipase comprises SEQ ID NO: 31 with the mutations D27R, G38A, D96E, D11 1A, G163K, T231 R, N233R, D254S and P256T; o the mannanase comprises SEQ ID NO: 32;
  • o the pectate lyase comprises SEQ ID NO: 33;
  • the cellulase comprises SEQ ID NO: 34 or SEQ ID NO: 35.
  • the composition comprises:
  • a GH39 polypeptide that comprises or consists of SEQ ID NO: 11 ;
  • a protease that comprises SEQ ID NO: 24 with the substitutions S9E, N42R, N74D, V199I, Q200L, Y203W, S253D, N255W and L256E;
  • o the amylase comprises SEQ ID NO: 29 with the mutations H 1 * , N54S, V56T, K72R, G109A, F113Q, R116Q, W167F, Q172G, A174S, G182 * , D183 * , G184T, N195F, V206L, K391A, P473R and G476K; and o the cellulase comprises SEQ ID NO: 34.
  • the composition comprises:
  • a DNase that comprises or consists of SEQ ID NO: 2, or which is a variant thereof having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity to SEQ ID NO: 2;
  • a GH39 polypeptide that comprises or consists of SEQ ID NO: 12, or which is a variant thereof having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity to SEQ ID NO: 12;
  • a protease selected from: a) a polypeptide that comprises or consists of SEQ ID NO: 24 or SEQ ID NO: 26, or a variant thereof having at least 80%, at least 85%, at least 90% or at least 95% sequence identity to SEQ ID NO: 24 or SEQ ID NO: 26; b) a polypeptide that comprises SEQ ID NO: 24 with the substitutions Y161A, R164S and A188P; c) a polypeptide that comprises SEQ ID NO: 24 with the substitutions S9E, N42R, N74D, V199I, Q200L, Y203W, S253D, N255W and L256E; and d) a polypeptide that comprises SEQ ID NO: 37; and
  • At least one enzyme selected from the group consisting of amylases, lipases, mannanases, pectate lyases and cellulases.
  • the composition comprises:
  • a GH39 polypeptide that comprises or consists of SEQ ID NO: 12;
  • amylase comprises SEQ ID NO: 30 with the mutations H183 * , G184 * , I405L, A421 H, A422P and A428T;
  • o the lipase comprises SEQ ID NO: 31 with the mutations D27R, G38A, D96E, D11 1A, G163K, T231 R, N233R, D254S and P256T; o the mannanase comprises SEQ ID NO: 32;
  • o the pectate lyase comprises SEQ ID NO: 33;
  • the cellulase comprises SEQ ID NO: 34 or SEQ ID NO: 35.
  • the composition comprises:
  • a GH39 polypeptide that comprises or consists of SEQ ID NO: 12;
  • a protease that comprises SEQ ID NO: 24 with the substitutions S9E, N42R, N74D, V199I, Q200L, Y203W, S253D, N255W and L256E;
  • the amylase comprises SEQ ID NO: 29 with the mutations H 1 * , N54S, V56T, K72R, G109A, F113Q, R116Q, W167F, Q172G, A174S, G182 * , D183 * , G184T, N195F, V206L, K391A, P473R and G476K; and o the cellulase comprises SEQ ID NO: 34.
  • the composition comprises:
  • a DNase that comprises or consists of SEQ ID NO: 3, or which is a variant thereof having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity to SEQ ID NO: 3;
  • a GH39 polypeptide that comprises or consists of SEQ ID NO: 10, or which is a variant thereof having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity to SEQ ID NO: 10;
  • a protease selected from: a) a polypeptide that comprises or consists of SEQ ID NO: 24 or SEQ ID NO: 26, or a variant thereof having at least 80%, at least 85%, at least 90% or at least 95% sequence identity to SEQ ID NO: 24 or SEQ ID NO: 26; b) a polypeptide that comprises SEQ ID NO: 24 with the substitutions Y161A, R164S and A188P; c) a polypeptide that comprises SEQ ID NO: 24 with the substitutions S9E, N42R, N74D, V199I, Q200L, Y203W, S253D, N255W and L256E; and d) a polypeptide that comprises SEQ ID NO: 37; and
  • At least one enzyme selected from the group consisting of amylases, lipases, mannanases, pectate lyases and cellulases.
  • the composition comprises:
  • a GH39 polypeptide that comprises or consists of SEQ ID NO: 10;
  • amylase comprises SEQ ID NO: 30 with the mutations H183 * , G184 * , I405L, A421 H, A422P and A428T;
  • o the lipase comprises SEQ ID NO: 31 with the mutations D27R, G38A, D96E, D11 1A, G163K, T231 R, N233R, D254S and P256T; o the mannanase comprises SEQ ID NO: 32;
  • o the pectate lyase comprises SEQ ID NO: 33;
  • the cellulase comprises SEQ ID NO: 34 or SEQ ID NO: 35.
  • the composition comprises:
  • a GH39 polypeptide that comprises or consists of SEQ ID NO: 10;
  • a protease that comprises SEQ ID NO: 24 with the substitutions S9E, N42R, N74D, V199I, Q200L, Y203W, S253D, N255W and L256E; and • at least one enzyme selected from the group consisting of amylases and cellulases; wherein:
  • o the amylase comprises SEQ ID NO: 29 with the mutations H 1 * , N54S, V56T, K72R, G109A, F113Q, R116Q, W167F, Q172G, A174S, G182 * , D183 * , G184T, N195F, V206L, K391A, P473R and G476K; and o the cellulase comprises SEQ ID NO: 34.
  • the composition comprises:
  • a DNase that comprises or consists of SEQ ID NO: 3, or which is a variant thereof having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity to SEQ ID NO: 3;
  • a GH39 polypeptide that comprises or consists of SEQ ID NO: 11 , or which is a variant thereof having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity to SEQ ID NO: 1 1 ;
  • a protease selected from: a) a polypeptide that comprises or consists of SEQ ID NO: 24 or SEQ ID NO: 26, or a variant thereof having at least 80%, at least 85%, at least 90% or at least 95% sequence identity to SEQ ID NO: 24 or SEQ ID NO: 26; b) a polypeptide that comprises SEQ ID NO: 24 with the substitutions Y161A, R164S and A188P; c) a polypeptide that comprises SEQ ID NO: 24 with the substitutions S9E, N42R, N74D, V199I, Q200L, Y203W, S253D, N255W and L256E; and d) a polypeptide that comprises SEQ ID NO: 37; and
  • At least one enzyme selected from the group consisting of amylases, lipases, mannanases, pectate lyases and cellulases.
  • the composition comprises:
  • a GH39 polypeptide that comprises or consists of SEQ ID NO: 11 ;
  • amylase comprises SEQ ID NO: 30 with the mutations H183 * , G184 * , I405L, A421 H, A422P and A428T;
  • o the lipase comprises SEQ ID NO: 31 with the mutations D27R, G38A, D96E, D11 1A, G163K, T231 R, N233R, D254S and P256T; o the mannanase comprises SEQ ID NO: 32;
  • o the pectate lyase comprises SEQ ID NO: 33; and o the cellulase comprises SEQ ID NO: 34 or SEQ ID NO: 35.
  • the composition comprises:
  • a GH39 polypeptide that comprises or consists of SEQ ID NO: 11 ;
  • a protease that comprises SEQ ID NO: 24 with the substitutions S9E, N42R, N74D, V199I, Q200L, Y203W, S253D, N255W and L256E;
  • o the amylase comprises SEQ ID NO: 29 with the mutations H 1 * , N54S, V56T, K72R, G109A, F113Q, R116Q, W167F, Q172G, A174S, G182 * , D183 * , G184T, N195F, V206L, K391A, P473R and G476K; and o the cellulase comprises SEQ ID NO: 34.
  • the composition comprises:
  • a DNase that comprises or consists of SEQ ID NO: 3, or which is a variant thereof having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity to SEQ ID NO: 3;
  • a GH39 polypeptide that comprises or consists of SEQ ID NO: 12, or which is a variant thereof having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity to SEQ ID NO: 12;
  • a protease selected from: a) a polypeptide that comprises or consists of SEQ ID NO: 24 or SEQ ID NO: 26, or a variant thereof having at least 80%, at least 85%, at least 90% or at least 95% sequence identity to SEQ ID NO: 24 or SEQ ID NO: 26; b) a polypeptide that comprises SEQ ID NO: 24 with the substitutions Y161A, R164S and A188P; c) a polypeptide that comprises SEQ ID NO: 24 with the substitutions S9E, N42R, N74D, V199I, Q200L, Y203W, S253D, N255W and L256E; and d) a polypeptide that comprises SEQ ID NO: 37; and
  • At least one enzyme selected from the group consisting of amylases, lipases, mannanases, pectate lyases and cellulases.
  • the composition comprises:
  • a GH39 polypeptide that comprises or consists of SEQ ID NO: 12;
  • amylases • at least one enzyme selected from the group consisting of amylases, lipases, mannanases, pectate lyases and cellulases; wherein: o the amylase comprises SEQ ID NO: 30 with the mutations H183 * , G184 * , I405L, A421 H, A422P and A428T;
  • o the lipase comprises SEQ ID NO: 31 with the mutations D27R, G38A, D96E, D11 1A, G163K, T231 R, N233R, D254S and P256T; o the mannanase comprises SEQ ID NO: 32;
  • o the pectate lyase comprises SEQ ID NO: 33;
  • the cellulase comprises SEQ ID NO: 34 or SEQ ID NO: 35.
  • the composition comprises:
  • a GH39 polypeptide that comprises or consists of SEQ ID NO: 12;
  • a protease that comprises SEQ ID NO: 24 with the substitutions S9E, N42R, N74D, V199I, Q200L, Y203W, S253D, N255W and L256E;
  • o the amylase comprises SEQ ID NO: 29 with the mutations H 1 * , N54S, V56T, K72R, G109A, F113Q, R116Q, W167F, Q172G, A174S, G182 * , D183 * , G184T, N195F, V206L, K391A, P473R and G476K; and o the cellulase comprises SEQ ID NO: 34.
  • the composition comprises:
  • a DNase that comprises or consists of SEQ ID NO: 4, or which is a variant thereof having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity to SEQ ID NO: 4;
  • a GH39 polypeptide that comprises or consists of SEQ ID NO: 10, or which is a variant thereof having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity to SEQ ID NO: 10;
  • a protease selected from: a) a polypeptide that comprises or consists of SEQ ID NO: 24 or SEQ ID NO: 26, or a variant thereof having at least 80%, at least 85%, at least 90% or at least 95% sequence identity to SEQ ID NO: 24 or SEQ ID NO: 26; b) a polypeptide that comprises SEQ ID NO: 24 with the substitutions Y161A, R164S and A188P; c) a polypeptide that comprises SEQ ID NO: 24 with the substitutions S9E, N42R, N74D, V199I, Q200L, Y203W, S253D, N255W and L256E; and d) a polypeptide that comprises SEQ ID NO: 37; and
  • At least one enzyme selected from the group consisting of amylases, lipases, mannanases, pectate lyases and cellulases.
  • the composition comprises: • a DNase that comprises or consists of SEQ ID NO: 4;
  • a GH39 polypeptide that comprises or consists of SEQ ID NO: 10;
  • amylase comprises SEQ ID NO: 30 with the mutations H183 * , G184 * , I405L, A421 H, A422P and A428T;
  • o the lipase comprises SEQ ID NO: 31 with the mutations D27R, G38A, D96E, D11 1A, G163K, T231 R, N233R, D254S and P256T; o the mannanase comprises SEQ ID NO: 32;
  • o the pectate lyase comprises SEQ ID NO: 33;
  • the cellulase comprises SEQ ID NO: 34 or SEQ ID NO: 35.
  • the composition comprises:
  • a GH39 polypeptide that comprises or consists of SEQ ID NO: 10;
  • a protease that comprises SEQ ID NO: 24 with the substitutions S9E, N42R, N74D, V199I, Q200L, Y203W, S253D, N255W and L256E;
  • o the amylase comprises SEQ ID NO: 29 with the mutations H 1 * , N54S, V56T, K72R, G109A, F113Q, R116Q, W167F, Q172G, A174S, G182 * , D183 * , G184T, N195F, V206L, K391A, P473R and G476K; and o the cellulase comprises SEQ ID NO: 34.
  • the composition comprises:
  • a DNase that comprises or consists of SEQ ID NO: 4, or which is a variant thereof having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity to SEQ ID NO: 4;
  • a GH39 polypeptide that comprises or consists of SEQ ID NO: 11 , or which is a variant thereof having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity to SEQ ID NO: 1 1 ;
  • a protease selected from: a) a polypeptide that comprises or consists of SEQ ID NO: 24 or SEQ ID NO: 26, or a variant thereof having at least 80%, at least 85%, at least 90% or at least 95% sequence identity to SEQ ID NO: 24 or SEQ ID NO: 26; b) a polypeptide that comprises SEQ ID NO: 24 with the substitutions Y161A, R164S and A188P; c) a polypeptide that comprises SEQ ID NO: 24 with the substitutions S9E, N42R, N74D, V199I, Q200L, Y203W, S253D, N255W and L256E; and d) a polypeptide that comprises SEQ ID NO: 37; and
  • At least one enzyme selected from the group consisting of amylases, lipases, mannanases, pectate lyases and cellulases.
  • the composition comprises:
  • a GH39 polypeptide that comprises or consists of SEQ ID NO: 11 ;
  • amylase comprises SEQ ID NO: 30 with the mutations H183 * , G184 * , I405L, A421 H, A422P and A428T;
  • o the lipase comprises SEQ ID NO: 31 with the mutations D27R, G38A, D96E, D11 1A, G163K, T231 R, N233R, D254S and P256T; o the mannanase comprises SEQ ID NO: 32;
  • o the pectate lyase comprises SEQ ID NO: 33;
  • the cellulase comprises SEQ ID NO: 34 or SEQ ID NO: 35.
  • the composition comprises:
  • a GH39 polypeptide that comprises or consists of SEQ ID NO: 11 ;
  • a protease that comprises SEQ ID NO: 24 with the substitutions S9E, N42R, N74D, V199I, Q200L, Y203W, S253D, N255W and L256E;
  • o the amylase comprises SEQ ID NO: 29 with the mutations H 1 * , N54S, V56T, K72R, G109A, F113Q, R116Q, W167F, Q172G, A174S, G182 * , D183 * , G184T, N195F, V206L, K391A, P473R and G476K; and o the cellulase comprises SEQ ID NO: 34.
  • the composition comprises:
  • a DNase that comprises or consists of SEQ ID NO: 4, or which is a variant thereof having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity to SEQ ID NO: 4;
  • a GH39 polypeptide that comprises or consists of SEQ ID NO: 12, or which is a variant thereof having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity to SEQ ID NO: 12;
  • a protease selected from: a) a polypeptide that comprises or consists of SEQ ID NO: 24 or SEQ ID NO: 26, or a variant thereof having at least 80%, at least 85%, at least 90% or at least 95% sequence identity to SEQ ID NO: 24 or SEQ ID NO: 26; b) a polypeptide that comprises SEQ ID NO: 24 with the substitutions Y161A, R164S and A188P; c) a polypeptide that comprises SEQ ID NO: 24 with the substitutions S9E, N42R, N74D, V199I, Q200L, Y203W, S253D, N255W and L256E; and d) a polypeptide that comprises SEQ ID NO: 37; and
  • At least one enzyme selected from the group consisting of amylases, lipases, mannanases, pectate lyases and cellulases.
  • the composition comprises:
  • a GH39 polypeptide that comprises or consists of SEQ ID NO: 12;
  • amylase comprises SEQ ID NO: 30 with the mutations H183 * , G184 * , I405L, A421 H, A422P and A428T;
  • o the lipase comprises SEQ ID NO: 31 with the mutations D27R, G38A, D96E, D11 1A, G163K, T231 R, N233R, D254S and P256T; o the mannanase comprises SEQ ID NO: 32;
  • o the pectate lyase comprises SEQ ID NO: 33;
  • the cellulase comprises SEQ ID NO: 34 or SEQ ID NO: 35.
  • the composition comprises:
  • a GH39 polypeptide that comprises or consists of SEQ ID NO: 12;
  • a protease that comprises SEQ ID NO: 24 with the substitutions S9E, N42R, N74D, V199I, Q200L, Y203W, S253D, N255W and L256E;
  • the amylase comprises SEQ ID NO: 29 with the mutations H 1 * , N54S, V56T, K72R, G109A, F113Q, R116Q, W167F, Q172G, A174S, G182 * , D183 * , G184T, N195F, V206L, K391A, P473R and G476K; and o the cellulase comprises SEQ ID NO: 34.
  • the composition comprises:
  • a DNase that comprises or consists of SEQ ID NO: 5, or which is a variant thereof having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity to SEQ ID NO: 5;
  • a GH39 polypeptide that comprises or consists of SEQ ID NO: 10, or which is a variant thereof having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity to SEQ ID NO: 10;
  • a protease selected from: a) a polypeptide that comprises or consists of SEQ ID NO: 24 or SEQ ID NO: 26, or a variant thereof having at least 80%, at least 85%, at least 90% or at least 95% sequence identity to SEQ ID NO: 24 or SEQ ID NO: 26; b) a polypeptide that comprises SEQ ID NO: 24 with the substitutions Y161A, R164S and A188P; c) a polypeptide that comprises SEQ ID NO: 24 with the substitutions S9E, N42R, N74D, V199I, Q200L, Y203W, S253D, N255W and L256E; and d) a polypeptide that comprises SEQ ID NO: 37; and
  • At least one enzyme selected from the group consisting of amylases, lipases, mannanases, pectate lyases and cellulases.
  • the composition comprises:
  • a GH39 polypeptide that comprises or consists of SEQ ID NO: 10;
  • amylase comprises SEQ ID NO: 30 with the mutations H183 * , G184 * , I405L, A421 H, A422P and A428T;
  • o the lipase comprises SEQ ID NO: 31 with the mutations D27R, G38A, D96E, D11 1A, G163K, T231 R, N233R, D254S and P256T; o the mannanase comprises SEQ ID NO: 32;
  • o the pectate lyase comprises SEQ ID NO: 33;
  • the cellulase comprises SEQ ID NO: 34 or SEQ ID NO: 35.
  • the composition comprises:
  • a GH39 polypeptide that comprises or consists of SEQ ID NO: 10;
  • a protease that comprises SEQ ID NO: 24 with the substitutions S9E, N42R, N74D, V199I, Q200L, Y203W, S253D, N255W and L256E; and • at least one enzyme selected from the group consisting of amylases and cellulases; wherein:
  • o the amylase comprises SEQ ID NO: 29 with the mutations H 1 * , N54S, V56T, K72R, G109A, F113Q, R116Q, W167F, Q172G, A174S, G182 * , D183 * , G184T, N195F, V206L, K391A, P473R and G476K; and o the cellulase comprises SEQ ID NO: 34.
  • the composition comprises:
  • a DNase that comprises or consists of SEQ ID NO: 5, or which is a variant thereof having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity to SEQ ID NO: 5;
  • a GH39 polypeptide that comprises or consists of SEQ ID NO: 11 , or which is a variant thereof having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity to SEQ ID NO: 1 1 ;
  • a protease selected from: a) a polypeptide that comprises or consists of SEQ ID NO: 24 or SEQ ID NO: 26, or a variant thereof having at least 80%, at least 85%, at least 90% or at least 95% sequence identity to SEQ ID NO: 24 or SEQ ID NO: 26; b) a polypeptide that comprises SEQ ID NO: 24 with the substitutions Y161A, R164S and A188P; c) a polypeptide that comprises SEQ ID NO: 24 with the substitutions S9E, N42R, N74D, V199I, Q200L, Y203W, S253D, N255W and L256E; and d) a polypeptide that comprises SEQ ID NO: 37; and
  • At least one enzyme selected from the group consisting of amylases, lipases, mannanases, pectate lyases and cellulases.
  • the composition comprises:
  • a GH39 polypeptide that comprises or consists of SEQ ID NO: 11 ;
  • amylase comprises SEQ ID NO: 30 with the mutations H183 * , G184 * , I405L, A421 H, A422P and A428T;
  • o the lipase comprises SEQ ID NO: 31 with the mutations D27R, G38A, D96E, D11 1A, G163K, T231 R, N233R, D254S and P256T; o the mannanase comprises SEQ ID NO: 32;
  • o the pectate lyase comprises SEQ ID NO: 33; and o the cellulase comprises SEQ ID NO: 34 or SEQ ID NO: 35.
  • the composition comprises:
  • a GH39 polypeptide that comprises or consists of SEQ ID NO: 11 ;
  • a protease that comprises SEQ ID NO: 24 with the substitutions S9E, N42R, N74D, V199I, Q200L, Y203W, S253D, N255W and L256E;
  • o the amylase comprises SEQ ID NO: 29 with the mutations H 1 * , N54S, V56T, K72R, G109A, F113Q, R116Q, W167F, Q172G, A174S, G182 * , D183 * , G184T, N195F, V206L, K391A, P473R and G476K; and o the cellulase comprises SEQ ID NO: 34.
  • the composition comprises:
  • a DNase that comprises or consists of SEQ ID NO: 5, or which is a variant thereof having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity to SEQ ID NO: 5;
  • a GH39 polypeptide that comprises or consists of SEQ ID NO: 12, or which is a variant thereof having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity to SEQ ID NO: 12;
  • a protease selected from: a) a polypeptide that comprises or consists of SEQ ID NO: 24 or SEQ ID NO: 26, or a variant thereof having at least 80%, at least 85%, at least 90% or at least 95% sequence identity to SEQ ID NO: 24 or SEQ ID NO: 26; b) a polypeptide that comprises SEQ ID NO: 24 with the substitutions Y161A, R164S and A188P; c) a polypeptide that comprises SEQ ID NO: 24 with the substitutions S9E, N42R, N74D, V199I, Q200L, Y203W, S253D, N255W and L256E; and d) a polypeptide that comprises SEQ ID NO: 37; and
  • At least one enzyme selected from the group consisting of amylases, lipases, mannanases, pectate lyases and cellulases.
  • the composition comprises:
  • a GH39 polypeptide that comprises or consists of SEQ ID NO: 12;
  • amylases • at least one enzyme selected from the group consisting of amylases, lipases, mannanases, pectate lyases and cellulases; wherein: o the amylase comprises SEQ ID NO: 30 with the mutations H183 * , G184 * , I405L, A421 H, A422P and A428T;
  • o the lipase comprises SEQ ID NO: 31 with the mutations D27R, G38A, D96E, D1 1 1A, G163K, T231 R, N233R, D254S and P256T;
  • o the mannanase comprises SEQ ID NO: 32;
  • o the pectate lyase comprises SEQ ID NO: 33;
  • the cellulase comprises SEQ ID NO: 34 or SEQ ID NO: 35.
  • the composition comprises:
  • a GH39 polypeptide that comprises or consists of SEQ ID NO: 12;
  • a protease that comprises SEQ ID NO: 24 with the substitutions S9E, N42R, N74D, V199I, Q200L, Y203W, S253D, N255W and L256E;
  • o the amylase comprises SEQ ID NO: 29 with the mutations H 1 * , N54S, V56T, K72R, G109A, F1 13Q, R1 16Q, W167F, Q172G, A174S, G182 * , D183 * , G184T, N 195F, V206L, K391A, P473R and G476K; and o the cellulase comprises SEQ ID NO: 34.
  • the cleaning composition may optionally comprise one or more of any of the other cleaning enzymes described herein. Any of these compositions may thus comprise one or more of an RNase, a Glyco_hydro_1 14 glucosyl hydrolase, a GHL13 glycosyl hydrolase or a hexosaminidase.
  • compositions comprising a DNase and a GHL13 polypeptide
  • One aspect of the invention relates to a cleaning composition
  • a cleaning composition comprising at least a DNase and a GHL13 glycosyl hydrolase as the cleaning enzymes. Exemplary embodiments of this aspect of the invention are described below.
  • the composition comprises:
  • a DNase that comprises or consists of SEQ ID NO: 1 , or which is a variant thereof having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity to SEQ ID NO: 1 ;
  • GHL13 polypeptide that comprises or consists of SEQ ID NO: 13, or which is a variant thereof having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity to SEQ ID NO: 13;
  • a protease selected from: a) a polypeptide that comprises or consists of SEQ ID NO: 24 or SEQ ID NO: 26, or a variant thereof having at least 80%, at least 85%, at least 90% or at least 95% sequence identity to SEQ ID NO: 24 or SEQ ID NO: 26; b) a polypeptide that comprises SEQ ID NO: 24 with the substitutions Y161A, R164S and A188P; c) a polypeptide that comprises SEQ ID NO: 24 with the substitutions S9E, N42R, N74D, V199I, Q200L, Y203W, S253D, N255W and L256E; and d) a polypeptide that comprises SEQ ID NO: 37; and
  • At least one enzyme selected from the group consisting of amylases, lipases, mannanases, pectate lyases and cellulases.
  • the composition comprises:
  • a DNase that comprises or consists of SEQ ID NO: 1 ;
  • amylase comprises SEQ ID NO: 30 with the mutations H183 * , G184 * , I405L, A421 H, A422P and A428T;
  • o the lipase comprises SEQ ID NO: 31 with the mutations D27R, G38A, D96E, D11 1A, G163K, T231 R, N233R, D254S and P256T; o the mannanase comprises SEQ ID NO: 32;
  • o the pectate lyase comprises SEQ ID NO: 33;
  • the cellulase comprises SEQ ID NO: 34 or SEQ ID NO: 35.
  • the composition comprises:
  • a DNase that comprises or consists of SEQ ID NO: 1 ;
  • a protease that comprises SEQ ID NO: 24 with the substitutions S9E, N42R, N74D, V199I, Q200L, Y203W, S253D, N255W and L256E;
  • the amylase comprises SEQ ID NO: 29 with the mutations H 1 * , N54S, V56T, K72R, G109A, F113Q, R116Q, W167F, Q172G, A174S, G182 * , D183 * , G184T, N195F, V206L, K391A, P473R and G476K; and o the cellulase comprises SEQ ID NO: 34.
  • the composition comprises:
  • a DNase that comprises or consists of SEQ ID NO: 1 , or which is a variant thereof having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity to SEQ ID NO: 1 ;
  • a GHL13 polypeptide that comprises or consists of SEQ ID NO: 14, or which is a variant thereof having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity to SEQ ID NO: 14;
  • a protease selected from: a) a polypeptide that comprises or consists of SEQ ID NO: 24 or SEQ ID NO: 26, or a variant thereof having at least 80%, at least 85%, at least 90% or at least 95% sequence identity to SEQ ID NO: 24 or SEQ ID NO: 26; b) a polypeptide that comprises SEQ ID NO: 24 with the substitutions Y161A, R164S and A188P; c) a polypeptide that comprises SEQ ID NO: 24 with the substitutions S9E, N42R, N74D, V199I, Q200L, Y203W, S253D, N255W and L256E; and d) a polypeptide that comprises SEQ ID NO: 37; and
  • At least one enzyme selected from the group consisting of amylases, lipases, mannanases, pectate lyases and cellulases.
  • the composition comprises:
  • a DNase that comprises or consists of SEQ ID NO: 1 ;
  • amylase comprises SEQ ID NO: 30 with the mutations H183 * , G184 * , I405L, A421 H, A422P and A428T;
  • o the lipase comprises SEQ ID NO: 31 with the mutations D27R, G38A, D96E, D11 1A, G163K, T231 R, N233R, D254S and P256T; o the mannanase comprises SEQ ID NO: 32;
  • o the pectate lyase comprises SEQ ID NO: 33;
  • the cellulase comprises SEQ ID NO: 34 or SEQ ID NO: 35.
  • the composition comprises:
  • a DNase that comprises or consists of SEQ ID NO: 1 ;
  • a protease that comprises SEQ ID NO: 24 with the substitutions S9E, N42R, N74D, V199I, Q200L, Y203W, S253D, N255W and L256E; and • at least one enzyme selected from the group consisting of amylases and cellulases; wherein:
  • o the amylase comprises SEQ ID NO: 29 with the mutations H 1 * , N54S, V56T, K72R, G109A, F113Q, R116Q, W167F, Q172G, A174S, G182 * , D183 * , G184T, N195F, V206L, K391A, P473R and G476K; and o the cellulase comprises SEQ ID NO: 34.
  • the composition comprises:
  • a DNase that comprises or consists of SEQ ID NO: 1 , or which is a variant thereof having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity to SEQ ID NO: 1 ;
  • a GHL13 polypeptide that comprises or consists of SEQ ID NO: 15, or which is a variant thereof having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity to SEQ ID NO: 15;
  • a protease selected from: a) a polypeptide that comprises or consists of SEQ ID NO: 24 or SEQ ID NO: 26, or a variant thereof having at least 80%, at least 85%, at least 90% or at least 95% sequence identity to SEQ ID NO: 24 or SEQ ID NO: 26; b) a polypeptide that comprises SEQ ID NO: 24 with the substitutions Y161A, R164S and A188P; c) a polypeptide that comprises SEQ ID NO: 24 with the substitutions S9E, N42R, N74D, V199I, Q200L, Y203W, S253D, N255W and L256E; and d) a polypeptide that comprises SEQ ID NO: 37; and
  • At least one enzyme selected from the group consisting of amylases, lipases, mannanases, pectate lyases and cellulases.
  • the composition comprises:
  • a DNase that comprises or consists of SEQ ID NO: 1 ;
  • amylase comprises SEQ ID NO: 30 with the mutations H183 * , G184 * , I405L, A421 H, A422P and A428T;
  • o the lipase comprises SEQ ID NO: 31 with the mutations D27R, G38A, D96E, D11 1A, G163K, T231 R, N233R, D254S and P256T; o the mannanase comprises SEQ ID NO: 32;
  • o the pectate lyase comprises SEQ ID NO: 33; and o the cellulase comprises SEQ ID NO: 34 or SEQ ID NO: 35.
  • the composition comprises:

Abstract

The present invention relates to a cleaning composition comprising at least two cleaning enzymes selected from the group consisting of nucleases, hexosaminidases and glycosyl hydrolases, and at least two detergent enzymes selected from the group consisting of proteases, amylases, lipases, mannanases, pectate lyases and cellulases.

Description

CLEANING COMPOSITIONS
Reference to a Sequence Listing
This application contains a Sequence Listing in computer readable form, which is incorporated herein by reference.
BACKGROUND OF THE INVENTION Field of the Invention
The present invention relates to cleaning compositions comprising a mix of enzymes. The invention further relates to use of compositions comprising such enzymes in cleaning processes and/or for deep cleaning of biofilm soiling, and methods for removal or reduction of biofilm related soiling.
Description of the Related Art
Enzymes have been used in detergents for decades. Usually a cocktail of various enzymes is added to detergent compositions. The enzyme cocktail often comprises various enzymes, wherein each enzyme targets a specific substrate, e.g. amylases are active towards starch stains, proteases towards protein stains and so forth. Textile surface and hard surfaces, such as dishes or the inner space of a laundry machine enduring a number of wash cycles, become soiled with many different types of soiling which may compose of proteins, grease, starch etc. One type of soiling may be organic matter, such as biofilm, extracellular polymeric substances (EPS), etc. Organic matter comprises different molecules such as polysaccharides, extracellular DNA (eDNA) and proteins. Some organic matter forms an extracellular polymeric matrix, which may be sticky or gluing, and which when present on textiles attracts soils and may cause redeposition or backstaining of soils, resulting in greying of the textile. Additionally, organic matter such as biofilms often cause malodor, as various malodor molecules can be adhered by the polysaccharides, extracellular eDNA and proteins in the complex extracellular matrix and be slowly released so as to result in noticeable malodor.
Although there have been certain disclosures of the use of e.g. polypeptides having DNase activity for reducing or removing a biofilm component from a textile item, there is still a need for cleaning compositions for“deep cleaning” that can effectively prevent, reduce or remove components of organic soiling. The present invention provides such compositions. SUMMARY OF THE INVENTION
The cleaning compositions of the present invention are useful in cleaning compositions and are effective in deep cleaning of surfaces such as fabrics, for example for reducing or removing biofilm. Biofilm is an extracellular matrix produced by various microorganisms that is typically composed of polysaccharides, extracellular RNA, DNA and proteins. The cleaning compositions of the invention are also useful for prevention, reduction or removal of malodor, for prevention or reduction of redeposition of soils, and for improving whiteness.
In a first aspect, the present invention thus relates to a cleaning composition comprising at least two cleaning enzymes selected from the group consisting of nucleases, hexosaminidases and glycosyl hydrolases and at least two detergent enzymes selected from the group consisting of proteases, amylases, lipases, mannanases, pectate lyases and cellulases. The nuclease is in particular a DNase or an RNase, and the glycosyl hydrolase is in particular a Glyco_hydro_1 14, GH39 or GHL13 glycosyl hydrolase.
In addition, the invention relates to use of the cleaning composition for cleaning an item such as a textile, for example for preventing, reducing or removing biofilm and/or body secretions such as dead cells, sebum or sweat from an item, and for a method of cleaning an item such as a textile with the cleaning composition.
Other aspects and particular embodiments of the invention will be apparent from the detailed description and the claims.
Overview of sequences
SEQ ID NO: 1 mature DNase polypeptide obtained from Bacillus cibi
SEQ ID NO: 2 mature DNase polypeptide obtained from Bacillus licheniformis
SEQ ID NO: 3 mature DNase polypeptide obtained from Bacillus subtilis
SEQ ID NO: 4 mature DNase polypeptide obtained from Aspergillus oryzae
SEQ ID NO: 5 mature DNase polypeptide obtained from Trichoderma harzianum
SEQ ID NO: 6 artificial Glyco_hydro_1 14 polypeptide
SEQ ID NO: 7 mature Glyco_hydro_1 14 polypeptide obtained from Burkholderia sp.
SEQ ID NO: 8 mature Glyco_hydro_1 14 polypeptide obtained from Myxococcus macrosporus SEQ ID NO: 9 mature Glyco_hydro_1 14 polypeptide obtained from Pseudomonas sp.
SEQ ID NO: 10 mature GH39 polypeptide obtained from Pseudomonas fluorescens
SEQ ID NO: 1 1 mature GH39 polypeptide obtained from Pseudomonas sp.
SEQ ID NO: 12 mature GH39 polypeptide obtained from Pseudomonas aeruginosa PA01 SEQ ID NO: 13 mature GHL13 polypeptide obtained from Pseudomonas meridiana
SEQ ID NO: 14 mature GHL13 polypeptide obtained from Escherichia coli
SEQ ID NO: 15 mature GHL13 polypeptide obtained from Silvimonas terrae
SEQ ID NO: 16 mature RNase polypeptide obtained from Erwinia persicina SEQ ID NO: 17 mature RNase polypeptide obtained from Paenibacillus sp.
SEQ ID NO: 18 mature RNase polypeptide obtained from Fusarium solani
SEQ ID NO: 19 mature hexosaminidase polypeptide obtained from Terribacillus saccharophilus
SEQ ID NO: 20 mature hexosaminidase polypeptide obtained from Terribacillus saccharophilus
SEQ ID NO: 21 mature hexosaminidase polypeptide obtained from Terribacillus saccharophilus
SEQ ID NO: 22 mature hexosaminidase polypeptide obtained from Aggregatibacter actinomycetemcomitans
SEQ ID NO: 23 mature hexosaminidase polypeptide obtained from Actinobacillus equuli subsp. equuli
SEQ ID NO: 24 mature protease polypeptide obtained from Bacillus lentus
SEQ ID NO: 25 mature protease polypeptide obtained from Bacillus amyloliquefaciens
SEQ ID NO: 26 mature protease polypeptide obtained from Bacillus sp. TY145
SEQ ID NO: 27 mature amylase polypeptide obtained from Bacillus sp.
SEQ ID NO: 28 mature amylase polypeptide obtained from Bacillus sp.
SEQ ID NO: 29 artificial amylase polypeptide
SEQ ID NO: 30 artificial amylase polypeptide
SEQ ID NO: 31 mature lipase polypeptide obtained from Thermomyces lanuginosus
SEQ ID NO: 32 mature mannanase polypeptide obtained from Bacillus bogoriensis
SEQ ID NO: 33 artificial pectate lyase polypeptide
SEQ ID NO: 34 mature cellulase polypeptide obtained from Bacillus subtilis
SEQ ID NO: 35 artificial cellulase polypeptide
SEQ ID NO: 36 artificial xyloglucanase polypeptide
SEQ ID NO: 37 artificial protease polypeptide
Definitions
Biofilm: A biofilm is organic matter produced by any group of microorganisms in which cells stick to each other or stick to a surface, such as a textile, dishware or hard surface or another kind of surface. These adherent cells are frequently embedded within a self-produced matrix of extracellular polymeric substance (EPS). Biofilm EPS is a polymeric conglomeration generally composed of extracellular DNA, proteins and polysaccharides. Biofilms may form on living or non-living surfaces. The microbial cells growing in a biofilm are physiologically distinct from planktonic cells of the same organism, which, by contrast, are single-cells that may float or swim in a liquid medium. EPS is the construction material of bacterial settlements and either remain attached to the cells’ outer surface, or is secreted into its growth medium. Despite the use of enzymes in detergents for laundry and dishwashing, organic matters such as EPS contained in many biofilms constitute a challenging type of soiling due to their complex nature. Detergents that are currently commercially available cannot effectively remove or reduce EPS- related soiling.
Bacteria living in a biofilm usually have significantly different properties from planktonic bacteria of the same species, as the dense and protected environment of the film allows them to cooperate and interact in various ways. One benefit of this environment for the microorganisms is increased resistance to detergents and antibiotics, as the dense extracellular matrix and the outer layer of cells protect the interior of the community. On laundry, biofilm or EPS-producing bacteria can be found e.g. among the following species: Acinetobacter sp., Aeromicrobium sp., Brevundimonas sp., Microbacterium sp., Micrococcus luteus, Pseudomonas sp., Staphylococcus epidermidis, and Stenotrophomonas sp. The biofilm-producing strain may e.g. be a species of Pseudomonas, for example Pseudomonas aeruginosa, Pseudomonas alcaliphila or Pseudomonas fluorescens.
In one embodiment, the biofilm is caused by microorganisms or a group of microorganisms which produce Pel. In another embodiment, the biofilm produces a polysaccharide that is degradable by the Glyco_hydro_1 14 glycosyl hydrolases of the invention.
In another embodiment, the biofilm is caused by microorganisms or a group of microorganisms which produce Psl. In another embodiment, the biofilm produces a polysaccharide that is degradable by the GH39 glycosyl hydrolases of the invention.
In a further embodiment, the biofilm may be caused by microorganisms that produce the linear exopolysaccharide poly-3-(1 ,6)-N-acetyl-D-glucosamine (PNAG). This exopolymer is found in biofilms of both Gram-positive bacteria, e.g. Staphylococcus species, where it is referred to as polysaccharide intercellular adhesion (PIA), and Gram-negative bacteria, e.g. Escherichia coli, where it is referred to as PGA, and species of Bordetella, where it is referred to as Bps.
The biofilm that may be formed on the surface of a material such as a textile may be caused by any microorganism or group of microorganisms that forms biofilm, for example a PelA- dependent biofilm, a PsIG-dependent biofilm or a PgaB-dependent biofilm. Such microorganisms include but are not limited to Acinetobacter sp., Aeromicrobium sp., Brevundimonas sp., Microbacterium sp., Micrococcus luteus, Staphylococcus epidermidis, Staphylococcus aureus, Pseudomonas sp., Pseudomonas aeruginosa, Pseudomonas alcaliphila, Pseudomonas fluorescens, Stenotrophomonas sp., Paraburkholderia, Burkolderia sp., Candida sp., Bordetella pertussis Yersinia pestis, Escherichia coli and Aspergillus sp.
Catalytic domain: The term “catalytic domain” means the region of an enzyme containing the catalytic machinery of the enzyme.
Clade: A clade is a group of polypeptides clustered together on the basis of homologous features traced to a common ancestor. Polypeptide clades can be visualized as phylogenetic trees and a clade is a group of polypeptides that consists of a common ancestor and all its lineal descendants. Cleaning enzyme: The term“cleaning enzyme” as used herein refers to an enzyme selected from the group consisting of nucleases, in particular DNases and RNases, hexosaminidases, in particular dispersins, and glycosyl hydrolases, in particular Glyco_hydro_1 14, GH39 and GHL13 glycosyl hydrolases.
cDNA: The term "cDNA" means a DNA molecule that can be prepared by reverse transcription from a mature, spliced, mRNA molecule obtained from a eukaryotic or prokaryotic cell. cDNA lacks intron sequences that may be present in the corresponding genomic DNA. The initial, primary RNA transcript is a precursor to mRNA that is processed through a series of steps, including splicing, before appearing as mature spliced mRNA.
Coding sequence: The term“coding sequence” means a polynucleotide, which directly specifies the amino acid sequence of a polypeptide. The boundaries of the coding sequence are generally determined by an open reading frame, which begins with a start codon such as ATG, GTG, or TTG and ends with a stop codon such as TAA, TAG, or TGA. The coding sequence may be a genomic DNA, cDNA, synthetic DNA, or a combination thereof.
Control sequences: The term “control sequences” means nucleic acid sequences necessary for expression of a polynucleotide encoding a mature polypeptide of the present invention. Each control sequence may be native (/'.e., from the same gene) or foreign (/'.e., from a different gene) to the polynucleotide encoding the polypeptide or native or foreign to each other. Such control sequences include, but are not limited to, a leader, polyadenylation sequence, propeptide sequence, promoter, signal peptide sequence, and transcription terminator. At a minimum, the control sequences include a promoter, and transcriptional and translational stop signals. The control sequences may be provided with linkers for the purpose of introducing specific restriction sites facilitating ligation of the control sequences with the coding region of the polynucleotide encoding a polypeptide.
Cleaning component: The cleaning component, e.g. a detergent adjunct ingredient, is different from the polypeptides (enzymes) of this invention. The precise nature of these additional cleaning or adjunct components, and levels of incorporation thereof, will depend on the physical form of the composition and the nature of the operation for which it is to be used. Suitable cleaning components include, but are not limited to the components described below such as surfactants, builders, flocculating aid, chelating agents, dye transfer inhibitors, other enzymes, enzyme stabilizers, enzyme inhibitors, catalytic materials, bleach activators, hydrogen peroxide, sources of hydrogen peroxide, preformed peracids, polymeric agents, clay soil removal/anti- redeposition agents, brighteners, suds suppressors, dyes, perfumes, structure elasticizing agents, fabric softeners, carriers, hydrotropes, builders and co-builders, fabric hueing agents, anti-foaming agents, dispersants, processing aids, and/or pigments.
Cleaning Composition: The term cleaning composition includes “detergent composition” and refers to compositions that find use in the removal of undesired compounds from items to be cleaned, such as textiles. The detergent composition may be used to e.g. clean textiles for both household cleaning and industrial cleaning. The term encompasses any materials/compounds selected for the particular type of cleaning composition desired and the form of the product (e.g., liquid, gel, powder, granulate, paste, or spray compositions) and includes, but is not limited to, detergent compositions (e.g., liquid and/or solid laundry detergents and fine fabric detergents; fabric fresheners; fabric softeners; and textile and laundry pre- spotters/pretreatment). In addition to containing the enzymes of the invention, the detergent formulation may contain one or more detergent adjunct ingredients such as surfactants, builders, chelators or chelating agents, bleach system or bleach components, polymers, fabric conditioners, foam boosters, suds suppressors, dyes, perfume, tannish inhibitors, optical brighteners, bactericides, fungicides, soil suspending agents, anti-corrosion agents, enzyme inhibitors or stabilizers, enzyme activators, transferase(s), hydrolytic enzymes, oxido reductases, bluing agents and fluorescent dyes, antioxidants, and solubilizers.
Deep cleaning: The term“deep cleaning” means disruption, reduction or removal of organic components such as polysaccharides such as Pel or PNAG, proteins, RNA, DNA, soil or other components present in organic matter such as biofilm.
Detergent enzyme: The term“detergent enzyme” as used herein refers to enzymes that are not encompassed by the term“cleaning enzyme” as defined above (i.e. enzymes that are not a DNase, an RNase, a hexosaminidase, a Glyco_hydro_1 14 glycosyl hydrolase, a GH39 glycosyl hydrolase or a GHL13 glycosyl hydrolase). The term “detergent enzyme” includes enzymes traditionally used in detergent compositions, including but not limited to proteases, amylases, lipases, mannanases, pectate lyases and cellulases. Other detergent enzymes may e.g. include carbohydrases, pectinases, arabinases, galactanases, xylanases, oxidases or peroxidases. It should be noted that in the context of the present invention an enzyme such as a mannanase is considered to be a“detergent enzyme”.
Enzyme detergency benefit: The term“enzyme detergency benefit” is defined herein as the advantageous effect an enzyme may add to a detergent compared to the same detergent without the enzyme. Important detergency benefits which can be provided by enzymes are stain removal with no or very little visible soils after washing and/or cleaning, prevention or reduction of redeposition of soils released in the washing process (an effect that also is termed anti- redeposition), restoring fully or partly the whiteness of textiles which originally were white but after repeated use and wash have obtained a greyish or yellowish appearance (an effect that also is termed whitening). Textile care benefits, which are not directly related to catalytic stain removal or prevention of redeposition of soils, are also important for enzyme detergency benefits. Examples of such textile care benefits are prevention or reduction of dye transfer from one fabric to another fabric or another part of the same fabric (an effect that is also termed dye transfer inhibition or anti-backstaining), removal of protruding or broken fibers from a fabric surface to decrease pilling tendencies or remove already existing pills or fuzz (an effect that also is termed anti-pilling), improvement of the fabric-softness, colour clarification of the fabric and removal of particulate soils which are trapped in the fibers of the fabric or garment. Enzymatic bleaching is a further enzyme detergency benefit where the catalytic activity generally is used to catalyze the formation of bleaching components such as hydrogen peroxide or other peroxides.
Expression: The term“expression” includes any step involved in the production of a polypeptide including, but not limited to, transcription, post-transcriptional modification, translation, post-translational modification, and secretion.
Expression vector: The term “expression vector” means a linear or circular DNA molecule that comprises a polynucleotide encoding a polypeptide and is operably linked to control sequences that provide for its expression.
Fragment: The term“fragment” means a polypeptide or a catalytic domain having one or more amino acids absent from the amino and/or carboxyl terminus of a mature polypeptide or domain; wherein the fragment has activity.
Host cell: The term "host cell" means any cell type that is susceptible to transformation, transfection, transduction, or the like with a nucleic acid construct or expression vector comprising a polynucleotide of the present invention. The term“host cell” encompasses any progeny of a parent cell that is not identical to the parent cell due to mutations that occur during replication.
Isolated: The term“isolated” means a substance in a form or environment that does not occur in nature. Non-limiting examples of isolated substances include (1 ) any non-naturally occurring substance, (2) any substance including, but not limited to, any enzyme, variant, nucleic acid, protein, peptide or cofactor, that is at least partially removed from one or more or all of the naturally occurring constituents with which it is associated in nature; (3) any substance modified by the hand of man relative to that substance found in nature; or (4) any substance modified by increasing the amount of the substance relative to other components with which it is naturally associated (e.g., recombinant production in a host cell; multiple copies of a gene encoding the substance; and use of a stronger promoter than the promoter naturally associated with the gene encoding the substance). An isolated substance may be present in a fermentation broth sample; e.g. a host cell may be genetically modified to express the polypeptide of the invention. The fermentation broth from that host cell will comprise the isolated polypeptide.
Improved wash performance: The term “improved wash performance” is defined herein as an enzyme displaying an increased wash performance in a detergent composition relative to the wash performance of same detergent composition without the enzyme e.g. by increased stain removal or less re-deposition. The term“improved wash performance” includes wash performance in laundry.
Laundering: The term“laundering” relates to both household laundering and industrial laundering and means the process of treating textiles with a solution containing a cleaning or detergent composition of the present invention. The laundering process can for example be carried out using e.g. a household or an industrial washing machine or can be carried out by hand.
Malodor: By the term“malodor” is meant an odor which is not desired on clean items. The cleaned item should smell fresh and clean without malodors adhered to the item. One example of malodor is compounds with an unpleasant smell, which may be produced by microorganisms. Another example is unpleasant smells can be sweat or body odor adhered to an item which has been in contact with human or animal. Another example of malodor can be the odor from spices which sticks to items, for example curry or other spices with a strong smell.
Mature polypeptide: The term“mature polypeptide” means a polypeptide in its final form following translation and any post-translational modifications, such as N-terminal processing, C-terminal truncation, glycosylation, phosphorylation, etc.
It is known in the art that a host cell may produce a mixture of two of more different mature polypeptides (/'.e., with a different C-terminal and/or N-terminal amino acid) expressed by the same polynucleotide. It is also known in the art that different host cells process polypeptides differently, and thus, one host cell expressing a polynucleotide may produce a different mature polypeptide (e.g., having a different C-terminal and/or N-terminal amino acid) as compared to another host cell expressing the same polynucleotide.
Mature polypeptide coding sequence: The term “mature polypeptide coding sequence” means a polynucleotide that encodes a mature polypeptide having activity.
Nucleic acid construct: The term "nucleic acid construct" means a nucleic acid molecule, either single- or double-stranded, which is isolated from a naturally occurring gene or is modified to contain segments of nucleic acids in a manner that would not otherwise exist in nature or which is synthetic, which comprises one or more control sequences.
Operably linked: The term“operably linked” means a configuration in which a control sequence is placed at an appropriate position relative to the coding sequence of a polynucleotide such that the control sequence directs expression of the coding sequence.
Sequence identity: The relatedness between two amino acid sequences or between two nucleotide sequences is described by the parameter“sequence identity”.
For purposes of the present invention, the sequence identity between two amino acid sequences is determined using the Needleman-Wunsch algorithm (Needleman and Wunsch, 1970, J. Mol. Biol. 48: 443-453) as implemented in the Needle program of the EMBOSS package (EMBOSS: The European Molecular Biology Open Software Suite, Rice et al., 2000, Trends Genet. 16: 276-277), preferably version 5.0.0 or later. The parameters used are gap open penalty of 10, gap extension penalty of 0.5, and the EBLOSUM62 (EMBOSS version of BLOSUM62) substitution matrix. The output of Needle labeled“longest identity” (obtained using the -nobrief option) is used as the percent identity and is calculated as follows:
(Identical Residues x 100)/(Length of Alignment - Total Number of Gaps in Alignment)
Variant: The term “variant” means a polypeptide having a given enzymatic activity comprising an alteration, i.e., a substitution, insertion and/or deletion, at one or more positions. A substitution means replacement of the amino acid occupying a position with a different amino acid; a deletion means removal of the amino acid occupying a position; and an insertion means adding an amino acid adjacent to and immediately following the amino acid occupying a position.
Nomenclature
For purposes of the present invention, the nomenclature“E/Q” means that the amino acid at a given position may be a glutamic acid (Glu, E) or a glutamine (Gin, Q). Likewise, the nomenclature“V/G/A l” means that the amino acid at this position may be a valine (Val, V), glycine (Gly, G), alanine (Ala, A) or isoleucine (lie, I), and so forth for other combinations as described herein. Unless otherwise limited further, the amino acid X is defined such that it may be any of the 20 natural amino acids.
Substitutions are typically indicated with the original amino acid, the position number, and the replacement amino acid. For example, A226V indicates that the original alanine residue in position 226 has been replaced by a valine residue.
Deletions are indicated with an asterisk (*). For example, G184* indicates that the original glycine residue in position 184 has been deleted.
Insertions are indicated by listing the original amino acid, the position number, the original amino acid and the inserted amino acid. For example, S97SD indicates that an aspartic acid residue has been inserted after the serine residue in position 97.
DETAILED DESCRIPTION OF THE INVENTION
As indicated above, the present invention relates to cleaning compositions comprising at least two cleaning enzymes selected from the group consisting of nucleases, hexosaminidases and glycosyl hydrolases and at least two detergent enzymes selected from the group consisting of proteases, amylases, lipases, mannanases, pectate lyases and cellulases, where the nuclease is a DNase or an RNase, the hexosaminidase is a dispersin, and the glycosyl hydrolase is a Glyco_hydro_1 14, GH39 or GHL13 glycosyl hydrolase.
Suitable enzymes as well as other optional components for use in the cleaning compositions are described in detail below. In addition to the cleaning enzymes and detergent enzymes, the cleaning compositions will typically contain additional components that are commonly used in detergent or cleaning compositions, typically at least one surfactant and optionally at least one additional cleaning component selected from builders and bleach components. Such additional cleaning components are also described in detail further below.
Although specific combinations of different cleaning enzymes and detergent enzymes are disclosed herein, it will be apparent to persons skilled in the art that other combinations are also contemplated. For example, the cleaning composition may comprise both a DNase and an RNase, more than one type of glycosyl hydrolase, more than one protease, more than one cellulase, etc.
Polypeptides Having DNase Activity
The term“DNase” means a nuclease polypeptide having DNase activity that catalyzes the hydrolytic cleavage of phosphodiester linkages in a DNA backbone, thus degrading DNA. The terms“DNase” and the expression“a polypeptide with/having DNase activity” are used interchangeably throughout the application. For purposes of the present invention, DNase activity may be determined according to the procedure described in the Assay 1 or 2 herein.
Preferably the DNase is selected from any of the enzyme classes E.C. 3.1.21.X, where X = 1 , 2, 3, 4, 5, 6, 7, 8 or 9, e.g. Deoxyribonuclease I, Deoxyribonuclease IV, Type I site-specific deoxyribonuclease, Type II site-specific deoxyribonuclease, Type III site-specific deoxyribonuclease, CC-preferring endo-deoxyribonuclease, Deoxyribonuclease V, T(4) deoxyribonuclease II, T(4) deoxyribonuclease IV or E.C. 3.1.22.Y where Y = 1 , 2, 4 or 5, e.g. Deoxyribonuclease II, Aspergillus deoxyribonuclease K(1 ), Crossover junction endo- deoxyribonuclease, or Deoxyribonuclease X.
Preferably, the DNase activity is obtained from a microorganism, and the DNase is a microbial enzyme. The DNase is preferably of fungal or bacterial origin.
The DNase may be obtained from a bacterium, e.g. Bacillus, such as Bacillus licheniformis, Bacillus subtilis, Bacillus sp., Bacillus ho koshii, Bacillus horneckiae, Bacillus cibi, Bacillus idriensis, Bacillus algicola, Bacillus vietnamensis, Bacillus hwajinpoensis, Bacillus indicus, Bacillus marisflavi, Bacillus luciferensis, or Bacillus sp. SA2-6.
The DNase may also be obtained from any of the following: Pyrenochaetopsis sp., Vibrissea flavovirens, Setosphaeria rostrate, Endophragmiella valdina, Corynespora cassiicola, Paraphoma sp., Monilinia fructicola, Curvularia lunata, Penicillium reticulisporum, Penicillium quercetorum, Setophaeosphaeria sp., Alternaria, Alternaria sp., Trichoderma reesei, Chaetomium thermophilum, Scytalidium thermophilum, Metapochonia suchlasporia, Daldinia fissa, Acremonium sp., Acremonium dichromosporum, Sarocladium sp., Metarhizium sp. HNA15-2, Isaria tenuipes Scytalidium circinatum, Metarhizium lepidiotae, Thermobispora bispora, Sporormia fimetaria, Pycnidiophora cf. dispera, Clavicipitaceae sp., Westerdykella sp., Humicolopsis cephalosporioides, Neosartorya massa, Roussoella intermedia, Pleosporales, Phaeosphaeria or Didymosphaeria futilis. In some embodiments, the polypeptides having DNase activity are polypeptides comprising the PFAM domain DUF1524 ((http://pfam.xfam.org/), “The Pfam protein families database: towards a more sustainable future”, R.D. Finn, et.al. Nucleic Acids Research (2016) Database Issue 44:D279-D285”). The DUF1524 domain contains a conserved HXXP sequence (where H is the amino acid histidine, P is the amino acid proline, and X is any amino acid motif) commonly found in nucleases (M.A. Machnicka, et al. Phylogenomics and sequence-structure- function relationships in the GmrSD family of Type IV restriction enzymes, BMC Bioinformatics, 2015, 16, 336). DUF stands for domain of unknown function, and the polypeptide families comprising, e.g., DUF have been collected together in the Pfam database, which provides sequence alignments and hidden Markov models that define the collected protein domains.
Thus, in some embodiments the polypeptides having DNase activity in the composition of the invention comprise the DUF1524 domain. For further information on DNases comprising the DUF1524 domain, see WO 2017/060475, which is hereby incorporated by reference.
In some embodiments, the DNase is a NUC1 or NUC1_A DNase. A NUC1 DNase is a DNase comprising a domain termed NUC1 , and polypeptides with this domain are in addition to having DNase activity characterized by comprising certain motifs. Similarly, a NUC1 sub-domain had been identified, termed the NUC1_A domain, which also is characterized by comprising certain motifs. The NUC1 and NUC1_A DNases are described in WO 2017/060475 and WO 2018/184873, which are hereby incorporated by reference.
The preparation of the polypeptide having DNase activity as described herein can e.g. be performed as described in WO 2017/059802, in particular in the sections Nucleic Acid Construct, Expression Vectors, Host Cells, Methods of Production and Fermentation Broth Formulations.
In one embodiment, the cleaning composition of the invention comprises a polypeptide having DNase activity and a sequence identity to the polypeptide shown in SEQ ID NO: 1 of at least 60%, e.g., at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100%. In one embodiment the polypeptide has an amino acid sequence that comprises or consists of SEQ ID NO: 1.
In one embodiment, the cleaning composition of the invention comprises a polypeptide having DNase activity and a sequence identity to the polypeptide shown in SEQ ID NO: 2 of at least 60%, e.g., at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100%. In one embodiment the polypeptide has an amino acid sequence that comprises or consists of SEQ ID NO: 2.
In one embodiment, the cleaning composition of the invention comprises a polypeptide having DNase activity and a sequence identity to the polypeptide shown in SEQ ID NO: 3 of at least 60%, e.g., at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100%. In one embodiment the polypeptide has an amino acid sequence that comprises or consists of SEQ ID NO: 3.
In one embodiment, the cleaning composition of the invention comprises a polypeptide having DNase activity and a sequence identity to the polypeptide shown in SEQ ID NO: 4 of at least 60%, e.g., at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100%. In one embodiment the polypeptide has an amino acid sequence that comprises or consists of SEQ ID NO: 4.
In one embodiment, the cleaning composition of the invention comprises a polypeptide having DNase activity and a sequence identity to the polypeptide shown in SEQ ID NO: 5 of at least 60%, e.g., at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100%. In one embodiment the polypeptide has an amino acid sequence that comprises or consists of SEQ ID NO: 5.
In another embodiment, the cleaning composition of the invention may comprise any of the DNase polypeptides disclosed in WO 2017/059802, WO 2017/060475, WO 2018/185285 or WO 2018/184873, the contents of which are incorporated herein by reference.
When present in a cleaning composition of the invention, the DNase polypeptide will typically be present in an amount of from 0.01 to 1000 ppm, from 0.1 to 1000 ppm, from 1 ppm to 1000 ppm, from 10 ppm to 1000 ppm, from 50 ppm to 1000 ppm, from 100 ppm to 1000 ppm, from 150 ppm to 1000 ppm, from 200 ppm to 1000 ppm, from 250 ppm to 1000 ppm, from 250 ppm to 750 ppm, or from 250 ppm to 500 ppm, based on active protein.
The DNases above may be combined with one or more other cleaning enzyme in the composition, e.g. a hexosaminidase and/or a glycosyl hydrolase, to form a blend to be added to the wash liquor solution according to the invention. The concentration of the DNase in the wash liquor solution is typically in the range of from 0.00001 ppm to 10 ppm, from 0.00002 ppm to 10 ppm, from 0.0001 ppm to 10 ppm, from 0.0002 ppm to 10 ppm, from 0.001 ppm to 10 ppms from 0.002 ppm to 10 ppm, from 0.01 ppm to 10 ppm, from 0.02 ppm to 10 ppm, from 0.1 ppm to 10 ppm, from 0.2ppm to 10 ppm, or from 0.5 ppm to 5 ppm.
Polypeptides having RNase activity
The term“RNase” means a nuclease polypeptide having RNase activity (EC 3.1 .2.7) that catalyzes the degradation of RNA into smaller components. Ribonucleases can be divided into endoribonucleases and exoribonucleases. The present invention relates especially to endoribonucleases. For purposes of the present invention, RNase activity may be determined according to the procedure described in Assay 3 herein. The polypeptides of the invention having RNase activity preferably comprise a domain from the RNase Barnase (UniProt P00648 (RNBR_BACAM), PF00545 family).
A phylogenetic tree has been constructed with polypeptide sequences containing a Barnase domain, as defined in PFAM (PF000545, Pfam version 30.0 Finn (2016), Nucleic Acids Research, Database Issue 44 D279-D285). The phylogenetic tree was constructed from a multiple alignment of mature polypeptide sequences containing at least one Barnase domain. The sequences were aligned using the MUSCLE algorithm version 3.8.31 (Edgar, 2004. Nucleic Acids Research 32(5): 1792-1797), and the trees were constructed using FastTree version 2.1 .8 (Price et al., 2010, PloS one 5(3)) and visualized using iTOL (Letunic & Bork, 2007. Bioinformatics 23(1 ): 127-128). Polypeptides comprising the Barnase domain can be separated into multiple distinct sub-clusters, or clades, which can be defined in terms of distinct motifs for each clade. See WO 2018/178061 for further information.
The RNase Barnase from the PF00545 family of ribonucleases catalyzes hydrolysis at diribonucleotide GpN sites. Cleavage occurs in two steps using a general acid-base mechanism: a cyclic intermediate is formed during the first transesterification step, which is then hydrolysed to release the cleaved RNA. The two most important residues involved in catalysis are Glu73 and His102, which are both believed to be essential for enzymatic activity. Glu73 is the general base whilst His102 is the general acid. Barnase has no disulfide bonds, nor does it require divalent cations or non-peptide components to fold.
A polypeptide having RNase activity of the present invention may be obtained from microorganisms of any genus. For purposes of the present invention, the term“obtained from” as used herein about a given source shall mean that the polypeptide encoded by a polynucleotide is produced by the source or by a strain in which the polynucleotide from the source has been inserted. In one aspect, the polypeptide obtained from a given source is secreted extracellularly. The RNase is preferably a microbial RNase, preferably obtained from a bacterium or a fungus.
In one aspect, the polypeptide is a Paenibacillus polypeptide. One embodiment of this aspect is e.g. a polypeptide obtained from Paenibacillus sp.. Another embodiment of this aspect is a polypeptide obtained from Paenibacillus tundrae.
In one aspect, the polypeptide is an Amycolatopsis polypeptide, e.g., a polypeptide obtained from Amycolatopsis azurea.
In one aspect, the polypeptide is an Acremonium polypeptide, e.g., a polypeptide obtained from Acremonium alcalophilum.
In one aspect, the polypeptide is a Stenotrophomonas polypeptide, e.g., a polypeptide obtained from Stenotrophomonas rhizophila.
In one aspect, the polypeptide is an Erwinia polypeptide, e.g., a polypeptide obtained from Erwinia persicina. In one aspect, the polypeptide is a Saccharothrix polypeptide, e.g., a polypeptide obtained from Saccharothrix sp.
In one aspect, the polypeptide is a Saccharopolyspora polypeptide, e.g., a polypeptide obtained from Saccharopolyspora endophytica.
In one aspect, the polypeptide is an Amycolatopsis polypeptide, e.g., a polypeptide obtained from Amycolatopsis circi.
In one aspect, the polypeptide is an Alkalimonas polypeptide, e.g., a polypeptide obtained from Alkalimonas sp.
In one aspect, the polypeptide is a Nonomuraea polypeptide, e.g., a polypeptide obtained from Nonomuraea dietziae.
In one aspect, the polypeptide is a Trichoderma polypeptide, e.g., a polypeptide obtained from Trichoderma harzianum.
In one aspect, the polypeptide is a Fusarium polypeptide, e.g., a polypeptide obtained from Fusarium solani.
It will be understood that for the aforementioned species, the invention encompasses both the perfect and imperfect states, and other taxonomic equivalents, e.g., anamorphs, regardless of the species name by which they are known. Those skilled in the art will readily recognize the identity of appropriate equivalents.
Strains of these species are readily accessible to the public in a number of culture collections, such as the American Type Culture Collection (ATCC), Deutsche Sammlung von Mikroorganismen und Zellkulturen GmbH (DSMZ), Centraalbureau Voor Schimmelcultures (CBS), and Agricultural Research Service Patent Culture Collection, Northern Regional Research Center (NRRL).
In one embodiment, the cleaning composition of the invention comprises a polypeptide having RNase activity and a sequence identity to the polypeptide shown in SEQ ID NO: 16 of at least 60%, e.g., at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100%. In one embodiment the polypeptide has an amino acid sequence that comprises or consists of SEQ ID NO: 16.
In one embodiment, the cleaning composition of the invention comprises a polypeptide having RNase activity and a sequence identity to the polypeptide shown in SEQ ID NO: 17 of at least 60%, e.g., at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100%. In one embodiment the polypeptide has an amino acid sequence that comprises or consists of SEQ ID NO: 17.
In one embodiment, the cleaning composition of the invention comprises a polypeptide having RNase activity and a sequence identity to the polypeptide shown in SEQ ID NO: 18 of at least 60%, e.g., at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100%. In one embodiment the polypeptide has an amino acid sequence that comprises or consists of SEQ ID NO: 18.
In another embodiment, the cleaning composition of the invention may comprise any of the RNase polypeptides disclosed in WO 2018/178061 , the contents of which are incorporated herein by reference.
When present in a cleaning composition of the invention, the RNase polypeptide will typically be present in an amount of from 0.01 to 1000 ppm, from 0.1 to 1000 ppm, from 1 ppm to 1000 ppm, from 10 ppm to 1000 ppm, from 50 ppm to 1000 ppm, from 100 ppm to 1000 ppm, from 150 ppm to 1000 ppm, from 200 ppm to 1000 ppm, from 250 ppm to 1000 ppm, from 250 ppm to 750 ppm, or from 250 ppm to 500 ppm, based on active protein.
The RNases above may be combined with one or more other cleaning enzyme in the composition, e.g. a hexosaminidase and/or a glycosyl hydrolase, to form a blend to be added to the wash liquor solution according to the invention. The concentration of the RNase in the wash liquor solution is typically in the range of from 0.00001 ppm to 10 ppm, from 0.00002 ppm to 10 ppm, from 0.0001 ppm to 10 ppm, from 0.0002 ppm to 10 ppm, from 0.001 ppm to 10 ppms from 0.002 ppm to 10 ppm, from 0.01 ppm to 10 ppm, from 0.02 ppm to 10 ppm, from 0.1 ppm to 10 ppm, from 0.2ppm to 10 ppm, or from 0.5 ppm to 5 ppm.
Polypeptides having hexosaminidase activity
The term“hexosaminidase”, including“dispersin’’ and the abbreviation“Dsp”, means a polypeptide having hexosaminidase activity, EC 3.2.1., that catalyzes the hydrolysis of b-1 ,6- glycosidic linkages of N-acetyl-glucosamine polymers found e.g. in biofilm. The term hexosaminidase includes polypeptides having N-acetylglucosaminidase activity and b-N- acetylglucosaminidase activity. Enzymes having hexosaminidase activity include dispersins such as dispersin B (DspB), which is a b-N-acetylglucosaminidase belonging to the Glycoside Hydrolase 20 family.
The term“polypeptide having hexosaminidase activity” may be used interchangeably with the term “hexosaminidase”, and similarly the term “polypeptide having b-N- acetylglucosaminidase activity” may be used interchangeably with the term “b-N- acetylglucosaminidases”. In a preferred embodiment, the polypeptide having hexosaminidase activity is a b-N-acetylglucosaminidase targeting poly-b-1 ,6-N-acetylglucosamine, preferably a dispersin.
For purposes of the present invention, hexosaminidase activity may be determined according to the procedure described in Assay 4 or 5 herein.
A polypeptide having hexosaminidase activity may be obtained from a microorganism of any genus. Preferably the hexosaminidase or the b-N-acetylglucosaminidase targeting poly-b- 1 ,6-N-acetylglucosamine e.g. a dispersin is obtained from Terribacillus, Curtobacterium, Aggregatibacter, Haemophilus or Actinobacillus, preferably Terribacillus.
In one embodiment, the cleaning composition of the invention comprises a polypeptide having hexosaminidase activity and a sequence identity to the polypeptide shown in SEQ ID NO: 19 of at least 60%, e.g., at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100%. In one embodiment the polypeptide has an amino acid sequence that comprises or consists of SEQ ID NO: 19.
In one embodiment, the cleaning composition of the invention comprises a polypeptide having hexosaminidase activity and a sequence identity to the polypeptide shown in SEQ ID NO: 20 of at least 60%, e.g., at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100%. In one embodiment the polypeptide has an amino acid sequence that comprises or consists of SEQ ID NO: 20.
In one embodiment, the cleaning composition of the invention comprises a polypeptide having hexosaminidase activity and a sequence identity to the polypeptide shown in SEQ ID NO: 21 of at least 60%, e.g., at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100%. In one embodiment the polypeptide has an amino acid sequence that comprises or consists of SEQ ID NO: 21 .
In one embodiment, the cleaning composition of the invention comprises a polypeptide having hexosaminidase activity and a sequence identity to the polypeptide shown in SEQ ID NO: 22 of at least 60%, e.g., at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100%. In one embodiment the polypeptide has an amino acid sequence that comprises or consists of SEQ ID NO: 22.
In one embodiment, the cleaning composition of the invention comprises a polypeptide having hexosaminidase activity and a sequence identity to the polypeptide shown in SEQ ID NO: 23 of at least 60%, e.g., at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100%. In one embodiment the polypeptide has an amino acid sequence that comprises or consists of SEQ ID NO: 23.
In another embodiment, the cleaning composition of the invention may comprise any of the hexosaminidase polypeptides disclosed in WO 2017/186936, WO 2017/186937, WO 2017/186943 or WO 2018/184873, the contents of which are incorporated herein by reference.
When present in a cleaning composition of the invention, the hexosaminidase polypeptide will typically be present in an amount of from 0.01 to 1000 ppm, from 0.1 to 1000 ppm, from 1 ppm to 1000 ppm, from 10 ppm to 1000 ppm, from 50 ppm to 1000 ppm, from 100 ppm to 1000 ppm, from 150 ppm to 1000 ppm, from 200 ppm to 1000 ppm, from 250 ppm to 1000 ppm, from 250 ppm to 750 ppm, or from 250 ppm to 500 ppm, based on active protein.
The hexosaminidases above may be combined with one or more other cleaning enzyme in the composition, e.g. a nuclease and/or a glycosyl hydrolase, to form a blend to be added to the wash liquor solution according to the invention. The concentration of the hexosaminidase in the wash liquor solution is typically in the range of from 0.00001 ppm to 10 ppm, from 0.00002 ppm to 10 ppm, from 0.0001 ppm to 10 ppm, from 0.0002 ppm to 10 ppm, from 0.001 ppm to 10 ppms from 0.002 ppm to 10 ppm, from 0.01 ppm to 10 ppm, from 0.02 ppm to 10 ppm, from 0.1 ppm to 10 ppm, from 0.2ppm to 10 ppm, or from 0.5 ppm to 5 ppm.
Polypeptides having glycosyl hydrolase activity
The present invention relates to cleaning compositions comprising glycosyl hydrolases (EC 3.2.1.-), which are a widespread group of enzymes that hydrolyze the glyosidic bond between two or more carbohydrates or between a carbohydrate and a non-carbohydrate moiety. A classification of glycoside hydrolases in families based on amino acid sequence similarities has been proposed. The glycosyl hydrolase polypeptides of the invention comprise at least one glycosyl hydrolase domain. The glycosyl hydrolase domain comprised in such polypeptides may for purposes of the present invention be classified into one of three groups: 1 ) Glyco_hydro_1 14 glycosyl hydrolases, 2) GH39 glycosyl hydrolases, and 3) GHL13 glycosyl hydrolases.
Glvco hydro 1 14 glycosyl hydrolases
A Glyco_hydro_1 14 glycosyl hydrolase is in the context of the present invention a glycosyl hydrolase comprising glycosyl hydrolase domain (DUF297), which here is termed Glyco_hydro_1 14 (Pfam domain id PF03537, Pfam version 31.0 Finn (2016) Nucleic Acids Research, Database Issue 44:D279-D285). These polypeptides may further comprise a polysaccharide deacetylase domain (CE4). In one preferred embodiment, the polypeptides of the invention are endo-alpha-1 ,4-polygalactosaminidases. The polypeptides of the invention have at least hydrolytic activity on glyosidic bonds and may also have deacetylase activity. In the context of the present invention the Glyco_hydro_1 14 glycosyl hydrolase is in particular a PelA enzyme, which is active towards the polysaccharide Pel that is present in many biofilms. The pellicle (Pel) polysaccharide is synthesized e.g. by Pseudomonas aeruginosa and is an important biofilm constituent critical for bacterial virulence and persistence. Pel is a cationic polymer composed of partially acetylated 1 4 glycosidic linkages of N-acetylgalactosamine and N-acetylglucosamine that promote cell-cell interactions within the biofilm matrix through electrostatic interactions with extracellular DNA (Jennings et al. PNAS Sept 2015, vol.1 12, no36, 1 1353-1 1358; Marmont et al. J Biol Chem. 2017 Nov 24;292(47):1941 1 -19422. 2017). For purposes of the present invention, Glyco_hydro_1 14 glycosyl hydrolase activity may be determined according to the procedure described in Assay 6 herein.
The Glyco_hydro_114 polypeptides of the invention comprise a domain termed here as a CE4_PelA_like domain, which is represented by a protein PelA that is encoded by a gene in the pelA-G gene cluster for pellicle production and biofilm formation in Pseudomonas aeruginosa. PelA and most of the family members contain a domain of unknown function, DUF297 (PF03537), in the N-terminus and a C-terminal domain that shows high sequence similarity to the catalytic domain of the six-stranded barrel rhizobial NodB-like proteins, which remove N-linked or O-linked acetyl groups from cell wall polysaccharides and belong to the larger carbohydrate esterase 4 (CE4) superfamily. The Glyco_hydro_114 polypeptides of the present invention also comprise several characteristic motifs.
In one embodiment, the cleaning composition of the invention comprises a polypeptide having Glyco_hydro_114 glycosyl hydrolase activity and a sequence identity to the polypeptide shown in SEQ ID NO: 6 of at least 60%, e.g., at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100%. In one embodiment the polypeptide has an amino acid sequence that comprises or consists of SEQ ID NO: 6.
In one embodiment, the cleaning composition of the invention comprises a polypeptide having Glyco_hydro_114 glycosyl hydrolase activity and a sequence identity to the polypeptide shown in SEQ ID NO: 7 of at least 60%, e.g., at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100%. In one embodiment the polypeptide has an amino acid sequence that comprises or consists of SEQ ID NO: 7.
In one embodiment, the cleaning composition of the invention comprises a polypeptide having Glyco_hydro_114 glycosyl hydrolase activity and a sequence identity to the polypeptide shown in SEQ ID NO: 8 of at least 60%, e.g., at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100%. In one embodiment the polypeptide has an amino acid sequence that comprises or consists of SEQ ID NO: 8.
In one embodiment, the cleaning composition of the invention comprises a polypeptide having Glyco_hydro_114 glycosyl hydrolase activity and a sequence identity to the polypeptide shown in SEQ ID NO: 9 of at least 60%, e.g., at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100%. In one embodiment the polypeptide has an amino acid sequence that comprises or consists of SEQ ID NO: 9. In another embodiment, the cleaning composition of the invention may comprise any of the Glyco_hydro_1 14 glycosyl hydrolase polypeptides disclosed in WO 2018/185181 , the contents of which are incorporated herein by reference.
When present in a cleaning composition of the invention, the Glyco_hydro_1 14 glycosyl hydrolase polypeptide will typically be present in an amount of from 0.01 to 1000 ppm, from 0.1 to 1000 ppm, from 1 ppm to 1000 ppm, from 10 ppm to 1000 ppm, from 50 ppm to 1000 ppm, from 100 ppm to 1000 ppm, from 150 ppm to 1000 ppm, from 200 ppm to 1000 ppm, from 250 ppm to 1000 ppm, from 250 ppm to 750 ppm, or from 250 ppm to 500 ppm, based on active protein.
The Glyco_hydro_1 14 glycosyl hydrolases above may be combined with one or more other cleaning enzyme in the composition, e.g. a hexosaminidase and/or a nuclease, to form a blend to be added to the wash liquor solution according to the invention. The concentration of the Glyco_hydro_1 14 glycosyl hydrolase in the wash liquor solution is typically in the range of from 0.00001 ppm to 10 ppm, from 0.00002 ppm to 10 ppm, from 0.0001 ppm to 10 ppm, from 0.0002 ppm to 10 ppm, from 0.001 ppm to 10 ppm, from 0.002 ppm to 10 ppm, from 0.01 ppm to 10 ppm, from 0.02 ppm to 10 ppm, from 0.1 ppm to 10 ppm, from 0.2ppm to 10 ppm, or from 0.5 ppm to 5 ppm.
GH39 glycosyl hydrolases
The glycosyl hydrolase in cleaning compositions of the invention may be a GH39 glycosyl hydrolase that comprises the CAZY database domain GH39 (GH, CAZY database http://www.cazy.org/ (Coutinho & Henrissat, 1999). The domain is a functional domain providing hydrolytic activity to the polypeptide. The GH39 glycoside hydrolase family contains two known enzyme activities: b-xylosidase and a-L-iduronidase. Both enzyme activities cleave equatorial glycosidic bonds. The most highly conserved regions in these enzymes are located in their N- terminal sections (Henrissat et al. (1995). "Conserved catalytic machinery and the prediction of a common fold for several families of glycosyl hydrolases". Proc. Natl. Acad. Sci. U.S.A. 92 (15): 7090-7094).
The polypeptides of the invention comprising a GH39 domain are homologues of PsIG enzymes, which are proteins that degrade the exopolysaccharide Psl. Psl is a pentasaccharide comprising D-glucose, L-rhamnose and D-mannose, which acts as a glue in e.g. bacteria surface interactions. PsIG is a protein involved in the synthesis of the biofilm matrix exopolysaccharide Psl in Pseudomonas aeruginosa. The polypeptides in GH39 can be separated into distinct sub- clusters defined by particular motifs.
In one embodiment, the cleaning composition of the invention comprises a polypeptide having GH39 glycosyl hydrolase activity and a sequence identity to the polypeptide shown in SEQ ID NO: 10 of at least 60%, e.g., at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100%. In one embodiment the polypeptide has an amino acid sequence that comprises or consists of SEQ ID NO: 10.
In one embodiment, the cleaning composition of the invention comprises a polypeptide having GH39 glycosyl hydrolase activity and a sequence identity to the polypeptide shown in SEQ ID NO: 1 1 of at least 60%, e.g., at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100%. In one embodiment the polypeptide has an amino acid sequence that comprises or consists of SEQ ID NO: 1 1.
In one embodiment, the cleaning composition of the invention comprises a polypeptide having GH39 glycosyl hydrolase activity and a sequence identity to the polypeptide shown in SEQ ID NO: 12 of at least 60%, e.g., at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100%. In one embodiment the polypeptide has an amino acid sequence that comprises or consists of SEQ ID NO: 12.
In another embodiment, the cleaning composition of the invention may comprise any of the GH39 glycosyl hydrolase polypeptides disclosed in WO 2018/185150, the contents of which are incorporated herein by reference.
When present in a cleaning composition of the invention, the GH39 glycosyl hydrolase polypeptide will typically be present in an amount of from 0.01 to 1000 ppm, from 0.1 to 1000 ppm, from 1 ppm to 1000 ppm, from 10 ppm to 1000 ppm, from 50 ppm to 1000 ppm, from 100 ppm to 1000 ppm, from 150 ppm to 1000 ppm, from 200 ppm to 1000 ppm, from 250 ppm to 1000 ppm, from 250 ppm to 750 ppm, or from 250 ppm to 500 ppm, based on active protein.
The GH39 glycosyl hydrolases above may be combined with one or more other cleaning enzyme in the composition, e.g. a hexosaminidase and/or a nuclease, to form a blend to be added to the wash liquor solution according to the invention. The concentration of the GH39 glycosyl hydrolase in the wash liquor solution is typically in the range of from 0.00001 ppm to 10 ppm, from 0.00002 ppm to 10 ppm, from 0.0001 ppm to 10 ppm, from 0.0002 ppm to 10 ppm, from 0.001 ppm to 10 ppm, from 0.002 ppm to 10 ppm, from 0.01 ppm to 10 ppm, from 0.02 ppm to 10 ppm, from 0.1 ppm to 10 ppm, from 0.2ppm to 10 ppm, or from 0.5 ppm to 5 ppm.
GHL13 glycosyl hydrolases
The GHL13 glycosyl hydrolase polypeptides in cleaning compositions of the invention are BpsB and PgaB homologs comprising a GHL13 domain and with activity on the PNAG substrate. Some GHL13 glycosyl hydrolases also comprise the CE4 domain. Provided here are thus PgaA/BpsB homologs comprising a C-terminus glycosyl hydrolase domain (GHL13) and optionally a N-terminus deacetylase domain (CE4). For purposes of the present invention, GHL13 glycosyl hydrolase activity may be determined according to the procedure described in Assay 7 herein.
The glycosyl hydrolase polypeptides comprise the Pfam database domain GHL13 (PFAM domain id PF14883, Pfam version 31.0 Finn (2016). Nucleic Acids Research, Database Issue 44:D279-D285), where this domain is a functional domain providing hydrolytic activity to the polypeptide. The polypeptides preferably in addition to the GHL13 domain also comprise the CE4 domain (CE, CAZY database http://www.cazy.org/ (Coutinho & Henrissat, 1999) and have deacetylase activity.
In one embodiment, the cleaning composition of the invention comprises a polypeptide having GHL13 glycosyl hydrolase activity and a sequence identity to the polypeptide shown in SEQ ID NO: 13 of at least 60%, e.g., at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100%. In one embodiment the polypeptide has an amino acid sequence that comprises or consists of SEQ ID NO: 13.
In one embodiment, the cleaning composition of the invention comprises a polypeptide having GHL13 glycosyl hydrolase activity and a sequence identity to the polypeptide shown in SEQ ID NO: 14 of at least 60%, e.g., at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100%. In one embodiment the polypeptide has an amino acid sequence that comprises or consists of SEQ ID NO: 14.
In one embodiment, the cleaning composition of the invention comprises a polypeptide having GHL13 glycosyl hydrolase activity and a sequence identity to the polypeptide shown in SEQ ID NO: 15 of at least 60%, e.g., at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100%. In one embodiment the polypeptide has an amino acid sequence that comprises or consists of SEQ ID NO: 15.
In another embodiment, the cleaning composition of the invention may comprise any of the GH39 glycosyl hydrolase polypeptides disclosed in WO 2018/185152, the contents of which are incorporated herein by reference.
When present in a cleaning composition of the invention, the GHL13 glycosyl hydrolase polypeptide will typically be present in an amount of from 0.01 to 1000 ppm, from 0.1 to 1000 ppm, from 1 ppm to 1000 ppm, from 10 ppm to 1000 ppm, from 50 ppm to 1000 ppm, from 100 ppm to 1000 ppm, from 150 ppm to 1000 ppm, from 200 ppm to 1000 ppm, from 250 ppm to 1000 ppm, from 250 ppm to 750 ppm, or from 250 ppm to 500 ppm, based on active protein.
The GHL13 glycosyl hydrolase above may be combined with one or more other cleaning enzyme in the composition, e.g. a hexosaminidase and/or a nuclease, to form a blend to be added to the wash liquor solution according to the invention. The concentration of the GHL13 glycosyl hydrolase in the wash liquor solution is typically in the range of from 0.00001 ppm to 10 ppm, from 0.00002 ppm to 10 ppm, from 0.0001 ppm to 10 ppm, from 0.0002 ppm to 10 ppm, from 0.001 ppm to 10 ppm, from 0.002 ppm to 10 ppm, from 0.01 ppm to 10 ppm, from 0.02 ppm to 10 ppm, from 0.1 ppm to 10 ppm, from 0.2ppm to 10 ppm, or from 0.5 ppm to 5 ppm.
Detergent enzymes
As explained above, the cleaning compositions of the invention include at least two detergent enzymes selected from the group consisting of proteases, amylases, lipases, mannanases, pectate lyases and cellulases. These detergent enzymes are described in more detail below.
The compositions will typically comprise at least a protease, for example a protease and an amylase. In some embodiments, the cleaning composition may comprise three, four, five or more detergent enzymes.
In one embodiment, the cleaning composition comprises at least one protease, at least one amylase, at least one lipase, at least one mannanase, at least on pectate lyase, and at least one cellulase. The composition may optionally include two or more different enzymes of one type, for example two proteases or two cellulases.
If desired, the composition may also contain one or more further enzymes such as a carbohydrase, a pectinase, an arabinase, a galactanase, a xylanase or an oxidase, e.g. a laccase and/or peroxidase.
Proteases
Suitable proteases for the compositions of the invention include those of bacterial, fungal, plant, viral or animal origin, although those of microbial origin are preferred, including chemically modified or protein engineered variants. The protease may be an alkaline protease, such as a serine protease or a metalloprotease. A serine protease may for example be of the S1 family, such as trypsin, or the S8 family such as subtilisin. A metalloprotease may for example be a thermolysin from e.g. family M4 or another metalloprotease such as those from the M5, M7 or M8 families.
Examples of subtilase proteases are those derived from Bacillus such as Bacillus lentus, Bacillus alkalophilus, Bacillus subtilis, Bacillus amyloliquefaciens, Bacillus pumilus and Bacillus gibsonii, described in e.g. US 7262042 and WO 2009/021867, Subtilisin lentus, Subtilisin Novo, subtilisin Carlsberg, Bacillus licheniformis, subtilisin BPN’, subtilisin 309, subtilisin 147 and subtilisin 168, and e.g. protease PD138 (described in WO 93/18140). Other useful proteases include e.g. those described in WO 01/016285 and WO 02/016547. Examples of trypsin-like proteases are trypsin (e.g. of porcine or bovine origin), the Fusarium protease described in WO 94/25583 and WO 2005/040372, and the chymotrypsin proteases derived from Cellumonas described in WO 2005/052161 and WO 2005/052146.
One preferred protease is the alkaline protease from Bacillus lentus DSM 5483, as described for example in WO 95/23221 , and variants thereof which are described in e.g. WO 92/21760, WO 95/23221 , EP 1921 147 and EP 1921 148.
Examples of metalloproteases are the neutral metalloprotease as described in WO 2007/044993 such as those derived from Bacillus amyloliquefaciens.
Other examples of useful proteases are the variants described in: WO 89/06279, WO 92/19729, WO 96/034946, WO 98/201 15, WO 98/201 16, WO 99/01 1768, WO 01/44452, WO 03/006602, WO 2004/03186, WO 2004/041979, WO 2007/006305, WO 201 1/036263, WO 201 1/036264, WO 2014/207227 and WO 2016/087617, especially variants with substitutions in one or more of the following positions: 3, 4, 9, 15, 24, 27, 42, 55, 59, 60, 66, 74, 85, 96, 97, 98, 99, 100, 101 , 102, 104, 1 16, 1 18, 121 , 126, 127, 128, 154, 156, 157, 158, 161 , 164, 176, 179, 182, 185, 188, 189, 193, 198, 199, 200, 203, 206, 21 1 , 212, 216, 218, 226, 229, 230, 239, 246, 255, 256, 268 and 269, wherein the positions correspond to the positions of the Bacillus lentus protease (also known as subtilisin 309 or Savinase®) shown in SEQ ID NO: 24. More preferred, the protease variants may comprise one or more of the mutations selected from the group consisting of: S3T, V4I, S9R, S9E, A15T, S24G, S24R, K27R, N42R, S55P, G59E, G59D, N60D, N60E, V66A, N74D, S85R, A96S, S97G, S97D, S97A, S97SD, S99E, S99D, S99G, S99M, S99N, S99R, S99H, S101A, V102I, V102Y, V102N, S104A, G1 16V, G1 16R, H1 18D, H1 18N, A120S, S126L, P127Q, S128A, S154D, A156E, G157D, G157P, G157P, S158E, Y161A,
R164S, Q176E, N179E, S182E, Q185N, A188P, G189E, V193M, N198D, V199I, Q200L,
Y203W, S206G, L21 1 Q, L21 1 D, N212D, N212S, M216S, A226V, K229L, Q230H, Q239R,
N246K, S253D, N255W, N255D, N255E, L256E, L256D T268A and R269H. The protease variants are preferably variants of the Bacillus lentus protease (Savinase®) shown in SEQ ID NO: 24 or the Bacillus amyloliquefaciens protease (BPN’) shown in SEQ ID NO: 25, preferably variants having at least 80% sequence identity to one of these two sequences.
Another preferred protease is the TY145 protease of SEQ ID NO: 26 or a variant thereof. Preferred variants of this protease are those comprising a substitution at one or more positions corresponding to positions 171 , 173, 175, 179 or 180 of SEQ ID NO: 26, wherein the variant has a sequence identity of at least 75% to SEQ ID NO: 26. Suitable variants of SEQ ID NO: 26 are disclosed e.g. in WO 2015/014790, WO 2016/097350, WO 2016/097352, WO 2016/097357 and WO 2016/097354, the contents of which are incorporated herein by reference.
Suitable commercially available protease enzymes include those sold under the trade names Alcalase®, DuralaseTm, DurazyrnTm, Relase®, Relase® Ultra, Savinase®, Savinase® Ultra, Primase®, Polarzyme®, Kannase®, Liquanase®, Liquanase® Ultra, Ovozyme®, Coronase®, Coronase® Ultra, Blaze®, Blaze Evity® 100T, Blaze Evity® 125T, Blaze Evity® 150T, Neutrase®, Everlase®, Esperase®, Progress® Uno, Progress® Excel and Progress® In (Novozymes A/S), those sold under the tradename Maxatase®, Maxacal®, Maxapem®, Purafect Ox®, Purafect OxP®, Puramax®, FN2®, FN3®, FN4®, Excellase®, Excellenz P1000™, Excellenz P1250™, Eraser®, Preferenz P100™, Purafect Prime®, Preferenz P1 10™, Effectenz P1000™, Purafect®™, Effectenz P1050™, Purafect Ox®™, Effectenz P2000™, Purafast®, Properase®, Opticlean®, Optimase®, and Preferenz™ P300 (Danisco/DuPont), Axapem™ (Gist-Brocases N.V.), BLAP (sequence shown in Figure 29 of US5352604) and variants hereof (Henkel AG) and KAP ( Bacillus alkalophilus subtilisin) from Kao.
Preferred proteases for use in the cleaning compositions of the present invention include a) variants of the polypeptide of SEQ ID NO: 24 having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97% or at least 98% sequence identity to SEQ ID NO: 24; b) variants of the polypeptide of SEQ ID NO: 26 having at least 80%, at least 85%, at least 90%, or at least 95% sequence identity to SEQ ID NO: 26; and c) variants of the polypeptide of SEQ ID NO: 37 having at least 90%, at least 95%, at least 96%, at least 97% or at least 98% sequence identity to SEQ ID NO: 37.
One preferred protease for use in the cleaning compositions of the present invention is a variant of the polypeptide of SEQ ID NO: 24 with the substitutions Y161A, R164S and A188P.
Another preferred protease for use in the cleaning compositions of the present invention is a variant of the polypeptide of SEQ ID NO: 24 with the substitutions S9E, N42R, N74D, V199I, Q200L, Y203W, S253D, N255W and L256E.
Another preferred protease for use in the cleaning compositions of the present invention is a variant of the polypeptide of SEQ ID NO: 26 with the substitutions S27K, N109K, S1 1 1 E, S171 E, S173P, G174K, S175P, F180Y, G182A, L184F, Q198E, N199K and T297P, corresponding to the polypeptide of SEQ ID NO: 37.
Amylases
Suitable amylases include alpha-amylases and/or glucoamylases and may be of bacterial orfungal origin. Chemically modified or protein engineered mutants are included. Amylases include, for example, alpha-amylases obtained from Bacillus, e.g., a special strain of Bacillus licheniformis, described in more detail in GB 1 ,296,839.
Suitable amylases include amylases having SEQ ID NO: 2 in WO 95/10603 or variants having 90% sequence identity to SEQ ID NO: 3 thereof. Preferred variants are described in WO 94/02597, WO 94/18314, WO 97/43424 and SEQ ID NO: 4 of WO 99/019467, such as variants with substitutions in one or more of the following positions: 15, 23, 105, 106, 124, 128, 133, 154, 156, 178, 179, 181 , 188, 190, 197, 201 , 202, 207, 208, 209, 21 1 , 243, 264, 304, 305, 391 , 408, and 444. Different suitable amylases include amylases having SEQ ID NO: 6 in WO 02/010355 or variants thereof having 90% sequence identity to SEQ ID NO: 6. Preferred variants of SEQ ID NO: 6 are those having a deletion in positions 181 and 182 and a substitution in position 193.
Other amylases which are suitable are hybrid alpha-amylase comprising residues 1-33 of the alpha-amylase derived from B. amyloliquefaciens shown in SEQ ID NO: 6 of WO 2006/066594 and residues 36-483 of the B. licheniformis alpha-amylase shown in SEQ ID NO: 4 of WO 2006/066594 or variants having 90% sequence identity thereof. Preferred variants of this hybrid alpha-amylase are those having a substitution, a deletion or an insertion in one of more of the following positions: G48, T49, G107, H156, A181 , N190, M197, 1201 , A209 and Q264. Most preferred variants of the hybrid alpha-amylase comprising residues 1 -33 of the alpha-amylase derived from B. amyloliquefaciens shown in SEQ ID NO: 6 of WO 2006/066594 and residues 36- 483 of SEQ ID NO: 4 are those having the substitutions:
M197T;
H156Y+A181T+N190F+A209V+Q264S; or
G48A+T49I+G107A+H 156Y+A181 T+N 190F+I201 F+A209V+Q264S.
Further amylases which are suitable are amylases having SEQ ID NO: 6 in WO 99/019467 or variants thereof having 90% sequence identity to SEQ ID NO: 6. Preferred variants of SEQ ID NO: 6 are those having a substitution, a deletion or an insertion in one or more of the following positions: R181 , G182, H183, G184, N195, I206, E212, E216 and K269. Particularly preferred amylases are those having deletion in positions R181 and G182, or positions H183 and G184.
Additional amylases which can be used are those having SEQ ID NO: 1 , SEQ ID NO: 3, SEQ ID NO: 2 or SEQ ID NO: 7 of WO 96/023873 or variants thereof having 90% sequence identity to SEQ ID NO: 1 , SEQ ID NO: 2, SEQ ID NO: 3 or SEQ ID NO: 7. Preferred variants of SEQ ID NO: 1 , SEQ ID NO: 2, SEQ ID NO: 3 or SEQ ID NO: 7 are those having a substitution, a deletion or an insertion in one or more of the following positions: 140, 181 , 182, 183, 184, 195, 206, 212, 243, 260, 269, 304 and 476, using SEQ ID 2 of WO 96/023873 for numbering. More preferred variants are those having a deletion in two positions selected from 181 , 182, 183 and 184, such as 181 and 182, 182 and 183, or positions 183 and 184. Most preferred amylase variants of SEQ ID NO: 1 , SEQ ID NO: 2 or SEQ ID NO: 7 are those having a deletion in positions 183 and 184 and a substitution in one or more of positions 140, 195, 206, 243, 260, 304 and 476.
Other amylases which can be used are amylases having SEQ ID NO: 2 of WO 08/153815, SEQ ID NO: 10 in WO 01/66712 or variants thereof having 90% sequence identity to SEQ ID NO: 2 of WO 08/153815 or 90% sequence identity to SEQ ID NO: 10 in WO 01/66712. Preferred variants of SEQ ID NO: 10 in WO 01/66712 are those having a substitution, a deletion or an insertion in one of more of the following positions: 176, 177, 178, 179, 190, 201 , 207, 21 1 and 264.
Further suitable amylases are amylases having SEQ ID NO: 2 of WO 09/061380 or variants having 90% sequence identity to SEQ ID NO: 2 thereof. Preferred variants of SEQ ID NO: 2 are those having a truncation of the C-terminus and/or a substitution, a deletion or an insertion in one of more of the following positions: Q87, Q98, S125, N128, T131 , T165, K178, R180, S181 , T182, G183, M201 , F202, N225, S243, N272, N282, Y305, R309, D319, Q320, Q359, K444 and G475. More preferred variants of SEQ ID NO: 2 are those having the substitution in one of more of the following positions: Q87E,R, Q98R, S125A, N128C, T131 I, T165I, K178L, T182G, M201 L, F202Y, N225E,R, N272E,R, S243Q,A,E,D, Y305R, R309A, Q320R, Q359E, K444E and G475K and/or deletion in position R180 and/or S181 or of T182 and/or G183. Most preferred amylase variants of SEQ ID NO: 2 are those having the substitutions:
N128C+K178L+T182G+Y305R+G475K;
N 128C+K178L+T182G+F202Y+Y305R+D319T+G475K;
S125A+N128C+K178L+T182G+Y305R+G475K; or
S125A+N 128C+T1311+T165I+K178L+T182G+Y305R+G475K wherein the variants are C- terminally truncated and optionally further comprises a substitution at position 243 and/or a deletion at position 180 and/or position 181 .
Further suitable amylases are amylases having SEQ ID NO: 1 of W013184577 or variants having 90% sequence identity to SEQ ID NO: 1 thereof. Preferred variants of SEQ ID NO: 1 are those having a substitution, a deletion or an insertion in one of more of the following positions: K176, R178, G179, T180, G181 , E187, N192, M199, I203, S241 , R458, T459, D460, G476 and G477. More preferred variants of SEQ ID NO: 1 are those having the substitution in one of more of the following positions: K176L, E187P, N192FYH, M199L, I203YF, S241 QADN, R458N, T459S, D460T, G476K and G477K and/or deletion in position R178 and/or S179 or of T180 and/or G181. Most preferred amylase variants of SEQ ID NO: 1 are those having the substitutions:
E187P+I203Y+G476K
E187P+I203Y+R458N+T459S+D460T+G476K
wherein the variants optionally further comprise a substitution at position 241 and/or a deletion at position 178 and/or position 179.
Further suitable amylases are amylases having SEQ ID NO: 1 of W010104675 or variants having 90% sequence identity to SEQ ID NO: 1 thereof. Preferred variants of SEQ ID NO: 1 are those having a substitution, a deletion or an insertion in one of more of the following positions: N21 , D97, V128 K177, R179, S180, 1181 , G182, M200, L204, E242, G477 and G478. More preferred variants of SEQ ID NO: 1 are those having the substitution in one of more of the following positions: N21 D, D97N, V128I K177L, M200L, L204YF, E242QA, G477K and G478K and/or deletion in position R179 and/or S180 or of 1181 and/or G182. Most preferred amylase variants of SEQ ID NO: 1 are those having the substitutions:
N21 D+D97N+V128I
wherein the variants optionally further comprise a substitution at position 200 and/or a deletion at position 180 and/or position 181. Other suitable amylases are the alpha-amylase having SEQ ID NO: 12 in WO01/66712 or a variant having at least 90% sequence identity to SEQ ID NO: 12. Preferred amylase variants are those having a substitution, a deletion or an insertion in one of more of the following positions of SEQ ID NO: 12 in WO01/66712: R28, R118, N174; R181 , G182, D183, G184, G186, W189, N195, M202, Y298, N299, K302, S303, N306, R310, N314; R320, H324, E345, Y396, R400, W439, R444, N445, K446, Q449, R458, N471 , N484. Preferred amylases include variants having a deletion of D183 and G184 and having the substitutions R1 18K, N195F, R320K and R458K, and a variant additionally having substitutions in one or more position selected from the group: M9, G149, G182, G186, M202, T257, Y295, N299, M323, E345 and A339, most preferred a variant that additionally has substitutions in all these positions.
Other examples are amylase variants such as those described in WO201 1/098531 , WO2013/001078 and WO2013/001087.
Commercially available amylases are Duramyl™, Termamyl™, Fungamyl™, Stainzyme™, Stainzyme Plus™, Natalase™, Liquozyme X, BAN™, Amplify® and Amplify® Prime (from Novozymes A/S), and Rapidase™, Purastar™/Effectenz™, Powerase, Preferenz S1000, Preferenz S100 and Preferenz S1 10 (from Genencor International Inc./DuPont).
In one embodiment, the cleaning composition of the invention comprises an amylase which is a variant of the polypeptide of SEQ ID NO: 27 with the mutations W140Y, N195F, D183*, G184*, V206Y, Y243F, E260G, G304R and G476K.
In another embodiment, the cleaning composition of the invention comprises an amylase which is a variant of the polypeptide of SEQ ID NO: 27 with the mutations H 1 *, G7A, G109A, W140Y, N195F, D183*, G184*, V206Y, Y243F, E260G, N280S, G304R, E391A and G476K.
In another embodiment, the cleaning composition of the invention comprises an amylase which is a variant of the polypeptide of SEQ ID NO: 28 with the mutations M9L, G149A, R1 18K, G182T, D183*, G184*, G186A, N195F, T246V, T257I, Y295F, N299Y, M323T, A339S and E345R.
In another embodiment, the cleaning composition of the invention comprises an amylase which is a variant of the polypeptide of SEQ ID NO: 28 with the mutations R1 18K, D183*, G184*, N195F, R320K and R458K.
In another embodiment, the cleaning composition of the invention comprises an amylase which is a variant of the polypeptide of SEQ ID NO: 28 with the mutations M9L, G149A, R1 18K, G182T, D183*, G184*, G186A, N195F, M202L, T257I, Y295F, N299Y, M323T, A339S and E345R.
In a preferred embodiment, the cleaning composition of the invention comprises an amylase which is a variant of the polypeptide of SEQ ID NO: 29 with the mutations H1 *, N54S, V56T, K72R, G109A, F1 13Q, R1 16Q, W167F, Q172G, A174S, G182*, D183*, G184T, N195F, V206L, K391A, P473R and G476K. In another preferred embodiment, the cleaning composition of the invention comprises an amylase which is a variant of the polypeptide of SEQ ID NO: 30 with the mutations H183*, G184*, I405L, A421 H, A422P and A428T.
Lipases
Suitable lipases include those of bacterial or fungal origin. Chemically modified or protein engineered mutant enzymes are included. Examples include lipase from Thermomyces, e.g. from T. lanuginosus (previously named Humicola lanuginosa) as described in EP258068 and EP305216, cutinase from Humicola, e.g. H. insolens (WO96/13580), lipase from strains of Pseudomonas (some of these now renamed to Burkholderia), e.g. P. alcaligenes or P. pseudoalcaligenes (EP218272), P. cepacia (EP331376), P. sp. strain SD705 (W095/06720 & W096/27002), P. wisconsinensis (WO96/12012), GDSL-type Streptomyces lipases (W010/065455), lipase from Thermobifida fusca (W01 1/084412), Geobacillus stearothermophilus lipase (W01 1/084417), lipase from Bacillus subtilis (W01 1/084599), and lipase from Streptomyces griseus (W01 1/150157) and S. pristinaespiralis (W012/137147).
Other examples are lipase variants such as those described in EP407225, WO92/05249, WO94/01541 , W094/25578, W095/14783, WO95/30744, W095/35381 , W095/22615,
W096/00292, W097/04079, W097/07202, WO00/34450, WO00/60063, W001/92502,
W007/87508 and WO09/109500.
Preferred commercial lipase products include Lipolase™, Lipex™, Lipolex™ and Lipoclean™ (Novozymes A/S), Lumafast (originally from Genencor) and Lipomax (originally from Gist-Brocades).
Still other examples are lipases sometimes referred to as acyltransferases or perhydrolases, e.g. acyltransferases with homology to Candida antarctica lipase A (W010/11 1 143), acyltransferase from Mycobacterium smegmatis (WO05/56782), perhydrolases from the CE 7 family (WO09/67279), and variants of the M. smegmatis perhydrolase in particular the S54V variant used in the commercial product Gentle Power Bleach from Huntsman Textile Effects Pte Ltd (W010/100028).
In some embodiments, the cleaning composition of the invention comprises a lipase which is a variant of the polypeptide of SEQ ID NO: 31.
In one embodiment, the cleaning composition of the invention comprises a lipase which is a variant of the polypeptide of SEQ ID NO: 31 with the mutations T231 R and N233R.
In one embodiment, the cleaning composition of the invention comprises a lipase which is a variant of the polypeptide of SEQ ID NO: 31 with the mutations N33Q, G91 Q, E210Q, T231 R, N233R and I255A. In one embodiment, the cleaning composition of the invention comprises a lipase which is a variant of the polypeptide of SEQ ID NO: 31 with the mutations E1 C, D27R, G38A, F51V, D96E, K98I, D1 1 1A, G163K, H198S, Y220F, T231 R, N233C, D254S and P256T.
In one embodiment, the cleaning composition of the invention comprises a lipase which is a variant of the polypeptide of SEQ ID NO: 31 with the mutations D27R, G38A, D96E, D1 1 1A, G163K, T231 R, N233R, D254S and P256T.
Mannanases
Suitable mannanases include those of bacterial or fungal origin. Chemically or genetically modified mutants are included. The mannanase may be an alkaline mannanase of Family 5 or 26. It may be a wild-type from Bacillus or Humicola, particularly B. agaradhaerens, B. licheniformis, B. halodurans, B. clausii, or H. insolens. Suitable mannanases are described e.g. in WO 1999/064619. A commercially available mannanase is Mannaway® (Novozymes A/S).
In a preferred embodiment, the cleaning composition of the invention comprises a mannanase with the amino acid sequence of SEQ ID NO: 32.
Pectate Lyase
A pectate lyase is an enzyme that catalyzes the random cleavage of alpha-1 ,4- glycosidic linkages in pectic acid, also known as polygalacturonic acid, by transelimination. Pectate lyases include the enzyme class polygalacturonate lyase (EC 4.2.2.2) (PGL), also known as poly(1 ,4-alpha-D-galacturonide) lyase.
Suitable pectate lyases include those of bacterial or fungal origin. Chemically or genetically modified pectate lyase are included. Pectate lyases have been cloned from different bacterial genera such as Erwinia, Pseudomonas, Klebsiella and Xanthomonas. Also from Bacillus subtilis (Nasser et al. (1993) FEBS 335:319-326) and Bacillus sp. YA-14 (Kim et al. (1994) Biosci. Biotech. Biochem. 58:947-949) cloning of a pectate lyase has been described. Variants of a pectate lyase from Bacillus subtilis have been disclosed in WO 2002/092741 and WO 2003/095638.
Commercially available pectate lyases include Xpect® (Novozymes, A/S), Pectawash® (Novozymes, A/S) and Pectaway® (Novozymes, A/S).
In a preferred embodiment, the cleaning composition of the invention comprises a pectate lyase with the amino acid sequence of SEQ ID NO: 33.
Cellulases and xyloglucanases
Suitable cellulases include those of bacterial or fungal origin. Chemically modified or protein engineered mutants are included. Suitable cellulases include those from the genera Bacillus, Pseudomonas, Humicola, Fusarium, Thielavia, or Acremonium, e.g., the fungal cellulases produced from Humicola insolens, Myceliophthora thermophila and Fusarium oxysporum disclosed in US 4,435,307, US 5,648,263, US 5,691 ,178, US 5,776,757 and WO 89/09259.
Especially suitable cellulases are the alkaline or neutral cellulases having colour care benefits. Examples of such cellulases are those described in EP 0 495 257, EP 0 531 372, WO 96/1 1262, WO 96/29397, WO 98/08940. Other examples are cellulase variants such as those described in WO 94/07998, EP 0 531 315, US 5,457,046, US 5,686,593, US 5,763,254, WO 95/24471 , WO 98/12307 and W099/001544.
Other cellulases are e.g. an endo-beta-1 ,4-glucanase enzyme having a sequence of at least 97% identity to the amino acid sequence of positions 1-773 of SEQ ID NO:2 of WO 02/099091 or a family 44 xyloglucanase, which a xyloglucanase enzyme having a sequence of at least 60% identity to positions 40-559 of SEQ ID NO: 2 of WO 01/062903.
Commercially available cellulases include Celluzyme™, and Carezyme™ (Novozymes A/S) Carezyme Premium™ (Novozymes A/S), Celluclean™ (Novozymes A/S), Celluclean Classic™ (Novozymes A/S), Cellusoft™ (Novozymes A/S), Whitezyme™ (Novozymes A/S), Clazinase™, and Puradax HA™ (Genencor International Inc.), and KAC-500(B)™ (Kao Corporation).
In one preferred embodiment, the cleaning composition of the invention comprises a cellulase with the amino acid sequence of SEQ ID NO: 34.
In another preferred embodiment, the cleaning composition of the invention comprises a cellulase with the amino acid sequence of SEQ ID NO: 35.
In a further preferred embodiment, the cleaning composition of the invention comprises two cellulases, in particular a cellulase with the amino acid sequence of SEQ ID NO: 34 and a cellulase with the amino acid sequence of SEQ ID NO: 35.
In another preferred embodiment, the cleaning composition of the invention comprises a xyloglucanase with the amino acid sequence of SEQ ID NO: 36.
Peroxidases/Oxidases
Suitable peroxidases/oxidases include those of plant, bacterial or fungal origin. Chemically modified or protein engineered mutants are included. A suitable peroxidase is a peroxidase enzyme comprised by the enzyme classification EC 1.1 1.1.7, as set out by the Nomenclature Committee of the International Union of Biochemistry and Molecular Biology (IUBMB), or any fragment derived therefrom, exhibiting peroxidase activity.
Examples of useful peroxidases include peroxidases from Coprinus, e.g., from C. cinereus, and variants thereof as those described in WO 93/24618, WO 95/10602, and WO 98/15257. Commercially available peroxidases include Guardzyme™ (Novozymes A/S).
Other suitable peroxidases are haloperoxidase enzymes, such as chloroperoxidase, bromoperoxidase and compounds exhibiting chloroperoxidase or bromoperoxidase activity. Haloperoxidases are classified according to their specificity for halide ions. Chloroperoxidases (E.C. 1.1 1.1.10) catalyze formation of hypochlorite from chloride ions. Preferably, the haloperoxidase is a vanadium haloperoxidase, i.e., a vanadate-containing haloperoxidase. Haloperoxidases have been isolated from many different fungi, in particular from the fungus group dematiaceous hyphomycetes, such as Caldariomyces, e.g., C. fumago, Alternaria, Curvularia, e.g., C. verruculosa and C. inaequalis, Drechslera, Ulocladium and Botrytis.
Haloperoxidases have also been isolated from bacteria such as Pseudomonas, e.g., P. pyrrocinia and Streptomyces, e.g., S. aureofaciens.
A suitable oxidase also includes any laccase enzyme comprised by the enzyme classification EC 1.10.3.2, or any fragment derived therefrom exhibiting laccase activity, or a compound exhibiting a similar activity, such as a catechol oxidase (EC 1.10.3.1 ), an o-aminophenol oxidase (EC 1.10.3.4), or a bilirubin oxidase (EC 1.3.3.5). Preferred laccase enzymes are enzymes of microbial origin. The enzymes may be derived from plants, bacteria or fungi (including filamentous fungi and yeasts). Suitable examples from fungi include a laccase derivable from a strain of Aspergillus, Neurospora, e.g., N. crassa, Podospora, Botrytis, Collybia, Fomes, Lentinus, Pleurotus, Trametes, e.g., T. villosa and T. versicolor, Rhizoctonia, e.g., R. solani, Coprinopsis, e.g., C. cinerea, C. comatus, C. friesii, and C. plicatilis, Psathyrella, e.g., P. condelleana, Panaeolus, e.g., P. papilionaceus, Myceliophthora, e.g., M. thermophila, Schytalidium, e.g., S. thermophilum, Polyporus, e.g., P. pinsitus, Phlebia, e.g., P. radiata (WO 92/01046), or Coriolus, e.g., C. hirsutus (JP 2238885). Suitable examples from bacteria include a laccase derivable from a strain ot Bacillus. A laccase derived from Coprinopsis or Myceliophthora is preferred; in particular, a laccase derived from Coprinopsis cinerea, as disclosed in WO 97/08325; or from Myceliophthora thermophila, as disclosed in WO 95/33836.
Cleaning compositions
As explained above, the cleaning composition of the invention in its broadest aspect comprises at least two cleaning enzymes selected from the group consisting of nucleases, hexosaminidases and glycosyl hydrolases and at least two detergent enzymes selected from the group consisting of proteases, amylases, lipases, mannanases, pectate lyases and cellulases.
More specifically, the invention relates to a cleaning composition comprising 1 ) at least two cleaning enzymes selected from the group consisting of nucleases, hexosaminidases and glycosyl hydrolases, wherein the nuclease is a DNase or an RNase, and the glycosyl hydrolase is a Glyco_hydro_1 14, GH39 or GHL13 glycosyl hydrolase; and 2) at least two detergent enzymes selected from the group consisting of proteases, amylases, lipases, mannanases, pectate lyases and cellulases.
The compositions of the invention will typically comprise a cleaning enzyme selected from at least two of the categories nucleases, hexosaminidases and glycosyl hydrolases. In other words, the compositions will typically comprise one of the following combinations: a) at least one nuclease and at least one hexosaminidase; b) at least one nuclease and at least one glycosyl hydrolase; or c) at least one hexosaminidase and at least one glycosyl hydrolase. The compositions may of course comprise one or more enzymes from each of these groups, i.e. at least one nuclease, at least one hexosaminidase and at least one glycosyl hydrolase.
Cleaning compositions comprising a DNase and a Glvco hydro 114 polypeptide
One aspect of the invention relates to a cleaning composition comprising at least a DNase and a Glyco_hydro_1 14 glycosyl hydrolase as the cleaning enzymes. Exemplary embodiments of this aspect of the invention are described below.
In one embodiment, the composition comprises:
• a DNase that comprises or consists of SEQ ID NO: 1 , or which is a variant thereof having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity to SEQ ID NO: 1 ;
• a Glyco_hydro_1 14 polypeptide that comprises or consists of SEQ ID NO: 6, or which is a variant thereof having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity to SEQ ID NO: 6;
• a protease selected from: a) a polypeptide that comprises or consists of SEQ ID NO: 24 or SEQ ID NO: 26, or a variant thereof having at least 80%, at least 85%, at least 90% or at least 95% sequence identity to SEQ ID NO: 24 or SEQ ID NO: 26; b) a polypeptide that comprises SEQ ID NO: 24 with the substitutions Y161A, R164S and A188P; c) a polypeptide that comprises SEQ ID NO: 24 with the substitutions S9E, N42R, N74D, V199I, Q200L, Y203W, S253D, N255W and L256E; and d) a polypeptide that comprises SEQ ID NO: 37; and
• at least one enzyme selected from the group consisting of amylases, lipases, mannanases, pectate lyases and cellulases.
In one embodiment, the composition comprises:
• a DNase that comprises or consists of SEQ ID NO: 1 ;
• a Glyco_hydro_1 14 polypeptide that comprises or consists of SEQ ID NO: 6;
• a protease that comprises SEQ ID NO: 24 with the substitutions Y161A, R164S and A188P, or that comprises SEQ ID NO: 37; and
• at least one enzyme selected from the group consisting of amylases, lipases, mannanases, pectate lyases and cellulases; wherein:
o the amylase comprises SEQ ID NO: 30 with the mutations H183*, G184*, I405L, A421 H, A422P and A428T; o the lipase comprises SEQ ID NO: 31 with the mutations D27R, G38A, D96E, D11 1A, G163K, T231 R, N233R, D254S and P256T; o the mannanase comprises SEQ ID NO: 32;
o the pectate lyase comprises SEQ ID NO: 33; and
o the cellulase comprises SEQ ID NO: 34 or SEQ ID NO: 35.
In one embodiment, the composition comprises:
• a DNase that comprises or consists of SEQ ID NO: 1 ;
• a Glyco_hydro_1 14 polypeptide that comprises or consists of SEQ ID NO: 6;
• a protease that comprises SEQ ID NO: 24 with the substitutions S9E, N42R, N74D, V199I, Q200L, Y203W, S253D, N255W and L256E; and
• at least one enzyme selected from the group consisting of amylases and cellulases; wherein:
o the amylase comprises SEQ ID NO: 29 with the mutations H 1 *, N54S, V56T, K72R, G109A, F113Q, R116Q, W167F, Q172G, A174S, G182*, D183*, G184T, N195F, V206L, K391A, P473R and G476K; and o the cellulase comprises SEQ ID NO: 34.
In one embodiment, the composition comprises:
• a DNase that comprises or consists of SEQ ID NO: 1 , or which is a variant thereof having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity to SEQ ID NO: 1 ;
• a Glyco_hydro_1 14 polypeptide that comprises or consists of SEQ ID NO: 7, or which is a variant thereof having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity to SEQ ID NO: 7;
• a protease selected from: a) a polypeptide that comprises or consists of SEQ ID NO: 24 or SEQ ID NO: 26, or a variant thereof having at least 80%, at least 85%, at least 90% or at least 95% sequence identity to SEQ ID NO: 24 or SEQ ID NO: 26; b) a polypeptide that comprises SEQ ID NO: 24 with the substitutions Y161A, R164S and A188P; c) a polypeptide that comprises SEQ ID NO: 24 with the substitutions S9E, N42R, N74D, V199I, Q200L, Y203W, S253D, N255W and L256E; and d) a polypeptide that comprises SEQ ID NO: 37; and
• at least one enzyme selected from the group consisting of amylases, lipases, mannanases, pectate lyases and cellulases.
In one embodiment, the composition comprises:
• a DNase that comprises or consists of SEQ ID NO: 1 ;
• a Glyco_hydro_1 14 polypeptide that comprises or consists of SEQ ID NO: 7; • a protease that comprises SEQ ID NO: 24 with the substitutions Y161A, R164S and A188P, or that comprises SEQ ID NO: 37; and
• at least one enzyme selected from the group consisting of amylases, lipases, mannanases, pectate lyases and cellulases; wherein:
o the amylase comprises SEQ ID NO: 30 with the mutations H183*, G184*, I405L, A421 H, A422P and A428T;
o the lipase comprises SEQ ID NO: 31 with the mutations D27R, G38A, D96E, D11 1A, G163K, T231 R, N233R, D254S and P256T; o the mannanase comprises SEQ ID NO: 32;
o the pectate lyase comprises SEQ ID NO: 33; and
o the cellulase comprises SEQ ID NO: 34 or SEQ ID NO: 35.
In one embodiment, the composition comprises:
• a DNase that comprises or consists of SEQ ID NO: 1 ;
• a Glyco_hydro_1 14 polypeptide that comprises or consists of SEQ ID NO: 7;
• a protease that comprises SEQ ID NO: 24 with the substitutions S9E, N42R, N74D, V199I, Q200L, Y203W, S253D, N255W and L256E; and
• at least one enzyme selected from the group consisting of amylases and cellulases; wherein:
o the amylase comprises SEQ ID NO: 29 with the mutations H 1 *, N54S, V56T, K72R, G109A, F113Q, R116Q, W167F, Q172G, A174S, G182*, D183*, G184T, N195F, V206L, K391A, P473R and G476K; and o the cellulase comprises SEQ ID NO: 34.
In one embodiment, the composition comprises:
• a DNase that comprises or consists of SEQ I D NO: 1 , or which is a variant thereof having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity to SEQ ID NO: 1 ;
• a Glyco_hydro_1 14 polypeptide that comprises or consists of SEQ ID NO: 8, or which is a variant thereof having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity to SEQ ID NO: 8;
• a protease selected from: a) a polypeptide that comprises or consists of SEQ ID NO: 24 or SEQ ID NO: 26, or a variant thereof having at least 80%, at least 85%, at least 90% or at least 95% sequence identity to SEQ ID NO: 24 or SEQ ID NO: 26; b) a polypeptide that comprises SEQ ID NO: 24 with the substitutions Y161A, R164S and A188P; c) a polypeptide that comprises SEQ ID NO: 24 with the substitutions S9E, N42R, N74D, V199I, Q200L, Y203W, S253D, N255W and L256E; and d) a polypeptide that comprises SEQ ID NO: 37; and
• at least one enzyme selected from the group consisting of amylases, lipases, mannanases, pectate lyases and cellulases.
In one embodiment, the composition comprises:
• a DNase that comprises or consists of SEQ ID NO: 1 ;
• a Glyco_hydro_1 14 polypeptide that comprises or consists of SEQ ID NO: 8;
• a protease that comprises SEQ ID NO: 24 with the substitutions Y161A, R164S and A188P, or that comprises SEQ ID NO: 37; and
• at least one enzyme selected from the group consisting of amylases, lipases, mannanases, pectate lyases and cellulases; wherein:
o the amylase comprises SEQ ID NO: 30 with the mutations H183*, G184*, I405L, A421 H, A422P and A428T;
o the lipase comprises SEQ ID NO: 31 with the mutations D27R, G38A, D96E, D11 1A, G163K, T231 R, N233R, D254S and P256T; o the mannanase comprises SEQ ID NO: 32;
o the pectate lyase comprises SEQ ID NO: 33; and
o the cellulase comprises SEQ ID NO: 34 or SEQ ID NO: 35.
In one embodiment, the composition comprises:
• a DNase that comprises or consists of SEQ ID NO: 1 ;
• a Glyco_hydro_1 14 polypeptide that comprises or consists of SEQ ID NO: 8;
• a protease that comprises SEQ ID NO: 24 with the substitutions S9E, N42R, N74D, V199I, Q200L, Y203W, S253D, N255W and L256E; and
• at least one enzyme selected from the group consisting of amylases and cellulases; wherein:
o the amylase comprises SEQ ID NO: 29 with the mutations H 1 *, N54S, V56T, K72R, G109A, F113Q, R116Q, W167F, Q172G, A174S, G182*, D183*, G184T, N195F, V206L, K391A, P473R and G476K; and o the cellulase comprises SEQ ID NO: 34.
In one embodiment, the composition comprises:
• a DNase that comprises or consists of SEQ ID NO: 1 , or which is a variant thereof having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity to SEQ ID NO: 1 ;
• a Glyco_hydro_1 14 polypeptide that comprises or consists of SEQ ID NO: 9, or which is a variant thereof having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity to SEQ ID NO: 9;
• a protease selected from: a) a polypeptide that comprises or consists of SEQ ID NO: 24 or SEQ ID NO: 26, or a variant thereof having at least 80%, at least 85%, at least 90% or at least 95% sequence identity to SEQ ID NO: 24 or SEQ ID NO: 26; b) a polypeptide that comprises SEQ ID NO: 24 with the substitutions Y161A, R164S and A188P; c) a polypeptide that comprises SEQ ID NO: 24 with the substitutions S9E, N42R, N74D, V199I, Q200L, Y203W, S253D, N255W and L256E; and d) a polypeptide that comprises SEQ ID NO: 37; and
• at least one enzyme selected from the group consisting of amylases, lipases, mannanases, pectate lyases and cellulases.
In one embodiment, the composition comprises:
• a DNase that comprises or consists of SEQ ID NO: 1 ;
• a Glyco_hydro_1 14 polypeptide that comprises or consists of SEQ ID NO: 9;
• a protease that comprises SEQ ID NO: 24 with the substitutions Y161A, R164S and A188P, or that comprises SEQ ID NO: 37; and
• at least one enzyme selected from the group consisting of amylases, lipases, mannanases, pectate lyases and cellulases; wherein:
o the amylase comprises SEQ ID NO: 30 with the mutations H183*, G184*, I405L, A421 H, A422P and A428T;
o the lipase comprises SEQ ID NO: 31 with the mutations D27R, G38A, D96E, D11 1A, G163K, T231 R, N233R, D254S and P256T; o the mannanase comprises SEQ ID NO: 32;
o the pectate lyase comprises SEQ ID NO: 33; and
o the cellulase comprises SEQ ID NO: 34 or SEQ ID NO: 35.
In one embodiment, the composition comprises:
• a DNase that comprises or consists of SEQ ID NO: 1 ;
• a Glyco_hydro_1 14 polypeptide that comprises or consists of SEQ ID NO: 9;
• a protease that comprises SEQ ID NO: 24 with the substitutions S9E, N42R, N74D, V199I, Q200L, Y203W, S253D, N255W and L256E; and
• at least one enzyme selected from the group consisting of amylases and cellulases; wherein:
o the amylase comprises SEQ ID NO: 29 with the mutations H 1 *, N54S, V56T, K72R, G109A, F113Q, R116Q, W167F, Q172G, A174S, G182*, D183*, G184T, N195F, V206L, K391A, P473R and G476K; and o the cellulase comprises SEQ ID NO: 34. In one embodiment, the composition comprises:
• a DNase that comprises or consists of SEQ ID NO: 2, or which is a variant thereof having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity to SEQ ID NO: 2;
• a Glyco_hydro_1 14 polypeptide that comprises or consists of SEQ ID NO: 6, or which is a variant thereof having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity to SEQ ID NO: 6;
• a protease selected from: a) a polypeptide that comprises or consists of SEQ ID NO: 24 or SEQ ID NO: 26, or a variant thereof having at least 80%, at least 85%, at least 90% or at least 95% sequence identity to SEQ ID NO: 24 or SEQ ID NO: 26; b) a polypeptide that comprises SEQ ID NO: 24 with the substitutions Y161A, R164S and A188P; c) a polypeptide that comprises SEQ ID NO: 24 with the substitutions S9E, N42R, N74D, V199I, Q200L, Y203W, S253D, N255W and L256E; and d) a polypeptide that comprises SEQ ID NO: 37; and
• at least one enzyme selected from the group consisting of amylases, lipases, mannanases, pectate lyases and cellulases.
In one embodiment, the composition comprises:
• a DNase that comprises or consists of SEQ ID NO: 2;
• a Glyco_hydro_1 14 polypeptide that comprises or consists of SEQ ID NO: 6;
• a protease that comprises SEQ ID NO: 24 with the substitutions Y161A, R164S and A188P, or that comprises SEQ ID NO: 37; and
• at least one enzyme selected from the group consisting of amylases, lipases, mannanases, pectate lyases and cellulases; wherein:
o the amylase comprises SEQ ID NO: 30 with the mutations H183*, G184*, I405L, A421 H, A422P and A428T;
o the lipase comprises SEQ ID NO: 31 with the mutations D27R, G38A, D96E, D11 1A, G163K, T231 R, N233R, D254S and P256T; o the mannanase comprises SEQ ID NO: 32;
o the pectate lyase comprises SEQ ID NO: 33; and
o the cellulase comprises SEQ ID NO: 34 or SEQ ID NO: 35.
In one embodiment, the composition comprises:
• a DNase that comprises or consists of SEQ ID NO: 2;
• a Glyco_hydro_1 14 polypeptide that comprises or consists of SEQ ID NO: 6;
• a protease that comprises SEQ ID NO: 24 with the substitutions S9E, N42R, N74D, V199I, Q200L, Y203W, S253D, N255W and L256E; and • at least one enzyme selected from the group consisting of amylases and cellulases; wherein:
o the amylase comprises SEQ ID NO: 29 with the mutations H 1 *, N54S, V56T, K72R, G109A, F113Q, R116Q, W167F, Q172G, A174S, G182*, D183*, G184T, N195F, V206L, K391A, P473R and G476K; and o the cellulase comprises SEQ ID NO: 34.
In one embodiment, the composition comprises:
• a DNase that comprises or consists of SEQ ID NO: 2, or which is a variant thereof having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity to SEQ ID NO: 2;
• a Glyco_hydro_1 14 polypeptide that comprises or consists of SEQ ID NO: 7, or which is a variant thereof having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity to SEQ ID NO: 7;
• a protease selected from: a) a polypeptide that comprises or consists of SEQ ID NO: 24 or SEQ ID NO: 26, or a variant thereof having at least 80%, at least 85%, at least 90% or at least 95% sequence identity to SEQ ID NO: 24 or SEQ ID NO: 26; b) a polypeptide that comprises SEQ ID NO: 24 with the substitutions Y161A, R164S and A188P; c) a polypeptide that comprises SEQ ID NO: 24 with the substitutions S9E, N42R, N74D, V199I, Q200L, Y203W, S253D, N255W and L256E; and d) a polypeptide that comprises SEQ ID NO: 37; and
• at least one enzyme selected from the group consisting of amylases, lipases, mannanases, pectate lyases and cellulases.
In one embodiment, the composition comprises:
• a DNase that comprises or consists of SEQ ID NO: 2;
• a Glyco_hydro_1 14 polypeptide that comprises or consists of SEQ ID NO: 7;
• a protease that comprises SEQ ID NO: 24 with the substitutions Y161A, R164S and A188P, or that comprises SEQ ID NO: 37; and
• at least one enzyme selected from the group consisting of amylases, lipases, mannanases, pectate lyases and cellulases; wherein:
o the amylase comprises SEQ ID NO: 30 with the mutations H183*, G184*, I405L, A421 H, A422P and A428T;
o the lipase comprises SEQ ID NO: 31 with the mutations D27R, G38A, D96E, D11 1A, G163K, T231 R, N233R, D254S and P256T; o the mannanase comprises SEQ ID NO: 32;
o the pectate lyase comprises SEQ ID NO: 33; and o the cellulase comprises SEQ ID NO: 34 or SEQ ID NO: 35.
In one embodiment, the composition comprises:
• a DNase that comprises or consists of SEQ ID NO: 2;
• a Glyco_hydro_1 14 polypeptide that comprises or consists of SEQ ID NO: 7;
• a protease that comprises SEQ ID NO: 24 with the substitutions S9E, N42R, N74D, V199I, Q200L, Y203W, S253D, N255W and L256E; and
• at least one enzyme selected from the group consisting of amylases and cellulases; wherein:
o the amylase comprises SEQ ID NO: 29 with the mutations H 1 *, N54S, V56T, K72R, G109A, F113Q, R116Q, W167F, Q172G, A174S, G182*, D183*, G184T, N195F, V206L, K391A, P473R and G476K; and o the cellulase comprises SEQ ID NO: 34.
In one embodiment, the composition comprises:
• a DNase that comprises or consists of SEQ ID NO: 2, or which is a variant thereof having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity to SEQ ID NO: 2;
• a Glyco_hydro_1 14 polypeptide that comprises or consists of SEQ ID NO: 8, or which is a variant thereof having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity to SEQ ID NO: 8;
• a protease selected from: a) a polypeptide that comprises or consists of SEQ ID NO: 24 or SEQ ID NO: 26, or a variant thereof having at least 80%, at least 85%, at least 90% or at least 95% sequence identity to SEQ ID NO: 24 or SEQ ID NO: 26; b) a polypeptide that comprises SEQ ID NO: 24 with the substitutions Y161A, R164S and A188P; c) a polypeptide that comprises SEQ ID NO: 24 with the substitutions S9E, N42R, N74D, V199I, Q200L, Y203W, S253D, N255W and L256E; and d) a polypeptide that comprises SEQ ID NO: 37; and
• at least one enzyme selected from the group consisting of amylases, lipases, mannanases, pectate lyases and cellulases.
In one embodiment, the composition comprises:
• a DNase that comprises or consists of SEQ ID NO: 2;
• a Glyco_hydro_1 14 polypeptide that comprises or consists of SEQ ID NO: 8;
• a protease that comprises SEQ ID NO: 24 with the substitutions Y161A, R164S and A188P, or that comprises SEQ ID NO: 37; and
• at least one enzyme selected from the group consisting of amylases, lipases, mannanases, pectate lyases and cellulases; wherein: o the amylase comprises SEQ ID NO: 30 with the mutations H183*, G184*, I405L, A421 H, A422P and A428T;
o the lipase comprises SEQ ID NO: 31 with the mutations D27R, G38A, D96E, D11 1A, G163K, T231 R, N233R, D254S and P256T; o the mannanase comprises SEQ ID NO: 32;
o the pectate lyase comprises SEQ ID NO: 33; and
o the cellulase comprises SEQ ID NO: 34 or SEQ ID NO: 35.
In one embodiment, the composition comprises:
• a DNase that comprises or consists of SEQ ID NO: 2;
• a Glyco_hydro_1 14 polypeptide that comprises or consists of SEQ ID NO: 8;
• a protease that comprises SEQ ID NO: 24 with the substitutions S9E, N42R, N74D, V199I, Q200L, Y203W, S253D, N255W and L256E; and
• at least one enzyme selected from the group consisting of amylases and cellulases; wherein:
o the amylase comprises SEQ ID NO: 29 with the mutations H 1 *, N54S, V56T, K72R, G109A, F113Q, R116Q, W167F, Q172G, A174S, G182*, D183*, G184T, N195F, V206L, K391A, P473R and G476K; and o the cellulase comprises SEQ ID NO: 34.
In one embodiment, the composition comprises:
• a DNase that comprises or consists of SEQ ID NO: 2, or which is a variant thereof having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity to SEQ ID NO: 2;
• a Glyco_hydro_1 14 polypeptide that comprises or consists of SEQ ID NO: 9, or which is a variant thereof having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity to SEQ ID NO: 9;
• a protease selected from: a) a polypeptide that comprises or consists of SEQ ID NO: 24 or SEQ ID NO: 26, or a variant thereof having at least 80%, at least 85%, at least 90% or at least 95% sequence identity to SEQ ID NO: 24 or SEQ ID NO: 26; b) a polypeptide that comprises SEQ ID NO: 24 with the substitutions Y161A, R164S and A188P; c) a polypeptide that comprises SEQ ID NO: 24 with the substitutions S9E, N42R, N74D, V199I, Q200L, Y203W, S253D, N255W and L256E; and d) a polypeptide that comprises SEQ ID NO: 37; and
• at least one enzyme selected from the group consisting of amylases, lipases, mannanases, pectate lyases and cellulases.
In one embodiment, the composition comprises: • a DNase that comprises or consists of SEQ ID NO: 2;
• a Glyco_hydro_1 14 polypeptide that comprises or consists of SEQ ID NO: 9;
• a protease that comprises SEQ ID NO: 24 with the substitutions Y161A, R164S and A188P, or that comprises SEQ ID NO: 37; and
• at least one enzyme selected from the group consisting of amylases, lipases, mannanases, pectate lyases and cellulases; wherein:
o the amylase comprises SEQ ID NO: 30 with the mutations H183*, G184*, I405L, A421 H, A422P and A428T;
o the lipase comprises SEQ ID NO: 31 with the mutations D27R, G38A, D96E, D11 1A, G163K, T231 R, N233R, D254S and P256T; o the mannanase comprises SEQ ID NO: 32;
o the pectate lyase comprises SEQ ID NO: 33; and
o the cellulase comprises SEQ ID NO: 34 or SEQ ID NO: 35.
In one embodiment, the composition comprises:
• a DNase that comprises or consists of SEQ ID NO: 2;
• a Glyco_hydro_1 14 polypeptide that comprises or consists of SEQ ID NO: 9;
• a protease that comprises SEQ ID NO: 24 with the substitutions S9E, N42R, N74D, V199I, Q200L, Y203W, S253D, N255W and L256E; and
• at least one enzyme selected from the group consisting of amylases and cellulases; wherein:
o the amylase comprises SEQ ID NO: 29 with the mutations H 1 *, N54S, V56T, K72R, G109A, F113Q, R116Q, W167F, Q172G, A174S, G182*, D183*, G184T, N195F, V206L, K391A, P473R and G476K; and o the cellulase comprises SEQ ID NO: 34.
In one embodiment, the composition comprises:
• a DNase that comprises or consists of SEQ ID NO: 3, or which is a variant thereof having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity to SEQ ID NO: 3;
• a Glyco_hydro_1 14 polypeptide that comprises or consists of SEQ ID NO: 6, or which is a variant thereof having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity to SEQ ID NO: 6;
• a protease selected from: a) a polypeptide that comprises or consists of SEQ ID NO: 24 or SEQ ID NO: 26, or a variant thereof having at least 80%, at least 85%, at least 90% or at least 95% sequence identity to SEQ ID NO: 24 or SEQ ID NO: 26; b) a polypeptide that comprises SEQ ID NO: 24 with the substitutions Y161A, R164S and A188P; c) a polypeptide that comprises SEQ ID NO: 24 with the substitutions S9E, N42R, N74D, V199I, Q200L, Y203W, S253D, N255W and L256E; and d) a polypeptide that comprises SEQ ID NO: 37; and
• at least one enzyme selected from the group consisting of amylases, lipases, mannanases, pectate lyases and cellulases.
In one embodiment, the composition comprises:
• a DNase that comprises or consists of SEQ ID NO: 3;
• a Glyco_hydro_1 14 polypeptide that comprises or consists of SEQ ID NO: 6;
• a protease that comprises SEQ ID NO: 24 with the substitutions Y161A, R164S and A188P, or that comprises SEQ ID NO: 37; and
• at least one enzyme selected from the group consisting of amylases, lipases, mannanases, pectate lyases and cellulases; wherein:
o the amylase comprises SEQ ID NO: 30 with the mutations H183*, G184*, I405L, A421 H, A422P and A428T;
o the lipase comprises SEQ ID NO: 31 with the mutations D27R, G38A, D96E, D11 1A, G163K, T231 R, N233R, D254S and P256T; o the mannanase comprises SEQ ID NO: 32;
o the pectate lyase comprises SEQ ID NO: 33; and
o the cellulase comprises SEQ ID NO: 34 or SEQ ID NO: 35.
In one embodiment, the composition comprises:
• a DNase that comprises or consists of SEQ ID NO: 3;
• a Glyco_hydro_1 14 polypeptide that comprises or consists of SEQ ID NO: 6;
• a protease that comprises SEQ ID NO: 24 with the substitutions S9E, N42R, N74D, V199I, Q200L, Y203W, S253D, N255W and L256E; and
• at least one enzyme selected from the group consisting of amylases and cellulases; wherein:
o the amylase comprises SEQ ID NO: 29 with the mutations H 1 *, N54S, V56T, K72R, G109A, F113Q, R116Q, W167F, Q172G, A174S, G182*, D183*, G184T, N195F, V206L, K391A, P473R and G476K; and o the cellulase comprises SEQ ID NO: 34.
In one embodiment, the composition comprises:
• a DNase that comprises or consists of SEQ ID NO: 3, or which is a variant thereof having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity to SEQ ID NO: 3;
• a Glyco_hydro_1 14 polypeptide that comprises or consists of SEQ ID NO: 7, or which is a variant thereof having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity to SEQ ID NO: 7;
• a protease selected from: a) a polypeptide that comprises or consists of SEQ ID NO: 24 or SEQ ID NO: 26, or a variant thereof having at least 80%, at least 85%, at least 90% or at least 95% sequence identity to SEQ ID NO: 24 or SEQ ID NO: 26; b) a polypeptide that comprises SEQ ID NO: 24 with the substitutions Y161A, R164S and A188P; c) a polypeptide that comprises SEQ ID NO: 24 with the substitutions S9E, N42R, N74D, V199I, Q200L, Y203W, S253D, N255W and L256E; and d) a polypeptide that comprises SEQ ID NO: 37; and
• at least one enzyme selected from the group consisting of amylases, lipases, mannanases, pectate lyases and cellulases.
In one embodiment, the composition comprises:
• a DNase that comprises or consists of SEQ ID NO: 3;
• a Glyco_hydro_1 14 polypeptide that comprises or consists of SEQ ID NO: 7;
• a protease that comprises SEQ ID NO: 24 with the substitutions Y161A, R164S and A188P, or that comprises SEQ ID NO: 37; and
• at least one enzyme selected from the group consisting of amylases, lipases, mannanases, pectate lyases and cellulases; wherein:
o the amylase comprises SEQ ID NO: 30 with the mutations H183*, G184*, I405L, A421 H, A422P and A428T;
o the lipase comprises SEQ ID NO: 31 with the mutations D27R, G38A, D96E, D11 1A, G163K, T231 R, N233R, D254S and P256T; o the mannanase comprises SEQ ID NO: 32;
o the pectate lyase comprises SEQ ID NO: 33; and
o the cellulase comprises SEQ ID NO: 34 or SEQ ID NO: 35.
In one embodiment, the composition comprises:
• a DNase that comprises or consists of SEQ ID NO: 3;
• a Glyco_hydro_1 14 polypeptide that comprises or consists of SEQ ID NO: 7;
• a protease that comprises SEQ ID NO: 24 with the substitutions S9E, N42R, N74D, V199I, Q200L, Y203W, S253D, N255W and L256E; and
• at least one enzyme selected from the group consisting of amylases and cellulases; wherein:
o the amylase comprises SEQ ID NO: 29 with the mutations H 1 *, N54S, V56T, K72R, G109A, F113Q, R116Q, W167F, Q172G, A174S, G182*, D183*, G184T, N195F, V206L, K391A, P473R and G476K; and o the cellulase comprises SEQ ID NO: 34. In one embodiment, the composition comprises:
• a DNase that comprises or consists of SEQ ID NO: 3, or which is a variant thereof having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity to SEQ ID NO: 3;
• a Glyco_hydro_1 14 polypeptide that comprises or consists of SEQ ID NO: 8, or which is a variant thereof having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity to SEQ ID NO: 8;
• a protease selected from: a) a polypeptide that comprises or consists of SEQ ID NO: 24 or SEQ ID NO: 26, or a variant thereof having at least 80%, at least 85%, at least 90% or at least 95% sequence identity to SEQ ID NO: 24 or SEQ ID NO: 26; b) a polypeptide that comprises SEQ ID NO: 24 with the substitutions Y161A, R164S and A188P; c) a polypeptide that comprises SEQ ID NO: 24 with the substitutions S9E, N42R, N74D, V199I, Q200L, Y203W, S253D, N255W and L256E; and d) a polypeptide that comprises SEQ ID NO: 37; and
• at least one enzyme selected from the group consisting of amylases, lipases, mannanases, pectate lyases and cellulases.
In one embodiment, the composition comprises:
• a DNase that comprises or consists of SEQ ID NO: 3;
• a Glyco_hydro_1 14 polypeptide that comprises or consists of SEQ ID NO: 8;
• a protease that comprises SEQ ID NO: 24 with the substitutions Y161A, R164S and A188P, or that comprises SEQ ID NO: 37; and
• at least one enzyme selected from the group consisting of amylases, lipases, mannanases, pectate lyases and cellulases; wherein:
o the amylase comprises SEQ ID NO: 30 with the mutations H183*, G184*, I405L, A421 H, A422P and A428T;
o the lipase comprises SEQ ID NO: 31 with the mutations D27R, G38A, D96E, D11 1A, G163K, T231 R, N233R, D254S and P256T; o the mannanase comprises SEQ ID NO: 32;
o the pectate lyase comprises SEQ ID NO: 33; and
o the cellulase comprises SEQ ID NO: 34 or SEQ ID NO: 35.
In one embodiment, the composition comprises:
• a DNase that comprises or consists of SEQ ID NO: 3;
• a Glyco_hydro_1 14 polypeptide that comprises or consists of SEQ ID NO: 8;
• a protease that comprises SEQ ID NO: 24 with the substitutions S9E, N42R, N74D, V199I, Q200L, Y203W, S253D, N255W and L256E; and • at least one enzyme selected from the group consisting of amylases and cellulases; wherein:
o the amylase comprises SEQ ID NO: 29 with the mutations H 1 *, N54S, V56T, K72R, G109A, F113Q, R116Q, W167F, Q172G, A174S, G182*, D183*, G184T, N195F, V206L, K391A, P473R and G476K; and o the cellulase comprises SEQ ID NO: 34.
In one embodiment, the composition comprises:
• a DNase that comprises or consists of SEQ ID NO: 3, or which is a variant thereof having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity to SEQ ID NO: 3;
• a Glyco_hydro_1 14 polypeptide that comprises or consists of SEQ ID NO: 9, or which is a variant thereof having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity to SEQ ID NO: 9;
• a protease selected from: a) a polypeptide that comprises or consists of SEQ ID NO: 24 or SEQ ID NO: 26, or a variant thereof having at least 80%, at least 85%, at least 90% or at least 95% sequence identity to SEQ ID NO: 24 or SEQ ID NO: 26; b) a polypeptide that comprises SEQ ID NO: 24 with the substitutions Y161A, R164S and A188P; c) a polypeptide that comprises SEQ ID NO: 24 with the substitutions S9E, N42R, N74D, V199I, Q200L, Y203W, S253D, N255W and L256E; and d) a polypeptide that comprises SEQ ID NO: 37; and
• at least one enzyme selected from the group consisting of amylases, lipases, mannanases, pectate lyases and cellulases.
In one embodiment, the composition comprises:
• a DNase that comprises or consists of SEQ ID NO: 3;
• a Glyco_hydro_1 14 polypeptide that comprises or consists of SEQ ID NO: 9;
• a protease that comprises SEQ ID NO: 24 with the substitutions Y161A, R164S and A188P, or that comprises SEQ ID NO: 37; and
• at least one enzyme selected from the group consisting of amylases, lipases, mannanases, pectate lyases and cellulases; wherein:
o the amylase comprises SEQ ID NO: 30 with the mutations H183*, G184*, I405L, A421 H, A422P and A428T;
o the lipase comprises SEQ ID NO: 31 with the mutations D27R, G38A, D96E, D11 1A, G163K, T231 R, N233R, D254S and P256T; o the mannanase comprises SEQ ID NO: 32;
o the pectate lyase comprises SEQ ID NO: 33; and o the cellulase comprises SEQ ID NO: 34 or SEQ ID NO: 35.
In one embodiment, the composition comprises:
• a DNase that comprises or consists of SEQ ID NO: 3;
• a Glyco_hydro_1 14 polypeptide that comprises or consists of SEQ ID NO: 9;
• a protease that comprises SEQ ID NO: 24 with the substitutions S9E, N42R, N74D, V199I, Q200L, Y203W, S253D, N255W and L256E; and
• at least one enzyme selected from the group consisting of amylases and cellulases; wherein:
o the amylase comprises SEQ ID NO: 29 with the mutations H 1 *, N54S, V56T, K72R, G109A, F113Q, R116Q, W167F, Q172G, A174S, G182*, D183*, G184T, N195F, V206L, K391A, P473R and G476K; and o the cellulase comprises SEQ ID NO: 34.
In one embodiment, the composition comprises:
• a DNase that comprises or consists of SEQ ID NO: 4, or which is a variant thereof having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity to SEQ ID NO: 4;
• a Glyco_hydro_1 14 polypeptide that comprises or consists of SEQ ID NO: 6, or which is a variant thereof having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity to SEQ ID NO: 6;
• a protease selected from: a) a polypeptide that comprises or consists of SEQ ID NO: 24 or SEQ ID NO: 26, or a variant thereof having at least 80%, at least 85%, at least 90% or at least 95% sequence identity to SEQ ID NO: 24 or SEQ ID NO: 26; b) a polypeptide that comprises SEQ ID NO: 24 with the substitutions Y161A, R164S and A188P; c) a polypeptide that comprises SEQ ID NO: 24 with the substitutions S9E, N42R, N74D, V199I, Q200L, Y203W, S253D, N255W and L256E; and d) a polypeptide that comprises SEQ ID NO: 37; and
• at least one enzyme selected from the group consisting of amylases, lipases, mannanases, pectate lyases and cellulases.
In one embodiment, the composition comprises:
• a DNase that comprises or consists of SEQ ID NO: 4;
• a Glyco_hydro_1 14 polypeptide that comprises or consists of SEQ ID NO: 6;
• a protease that comprises SEQ ID NO: 24 with the substitutions Y161A, R164S and A188P, or that comprises SEQ ID NO: 37; and
• at least one enzyme selected from the group consisting of amylases, lipases, mannanases, pectate lyases and cellulases; wherein: o the amylase comprises SEQ ID NO: 30 with the mutations H183*, G184*, I405L, A421 H, A422P and A428T;
o the lipase comprises SEQ ID NO: 31 with the mutations D27R, G38A, D96E, D11 1A, G163K, T231 R, N233R, D254S and P256T; o the mannanase comprises SEQ ID NO: 32;
o the pectate lyase comprises SEQ ID NO: 33; and
o the cellulase comprises SEQ ID NO: 34 or SEQ ID NO: 35.
In one embodiment, the composition comprises:
• a DNase that comprises or consists of SEQ ID NO: 4;
• a Glyco_hydro_1 14 polypeptide that comprises or consists of SEQ ID NO: 6;
• a protease that comprises SEQ ID NO: 24 with the substitutions S9E, N42R, N74D, V199I, Q200L, Y203W, S253D, N255W and L256E; and
• at least one enzyme selected from the group consisting of amylases and cellulases; wherein:
o the amylase comprises SEQ ID NO: 29 with the mutations H 1 *, N54S, V56T, K72R, G109A, F113Q, R116Q, W167F, Q172G, A174S, G182*, D183*, G184T, N195F, V206L, K391A, P473R and G476K; and o the cellulase comprises SEQ ID NO: 34.
In one embodiment, the composition comprises:
• a DNase that comprises or consists of SEQ ID NO: 4, or which is a variant thereof having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity to SEQ ID NO: 4;
• a Glyco_hydro_114 polypeptide that comprises or consists of SEQ ID NO: 7, or which is a variant thereof having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity to SEQ ID NO: 7;
• a protease selected from: a) a polypeptide that comprises or consists of SEQ ID NO: 24 or SEQ ID NO: 26, or a variant thereof having at least 80%, at least 85%, at least 90% or at least 95% sequence identity to SEQ ID NO: 24 or SEQ ID NO: 26; b) a polypeptide that comprises SEQ ID NO: 24 with the substitutions Y161A, R164S and A188P; c) a polypeptide that comprises SEQ ID NO: 24 with the substitutions S9E, N42R, N74D, V199I, Q200L, Y203W, S253D, N255W and L256E; and d) a polypeptide that comprises SEQ ID NO: 37; and
• at least one enzyme selected from the group consisting of amylases, lipases, mannanases, pectate lyases and cellulases.
In one embodiment, the composition comprises: • a DNase that comprises or consists of SEQ ID NO: 4;
• a Glyco_hydro_1 14 polypeptide that comprises or consists of SEQ ID NO: 7;
• a protease that comprises SEQ ID NO: 24 with the substitutions Y161A, R164S and A188P, or that comprises SEQ ID NO: 37; and
• at least one enzyme selected from the group consisting of amylases, lipases, mannanases, pectate lyases and cellulases; wherein:
o the amylase comprises SEQ ID NO: 30 with the mutations H183*, G184*, I405L, A421 H, A422P and A428T;
o the lipase comprises SEQ ID NO: 31 with the mutations D27R, G38A, D96E, D11 1A, G163K, T231 R, N233R, D254S and P256T; o the mannanase comprises SEQ ID NO: 32;
o the pectate lyase comprises SEQ ID NO: 33; and
o the cellulase comprises SEQ ID NO: 34 or SEQ ID NO: 35.
In one embodiment, the composition comprises:
• a DNase that comprises or consists of SEQ ID NO: 4;
• a Glyco_hydro_1 14 polypeptide that comprises or consists of SEQ ID NO: 7;
• a protease that comprises SEQ ID NO: 24 with the substitutions S9E, N42R, N74D, V199I, Q200L, Y203W, S253D, N255W and L256E; and
• at least one enzyme selected from the group consisting of amylases and cellulases; wherein:
o the amylase comprises SEQ ID NO: 29 with the mutations H 1 *, N54S, V56T, K72R, G109A, F113Q, R116Q, W167F, Q172G, A174S, G182*, D183*, G184T, N195F, V206L, K391A, P473R and G476K; and o the cellulase comprises SEQ ID NO: 34.
In one embodiment, the composition comprises:
• a DNase that comprises or consists of SEQ ID NO: 4, or which is a variant thereof having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity to SEQ ID NO: 4;
• a Glyco_hydro_1 14 polypeptide that comprises or consists of SEQ ID NO: 8, or which is a variant thereof having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity to SEQ ID NO: 8;
• a protease selected from: a) a polypeptide that comprises or consists of SEQ ID NO: 24 or SEQ ID NO: 26, or a variant thereof having at least 80%, at least 85%, at least 90% or at least 95% sequence identity to SEQ ID NO: 24 or SEQ ID NO: 26; b) a polypeptide that comprises SEQ ID NO: 24 with the substitutions Y161A, R164S and A188P; c) a polypeptide that comprises SEQ ID NO: 24 with the substitutions S9E, N42R, N74D, V199I, Q200L, Y203W, S253D, N255W and L256E; and d) a polypeptide that comprises SEQ ID NO: 37; and
• at least one enzyme selected from the group consisting of amylases, lipases, mannanases, pectate lyases and cellulases.
In one embodiment, the composition comprises:
• a DNase that comprises or consists of SEQ ID NO: 4;
• a Glyco_hydro_114 polypeptide that comprises or consists of SEQ ID NO: 8;
• a protease that comprises SEQ ID NO: 24 with the substitutions Y161A, R164S and A188P, or that comprises SEQ ID NO: 37; and
• at least one enzyme selected from the group consisting of amylases, lipases, mannanases, pectate lyases and cellulases; wherein:
o the amylase comprises SEQ ID NO: 30 with the mutations H183*, G184*, I405L, A421 H, A422P and A428T;
o the lipase comprises SEQ ID NO: 31 with the mutations D27R, G38A, D96E, D11 1A, G163K, T231 R, N233R, D254S and P256T; o the mannanase comprises SEQ ID NO: 32;
o the pectate lyase comprises SEQ ID NO: 33; and
o the cellulase comprises SEQ ID NO: 34 or SEQ ID NO: 35.
In one embodiment, the composition comprises:
• a DNase that comprises or consists of SEQ ID NO: 4;
• a Glyco_hydro_1 14 polypeptide that comprises or consists of SEQ ID NO: 8;
• a protease that comprises SEQ ID NO: 24 with the substitutions S9E, N42R, N74D, V199I, Q200L, Y203W, S253D, N255W and L256E; and
• at least one enzyme selected from the group consisting of amylases and cellulases; wherein:
o the amylase comprises SEQ ID NO: 29 with the mutations H 1 *, N54S, V56T, K72R, G109A, F113Q, R116Q, W167F, Q172G, A174S, G182*, D183*, G184T, N195F, V206L, K391A, P473R and G476K; and o the cellulase comprises SEQ ID NO: 34.
In one embodiment, the composition comprises:
• a DNase that comprises or consists of SEQ ID NO: 4, or which is a variant thereof having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity to SEQ ID NO: 4;
• a Glyco_hydro_1 14 polypeptide that comprises or consists of SEQ ID NO: 9, or which is a variant thereof having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity to SEQ ID NO: 9;
• a protease selected from: a) a polypeptide that comprises or consists of SEQ ID NO: 24 or SEQ ID NO: 26, or a variant thereof having at least 80%, at least 85%, at least 90% or at least 95% sequence identity to SEQ ID NO: 24 or SEQ ID NO: 26; b) a polypeptide that comprises SEQ ID NO: 24 with the substitutions Y161A, R164S and A188P; c) a polypeptide that comprises SEQ ID NO: 24 with the substitutions S9E, N42R, N74D, V199I, Q200L, Y203W, S253D, N255W and L256E; and d) a polypeptide that comprises SEQ ID NO: 37; and
• at least one enzyme selected from the group consisting of amylases, lipases, mannanases, pectate lyases and cellulases.
In one embodiment, the composition comprises:
• a DNase that comprises or consists of SEQ ID NO: 4;
• a Glyco_hydro_1 14 polypeptide that comprises or consists of SEQ ID NO: 9;
• a protease that comprises SEQ ID NO: 24 with the substitutions Y161A, R164S and A188P, or that comprises SEQ ID NO: 37; and
• at least one enzyme selected from the group consisting of amylases, lipases, mannanases, pectate lyases and cellulases; wherein:
o the amylase comprises SEQ ID NO: 30 with the mutations H183*, G184*, I405L, A421 H, A422P and A428T;
o the lipase comprises SEQ ID NO: 31 with the mutations D27R, G38A, D96E, D11 1A, G163K, T231 R, N233R, D254S and P256T; o the mannanase comprises SEQ ID NO: 32;
o the pectate lyase comprises SEQ ID NO: 33; and
o the cellulase comprises SEQ ID NO: 34 or SEQ ID NO: 35.
In one embodiment, the composition comprises:
• a DNase that comprises or consists of SEQ ID NO: 4;
• a Glyco_hydro_1 14 polypeptide that comprises or consists of SEQ ID NO: 9;
• a protease that comprises SEQ ID NO: 24 with the substitutions S9E, N42R, N74D, V199I, Q200L, Y203W, S253D, N255W and L256E; and
• at least one enzyme selected from the group consisting of amylases and cellulases; wherein:
o the amylase comprises SEQ ID NO: 29 with the mutations H 1 *, N54S, V56T, K72R, G109A, F113Q, R116Q, W167F, Q172G, A174S, G182*, D183*, G184T, N195F, V206L, K391A, P473R and G476K; and o the cellulase comprises SEQ ID NO: 34. In one embodiment, the composition comprises:
• a DNase that comprises or consists of SEQ ID NO: 5, or which is a variant thereof having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity to SEQ ID NO: 5;
• a Glyco_hydro_1 14 polypeptide that comprises or consists of SEQ ID NO: 6, or which is a variant thereof having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity to SEQ ID NO: 6;
• a protease selected from: a) a polypeptide that comprises or consists of SEQ ID NO: 24 or SEQ ID NO: 26, or a variant thereof having at least 80%, at least 85%, at least 90% or at least 95% sequence identity to SEQ ID NO: 24 or SEQ ID NO: 26; b) a polypeptide that comprises SEQ ID NO: 24 with the substitutions Y161A, R164S and A188P; c) a polypeptide that comprises SEQ ID NO: 24 with the substitutions S9E, N42R, N74D, V199I, Q200L, Y203W, S253D, N255W and L256E; and d) a polypeptide that comprises SEQ ID NO: 37; and
• at least one enzyme selected from the group consisting of amylases, lipases, mannanases, pectate lyases and cellulases.
In one embodiment, the composition comprises:
• a DNase that comprises or consists of SEQ ID NO: 5;
• a Glyco_hydro_1 14 polypeptide that comprises or consists of SEQ ID NO: 6;
• a protease that comprises SEQ ID NO: 24 with the substitutions Y161A, R164S and A188P, or that comprises SEQ ID NO: 37; and
• at least one enzyme selected from the group consisting of amylases, lipases, mannanases, pectate lyases and cellulases; wherein:
o the amylase comprises SEQ ID NO: 30 with the mutations H183*, G184*, I405L, A421 H, A422P and A428T;
o the lipase comprises SEQ ID NO: 31 with the mutations D27R, G38A, D96E, D11 1A, G163K, T231 R, N233R, D254S and P256T; o the mannanase comprises SEQ ID NO: 32;
o the pectate lyase comprises SEQ ID NO: 33; and
o the cellulase comprises SEQ ID NO: 34 or SEQ ID NO: 35.
In one embodiment, the composition comprises:
• a DNase that comprises or consists of SEQ ID NO: 5;
• a Glyco_hydro_1 14 polypeptide that comprises or consists of SEQ ID NO: 6;
• a protease that comprises SEQ ID NO: 24 with the substitutions S9E, N42R, N74D, V199I, Q200L, Y203W, S253D, N255W and L256E; and • at least one enzyme selected from the group consisting of amylases and cellulases; wherein:
o the amylase comprises SEQ ID NO: 29 with the mutations H 1 *, N54S, V56T, K72R, G109A, F113Q, R116Q, W167F, Q172G, A174S, G182*, D183*, G184T, N195F, V206L, K391A, P473R and G476K; and o the cellulase comprises SEQ ID NO: 34.
In one embodiment, the composition comprises:
• a DNase that comprises or consists of SEQ ID NO: 5, or which is a variant thereof having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity to SEQ ID NO: 5;
• a Glyco_hydro_1 14 polypeptide that comprises or consists of SEQ ID NO: 7, or which is a variant thereof having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity to SEQ ID NO: 7;
• a protease selected from: a) a polypeptide that comprises or consists of SEQ ID NO: 24 or SEQ ID NO: 26, or a variant thereof having at least 80%, at least 85%, at least 90% or at least 95% sequence identity to SEQ ID NO: 24 or SEQ ID NO: 26; b) a polypeptide that comprises SEQ ID NO: 24 with the substitutions Y161A, R164S and A188P; c) a polypeptide that comprises SEQ ID NO: 24 with the substitutions S9E, N42R, N74D, V199I, Q200L, Y203W, S253D, N255W and L256E; and d) a polypeptide that comprises SEQ ID NO: 37; and
• at least one enzyme selected from the group consisting of amylases, lipases, mannanases, pectate lyases and cellulases.
In one embodiment, the composition comprises:
• a DNase that comprises or consists of SEQ ID NO: 5;
• a Glyco_hydro_1 14 polypeptide that comprises or consists of SEQ ID NO: 7;
• a protease that comprises SEQ ID NO: 24 with the substitutions Y161A, R164S and A188P, or that comprises SEQ ID NO: 37; and
• at least one enzyme selected from the group consisting of amylases, lipases, mannanases, pectate lyases and cellulases; wherein:
o the amylase comprises SEQ ID NO: 30 with the mutations H183*, G184*, I405L, A421 H, A422P and A428T;
o the lipase comprises SEQ ID NO: 31 with the mutations D27R, G38A, D96E, D11 1A, G163K, T231 R, N233R, D254S and P256T; o the mannanase comprises SEQ ID NO: 32;
o the pectate lyase comprises SEQ ID NO: 33; and o the cellulase comprises SEQ ID NO: 34 or SEQ ID NO: 35.
In one embodiment, the composition comprises:
• a DNase that comprises or consists of SEQ ID NO: 5;
• a Glyco_hydro_1 14 polypeptide that comprises or consists of SEQ ID NO: 7;
• a protease that comprises SEQ ID NO: 24 with the substitutions S9E, N42R, N74D, V199I, Q200L, Y203W, S253D, N255W and L256E; and
• at least one enzyme selected from the group consisting of amylases and cellulases; wherein:
o the amylase comprises SEQ ID NO: 29 with the mutations H 1 *, N54S, V56T, K72R, G109A, F113Q, R116Q, W167F, Q172G, A174S, G182*, D183*, G184T, N195F, V206L, K391A, P473R and G476K; and o the cellulase comprises SEQ ID NO: 34.
In one embodiment, the composition comprises:
• a DNase that comprises or consists of SEQ ID NO: 5, or which is a variant thereof having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity to SEQ ID NO: 5;
• a Glyco_hydro_1 14 polypeptide that comprises or consists of SEQ ID NO: 8, or which is a variant thereof having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity to SEQ ID NO: 8;
• a protease selected from: a) a polypeptide that comprises or consists of SEQ ID NO: 24 or SEQ ID NO: 26, or a variant thereof having at least 80%, at least 85%, at least 90% or at least 95% sequence identity to SEQ ID NO: 24 or SEQ ID NO: 26; b) a polypeptide that comprises SEQ ID NO: 24 with the substitutions Y161A, R164S and A188P; c) a polypeptide that comprises SEQ ID NO: 24 with the substitutions S9E, N42R, N74D, V199I, Q200L, Y203W, S253D, N255W and L256E; and d) a polypeptide that comprises SEQ ID NO: 37; and
• at least one enzyme selected from the group consisting of amylases, lipases, mannanases, pectate lyases and cellulases.
In one embodiment, the composition comprises:
• a DNase that comprises or consists of SEQ ID NO: 5;
• a Glyco_hydro_1 14 polypeptide that comprises or consists of SEQ ID NO: 8;
• a protease that comprises SEQ ID NO: 24 with the substitutions Y161A, R164S and A188P, or that comprises SEQ ID NO: 37; and
• at least one enzyme selected from the group consisting of amylases, lipases, mannanases, pectate lyases and cellulases; wherein: o the amylase comprises SEQ ID NO: 30 with the mutations H183*, G184*, I405L, A421 H, A422P and A428T;
o the lipase comprises SEQ ID NO: 31 with the mutations D27R, G38A, D96E, D11 1A, G163K, T231 R, N233R, D254S and P256T; o the mannanase comprises SEQ ID NO: 32;
o the pectate lyase comprises SEQ ID NO: 33; and
o the cellulase comprises SEQ ID NO: 34 or SEQ ID NO: 35.
In one embodiment, the composition comprises:
• a DNase that comprises or consists of SEQ ID NO: 5;
• a Glyco_hydro_1 14 polypeptide that comprises or consists of SEQ ID NO: 8;
• a protease that comprises SEQ ID NO: 24 with the substitutions S9E, N42R, N74D, V199I, Q200L, Y203W, S253D, N255W and L256E; and
• at least one enzyme selected from the group consisting of amylases and cellulases; wherein:
o the amylase comprises SEQ ID NO: 29 with the mutations H 1 *, N54S, V56T, K72R, G109A, F113Q, R116Q, W167F, Q172G, A174S, G182*, D183*, G184T, N195F, V206L, K391A, P473R and G476K; and o the cellulase comprises SEQ ID NO: 34.
In one embodiment, the composition comprises:
• a DNase that comprises or consists of SEQ ID NO: 5, or which is a variant thereof having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity to SEQ ID NO: 5;
• a Glyco_hydro_1 14 polypeptide that comprises or consists of SEQ ID NO: 9, or which is a variant thereof having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity to SEQ ID NO: 9;
• a protease selected from: a) a polypeptide that comprises or consists of SEQ ID NO: 24 or SEQ ID NO: 26, or a variant thereof having at least 80%, at least 85%, at least 90% or at least 95% sequence identity to SEQ ID NO: 24 or SEQ ID NO: 26; b) a polypeptide that comprises SEQ ID NO: 24 with the substitutions Y161A, R164S and A188P; c) a polypeptide that comprises SEQ ID NO: 24 with the substitutions S9E, N42R, N74D, V199I, Q200L, Y203W, S253D, N255W and L256E; and d) a polypeptide that comprises SEQ ID NO: 37; and
• at least one enzyme selected from the group consisting of amylases, lipases, mannanases, pectate lyases and cellulases.
In one embodiment, the composition comprises: • a DNase that comprises or consists of SEQ ID NO: 5;
• a Glyco_hydro_1 14 polypeptide that comprises or consists of SEQ ID NO: 9;
• a protease that comprises SEQ ID NO: 24 with the substitutions Y161A, R164S and A188P, or that comprises SEQ ID NO: 37; and
• at least one enzyme selected from the group consisting of amylases, lipases, mannanases, pectate lyases and cellulases; wherein:
o the amylase comprises SEQ ID NO: 30 with the mutations H183*, G184*, I405L, A421 H, A422P and A428T;
o the lipase comprises SEQ ID NO: 31 with the mutations D27R, G38A, D96E, D1 1 1A, G163K, T231 R, N233R, D254S and P256T;
o the mannanase comprises SEQ ID NO: 32;
o the pectate lyase comprises SEQ ID NO: 33; and
o the cellulase comprises SEQ ID NO: 34 or SEQ ID NO: 35.
In one embodiment, the composition comprises:
• a DNase that comprises or consists of SEQ ID NO: 5;
• a Glyco_hydro_1 14 polypeptide that comprises or consists of SEQ ID NO: 9;
• a protease that comprises SEQ ID NO: 24 with the substitutions S9E, N42R, N74D, V199I, Q200L, Y203W, S253D, N255W and L256E; and
• at least one enzyme selected from the group consisting of amylases and cellulases; wherein:
o the amylase comprises SEQ ID NO: 29 with the mutations H 1 *, N54S, V56T, K72R, G109A, F1 13Q, R1 16Q, W167F, Q172G, A174S, G182*, D183*, G184T, N 195F, V206L, K391A, P473R and G476K; and o the cellulase comprises SEQ ID NO: 34.
In any of the embodiments described above comprising at least a DNase and a Glyco_hydro_1 14 glycosyl hydrolase as the cleaning enzymes, the cleaning composition may optionally comprise one or more of any of the other cleaning enzymes described herein. Any of these compositions may thus comprise one or more of an RNase, a GH39 glycosyl hydrolase, a GHL13 glycosyl hydrolase or a hexosaminidase.
Cleaning compositions comprising a DNase and a GH39 polypeptide
One aspect of the invention relates to a cleaning composition comprising at least a DNase and a GH39 glycosyl hydrolase as the cleaning enzymes. Exemplary embodiments of this aspect of the invention are described below.
In one embodiment, the composition comprises: • a DNase that comprises or consists of SEQ ID NO: 1 , or which is a variant thereof having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity to SEQ ID NO: 1 ;
• a GH39 polypeptide that comprises or consists of SEQ ID NO: 10, or which is a variant thereof having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity to SEQ ID NO: 10;
• a protease selected from: a) a polypeptide that comprises or consists of SEQ ID NO: 24 or SEQ ID NO: 26, or a variant thereof having at least 80%, at least 85%, at least 90% or at least 95% sequence identity to SEQ ID NO: 24 or SEQ ID NO: 26; b) a polypeptide that comprises SEQ ID NO: 24 with the substitutions Y161A, R164S and A188P; c) a polypeptide that comprises SEQ ID NO: 24 with the substitutions S9E, N42R, N74D, V199I, Q200L, Y203W, S253D, N255W and L256E; and d) a polypeptide that comprises SEQ ID NO: 37; and
• at least one enzyme selected from the group consisting of amylases, lipases, mannanases, pectate lyases and cellulases.
In one embodiment, the composition comprises:
• a DNase that comprises or consists of SEQ ID NO: 1 ;
• a GH39 polypeptide that comprises or consists of SEQ ID NO: 10;
• a protease that comprises SEQ ID NO: 24 with the substitutions Y161A, R164S and A188P, or that comprises SEQ ID NO: 37; and
• at least one enzyme selected from the group consisting of amylases, lipases, mannanases, pectate lyases and cellulases; wherein:
o the amylase comprises SEQ ID NO: 30 with the mutations H183*, G184*, I405L, A421 H, A422P and A428T;
o the lipase comprises SEQ ID NO: 31 with the mutations D27R, G38A, D96E, D11 1A, G163K, T231 R, N233R, D254S and P256T; o the mannanase comprises SEQ ID NO: 32;
o the pectate lyase comprises SEQ ID NO: 33; and
o the cellulase comprises SEQ ID NO: 34 or SEQ ID NO: 35.
In one embodiment, the composition comprises:
• a DNase that comprises or consists of SEQ ID NO: 1 ;
• a GH39 polypeptide that comprises or consists of SEQ ID NO: 10;
• a protease that comprises SEQ ID NO: 24 with the substitutions S9E, N42R, N74D, V199I, Q200L, Y203W, S253D, N255W and L256E; and
• at least one enzyme selected from the group consisting of amylases and cellulases; wherein: o the amylase comprises SEQ ID NO: 29 with the mutations H 1 *, N54S, V56T, K72R, G109A, F113Q, R116Q, W167F, Q172G, A174S, G182*, D183*, G184T, N195F, V206L, K391A, P473R and G476K; and o the cellulase comprises SEQ ID NO: 34.
In one embodiment, the composition comprises:
• a DNase that comprises or consists of SEQ ID NO: 1 , or which is a variant thereof having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity to SEQ ID NO: 1 ;
• a GH39 polypeptide that comprises or consists of SEQ ID NO: 11 , or which is a variant thereof having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity to SEQ ID NO: 1 1 ;
• a protease selected from: a) a polypeptide that comprises or consists of SEQ ID NO: 24 or SEQ ID NO: 26, or a variant thereof having at least 80%, at least 85%, at least 90% or at least 95% sequence identity to SEQ ID NO: 24 or SEQ ID NO: 26; b) a polypeptide that comprises SEQ ID NO: 24 with the substitutions Y161A, R164S and A188P; c) a polypeptide that comprises SEQ ID NO: 24 with the substitutions S9E, N42R, N74D, V199I, Q200L, Y203W, S253D, N255W and L256E; and d) a polypeptide that comprises SEQ ID NO: 37; and
• at least one enzyme selected from the group consisting of amylases, lipases, mannanases, pectate lyases and cellulases.
In one embodiment, the composition comprises:
• a DNase that comprises or consists of SEQ ID NO: 1 ;
• a GH39 polypeptide that comprises or consists of SEQ ID NO: 11 ;
• a protease that comprises SEQ ID NO: 24 with the substitutions Y161A, R164S and A188P, or that comprises SEQ ID NO: 37; and
• at least one enzyme selected from the group consisting of amylases, lipases, mannanases, pectate lyases and cellulases; wherein:
o the amylase comprises SEQ ID NO: 30 with the mutations H183*, G184*, I405L, A421 H, A422P and A428T;
o the lipase comprises SEQ ID NO: 31 with the mutations D27R, G38A, D96E, D11 1A, G163K, T231 R, N233R, D254S and P256T; o the mannanase comprises SEQ ID NO: 32;
o the pectate lyase comprises SEQ ID NO: 33; and
o the cellulase comprises SEQ ID NO: 34 or SEQ ID NO: 35.
In one embodiment, the composition comprises: • a DNase that comprises or consists of SEQ ID NO: 1 ;
• a GH39 polypeptide that comprises or consists of SEQ ID NO: 11 ;
• a protease that comprises SEQ ID NO: 24 with the substitutions S9E, N42R, N74D, V199I, Q200L, Y203W, S253D, N255W and L256E; and
• at least one enzyme selected from the group consisting of amylases and cellulases; wherein:
o the amylase comprises SEQ ID NO: 29 with the mutations H 1 *, N54S, V56T, K72R, G109A, F113Q, R116Q, W167F, Q172G, A174S, G182*, D183*, G184T, N195F, V206L, K391A, P473R and G476K; and o the cellulase comprises SEQ ID NO: 34.
In one embodiment, the composition comprises:
• a DNase that comprises or consists of SEQ ID NO: 1 , or which is a variant thereof having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity to SEQ ID NO: 1 ;
• a GH39 polypeptide that comprises or consists of SEQ ID NO: 12, or which is a variant thereof having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity to SEQ ID NO: 12;
• a protease selected from: a) a polypeptide that comprises or consists of SEQ ID NO: 24 or SEQ ID NO: 26, or a variant thereof having at least 80%, at least 85%, at least 90% or at least 95% sequence identity to SEQ ID NO: 24 or SEQ ID NO: 26; b) a polypeptide that comprises SEQ ID NO: 24 with the substitutions Y161A, R164S and A188P; c) a polypeptide that comprises SEQ ID NO: 24 with the substitutions S9E, N42R, N74D, V199I, Q200L, Y203W, S253D, N255W and L256E; and d) a polypeptide that comprises SEQ ID NO: 37; and
• at least one enzyme selected from the group consisting of amylases, lipases, mannanases, pectate lyases and cellulases.
In one embodiment, the composition comprises:
• a DNase that comprises or consists of SEQ ID NO: 1 ;
• a GH39 polypeptide that comprises or consists of SEQ ID NO: 12;
• a protease that comprises SEQ ID NO: 24 with the substitutions Y161A, R164S and A188P, or that comprises SEQ ID NO: 37; and
• at least one enzyme selected from the group consisting of amylases, lipases, mannanases, pectate lyases and cellulases; wherein:
o the amylase comprises SEQ ID NO: 30 with the mutations H183*, G184*, I405L, A421 H, A422P and A428T; o the lipase comprises SEQ ID NO: 31 with the mutations D27R, G38A, D96E, D11 1A, G163K, T231 R, N233R, D254S and P256T; o the mannanase comprises SEQ ID NO: 32;
o the pectate lyase comprises SEQ ID NO: 33; and
o the cellulase comprises SEQ ID NO: 34 or SEQ ID NO: 35.
In one embodiment, the composition comprises:
• a DNase that comprises or consists of SEQ ID NO: 1 ;
• a GH39 polypeptide that comprises or consists of SEQ ID NO: 12;
• a protease that comprises SEQ ID NO: 24 with the substitutions S9E, N42R, N74D, V199I, Q200L, Y203W, S253D, N255W and L256E; and
• at least one enzyme selected from the group consisting of amylases and cellulases; wherein:
o the amylase comprises SEQ ID NO: 29 with the mutations H 1 *, N54S, V56T, K72R, G109A, F113Q, R116Q, W167F, Q172G, A174S, G182*, D183*, G184T, N195F, V206L, K391A, P473R and G476K; and o the cellulase comprises SEQ ID NO: 34.
In one embodiment, the composition comprises:
• a DNase that comprises or consists of SEQ ID NO: 2, or which is a variant thereof having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity to SEQ ID NO: 2;
• a GH39 polypeptide that comprises or consists of SEQ ID NO: 10, or which is a variant thereof having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity to SEQ ID NO: 10;
• a protease selected from: a) a polypeptide that comprises or consists of SEQ ID NO: 24 or SEQ ID NO: 26, or a variant thereof having at least 80%, at least 85%, at least 90% or at least 95% sequence identity to SEQ ID NO: 24 or SEQ ID NO: 26; b) a polypeptide that comprises SEQ ID NO: 24 with the substitutions Y161A, R164S and A188P; c) a polypeptide that comprises SEQ ID NO: 24 with the substitutions S9E, N42R, N74D, V199I, Q200L, Y203W, S253D, N255W and L256E; and d) a polypeptide that comprises SEQ ID NO: 37; and
• at least one enzyme selected from the group consisting of amylases, lipases, mannanases, pectate lyases and cellulases.
In one embodiment, the composition comprises:
• a DNase that comprises or consists of SEQ ID NO: 2;
• a GH39 polypeptide that comprises or consists of SEQ ID NO: 10; • a protease that comprises SEQ ID NO: 24 with the substitutions Y161A, R164S and A188P, or that comprises SEQ ID NO: 37; and
• at least one enzyme selected from the group consisting of amylases, lipases, mannanases, pectate lyases and cellulases; wherein:
o the amylase comprises SEQ ID NO: 30 with the mutations H183*, G184*, I405L, A421 H, A422P and A428T;
o the lipase comprises SEQ ID NO: 31 with the mutations D27R, G38A, D96E, D11 1A, G163K, T231 R, N233R, D254S and P256T; o the mannanase comprises SEQ ID NO: 32;
o the pectate lyase comprises SEQ ID NO: 33; and
o the cellulase comprises SEQ ID NO: 34 or SEQ ID NO: 35.
In one embodiment, the composition comprises:
• a DNase that comprises or consists of SEQ ID NO: 2;
• a GH39 polypeptide that comprises or consists of SEQ ID NO: 10;
• a protease that comprises SEQ ID NO: 24 with the substitutions S9E, N42R, N74D, V199I, Q200L, Y203W, S253D, N255W and L256E; and
• at least one enzyme selected from the group consisting of amylases and cellulases; wherein:
o the amylase comprises SEQ ID NO: 29 with the mutations H 1 *, N54S, V56T, K72R, G109A, F113Q, R116Q, W167F, Q172G, A174S, G182*, D183*, G184T, N195F, V206L, K391A, P473R and G476K; and o the cellulase comprises SEQ ID NO: 34.
In one embodiment, the composition comprises:
• a DNase that comprises or consists of SEQ ID NO: 2, or which is a variant thereof having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity to SEQ ID NO: 2;
• a GH39 polypeptide that comprises or consists of SEQ ID NO: 11 , or which is a variant thereof having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity to SEQ ID NO: 1 1 ;
• a protease selected from: a) a polypeptide that comprises or consists of SEQ ID NO: 24 or SEQ ID NO: 26, or a variant thereof having at least 80%, at least 85%, at least 90% or at least 95% sequence identity to SEQ ID NO: 24 or SEQ ID NO: 26; b) a polypeptide that comprises SEQ ID NO: 24 with the substitutions Y161A, R164S and A188P; c) a polypeptide that comprises SEQ ID NO: 24 with the substitutions S9E, N42R, N74D, V199I, Q200L, Y203W, S253D, N255W and L256E; and d) a polypeptide that comprises SEQ ID NO: 37; and
• at least one enzyme selected from the group consisting of amylases, lipases, mannanases, pectate lyases and cellulases.
In one embodiment, the composition comprises:
• a DNase that comprises or consists of SEQ ID NO: 2;
• a GH39 polypeptide that comprises or consists of SEQ ID NO: 11 ;
• a protease that comprises SEQ ID NO: 24 with the substitutions Y161A, R164S and A188P, or that comprises SEQ ID NO: 37; and
• at least one enzyme selected from the group consisting of amylases, lipases, mannanases, pectate lyases and cellulases; wherein:
o the amylase comprises SEQ ID NO: 30 with the mutations H183*, G184*, I405L, A421 H, A422P and A428T;
o the lipase comprises SEQ ID NO: 31 with the mutations D27R, G38A, D96E, D11 1A, G163K, T231 R, N233R, D254S and P256T; o the mannanase comprises SEQ ID NO: 32;
o the pectate lyase comprises SEQ ID NO: 33; and
o the cellulase comprises SEQ ID NO: 34 or SEQ ID NO: 35.
In one embodiment, the composition comprises:
• a DNase that comprises or consists of SEQ ID NO: 2;
• a GH39 polypeptide that comprises or consists of SEQ ID NO: 11 ;
• a protease that comprises SEQ ID NO: 24 with the substitutions S9E, N42R, N74D, V199I, Q200L, Y203W, S253D, N255W and L256E; and
• at least one enzyme selected from the group consisting of amylases and cellulases; wherein:
o the amylase comprises SEQ ID NO: 29 with the mutations H 1 *, N54S, V56T, K72R, G109A, F113Q, R116Q, W167F, Q172G, A174S, G182*, D183*, G184T, N195F, V206L, K391A, P473R and G476K; and o the cellulase comprises SEQ ID NO: 34.
In one embodiment, the composition comprises:
• a DNase that comprises or consists of SEQ ID NO: 2, or which is a variant thereof having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity to SEQ ID NO: 2;
• a GH39 polypeptide that comprises or consists of SEQ ID NO: 12, or which is a variant thereof having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity to SEQ ID NO: 12;
• a protease selected from: a) a polypeptide that comprises or consists of SEQ ID NO: 24 or SEQ ID NO: 26, or a variant thereof having at least 80%, at least 85%, at least 90% or at least 95% sequence identity to SEQ ID NO: 24 or SEQ ID NO: 26; b) a polypeptide that comprises SEQ ID NO: 24 with the substitutions Y161A, R164S and A188P; c) a polypeptide that comprises SEQ ID NO: 24 with the substitutions S9E, N42R, N74D, V199I, Q200L, Y203W, S253D, N255W and L256E; and d) a polypeptide that comprises SEQ ID NO: 37; and
• at least one enzyme selected from the group consisting of amylases, lipases, mannanases, pectate lyases and cellulases.
In one embodiment, the composition comprises:
• a DNase that comprises or consists of SEQ ID NO: 2;
• a GH39 polypeptide that comprises or consists of SEQ ID NO: 12;
• a protease that comprises SEQ ID NO: 24 with the substitutions Y161A, R164S and A188P, or that comprises SEQ ID NO: 37; and
• at least one enzyme selected from the group consisting of amylases, lipases, mannanases, pectate lyases and cellulases; wherein:
o the amylase comprises SEQ ID NO: 30 with the mutations H183*, G184*, I405L, A421 H, A422P and A428T;
o the lipase comprises SEQ ID NO: 31 with the mutations D27R, G38A, D96E, D11 1A, G163K, T231 R, N233R, D254S and P256T; o the mannanase comprises SEQ ID NO: 32;
o the pectate lyase comprises SEQ ID NO: 33; and
o the cellulase comprises SEQ ID NO: 34 or SEQ ID NO: 35.
In one embodiment, the composition comprises:
• a DNase that comprises or consists of SEQ ID NO: 2;
• a GH39 polypeptide that comprises or consists of SEQ ID NO: 12;
• a protease that comprises SEQ ID NO: 24 with the substitutions S9E, N42R, N74D, V199I, Q200L, Y203W, S253D, N255W and L256E; and
• at least one enzyme selected from the group consisting of amylases and cellulases; wherein:
o the amylase comprises SEQ ID NO: 29 with the mutations H 1 *, N54S, V56T, K72R, G109A, F113Q, R116Q, W167F, Q172G, A174S, G182*, D183*, G184T, N195F, V206L, K391A, P473R and G476K; and o the cellulase comprises SEQ ID NO: 34. In one embodiment, the composition comprises:
• a DNase that comprises or consists of SEQ ID NO: 3, or which is a variant thereof having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity to SEQ ID NO: 3;
• a GH39 polypeptide that comprises or consists of SEQ ID NO: 10, or which is a variant thereof having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity to SEQ ID NO: 10;
• a protease selected from: a) a polypeptide that comprises or consists of SEQ ID NO: 24 or SEQ ID NO: 26, or a variant thereof having at least 80%, at least 85%, at least 90% or at least 95% sequence identity to SEQ ID NO: 24 or SEQ ID NO: 26; b) a polypeptide that comprises SEQ ID NO: 24 with the substitutions Y161A, R164S and A188P; c) a polypeptide that comprises SEQ ID NO: 24 with the substitutions S9E, N42R, N74D, V199I, Q200L, Y203W, S253D, N255W and L256E; and d) a polypeptide that comprises SEQ ID NO: 37; and
• at least one enzyme selected from the group consisting of amylases, lipases, mannanases, pectate lyases and cellulases.
In one embodiment, the composition comprises:
• a DNase that comprises or consists of SEQ ID NO: 3;
• a GH39 polypeptide that comprises or consists of SEQ ID NO: 10;
• a protease that comprises SEQ ID NO: 24 with the substitutions Y161A, R164S and A188P, or that comprises SEQ ID NO: 37; and
• at least one enzyme selected from the group consisting of amylases, lipases, mannanases, pectate lyases and cellulases; wherein:
o the amylase comprises SEQ ID NO: 30 with the mutations H183*, G184*, I405L, A421 H, A422P and A428T;
o the lipase comprises SEQ ID NO: 31 with the mutations D27R, G38A, D96E, D11 1A, G163K, T231 R, N233R, D254S and P256T; o the mannanase comprises SEQ ID NO: 32;
o the pectate lyase comprises SEQ ID NO: 33; and
o the cellulase comprises SEQ ID NO: 34 or SEQ ID NO: 35.
In one embodiment, the composition comprises:
• a DNase that comprises or consists of SEQ ID NO: 3;
• a GH39 polypeptide that comprises or consists of SEQ ID NO: 10;
• a protease that comprises SEQ ID NO: 24 with the substitutions S9E, N42R, N74D, V199I, Q200L, Y203W, S253D, N255W and L256E; and • at least one enzyme selected from the group consisting of amylases and cellulases; wherein:
o the amylase comprises SEQ ID NO: 29 with the mutations H 1 *, N54S, V56T, K72R, G109A, F113Q, R116Q, W167F, Q172G, A174S, G182*, D183*, G184T, N195F, V206L, K391A, P473R and G476K; and o the cellulase comprises SEQ ID NO: 34.
In one embodiment, the composition comprises:
• a DNase that comprises or consists of SEQ ID NO: 3, or which is a variant thereof having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity to SEQ ID NO: 3;
• a GH39 polypeptide that comprises or consists of SEQ ID NO: 11 , or which is a variant thereof having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity to SEQ ID NO: 1 1 ;
• a protease selected from: a) a polypeptide that comprises or consists of SEQ ID NO: 24 or SEQ ID NO: 26, or a variant thereof having at least 80%, at least 85%, at least 90% or at least 95% sequence identity to SEQ ID NO: 24 or SEQ ID NO: 26; b) a polypeptide that comprises SEQ ID NO: 24 with the substitutions Y161A, R164S and A188P; c) a polypeptide that comprises SEQ ID NO: 24 with the substitutions S9E, N42R, N74D, V199I, Q200L, Y203W, S253D, N255W and L256E; and d) a polypeptide that comprises SEQ ID NO: 37; and
• at least one enzyme selected from the group consisting of amylases, lipases, mannanases, pectate lyases and cellulases.
In one embodiment, the composition comprises:
• a DNase that comprises or consists of SEQ ID NO: 3;
• a GH39 polypeptide that comprises or consists of SEQ ID NO: 11 ;
• a protease that comprises SEQ ID NO: 24 with the substitutions Y161A, R164S and A188P, or that comprises SEQ ID NO: 37; and
• at least one enzyme selected from the group consisting of amylases, lipases, mannanases, pectate lyases and cellulases; wherein:
o the amylase comprises SEQ ID NO: 30 with the mutations H183*, G184*, I405L, A421 H, A422P and A428T;
o the lipase comprises SEQ ID NO: 31 with the mutations D27R, G38A, D96E, D11 1A, G163K, T231 R, N233R, D254S and P256T; o the mannanase comprises SEQ ID NO: 32;
o the pectate lyase comprises SEQ ID NO: 33; and o the cellulase comprises SEQ ID NO: 34 or SEQ ID NO: 35.
In one embodiment, the composition comprises:
• a DNase that comprises or consists of SEQ ID NO: 3;
• a GH39 polypeptide that comprises or consists of SEQ ID NO: 11 ;
• a protease that comprises SEQ ID NO: 24 with the substitutions S9E, N42R, N74D, V199I, Q200L, Y203W, S253D, N255W and L256E; and
• at least one enzyme selected from the group consisting of amylases and cellulases; wherein:
o the amylase comprises SEQ ID NO: 29 with the mutations H 1 *, N54S, V56T, K72R, G109A, F113Q, R116Q, W167F, Q172G, A174S, G182*, D183*, G184T, N195F, V206L, K391A, P473R and G476K; and o the cellulase comprises SEQ ID NO: 34.
In one embodiment, the composition comprises:
• a DNase that comprises or consists of SEQ ID NO: 3, or which is a variant thereof having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity to SEQ ID NO: 3;
• a GH39 polypeptide that comprises or consists of SEQ ID NO: 12, or which is a variant thereof having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity to SEQ ID NO: 12;
• a protease selected from: a) a polypeptide that comprises or consists of SEQ ID NO: 24 or SEQ ID NO: 26, or a variant thereof having at least 80%, at least 85%, at least 90% or at least 95% sequence identity to SEQ ID NO: 24 or SEQ ID NO: 26; b) a polypeptide that comprises SEQ ID NO: 24 with the substitutions Y161A, R164S and A188P; c) a polypeptide that comprises SEQ ID NO: 24 with the substitutions S9E, N42R, N74D, V199I, Q200L, Y203W, S253D, N255W and L256E; and d) a polypeptide that comprises SEQ ID NO: 37; and
• at least one enzyme selected from the group consisting of amylases, lipases, mannanases, pectate lyases and cellulases.
In one embodiment, the composition comprises:
• a DNase that comprises or consists of SEQ ID NO: 3;
• a GH39 polypeptide that comprises or consists of SEQ ID NO: 12;
• a protease that comprises SEQ ID NO: 24 with the substitutions Y161A, R164S and A188P, or that comprises SEQ ID NO: 37; and
• at least one enzyme selected from the group consisting of amylases, lipases, mannanases, pectate lyases and cellulases; wherein: o the amylase comprises SEQ ID NO: 30 with the mutations H183*, G184*, I405L, A421 H, A422P and A428T;
o the lipase comprises SEQ ID NO: 31 with the mutations D27R, G38A, D96E, D11 1A, G163K, T231 R, N233R, D254S and P256T; o the mannanase comprises SEQ ID NO: 32;
o the pectate lyase comprises SEQ ID NO: 33; and
o the cellulase comprises SEQ ID NO: 34 or SEQ ID NO: 35.
In one embodiment, the composition comprises:
• a DNase that comprises or consists of SEQ ID NO: 3;
• a GH39 polypeptide that comprises or consists of SEQ ID NO: 12;
• a protease that comprises SEQ ID NO: 24 with the substitutions S9E, N42R, N74D, V199I, Q200L, Y203W, S253D, N255W and L256E; and
• at least one enzyme selected from the group consisting of amylases and cellulases; wherein:
o the amylase comprises SEQ ID NO: 29 with the mutations H 1 *, N54S, V56T, K72R, G109A, F113Q, R116Q, W167F, Q172G, A174S, G182*, D183*, G184T, N195F, V206L, K391A, P473R and G476K; and o the cellulase comprises SEQ ID NO: 34.
In one embodiment, the composition comprises:
• a DNase that comprises or consists of SEQ ID NO: 4, or which is a variant thereof having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity to SEQ ID NO: 4;
• a GH39 polypeptide that comprises or consists of SEQ ID NO: 10, or which is a variant thereof having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity to SEQ ID NO: 10;
• a protease selected from: a) a polypeptide that comprises or consists of SEQ ID NO: 24 or SEQ ID NO: 26, or a variant thereof having at least 80%, at least 85%, at least 90% or at least 95% sequence identity to SEQ ID NO: 24 or SEQ ID NO: 26; b) a polypeptide that comprises SEQ ID NO: 24 with the substitutions Y161A, R164S and A188P; c) a polypeptide that comprises SEQ ID NO: 24 with the substitutions S9E, N42R, N74D, V199I, Q200L, Y203W, S253D, N255W and L256E; and d) a polypeptide that comprises SEQ ID NO: 37; and
• at least one enzyme selected from the group consisting of amylases, lipases, mannanases, pectate lyases and cellulases.
In one embodiment, the composition comprises: • a DNase that comprises or consists of SEQ ID NO: 4;
• a GH39 polypeptide that comprises or consists of SEQ ID NO: 10;
• a protease that comprises SEQ ID NO: 24 with the substitutions Y161A, R164S and A188P, or that comprises SEQ ID NO: 37; and
• at least one enzyme selected from the group consisting of amylases, lipases, mannanases, pectate lyases and cellulases; wherein:
o the amylase comprises SEQ ID NO: 30 with the mutations H183*, G184*, I405L, A421 H, A422P and A428T;
o the lipase comprises SEQ ID NO: 31 with the mutations D27R, G38A, D96E, D11 1A, G163K, T231 R, N233R, D254S and P256T; o the mannanase comprises SEQ ID NO: 32;
o the pectate lyase comprises SEQ ID NO: 33; and
o the cellulase comprises SEQ ID NO: 34 or SEQ ID NO: 35.
In one embodiment, the composition comprises:
• a DNase that comprises or consists of SEQ ID NO: 4;
• a GH39 polypeptide that comprises or consists of SEQ ID NO: 10;
• a protease that comprises SEQ ID NO: 24 with the substitutions S9E, N42R, N74D, V199I, Q200L, Y203W, S253D, N255W and L256E; and
• at least one enzyme selected from the group consisting of amylases and cellulases; wherein:
o the amylase comprises SEQ ID NO: 29 with the mutations H 1 *, N54S, V56T, K72R, G109A, F113Q, R116Q, W167F, Q172G, A174S, G182*, D183*, G184T, N195F, V206L, K391A, P473R and G476K; and o the cellulase comprises SEQ ID NO: 34.
In one embodiment, the composition comprises:
• a DNase that comprises or consists of SEQ ID NO: 4, or which is a variant thereof having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity to SEQ ID NO: 4;
• a GH39 polypeptide that comprises or consists of SEQ ID NO: 11 , or which is a variant thereof having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity to SEQ ID NO: 1 1 ;
• a protease selected from: a) a polypeptide that comprises or consists of SEQ ID NO: 24 or SEQ ID NO: 26, or a variant thereof having at least 80%, at least 85%, at least 90% or at least 95% sequence identity to SEQ ID NO: 24 or SEQ ID NO: 26; b) a polypeptide that comprises SEQ ID NO: 24 with the substitutions Y161A, R164S and A188P; c) a polypeptide that comprises SEQ ID NO: 24 with the substitutions S9E, N42R, N74D, V199I, Q200L, Y203W, S253D, N255W and L256E; and d) a polypeptide that comprises SEQ ID NO: 37; and
• at least one enzyme selected from the group consisting of amylases, lipases, mannanases, pectate lyases and cellulases.
In one embodiment, the composition comprises:
• a DNase that comprises or consists of SEQ ID NO: 4;
• a GH39 polypeptide that comprises or consists of SEQ ID NO: 11 ;
• a protease that comprises SEQ ID NO: 24 with the substitutions Y161A, R164S and A188P, or that comprises SEQ ID NO: 37; and
• at least one enzyme selected from the group consisting of amylases, lipases, mannanases, pectate lyases and cellulases; wherein:
o the amylase comprises SEQ ID NO: 30 with the mutations H183*, G184*, I405L, A421 H, A422P and A428T;
o the lipase comprises SEQ ID NO: 31 with the mutations D27R, G38A, D96E, D11 1A, G163K, T231 R, N233R, D254S and P256T; o the mannanase comprises SEQ ID NO: 32;
o the pectate lyase comprises SEQ ID NO: 33; and
o the cellulase comprises SEQ ID NO: 34 or SEQ ID NO: 35.
In one embodiment, the composition comprises:
• a DNase that comprises or consists of SEQ ID NO: 4;
• a GH39 polypeptide that comprises or consists of SEQ ID NO: 11 ;
• a protease that comprises SEQ ID NO: 24 with the substitutions S9E, N42R, N74D, V199I, Q200L, Y203W, S253D, N255W and L256E; and
• at least one enzyme selected from the group consisting of amylases and cellulases; wherein:
o the amylase comprises SEQ ID NO: 29 with the mutations H 1 *, N54S, V56T, K72R, G109A, F113Q, R116Q, W167F, Q172G, A174S, G182*, D183*, G184T, N195F, V206L, K391A, P473R and G476K; and o the cellulase comprises SEQ ID NO: 34.
In one embodiment, the composition comprises:
• a DNase that comprises or consists of SEQ ID NO: 4, or which is a variant thereof having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity to SEQ ID NO: 4;
• a GH39 polypeptide that comprises or consists of SEQ ID NO: 12, or which is a variant thereof having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity to SEQ ID NO: 12;
• a protease selected from: a) a polypeptide that comprises or consists of SEQ ID NO: 24 or SEQ ID NO: 26, or a variant thereof having at least 80%, at least 85%, at least 90% or at least 95% sequence identity to SEQ ID NO: 24 or SEQ ID NO: 26; b) a polypeptide that comprises SEQ ID NO: 24 with the substitutions Y161A, R164S and A188P; c) a polypeptide that comprises SEQ ID NO: 24 with the substitutions S9E, N42R, N74D, V199I, Q200L, Y203W, S253D, N255W and L256E; and d) a polypeptide that comprises SEQ ID NO: 37; and
• at least one enzyme selected from the group consisting of amylases, lipases, mannanases, pectate lyases and cellulases.
In one embodiment, the composition comprises:
• a DNase that comprises or consists of SEQ ID NO: 4;
• a GH39 polypeptide that comprises or consists of SEQ ID NO: 12;
• a protease that comprises SEQ ID NO: 24 with the substitutions Y161A, R164S and A188P, or that comprises SEQ ID NO: 37; and
• at least one enzyme selected from the group consisting of amylases, lipases, mannanases, pectate lyases and cellulases; wherein:
o the amylase comprises SEQ ID NO: 30 with the mutations H183*, G184*, I405L, A421 H, A422P and A428T;
o the lipase comprises SEQ ID NO: 31 with the mutations D27R, G38A, D96E, D11 1A, G163K, T231 R, N233R, D254S and P256T; o the mannanase comprises SEQ ID NO: 32;
o the pectate lyase comprises SEQ ID NO: 33; and
o the cellulase comprises SEQ ID NO: 34 or SEQ ID NO: 35.
In one embodiment, the composition comprises:
• a DNase that comprises or consists of SEQ ID NO: 4;
• a GH39 polypeptide that comprises or consists of SEQ ID NO: 12;
• a protease that comprises SEQ ID NO: 24 with the substitutions S9E, N42R, N74D, V199I, Q200L, Y203W, S253D, N255W and L256E; and
• at least one enzyme selected from the group consisting of amylases and cellulases; wherein:
o the amylase comprises SEQ ID NO: 29 with the mutations H 1 *, N54S, V56T, K72R, G109A, F113Q, R116Q, W167F, Q172G, A174S, G182*, D183*, G184T, N195F, V206L, K391A, P473R and G476K; and o the cellulase comprises SEQ ID NO: 34. In one embodiment, the composition comprises:
• a DNase that comprises or consists of SEQ ID NO: 5, or which is a variant thereof having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity to SEQ ID NO: 5;
• a GH39 polypeptide that comprises or consists of SEQ ID NO: 10, or which is a variant thereof having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity to SEQ ID NO: 10;
• a protease selected from: a) a polypeptide that comprises or consists of SEQ ID NO: 24 or SEQ ID NO: 26, or a variant thereof having at least 80%, at least 85%, at least 90% or at least 95% sequence identity to SEQ ID NO: 24 or SEQ ID NO: 26; b) a polypeptide that comprises SEQ ID NO: 24 with the substitutions Y161A, R164S and A188P; c) a polypeptide that comprises SEQ ID NO: 24 with the substitutions S9E, N42R, N74D, V199I, Q200L, Y203W, S253D, N255W and L256E; and d) a polypeptide that comprises SEQ ID NO: 37; and
• at least one enzyme selected from the group consisting of amylases, lipases, mannanases, pectate lyases and cellulases.
In one embodiment, the composition comprises:
• a DNase that comprises or consists of SEQ ID NO: 5;
• a GH39 polypeptide that comprises or consists of SEQ ID NO: 10;
• a protease that comprises SEQ ID NO: 24 with the substitutions Y161A, R164S and A188P, or that comprises SEQ ID NO: 37; and
• at least one enzyme selected from the group consisting of amylases, lipases, mannanases, pectate lyases and cellulases; wherein:
o the amylase comprises SEQ ID NO: 30 with the mutations H183*, G184*, I405L, A421 H, A422P and A428T;
o the lipase comprises SEQ ID NO: 31 with the mutations D27R, G38A, D96E, D11 1A, G163K, T231 R, N233R, D254S and P256T; o the mannanase comprises SEQ ID NO: 32;
o the pectate lyase comprises SEQ ID NO: 33; and
o the cellulase comprises SEQ ID NO: 34 or SEQ ID NO: 35.
In one embodiment, the composition comprises:
• a DNase that comprises or consists of SEQ ID NO: 5;
• a GH39 polypeptide that comprises or consists of SEQ ID NO: 10;
• a protease that comprises SEQ ID NO: 24 with the substitutions S9E, N42R, N74D, V199I, Q200L, Y203W, S253D, N255W and L256E; and • at least one enzyme selected from the group consisting of amylases and cellulases; wherein:
o the amylase comprises SEQ ID NO: 29 with the mutations H 1 *, N54S, V56T, K72R, G109A, F113Q, R116Q, W167F, Q172G, A174S, G182*, D183*, G184T, N195F, V206L, K391A, P473R and G476K; and o the cellulase comprises SEQ ID NO: 34.
In one embodiment, the composition comprises:
• a DNase that comprises or consists of SEQ ID NO: 5, or which is a variant thereof having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity to SEQ ID NO: 5;
• a GH39 polypeptide that comprises or consists of SEQ ID NO: 11 , or which is a variant thereof having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity to SEQ ID NO: 1 1 ;
• a protease selected from: a) a polypeptide that comprises or consists of SEQ ID NO: 24 or SEQ ID NO: 26, or a variant thereof having at least 80%, at least 85%, at least 90% or at least 95% sequence identity to SEQ ID NO: 24 or SEQ ID NO: 26; b) a polypeptide that comprises SEQ ID NO: 24 with the substitutions Y161A, R164S and A188P; c) a polypeptide that comprises SEQ ID NO: 24 with the substitutions S9E, N42R, N74D, V199I, Q200L, Y203W, S253D, N255W and L256E; and d) a polypeptide that comprises SEQ ID NO: 37; and
• at least one enzyme selected from the group consisting of amylases, lipases, mannanases, pectate lyases and cellulases.
In one embodiment, the composition comprises:
• a DNase that comprises or consists of SEQ ID NO: 5;
• a GH39 polypeptide that comprises or consists of SEQ ID NO: 11 ;
• a protease that comprises SEQ ID NO: 24 with the substitutions Y161A, R164S and A188P, or that comprises SEQ ID NO: 37; and
• at least one enzyme selected from the group consisting of amylases, lipases, mannanases, pectate lyases and cellulases; wherein:
o the amylase comprises SEQ ID NO: 30 with the mutations H183*, G184*, I405L, A421 H, A422P and A428T;
o the lipase comprises SEQ ID NO: 31 with the mutations D27R, G38A, D96E, D11 1A, G163K, T231 R, N233R, D254S and P256T; o the mannanase comprises SEQ ID NO: 32;
o the pectate lyase comprises SEQ ID NO: 33; and o the cellulase comprises SEQ ID NO: 34 or SEQ ID NO: 35.
In one embodiment, the composition comprises:
• a DNase that comprises or consists of SEQ ID NO: 5;
• a GH39 polypeptide that comprises or consists of SEQ ID NO: 11 ;
• a protease that comprises SEQ ID NO: 24 with the substitutions S9E, N42R, N74D, V199I, Q200L, Y203W, S253D, N255W and L256E; and
• at least one enzyme selected from the group consisting of amylases and cellulases; wherein:
o the amylase comprises SEQ ID NO: 29 with the mutations H 1 *, N54S, V56T, K72R, G109A, F113Q, R116Q, W167F, Q172G, A174S, G182*, D183*, G184T, N195F, V206L, K391A, P473R and G476K; and o the cellulase comprises SEQ ID NO: 34.
In one embodiment, the composition comprises:
• a DNase that comprises or consists of SEQ ID NO: 5, or which is a variant thereof having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity to SEQ ID NO: 5;
• a GH39 polypeptide that comprises or consists of SEQ ID NO: 12, or which is a variant thereof having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity to SEQ ID NO: 12;
• a protease selected from: a) a polypeptide that comprises or consists of SEQ ID NO: 24 or SEQ ID NO: 26, or a variant thereof having at least 80%, at least 85%, at least 90% or at least 95% sequence identity to SEQ ID NO: 24 or SEQ ID NO: 26; b) a polypeptide that comprises SEQ ID NO: 24 with the substitutions Y161A, R164S and A188P; c) a polypeptide that comprises SEQ ID NO: 24 with the substitutions S9E, N42R, N74D, V199I, Q200L, Y203W, S253D, N255W and L256E; and d) a polypeptide that comprises SEQ ID NO: 37; and
• at least one enzyme selected from the group consisting of amylases, lipases, mannanases, pectate lyases and cellulases.
In one embodiment, the composition comprises:
• a DNase that comprises or consists of SEQ ID NO: 5;
• a GH39 polypeptide that comprises or consists of SEQ ID NO: 12;
• a protease that comprises SEQ ID NO: 24 with the substitutions Y161A, R164S and A188P, or that comprises SEQ ID NO: 37; and
• at least one enzyme selected from the group consisting of amylases, lipases, mannanases, pectate lyases and cellulases; wherein: o the amylase comprises SEQ ID NO: 30 with the mutations H183*, G184*, I405L, A421 H, A422P and A428T;
o the lipase comprises SEQ ID NO: 31 with the mutations D27R, G38A, D96E, D1 1 1A, G163K, T231 R, N233R, D254S and P256T;
o the mannanase comprises SEQ ID NO: 32;
o the pectate lyase comprises SEQ ID NO: 33; and
o the cellulase comprises SEQ ID NO: 34 or SEQ ID NO: 35.
In one embodiment, the composition comprises:
• a DNase that comprises or consists of SEQ ID NO: 5;
• a GH39 polypeptide that comprises or consists of SEQ ID NO: 12;
• a protease that comprises SEQ ID NO: 24 with the substitutions S9E, N42R, N74D, V199I, Q200L, Y203W, S253D, N255W and L256E; and
• at least one enzyme selected from the group consisting of amylases and cellulases; wherein:
o the amylase comprises SEQ ID NO: 29 with the mutations H 1 *, N54S, V56T, K72R, G109A, F1 13Q, R1 16Q, W167F, Q172G, A174S, G182*, D183*, G184T, N 195F, V206L, K391A, P473R and G476K; and o the cellulase comprises SEQ ID NO: 34.
In any of the embodiments described above comprising at least a DNase and a GH39 glycosyl hydrolase as the cleaning enzymes, the cleaning composition may optionally comprise one or more of any of the other cleaning enzymes described herein. Any of these compositions may thus comprise one or more of an RNase, a Glyco_hydro_1 14 glucosyl hydrolase, a GHL13 glycosyl hydrolase or a hexosaminidase.
Cleaning compositions comprising a DNase and a GHL13 polypeptide
One aspect of the invention relates to a cleaning composition comprising at least a DNase and a GHL13 glycosyl hydrolase as the cleaning enzymes. Exemplary embodiments of this aspect of the invention are described below.
In one embodiment, the composition comprises:
• a DNase that comprises or consists of SEQ ID NO: 1 , or which is a variant thereof having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity to SEQ ID NO: 1 ;
• a GHL13 polypeptide that comprises or consists of SEQ ID NO: 13, or which is a variant thereof having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity to SEQ ID NO: 13;
• a protease selected from: a) a polypeptide that comprises or consists of SEQ ID NO: 24 or SEQ ID NO: 26, or a variant thereof having at least 80%, at least 85%, at least 90% or at least 95% sequence identity to SEQ ID NO: 24 or SEQ ID NO: 26; b) a polypeptide that comprises SEQ ID NO: 24 with the substitutions Y161A, R164S and A188P; c) a polypeptide that comprises SEQ ID NO: 24 with the substitutions S9E, N42R, N74D, V199I, Q200L, Y203W, S253D, N255W and L256E; and d) a polypeptide that comprises SEQ ID NO: 37; and
• at least one enzyme selected from the group consisting of amylases, lipases, mannanases, pectate lyases and cellulases.
In one embodiment, the composition comprises:
• a DNase that comprises or consists of SEQ ID NO: 1 ;
• a GHL13 polypeptide that comprises or consists of SEQ ID NO: 13;
• a protease that comprises SEQ ID NO: 24 with the substitutions Y161A, R164S and A188P, or that comprises SEQ ID NO: 37; and
• at least one enzyme selected from the group consisting of amylases, lipases, mannanases, pectate lyases and cellulases; wherein:
o the amylase comprises SEQ ID NO: 30 with the mutations H183*, G184*, I405L, A421 H, A422P and A428T;
o the lipase comprises SEQ ID NO: 31 with the mutations D27R, G38A, D96E, D11 1A, G163K, T231 R, N233R, D254S and P256T; o the mannanase comprises SEQ ID NO: 32;
o the pectate lyase comprises SEQ ID NO: 33; and
o the cellulase comprises SEQ ID NO: 34 or SEQ ID NO: 35.
In one embodiment, the composition comprises:
• a DNase that comprises or consists of SEQ ID NO: 1 ;
• a GHL13 polypeptide that comprises or consists of SEQ ID NO: 13;
• a protease that comprises SEQ ID NO: 24 with the substitutions S9E, N42R, N74D, V199I, Q200L, Y203W, S253D, N255W and L256E; and
• at least one enzyme selected from the group consisting of amylases and cellulases; wherein:
o the amylase comprises SEQ ID NO: 29 with the mutations H 1 *, N54S, V56T, K72R, G109A, F113Q, R116Q, W167F, Q172G, A174S, G182*, D183*, G184T, N195F, V206L, K391A, P473R and G476K; and o the cellulase comprises SEQ ID NO: 34. In one embodiment, the composition comprises:
• a DNase that comprises or consists of SEQ ID NO: 1 , or which is a variant thereof having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity to SEQ ID NO: 1 ;
• a GHL13 polypeptide that comprises or consists of SEQ ID NO: 14, or which is a variant thereof having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity to SEQ ID NO: 14;
• a protease selected from: a) a polypeptide that comprises or consists of SEQ ID NO: 24 or SEQ ID NO: 26, or a variant thereof having at least 80%, at least 85%, at least 90% or at least 95% sequence identity to SEQ ID NO: 24 or SEQ ID NO: 26; b) a polypeptide that comprises SEQ ID NO: 24 with the substitutions Y161A, R164S and A188P; c) a polypeptide that comprises SEQ ID NO: 24 with the substitutions S9E, N42R, N74D, V199I, Q200L, Y203W, S253D, N255W and L256E; and d) a polypeptide that comprises SEQ ID NO: 37; and
• at least one enzyme selected from the group consisting of amylases, lipases, mannanases, pectate lyases and cellulases.
In one embodiment, the composition comprises:
• a DNase that comprises or consists of SEQ ID NO: 1 ;
• a GHL13 polypeptide that comprises or consists of SEQ ID NO: 14;
• a protease that comprises SEQ ID NO: 24 with the substitutions Y161A, R164S and A188P, or that comprises SEQ ID NO: 37; and
• at least one enzyme selected from the group consisting of amylases, lipases, mannanases, pectate lyases and cellulases; wherein:
o the amylase comprises SEQ ID NO: 30 with the mutations H183*, G184*, I405L, A421 H, A422P and A428T;
o the lipase comprises SEQ ID NO: 31 with the mutations D27R, G38A, D96E, D11 1A, G163K, T231 R, N233R, D254S and P256T; o the mannanase comprises SEQ ID NO: 32;
o the pectate lyase comprises SEQ ID NO: 33; and
o the cellulase comprises SEQ ID NO: 34 or SEQ ID NO: 35.
In one embodiment, the composition comprises:
• a DNase that comprises or consists of SEQ ID NO: 1 ;
• a GHL13 polypeptide that comprises or consists of SEQ ID NO: 14;
• a protease that comprises SEQ ID NO: 24 with the substitutions S9E, N42R, N74D, V199I, Q200L, Y203W, S253D, N255W and L256E; and • at least one enzyme selected from the group consisting of amylases and cellulases; wherein:
o the amylase comprises SEQ ID NO: 29 with the mutations H 1 *, N54S, V56T, K72R, G109A, F113Q, R116Q, W167F, Q172G, A174S, G182*, D183*, G184T, N195F, V206L, K391A, P473R and G476K; and o the cellulase comprises SEQ ID NO: 34.
In one embodiment, the composition comprises:
• a DNase that comprises or consists of SEQ ID NO: 1 , or which is a variant thereof having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity to SEQ ID NO: 1 ;
• a GHL13 polypeptide that comprises or consists of SEQ ID NO: 15, or which is a variant thereof having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity to SEQ ID NO: 15;
• a protease selected from: a) a polypeptide that comprises or consists of SEQ ID NO: 24 or SEQ ID NO: 26, or a variant thereof having at least 80%, at least 85%, at least 90% or at least 95% sequence identity to SEQ ID NO: 24 or SEQ ID NO: 26; b) a polypeptide that comprises SEQ ID NO: 24 with the substitutions Y161A, R164S and A188P; c) a polypeptide that comprises SEQ ID NO: 24 with the substitutions S9E, N42R, N74D, V199I, Q200L, Y203W, S253D, N255W and L256E; and d) a polypeptide that comprises SEQ ID NO: 37; and
• at least one enzyme selected from the group consisting of amylases, lipases, mannanases, pectate lyases and cellulases.
In one embodiment, the composition comprises:
• a DNase that comprises or consists of SEQ ID NO: 1 ;
• a GHL13 polypeptide that comprises or consists of SEQ ID NO: 15;
• a protease that comprises SEQ ID NO: 24 with the substitutions Y161A, R164S and A188P, or that comprises SEQ ID NO: 37; and
• at least one enzyme selected from the group consisting of amylases, lipases, mannanases, pectate lyases and cellulases; wherein:
o the amylase comprises SEQ ID NO: 30 with the mutations H183*, G184*, I405L, A421 H, A422P and A428T;
o the lipase comprises SEQ ID NO: 31 with the mutations D27R, G38A, D96E, D11 1A, G163K, T231 R, N233R, D254S and P256T; o the mannanase comprises SEQ ID NO: 32;
o the pectate lyase comprises SEQ ID NO: 33; and o the cellulase comprises SEQ ID NO: 34 or SEQ ID NO: 35.
In one embodiment, the composition comprises:
• a DNase that comprises or consists of SEQ ID NO: 1 ;
• a GHL13 polypeptide that comprises or consists of SEQ ID NO: 15;
• a protease that comprises SEQ ID NO: 24 with the substitutions S9E, N42R, N74D, V199I, Q200L, Y203W, S253D, N255W and L256E; and
• at least one enzyme selected from the group consisting of amylases and cellulases; wherein:
o the amylase comprises SEQ ID NO: 29 with the mutations H 1 *, N54S, V56T, K72R, G109A, F113Q, R116Q, W167F, Q172G, A174S, G182*, D183*, G184T, N195F, V206L, K391A, P473R and G476K; and o the cellulase comprises SEQ ID NO: 34.
In one embodiment, the composition comprises:
• a DNase that comprises or consists of SEQ ID NO: 2, or which is a variant thereof having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity to SEQ ID NO: 2;
• a GHL13 polypeptide that comprises or consists of SEQ ID NO: 13, or which is a variant thereof having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity to SEQ ID NO: 13;
• a protease selected from: a) a polypeptide that comprises or consists of SEQ ID NO: 24 or SEQ ID NO: 26, or a variant thereof having at least 80%, at least 85%, at least 90% or at least 95% sequence identity to SEQ ID NO: 24 or SEQ ID NO: 26; b) a polypeptide that comprises SEQ ID NO: 24 with the substitutions Y161A, R164S and A188P; c) a polypeptide that comprises SEQ ID NO: 24 with the substitutions S9E, N42R, N74D, V199I, Q200L, Y203W, S253D, N255W and L256E; and d) a polypeptide that comprises SEQ ID NO: 37; and
• at least one enzyme selected from the group consisting of amylases, lipases, mannanases, pectate lyases and cellulases.
In one embodiment, the composition comprises:
• a DNase that comprises or consists of SEQ ID NO: 2;
• a GHL13 polypeptide that comprises or consists of SEQ ID NO: 13;
• a protease that comprises SEQ ID NO: 24 with the substitutions Y161A, R164S and A188P, or that comprises SEQ ID NO: 37; and
• at least one enzyme selected from the group consisting of amylases, lipases, mannanases, pectate lyases and cellulases; wherein: o the amylase comprises SEQ ID NO: 30 with the mutations H183*, G184*, I405L, A421 H, A422P and A428T;
o the lipase comprises SEQ ID NO: 31 with the mutations D27R, G38A, D96E, D11 1A, G163K, T231 R, N233R, D254S and P256T; o the mannanase comprises SEQ ID NO: 32;
o the pectate lyase comprises SEQ ID NO: 33; and
o the cellulase comprises SEQ ID NO: 34 or SEQ ID NO: 35.
In one embodiment, the composition comprises:
• a DNase that comprises or consists of SEQ ID NO: 2;
• a GHL13 polypeptide that comprises or consists of SEQ ID NO: 13;
• a protease that comprises SEQ ID NO: 24 with the substitutions S9E, N42R, N74D, V199I, Q200L, Y203W, S253D, N255W and L256E; and
• at least one enzyme selected from the group consisting of amylases and cellulases; wherein:
o the amylase comprises SEQ ID NO: 29 with the mutations H 1 *, N54S, V56T, K72R, G109A, F113Q, R116Q, W167F, Q172G, A174S, G182*, D183*, G184T, N195F, V206L, K391A, P473R and G476K; and o the cellulase comprises SEQ ID NO: 34.
In one embodiment, the composition comprises:
• a DNase that comprises or consists of SEQ ID NO: 2, or which is a variant thereof having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity to SEQ ID NO: 2;
• a GHL13 polypeptide that comprises or consists of SEQ ID NO: 14, or which is a variant thereof having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity to SEQ ID NO: 14;
• a protease selected from: a) a polypeptide that comprises or consists of SEQ ID NO: 24 or SEQ ID NO: 26, or a variant thereof having at least 80%, at least 85%, at least 90% or at least 95% sequence identity to SEQ ID NO: 24 or SEQ ID NO: 26; b) a polypeptide that comprises SEQ ID NO: 24 with the substitutions Y161A, R164S and A188P; c) a polypeptide that comprises SEQ ID NO: 24 with the substitutions S9E, N42R, N74D, V199I, Q200L, Y203W, S253D, N255W and L256E; and d) a polypeptide that comprises SEQ ID NO: 37; and
• at least one enzyme selected from the group consisting of amylases, lipases, mannanases, pectate lyases and cellulases.
In one embodiment, the composition comprises: • a DNase that comprises or consists of SEQ ID NO: 2;
• a GHL13 polypeptide that comprises or consists of SEQ ID NO: 14;
• a protease that comprises SEQ ID NO: 24 with the substitutions Y161A, R164S and A188P, or that comprises SEQ ID NO: 37; and
• at least one enzyme selected from the group consisting of amylases, lipases, mannanases, pectate lyases and cellulases; wherein:
o the amylase comprises SEQ ID NO: 30 with the mutations H183*, G184*, I405L, A421 H, A422P and A428T;
o the lipase comprises SEQ ID NO: 31 with the mutations D27R, G38A, D96E, D11 1A, G163K, T231 R, N233R, D254S and P256T; o the mannanase comprises SEQ ID NO: 32;
o the pectate lyase comprises SEQ ID NO: 33; and
o the cellulase comprises SEQ ID NO: 34 or SEQ ID NO: 35.
In one embodiment, the composition comprises:
• a DNase that comprises or consists of SEQ ID NO: 2;
• a GHL13 polypeptide that comprises or consists of SEQ ID NO: 14;
• a protease that comprises SEQ ID NO: 24 with the substitutions S9E, N42R, N74D, V199I, Q200L, Y203W, S253D, N255W and L256E; and
• at least one enzyme selected from the group consisting of amylases and cellulases; wherein:
o the amylase comprises SEQ ID NO: 29 with the mutations H 1 *, N54S, V56T, K72R, G109A, F113Q, R116Q, W167F, Q172G, A174S, G182*, D183*, G184T, N195F, V206L, K391A, P473R and G476K; and o the cellulase comprises SEQ ID NO: 34.
In one embodiment, the composition comprises:
• a DNase that comprises or consists of SEQ ID NO: 2, or which is a variant thereof having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity to SEQ ID NO: 2;
• a GHL13 polypeptide that comprises or consists of SEQ ID NO: 15, or which is a variant thereof having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity to SEQ ID NO: 15;
• a protease selected from: a) a polypeptide that comprises or consists of SEQ ID NO: 24 or SEQ ID NO: 26, or a variant thereof having at least 80%, at least 85%, at least 90% or at least 95% sequence identity to SEQ ID NO: 24 or SEQ ID NO: 26; b) a polypeptide that comprises SEQ ID NO: 24 with the substitutions Y161A, R164S and A188P; c) a polypeptide that comprises SEQ ID NO: 24 with the substitutions S9E, N42R, N74D, V199I, Q200L, Y203W, S253D, N255W and L256E; and d) a polypeptide that comprises SEQ ID NO: 37; and
• at least one enzyme selected from the group consisting of amylases, lipases, mannanases, pectate lyases and cellulases.
In one embodiment, the composition comprises:
• a DNase that comprises or consists of SEQ ID NO: 2;
• a GHL13 polypeptide that comprises or consists of SEQ ID NO: 15;
• a protease that comprises SEQ ID NO: 24 with the substitutions Y161A, R164S and A188P, or that comprises SEQ ID NO: 37; and
• at least one enzyme selected from the group consisting of amylases, lipases, mannanases, pectate lyases and cellulases; wherein:
o the amylase comprises SEQ ID NO: 30 with the mutations H183*, G184*, I405L, A421 H, A422P and A428T;
o the lipase comprises SEQ ID NO: 31 with the mutations D27R, G38A, D96E, D11 1A, G163K, T231 R, N233R, D254S and P256T; o the mannanase comprises SEQ ID NO: 32;
o the pectate lyase comprises SEQ ID NO: 33; and
o the cellulase comprises SEQ ID NO: 34 or SEQ ID NO: 35.
In one embodiment, the composition comprises:
• a DNase that comprises or consists of SEQ ID NO: 2;
• a GHL13 polypeptide that comprises or consists of SEQ ID NO: 15;
• a protease that comprises SEQ ID NO: 24 with the substitutions S9E, N42R, N74D, V199I, Q200L, Y203W, S253D, N255W and L256E; and
• at least one enzyme selected from the group consisting of amylases and cellulases; wherein:
o the amylase comprises SEQ ID NO: 29 with the mutations H 1 *, N54S, V56T, K72R, G109A, F113Q, R116Q, W167F, Q172G, A174S, G182*, D183*, G184T, N195F, V206L, K391A, P473R and G476K; and o the cellulase comprises SEQ ID NO: 34.
In one embodiment, the composition comprises:
• a DNase that comprises or consists of SEQ ID NO: 3, or which is a variant thereof having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity to SEQ ID NO: 3;
• a GHL13 polypeptide that comprises or consists of SEQ ID NO: 13, or which is a variant thereof having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity to SEQ ID NO: 13;
• a protease selected from: a) a polypeptide that comprises or consists of SEQ ID NO: 24 or SEQ ID NO: 26, or a variant thereof having at least 80%, at least 85%, at least 90% or at least 95% sequence identity to SEQ ID NO: 24 or SEQ ID NO: 26; b) a polypeptide that comprises SEQ ID NO: 24 with the substitutions Y161A, R164S and A188P; c) a polypeptide that comprises SEQ ID NO: 24 with the substitutions S9E, N42R, N74D, V199I, Q200L, Y203W, S253D, N255W and L256E; and d) a polypeptide that comprises SEQ ID NO: 37; and
• at least one enzyme selected from the group consisting of amylases, lipases, mannanases, pectate lyases and cellulases.
In one embodiment, the composition comprises:
• a DNase that comprises or consists of SEQ ID NO: 3;
• a GHL13 polypeptide that comprises or consists of SEQ ID NO: 13;
• a protease that comprises SEQ ID NO: 24 with the substitutions Y161A, R164S and A188P, or that comprises SEQ ID NO: 37; and
• at least one enzyme selected from the group consisting of amylases, lipases, mannanases, pectate lyases and cellulases; wherein:
o the amylase comprises SEQ ID NO: 30 with the mutations H183*, G184*, I405L, A421 H, A422P and A428T;
o the lipase comprises SEQ ID NO: 31 with the mutations D27R, G38A, D96E, D11 1A, G163K, T231 R, N233R, D254S and P256T; o the mannanase comprises SEQ ID NO: 32;
o the pectate lyase comprises SEQ ID NO: 33; and
o the cellulase comprises SEQ ID NO: 34 or SEQ ID NO: 35.
In one embodiment, the composition comprises:
• a DNase that comprises or consists of SEQ ID NO: 3;
• a GHL13 polypeptide that comprises or consists of SEQ ID NO: 13;
• a protease that comprises SEQ ID NO: 24 with the substitutions S9E, N42R, N74D, V199I, Q200L, Y203W, S253D, N255W and L256E; and
• at least one enzyme selected from the group consisting of amylases and cellulases; wherein:
o the amylase comprises SEQ ID NO: 29 with the mutations H 1 *, N54S, V56T, K72R, G109A, F113Q, R116Q, W167F, Q172G, A174S, G182*, D183*, G184T, N195F, V206L, K391A, P473R and G476K; and o the cellulase comprises SEQ ID NO: 34. In one embodiment, the composition comprises:
• a DNase that comprises or consists of SEQ ID NO: 3, or which is a variant thereof having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity to SEQ ID NO: 3;
• a GHL13 polypeptide that comprises or consists of SEQ ID NO: 14, or which is a variant thereof having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity to SEQ ID NO: 14;
• a protease selected from: a) a polypeptide that comprises or consists of SEQ ID NO: 24 or SEQ ID NO: 26, or a variant thereof having at least 80%, at least 85%, at least 90% or at least 95% sequence identity to SEQ ID NO: 24 or SEQ ID NO: 26; b) a polypeptide that comprises SEQ ID NO: 24 with the substitutions Y161A, R164S and A188P; c) a polypeptide that comprises SEQ ID NO: 24 with the substitutions S9E, N42R, N74D, V199I, Q200L, Y203W, S253D, N255W and L256E; and d) a polypeptide that comprises SEQ ID NO: 37; and
• at least one enzyme selected from the group consisting of amylases, lipases, mannanases, pectate lyases and cellulases.
In one embodiment, the composition comprises:
• a DNase that comprises or consists of SEQ ID NO: 3;
• a GHL13 polypeptide that comprises or consists of SEQ ID NO: 14;
• a protease that comprises SEQ ID NO: 24 with the substitutions Y161A, R164S and A188P, or that comprises SEQ ID NO: 37; and
• at least one enzyme selected from the group consisting of amylases, lipases, mannanases, pectate lyases and cellulases; wherein:
o the amylase comprises SEQ ID NO: 30 with the mutations H183*, G184*, I405L, A421 H, A422P and A428T;
o the lipase comprises SEQ ID NO: 31 with the mutations D27R, G38A, D96E, D11 1A, G163K, T231 R, N233R, D254S and P256T; o the mannanase comprises SEQ ID NO: 32;
o the pectate lyase comprises SEQ ID NO: 33; and
o the cellulase comprises SEQ ID NO: 34 or SEQ ID NO: 35.
In one embodiment, the composition comprises:
• a DNase that comprises or consists of SEQ ID NO: 3;
• a GHL13 polypeptide that comprises or consists of SEQ ID NO: 14;
• a protease that comprises SEQ ID NO: 24 with the substitutions S9E, N42R, N74D, V199I, Q200L, Y203W, S253D, N255W and L256E; and • at least one enzyme selected from the group consisting of amylases and cellulases; wherein:
o the amylase comprises SEQ ID NO: 29 with the mutations H 1 *, N54S, V56T, K72R, G109A, F113Q, R116Q, W167F, Q172G, A174S, G182*, D183*, G184T, N195F, V206L, K391A, P473R and G476K; and o the cellulase comprises SEQ ID NO: 34.
In one embodiment, the composition comprises:
• a DNase that comprises or consists of SEQ ID NO: 3, or which is a variant thereof having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity to SEQ ID NO: 3;
• a GHL13 polypeptide that comprises or consists of SEQ ID NO: 15, or which is a variant thereof having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity to SEQ ID NO: 15;
• a protease selected from: a) a polypeptide that comprises or consists of SEQ ID NO: 24 or SEQ ID NO: 26, or a variant thereof having at least 80%, at least 85%, at least 90% or at least 95% sequence identity to SEQ ID NO: 24 or SEQ ID NO: 26; b) a polypeptide that comprises SEQ ID NO: 24 with the substitutions Y161A, R164S and A188P; c) a polypeptide that comprises SEQ ID NO: 24 with the substitutions S9E, N42R, N74D, V199I, Q200L, Y203W, S253D, N255W and L256E; and d) a polypeptide that comprises SEQ ID NO: 37; and
• at least one enzyme selected from the group consisting of amylases, lipases, mannanases, pectate lyases and cellulases.
In one embodiment, the composition comprises:
• a DNase that comprises or consists of SEQ ID NO: 3;
• a GHL13 polypeptide that comprises or consists of SEQ ID NO: 15;
• a protease that comprises SEQ ID NO: 24 with the substitutions Y161A, R164S and A188P, or that comprises SEQ ID NO: 37; and
• at least one enzyme selected from the group consisting of amylases, lipases, mannanases, pectate lyases and cellulases; wherein:
o the amylase comprises SEQ ID NO: 30 with the mutations H183*, G184*, I405L, A421 H, A422P and A428T;
o the lipase comprises SEQ ID NO: 31 with the mutations D27R, G38A, D96E, D11 1A, G163K, T231 R, N233R, D254S and P256T; o the mannanase comprises SEQ ID NO: 32;
o the pectate lyase comprises SEQ ID NO: 33; and o the cellulase comprises SEQ ID NO: 34 or SEQ ID NO: 35.
In one embodiment, the composition comprises:
• a DNase that comprises or consists of SEQ ID NO: 3;
• a GHL13 polypeptide that comprises or consists of SEQ ID NO: 15;
• a protease that comprises SEQ ID NO: 24 with the substitutions S9E, N42R, N74D, V199I, Q200L, Y203W, S253D, N255W and L256E; and
• at least one enzyme selected from the group consisting of amylases and cellulases; wherein:
o the amylase comprises SEQ ID NO: 29 with the mutations H 1 *, N54S, V56T, K72R, G109A, F113Q, R116Q, W167F, Q172G, A174S, G182*, D183*, G184T, N195F, V206L, K391A, P473R and G476K; and o the cellulase comprises SEQ ID NO: 34.
In one embodiment, the composition comprises:
• a DNase that comprises or consists of SEQ ID NO: 4, or which is a variant thereof having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity to SEQ ID NO: 4;
• a GHL13 polypeptide that comprises or consists of SEQ ID NO: 13, or which is a variant thereof having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity to SEQ ID NO: 13;
• a protease selected from: a) a polypeptide that comprises or consists of SEQ ID NO: 24 or SEQ ID NO: 26, or a variant thereof having at least 80%, at least 85%, at least 90% or at least 95% sequence identity to SEQ ID NO: 24 or SEQ ID NO: 26; b) a polypeptide that comprises SEQ ID NO: 24 with the substitutions Y161A, R164S and A188P; c) a polypeptide that comprises SEQ ID NO: 24 with the substitutions S9E, N42R, N74D, V199I, Q200L, Y203W, S253D, N255W and L256E; and d) a polypeptide that comprises SEQ ID NO: 37; and
• at least one enzyme selected from the group consisting of amylases, lipases, mannanases, pectate lyases and cellulases.
In one embodiment, the composition comprises:
• a DNase that comprises or consists of SEQ ID NO: 4;
• a GHL13 polypeptide that comprises or consists of SEQ ID NO: 13;
• a protease that comprises SEQ ID NO: 24 with the substitutions Y161A, R164S and A188P, or that comprises SEQ ID NO: 37; and
• at least one enzyme selected from the group consisting of amylases, lipases, mannanases, pectate lyases and cellulases; wherein: o the amylase comprises SEQ ID NO: 30 with the mutations H183*, G184*, I405L, A421 H, A422P and A428T;
o the lipase comprises SEQ ID NO: 31 with the mutations D27R, G38A, D96E, D11 1A, G163K, T231 R, N233R, D254S and P256T; o the mannanase comprises SEQ ID NO: 32;
o the pectate lyase comprises SEQ ID NO: 33; and
o the cellulase comprises SEQ ID NO: 34 or SEQ ID NO: 35.
In one embodiment, the composition comprises:
• a DNase that comprises or consists of SEQ ID NO: 4;
• a GHL13 polypeptide that comprises or consists of SEQ ID NO: 13;
• a protease that comprises SEQ ID NO: 24 with the substitutions S9E, N42R, N74D, V199I, Q200L, Y203W, S253D, N255W and L256E; and
• at least one enzyme selected from the group consisting of amylases and cellulases; wherein:
o the amylase comprises SEQ ID NO: 29 with the mutations H 1 *, N54S, V56T, K72R, G109A, F113Q, R116Q, W167F, Q172G, A174S, G182*, D183*, G184T, N195F, V206L, K391A, P473R and G476K; and o the cellulase comprises SEQ ID NO: 34.
In one embodiment, the composition comprises:
• a DNase that comprises or consists of SEQ ID NO: 4, or which is a variant thereof having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity to SEQ ID NO: 4;
• a GHL13 polypeptide that comprises or consists of SEQ ID NO: 14, or which is a variant thereof having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity to SEQ ID NO: 14;
• a protease selected from: a) a polypeptide that comprises or consists of SEQ ID NO: 24 or SEQ ID NO: 26, or a variant thereof having at least 80%, at least 85%, at least 90% or at least 95% sequence identity to SEQ ID NO: 24 or SEQ ID NO: 26; b) a polypeptide that comprises SEQ ID NO: 24 with the substitutions Y161A, R164S and A188P; c) a polypeptide that comprises SEQ ID NO: 24 with the substitutions S9E, N42R, N74D, V199I, Q200L, Y203W, S253D, N255W and L256E; and d) a polypeptide that comprises SEQ ID NO: 37; and
• at least one enzyme selected from the group consisting of amylases, lipases, mannanases, pectate lyases and cellulases.
In one embodiment, the composition comprises: • a DNase that comprises or consists of SEQ ID NO: 4;
• a GHL13 polypeptide that comprises or consists of SEQ ID NO: 14;
• a protease that comprises SEQ ID NO: 24 with the substitutions Y161A, R164S and A188P, or that comprises SEQ ID NO: 37; and
• at least one enzyme selected from the group consisting of amylases, lipases, mannanases, pectate lyases and cellulases; wherein:
o the amylase comprises SEQ ID NO: 30 with the mutations H183*, G184*, I405L, A421 H, A422P and A428T;
o the lipase comprises SEQ ID NO: 31 with the mutations D27R, G38A, D96E, D11 1A, G163K, T231 R, N233R, D254S and P256T; o the mannanase comprises SEQ ID NO: 32;
o the pectate lyase comprises SEQ ID NO: 33; and
o the cellulase comprises SEQ ID NO: 34 or SEQ ID NO: 35.
In one embodiment, the composition comprises:
• a DNase that comprises or consists of SEQ ID NO: 4;
• a GHL13 polypeptide that comprises or consists of SEQ ID NO: 14;
• a protease that comprises SEQ ID NO: 24 with the substitutions S9E, N42R, N74D, V199I, Q200L, Y203W, S253D, N255W and L256E; and
• at least one enzyme selected from the group consisting of amylases and cellulases; wherein:
o the amylase comprises SEQ ID NO: 29 with the mutations H 1 *, N54S, V56T, K72R, G109A, F113Q, R116Q, W167F, Q172G, A174S, G182*, D183*, G184T, N195F, V206L, K391A, P473R and G476K; and o the cellulase comprises SEQ ID NO: 34.
In one embodiment, the composition comprises:
• a DNase that comprises or consists of SEQ ID NO: 4, or which is a variant thereof having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity to SEQ ID NO: 4;
• a GHL13 polypeptide that comprises or consists of SEQ ID NO: 15, or which is a variant thereof having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity to SEQ ID NO: 15;
• a protease selected from: a) a polypeptide that comprises or consists of SEQ ID NO: 24 or SEQ ID NO: 26, or a variant thereof having at least 80%, at least 85%, at least 90% or at least 95% sequence identity to SEQ ID NO: 24 or SEQ ID NO: 26; b) a polypeptide that comprises SEQ ID NO: 24 with the substitutions Y161A, R164S and A188P; c) a polypeptide that comprises SEQ ID NO: 24 with the substitutions S9E, N42R, N74D, V199I, Q200L, Y203W, S253D, N255W and L256E; and d) a polypeptide that comprises SEQ ID NO: 37; and
• at least one enzyme selected from the group consisting of amylases, lipases, mannanases, pectate lyases and cellulases.
In one embodiment, the composition comprises:
• a DNase that comprises or consists of SEQ ID NO: 4;
• a GHL13 polypeptide that comprises or consists of SEQ ID NO: 15;
• a protease that comprises SEQ ID NO: 24 with the substitutions Y161A, R164S and A188P, or that comprises SEQ ID NO: 37; and
• at least one enzyme selected from the group consisting of amylases, lipases, mannanases, pectate lyases and cellulases; wherein:
o the amylase comprises SEQ ID NO: 30 with the mutations H183*, G184*, I405L, A421 H, A422P and A428T;
o the lipase comprises SEQ ID NO: 31 with the mutations D27R, G38A, D96E, D11 1A, G163K, T231 R, N233R, D254S and P256T; o the mannanase comprises SEQ ID NO: 32;
o the pectate lyase comprises SEQ ID NO: 33; and
o the cellulase comprises SEQ ID NO: 34 or SEQ ID NO: 35.
In one embodiment, the composition comprises:
• a DNase that comprises or consists of SEQ ID NO: 4;
• a GHL13 polypeptide that comprises or consists of SEQ ID NO: 15;
• a protease that comprises SEQ ID NO: 24 with the substitutions S9E, N42R, N74D, V199I, Q200L, Y203W, S253D, N255W and L256E; and
• at least one enzyme selected from the group consisting of amylases and cellulases; wherein:
o the amylase comprises SEQ ID NO: 29 with the mutations H 1 *, N54S, V56T, K72R, G109A, F113Q, R116Q, W167F, Q172G, A174S, G182*, D183*, G184T, N195F, V206L, K391A, P473R and G476K; and o the cellulase comprises SEQ ID NO: 34.
In one embodiment, the composition comprises:
• a DNase that comprises or consists of SEQ ID NO: 5, or which is a variant thereof having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity to SEQ ID NO: 5;
• a GHL13 polypeptide that comprises or consists of SEQ ID NO: 13, or which is a variant thereof having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity to SEQ ID NO: 13;
• a protease selected from: a) a polypeptide that comprises or consists of SEQ ID NO: 24 or SEQ ID NO: 26, or a variant thereof having at least 80%, at least 85%, at least 90% or at least 95% sequence identity to SEQ ID NO: 24 or SEQ ID NO: 26; b) a polypeptide that comprises SEQ ID NO: 24 with the substitutions Y161A, R164S and A188P; c) a polypeptide that comprises SEQ ID NO: 24 with the substitutions S9E, N42R, N74D, V199I, Q200L, Y203W, S253D, N255W and L256E; and d) a polypeptide that comprises SEQ ID NO: 37; and
• at least one enzyme selected from the group consisting of amylases, lipases, mannanases, pectate lyases and cellulases.
In one embodiment, the composition comprises:
• a DNase that comprises or consists of SEQ ID NO: 5;
• a GHL13 polypeptide that comprises or consists of SEQ ID NO: 13;
• a protease that comprises SEQ ID NO: 24 with the substitutions Y161A, R164S and A188P, or that comprises SEQ ID NO: 37; and
• at least one enzyme selected from the group consisting of amylases, lipases, mannanases, pectate lyases and cellulases; wherein:
o the amylase comprises SEQ ID NO: 30 with the mutations H183*, G184*, I405L, A421 H, A422P and A428T;
o the lipase comprises SEQ ID NO: 31 with the mutations D27R, G38A, D96E, D11 1A, G163K, T231 R, N233R, D254S and P256T; o the mannanase comprises SEQ ID NO: 32;
o the pectate lyase comprises SEQ ID NO: 33; and
o the cellulase comprises SEQ ID NO: 34 or SEQ ID NO: 35.
In one embodiment, the composition comprises:
• a DNase that comprises or consists of SEQ ID NO: 5;
• a GHL13 polypeptide that comprises or consists of SEQ ID NO: 13;
• a protease that comprises SEQ ID NO: 24 with the substitutions S9E, N42R, N74D, V199I, Q200L, Y203W, S253D, N255W and L256E; and
• at least one enzyme selected from the group consisting of amylases and cellulases; wherein:
o the amylase comprises SEQ ID NO: 29 with the mutations H 1 *, N54S, V56T, K72R, G109A, F113Q, R116Q, W167F, Q172G, A174S, G182*, D183*, G184T, N195F, V206L, K391A, P473R and G476K; and o the cellulase comprises SEQ ID NO: 34. In one embodiment, the composition comprises:
• a DNase that comprises or consists of SEQ ID NO: 5, or which is a variant thereof having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity to SEQ ID NO: 5;
• a GHL13 polypeptide that comprises or consists of SEQ ID NO: 14, or which is a variant thereof having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity to SEQ ID NO: 14;
• a protease selected from: a) a polypeptide that comprises or consists of SEQ ID NO: 24 or SEQ ID NO: 26, or a variant thereof having at least 80%, at least 85%, at least 90% or at least 95% sequence identity to SEQ ID NO: 24 or SEQ ID NO: 26; b) a polypeptide that comprises SEQ ID NO: 24 with the substitutions Y161A, R164S and A188P; c) a polypeptide that comprises SEQ ID NO: 24 with the substitutions S9E, N42R, N74D, V199I, Q200L, Y203W, S253D, N255W and L256E; and d) a polypeptide that comprises SEQ ID NO: 37; and
• at least one enzyme selected from the group consisting of amylases, lipases, mannanases, pectate lyases and cellulases.
In one embodiment, the composition comprises:
• a DNase that comprises or consists of SEQ ID NO: 5;
• a GHL13 polypeptide that comprises or consists of SEQ ID NO: 14;
• a protease that comprises SEQ ID NO: 24 with the substitutions Y161A, R164S and A188P, or that comprises SEQ ID NO: 37; and
• at least one enzyme selected from the group consisting of amylases, lipases, mannanases, pectate lyases and cellulases; wherein:
o the amylase comprises SEQ ID NO: 30 with the mutations H183*, G184*, I405L, A421 H, A422P and A428T;
o the lipase comprises SEQ ID NO: 31 with the mutations D27R, G38A, D96E, D11 1A, G163K, T231 R, N233R, D254S and P256T; o the mannanase comprises SEQ ID NO: 32;
o the pectate lyase comprises SEQ ID NO: 33; and
o the cellulase comprises SEQ ID NO: 34 or SEQ ID NO: 35.
In one embodiment, the composition comprises:
• a DNase that comprises or consists of SEQ ID NO: 5;
• a GHL13 polypeptide that comprises or consists of SEQ ID NO: 14;
• a protease that comprises SEQ ID NO: 24 with the substitutions S9E, N42R, N74D, V199I, Q200L, Y203W, S253D, N255W and L256E; and • at least one enzyme selected from the group consisting of amylases and cellulases; wherein:
o the amylase comprises SEQ ID NO: 29 with the mutations H 1 *, N54S, V56T, K72R, G109A, F113Q, R116Q, W167F, Q172G, A174S, G182*, D183*, G184T, N195F, V206L, K391A, P473R and G476K; and o the cellulase comprises SEQ ID NO: 34.
In one embodiment, the composition comprises:
• a DNase that comprises or consists of SEQ ID NO: 5, or which is a variant thereof having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity to SEQ ID NO: 5;
• a GHL13 polypeptide that comprises or consists of SEQ ID NO: 15, or which is a variant thereof having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity to SEQ ID NO: 15;
• a protease selected from: a) a polypeptide that comprises or consists of SEQ ID NO: 24 or SEQ ID NO: 26, or a variant thereof having at least 80%, at least 85%, at least 90% or at least 95% sequence identity to SEQ ID NO: 24 or SEQ ID NO: 26; b) a polypeptide that comprises SEQ ID NO: 24 with the substitutions Y161A, R164S and A188P; c) a polypeptide that comprises SEQ ID NO: 24 with the substitutions S9E, N42R, N74D, V199I, Q200L, Y203W, S253D, N255W and L256E; and d) a polypeptide that comprises SEQ ID NO: 37; and
• at least one enzyme selected from the group consisting of amylases, lipases, mannanases, pectate lyases and cellulases.
In one embodiment, the composition comprises:
• a DNase that comprises or consists of SEQ ID NO: 5;
• a GHL13 polypeptide that comprises or consists of SEQ ID NO: 15;
• a protease that comprises SEQ ID NO: 24 with the substitutions Y161A, R164S and A188P, or that comprises SEQ ID NO: 37; and
• at least one enzyme selected from the group consisting of amylases, lipases, mannanases, pectate lyases and cellulases; wherein:
o the amylase comprises SEQ ID NO: 30 with the mutations H183*, G184*, I405L, A421 H, A422P and A428T;
o the lipase comprises SEQ ID NO: 31 with the mutations D27R, G38A, D96E, D11 1A, G163K, T231 R, N233R, D254S and P256T; o the mannanase comprises SEQ ID NO: 32;
o the pectate lyase comprises SEQ ID NO: 33; and o the cellulase comprises SEQ ID NO: 34 or SEQ ID NO: 35.
In one embodiment, the composition comprises:
• a DNase that comprises or consists of SEQ ID NO: 5;
• a GHL13 polypeptide that comprises or consists of SEQ ID NO: 15;
• a protease that comprises SEQ ID NO: 24 with the substitutions S9E, N42R, N74D, V199I, Q200L, Y203W, S253D, N255W and L256E; and
• at least one enzyme selected from the group consisting of amylases and cellulases; wherein:
o the amylase comprises SEQ ID NO: 29 with the mutations H 1 *, N54S, V56T, K72R, G109A, F1 13Q, R1 16Q, W167F, Q172G, A174S, G182*, D183*, G184T, N 195F, V206L, K391A, P473R and G476K; and o the cellulase comprises SEQ ID NO: 34.
In any of the embodiments described above comprising at least a DNase and a GHL13 glycosyl hydrolase as the cleaning enzymes, the cleaning composition may optionally comprise one or more of any of the other cleaning enzymes described herein. Any of these compositions may thus comprise one or more of an RNase, a Glyco_hydro_1 14 glucosyl hydrolase, a GH39 glycosyl hydrolase or a hexosaminidase.
Cleaning compositions comprising a DNase and a hexosaminidase
One aspect of the invention relates to a cleaning composition comprising at least a DNase and a hexosaminidase as the cleaning enzymes. Exemplary embodiments of this aspect of the invention are described below.
In one embodiment, the composition comprises:
• a DNase that comprises or consists of SEQ ID NO: 1 , or which is a variant thereof having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity to SEQ ID NO: 1 ;
• a hexosaminidase that comprises or consists of SEQ ID NO: 19, or which is a variant thereof having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity to SEQ ID NO: 19;
• a protease selected from: a) a polypeptide that comprises or consists of SEQ ID NO: 24 or SEQ ID NO: 26, or a variant thereof having at least 80%, at least 85%, at least 90% or at least 95% sequence identity to SEQ ID NO: 24 or SEQ ID NO: 26; b) a polypeptide that comprises SEQ ID NO: 24 with the substitutions Y161A, R164S and A188P; c) a polypeptide that comprises SEQ ID NO: 24 with the substitutions S9E, N42R, N74D, V199I, Q200L, Y203W, S253D, N255W and L256E; and d) a polypeptide that comprises SEQ ID NO: 37; and
• at least one enzyme selected from the group consisting of amylases, lipases, mannanases, pectate lyases and cellulases.
In one embodiment, the composition comprises:
• a DNase that comprises or consists of SEQ ID NO: 1 ;
• a hexosaminidase that comprises or consists of SEQ ID NO: 19;
• a protease that comprises SEQ ID NO: 24 with the substitutions Y161A, R164S and A188P, or that comprises SEQ ID NO: 37; and
• at least one enzyme selected from the group consisting of amylases, lipases, mannanases, pectate lyases and cellulases; wherein:
o the amylase comprises SEQ ID NO: 30 with the mutations H183*, G184*, I405L, A421 H, A422P and A428T;
o the lipase comprises SEQ ID NO: 31 with the mutations D27R, G38A, D96E, D11 1A, G163K, T231 R, N233R, D254S and P256T; o the mannanase comprises SEQ ID NO: 32;
o the pectate lyase comprises SEQ ID NO: 33; and
o the cellulase comprises SEQ ID NO: 34 or SEQ ID NO: 35.
In one embodiment, the composition comprises:
• a DNase that comprises or consists of SEQ ID NO: 1 ;
• a hexosaminidase that comprises or consists of SEQ ID NO: 19;
• a protease that comprises SEQ ID NO: 24 with the substitutions S9E, N42R, N74D, V199I, Q200L, Y203W, S253D, N255W and L256E; and
• at least one enzyme selected from the group consisting of amylases and cellulases; wherein:
o the amylase comprises SEQ ID NO: 29 with the mutations H 1 *, N54S, V56T, K72R, G109A, F113Q, R116Q, W167F, Q172G, A174S, G182*, D183*, G184T, N195F, V206L, K391A, P473R and G476K; and o the cellulase comprises SEQ ID NO: 34.
In one embodiment, the composition comprises:
• a DNase that comprises or consists of SEQ ID NO: 1 , or which is a variant thereof having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity to SEQ ID NO: 1 ;
• a hexosaminidase that comprises or consists of SEQ ID NO: 20, or which is a variant thereof having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity to SEQ ID NO: 20;
• a protease selected from: a) a polypeptide that comprises or consists of SEQ ID NO: 24 or SEQ ID NO: 26, or a variant thereof having at least 80%, at least 85%, at least 90% or at least 95% sequence identity to SEQ ID NO: 24 or SEQ ID NO: 26; b) a polypeptide that comprises SEQ ID NO: 24 with the substitutions Y161A, R164S and A188P; c) a polypeptide that comprises SEQ ID NO: 24 with the substitutions S9E, N42R, N74D, V199I, Q200L, Y203W, S253D, N255W and L256E; and d) a polypeptide that comprises SEQ ID NO: 37; and
• at least one enzyme selected from the group consisting of amylases, lipases, mannanases, pectate lyases and cellulases.
In one embodiment, the composition comprises:
• a DNase that comprises or consists of SEQ ID NO: 1 ;
• a hexosaminidase that comprises or consists of SEQ ID NO: 20;
• a protease that comprises SEQ ID NO: 24 with the substitutions Y161A, R164S and A188P, or that comprises SEQ ID NO: 37; and
• at least one enzyme selected from the group consisting of amylases, lipases, mannanases, pectate lyases and cellulases; wherein:
o the amylase comprises SEQ ID NO: 30 with the mutations H183*, G184*, I405L, A421 H, A422P and A428T;
o the lipase comprises SEQ ID NO: 31 with the mutations D27R, G38A, D96E, D11 1A, G163K, T231 R, N233R, D254S and P256T; o the mannanase comprises SEQ ID NO: 32;
o the pectate lyase comprises SEQ ID NO: 33; and
o the cellulase comprises SEQ ID NO: 34 or SEQ ID NO: 35.
In one embodiment, the composition comprises:
• a DNase that comprises or consists of SEQ ID NO: 1 ;
• a hexosaminidase that comprises or consists of SEQ ID NO: 20;
• a protease that comprises SEQ ID NO: 24 with the substitutions S9E, N42R, N74D, V199I, Q200L, Y203W, S253D, N255W and L256E; and
• at least one enzyme selected from the group consisting of amylases and cellulases; wherein:
o the amylase comprises SEQ ID NO: 29 with the mutations H 1 *, N54S, V56T, K72R, G109A, F113Q, R116Q, W167F, Q172G, A174S, G182*, D183*, G184T, N195F, V206L, K391A, P473R and G476K; and o the cellulase comprises SEQ ID NO: 34. In one embodiment, the composition comprises:
• a DNase that comprises or consists of SEQ ID NO: 1 , or which is a variant thereof having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity to SEQ ID NO: 1 ;
• a hexosaminidase that comprises or consists of SEQ ID NO: 21 , or which is a variant thereof having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity to SEQ ID NO: 21 ;
• a protease selected from: a) a polypeptide that comprises or consists of SEQ ID NO: 24 or SEQ ID NO: 26, or a variant thereof having at least 80%, at least 85%, at least 90% or at least 95% sequence identity to SEQ ID NO: 24 or SEQ ID NO: 26; b) a polypeptide that comprises SEQ ID NO: 24 with the substitutions Y161A, R164S and A188P; c) a polypeptide that comprises SEQ ID NO: 24 with the substitutions S9E, N42R, N74D, V199I, Q200L, Y203W, S253D, N255W and L256E; and d) a polypeptide that comprises SEQ ID NO: 37; and
• at least one enzyme selected from the group consisting of amylases, lipases, mannanases, pectate lyases and cellulases.
In one embodiment, the composition comprises:
• a DNase that comprises or consists of SEQ ID NO: 1 ;
• a hexosaminidase that comprises or consists of SEQ ID NO: 21 ;
• a protease that comprises SEQ ID NO: 24 with the substitutions Y161A, R164S and A188P, or that comprises SEQ ID NO: 37; and
• at least one enzyme selected from the group consisting of amylases, lipases, mannanases, pectate lyases and cellulases; wherein:
o the amylase comprises SEQ ID NO: 30 with the mutations H183*, G184*, I405L, A421 H, A422P and A428T;
o the lipase comprises SEQ ID NO: 31 with the mutations D27R, G38A, D96E, D11 1A, G163K, T231 R, N233R, D254S and P256T; o the mannanase comprises SEQ ID NO: 32;
o the pectate lyase comprises SEQ ID NO: 33; and
o the cellulase comprises SEQ ID NO: 34 or SEQ ID NO: 35.
In one embodiment, the composition comprises:
• a DNase that comprises or consists of SEQ ID NO: 1 ;
• a hexosaminidase that comprises or consists of SEQ ID NO: 21 ;
• a protease that comprises SEQ ID NO: 24 with the substitutions S9E, N42R, N74D, V199I, Q200L, Y203W, S253D, N255W and L256E; and • at least one enzyme selected from the group consisting of amylases and cellulases; wherein:
o the amylase comprises SEQ ID NO: 29 with the mutations H 1 *, N54S, V56T, K72R, G109A, F113Q, R116Q, W167F, Q172G, A174S, G182*, D183*, G184T, N195F, V206L, K391A, P473R and G476K; and o the cellulase comprises SEQ ID NO: 34.
In one embodiment, the composition comprises:
• a DNase that comprises or consists of SEQ ID NO: 1 , or which is a variant thereof having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity to SEQ ID NO: 1 ;
• a hexosaminidase that comprises or consists of SEQ ID NO: 22, or which is a variant thereof having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity to SEQ ID NO: 22;
• a protease selected from: a) a polypeptide that comprises or consists of SEQ ID NO: 24 or SEQ ID NO: 26, or a variant thereof having at least 80%, at least 85%, at least 90% or at least 95% sequence identity to SEQ ID NO: 24 or SEQ ID NO: 26; b) a polypeptide that comprises SEQ ID NO: 24 with the substitutions Y161A, R164S and A188P; c) a polypeptide that comprises SEQ ID NO: 24 with the substitutions S9E, N42R, N74D, V199I, Q200L, Y203W, S253D, N255W and L256E; and d) a polypeptide that comprises SEQ ID NO: 37; and
• at least one enzyme selected from the group consisting of amylases, lipases, mannanases, pectate lyases and cellulases.
In one embodiment, the composition comprises:
• a DNase that comprises or consists of SEQ ID NO: 1 ;
• a hexosaminidase that comprises or consists of SEQ ID NO: 22;
• a protease that comprises SEQ ID NO: 24 with the substitutions Y161A, R164S and A188P, or that comprises SEQ ID NO: 37; and
• at least one enzyme selected from the group consisting of amylases, lipases, mannanases, pectate lyases and cellulases; wherein:
o the amylase comprises SEQ ID NO: 30 with the mutations H183*, G184*, I405L, A421 H, A422P and A428T;
o the lipase comprises SEQ ID NO: 31 with the mutations D27R, G38A, D96E, D11 1A, G163K, T231 R, N233R, D254S and P256T; o the mannanase comprises SEQ ID NO: 32;
o the pectate lyase comprises SEQ ID NO: 33; and o the cellulase comprises SEQ ID NO: 34 or SEQ ID NO: 35.
In one embodiment, the composition comprises:
• a DNase that comprises or consists of SEQ ID NO: 1 ;
• a hexosaminidase that comprises or consists of SEQ ID NO: 22;
• a protease that comprises SEQ ID NO: 24 with the substitutions S9E, N42R, N74D, V199I, Q200L, Y203W, S253D, N255W and L256E; and
• at least one enzyme selected from the group consisting of amylases and cellulases; wherein:
o the amylase comprises SEQ ID NO: 29 with the mutations H 1 *, N54S, V56T, K72R, G109A, F113Q, R116Q, W167F, Q172G, A174S, G182*, D183*, G184T, N195F, V206L, K391A, P473R and G476K; and o the cellulase comprises SEQ ID NO: 34.
In one embodiment, the composition comprises:
• a DNase that comprises or consists of SEQ ID NO: 1 , or which is a variant thereof having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity to SEQ ID NO: 1 ;
• a hexosaminidase that comprises or consists of SEQ ID NO: 23, or which is a variant thereof having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity to SEQ ID NO: 23;
• a protease selected from: a) a polypeptide that comprises or consists of SEQ ID NO: 24 or SEQ ID NO: 26, or a variant thereof having at least 80%, at least 85%, at least 90% or at least 95% sequence identity to SEQ ID NO: 24 or SEQ ID NO: 26; b) a polypeptide that comprises SEQ ID NO: 24 with the substitutions Y161A, R164S and A188P; c) a polypeptide that comprises SEQ ID NO: 24 with the substitutions S9E, N42R, N74D, V199I, Q200L, Y203W, S253D, N255W and L256E; and d) a polypeptide that comprises SEQ ID NO: 37; and
• at least one enzyme selected from the group consisting of amylases, lipases, mannanases, pectate lyases and cellulases.
In one embodiment, the composition comprises:
• a DNase that comprises or consists of SEQ ID NO: 1 ;
• a hexosaminidase that comprises or consists of SEQ ID NO: 23;
• a protease that comprises SEQ ID NO: 24 with the substitutions Y161A, R164S and A188P, or that comprises SEQ ID NO: 37; and
• at least one enzyme selected from the group consisting of amylases, lipases, mannanases, pectate lyases and cellulases; wherein: o the amylase comprises SEQ ID NO: 30 with the mutations H183*, G184*, I405L, A421 H, A422P and A428T;
o the lipase comprises SEQ ID NO: 31 with the mutations D27R, G38A, D96E, D11 1A, G163K, T231 R, N233R, D254S and P256T; o the mannanase comprises SEQ ID NO: 32;
o the pectate lyase comprises SEQ ID NO: 33; and
o the cellulase comprises SEQ ID NO: 34 or SEQ ID NO: 35.
In one embodiment, the composition comprises:
• a DNase that comprises or consists of SEQ ID NO: 1 ;
• a hexosaminidase that comprises or consists of SEQ ID NO: 23;
• a protease that comprises SEQ ID NO: 24 with the substitutions S9E, N42R, N74D, V199I, Q200L, Y203W, S253D, N255W and L256E; and
• at least one enzyme selected from the group consisting of amylases and cellulases; wherein:
o the amylase comprises SEQ ID NO: 29 with the mutations H 1 *, N54S, V56T, K72R, G109A, F113Q, R116Q, W167F, Q172G, A174S, G182*, D183*, G184T, N195F, V206L, K391A, P473R and G476K; and o the cellulase comprises SEQ ID NO: 34.
In one embodiment, the composition comprises:
• a DNase that comprises or consists of SEQ ID NO: 2, or which is a variant thereof having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity to SEQ ID NO: 2;
• a hexosaminidase that comprises or consists of SEQ ID NO: 19, or which is a variant thereof having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity to SEQ ID NO: 19;
• a protease selected from: a) a polypeptide that comprises or consists of SEQ ID NO: 24 or SEQ ID NO: 26, or a variant thereof having at least 80%, at least 85%, at least 90% or at least 95% sequence identity to SEQ ID NO: 24 or SEQ ID NO: 26; b) a polypeptide that comprises SEQ ID NO: 24 with the substitutions Y161A, R164S and A188P; c) a polypeptide that comprises SEQ ID NO: 24 with the substitutions S9E, N42R, N74D, V199I, Q200L, Y203W, S253D, N255W and L256E; and d) a polypeptide that comprises SEQ ID NO: 37; and
• at least one enzyme selected from the group consisting of amylases, lipases, mannanases, pectate lyases and cellulases.
In one embodiment, the composition comprises: • a DNase that comprises or consists of SEQ ID NO: 2;
• a hexosaminidase that comprises or consists of SEQ ID NO: 19;
• a protease that comprises SEQ ID NO: 24 with the substitutions Y161A, R164S and A188P, or that comprises SEQ ID NO: 37; and
• at least one enzyme selected from the group consisting of amylases, lipases, mannanases, pectate lyases and cellulases; wherein:
o the amylase comprises SEQ ID NO: 30 with the mutations H183*, G184*, I405L, A421 H, A422P and A428T;
o the lipase comprises SEQ ID NO: 31 with the mutations D27R, G38A, D96E, D11 1A, G163K, T231 R, N233R, D254S and P256T; o the mannanase comprises SEQ ID NO: 32;
o the pectate lyase comprises SEQ ID NO: 33; and
o the cellulase comprises SEQ ID NO: 34 or SEQ ID NO: 35.
In one embodiment, the composition comprises:
• a DNase that comprises or consists of SEQ ID NO: 2;
• a hexosaminidase that comprises or consists of SEQ ID NO: 19;
• a protease that comprises SEQ ID NO: 24 with the substitutions S9E, N42R, N74D, V199I, Q200L, Y203W, S253D, N255W and L256E; and
• at least one enzyme selected from the group consisting of amylases and cellulases; wherein:
o the amylase comprises SEQ ID NO: 29 with the mutations H 1 *, N54S, V56T, K72R, G109A, F113Q, R116Q, W167F, Q172G, A174S, G182*, D183*, G184T, N195F, V206L, K391A, P473R and G476K; and o the cellulase comprises SEQ ID NO: 34.
In one embodiment, the composition comprises:
• a DNase that comprises or consists of SEQ ID NO: 2, or which is a variant thereof having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity to SEQ ID NO: 2;
• a hexosaminidase that comprises or consists of SEQ ID NO: 20, or which is a variant thereof having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity to SEQ ID NO: 20;
• a protease selected from: a) a polypeptide that comprises or consists of SEQ ID NO: 24 or SEQ ID NO: 26, or a variant thereof having at least 80%, at least 85%, at least 90% or at least 95% sequence identity to SEQ ID NO: 24 or SEQ ID NO: 26; b) a polypeptide that comprises SEQ ID NO: 24 with the substitutions Y161A, R164S and A188P; c) a polypeptide that comprises SEQ ID NO: 24 with the substitutions S9E, N42R, N74D, V199I, Q200L, Y203W, S253D, N255W and L256E; and d) a polypeptide that comprises SEQ ID NO: 37; and
• at least one enzyme selected from the group consisting of amylases, lipases, mannanases, pectate lyases and cellulases.
In one embodiment, the composition comprises:
• a DNase that comprises or consists of SEQ ID NO: 2;
• a hexosaminidase that comprises or consists of SEQ ID NO: 20;
• a protease that comprises SEQ ID NO: 24 with the substitutions Y161A, R164S and A188P, or that comprises SEQ ID NO: 37; and
• at least one enzyme selected from the group consisting of amylases, lipases, mannanases, pectate lyases and cellulases; wherein:
o the amylase comprises SEQ ID NO: 30 with the mutations H183*, G184*, I405L, A421 H, A422P and A428T;
o the lipase comprises SEQ ID NO: 31 with the mutations D27R, G38A, D96E, D11 1A, G163K, T231 R, N233R, D254S and P256T; o the mannanase comprises SEQ ID NO: 32;
o the pectate lyase comprises SEQ ID NO: 33; and
o the cellulase comprises SEQ ID NO: 34 or SEQ ID NO: 35.
In one embodiment, the composition comprises:
• a DNase that comprises or consists of SEQ ID NO: 2;
• a hexosaminidase that comprises or consists of SEQ ID NO: 20;
• a protease that comprises SEQ ID NO: 24 with the substitutions S9E, N42R, N74D, V199I, Q200L, Y203W, S253D, N255W and L256E; and
• at least one enzyme selected from the group consisting of amylases and cellulases; wherein:
o the amylase comprises SEQ ID NO: 29 with the mutations H 1 *, N54S, V56T, K72R, G109A, F113Q, R116Q, W167F, Q172G, A174S, G182*, D183*, G184T, N195F, V206L, K391A, P473R and G476K; and o the cellulase comprises SEQ ID NO: 34.
In one embodiment, the composition comprises:
• a DNase that comprises or consists of SEQ ID NO: 2, or which is a variant thereof having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity to SEQ ID NO: 2;
• a hexosaminidase that comprises or consists of SEQ ID NO: 21 , or which is a variant thereof having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity to SEQ ID NO: 21 ;
• a protease selected from: a) a polypeptide that comprises or consists of SEQ ID NO: 24 or SEQ ID NO: 26, or a variant thereof having at least 80%, at least 85%, at least 90% or at least 95% sequence identity to SEQ ID NO: 24 or SEQ ID NO: 26; b) a polypeptide that comprises SEQ ID NO: 24 with the substitutions Y161A, R164S and A188P; c) a polypeptide that comprises SEQ ID NO: 24 with the substitutions S9E, N42R, N74D, V199I, Q200L, Y203W, S253D, N255W and L256E; and d) a polypeptide that comprises SEQ ID NO: 37; and
• at least one enzyme selected from the group consisting of amylases, lipases, mannanases, pectate lyases and cellulases.
In one embodiment, the composition comprises:
• a DNase that comprises or consists of SEQ ID NO: 2;
• a hexosaminidase that comprises or consists of SEQ ID NO: 21 ;
• a protease that comprises SEQ ID NO: 24 with the substitutions Y161A, R164S and A188P, or that comprises SEQ ID NO: 37; and
• at least one enzyme selected from the group consisting of amylases, lipases, mannanases, pectate lyases and cellulases; wherein:
o the amylase comprises SEQ ID NO: 30 with the mutations H183*, G184*, I405L, A421 H, A422P and A428T;
o the lipase comprises SEQ ID NO: 31 with the mutations D27R, G38A, D96E, D11 1A, G163K, T231 R, N233R, D254S and P256T; o the mannanase comprises SEQ ID NO: 32;
o the pectate lyase comprises SEQ ID NO: 33; and
o the cellulase comprises SEQ ID NO: 34 or SEQ ID NO: 35.
In one embodiment, the composition comprises:
• a DNase that comprises or consists of SEQ ID NO: 2;
• a hexosaminidase that comprises or consists of SEQ ID NO: 21 ;
• a protease that comprises SEQ ID NO: 24 with the substitutions S9E, N42R, N74D, V199I, Q200L, Y203W, S253D, N255W and L256E; and
• at least one enzyme selected from the group consisting of amylases and cellulases; wherein:
o the amylase comprises SEQ ID NO: 29 with the mutations H 1 *, N54S, V56T, K72R, G109A, F113Q, R116Q, W167F, Q172G, A174S, G182*, D183*, G184T, N195F, V206L, K391A, P473R and G476K; and o the cellulase comprises SEQ ID NO: 34. In one embodiment, the composition comprises:
• a DNase that comprises or consists of SEQ ID NO: 2, or which is a variant thereof having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity to SEQ ID NO: 2;
• a hexosaminidase that comprises or consists of SEQ ID NO: 22, or which is a variant thereof having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity to SEQ ID NO: 22;
• a protease selected from: a) a polypeptide that comprises or consists of SEQ ID NO: 24 or SEQ ID NO: 26, or a variant thereof having at least 80%, at least 85%, at least 90% or at least 95% sequence identity to SEQ ID NO: 24 or SEQ ID NO: 26; b) a polypeptide that comprises SEQ ID NO: 24 with the substitutions Y161A, R164S and A188P; c) a polypeptide that comprises SEQ ID NO: 24 with the substitutions S9E, N42R, N74D, V199I, Q200L, Y203W, S253D, N255W and L256E; and d) a polypeptide that comprises SEQ ID NO: 37; and
• at least one enzyme selected from the group consisting of amylases, lipases, mannanases, pectate lyases and cellulases.
In one embodiment, the composition comprises:
• a DNase that comprises or consists of SEQ ID NO: 2;
• a hexosaminidase that comprises or consists of SEQ ID NO: 22;
• a protease that comprises SEQ ID NO: 24 with the substitutions Y161A, R164S and A188P, or that comprises SEQ ID NO: 37; and
• at least one enzyme selected from the group consisting of amylases, lipases, mannanases, pectate lyases and cellulases; wherein:
o the amylase comprises SEQ ID NO: 30 with the mutations H183*, G184*, I405L, A421 H, A422P and A428T;
o the lipase comprises SEQ ID NO: 31 with the mutations D27R, G38A, D96E, D11 1A, G163K, T231 R, N233R, D254S and P256T; o the mannanase comprises SEQ ID NO: 32;
o the pectate lyase comprises SEQ ID NO: 33; and
o the cellulase comprises SEQ ID NO: 34 or SEQ ID NO: 35.
In one embodiment, the composition comprises:
• a DNase that comprises or consists of SEQ ID NO: 2;
• a hexosaminidase that comprises or consists of SEQ ID NO: 22;
• a protease that comprises SEQ ID NO: 24 with the substitutions S9E, N42R, N74D, V199I, Q200L, Y203W, S253D, N255W and L256E; and • at least one enzyme selected from the group consisting of amylases and cellulases; wherein:
o the amylase comprises SEQ ID NO: 29 with the mutations H 1 *, N54S, V56T, K72R, G109A, F113Q, R116Q, W167F, Q172G, A174S, G182*, D183*, G184T, N195F, V206L, K391A, P473R and G476K; and o the cellulase comprises SEQ ID NO: 34.
In one embodiment, the composition comprises:
• a DNase that comprises or consists of SEQ ID NO: 2, or which is a variant thereof having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity to SEQ ID NO: 2;
• a hexosaminidase that comprises or consists of SEQ ID NO: 23, or which is a variant thereof having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity to SEQ ID NO: 23;
• a protease selected from: a) a polypeptide that comprises or consists of SEQ ID NO: 24 or SEQ ID NO: 26, or a variant thereof having at least 80%, at least 85%, at least 90% or at least 95% sequence identity to SEQ ID NO: 24 or SEQ ID NO: 26; b) a polypeptide that comprises SEQ ID NO: 24 with the substitutions Y161A, R164S and A188P; c) a polypeptide that comprises SEQ ID NO: 24 with the substitutions S9E, N42R, N74D, V199I, Q200L, Y203W, S253D, N255W and L256E; and d) a polypeptide that comprises SEQ ID NO: 37; and
• at least one enzyme selected from the group consisting of amylases, lipases, mannanases, pectate lyases and cellulases.
In one embodiment, the composition comprises:
• a DNase that comprises or consists of SEQ ID NO: 2;
• a hexosaminidase that comprises or consists of SEQ ID NO: 23;
• a protease that comprises SEQ ID NO: 24 with the substitutions Y161A, R164S and A188P, or that comprises SEQ ID NO: 37; and
• at least one enzyme selected from the group consisting of amylases, lipases, mannanases, pectate lyases and cellulases; wherein:
o the amylase comprises SEQ ID NO: 30 with the mutations H183*, G184*, I405L, A421 H, A422P and A428T;
o the lipase comprises SEQ ID NO: 31 with the mutations D27R, G38A, D96E, D11 1A, G163K, T231 R, N233R, D254S and P256T; o the mannanase comprises SEQ ID NO: 32;
o the pectate lyase comprises SEQ ID NO: 33; and o the cellulase comprises SEQ ID NO: 34 or SEQ ID NO: 35.
In one embodiment, the composition comprises:
• a DNase that comprises or consists of SEQ ID NO: 2;
• a hexosaminidase that comprises or consists of SEQ ID NO: 23;
• a protease that comprises SEQ ID NO: 24 with the substitutions S9E, N42R, N74D, V199I, Q200L, Y203W, S253D, N255W and L256E; and
• at least one enzyme selected from the group consisting of amylases and cellulases; wherein:
o the amylase comprises SEQ ID NO: 29 with the mutations H 1 *, N54S, V56T, K72R, G109A, F113Q, R116Q, W167F, Q172G, A174S, G182*, D183*, G184T, N195F, V206L, K391A, P473R and G476K; and o the cellulase comprises SEQ ID NO: 34.
In one embodiment, the composition comprises:
• a DNase that comprises or consists of SEQ ID NO: 3, or which is a variant thereof having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity to SEQ ID NO: 3;
• a hexosaminidase that comprises or consists of SEQ ID NO: 19, or which is a variant thereof having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity to SEQ ID NO: 19;
• a protease selected from: a) a polypeptide that comprises or consists of SEQ ID NO: 24 or SEQ ID NO: 26, or a variant thereof having at least 80%, at least 85%, at least 90% or at least 95% sequence identity to SEQ ID NO: 24 or SEQ ID NO: 26; b) a polypeptide that comprises SEQ ID NO: 24 with the substitutions Y161A, R164S and A188P; c) a polypeptide that comprises SEQ ID NO: 24 with the substitutions S9E, N42R, N74D, V199I, Q200L, Y203W, S253D, N255W and L256E; and d) a polypeptide that comprises SEQ ID NO: 37; and
• at least one enzyme selected from the group consisting of amylases, lipases, mannanases, pectate lyases and cellulases.
In one embodiment, the composition comprises:
• a DNase that comprises or consists of SEQ ID NO: 3;
• a hexosaminidase that comprises or consists of SEQ ID NO: 19;
• a protease that comprises SEQ ID NO: 24 with the substitutions Y161A, R164S and A188P, or that comprises SEQ ID NO: 37; and
• at least one enzyme selected from the group consisting of amylases, lipases, mannanases, pectate lyases and cellulases; wherein: o the amylase comprises SEQ ID NO: 30 with the mutations H183*, G184*, I405L, A421 H, A422P and A428T;
o the lipase comprises SEQ ID NO: 31 with the mutations D27R, G38A, D96E, D11 1A, G163K, T231 R, N233R, D254S and P256T; o the mannanase comprises SEQ ID NO: 32;
o the pectate lyase comprises SEQ ID NO: 33; and
o the cellulase comprises SEQ ID NO: 34 or SEQ ID NO: 35.
In one embodiment, the composition comprises:
• a DNase that comprises or consists of SEQ ID NO: 3;
• a hexosaminidase that comprises or consists of SEQ ID NO: 19;
• a protease that comprises SEQ ID NO: 24 with the substitutions S9E, N42R, N74D, V199I, Q200L, Y203W, S253D, N255W and L256E; and
• at least one enzyme selected from the group consisting of amylases and cellulases; wherein:
o the amylase comprises SEQ ID NO: 29 with the mutations H 1 *, N54S, V56T, K72R, G109A, F113Q, R116Q, W167F, Q172G, A174S, G182*, D183*, G184T, N195F, V206L, K391A, P473R and G476K; and o the cellulase comprises SEQ ID NO: 34.
In one embodiment, the composition comprises:
• a DNase that comprises or consists of SEQ ID NO: 3, or which is a variant thereof having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity to SEQ ID NO: 3;
• a hexosaminidase that comprises or consists of SEQ ID NO: 20, or which is a variant thereof having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity to SEQ ID NO: 20;
• a protease selected from: a) a polypeptide that comprises or consists of SEQ ID NO: 24 or SEQ ID NO: 26, or a variant thereof having at least 80%, at least 85%, at least 90% or at least 95% sequence identity to SEQ ID NO: 24 or SEQ ID NO: 26; b) a polypeptide that comprises SEQ ID NO: 24 with the substitutions Y161A, R164S and A188P; c) a polypeptide that comprises SEQ ID NO: 24 with the substitutions S9E, N42R, N74D, V199I, Q200L, Y203W, S253D, N255W and L256E; and d) a polypeptide that comprises SEQ ID NO: 37; and
• at least one enzyme selected from the group consisting of amylases, lipases, mannanases, pectate lyases and cellulases.
In one embodiment, the composition comprises: • a DNase that comprises or consists of SEQ ID NO: 3;
• a hexosaminidase that comprises or consists of SEQ ID NO: 20;
• a protease that comprises SEQ ID NO: 24 with the substitutions Y161A, R164S and A188P, or that comprises SEQ ID NO: 37; and
• at least one enzyme selected from the group consisting of amylases, lipases, mannanases, pectate lyases and cellulases; wherein:
o the amylase comprises SEQ ID NO: 30 with the mutations H183*, G184*, I405L, A421 H, A422P and A428T;
o the lipase comprises SEQ ID NO: 31 with the mutations D27R, G38A, D96E, D11 1A, G163K, T231 R, N233R, D254S and P256T; o the mannanase comprises SEQ ID NO: 32;
o the pectate lyase comprises SEQ ID NO: 33; and
o the cellulase comprises SEQ ID NO: 34 or SEQ ID NO: 35.
In one embodiment, the composition comprises:
• a DNase that comprises or consists of SEQ ID NO: 3;
• a hexosaminidase that comprises or consists of SEQ ID NO: 20;
• a protease that comprises SEQ ID NO: 24 with the substitutions S9E, N42R, N74D, V199I, Q200L, Y203W, S253D, N255W and L256E; and
• at least one enzyme selected from the group consisting of amylases and cellulases; wherein:
o the amylase comprises SEQ ID NO: 29 with the mutations H 1 *, N54S, V56T, K72R, G109A, F113Q, R116Q, W167F, Q172G, A174S, G182*, D183*, G184T, N195F, V206L, K391A, P473R and G476K; and o the cellulase comprises SEQ ID NO: 34.
In one embodiment, the composition comprises:
• a DNase that comprises or consists of SEQ ID NO: 3, or which is a variant thereof having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity to SEQ ID NO: 3;
• a hexosaminidase that comprises or consists of SEQ ID NO: 21 , or which is a variant thereof having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity to SEQ ID NO: 21 ;
• a protease selected from: a) a polypeptide that comprises or consists of SEQ ID NO: 24 or SEQ ID NO: 26, or a variant thereof having at least 80%, at least 85%, at least 90% or at least 95% sequence identity to SEQ ID NO: 24 or SEQ ID NO: 26; b) a polypeptide that comprises SEQ ID NO: 24 with the substitutions Y161A, R164S and A188P; c) a polypeptide that comprises SEQ ID NO: 24 with the substitutions S9E, N42R, N74D, V199I, Q200L, Y203W, S253D, N255W and L256E; and d) a polypeptide that comprises SEQ ID NO: 37; and
• at least one enzyme selected from the group consisting of amylases, lipases, mannanases, pectate lyases and cellulases.
In one embodiment, the composition comprises:
• a DNase that comprises or consists of SEQ ID NO: 3;
• a hexosaminidase that comprises or consists of SEQ ID NO: 21 ;
• a protease that comprises SEQ ID NO: 24 with the substitutions Y161A, R164S and A188P, or that comprises SEQ ID NO: 37; and
• at least one enzyme selected from the group consisting of amylases, lipases, mannanases, pectate lyases and cellulases; wherein:
o the amylase comprises SEQ ID NO: 30 with the mutations H183*, G184*, I405L, A421 H, A422P and A428T;
o the lipase comprises SEQ ID NO: 31 with the mutations D27R, G38A, D96E, D11 1A, G163K, T231 R, N233R, D254S and P256T; o the mannanase comprises SEQ ID NO: 32;
o the pectate lyase comprises SEQ ID NO: 33; and
o the cellulase comprises SEQ ID NO: 34 or SEQ ID NO: 35.
In one embodiment, the composition comprises:
• a DNase that comprises or consists of SEQ ID NO: 3;
• a hexosaminidase that comprises or consists of SEQ ID NO: 21 ;
• a protease that comprises SEQ ID NO: 24 with the substitutions S9E, N42R, N74D, V199I, Q200L, Y203W, S253D, N255W and L256E; and
• at least one enzyme selected from the group consisting of amylases and cellulases; wherein:
o the amylase comprises SEQ ID NO: 29 with the mutations H 1 *, N54S, V56T, K72R, G109A, F113Q, R116Q, W167F, Q172G, A174S, G182*, D183*, G184T, N195F, V206L, K391A, P473R and G476K; and o the cellulase comprises SEQ ID NO: 34.
In one embodiment, the composition comprises:
• a DNase that comprises or consists of SEQ ID NO: 3, or which is a variant thereof having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity to SEQ ID NO: 3;
• a hexosaminidase that comprises or consists of SEQ ID NO: 22, or which is a variant thereof having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity to SEQ ID NO: 22;
• a protease selected from: a) a polypeptide that comprises or consists of SEQ ID NO: 24 or SEQ ID NO: 26, or a variant thereof having at least 80%, at least 85%, at least 90% or at least 95% sequence identity to SEQ ID NO: 24 or SEQ ID NO: 26; b) a polypeptide that comprises SEQ ID NO: 24 with the substitutions Y161A, R164S and A188P; c) a polypeptide that comprises SEQ ID NO: 24 with the substitutions S9E, N42R, N74D, V199I, Q200L, Y203W, S253D, N255W and L256E; and d) a polypeptide that comprises SEQ ID NO: 37; and
• at least one enzyme selected from the group consisting of amylases, lipases, mannanases, pectate lyases and cellulases.
In one embodiment, the composition comprises:
• a DNase that comprises or consists of SEQ ID NO: 3;
• a hexosaminidase that comprises or consists of SEQ ID NO: 22;
• a protease that comprises SEQ ID NO: 24 with the substitutions Y161A, R164S and A188P, or that comprises SEQ ID NO: 37; and
• at least one enzyme selected from the group consisting of amylases, lipases, mannanases, pectate lyases and cellulases; wherein:
o the amylase comprises SEQ ID NO: 30 with the mutations H183*, G184*, I405L, A421 H, A422P and A428T;
o the lipase comprises SEQ ID NO: 31 with the mutations D27R, G38A, D96E, D1 11A, G163K, T231 R, N233R, D254S and P256T; o the mannanase comprises SEQ ID NO: 32;
o the pectate lyase comprises SEQ ID NO: 33; and
o the cellulase comprises SEQ ID NO: 34 or SEQ ID NO: 35.
In one embodiment, the composition comprises:
• a DNase that comprises or consists of SEQ ID NO: 3;
• a hexosaminidase that comprises or consists of SEQ ID NO: 22;
• a protease that comprises SEQ ID NO: 24 with the substitutions S9E, N42R, N74D, V199I, Q200L, Y203W, S253D, N255W and L256E; and
• at least one enzyme selected from the group consisting of amylases and cellulases; wherein:
o the amylase comprises SEQ ID NO: 29 with the mutations H 1 *, N54S, V56T, K72R, G109A, F113Q, R116Q, W167F, Q172G, A174S, G182*, D183*, G184T, N195F, V206L, K391A, P473R and G476K; and o the cellulase comprises SEQ ID NO: 34. In one embodiment, the composition comprises:
• a DNase that comprises or consists of SEQ ID NO: 3, or which is a variant thereof having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity to SEQ ID NO: 3;
• a hexosaminidase that comprises or consists of SEQ ID NO: 23, or which is a variant thereof having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity to SEQ ID NO: 23;
• a protease selected from: a) a polypeptide that comprises or consists of SEQ ID NO: 24 or SEQ ID NO: 26, or a variant thereof having at least 80%, at least 85%, at least 90% or at least 95% sequence identity to SEQ ID NO: 24 or SEQ ID NO: 26; b) a polypeptide that comprises SEQ ID NO: 24 with the substitutions Y161A, R164S and A188P; c) a polypeptide that comprises SEQ ID NO: 24 with the substitutions S9E, N42R, N74D, V199I, Q200L, Y203W, S253D, N255W and L256E; and d) a polypeptide that comprises SEQ ID NO: 37; and
• at least one enzyme selected from the group consisting of amylases, lipases, mannanases, pectate lyases and cellulases.
In one embodiment, the composition comprises:
• a DNase that comprises or consists of SEQ ID NO: 3;
• a hexosaminidase that comprises or consists of SEQ ID NO: 23;
• a protease that comprises SEQ ID NO: 24 with the substitutions Y161A, R164S and A188P, or that comprises SEQ ID NO: 37; and
• at least one enzyme selected from the group consisting of amylases, lipases, mannanases, pectate lyases and cellulases; wherein:
o the amylase comprises SEQ ID NO: 30 with the mutations H183*, G184*, I405L, A421 H, A422P and A428T;
o the lipase comprises SEQ ID NO: 31 with the mutations D27R, G38A, D96E, D11 1A, G163K, T231 R, N233R, D254S and P256T; o the mannanase comprises SEQ ID NO: 32;
o the pectate lyase comprises SEQ ID NO: 33; and
o the cellulase comprises SEQ ID NO: 34 or SEQ ID NO: 35.
In one embodiment, the composition comprises:
• a DNase that comprises or consists of SEQ ID NO: 3;
• a hexosaminidase that comprises or consists of SEQ ID NO: 23;
• a protease that comprises SEQ ID NO: 24 with the substitutions S9E, N42R, N74D, V199I, Q200L, Y203W, S253D, N255W and L256E; and • at least one enzyme selected from the group consisting of amylases and cellulases; wherein:
o the amylase comprises SEQ ID NO: 29 with the mutations H 1 *, N54S, V56T, K72R, G109A, F113Q, R116Q, W167F, Q172G, A174S, G182*, D183*, G184T, N195F, V206L, K391A, P473R and G476K; and o the cellulase comprises SEQ ID NO: 34.
In one embodiment, the composition comprises:
• a DNase that comprises or consists of SEQ ID NO: 4, or which is a variant thereof having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity to SEQ ID NO: 4;
• a hexosaminidase that comprises or consists of SEQ ID NO: 19, or which is a variant thereof having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity to SEQ ID NO: 19;
• a protease selected from: a) a polypeptide that comprises or consists of SEQ ID NO: 24 or SEQ ID NO: 26, or a variant thereof having at least 80%, at least 85%, at least 90% or at least 95% sequence identity to SEQ ID NO: 24 or SEQ ID NO: 26; b) a polypeptide that comprises SEQ ID NO: 24 with the substitutions Y161A, R164S and A188P; c) a polypeptide that comprises SEQ ID NO: 24 with the substitutions S9E, N42R, N74D, V199I, Q200L, Y203W, S253D, N255W and L256E; and d) a polypeptide that comprises SEQ ID NO: 37; and
• at least one enzyme selected from the group consisting of amylases, lipases, mannanases, pectate lyases and cellulases.
In one embodiment, the composition comprises:
• a DNase that comprises or consists of SEQ ID NO: 4;
• a hexosaminidase that comprises or consists of SEQ ID NO: 19;
• a protease that comprises SEQ ID NO: 24 with the substitutions Y161A, R164S and A188P, or that comprises SEQ ID NO: 37; and
• at least one enzyme selected from the group consisting of amylases, lipases, mannanases, pectate lyases and cellulases; wherein:
o the amylase comprises SEQ ID NO: 30 with the mutations H183*, G184*, I405L, A421 H, A422P and A428T;
o the lipase comprises SEQ ID NO: 31 with the mutations D27R, G38A, D96E, D11 1A, G163K, T231 R, N233R, D254S and P256T; o the mannanase comprises SEQ ID NO: 32;
o the pectate lyase comprises SEQ ID NO: 33; and o the cellulase comprises SEQ ID NO: 34 or SEQ ID NO: 35.
In one embodiment, the composition comprises:
• a DNase that comprises or consists of SEQ ID NO: 4;
• a hexosaminidase that comprises or consists of SEQ ID NO: 19;
• a protease that comprises SEQ ID NO: 24 with the substitutions S9E, N42R, N74D, V199I, Q200L, Y203W, S253D, N255W and L256E; and
• at least one enzyme selected from the group consisting of amylases and cellulases; wherein:
o the amylase comprises SEQ ID NO: 29 with the mutations H 1 *, N54S, V56T, K72R, G109A, F113Q, R116Q, W167F, Q172G, A174S, G182*, D183*, G184T, N195F, V206L, K391A, P473R and G476K; and o the cellulase comprises SEQ ID NO: 34.
In one embodiment, the composition comprises:
• a DNase that comprises or consists of SEQ ID NO: 4, or which is a variant thereof having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity to SEQ ID NO: 4;
• a hexosaminidase that comprises or consists of SEQ ID NO: 20, or which is a variant thereof having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity to SEQ ID NO: 20;
• a protease selected from: a) a polypeptide that comprises or consists of SEQ ID NO: 24 or SEQ ID NO: 26, or a variant thereof having at least 80%, at least 85%, at least 90% or at least 95% sequence identity to SEQ ID NO: 24 or SEQ ID NO: 26; b) a polypeptide that comprises SEQ ID NO: 24 with the substitutions Y161A, R164S and A188P; c) a polypeptide that comprises SEQ ID NO: 24 with the substitutions S9E, N42R, N74D, V199I, Q200L, Y203W, S253D, N255W and L256E; and d) a polypeptide that comprises SEQ ID NO: 37; and
• at least one enzyme selected from the group consisting of amylases, lipases, mannanases, pectate lyases and cellulases.
In one embodiment, the composition comprises:
• a DNase that comprises or consists of SEQ ID NO: 4;
• a hexosaminidase that comprises or consists of SEQ ID NO: 20;
• a protease that comprises SEQ ID NO: 24 with the substitutions Y161A, R164S and A188P, or that comprises SEQ ID NO: 37; and
• at least one enzyme selected from the group consisting of amylases, lipases, mannanases, pectate lyases and cellulases; wherein: o the amylase comprises SEQ ID NO: 30 with the mutations H183*, G184*, I405L, A421 H, A422P and A428T;
o the lipase comprises SEQ ID NO: 31 with the mutations D27R, G38A, D96E, D11 1A, G163K, T231 R, N233R, D254S and P256T; o the mannanase comprises SEQ ID NO: 32;
o the pectate lyase comprises SEQ ID NO: 33; and
o the cellulase comprises SEQ ID NO: 34 or SEQ ID NO: 35.
In one embodiment, the composition comprises:
• a DNase that comprises or consists of SEQ ID NO: 4;
• a hexosaminidase that comprises or consists of SEQ ID NO: 20;
• a protease that comprises SEQ ID NO: 24 with the substitutions S9E, N42R, N74D, V199I, Q200L, Y203W, S253D, N255W and L256E; and
• at least one enzyme selected from the group consisting of amylases and cellulases; wherein:
o the amylase comprises SEQ ID NO: 29 with the mutations H 1 *, N54S, V56T, K72R, G109A, F113Q, R116Q, W167F, Q172G, A174S, G182*, D183*, G184T, N195F, V206L, K391A, P473R and G476K; and o the cellulase comprises SEQ ID NO: 34.
In one embodiment, the composition comprises:
• a DNase that comprises or consists of SEQ ID NO: 4, or which is a variant thereof having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity to SEQ ID NO: 4;
• a hexosaminidase that comprises or consists of SEQ ID NO: 21 , or which is a variant thereof having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity to SEQ ID NO: 21 ;
• a protease selected from: a) a polypeptide that comprises or consists of SEQ ID NO: 24 or SEQ ID NO: 26, or a variant thereof having at least 80%, at least 85%, at least 90% or at least 95% sequence identity to SEQ ID NO: 24 or SEQ ID NO: 26; b) a polypeptide that comprises SEQ ID NO: 24 with the substitutions Y161A, R164S and A188P; c) a polypeptide that comprises SEQ ID NO: 24 with the substitutions S9E, N42R, N74D, V199I, Q200L, Y203W, S253D, N255W and L256E; and d) a polypeptide that comprises SEQ ID NO: 37; and
• at least one enzyme selected from the group consisting of amylases, lipases, mannanases, pectate lyases and cellulases.
In one embodiment, the composition comprises: • a DNase that comprises or consists of SEQ ID NO: 4;
• a hexosaminidase that comprises or consists of SEQ ID NO: 21 ;
• a protease that comprises SEQ ID NO: 24 with the substitutions Y161A, R164S and A188P, or that comprises SEQ ID NO: 37; and
• at least one enzyme selected from the group consisting of amylases, lipases, mannanases, pectate lyases and cellulases; wherein:
o the amylase comprises SEQ ID NO: 30 with the mutations H183*, G184*, I405L, A421 H, A422P and A428T;
o the lipase comprises SEQ ID NO: 31 with the mutations D27R, G38A, D96E, D11 1A, G163K, T231 R, N233R, D254S and P256T; o the mannanase comprises SEQ ID NO: 32;
o the pectate lyase comprises SEQ ID NO: 33; and
o the cellulase comprises SEQ ID NO: 34 or SEQ ID NO: 35.
In one embodiment, the composition comprises:
• a DNase that comprises or consists of SEQ ID NO: 4;
• a hexosaminidase that comprises or consists of SEQ ID NO: 21 ;
• a protease that comprises SEQ ID NO: 24 with the substitutions S9E, N42R, N74D, V199I, Q200L, Y203W, S253D, N255W and L256E; and
• at least one enzyme selected from the group consisting of amylases and cellulases; wherein:
o the amylase comprises SEQ ID NO: 29 with the mutations H 1 *, N54S, V56T, K72R, G109A, F113Q, R116Q, W167F, Q172G, A174S, G182*, D183*, G184T, N195F, V206L, K391A, P473R and G476K; and o the cellulase comprises SEQ ID NO: 34.
In one embodiment, the composition comprises:
• a DNase that comprises or consists of SEQ ID NO: 4, or which is a variant thereof having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity to SEQ ID NO: 4;
• a hexosaminidase that comprises or consists of SEQ ID NO: 22, or which is a variant thereof having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity to SEQ ID NO: 22;
• a protease selected from: a) a polypeptide that comprises or consists of SEQ ID NO: 24 or SEQ ID NO: 26, or a variant thereof having at least 80%, at least 85%, at least 90% or at least 95% sequence identity to SEQ ID NO: 24 or SEQ ID NO: 26; b) a polypeptide that comprises SEQ ID NO: 24 with the substitutions Y161A, R164S and A188P; c) a polypeptide that comprises SEQ ID NO: 24 with the substitutions S9E, N42R, N74D, V199I, Q200L, Y203W, S253D, N255W and L256E; and d) a polypeptide that comprises SEQ ID NO: 37; and
• at least one enzyme selected from the group consisting of amylases, lipases, mannanases, pectate lyases and cellulases.
In one embodiment, the composition comprises:
• a DNase that comprises or consists of SEQ ID NO: 4;
• a hexosaminidase that comprises or consists of SEQ ID NO: 22;
• a protease that comprises SEQ ID NO: 24 with the substitutions Y161A, R164S and A188P, or that comprises SEQ ID NO: 37; and
• at least one enzyme selected from the group consisting of amylases, lipases, mannanases, pectate lyases and cellulases; wherein:
o the amylase comprises SEQ ID NO: 30 with the mutations H183*, G184*, I405L, A421 H, A422P and A428T;
o the lipase comprises SEQ ID NO: 31 with the mutations D27R, G38A, D96E, D11 1A, G163K, T231 R, N233R, D254S and P256T; o the mannanase comprises SEQ ID NO: 32;
o the pectate lyase comprises SEQ ID NO: 33; and
o the cellulase comprises SEQ ID NO: 34 or SEQ ID NO: 35.
In one embodiment, the composition comprises:
• a DNase that comprises or consists of SEQ ID NO: 4;
• a hexosaminidase that comprises or consists of SEQ ID NO: 22;
• a protease that comprises SEQ ID NO: 24 with the substitutions S9E, N42R, N74D, V199I, Q200L, Y203W, S253D, N255W and L256E; and
• at least one enzyme selected from the group consisting of amylases and cellulases; wherein:
o the amylase comprises SEQ ID NO: 29 with the mutations H 1 *, N54S, V56T, K72R, G109A, F113Q, R116Q, W167F, Q172G, A174S, G182*, D183*, G184T, N195F, V206L, K391A, P473R and G476K; and o the cellulase comprises SEQ ID NO: 34.
In one embodiment, the composition comprises:
• a DNase that comprises or consists of SEQ ID NO: 4, or which is a variant thereof having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity to SEQ ID NO: 4;
• a hexosaminidase that comprises or consists of SEQ ID NO: 23, or which is a variant thereof having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity to SEQ ID NO: 23;
• a protease selected from: a) a polypeptide that comprises or consists of SEQ ID NO: 24 or SEQ ID NO: 26, or a variant thereof having at least 80%, at least 85%, at least 90% or at least 95% sequence identity to SEQ ID NO: 24 or SEQ ID NO: 26; b) a polypeptide that comprises SEQ ID NO: 24 with the substitutions Y161A, R164S and A188P; c) a polypeptide that comprises SEQ ID NO: 24 with the substitutions S9E, N42R, N74D, V199I, Q200L, Y203W, S253D, N255W and L256E; and d) a polypeptide that comprises SEQ ID NO: 37; and
• at least one enzyme selected from the group consisting of amylases, lipases, mannanases, pectate lyases and cellulases.
In one embodiment, the composition comprises:
• a DNase that comprises or consists of SEQ ID NO: 4;
• a hexosaminidase that comprises or consists of SEQ ID NO: 23;
• a protease that comprises SEQ ID NO: 24 with the substitutions Y161A, R164S and A188P, or that comprises SEQ ID NO: 37; and
• at least one enzyme selected from the group consisting of amylases, lipases, mannanases, pectate lyases and cellulases; wherein:
o the amylase comprises SEQ ID NO: 30 with the mutations H183*, G184*, I405L, A421 H, A422P and A428T;
o the lipase comprises SEQ ID NO: 31 with the mutations D27R, G38A, D96E, D11 1A, G163K, T231 R, N233R, D254S and P256T; o the mannanase comprises SEQ ID NO: 32;
o the pectate lyase comprises SEQ ID NO: 33; and
o the cellulase comprises SEQ ID NO: 34 or SEQ ID NO: 35.
In one embodiment, the composition comprises:
• a DNase that comprises or consists of SEQ ID NO: 4;
• a hexosaminidase that comprises or consists of SEQ ID NO: 23;
• a protease that comprises SEQ ID NO: 24 with the substitutions S9E, N42R, N74D, V199I, Q200L, Y203W, S253D, N255W and L256E; and
• at least one enzyme selected from the group consisting of amylases and cellulases; wherein:
o the amylase comprises SEQ ID NO: 29 with the mutations H 1 *, N54S, V56T, K72R, G109A, F113Q, R116Q, W167F, Q172G, A174S, G182*, D183*, G184T, N195F, V206L, K391A, P473R and G476K; and o the cellulase comprises SEQ ID NO: 34. In one embodiment, the composition comprises:
• a DNase that comprises or consists of SEQ ID NO: 5, or which is a variant thereof having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity to SEQ ID NO: 5;
• a hexosaminidase that comprises or consists of SEQ ID NO: 19, or which is a variant thereof having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity to SEQ ID NO: 19;
• a protease selected from: a) a polypeptide that comprises or consists of SEQ ID NO: 24 or SEQ ID NO: 26, or a variant thereof having at least 80%, at least 85%, at least 90% or at least 95% sequence identity to SEQ ID NO: 24 or SEQ ID NO: 26; b) a polypeptide that comprises SEQ ID NO: 24 with the substitutions Y161A, R164S and A188P; c) a polypeptide that comprises SEQ ID NO: 24 with the substitutions S9E, N42R, N74D, V199I, Q200L, Y203W, S253D, N255W and L256E; and d) a polypeptide that comprises SEQ ID NO: 37; and
• at least one enzyme selected from the group consisting of amylases, lipases, mannanases, pectate lyases and cellulases.
In one embodiment, the composition comprises:
• a DNase that comprises or consists of SEQ ID NO: 5;
• a hexosaminidase that comprises or consists of SEQ ID NO: 19;
• a protease that comprises SEQ ID NO: 24 with the substitutions Y161A, R164S and A188P, or that comprises SEQ ID NO: 37; and
• at least one enzyme selected from the group consisting of amylases, lipases, mannanases, pectate lyases and cellulases; wherein:
o the amylase comprises SEQ ID NO: 30 with the mutations H183*, G184*, I405L, A421 H, A422P and A428T;
o the lipase comprises SEQ ID NO: 31 with the mutations D27R, G38A, D96E, D11 1A, G163K, T231 R, N233R, D254S and P256T; o the mannanase comprises SEQ ID NO: 32;
o the pectate lyase comprises SEQ ID NO: 33; and
o the cellulase comprises SEQ ID NO: 34 or SEQ ID NO: 35.
In one embodiment, the composition comprises:
• a DNase that comprises or consists of SEQ ID NO: 5;
• a hexosaminidase that comprises or consists of SEQ ID NO: 19;
• a protease that comprises SEQ ID NO: 24 with the substitutions S9E, N42R, N74D, V199I, Q200L, Y203W, S253D, N255W and L256E; and • at least one enzyme selected from the group consisting of amylases and cellulases; wherein:
o the amylase comprises SEQ ID NO: 29 with the mutations H 1 *, N54S, V56T, K72R, G109A, F113Q, R116Q, W167F, Q172G, A174S, G182*, D183*, G184T, N195F, V206L, K391A, P473R and G476K; and o the cellulase comprises SEQ ID NO: 34.
In one embodiment, the composition comprises:
• a DNase that comprises or consists of SEQ ID NO: 5, or which is a variant thereof having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity to SEQ ID NO: 5;
• a hexosaminidase that comprises or consists of SEQ ID NO: 20, or which is a variant thereof having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity to SEQ ID NO: 20;
• a protease selected from: a) a polypeptide that comprises or consists of SEQ ID NO: 24 or SEQ ID NO: 26, or a variant thereof having at least 80%, at least 85%, at least 90% or at least 95% sequence identity to SEQ ID NO: 24 or SEQ ID NO: 26; b) a polypeptide that comprises SEQ ID NO: 24 with the substitutions Y161A, R164S and A188P; c) a polypeptide that comprises SEQ ID NO: 24 with the substitutions S9E, N42R, N74D, V199I, Q200L, Y203W, S253D, N255W and L256E; and d) a polypeptide that comprises SEQ ID NO: 37; and
• at least one enzyme selected from the group consisting of amylases, lipases, mannanases, pectate lyases and cellulases.
In one embodiment, the composition comprises:
• a DNase that comprises or consists of SEQ ID NO: 5;
• a hexosaminidase that comprises or consists of SEQ ID NO: 20;
• a protease that comprises SEQ ID NO: 24 with the substitutions Y161A, R164S and A188P, or that comprises SEQ ID NO: 37; and
• at least one enzyme selected from the group consisting of amylases, lipases, mannanases, pectate lyases and cellulases; wherein:
o the amylase comprises SEQ ID NO: 30 with the mutations H183*, G184*, I405L, A421 H, A422P and A428T;
o the lipase comprises SEQ ID NO: 31 with the mutations D27R, G38A, D96E, D11 1A, G163K, T231 R, N233R, D254S and P256T; o the mannanase comprises SEQ ID NO: 32;
o the pectate lyase comprises SEQ ID NO: 33; and o the cellulase comprises SEQ ID NO: 34 or SEQ ID NO: 35.
In one embodiment, the composition comprises:
• a DNase that comprises or consists of SEQ ID NO: 5;
• a hexosaminidase that comprises or consists of SEQ ID NO: 20;
• a protease that comprises SEQ ID NO: 24 with the substitutions S9E, N42R, N74D, V199I, Q200L, Y203W, S253D, N255W and L256E; and
• at least one enzyme selected from the group consisting of amylases and cellulases; wherein:
o the amylase comprises SEQ ID NO: 29 with the mutations H 1 *, N54S, V56T, K72R, G109A, F113Q, R116Q, W167F, Q172G, A174S, G182*, D183*, G184T, N195F, V206L, K391A, P473R and G476K; and o the cellulase comprises SEQ ID NO: 34.
In one embodiment, the composition comprises:
• a DNase that comprises or consists of SEQ ID NO: 5, or which is a variant thereof having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity to SEQ ID NO: 5;
• a hexosaminidase that comprises or consists of SEQ ID NO: 21 , or which is a variant thereof having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity to SEQ ID NO: 21 ;
• a protease selected from: a) a polypeptide that comprises or consists of SEQ ID NO: 24 or SEQ ID NO: 26, or a variant thereof having at least 80%, at least 85%, at least 90% or at least 95% sequence identity to SEQ ID NO: 24 or SEQ ID NO: 26; b) a polypeptide that comprises SEQ ID NO: 24 with the substitutions Y161A, R164S and A188P; c) a polypeptide that comprises SEQ ID NO: 24 with the substitutions S9E, N42R, N74D, V199I, Q200L, Y203W, S253D, N255W and L256E; and d) a polypeptide that comprises SEQ ID NO: 37; and
• at least one enzyme selected from the group consisting of amylases, lipases, mannanases, pectate lyases and cellulases.
In one embodiment, the composition comprises:
• a DNase that comprises or consists of SEQ ID NO: 5;
• a hexosaminidase that comprises or consists of SEQ ID NO: 21 ;
• a protease that comprises SEQ ID NO: 24 with the substitutions Y161A, R164S and A188P, or that comprises SEQ ID NO: 37; and
• at least one enzyme selected from the group consisting of amylases, lipases, mannanases, pectate lyases and cellulases; wherein: o the amylase comprises SEQ ID NO: 30 with the mutations H183*, G184*, I405L, A421 H, A422P and A428T;
o the lipase comprises SEQ ID NO: 31 with the mutations D27R, G38A, D96E, D11 1A, G163K, T231 R, N233R, D254S and P256T; o the mannanase comprises SEQ ID NO: 32;
o the pectate lyase comprises SEQ ID NO: 33; and
o the cellulase comprises SEQ ID NO: 34 or SEQ ID NO: 35.
In one embodiment, the composition comprises:
• a DNase that comprises or consists of SEQ ID NO: 5;
• a hexosaminidase that comprises or consists of SEQ ID NO: 21 ;
• a protease that comprises SEQ ID NO: 24 with the substitutions S9E, N42R, N74D, V199I, Q200L, Y203W, S253D, N255W and L256E; and
• at least one enzyme selected from the group consisting of amylases and cellulases; wherein:
o the amylase comprises SEQ ID NO: 29 with the mutations H 1 *, N54S, V56T, K72R, G109A, F113Q, R116Q, W167F, Q172G, A174S, G182*, D183*, G184T, N195F, V206L, K391A, P473R and G476K; and o the cellulase comprises SEQ ID NO: 34.
In one embodiment, the composition comprises:
• a DNase that comprises or consists of SEQ ID NO: 5, or which is a variant thereof having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity to SEQ ID NO: 5;
• a hexosaminidase that comprises or consists of SEQ ID NO: 22, or which is a variant thereof having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity to SEQ ID NO: 22;
• a protease selected from: a) a polypeptide that comprises or consists of SEQ ID NO: 24 or SEQ ID NO: 26, or a variant thereof having at least 80%, at least 85%, at least 90% or at least 95% sequence identity to SEQ ID NO: 24 or SEQ ID NO: 26; b) a polypeptide that comprises SEQ ID NO: 24 with the substitutions Y161A, R164S and A188P; c) a polypeptide that comprises SEQ ID NO: 24 with the substitutions S9E, N42R, N74D, V199I, Q200L, Y203W, S253D, N255W and L256E; and d) a polypeptide that comprises SEQ ID NO: 37; and
• at least one enzyme selected from the group consisting of amylases, lipases, mannanases, pectate lyases and cellulases.
In one embodiment, the composition comprises: • a DNase that comprises or consists of SEQ ID NO: 5;
• a hexosaminidase that comprises or consists of SEQ ID NO: 22;
• a protease that comprises SEQ ID NO: 24 with the substitutions Y161A, R164S and A188P, or that comprises SEQ ID NO: 37; and
• at least one enzyme selected from the group consisting of amylases, lipases, mannanases, pectate lyases and cellulases; wherein:
o the amylase comprises SEQ ID NO: 30 with the mutations H183*, G184*, I405L, A421 H, A422P and A428T;
o the lipase comprises SEQ ID NO: 31 with the mutations D27R, G38A, D96E, D11 1A, G163K, T231 R, N233R, D254S and P256T; o the mannanase comprises SEQ ID NO: 32;
o the pectate lyase comprises SEQ ID NO: 33; and
o the cellulase comprises SEQ ID NO: 34 or SEQ ID NO: 35.
In one embodiment, the composition comprises:
• a DNase that comprises or consists of SEQ ID NO: 5;
• a hexosaminidase that comprises or consists of SEQ ID NO: 22;
• a protease that comprises SEQ ID NO: 24 with the substitutions S9E, N42R, N74D, V199I, Q200L, Y203W, S253D, N255W and L256E; and
• at least one enzyme selected from the group consisting of amylases and cellulases; wherein:
o the amylase comprises SEQ ID NO: 29 with the mutations H 1 *, N54S, V56T, K72R, G109A, F113Q, R116Q, W167F, Q172G, A174S, G182*, D183*, G184T, N195F, V206L, K391A, P473R and G476K; and o the cellulase comprises SEQ ID NO: 34.
In one embodiment, the composition comprises:
• a DNase that comprises or consists of SEQ ID NO: 5, or which is a variant thereof having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity to SEQ ID NO: 5;
• a hexosaminidase that comprises or consists of SEQ ID NO: 23, or which is a variant thereof having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity to SEQ ID NO: 23;
• a protease selected from: a) a polypeptide that comprises or consists of SEQ ID NO: 24 or SEQ ID NO: 26, or a variant thereof having at least 80%, at least 85%, at least 90% or at least 95% sequence identity to SEQ ID NO: 24 or SEQ ID NO: 26; b) a polypeptide that comprises SEQ ID NO: 24 with the substitutions Y161A, R164S and A188P; c) a polypeptide that comprises SEQ ID NO: 24 with the substitutions S9E, N42R, N74D, V199I, Q200L, Y203W, S253D, N255W and L256E; and d) a polypeptide that comprises SEQ ID NO: 37; and
• at least one enzyme selected from the group consisting of amylases, lipases, mannanases, pectate lyases and cellulases.
In one embodiment, the composition comprises:
• a DNase that comprises or consists of SEQ ID NO: 5;
• a hexosaminidase that comprises or consists of SEQ ID NO: 23;
• a protease that comprises SEQ ID NO: 24 with the substitutions Y161A, R164S and A188P, or that comprises SEQ ID NO: 37; and
• at least one enzyme selected from the group consisting of amylases, lipases, mannanases, pectate lyases and cellulases; wherein:
o the amylase comprises SEQ ID NO: 30 with the mutations H183*, G184*, I405L, A421 H, A422P and A428T;
o the lipase comprises SEQ ID NO: 31 with the mutations D27R, G38A, D96E, D11 1A, G163K, T231 R, N233R, D254S and P256T;
o the mannanase comprises SEQ ID NO: 32;
o the pectate lyase comprises SEQ ID NO: 33; and
o the cellulase comprises SEQ ID NO: 34 or SEQ ID NO: 35.
In one embodiment, the composition comprises:
• a DNase that comprises or consists of SEQ ID NO: 5;
• a hexosaminidase that comprises or consists of SEQ ID NO: 23;
• a protease that comprises SEQ ID NO: 24 with the substitutions S9E, N42R, N74D, V199I, Q200L, Y203W, S253D, N255W and L256E; and
• at least one enzyme selected from the group consisting of amylases and cellulases; wherein:
o the amylase comprises SEQ ID NO: 29 with the mutations H 1 *, N54S, V56T, K72R, G109A, F113Q, R116Q, W167F, Q172G, A174S, G182*, D183*, G184T, N195F, V206L, K391A, P473R and G476K; and o the cellulase comprises SEQ ID NO: 34.
In any of the embodiments described above comprising at least a DNase and a hexosaminidase as the cleaning enzymes, the cleaning composition may optionally comprise one or more of any of the other cleaning enzymes described herein. Any of these compositions may thus comprise one or more of an RNase, a Glyco_hydro_114 glucosyl hydrolase, a GH39 glycosyl hydrolase or a GHL13 glycosyl hydrolase. Cleaning compositions comprising an RNase and a Glyco hydro 114 polypeptide
One aspect of the invention relates to a cleaning composition comprising at least an RNase and a Glyco_hydro_1 14 glycosyl hydrolase as the cleaning enzymes. Exemplary embodiments of this aspect of the invention are described below.
In one embodiment, the composition comprises:
• an RNase that comprises or consists of SEQ ID NO: 16, or which is a variant thereof having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity to SEQ ID NO: 16;
• a Glyco_hydro_1 14 polypeptide that comprises or consists of SEQ ID NO: 6, or which is a variant thereof having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity to SEQ ID NO: 6;
• a protease selected from: a) a polypeptide that comprises or consists of SEQ ID NO: 24 or SEQ ID NO: 26, or a variant thereof having at least 80%, at least 85%, at least 90% or at least 95% sequence identity to SEQ ID NO: 24 or SEQ ID NO: 26; b) a polypeptide that comprises SEQ ID NO: 24 with the substitutions Y161A, R164S and A188P; c) a polypeptide that comprises SEQ ID NO: 24 with the substitutions S9E, N42R, N74D, V199I, Q200L, Y203W, S253D, N255W and L256E; and d) a polypeptide that comprises SEQ ID NO: 37; and
• at least one enzyme selected from the group consisting of amylases, lipases, mannanases, pectate lyases and cellulases.
In one embodiment, the composition comprises:
• an RNase that comprises or consists of SEQ ID NO: 16;
• a Glyco_hydro_1 14 polypeptide that comprises or consists of SEQ ID NO: 6;
• a protease that comprises SEQ ID NO: 24 with the substitutions Y161A, R164S and A188P, or that comprises SEQ ID NO: 37; and
• at least one enzyme selected from the group consisting of amylases, lipases, mannanases, pectate lyases and cellulases; wherein:
o the amylase comprises SEQ ID NO: 30 with the mutations H183*, G184*, I405L, A421 H, A422P and A428T;
o the lipase comprises SEQ ID NO: 31 with the mutations D27R, G38A, D96E, D11 1A, G163K, T231 R, N233R, D254S and P256T;
o the mannanase comprises SEQ ID NO: 32;
o the pectate lyase comprises SEQ ID NO: 33; and
o the cellulase comprises SEQ ID NO: 34 or SEQ ID NO: 35. In one embodiment, the composition comprises:
• an RNase that comprises or consists of SEQ ID NO: 16;
• a Glyco_hydro_1 14 polypeptide that comprises or consists of SEQ ID NO: 6;
• a protease that comprises SEQ ID NO: 24 with the substitutions S9E, N42R, N74D, V199I, Q200L, Y203W, S253D, N255W and L256E; and
• at least one enzyme selected from the group consisting of amylases and cellulases; wherein:
o the amylase comprises SEQ ID NO: 29 with the mutations H 1 *, N54S, V56T, K72R, G109A, F113Q, R116Q, W167F, Q172G, A174S, G182*, D183*, G184T, N195F, V206L, K391A, P473R and G476K; and o the cellulase comprises SEQ ID NO: 34.
In one embodiment, the composition comprises:
• an RNase that comprises or consists of SEQ ID NO: 16, or which is a variant thereof having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity to SEQ ID NO: 16;
• a Glyco_hydro_1 14 polypeptide that comprises or consists of SEQ ID NO: 7, or which is a variant thereof having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity to SEQ ID NO: 7;
• a protease selected from: a) a polypeptide that comprises or consists of SEQ ID NO: 24 or SEQ ID NO: 26, or a variant thereof having at least 80%, at least 85%, at least 90% or at least 95% sequence identity to SEQ ID NO: 24 or SEQ ID NO: 26; b) a polypeptide that comprises SEQ ID NO: 24 with the substitutions Y161A, R164S and A188P; c) a polypeptide that comprises SEQ ID NO: 24 with the substitutions S9E, N42R, N74D, V199I, Q200L, Y203W, S253D, N255W and L256E; and d) a polypeptide that comprises SEQ ID NO: 37; and
• at least one enzyme selected from the group consisting of amylases, lipases, mannanases, pectate lyases and cellulases.
In one embodiment, the composition comprises:
• an RNase that comprises or consists of SEQ ID NO: 16;
• a Glyco_hydro_1 14 polypeptide that comprises or consists of SEQ ID NO: 7;
• a protease that comprises SEQ ID NO: 24 with the substitutions Y161A, R164S and A188P, or that comprises SEQ ID NO: 37; and
• at least one enzyme selected from the group consisting of amylases, lipases, mannanases, pectate lyases and cellulases; wherein: o the amylase comprises SEQ ID NO: 30 with the mutations H183*, G184*, I405L, A421 H, A422P and A428T;
o the lipase comprises SEQ ID NO: 31 with the mutations D27R, G38A, D96E, D11 1A, G163K, T231 R, N233R, D254S and P256T; o the mannanase comprises SEQ ID NO: 32;
o the pectate lyase comprises SEQ ID NO: 33; and
o the cellulase comprises SEQ ID NO: 34 or SEQ ID NO: 35.
In one embodiment, the composition comprises:
• an RNase that comprises or consists of SEQ ID NO: 16;
• a Glyco_hydro_1 14 polypeptide that comprises or consists of SEQ ID NO: 7;
• a protease that comprises SEQ ID NO: 24 with the substitutions S9E, N42R, N74D, V199I, Q200L, Y203W, S253D, N255W and L256E; and
• at least one enzyme selected from the group consisting of amylases and cellulases; wherein:
o the amylase comprises SEQ ID NO: 29 with the mutations H 1 *, N54S, V56T, K72R, G109A, F113Q, R116Q, W167F, Q172G, A174S, G182*, D183*, G184T, N195F, V206L, K391A, P473R and G476K; and o the cellulase comprises SEQ ID NO: 34.
In one embodiment, the composition comprises:
• an RNase that comprises or consists of SEQ ID NO: 16, or which is a variant thereof having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity to SEQ ID NO: 16;
• a Glyco_hydro_1 14 polypeptide that comprises or consists of SEQ ID NO: 8, or which is a variant thereof having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity to SEQ ID NO: 8;
• a protease selected from: a) a polypeptide that comprises or consists of SEQ ID NO: 24 or SEQ ID NO: 26, or a variant thereof having at least 80%, at least 85%, at least 90% or at least 95% sequence identity to SEQ ID NO: 24 or SEQ ID NO: 26; b) a polypeptide that comprises SEQ ID NO: 24 with the substitutions Y161A, R164S and A188P; c) a polypeptide that comprises SEQ ID NO: 24 with the substitutions S9E, N42R, N74D, V199I, Q200L, Y203W, S253D, N255W and L256E; and d) a polypeptide that comprises SEQ ID NO: 37; and
• at least one enzyme selected from the group consisting of amylases, lipases, mannanases, pectate lyases and cellulases. In one embodiment, the composition comprises:
• an RNase that comprises or consists of SEQ ID NO: 16;
• a Glyco_hydro_1 14 polypeptide that comprises or consists of SEQ ID NO: 8;
• a protease that comprises SEQ ID NO: 24 with the substitutions Y161A, R164S and A188P, or that comprises SEQ ID NO: 37; and
• at least one enzyme selected from the group consisting of amylases, lipases, mannanases, pectate lyases and cellulases; wherein:
o the amylase comprises SEQ ID NO: 30 with the mutations H183*, G184*, I405L, A421 H, A422P and A428T;
o the lipase comprises SEQ ID NO: 31 with the mutations D27R, G38A, D96E, D11 1A, G163K, T231 R, N233R, D254S and P256T; o the mannanase comprises SEQ ID NO: 32;
o the pectate lyase comprises SEQ ID NO: 33; and
o the cellulase comprises SEQ ID NO: 34 or SEQ ID NO: 35.
In one embodiment, the composition comprises:
• an RNase that comprises or consists of SEQ ID NO: 16;
• a Glyco_hydro_1 14 polypeptide that comprises or consists of SEQ ID NO: 8;
• a protease that comprises SEQ ID NO: 24 with the substitutions S9E, N42R, N74D, V199I, Q200L, Y203W, S253D, N255W and L256E; and
• at least one enzyme selected from the group consisting of amylases and cellulases; wherein:
o the amylase comprises SEQ ID NO: 29 with the mutations H 1 *, N54S, V56T, K72R, G109A, F113Q, R116Q, W167F, Q172G, A174S, G182*, D183*, G184T, N195F, V206L, K391A, P473R and G476K; and o the cellulase comprises SEQ ID NO: 34.
In one embodiment, the composition comprises:
• an RNase that comprises or consists of SEQ ID NO: 16, or which is a variant thereof having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity to SEQ ID NO: 16;
• a Glyco_hydro_1 14 polypeptide that comprises or consists of SEQ ID NO: 9, or which is a variant thereof having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity to SEQ ID NO: 9;
• a protease selected from: a) a polypeptide that comprises or consists of SEQ ID NO: 24 or SEQ ID NO: 26, or a variant thereof having at least 80%, at least 85%, at least 90% or at least 95% sequence identity to SEQ ID NO: 24 or SEQ ID NO: 26; b) a polypeptide that comprises SEQ ID NO: 24 with the substitutions Y161A, R164S and A188P; c) a polypeptide that comprises SEQ ID NO: 24 with the substitutions S9E, N42R, N74D, V199I, Q200L, Y203W, S253D, N255W and L256E; and d) a polypeptide that comprises SEQ ID NO: 37; and
• at least one enzyme selected from the group consisting of amylases, lipases, mannanases, pectate lyases and cellulases.
In one embodiment, the composition comprises:
• an RNase that comprises or consists of SEQ ID NO: 16;
• a Glyco_hydro_114 polypeptide that comprises or consists of SEQ ID NO: 9;
• a protease that comprises SEQ ID NO: 24 with the substitutions Y161A, R164S and A188P, or that comprises SEQ ID NO: 37; and
• at least one enzyme selected from the group consisting of amylases, lipases, mannanases, pectate lyases and cellulases; wherein:
o the amylase comprises SEQ ID NO: 30 with the mutations H183*, G184*, I405L, A421 H, A422P and A428T;
o the lipase comprises SEQ ID NO: 31 with the mutations D27R, G38A, D96E, D11 1A, G163K, T231 R, N233R, D254S and P256T; o the mannanase comprises SEQ ID NO: 32;
o the pectate lyase comprises SEQ ID NO: 33; and
o the cellulase comprises SEQ ID NO: 34 or SEQ ID NO: 35.
In one embodiment, the composition comprises:
• an RNase that comprises or consists of SEQ ID NO: 16;
• a Glyco_hydro_1 14 polypeptide that comprises or consists of SEQ ID NO: 9;
• a protease that comprises SEQ ID NO: 24 with the substitutions S9E, N42R, N74D, V199I, Q200L, Y203W, S253D, N255W and L256E; and
• at least one enzyme selected from the group consisting of amylases and cellulases; wherein:
o the amylase comprises SEQ ID NO: 29 with the mutations H 1 *, N54S, V56T, K72R, G109A, F113Q, R116Q, W167F, Q172G, A174S, G182*, D183*, G184T, N195F, V206L, K391A, P473R and G476K; and o the cellulase comprises SEQ ID NO: 34.
In one embodiment, the composition comprises:
• an RNase that comprises or consists of SEQ ID NO: 17, or which is a variant thereof having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity to SEQ ID NO: 17;
• a Glyco_hydro_1 14 polypeptide that comprises or consists of SEQ ID NO: 6, or which is a variant thereof having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity to SEQ ID NO: 6;
• a protease selected from: a) a polypeptide that comprises or consists of SEQ ID NO: 24 or SEQ ID NO: 26, or a variant thereof having at least 80%, at least 85%, at least 90% or at least 95% sequence identity to SEQ ID NO: 24 or SEQ ID NO: 26; b) a polypeptide that comprises SEQ ID NO: 24 with the substitutions Y161A, R164S and A188P; c) a polypeptide that comprises SEQ ID NO: 24 with the substitutions S9E, N42R, N74D, V199I, Q200L, Y203W, S253D, N255W and L256E; and d) a polypeptide that comprises SEQ ID NO: 37; and
• at least one enzyme selected from the group consisting of amylases, lipases, mannanases, pectate lyases and cellulases.
In one embodiment, the composition comprises:
• an RNase that comprises or consists of SEQ ID NO: 17;
• a Glyco_hydro_1 14 polypeptide that comprises or consists of SEQ ID NO: 6;
• a protease that comprises SEQ ID NO: 24 with the substitutions Y161A, R164S and A188P, or that comprises SEQ ID NO: 37; and
• at least one enzyme selected from the group consisting of amylases, lipases, mannanases, pectate lyases and cellulases; wherein:
o the amylase comprises SEQ ID NO: 30 with the mutations H183*, G184*, I405L, A421 H, A422P and A428T;
o the lipase comprises SEQ ID NO: 31 with the mutations D27R, G38A, D96E, D11 1A, G163K, T231 R, N233R, D254S and P256T; o the mannanase comprises SEQ ID NO: 32;
o the pectate lyase comprises SEQ ID NO: 33; and
o the cellulase comprises SEQ ID NO: 34 or SEQ ID NO: 35.
In one embodiment, the composition comprises:
• an RNase that comprises or consists of SEQ ID NO: 17;
• a Glyco_hydro_1 14 polypeptide that comprises or consists of SEQ ID NO: 6;
• a protease that comprises SEQ ID NO: 24 with the substitutions S9E, N42R, N74D, V199I, Q200L, Y203W, S253D, N255W and L256E; and
• at least one enzyme selected from the group consisting of amylases and cellulases; wherein: o the amylase comprises SEQ ID NO: 29 with the mutations H 1 *, N54S, V56T, K72R, G109A, F113Q, R116Q, W167F, Q172G, A174S, G182*, D183*, G184T, N195F, V206L, K391A, P473R and G476K; and o the cellulase comprises SEQ ID NO: 34.
In one embodiment, the composition comprises:
• an RNase that comprises or consists of SEQ ID NO: 17, or which is a variant thereof having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity to SEQ ID NO: 17;
• a Glyco_hydro_1 14 polypeptide that comprises or consists of SEQ ID NO: 7, or which is a variant thereof having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity to SEQ ID NO: 7;
• a protease selected from: a) a polypeptide that comprises or consists of SEQ ID NO: 24 or SEQ ID NO: 26, or a variant thereof having at least 80%, at least 85%, at least 90% or at least 95% sequence identity to SEQ ID NO: 24 or SEQ ID NO: 26; b) a polypeptide that comprises SEQ ID NO: 24 with the substitutions Y161A, R164S and A188P; c) a polypeptide that comprises SEQ ID NO: 24 with the substitutions S9E, N42R, N74D, V199I, Q200L, Y203W, S253D, N255W and L256E; and d) a polypeptide that comprises SEQ ID NO: 37; and
• at least one enzyme selected from the group consisting of amylases, lipases, mannanases, pectate lyases and cellulases.
In one embodiment, the composition comprises:
• an RNase that comprises or consists of SEQ ID NO: 17;
• a Glyco_hydro_1 14 polypeptide that comprises or consists of SEQ ID NO: 7;
• a protease that comprises SEQ ID NO: 24 with the substitutions Y161A, R164S and A188P, or that comprises SEQ ID NO: 37; and
• at least one enzyme selected from the group consisting of amylases, lipases, mannanases, pectate lyases and cellulases; wherein:
o the amylase comprises SEQ ID NO: 30 with the mutations H183*, G184*, I405L, A421 H, A422P and A428T;
o the lipase comprises SEQ ID NO: 31 with the mutations D27R, G38A, D96E, D11 1A, G163K, T231 R, N233R, D254S and P256T; o the mannanase comprises SEQ ID NO: 32;
o the pectate lyase comprises SEQ ID NO: 33; and
o the cellulase comprises SEQ ID NO: 34 or SEQ ID NO: 35. In one embodiment, the composition comprises:
• an RNase that comprises or consists of SEQ ID NO: 17;
• a Glyco_hydro_1 14 polypeptide that comprises or consists of SEQ ID NO: 7;
• a protease that comprises SEQ ID NO: 24 with the substitutions S9E, N42R, N74D, V199I, Q200L, Y203W, S253D, N255W and L256E; and
• at least one enzyme selected from the group consisting of amylases and cellulases; wherein:
o the amylase comprises SEQ ID NO: 29 with the mutations H 1 *, N54S, V56T, K72R, G109A, F113Q, R116Q, W167F, Q172G, A174S, G182*, D183*, G184T, N195F, V206L, K391A, P473R and G476K; and o the cellulase comprises SEQ ID NO: 34.
In one embodiment, the composition comprises:
• an RNase that comprises or consists of SEQ ID NO: 17, or which is a variant thereof having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity to SEQ ID NO: 17;
• a Glyco_hydro_1 14 polypeptide that comprises or consists of SEQ ID NO: 8, or which is a variant thereof having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity to SEQ ID NO: 8;
• a protease selected from: a) a polypeptide that comprises or consists of SEQ ID NO: 24 or SEQ ID NO: 26, or a variant thereof having at least 80%, at least 85%, at least 90% or at least 95% sequence identity to SEQ ID NO: 24 or SEQ ID NO: 26; b) a polypeptide that comprises SEQ ID NO: 24 with the substitutions Y161A, R164S and A188P; c) a polypeptide that comprises SEQ ID NO: 24 with the substitutions S9E, N42R, N74D, V199I, Q200L, Y203W, S253D, N255W and L256E; and d) a polypeptide that comprises SEQ ID NO: 37; and
• at least one enzyme selected from the group consisting of amylases, lipases, mannanases, pectate lyases and cellulases.
In one embodiment, the composition comprises:
• an RNase that comprises or consists of SEQ ID NO: 17;
• a Glyco_hydro_1 14 polypeptide that comprises or consists of SEQ ID NO: 8;
• a protease that comprises SEQ ID NO: 24 with the substitutions Y161A, R164S and A188P, or that comprises SEQ ID NO: 37; and
• at least one enzyme selected from the group consisting of amylases, lipases, mannanases, pectate lyases and cellulases; wherein: o the amylase comprises SEQ ID NO: 30 with the mutations H183*, G184*, I405L, A421 H, A422P and A428T;
o the lipase comprises SEQ ID NO: 31 with the mutations D27R, G38A, D96E, D11 1A, G163K, T231 R, N233R, D254S and P256T; o the mannanase comprises SEQ ID NO: 32;
o the pectate lyase comprises SEQ ID NO: 33; and
o the cellulase comprises SEQ ID NO: 34 or SEQ ID NO: 35.
In one embodiment, the composition comprises:
• an RNase that comprises or consists of SEQ ID NO: 17;
• a Glyco_hydro_1 14 polypeptide that comprises or consists of SEQ ID NO: 8;
• a protease that comprises SEQ ID NO: 24 with the substitutions S9E, N42R, N74D, V199I, Q200L, Y203W, S253D, N255W and L256E; and
• at least one enzyme selected from the group consisting of amylases and cellulases; wherein:
o the amylase comprises SEQ ID NO: 29 with the mutations H 1 *, N54S, V56T, K72R, G109A, F113Q, R116Q, W167F, Q172G, A174S, G182*, D183*, G184T, N195F, V206L, K391A, P473R and G476K; and o the cellulase comprises SEQ ID NO: 34.
In one embodiment, the composition comprises:
• an RNase that comprises or consists of SEQ ID NO: 17, or which is a variant thereof having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity to SEQ ID NO: 17;
• a Glyco_hydro_1 14 polypeptide that comprises or consists of SEQ ID NO: 9, or which is a variant thereof having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity to SEQ ID NO: 9;
• a protease selected from: a) a polypeptide that comprises or consists of SEQ ID NO: 24 or SEQ ID NO: 26, or a variant thereof having at least 80%, at least 85%, at least 90% or at least 95% sequence identity to SEQ ID NO: 24 or SEQ ID NO: 26; b) a polypeptide that comprises SEQ ID NO: 24 with the substitutions Y161A, R164S and A188P; c) a polypeptide that comprises SEQ ID NO: 24 with the substitutions S9E, N42R, N74D, V199I, Q200L, Y203W, S253D, N255W and L256E; and d) a polypeptide that comprises SEQ ID NO: 37; and
• at least one enzyme selected from the group consisting of amylases, lipases, mannanases, pectate lyases and cellulases. In one embodiment, the composition comprises:
• an RNase that comprises or consists of SEQ ID NO: 17;
• a Glyco_hydro_1 14 polypeptide that comprises or consists of SEQ ID NO: 9;
• a protease that comprises SEQ ID NO: 24 with the substitutions Y161A, R164S and A188P, or that comprises SEQ ID NO: 37; and
• at least one enzyme selected from the group consisting of amylases, lipases, mannanases, pectate lyases and cellulases; wherein:
o the amylase comprises SEQ ID NO: 30 with the mutations H183*, G184*, I405L, A421 H, A422P and A428T;
o the lipase comprises SEQ ID NO: 31 with the mutations D27R, G38A, D96E, D11 1A, G163K, T231 R, N233R, D254S and P256T; o the mannanase comprises SEQ ID NO: 32;
o the pectate lyase comprises SEQ ID NO: 33; and
o the cellulase comprises SEQ ID NO: 34 or SEQ ID NO: 35.
In one embodiment, the composition comprises:
• an RNase that comprises or consists of SEQ ID NO: 17;
• a Glyco_hydro_1 14 polypeptide that comprises or consists of SEQ ID NO: 9;
• a protease that comprises SEQ ID NO: 24 with the substitutions S9E, N42R, N74D, V199I, Q200L, Y203W, S253D, N255W and L256E; and
• at least one enzyme selected from the group consisting of amylases and cellulases; wherein:
o the amylase comprises SEQ ID NO: 29 with the mutations H 1 *, N54S, V56T, K72R, G109A, F113Q, R116Q, W167F, Q172G, A174S, G182*, D183*, G184T, N195F, V206L, K391A, P473R and G476K; and o the cellulase comprises SEQ ID NO: 34.
In one embodiment, the composition comprises:
• an RNase that comprises or consists of SEQ ID NO: 18, or which is a variant thereof having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity to SEQ ID NO: 18;
• a Glyco_hydro_1 14 polypeptide that comprises or consists of SEQ ID NO: 6, or which is a variant thereof having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity to SEQ ID NO: 6;
• a protease selected from: a) a polypeptide that comprises or consists of SEQ ID NO: 24 or SEQ ID NO: 26, or a variant thereof having at least 80%, at least 85%, at least 90% or at least 95% sequence identity to SEQ ID NO: 24 or SEQ ID NO: 26; b) a polypeptide that comprises SEQ ID NO: 24 with the substitutions Y161A, R164S and A188P; c) a polypeptide that comprises SEQ ID NO: 24 with the substitutions S9E, N42R, N74D, V199I, Q200L, Y203W, S253D, N255W and L256E; and d) a polypeptide that comprises SEQ ID NO: 37; and
• at least one enzyme selected from the group consisting of amylases, lipases, mannanases, pectate lyases and cellulases.
In one embodiment, the composition comprises:
• an RNase that comprises or consists of SEQ ID NO: 18;
• a Glyco_hydro_1 14 polypeptide that comprises or consists of SEQ ID NO: 6;
• a protease that comprises SEQ ID NO: 24 with the substitutions Y161A, R164S and A188P, or that comprises SEQ ID NO: 37; and
• at least one enzyme selected from the group consisting of amylases, lipases, mannanases, pectate lyases and cellulases; wherein:
o the amylase comprises SEQ ID NO: 30 with the mutations H183*, G184*, I405L, A421 H, A422P and A428T;
o the lipase comprises SEQ ID NO: 31 with the mutations D27R, G38A, D96E, D11 1A, G163K, T231 R, N233R, D254S and P256T; o the mannanase comprises SEQ ID NO: 32;
o the pectate lyase comprises SEQ ID NO: 33; and
o the cellulase comprises SEQ ID NO: 34 or SEQ ID NO: 35.
In one embodiment, the composition comprises:
• an RNase that comprises or consists of SEQ ID NO: 18;
• a Glyco_hydro_1 14 polypeptide that comprises or consists of SEQ ID NO: 6;
• a protease that comprises SEQ ID NO: 24 with the substitutions S9E, N42R, N74D, V199I, Q200L, Y203W, S253D, N255W and L256E; and
• at least one enzyme selected from the group consisting of amylases and cellulases; wherein:
o the amylase comprises SEQ ID NO: 29 with the mutations H 1 *, N54S, V56T, K72R, G109A, F113Q, R116Q, W167F, Q172G, A174S, G182*, D183*, G184T, N195F, V206L, K391A, P473R and G476K; and o the cellulase comprises SEQ ID NO: 34.
In one embodiment, the composition comprises:
• an RNase that comprises or consists of SEQ ID NO: 18, or which is a variant thereof having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity to SEQ ID NO: 18;
• a Glyco_hydro_1 14 polypeptide that comprises or consists of SEQ ID NO: 7, or which is a variant thereof having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity to SEQ ID NO: 7;
• a protease selected from: a) a polypeptide that comprises or consists of SEQ ID NO: 24 or SEQ ID NO: 26, or a variant thereof having at least 80%, at least 85%, at least 90% or at least 95% sequence identity to SEQ ID NO: 24 or SEQ ID NO: 26; b) a polypeptide that comprises SEQ ID NO: 24 with the substitutions Y161A, R164S and A188P; c) a polypeptide that comprises SEQ ID NO: 24 with the substitutions S9E, N42R, N74D, V199I, Q200L, Y203W, S253D, N255W and L256E; and d) a polypeptide that comprises SEQ ID NO: 37; and
• at least one enzyme selected from the group consisting of amylases, lipases, mannanases, pectate lyases and cellulases.
In one embodiment, the composition comprises:
• an RNase that comprises or consists of SEQ ID NO: 18;
• a Glyco_hydro_114 polypeptide that comprises or consists of SEQ ID NO: 7;
• a protease that comprises SEQ ID NO: 24 with the substitutions Y161A, R164S and A188P, or that comprises SEQ ID NO: 37; and
• at least one enzyme selected from the group consisting of amylases, lipases, mannanases, pectate lyases and cellulases; wherein:
o the amylase comprises SEQ ID NO: 30 with the mutations H183*, G184*, I405L, A421 H, A422P and A428T;
o the lipase comprises SEQ ID NO: 31 with the mutations D27R, G38A, D96E, D11 1A, G163K, T231 R, N233R, D254S and P256T; o the mannanase comprises SEQ ID NO: 32;
o the pectate lyase comprises SEQ ID NO: 33; and
o the cellulase comprises SEQ ID NO: 34 or SEQ ID NO: 35.
In one embodiment, the composition comprises:
• an RNase that comprises or consists of SEQ ID NO: 18;
• a Glyco_hydro_1 14 polypeptide that comprises or consists of SEQ ID NO: 7;
• a protease that comprises SEQ ID NO: 24 with the substitutions S9E, N42R, N74D, V199I, Q200L, Y203W, S253D, N255W and L256E; and
• at least one enzyme selected from the group consisting of amylases and cellulases; wherein: o the amylase comprises SEQ ID NO: 29 with the mutations H 1 *, N54S, V56T, K72R, G109A, F113Q, R116Q, W167F, Q172G, A174S, G182*, D183*, G184T, N195F, V206L, K391A, P473R and G476K; and o the cellulase comprises SEQ ID NO: 34.
In one embodiment, the composition comprises:
• an RNase that comprises or consists of SEQ ID NO: 18, or which is a variant thereof having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity to SEQ ID NO: 18;
• a Glyco_hydro_1 14 polypeptide that comprises or consists of SEQ ID NO: 8, or which is a variant thereof having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity to SEQ ID NO: 8;
• a protease selected from: a) a polypeptide that comprises or consists of SEQ ID NO: 24 or SEQ ID NO: 26, or a variant thereof having at least 80%, at least 85%, at least 90% or at least 95% sequence identity to SEQ ID NO: 24 or SEQ ID NO: 26; b) a polypeptide that comprises SEQ ID NO: 24 with the substitutions Y161A, R164S and A188P; c) a polypeptide that comprises SEQ ID NO: 24 with the substitutions S9E, N42R, N74D, V199I, Q200L, Y203W, S253D, N255W and L256E; and d) a polypeptide that comprises SEQ ID NO: 37; and
• at least one enzyme selected from the group consisting of amylases, lipases, mannanases, pectate lyases and cellulases.
In one embodiment, the composition comprises:
• an RNase that comprises or consists of SEQ ID NO: 18;
• a Glyco_hydro_1 14 polypeptide that comprises or consists of SEQ ID NO: 8;
• a protease that comprises SEQ ID NO: 24 with the substitutions Y161A, R164S and A188P, or that comprises SEQ ID NO: 37; and
• at least one enzyme selected from the group consisting of amylases, lipases, mannanases, pectate lyases and cellulases; wherein:
o the amylase comprises SEQ ID NO: 30 with the mutations H183*, G184*, I405L, A421 H, A422P and A428T;
o the lipase comprises SEQ ID NO: 31 with the mutations D27R, G38A, D96E, D11 1A, G163K, T231 R, N233R, D254S and P256T; o the mannanase comprises SEQ ID NO: 32;
o the pectate lyase comprises SEQ ID NO: 33; and
o the cellulase comprises SEQ ID NO: 34 or SEQ ID NO: 35. In one embodiment, the composition comprises:
• an RNase that comprises or consists of SEQ ID NO: 18;
• a Glyco_hydro_1 14 polypeptide that comprises or consists of SEQ ID NO: 8;
• a protease that comprises SEQ ID NO: 24 with the substitutions S9E, N42R, N74D, V199I, Q200L, Y203W, S253D, N255W and L256E; and
• at least one enzyme selected from the group consisting of amylases and cellulases; wherein:
o the amylase comprises SEQ ID NO: 29 with the mutations H 1 *, N54S, V56T, K72R, G109A, F113Q, R116Q, W167F, Q172G, A174S, G182*, D183*, G184T, N195F, V206L, K391A, P473R and G476K; and o the cellulase comprises SEQ ID NO: 34.
In one embodiment, the composition comprises:
• an RNase that comprises or consists of SEQ ID NO: 18, or which is a variant thereof having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity to SEQ ID NO: 18;
• a Glyco_hydro_1 14 polypeptide that comprises or consists of SEQ ID NO: 9, or which is a variant thereof having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity to SEQ ID NO: 9;
• a protease selected from: a) a polypeptide that comprises or consists of SEQ ID NO: 24 or SEQ ID NO: 26, or a variant thereof having at least 80%, at least 85%, at least 90% or at least 95% sequence identity to SEQ ID NO: 24 or SEQ ID NO: 26; b) a polypeptide that comprises SEQ ID NO: 24 with the substitutions Y161A, R164S and A188P; c) a polypeptide that comprises SEQ ID NO: 24 with the substitutions S9E, N42R, N74D, V199I, Q200L, Y203W, S253D, N255W and L256E; and d) a polypeptide that comprises SEQ ID NO: 37; and
• at least one enzyme selected from the group consisting of amylases, lipases, mannanases, pectate lyases and cellulases.
In one embodiment, the composition comprises:
• an RNase that comprises or consists of SEQ ID NO: 18;
• a Glyco_hydro_1 14 polypeptide that comprises or consists of SEQ ID NO: 9;
• a protease that comprises SEQ ID NO: 24 with the substitutions Y161A, R164S and A188P, or that comprises SEQ ID NO: 37; and
• at least one enzyme selected from the group consisting of amylases, lipases, mannanases, pectate lyases and cellulases; wherein: o the amylase comprises SEQ ID NO: 30 with the mutations H183*, G184*, I405L, A421 H, A422P and A428T;
o the lipase comprises SEQ ID NO: 31 with the mutations D27R, G38A, D96E, D11 1A, G163K, T231 R, N233R, D254S and P256T;
o the mannanase comprises SEQ ID NO: 32;
o the pectate lyase comprises SEQ ID NO: 33; and
o the cellulase comprises SEQ ID NO: 34 or SEQ ID NO: 35.
In one embodiment, the composition comprises:
• an RNase that comprises or consists of SEQ ID NO: 18;
• a Glyco_hydro_1 14 polypeptide that comprises or consists of SEQ ID NO: 9;
• a protease that comprises SEQ ID NO: 24 with the substitutions S9E, N42R, N74D, V199I, Q200L, Y203W, S253D, N255W and L256E; and
• at least one enzyme selected from the group consisting of amylases and cellulases; wherein:
o the amylase comprises SEQ ID NO: 29 with the mutations H 1 *, N54S, V56T, K72R, G109A, F113Q, R116Q, W167F, Q172G, A174S, G182*, D183*, G184T, N195F, V206L, K391A, P473R and G476K; and o the cellulase comprises SEQ ID NO: 34.
In any of the embodiments described above comprising at least an RNase and a Glyco_hydro_1 14 glycosyl hydrolase as the cleaning enzymes, the cleaning composition may optionally comprise one or more of any of the other cleaning enzymes described herein. Any of these compositions may thus comprise one or more of a DNase, a GH39 glycosyl hydrolase, a GHL13 glycosyl hydrolase or a hexosaminidase.
Cleaning compositions comprising an RNase and a GH39 polypeptide
One aspect of the invention relates to a cleaning composition comprising at least an RNase and a GH39 glycosyl hydrolase as the cleaning enzymes. Exemplary embodiments of this aspect of the invention are described below.
In one embodiment, the composition comprises:
• an RNase that comprises or consists of SEQ ID NO: 16, or which is a variant thereof having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity to SEQ ID NO: 16;
• a GH39 polypeptide that comprises or consists of SEQ ID NO: 10, or which is a variant thereof having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity to SEQ ID NO: 10;
• a protease selected from: a) a polypeptide that comprises or consists of SEQ ID NO: 24 or SEQ ID NO: 26, or a variant thereof having at least 80%, at least 85%, at least 90% or at least 95% sequence identity to SEQ ID NO: 24 or SEQ ID NO: 26; b) a polypeptide that comprises SEQ ID NO: 24 with the substitutions Y161A, R164S and A188P; c) a polypeptide that comprises SEQ ID NO: 24 with the substitutions S9E, N42R, N74D, V199I, Q200L, Y203W, S253D, N255W and L256E; and d) a polypeptide that comprises SEQ ID NO: 37; and
• at least one enzyme selected from the group consisting of amylases, lipases, mannanases, pectate lyases and cellulases.
In one embodiment, the composition comprises:
• an RNase that comprises or consists of SEQ ID NO: 16;
• a GH39 polypeptide that comprises or consists of SEQ ID NO: 10;
• a protease that comprises SEQ ID NO: 24 with the substitutions Y161A, R164S and A188P, or that comprises SEQ ID NO: 37; and
• at least one enzyme selected from the group consisting of amylases, lipases, mannanases, pectate lyases and cellulases; wherein:
o the amylase comprises SEQ ID NO: 30 with the mutations H183*, G184*, I405L, A421 H, A422P and A428T;
o the lipase comprises SEQ ID NO: 31 with the mutations D27R, G38A, D96E, D11 1A, G163K, T231 R, N233R, D254S and P256T; o the mannanase comprises SEQ ID NO: 32;
o the pectate lyase comprises SEQ ID NO: 33; and
o the cellulase comprises SEQ ID NO: 34 or SEQ ID NO: 35.
In one embodiment, the composition comprises:
• an RNase that comprises or consists of SEQ ID NO: 16;
• a GH39 polypeptide that comprises or consists of SEQ ID NO: 10;
• a protease that comprises SEQ ID NO: 24 with the substitutions S9E, N42R, N74D, V199I, Q200L, Y203W, S253D, N255W and L256E; and
• at least one enzyme selected from the group consisting of amylases and cellulases; wherein:
o the amylase comprises SEQ ID NO: 29 with the mutations H 1 *, N54S, V56T, K72R, G109A, F113Q, R116Q, W167F, Q172G, A174S, G182*, D183*, G184T, N195F, V206L, K391A, P473R and G476K; and o the cellulase comprises SEQ ID NO: 34. In one embodiment, the composition comprises:
• an RNase that comprises or consists of SEQ ID NO: 16, or which is a variant thereof having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity to SEQ ID NO: 16;
• a GH39 polypeptide that comprises or consists of SEQ ID NO: 11 , or which is a variant thereof having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity to SEQ ID NO: 1 1 ;
• a protease selected from: a) a polypeptide that comprises or consists of SEQ ID NO: 24 or SEQ ID NO: 26, or a variant thereof having at least 80%, at least 85%, at least 90% or at least 95% sequence identity to SEQ ID NO: 24 or SEQ ID NO: 26; b) a polypeptide that comprises SEQ ID NO: 24 with the substitutions Y161A, R164S and A188P; c) a polypeptide that comprises SEQ ID NO: 24 with the substitutions S9E, N42R, N74D, V199I, Q200L, Y203W, S253D, N255W and L256E; and d) a polypeptide that comprises SEQ ID NO: 37; and
• at least one enzyme selected from the group consisting of amylases, lipases, mannanases, pectate lyases and cellulases.
In one embodiment, the composition comprises:
• an RNase that comprises or consists of SEQ ID NO: 16;
• a GH39 polypeptide that comprises or consists of SEQ ID NO: 1 1 ;
• a protease that comprises SEQ ID NO: 24 with the substitutions Y161A, R164S and A188P, or that comprises SEQ ID NO: 37; and
• at least one enzyme selected from the group consisting of amylases, lipases, mannanases, pectate lyases and cellulases; wherein:
o the amylase comprises SEQ ID NO: 30 with the mutations H183*, G184*, I405L, A421 H, A422P and A428T;
o the lipase comprises SEQ ID NO: 31 with the mutations D27R, G38A, D96E, D11 1A, G163K, T231 R, N233R, D254S and P256T; o the mannanase comprises SEQ ID NO: 32;
o the pectate lyase comprises SEQ ID NO: 33; and
o the cellulase comprises SEQ ID NO: 34 or SEQ ID NO: 35.
In one embodiment, the composition comprises:
• an RNase that comprises or consists of SEQ ID NO: 16;
• a GH39 polypeptide that comprises or consists of SEQ ID NO: 11 ;
• a protease that comprises SEQ ID NO: 24 with the substitutions S9E, N42R, N74D, V199I, Q200L, Y203W, S253D, N255W and L256E; and • at least one enzyme selected from the group consisting of amylases and cellulases; wherein:
o the amylase comprises SEQ ID NO: 29 with the mutations H 1 *, N54S, V56T, K72R, G109A, F113Q, R116Q, W167F, Q172G, A174S, G182*, D183*, G184T, N195F, V206L, K391A, P473R and G476K; and o the cellulase comprises SEQ ID NO: 34.
In one embodiment, the composition comprises:
• an RNase that comprises or consists of SEQ ID NO: 16, or which is a variant thereof having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity to SEQ ID NO: 16;
• a GH39 polypeptide that comprises or consists of SEQ ID NO: 12, or which is a variant thereof having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity to SEQ ID NO: 12;
• a protease selected from: a) a polypeptide that comprises or consists of SEQ ID NO: 24 or SEQ ID NO: 26, or a variant thereof having at least 80%, at least 85%, at least 90% or at least 95% sequence identity to SEQ ID NO: 24 or SEQ ID NO: 26; b) a polypeptide that comprises SEQ ID NO: 24 with the substitutions Y161A, R164S and A188P; c) a polypeptide that comprises SEQ ID NO: 24 with the substitutions S9E, N42R, N74D, V199I, Q200L, Y203W, S253D, N255W and L256E; and d) a polypeptide that comprises SEQ ID NO: 37; and
• at least one enzyme selected from the group consisting of amylases, lipases, mannanases, pectate lyases and cellulases.
In one embodiment, the composition comprises:
• an RNase that comprises or consists of SEQ ID NO: 16;
• a GH39 polypeptide that comprises or consists of SEQ ID NO: 12;
• a protease that comprises SEQ ID NO: 24 with the substitutions Y161A, R164S and A188P, or that comprises SEQ ID NO: 37; and
• at least one enzyme selected from the group consisting of amylases, lipases, mannanases, pectate lyases and cellulases; wherein:
o the amylase comprises SEQ ID NO: 30 with the mutations H183*, G184*, I405L, A421 H, A422P and A428T;
o the lipase comprises SEQ ID NO: 31 with the mutations D27R, G38A, D96E, D11 1A, G163K, T231 R, N233R, D254S and P256T; o the mannanase comprises SEQ ID NO: 32; o the pectate lyase comprises SEQ ID NO: 33; and
o the cellulase comprises SEQ ID NO: 34 or SEQ ID NO: 35.
In one embodiment, the composition comprises:
• an RNase that comprises or consists of SEQ ID NO: 16;
• a GH39 polypeptide that comprises or consists of SEQ ID NO: 12;
• a protease that comprises SEQ ID NO: 24 with the substitutions S9E, N42R, N74D, V199I, Q200L, Y203W, S253D, N255W and L256E; and
• at least one enzyme selected from the group consisting of amylases and cellulases; wherein:
o the amylase comprises SEQ ID NO: 29 with the mutations H 1 *, N54S, V56T, K72R, G109A, F113Q, R116Q, W167F, Q172G, A174S, G182*, D183*, G184T, N195F, V206L, K391A, P473R and G476K; and o the cellulase comprises SEQ ID NO: 34.
In one embodiment, the composition comprises:
• an RNase that comprises or consists of SEQ ID NO: 17, or which is a variant thereof having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity to SEQ ID NO: 17;
• a GH39 polypeptide that comprises or consists of SEQ ID NO: 10, or which is a variant thereof having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity to SEQ ID NO: 10;
• a protease selected from: a) a polypeptide that comprises or consists of SEQ ID NO: 24 or SEQ ID NO: 26, or a variant thereof having at least 80%, at least 85%, at least 90% or at least 95% sequence identity to SEQ ID NO: 24 or SEQ ID NO: 26; b) a polypeptide that comprises SEQ ID NO: 24 with the substitutions Y161A, R164S and A188P; c) a polypeptide that comprises SEQ ID NO: 24 with the substitutions S9E, N42R, N74D, V199I, Q200L, Y203W, S253D, N255W and L256E; and d) a polypeptide that comprises SEQ ID NO: 37; and
• at least one enzyme selected from the group consisting of amylases, lipases, mannanases, pectate lyases and cellulases.
In one embodiment, the composition comprises:
• an RNase that comprises or consists of SEQ ID NO: 17;
• a GH39 polypeptide that comprises or consists of SEQ ID NO: 10;
• a protease that comprises SEQ ID NO: 24 with the substitutions Y161A, R164S and A188P, or that comprises SEQ ID NO: 37; and • at least one enzyme selected from the group consisting of amylases, lipases, mannanases, pectate lyases and cellulases; wherein:
o the amylase comprises SEQ ID NO: 30 with the mutations H183*, G184*, I405L, A421 H, A422P and A428T;
o the lipase comprises SEQ ID NO: 31 with the mutations D27R, G38A, D96E, D11 1A, G163K, T231 R, N233R, D254S and P256T; o the mannanase comprises SEQ ID NO: 32;
o the pectate lyase comprises SEQ ID NO: 33; and
o the cellulase comprises SEQ ID NO: 34 or SEQ ID NO: 35.
In one embodiment, the composition comprises:
• an RNase that comprises or consists of SEQ ID NO: 17;
• a GH39 polypeptide that comprises or consists of SEQ ID NO: 10;
• a protease that comprises SEQ ID NO: 24 with the substitutions S9E, N42R, N74D, V199I, Q200L, Y203W, S253D, N255W and L256E; and
• at least one enzyme selected from the group consisting of amylases and cellulases; wherein:
o the amylase comprises SEQ ID NO: 29 with the mutations H 1 *, N54S, V56T, K72R, G109A, F113Q, R116Q, W167F, Q172G, A174S, G182*, D183*, G184T, N195F, V206L, K391A, P473R and G476K; and o the cellulase comprises SEQ ID NO: 34.
In one embodiment, the composition comprises:
• an RNase that comprises or consists of SEQ ID NO: 17, or which is a variant thereof having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity to SEQ ID NO: 17;
• a GH39 polypeptide that comprises or consists of SEQ ID NO: 11 , or which is a variant thereof having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity to SEQ ID NO: 1 1 ;
• a protease selected from: a) a polypeptide that comprises or consists of SEQ ID NO: 24 or SEQ ID NO: 26, or a variant thereof having at least 80%, at least 85%, at least 90% or at least 95% sequence identity to SEQ ID NO: 24 or SEQ ID NO: 26; b) a polypeptide that comprises SEQ ID NO: 24 with the substitutions Y161A, R164S and A188P; c) a polypeptide that comprises SEQ ID NO: 24 with the substitutions S9E, N42R, N74D, V199I, Q200L, Y203W, S253D, N255W and L256E; and d) a polypeptide that comprises SEQ ID NO: 37; and • at least one enzyme selected from the group consisting of amylases, lipases, mannanases, pectate lyases and cellulases.
In one embodiment, the composition comprises:
• an RNase that comprises or consists of SEQ ID NO: 17;
• a GH39 polypeptide that comprises or consists of SEQ ID NO: 1 1 ;
• a protease that comprises SEQ ID NO: 24 with the substitutions Y161A, R164S and A188P, or that comprises SEQ ID NO: 37; and
• at least one enzyme selected from the group consisting of amylases, lipases, mannanases, pectate lyases and cellulases; wherein:
o the amylase comprises SEQ ID NO: 30 with the mutations H183*, G184*, I405L, A421 H, A422P and A428T;
o the lipase comprises SEQ ID NO: 31 with the mutations D27R, G38A, D96E, D11 1A, G163K, T231 R, N233R, D254S and P256T; o the mannanase comprises SEQ ID NO: 32;
o the pectate lyase comprises SEQ ID NO: 33; and
o the cellulase comprises SEQ ID NO: 34 or SEQ ID NO: 35.
In one embodiment, the composition comprises:
• an RNase that comprises or consists of SEQ ID NO: 17;
• a GH39 polypeptide that comprises or consists of SEQ ID NO: 1 1 ;
• a protease that comprises SEQ ID NO: 24 with the substitutions S9E, N42R, N74D, V199I, Q200L, Y203W, S253D, N255W and L256E; and
• at least one enzyme selected from the group consisting of amylases and cellulases; wherein:
o the amylase comprises SEQ ID NO: 29 with the mutations H 1 *, N54S, V56T, K72R, G109A, F113Q, R116Q, W167F, Q172G, A174S, G182*, D183*, G184T, N195F, V206L, K391A, P473R and G476K; and o the cellulase comprises SEQ ID NO: 34.
In one embodiment, the composition comprises:
• an RNase that comprises or consists of SEQ ID NO: 17, or which is a variant thereof having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity to SEQ ID NO: 17;
• a GH39 polypeptide that comprises or consists of SEQ ID NO: 12, or which is a variant thereof having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity to SEQ ID NO: 12; • a protease selected from: a) a polypeptide that comprises or consists of SEQ ID NO: 24 or SEQ ID NO: 26, or a variant thereof having at least 80%, at least 85%, at least 90% or at least 95% sequence identity to SEQ ID NO: 24 or SEQ ID NO: 26; b) a polypeptide that comprises SEQ ID NO: 24 with the substitutions Y161A, R164S and A188P; c) a polypeptide that comprises SEQ ID NO: 24 with the substitutions S9E, N42R, N74D, V199I, Q200L, Y203W, S253D, N255W and L256E; and d) a polypeptide that comprises SEQ ID NO: 37; and
• at least one enzyme selected from the group consisting of amylases, lipases, mannanases, pectate lyases and cellulases.
In one embodiment, the composition comprises:
• an RNase that comprises or consists of SEQ ID NO: 17;
• a GH39 polypeptide that comprises or consists of SEQ ID NO: 12;
• a protease that comprises SEQ ID NO: 24 with the substitutions Y161A, R164S and A188P, or that comprises SEQ ID NO: 37; and
• at least one enzyme selected from the group consisting of amylases, lipases, mannanases, pectate lyases and cellulases; wherein:
o the amylase comprises SEQ ID NO: 30 with the mutations H183*, G184*, I405L, A421 H, A422P and A428T;
o the lipase comprises SEQ ID NO: 31 with the mutations D27R, G38A, D96E, D11 1A, G163K, T231 R, N233R, D254S and P256T; o the mannanase comprises SEQ ID NO: 32;
o the pectate lyase comprises SEQ ID NO: 33; and
o the cellulase comprises SEQ ID NO: 34 or SEQ ID NO: 35.
In one embodiment, the composition comprises:
• an RNase that comprises or consists of SEQ ID NO: 17;
• a GH39 polypeptide that comprises or consists of SEQ ID NO: 12;
• a protease that comprises SEQ ID NO: 24 with the substitutions S9E, N42R, N74D, V199I, Q200L, Y203W, S253D, N255W and L256E; and
• at least one enzyme selected from the group consisting of amylases and cellulases; wherein:
o the amylase comprises SEQ ID NO: 29 with the mutations H 1 *, N54S, V56T, K72R, G109A, F113Q, R116Q, W167F, Q172G, A174S, G182*, D183*, G184T, N195F, V206L, K391A, P473R and G476K; and o the cellulase comprises SEQ ID NO: 34.
In one embodiment, the composition comprises: • an RNase that comprises or consists of SEQ ID NO: 18, or which is a variant thereof having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity to SEQ ID NO: 18;
• a GH39 polypeptide that comprises or consists of SEQ ID NO: 10, or which is a variant thereof having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity to SEQ ID NO: 10;
• a protease selected from: a) a polypeptide that comprises or consists of SEQ ID NO: 24 or SEQ ID NO: 26, or a variant thereof having at least 80%, at least 85%, at least 90% or at least 95% sequence identity to SEQ ID NO: 24 or SEQ ID NO: 26; b) a polypeptide that comprises SEQ ID NO: 24 with the substitutions Y161A, R164S and A188P; c) a polypeptide that comprises SEQ ID NO: 24 with the substitutions S9E, N42R, N74D, V199I, Q200L, Y203W, S253D, N255W and L256E; and d) a polypeptide that comprises SEQ ID NO: 37; and
• at least one enzyme selected from the group consisting of amylases, lipases, mannanases, pectate lyases and cellulases.
In one embodiment, the composition comprises:
• an RNase that comprises or consists of SEQ ID NO: 18;
• a GH39 polypeptide that comprises or consists of SEQ ID NO: 10;
• a protease that comprises SEQ ID NO: 24 with the substitutions Y161A, R164S and A188P, or that comprises SEQ ID NO: 37; and
• at least one enzyme selected from the group consisting of amylases, lipases, mannanases, pectate lyases and cellulases; wherein:
o the amylase comprises SEQ ID NO: 30 with the mutations H183*, G184*, I405L, A421 H, A422P and A428T;
o the lipase comprises SEQ ID NO: 31 with the mutations D27R, G38A, D96E, D11 1A, G163K, T231 R, N233R, D254S and P256T; o the mannanase comprises SEQ ID NO: 32;
o the pectate lyase comprises SEQ ID NO: 33; and
o the cellulase comprises SEQ ID NO: 34 or SEQ ID NO: 35.
In one embodiment, the composition comprises:
• an RNase that comprises or consists of SEQ ID NO: 18;
• a GH39 polypeptide that comprises or consists of SEQ ID NO: 10;
• a protease that comprises SEQ ID NO: 24 with the substitutions S9E, N42R, N74D, V199I, Q200L, Y203W, S253D, N255W and L256E; and • at least one enzyme selected from the group consisting of amylases and cellulases; wherein:
o the amylase comprises SEQ ID NO: 29 with the mutations H 1 *, N54S, V56T, K72R, G109A, F113Q, R116Q, W167F, Q172G, A174S, G182*, D183*, G184T, N195F, V206L, K391A, P473R and G476K; and o the cellulase comprises SEQ ID NO: 34.
In one embodiment, the composition comprises:
• an RNase that comprises or consists of SEQ ID NO: 18, or which is a variant thereof having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity to SEQ ID NO: 18;
• a GH39 polypeptide that comprises or consists of SEQ ID NO: 11 , or which is a variant thereof having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity to SEQ ID NO: 1 1 ;
• a protease selected from: a) a polypeptide that comprises or consists of SEQ ID NO: 24 or SEQ ID NO: 26, or a variant thereof having at least 80%, at least 85%, at least 90% or at least 95% sequence identity to SEQ ID NO: 24 or SEQ ID NO: 26; b) a polypeptide that comprises SEQ ID NO: 24 with the substitutions Y161A, R164S and A188P; c) a polypeptide that comprises SEQ ID NO: 24 with the substitutions S9E, N42R, N74D, V199I, Q200L, Y203W, S253D, N255W and L256E; and d) a polypeptide that comprises SEQ ID NO: 37; and
• at least one enzyme selected from the group consisting of amylases, lipases, mannanases, pectate lyases and cellulases.
In one embodiment, the composition comprises:
• an RNase that comprises or consists of SEQ ID NO: 18;
• a GH39 polypeptide that comprises or consists of SEQ ID NO: 1 1 ;
• a protease that comprises SEQ ID NO: 24 with the substitutions Y161A, R164S and A188P, or that comprises SEQ ID NO: 37; and
• at least one enzyme selected from the group consisting of amylases, lipases, mannanases, pectate lyases and cellulases; wherein:
o the amylase comprises SEQ ID NO: 30 with the mutations H183*, G184*, I405L, A421 H, A422P and A428T;
o the lipase comprises SEQ ID NO: 31 with the mutations D27R, G38A, D96E, D11 1A, G163K, T231 R, N233R, D254S and P256T; o the mannanase comprises SEQ ID NO: 32; o the pectate lyase comprises SEQ ID NO: 33; and
o the cellulase comprises SEQ ID NO: 34 or SEQ ID NO: 35.
In one embodiment, the composition comprises:
• an RNase that comprises or consists of SEQ ID NO: 18;
• a GH39 polypeptide that comprises or consists of SEQ ID NO: 1 1 ;
• a protease that comprises SEQ ID NO: 24 with the substitutions S9E, N42R, N74D, V199I, Q200L, Y203W, S253D, N255W and L256E; and
• at least one enzyme selected from the group consisting of amylases and cellulases; wherein:
o the amylase comprises SEQ ID NO: 29 with the mutations H 1 *, N54S, V56T, K72R, G109A, F113Q, R116Q, W167F, Q172G, A174S, G182*, D183*, G184T, N195F, V206L, K391A, P473R and G476K; and o the cellulase comprises SEQ ID NO: 34.
In one embodiment, the composition comprises:
• an RNase that comprises or consists of SEQ ID NO: 18, or which is a variant thereof having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity to SEQ ID NO: 18;
• a GH39 polypeptide that comprises or consists of SEQ ID NO: 12, or which is a variant thereof having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity to SEQ ID NO: 12;
• a protease selected from: a) a polypeptide that comprises or consists of SEQ ID NO: 24 or SEQ ID NO: 26, or a variant thereof having at least 80%, at least 85%, at least 90% or at least 95% sequence identity to SEQ ID NO: 24 or SEQ ID NO: 26; b) a polypeptide that comprises SEQ ID NO: 24 with the substitutions Y161A, R164S and A188P; c) a polypeptide that comprises SEQ ID NO: 24 with the substitutions S9E, N42R, N74D, V199I, Q200L, Y203W, S253D, N255W and L256E; and d) a polypeptide that comprises SEQ ID NO: 37; and
• at least one enzyme selected from the group consisting of amylases, lipases, mannanases, pectate lyases and cellulases.
In one embodiment, the composition comprises:
• an RNase that comprises or consists of SEQ ID NO: 18;
• a GH39 polypeptide that comprises or consists of SEQ ID NO: 12;
• a protease that comprises SEQ ID NO: 24 with the substitutions Y161A, R164S and A188P, or that comprises SEQ ID NO: 37; and • at least one enzyme selected from the group consisting of amylases, lipases, mannanases, pectate lyases and cellulases; wherein:
o the amylase comprises SEQ ID NO: 30 with the mutations H183*, G184*, I405L, A421 H, A422P and A428T;
o the lipase comprises SEQ ID NO: 31 with the mutations D27R, G38A, D96E, D11 1A, G163K, T231 R, N233R, D254S and P256T;
o the mannanase comprises SEQ ID NO: 32;
o the pectate lyase comprises SEQ ID NO: 33; and
o the cellulase comprises SEQ ID NO: 34 or SEQ ID NO: 35.
In one embodiment, the composition comprises:
• an RNase that comprises or consists of SEQ ID NO: 18;
• a GH39 polypeptide that comprises or consists of SEQ ID NO: 12;
• a protease that comprises SEQ ID NO: 24 with the substitutions S9E, N42R, N74D, V199I, Q200L, Y203W, S253D, N255W and L256E; and
• at least one enzyme selected from the group consisting of amylases and cellulases; wherein:
o the amylase comprises SEQ ID NO: 29 with the mutations H 1 *, N54S, V56T, K72R, G109A, F113Q, R116Q, W167F, Q172G, A174S, G182*, D183*, G184T, N195F, V206L, K391A, P473R and G476K; and o the cellulase comprises SEQ ID NO: 34.
In any of the embodiments described above comprising at least an RNase and a GH39 glycosyl hydrolase as the cleaning enzymes, the cleaning composition may optionally comprise one or more of any of the other cleaning enzymes described herein. Any of these compositions may thus comprise one or more of a DNase, a Glyco_hydro_1 14 glucosyl hydrolase, a GHL13 glycosyl hydrolase or a hexosaminidase.
Cleaning compositions comprising an RNase and a GHL13 polypeptide
One aspect of the invention relates to a cleaning composition comprising at least an RNase and a GHL13 glycosyl hydrolase as the cleaning enzymes. Exemplary embodiments of this aspect of the invention are described below.
In one embodiment, the composition comprises:
• an RNase that comprises or consists of SEQ ID NO: 16, or which is a variant thereof having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity to SEQ ID NO: 16; • a GHL13 polypeptide that comprises or consists of SEQ ID NO: 13, or which is a variant thereof having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity to SEQ ID NO: 13;
• a protease selected from: a) a polypeptide that comprises or consists of SEQ ID NO: 24 or SEQ ID NO: 26, or a variant thereof having at least 80%, at least 85%, at least 90% or at least 95% sequence identity to SEQ ID NO: 24 or SEQ ID NO: 26; b) a polypeptide that comprises SEQ ID NO: 24 with the substitutions Y161A, R164S and A188P; c) a polypeptide that comprises SEQ ID NO: 24 with the substitutions S9E, N42R, N74D, V199I, Q200L, Y203W, S253D, N255W and L256E; and d) a polypeptide that comprises SEQ ID NO: 37; and
• at least one enzyme selected from the group consisting of amylases, lipases, mannanases, pectate lyases and cellulases.
In one embodiment, the composition comprises:
• an RNase that comprises or consists of SEQ ID NO: 16;
• a GHL13 polypeptide that comprises or consists of SEQ ID NO: 13;
• a protease that comprises SEQ ID NO: 24 with the substitutions Y161A, R164S and A188P, or that comprises SEQ ID NO: 37; and
• at least one enzyme selected from the group consisting of amylases, lipases, mannanases, pectate lyases and cellulases; wherein:
o the amylase comprises SEQ ID NO: 30 with the mutations H183*, G184*, I405L, A421 H, A422P and A428T;
o the lipase comprises SEQ ID NO: 31 with the mutations D27R, G38A, D96E, D11 1A, G163K, T231 R, N233R, D254S and P256T; o the mannanase comprises SEQ ID NO: 32;
o the pectate lyase comprises SEQ ID NO: 33; and
o the cellulase comprises SEQ ID NO: 34 or SEQ ID NO: 35.
In one embodiment, the composition comprises:
• an RNase that comprises or consists of SEQ ID NO: 16;
• a GHL13 polypeptide that comprises or consists of SEQ ID NO: 13;
• a protease that comprises SEQ ID NO: 24 with the substitutions S9E, N42R, N74D, V199I, Q200L, Y203W, S253D, N255W and L256E; and
• at least one enzyme selected from the group consisting of amylases and cellulases; wherein:
o the amylase comprises SEQ ID NO: 29 with the mutations H 1 *, N54S, V56T, K72R, G109A, F113Q, R116Q, W167F, Q172G, A174S, G182*, D183*, G184T, N195F, V206L, K391A, P473R and G476K; and o the cellulase comprises SEQ ID NO: 34.
In one embodiment, the composition comprises:
• an RNase that comprises or consists of SEQ ID NO: 16, or which is a variant thereof having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity to SEQ ID NO: 16;
• a GHL13 polypeptide that comprises or consists of SEQ ID NO: 14, or which is a variant thereof having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity to SEQ ID NO: 14;
• a protease selected from: a) a polypeptide that comprises or consists of SEQ ID NO: 24 or SEQ ID NO: 26, or a variant thereof having at least 80%, at least 85%, at least 90% or at least 95% sequence identity to SEQ ID NO: 24 or SEQ ID NO: 26; b) a polypeptide that comprises SEQ ID NO: 24 with the substitutions Y161A, R164S and A188P; c) a polypeptide that comprises SEQ ID NO: 24 with the substitutions S9E, N42R, N74D, V199I, Q200L, Y203W, S253D, N255W and L256E; and d) a polypeptide that comprises SEQ ID NO: 37; and
• at least one enzyme selected from the group consisting of amylases, lipases, mannanases, pectate lyases and cellulases.
In one embodiment, the composition comprises:
• an RNase that comprises or consists of SEQ ID NO: 16;
• a GHL13 polypeptide that comprises or consists of SEQ ID NO: 14;
• a protease that comprises SEQ ID NO: 24 with the substitutions Y161A, R164S and A188P, or that comprises SEQ ID NO: 37; and
• at least one enzyme selected from the group consisting of amylases, lipases, mannanases, pectate lyases and cellulases; wherein:
o the amylase comprises SEQ ID NO: 30 with the mutations H183*, G184*, I405L, A421 H, A422P and A428T;
o the lipase comprises SEQ ID NO: 31 with the mutations D27R, G38A, D96E, D11 1A, G163K, T231 R, N233R, D254S and P256T; o the mannanase comprises SEQ ID NO: 32;
o the pectate lyase comprises SEQ ID NO: 33; and
o the cellulase comprises SEQ ID NO: 34 or SEQ ID NO: 35.
In one embodiment, the composition comprises:
• an RNase that comprises or consists of SEQ ID NO: 16;
• a GHL13 polypeptide that comprises or consists of SEQ ID NO: 14; • a protease that comprises SEQ ID NO: 24 with the substitutions S9E, N42R, N74D, V199I, Q200L, Y203W, S253D, N255W and L256E; and
• at least one enzyme selected from the group consisting of amylases and cellulases; wherein:
o the amylase comprises SEQ ID NO: 29 with the mutations H 1 *, N54S, V56T, K72R, G109A, F113Q, R116Q, W167F, Q172G, A174S, G182*, D183*, G184T, N195F, V206L, K391A, P473R and G476K; and o the cellulase comprises SEQ ID NO: 34.
In one embodiment, the composition comprises:
• an RNase that comprises or consists of SEQ ID NO: 16, or which is a variant thereof having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity to SEQ ID NO: 16;
• a GHL13 polypeptide that comprises or consists of SEQ ID NO: 15, or which is a variant thereof having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity to SEQ ID NO: 15;
• a protease selected from: a) a polypeptide that comprises or consists of SEQ ID NO: 24 or SEQ ID NO: 26, or a variant thereof having at least 80%, at least 85%, at least 90% or at least 95% sequence identity to SEQ ID NO: 24 or SEQ ID NO: 26; b) a polypeptide that comprises SEQ ID NO: 24 with the substitutions Y161A, R164S and A188P; c) a polypeptide that comprises SEQ ID NO: 24 with the substitutions S9E, N42R, N74D, V199I, Q200L, Y203W, S253D, N255W and L256E; and d) a polypeptide that comprises SEQ ID NO: 37; and
• at least one enzyme selected from the group consisting of amylases, lipases, mannanases, pectate lyases and cellulases.
In one embodiment, the composition comprises:
• an RNase that comprises or consists of SEQ ID NO: 16;
• a GHL13 polypeptide that comprises or consists of SEQ ID NO: 15;
• a protease that comprises SEQ ID NO: 24 with the substitutions Y161A, R164S and A188P, or that comprises SEQ ID NO: 37; and
• at least one enzyme selected from the group consisting of amylases, lipases, mannanases, pectate lyases and cellulases; wherein:
o the amylase comprises SEQ ID NO: 30 with the mutations H183*, G184*, I405L, A421 H, A422P and A428T; o the lipase comprises SEQ ID NO: 31 with the mutations D27R, G38A, D96E, D11 1A, G163K, T231 R, N233R, D254S and P256T; o the mannanase comprises SEQ ID NO: 32;
o the pectate lyase comprises SEQ ID NO: 33; and
o the cellulase comprises SEQ ID NO: 34 or SEQ ID NO: 35.
In one embodiment, the composition comprises:
• an RNase that comprises or consists of SEQ ID NO: 16;
• a GHL13 polypeptide that comprises or consists of SEQ ID NO: 15;
• a protease that comprises SEQ ID NO: 24 with the substitutions S9E, N42R, N74D, V199I, Q200L, Y203W, S253D, N255W and L256E; and
• at least one enzyme selected from the group consisting of amylases and cellulases; wherein:
o the amylase comprises SEQ ID NO: 29 with the mutations H 1 *, N54S, V56T, K72R, G109A, F113Q, R116Q, W167F, Q172G, A174S, G182*, D183*, G184T, N195F, V206L, K391A, P473R and G476K; and o the cellulase comprises SEQ ID NO: 34.
In one embodiment, the composition comprises:
• an RNase that comprises or consists of SEQ ID NO: 17, or which is a variant thereof having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity to SEQ ID NO: 17;
• a GHL13 polypeptide that comprises or consists of SEQ ID NO: 13, or which is a variant thereof having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity to SEQ ID NO: 13;
• a protease selected from: a) a polypeptide that comprises or consists of SEQ ID NO: 24 or SEQ ID NO: 26, or a variant thereof having at least 80%, at least 85%, at least 90% or at least 95% sequence identity to SEQ ID NO: 24 or SEQ ID NO: 26; b) a polypeptide that comprises SEQ ID NO: 24 with the substitutions Y161A, R164S and A188P; c) a polypeptide that comprises SEQ ID NO: 24 with the substitutions S9E, N42R, N74D, V199I, Q200L, Y203W, S253D, N255W and L256E; and d) a polypeptide that comprises SEQ ID NO: 37; and
• at least one enzyme selected from the group consisting of amylases, lipases, mannanases, pectate lyases and cellulases.
In one embodiment, the composition comprises:
• an RNase that comprises or consists of SEQ ID NO: 17; • a GHL13 polypeptide that comprises or consists of SEQ ID NO: 13;
• a protease that comprises SEQ ID NO: 24 with the substitutions Y161A, R164S and A188P, or that comprises SEQ ID NO: 37; and
• at least one enzyme selected from the group consisting of amylases, lipases, mannanases, pectate lyases and cellulases; wherein:
o the amylase comprises SEQ ID NO: 30 with the mutations H183*, G184*, I405L, A421 H, A422P and A428T;
o the lipase comprises SEQ ID NO: 31 with the mutations D27R, G38A, D96E, D11 1A, G163K, T231 R, N233R, D254S and P256T; o the mannanase comprises SEQ ID NO: 32;
o the pectate lyase comprises SEQ ID NO: 33; and
o the cellulase comprises SEQ ID NO: 34 or SEQ ID NO: 35.
In one embodiment, the composition comprises:
• an RNase that comprises or consists of SEQ ID NO: 17;
• a GHL13 polypeptide that comprises or consists of SEQ ID NO: 13;
• a protease that comprises SEQ ID NO: 24 with the substitutions S9E, N42R, N74D, V199I, Q200L, Y203W, S253D, N255W and L256E; and
• at least one enzyme selected from the group consisting of amylases and cellulases; wherein:
o the amylase comprises SEQ ID NO: 29 with the mutations H 1 *, N54S, V56T, K72R, G109A, F113Q, R116Q, W167F, Q172G, A174S, G182*, D183*, G184T, N195F, V206L, K391A, P473R and G476K; and o the cellulase comprises SEQ ID NO: 34.
In one embodiment, the composition comprises:
• an RNase that comprises or consists of SEQ ID NO: 17, or which is a variant thereof having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity to SEQ ID NO: 17;
• a GHL13 polypeptide that comprises or consists of SEQ ID NO: 14, or which is a variant thereof having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity to SEQ ID NO: 14;
• a protease selected from: a) a polypeptide that comprises or consists of SEQ ID NO: 24 or SEQ ID NO: 26, or a variant thereof having at least 80%, at least 85%, at least 90% or at least 95% sequence identity to SEQ ID NO: 24 or SEQ ID NO: 26; b) a polypeptide that comprises SEQ ID NO: 24 with the substitutions Y161A, R164S and A188P; c) a polypeptide that comprises SEQ ID NO: 24 with the substitutions S9E, N42R, N74D, V199I, Q200L, Y203W, S253D, N255W and L256E; and d) a polypeptide that comprises SEQ ID NO: 37; and
• at least one enzyme selected from the group consisting of amylases, lipases, mannanases, pectate lyases and cellulases.
In one embodiment, the composition comprises:
• an RNase that comprises or consists of SEQ ID NO: 17;
• a GHL13 polypeptide that comprises or consists of SEQ ID NO: 14;
• a protease that comprises SEQ ID NO: 24 with the substitutions Y161A, R164S and A188P, or that comprises SEQ ID NO: 37; and
• at least one enzyme selected from the group consisting of amylases, lipases, mannanases, pectate lyases and cellulases; wherein:
o the amylase comprises SEQ ID NO: 30 with the mutations H183*, G184*, I405L, A421 H, A422P and A428T;
o the lipase comprises SEQ ID NO: 31 with the mutations D27R, G38A, D96E, D11 1A, G163K, T231 R, N233R, D254S and P256T; o the mannanase comprises SEQ ID NO: 32;
o the pectate lyase comprises SEQ ID NO: 33; and
o the cellulase comprises SEQ ID NO: 34 or SEQ ID NO: 35.
In one embodiment, the composition comprises:
• an RNase that comprises or consists of SEQ ID NO: 17;
• a GHL13 polypeptide that comprises or consists of SEQ ID NO: 14;
• a protease that comprises SEQ ID NO: 24 with the substitutions S9E, N42R, N74D, V199I, Q200L, Y203W, S253D, N255W and L256E; and
• at least one enzyme selected from the group consisting of amylases and cellulases; wherein:
o the amylase comprises SEQ ID NO: 29 with the mutations H 1 *, N54S, V56T, K72R, G109A, F113Q, R116Q, W167F, Q172G, A174S, G182*, D183*, G184T, N195F, V206L, K391A, P473R and G476K; and o the cellulase comprises SEQ ID NO: 34.
In one embodiment, the composition comprises:
• an RNase that comprises or consists of SEQ ID NO: 17, or which is a variant thereof having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity to SEQ ID NO: 17; • a GHL13 polypeptide that comprises or consists of SEQ ID NO: 15, or which is a variant thereof having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity to SEQ ID NO: 15;
• a protease selected from: a) a polypeptide that comprises or consists of SEQ ID NO: 24 or SEQ ID NO: 26, or a variant thereof having at least 80%, at least 85%, at least 90% or at least 95% sequence identity to SEQ ID NO: 24 or SEQ ID NO: 26; b) a polypeptide that comprises SEQ ID NO: 24 with the substitutions Y161A, R164S and A188P; c) a polypeptide that comprises SEQ ID NO: 24 with the substitutions S9E, N42R, N74D, V199I, Q200L, Y203W, S253D, N255W and L256E; and d) a polypeptide that comprises SEQ ID NO: 37; and
• at least one enzyme selected from the group consisting of amylases, lipases, mannanases, pectate lyases and cellulases.
In one embodiment, the composition comprises:
• an RNase that comprises or consists of SEQ ID NO: 17;
• a GHL13 polypeptide that comprises or consists of SEQ ID NO: 15;
• a protease that comprises SEQ ID NO: 24 with the substitutions Y161A, R164S and A188P, or that comprises SEQ ID NO: 37; and
• at least one enzyme selected from the group consisting of amylases, lipases, mannanases, pectate lyases and cellulases; wherein:
o the amylase comprises SEQ ID NO: 30 with the mutations H183*, G184*, I405L, A421 H, A422P and A428T;
o the lipase comprises SEQ ID NO: 31 with the mutations D27R, G38A, D96E, D11 1A, G163K, T231 R, N233R, D254S and P256T; o the mannanase comprises SEQ ID NO: 32;
o the pectate lyase comprises SEQ ID NO: 33; and
o the cellulase comprises SEQ ID NO: 34 or SEQ ID NO: 35.
In one embodiment, the composition comprises:
• an RNase that comprises or consists of SEQ ID NO: 17;
• a GHL13 polypeptide that comprises or consists of SEQ ID NO: 15;
• a protease that comprises SEQ ID NO: 24 with the substitutions S9E, N42R, N74D, V199I, Q200L, Y203W, S253D, N255W and L256E; and
• at least one enzyme selected from the group consisting of amylases and cellulases; wherein:
o the amylase comprises SEQ ID NO: 29 with the mutations H 1 *, N54S, V56T, K72R, G109A, F113Q, R116Q, W167F, Q172G, A174S, G182*, D183*, G184T, N195F, V206L, K391A, P473R and G476K; and o the cellulase comprises SEQ ID NO: 34.
In one embodiment, the composition comprises:
• an RNase that comprises or consists of SEQ ID NO: 18, or which is a variant thereof having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity to SEQ ID NO: 18;
• a GHL13 polypeptide that comprises or consists of SEQ ID NO: 13, or which is a variant thereof having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity to SEQ ID NO: 13;
• a protease selected from: a) a polypeptide that comprises or consists of SEQ ID NO: 24 or SEQ ID NO: 26, or a variant thereof having at least 80%, at least 85%, at least 90% or at least 95% sequence identity to SEQ ID NO: 24 or SEQ ID NO: 26; b) a polypeptide that comprises SEQ ID NO: 24 with the substitutions Y161A, R164S and A188P; c) a polypeptide that comprises SEQ ID NO: 24 with the substitutions S9E, N42R, N74D, V199I, Q200L, Y203W, S253D, N255W and L256E; and d) a polypeptide that comprises SEQ ID NO: 37; and
• at least one enzyme selected from the group consisting of amylases, lipases, mannanases, pectate lyases and cellulases.
In one embodiment, the composition comprises:
• an RNase that comprises or consists of SEQ ID NO: 18;
• a GHL13 polypeptide that comprises or consists of SEQ ID NO: 13;
• a protease that comprises SEQ ID NO: 24 with the substitutions Y161A, R164S and A188P, or that comprises SEQ ID NO: 37; and
• at least one enzyme selected from the group consisting of amylases, lipases, mannanases, pectate lyases and cellulases; wherein:
o the amylase comprises SEQ ID NO: 30 with the mutations H183*, G184*, I405L, A421 H, A422P and A428T;
o the lipase comprises SEQ ID NO: 31 with the mutations D27R, G38A, D96E, D11 1A, G163K, T231 R, N233R, D254S and P256T; o the mannanase comprises SEQ ID NO: 32;
o the pectate lyase comprises SEQ ID NO: 33; and
o the cellulase comprises SEQ ID NO: 34 or SEQ ID NO: 35.
In one embodiment, the composition comprises:
• an RNase that comprises or consists of SEQ ID NO: 18;
• a GHL13 polypeptide that comprises or consists of SEQ ID NO: 13; • a protease that comprises SEQ ID NO: 24 with the substitutions S9E, N42R, N74D, V199I, Q200L, Y203W, S253D, N255W and L256E; and
• at least one enzyme selected from the group consisting of amylases and cellulases; wherein:
o the amylase comprises SEQ ID NO: 29 with the mutations H 1 *, N54S, V56T, K72R, G109A, F113Q, R116Q, W167F, Q172G, A174S, G182*, D183*, G184T, N195F, V206L, K391A, P473R and G476K; and o the cellulase comprises SEQ ID NO: 34.
In one embodiment, the composition comprises:
• an RNase that comprises or consists of SEQ ID NO: 18, or which is a variant thereof having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity to SEQ ID NO: 18;
• a GHL13 polypeptide that comprises or consists of SEQ ID NO: 14, or which is a variant thereof having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity to SEQ ID NO: 14;
• a protease selected from: a) a polypeptide that comprises or consists of SEQ ID NO: 24 or SEQ ID NO: 26, or a variant thereof having at least 80%, at least 85%, at least 90% or at least 95% sequence identity to SEQ ID NO: 24 or SEQ ID NO: 26; b) a polypeptide that comprises SEQ ID NO: 24 with the substitutions Y161A, R164S and A188P; c) a polypeptide that comprises SEQ ID NO: 24 with the substitutions S9E, N42R, N74D, V199I, Q200L, Y203W, S253D, N255W and L256E; and d) a polypeptide that comprises SEQ ID NO: 37; and
• at least one enzyme selected from the group consisting of amylases, lipases, mannanases, pectate lyases and cellulases.
In one embodiment, the composition comprises:
• an RNase that comprises or consists of SEQ ID NO: 18;
• a GHL13 polypeptide that comprises or consists of SEQ ID NO: 14;
• a protease that comprises SEQ ID NO: 24 with the substitutions Y161A, R164S and A188P, or that comprises SEQ ID NO: 37; and
• at least one enzyme selected from the group consisting of amylases, lipases, mannanases, pectate lyases and cellulases; wherein:
o the amylase comprises SEQ ID NO: 30 with the mutations H183*, G184*, I405L, A421 H, A422P and A428T; o the lipase comprises SEQ ID NO: 31 with the mutations D27R, G38A, D96E, D11 1A, G163K, T231 R, N233R, D254S and P256T; o the mannanase comprises SEQ ID NO: 32;
o the pectate lyase comprises SEQ ID NO: 33; and
o the cellulase comprises SEQ ID NO: 34 or SEQ ID NO: 35.
In one embodiment, the composition comprises:
• an RNase that comprises or consists of SEQ ID NO: 18;
• a GHL13 polypeptide that comprises or consists of SEQ ID NO: 14;
• a protease that comprises SEQ ID NO: 24 with the substitutions S9E, N42R, N74D, V199I, Q200L, Y203W, S253D, N255W and L256E; and
• at least one enzyme selected from the group consisting of amylases and cellulases; wherein:
o the amylase comprises SEQ ID NO: 29 with the mutations H 1 *, N54S, V56T, K72R, G109A, F113Q, R116Q, W167F, Q172G, A174S, G182*, D183*, G184T, N195F, V206L, K391A, P473R and G476K; and o the cellulase comprises SEQ ID NO: 34.
In one embodiment, the composition comprises:
• an RNase that comprises or consists of SEQ ID NO: 18, or which is a variant thereof having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity to SEQ ID NO: 18;
• a GHL13 polypeptide that comprises or consists of SEQ ID NO: 15, or which is a variant thereof having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity to SEQ ID NO: 15;
• a protease selected from: a) a polypeptide that comprises or consists of SEQ ID NO: 24 or SEQ ID NO: 26, or a variant thereof having at least 80%, at least 85%, at least 90% or at least 95% sequence identity to SEQ ID NO: 24 or SEQ ID NO: 26; b) a polypeptide that comprises SEQ ID NO: 24 with the substitutions Y161A, R164S and A188P; c) a polypeptide that comprises SEQ ID NO: 24 with the substitutions S9E, N42R, N74D, V199I, Q200L, Y203W, S253D, N255W and L256E; and d) a polypeptide that comprises SEQ ID NO: 37; and
• at least one enzyme selected from the group consisting of amylases, lipases, mannanases, pectate lyases and cellulases.
In one embodiment, the composition comprises:
• an RNase that comprises or consists of SEQ ID NO: 18; • a GHL13 polypeptide that comprises or consists of SEQ ID NO: 15;
• a protease that comprises SEQ ID NO: 24 with the substitutions Y161A, R164S and A188P, or that comprises SEQ ID NO: 37; and
• at least one enzyme selected from the group consisting of amylases, lipases, mannanases, pectate lyases and cellulases; wherein:
o the amylase comprises SEQ ID NO: 30 with the mutations H183*, G184*, I405L, A421 H, A422P and A428T;
o the lipase comprises SEQ ID NO: 31 with the mutations D27R, G38A, D96E, D1 1 1A, G163K, T231 R, N233R, D254S and P256T;
o the mannanase comprises SEQ ID NO: 32;
o the pectate lyase comprises SEQ ID NO: 33; and
o the cellulase comprises SEQ ID NO: 34 or SEQ ID NO: 35.
In one embodiment, the composition comprises:
• an RNase that comprises or consists of SEQ ID NO: 18;
• a GHL13 polypeptide that comprises or consists of SEQ ID NO: 15;
• a protease that comprises SEQ ID NO: 24 with the substitutions S9E, N42R, N74D, V199I, Q200L, Y203W, S253D, N255W and L256E; and
• at least one enzyme selected from the group consisting of amylases and cellulases; wherein:
o the amylase comprises SEQ ID NO: 29 with the mutations H 1 *, N54S, V56T, K72R, G109A, F1 13Q, R1 16Q, W167F, Q172G, A174S, G182*, D183*, G184T, N 195F, V206L, K391A, P473R and G476K; and o the cellulase comprises SEQ ID NO: 34.
In any of the embodiments described above comprising at least an RNase and a GHL13 glycosyl hydrolase as the cleaning enzymes, the cleaning composition may optionally comprise one or more of any of the other cleaning enzymes described herein. Any of these compositions may thus comprise one or more of a DNase, a Glyco_hydro_1 14 glucosyl hydrolase, a GH39 glycosyl hydrolase or a hexosaminidase.
Cleaning compositions comprising an RNase and a hexosaminidase
One aspect of the invention relates to a cleaning composition comprising at least an RNase and a hexosaminidase as the cleaning enzymes. Exemplary embodiments of this aspect of the invention are described below.
In one embodiment, the composition comprises: • an RNase that comprises or consists of SEQ ID NO: 16, or which is a variant thereof having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity to SEQ ID NO: 16;
• a hexosaminidase that comprises or consists of SEQ ID NO: 19, or which is a variant thereof having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity to SEQ ID NO: 19;
• a protease selected from: a) a polypeptide that comprises or consists of SEQ ID NO: 24 or SEQ ID NO: 26, or a variant thereof having at least 80%, at least 85%, at least 90% or at least 95% sequence identity to SEQ ID NO: 24 or SEQ ID NO: 26; b) a polypeptide that comprises SEQ ID NO: 24 with the substitutions Y161A, R164S and A188P; c) a polypeptide that comprises SEQ ID NO: 24 with the substitutions S9E, N42R, N74D, V199I, Q200L, Y203W, S253D, N255W and L256E; and d) a polypeptide that comprises SEQ ID NO: 37; and
• at least one enzyme selected from the group consisting of amylases, lipases, mannanases, pectate lyases and cellulases.
In one embodiment, the composition comprises:
• an RNase that comprises or consists of SEQ ID NO: 16;
• a hexosaminidase that comprises or consists of SEQ ID NO: 19;
• a protease that comprises SEQ ID NO: 24 with the substitutions Y161A, R164S and A188P, or that comprises SEQ ID NO: 37; and
• at least one enzyme selected from the group consisting of amylases, lipases, mannanases, pectate lyases and cellulases; wherein:
o the amylase comprises SEQ ID NO: 30 with the mutations H183*, G184*, I405L, A421 H, A422P and A428T;
o the lipase comprises SEQ ID NO: 31 with the mutations D27R, G38A, D96E, D11 1A, G163K, T231 R, N233R, D254S and P256T; o the mannanase comprises SEQ ID NO: 32;
o the pectate lyase comprises SEQ ID NO: 33; and
o the cellulase comprises SEQ ID NO: 34 or SEQ ID NO: 35.
In one embodiment, the composition comprises:
• an RNase that comprises or consists of SEQ ID NO: 16;
• a hexosaminidase that comprises or consists of SEQ ID NO: 19;
• a protease that comprises SEQ ID NO: 24 with the substitutions S9E, N42R, N74D, V199I, Q200L, Y203W, S253D, N255W and L256E; and • at least one enzyme selected from the group consisting of amylases and cellulases; wherein:
o the amylase comprises SEQ ID NO: 29 with the mutations H 1 *, N54S, V56T, K72R, G109A, F113Q, R116Q, W167F, Q172G, A174S, G182*, D183*, G184T, N195F, V206L, K391A, P473R and G476K; and o the cellulase comprises SEQ ID NO: 34.
In one embodiment, the composition comprises:
• an RNase that comprises or consists of SEQ ID NO: 16, or which is a variant thereof having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity to SEQ ID NO: 16;
• a hexosaminidase that comprises or consists of SEQ ID NO: 20, or which is a variant thereof having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity to SEQ ID NO: 20;
• a protease selected from: a) a polypeptide that comprises or consists of SEQ ID NO: 24 or SEQ ID NO: 26, or a variant thereof having at least 80%, at least 85%, at least 90% or at least 95% sequence identity to SEQ ID NO: 24 or SEQ ID NO: 26; b) a polypeptide that comprises SEQ ID NO: 24 with the substitutions Y161A, R164S and A188P; c) a polypeptide that comprises SEQ ID NO: 24 with the substitutions S9E, N42R, N74D, V199I, Q200L, Y203W, S253D, N255W and L256E; and d) a polypeptide that comprises SEQ ID NO: 37; and
• at least one enzyme selected from the group consisting of amylases, lipases, mannanases, pectate lyases and cellulases.
In one embodiment, the composition comprises:
• an RNase that comprises or consists of SEQ ID NO: 16;
• a hexosaminidase that comprises or consists of SEQ ID NO: 20;
• a protease that comprises SEQ ID NO: 24 with the substitutions Y161A, R164S and A188P, or that comprises SEQ ID NO: 37; and
• at least one enzyme selected from the group consisting of amylases, lipases, mannanases, pectate lyases and cellulases; wherein:
o the amylase comprises SEQ ID NO: 30 with the mutations H183*, G184*, I405L, A421 H, A422P and A428T;
o the lipase comprises SEQ ID NO: 31 with the mutations D27R, G38A, D96E, D11 1A, G163K, T231 R, N233R, D254S and P256T; o the mannanase comprises SEQ ID NO: 32; o the pectate lyase comprises SEQ ID NO: 33; and
o the cellulase comprises SEQ ID NO: 34 or SEQ ID NO: 35.
In one embodiment, the composition comprises:
• an RNase that comprises or consists of SEQ ID NO: 16;
• a hexosaminidase that comprises or consists of SEQ ID NO: 20;
• a protease that comprises SEQ ID NO: 24 with the substitutions S9E, N42R, N74D, V199I, Q200L, Y203W, S253D, N255W and L256E; and
• at least one enzyme selected from the group consisting of amylases and cellulases; wherein:
o the amylase comprises SEQ ID NO: 29 with the mutations H 1 *, N54S, V56T, K72R, G109A, F113Q, R116Q, W167F, Q172G, A174S, G182*, D183*, G184T, N195F, V206L, K391A, P473R and G476K; and o the cellulase comprises SEQ ID NO: 34.
In one embodiment, the composition comprises:
• an RNase that comprises or consists of SEQ ID NO: 16, or which is a variant thereof having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity to SEQ ID NO: 16;
• a hexosaminidase that comprises or consists of SEQ ID NO: 21 , or which is a variant thereof having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity to SEQ ID NO: 21 ;
• a protease selected from: a) a polypeptide that comprises or consists of SEQ ID NO: 24 or SEQ ID NO: 26, or a variant thereof having at least 80%, at least 85%, at least 90% or at least 95% sequence identity to SEQ ID NO: 24 or SEQ ID NO: 26; b) a polypeptide that comprises SEQ ID NO: 24 with the substitutions Y161A, R164S and A188P; c) a polypeptide that comprises SEQ ID NO: 24 with the substitutions S9E, N42R, N74D, V199I, Q200L, Y203W, S253D, N255W and L256E; and d) a polypeptide that comprises SEQ ID NO: 37; and
• at least one enzyme selected from the group consisting of amylases, lipases, mannanases, pectate lyases and cellulases.
In one embodiment, the composition comprises:
• an RNase that comprises or consists of SEQ ID NO: 16;
• a hexosaminidase that comprises or consists of SEQ ID NO: 21 ;
• a protease that comprises SEQ ID NO: 24 with the substitutions Y161A, R164S and A188P, or that comprises SEQ ID NO: 37; and • at least one enzyme selected from the group consisting of amylases, lipases, mannanases, pectate lyases and cellulases; wherein:
o the amylase comprises SEQ ID NO: 30 with the mutations H183*, G184*, I405L, A421 H, A422P and A428T;
o the lipase comprises SEQ ID NO: 31 with the mutations D27R, G38A, D96E, D11 1A, G163K, T231 R, N233R, D254S and P256T; o the mannanase comprises SEQ ID NO: 32;
o the pectate lyase comprises SEQ ID NO: 33; and
o the cellulase comprises SEQ ID NO: 34 or SEQ ID NO: 35.
In one embodiment, the composition comprises:
• an RNase that comprises or consists of SEQ ID NO: 16;
• a hexosaminidase that comprises or consists of SEQ ID NO: 21 ;
• a protease that comprises SEQ ID NO: 24 with the substitutions S9E, N42R, N74D, V199I, Q200L, Y203W, S253D, N255W and L256E; and
• at least one enzyme selected from the group consisting of amylases and cellulases; wherein:
o the amylase comprises SEQ ID NO: 29 with the mutations H 1 *, N54S, V56T, K72R, G109A, F113Q, R116Q, W167F, Q172G, A174S, G182*, D183*, G184T, N195F, V206L, K391A, P473R and G476K; and o the cellulase comprises SEQ ID NO: 34.
In one embodiment, the composition comprises:
• an RNase that comprises or consists of SEQ ID NO: 16, or which is a variant thereof having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity to SEQ ID NO: 16;
• a hexosaminidase that comprises or consists of SEQ ID NO: 22, or which is a variant thereof having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity to SEQ ID NO: 22;
• a protease selected from: a) a polypeptide that comprises or consists of SEQ ID NO: 24 or SEQ ID NO: 26, or a variant thereof having at least 80%, at least 85%, at least 90% or at least 95% sequence identity to SEQ ID NO: 24 or SEQ ID NO: 26; b) a polypeptide that comprises SEQ ID NO: 24 with the substitutions Y161A, R164S and A188P; c) a polypeptide that comprises SEQ ID NO: 24 with the substitutions S9E, N42R, N74D, V199I, Q200L, Y203W, S253D, N255W and L256E; and d) a polypeptide that comprises SEQ ID NO: 37; and • at least one enzyme selected from the group consisting of amylases, lipases, mannanases, pectate lyases and cellulases.
In one embodiment, the composition comprises:
• an RNase that comprises or consists of SEQ ID NO: 16;
• a hexosaminidase that comprises or consists of SEQ ID NO: 22;
• a protease that comprises SEQ ID NO: 24 with the substitutions Y161A, R164S and A188P, or that comprises SEQ ID NO: 37; and
• at least one enzyme selected from the group consisting of amylases, lipases, mannanases, pectate lyases and cellulases; wherein:
o the amylase comprises SEQ ID NO: 30 with the mutations H183*, G184*, I405L, A421 H, A422P and A428T;
o the lipase comprises SEQ ID NO: 31 with the mutations D27R, G38A, D96E, D11 1A, G163K, T231 R, N233R, D254S and P256T; o the mannanase comprises SEQ ID NO: 32;
o the pectate lyase comprises SEQ ID NO: 33; and
o the cellulase comprises SEQ ID NO: 34 or SEQ ID NO: 35.
In one embodiment, the composition comprises:
• an RNase that comprises or consists of SEQ ID NO: 16;
• a hexosaminidase that comprises or consists of SEQ ID NO: 22;
• a protease that comprises SEQ ID NO: 24 with the substitutions S9E, N42R, N74D, V199I, Q200L, Y203W, S253D, N255W and L256E; and
• at least one enzyme selected from the group consisting of amylases and cellulases; wherein:
o the amylase comprises SEQ ID NO: 29 with the mutations H 1 *, N54S, V56T, K72R, G109A, F113Q, R116Q, W167F, Q172G, A174S, G182*, D183*, G184T, N195F, V206L, K391A, P473R and G476K; and o the cellulase comprises SEQ ID NO: 34.
In one embodiment, the composition comprises:
• an RNase that comprises or consists of SEQ ID NO: 16, or which is a variant thereof having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity to SEQ ID NO: 16;
• a hexosaminidase that comprises or consists of SEQ ID NO: 23, or which is a variant thereof having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity to SEQ ID NO: 23; • a protease selected from: a) a polypeptide that comprises or consists of SEQ ID NO: 24 or SEQ ID NO: 26, or a variant thereof having at least 80%, at least 85%, at least 90% or at least 95% sequence identity to SEQ ID NO: 24 or SEQ ID NO: 26; b) a polypeptide that comprises SEQ ID NO: 24 with the substitutions Y161A, R164S and A188P; c) a polypeptide that comprises SEQ ID NO: 24 with the substitutions S9E, N42R, N74D, V199I, Q200L, Y203W, S253D, N255W and L256E; and d) a polypeptide that comprises SEQ ID NO: 37; and
• at least one enzyme selected from the group consisting of amylases, lipases, mannanases, pectate lyases and cellulases.
In one embodiment, the composition comprises:
• an RNase that comprises or consists of SEQ ID NO: 16;
• a hexosaminidase that comprises or consists of SEQ ID NO: 23;
• a protease that comprises SEQ ID NO: 24 with the substitutions Y161A, R164S and A188P, or that comprises SEQ ID NO: 37; and
• at least one enzyme selected from the group consisting of amylases, lipases, mannanases, pectate lyases and cellulases; wherein:
o the amylase comprises SEQ ID NO: 30 with the mutations H183*, G184*, I405L, A421 H, A422P and A428T;
o the lipase comprises SEQ ID NO: 31 with the mutations D27R, G38A, D96E, D11 1A, G163K, T231 R, N233R, D254S and P256T; o the mannanase comprises SEQ ID NO: 32;
o the pectate lyase comprises SEQ ID NO: 33; and
o the cellulase comprises SEQ ID NO: 34 or SEQ ID NO: 35.
In one embodiment, the composition comprises:
• an RNase that comprises or consists of SEQ ID NO: 16;
• a hexosaminidase that comprises or consists of SEQ ID NO: 23;
• a protease that comprises SEQ ID NO: 24 with the substitutions S9E, N42R, N74D, V199I, Q200L, Y203W, S253D, N255W and L256E; and
• at least one enzyme selected from the group consisting of amylases and cellulases; wherein:
o the amylase comprises SEQ ID NO: 29 with the mutations H 1 *, N54S, V56T, K72R, G109A, F113Q, R116Q, W167F, Q172G, A174S, G182*, D183*, G184T, N195F, V206L, K391A, P473R and G476K; and o the cellulase comprises SEQ ID NO: 34.
In one embodiment, the composition comprises: • an RNase that comprises or consists of SEQ ID NO: 17, or which is a variant thereof having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity to SEQ ID NO: 17;
• a hexosaminidase that comprises or consists of SEQ ID NO: 19, or which is a variant thereof having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity to SEQ ID NO: 19;
• a protease selected from: a) a polypeptide that comprises or consists of SEQ ID NO: 24 or SEQ ID NO: 26, or a variant thereof having at least 80%, at least 85%, at least 90% or at least 95% sequence identity to SEQ ID NO: 24 or SEQ ID NO: 26; b) a polypeptide that comprises SEQ ID NO: 24 with the substitutions Y161A, R164S and A188P; c) a polypeptide that comprises SEQ ID NO: 24 with the substitutions S9E, N42R, N74D, V199I, Q200L, Y203W, S253D, N255W and L256E; and d) a polypeptide that comprises SEQ ID NO: 37; and
• at least one enzyme selected from the group consisting of amylases, lipases, mannanases, pectate lyases and cellulases.
In one embodiment, the composition comprises:
• an RNase that comprises or consists of SEQ ID NO: 17;
• a hexosaminidase that comprises or consists of SEQ ID NO: 19;
• a protease that comprises SEQ ID NO: 24 with the substitutions Y161A, R164S and A188P, or that comprises SEQ ID NO: 37; and
• at least one enzyme selected from the group consisting of amylases, lipases, mannanases, pectate lyases and cellulases; wherein:
o the amylase comprises SEQ ID NO: 30 with the mutations H183*, G184*, I405L, A421 H, A422P and A428T;
o the lipase comprises SEQ ID NO: 31 with the mutations D27R, G38A, D96E, D11 1A, G163K, T231 R, N233R, D254S and P256T; o the mannanase comprises SEQ ID NO: 32;
o the pectate lyase comprises SEQ ID NO: 33; and
o the cellulase comprises SEQ ID NO: 34 or SEQ ID NO: 35.
In one embodiment, the composition comprises:
• an RNase that comprises or consists of SEQ ID NO: 17;
• a hexosaminidase that comprises or consists of SEQ ID NO: 19;
• a protease that comprises SEQ ID NO: 24 with the substitutions S9E, N42R, N74D, V199I, Q200L, Y203W, S253D, N255W and L256E; and • at least one enzyme selected from the group consisting of amylases and cellulases; wherein:
o the amylase comprises SEQ ID NO: 29 with the mutations H 1 *, N54S, V56T, K72R, G109A, F113Q, R116Q, W167F, Q172G, A174S, G182*, D183*, G184T, N195F, V206L, K391A, P473R and G476K; and o the cellulase comprises SEQ ID NO: 34.
In one embodiment, the composition comprises:
• an RNase that comprises or consists of SEQ ID NO: 17, or which is a variant thereof having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity to SEQ ID NO: 17;
• a hexosaminidase that comprises or consists of SEQ ID NO: 20, or which is a variant thereof having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity to SEQ ID NO: 20;
• a protease selected from: a) a polypeptide that comprises or consists of SEQ ID NO: 24 or SEQ ID NO: 26, or a variant thereof having at least 80%, at least 85%, at least 90% or at least 95% sequence identity to SEQ ID NO: 24 or SEQ ID NO: 26; b) a polypeptide that comprises SEQ ID NO: 24 with the substitutions Y161A, R164S and A188P; c) a polypeptide that comprises SEQ ID NO: 24 with the substitutions S9E, N42R, N74D, V199I, Q200L, Y203W, S253D, N255W and L256E; and d) a polypeptide that comprises SEQ ID NO: 37; and
• at least one enzyme selected from the group consisting of amylases, lipases, mannanases, pectate lyases and cellulases.
In one embodiment, the composition comprises:
• an RNase that comprises or consists of SEQ ID NO: 17;
• a hexosaminidase that comprises or consists of SEQ ID NO: 20;
• a protease that comprises SEQ ID NO: 24 with the substitutions Y161A, R164S and A188P, or that comprises SEQ ID NO: 37; and
• at least one enzyme selected from the group consisting of amylases, lipases, mannanases, pectate lyases and cellulases; wherein:
o the amylase comprises SEQ ID NO: 30 with the mutations H183*, G184*, I405L, A421 H, A422P and A428T;
o the lipase comprises SEQ ID NO: 31 with the mutations D27R, G38A, D96E, D11 1A, G163K, T231 R, N233R, D254S and P256T; o the mannanase comprises SEQ ID NO: 32; o the pectate lyase comprises SEQ ID NO: 33; and
o the cellulase comprises SEQ ID NO: 34 or SEQ ID NO: 35.
In one embodiment, the composition comprises:
• an RNase that comprises or consists of SEQ ID NO: 17;
• a hexosaminidase that comprises or consists of SEQ ID NO: 20;
• a protease that comprises SEQ ID NO: 24 with the substitutions S9E, N42R, N74D, V199I, Q200L, Y203W, S253D, N255W and L256E; and
• at least one enzyme selected from the group consisting of amylases and cellulases; wherein:
o the amylase comprises SEQ ID NO: 29 with the mutations H 1 *, N54S, V56T, K72R, G109A, F113Q, R1 16Q, W167F, Q172G, A174S, G182*, D183*, G184T, N195F, V206L, K391A, P473R and G476K; and o the cellulase comprises SEQ ID NO: 34.
In one embodiment, the composition comprises:
• an RNase that comprises or consists of SEQ ID NO: 17, or which is a variant thereof having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity to SEQ ID NO: 17;
• a hexosaminidase that comprises or consists of SEQ ID NO: 21 , or which is a variant thereof having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity to SEQ ID NO: 21 ;
• a protease selected from: a) a polypeptide that comprises or consists of SEQ ID NO: 24 or SEQ ID NO: 26, or a variant thereof having at least 80%, at least 85%, at least 90% or at least 95% sequence identity to SEQ ID NO: 24 or SEQ ID NO: 26; b) a polypeptide that comprises SEQ ID NO: 24 with the substitutions Y161A, R164S and A188P; c) a polypeptide that comprises SEQ ID NO: 24 with the substitutions S9E, N42R, N74D, V199I, Q200L, Y203W, S253D, N255W and L256E; and d) a polypeptide that comprises SEQ ID NO: 37; and
• at least one enzyme selected from the group consisting of amylases, lipases, mannanases, pectate lyases and cellulases.
In one embodiment, the composition comprises:
• an RNase that comprises or consists of SEQ ID NO: 17;
• a hexosaminidase that comprises or consists of SEQ ID NO: 21 ;
• a protease that comprises SEQ ID NO: 24 with the substitutions Y161A, R164S and A188P, or that comprises SEQ ID NO: 37; and • at least one enzyme selected from the group consisting of amylases, lipases, mannanases, pectate lyases and cellulases; wherein:
o the amylase comprises SEQ ID NO: 30 with the mutations H183*, G184*, I405L, A421 H, A422P and A428T;
o the lipase comprises SEQ ID NO: 31 with the mutations D27R, G38A, D96E, D11 1A, G163K, T231 R, N233R, D254S and P256T; o the mannanase comprises SEQ ID NO: 32;
o the pectate lyase comprises SEQ ID NO: 33; and
o the cellulase comprises SEQ ID NO: 34 or SEQ ID NO: 35.
In one embodiment, the composition comprises:
• an RNase that comprises or consists of SEQ ID NO: 17;
• a hexosaminidase that comprises or consists of SEQ ID NO: 21 ;
• a protease that comprises SEQ ID NO: 24 with the substitutions S9E, N42R, N74D, V199I, Q200L, Y203W, S253D, N255W and L256E; and
• at least one enzyme selected from the group consisting of amylases and cellulases; wherein:
o the amylase comprises SEQ ID NO: 29 with the mutations H 1 *, N54S, V56T, K72R, G109A, F113Q, R116Q, W167F, Q172G, A174S, G182*, D183*, G184T, N195F, V206L, K391A, P473R and G476K; and o the cellulase comprises SEQ ID NO: 34.
In one embodiment, the composition comprises:
• an RNase that comprises or consists of SEQ ID NO: 17, or which is a variant thereof having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity to SEQ ID NO: 17;
• a hexosaminidase that comprises or consists of SEQ ID NO: 22, or which is a variant thereof having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity to SEQ ID NO: 22;
• a protease selected from: a) a polypeptide that comprises or consists of SEQ ID NO: 24 or SEQ ID NO: 26, or a variant thereof having at least 80%, at least 85%, at least 90% or at least 95% sequence identity to SEQ ID NO: 24 or SEQ ID NO: 26; b) a polypeptide that comprises SEQ ID NO: 24 with the substitutions Y161A, R164S and A188P; c) a polypeptide that comprises SEQ ID NO: 24 with the substitutions S9E, N42R, N74D, V199I, Q200L, Y203W, S253D, N255W and L256E; and d) a polypeptide that comprises SEQ ID NO: 37; and • at least one enzyme selected from the group consisting of amylases, lipases, mannanases, pectate lyases and cellulases.
In one embodiment, the composition comprises:
• an RNase that comprises or consists of SEQ ID NO: 17;
• a hexosaminidase that comprises or consists of SEQ ID NO: 22;
• a protease that comprises SEQ ID NO: 24 with the substitutions Y161A, R164S and A188P, or that comprises SEQ ID NO: 37; and
• at least one enzyme selected from the group consisting of amylases, lipases, mannanases, pectate lyases and cellulases; wherein:
o the amylase comprises SEQ ID NO: 30 with the mutations H183*, G184*, I405L, A421 H, A422P and A428T;
o the lipase comprises SEQ ID NO: 31 with the mutations D27R, G38A, D96E, D11 1A, G163K, T231 R, N233R, D254S and P256T; o the mannanase comprises SEQ ID NO: 32;
o the pectate lyase comprises SEQ ID NO: 33; and
o the cellulase comprises SEQ ID NO: 34 or SEQ ID NO: 35.
In one embodiment, the composition comprises:
• an RNase that comprises or consists of SEQ ID NO: 17;
• a hexosaminidase that comprises or consists of SEQ ID NO: 22;
• a protease that comprises SEQ ID NO: 24 with the substitutions S9E, N42R, N74D, V199I, Q200L, Y203W, S253D, N255W and L256E; and
• at least one enzyme selected from the group consisting of amylases and cellulases; wherein:
o the amylase comprises SEQ ID NO: 29 with the mutations H 1 *, N54S, V56T, K72R, G109A, F113Q, R116Q, W167F, Q172G, A174S, G182*, D183*, G184T, N195F, V206L, K391A, P473R and G476K; and o the cellulase comprises SEQ ID NO: 34.
In one embodiment, the composition comprises:
• an RNase that comprises or consists of SEQ ID NO: 17, or which is a variant thereof having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity to SEQ ID NO: 17;
• a hexosaminidase that comprises or consists of SEQ ID NO: 23, or which is a variant thereof having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity to SEQ ID NO: 23; • a protease selected from: a) a polypeptide that comprises or consists of SEQ ID NO: 24 or SEQ ID NO: 26, or a variant thereof having at least 80%, at least 85%, at least 90% or at least 95% sequence identity to SEQ ID NO: 24 or SEQ ID NO: 26; b) a polypeptide that comprises SEQ ID NO: 24 with the substitutions Y161A, R164S and A188P; c) a polypeptide that comprises SEQ ID NO: 24 with the substitutions S9E, N42R, N74D, V199I, Q200L, Y203W, S253D, N255W and L256E; and d) a polypeptide that comprises SEQ ID NO: 37; and
• at least one enzyme selected from the group consisting of amylases, lipases, mannanases, pectate lyases and cellulases.
In one embodiment, the composition comprises:
• an RNase that comprises or consists of SEQ ID NO: 17;
• a hexosaminidase that comprises or consists of SEQ ID NO: 23;
• a protease that comprises SEQ ID NO: 24 with the substitutions Y161A, R164S and A188P, or that comprises SEQ ID NO: 37; and
• at least one enzyme selected from the group consisting of amylases, lipases, mannanases, pectate lyases and cellulases; wherein:
o the amylase comprises SEQ ID NO: 30 with the mutations H183*, G184*, I405L, A421 H, A422P and A428T;
o the lipase comprises SEQ ID NO: 31 with the mutations D27R, G38A, D96E, D11 1A, G163K, T231 R, N233R, D254S and P256T; o the mannanase comprises SEQ ID NO: 32;
o the pectate lyase comprises SEQ ID NO: 33; and
o the cellulase comprises SEQ ID NO: 34 or SEQ ID NO: 35.
In one embodiment, the composition comprises:
• an RNase that comprises or consists of SEQ ID NO: 17;
• a hexosaminidase that comprises or consists of SEQ ID NO: 23;
• a protease that comprises SEQ ID NO: 24 with the substitutions S9E, N42R, N74D, V199I, Q200L, Y203W, S253D, N255W and L256E; and
• at least one enzyme selected from the group consisting of amylases and cellulases; wherein:
o the amylase comprises SEQ ID NO: 29 with the mutations H 1 *, N54S, V56T, K72R, G109A, F113Q, R116Q, W167F, Q172G, A174S, G182*, D183*, G184T, N195F, V206L, K391A, P473R and G476K; and o the cellulase comprises SEQ ID NO: 34.
In one embodiment, the composition comprises: • an RNase that comprises or consists of SEQ ID NO: 18, or which is a variant thereof having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity to SEQ ID NO: 18;
• a hexosaminidase that comprises or consists of SEQ ID NO: 19, or which is a variant thereof having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity to SEQ ID NO: 19;
• a protease selected from: a) a polypeptide that comprises or consists of SEQ ID NO: 24 or SEQ ID NO: 26, or a variant thereof having at least 80%, at least 85%, at least 90% or at least 95% sequence identity to SEQ ID NO: 24 or SEQ ID NO: 26; b) a polypeptide that comprises SEQ ID NO: 24 with the substitutions Y161A, R164S and A188P; c) a polypeptide that comprises SEQ ID NO: 24 with the substitutions S9E, N42R, N74D, V199I, Q200L, Y203W, S253D, N255W and L256E; and d) a polypeptide that comprises SEQ ID NO: 37; and
• at least one enzyme selected from the group consisting of amylases, lipases, mannanases, pectate lyases and cellulases.
In one embodiment, the composition comprises:
• an RNase that comprises or consists of SEQ ID NO: 18;
• a hexosaminidase that comprises or consists of SEQ ID NO: 19;
• a protease that comprises SEQ ID NO: 24 with the substitutions Y161A, R164S and A188P, or that comprises SEQ ID NO: 37; and
• at least one enzyme selected from the group consisting of amylases, lipases, mannanases, pectate lyases and cellulases; wherein:
o the amylase comprises SEQ ID NO: 30 with the mutations H183*, G184*, I405L, A421 H, A422P and A428T;
o the lipase comprises SEQ ID NO: 31 with the mutations D27R, G38A, D96E, D11 1A, G163K, T231 R, N233R, D254S and P256T; o the mannanase comprises SEQ ID NO: 32;
o the pectate lyase comprises SEQ ID NO: 33; and
o the cellulase comprises SEQ ID NO: 34 or SEQ ID NO: 35.
In one embodiment, the composition comprises:
• an RNase that comprises or consists of SEQ ID NO: 18;
• a hexosaminidase that comprises or consists of SEQ ID NO: 19;
• a protease that comprises SEQ ID NO: 24 with the substitutions S9E, N42R, N74D, V199I, Q200L, Y203W, S253D, N255W and L256E; and • at least one enzyme selected from the group consisting of amylases and cellulases; wherein:
o the amylase comprises SEQ ID NO: 29 with the mutations H 1 *, N54S, V56T, K72R, G109A, F113Q, R116Q, W167F, Q172G, A174S, G182*, D183*, G184T, N195F, V206L, K391A, P473R and G476K; and o the cellulase comprises SEQ ID NO: 34.
In one embodiment, the composition comprises:
• an RNase that comprises or consists of SEQ ID NO: 18, or which is a variant thereof having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity to SEQ ID NO: 18;
• a hexosaminidase that comprises or consists of SEQ ID NO: 20, or which is a variant thereof having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity to SEQ ID NO: 20;
• a protease selected from: a) a polypeptide that comprises or consists of SEQ ID NO: 24 or SEQ ID NO: 26, or a variant thereof having at least 80%, at least 85%, at least 90% or at least 95% sequence identity to SEQ ID NO: 24 or SEQ ID NO: 26; b) a polypeptide that comprises SEQ ID NO: 24 with the substitutions Y161A, R164S and A188P; c) a polypeptide that comprises SEQ ID NO: 24 with the substitutions S9E, N42R, N74D, V199I, Q200L, Y203W, S253D, N255W and L256E; and d) a polypeptide that comprises SEQ ID NO: 37; and
• at least one enzyme selected from the group consisting of amylases, lipases, mannanases, pectate lyases and cellulases.
In one embodiment, the composition comprises:
• an RNase that comprises or consists of SEQ ID NO: 18;
• a hexosaminidase that comprises or consists of SEQ ID NO: 20;
• a protease that comprises SEQ ID NO: 24 with the substitutions Y161A, R164S and A188P, or that comprises SEQ ID NO: 37; and
• at least one enzyme selected from the group consisting of amylases, lipases, mannanases, pectate lyases and cellulases; wherein:
o the amylase comprises SEQ ID NO: 30 with the mutations H183*, G184*, I405L, A421 H, A422P and A428T;
o the lipase comprises SEQ ID NO: 31 with the mutations D27R, G38A, D96E, D11 1A, G163K, T231 R, N233R, D254S and P256T; o the mannanase comprises SEQ ID NO: 32; o the pectate lyase comprises SEQ ID NO: 33; and
o the cellulase comprises SEQ ID NO: 34 or SEQ ID NO: 35.
In one embodiment, the composition comprises:
• an RNase that comprises or consists of SEQ ID NO: 18;
• a hexosaminidase that comprises or consists of SEQ ID NO: 20;
• a protease that comprises SEQ ID NO: 24 with the substitutions S9E, N42R, N74D, V199I, Q200L, Y203W, S253D, N255W and L256E; and
• at least one enzyme selected from the group consisting of amylases and cellulases; wherein:
o the amylase comprises SEQ ID NO: 29 with the mutations H 1 *, N54S, V56T, K72R, G109A, F113Q, R116Q, W167F, Q172G, A174S, G182*, D183*, G184T, N195F, V206L, K391A, P473R and G476K; and o the cellulase comprises SEQ ID NO: 34.
In one embodiment, the composition comprises:
• an RNase that comprises or consists of SEQ ID NO: 18, or which is a variant thereof having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity to SEQ ID NO: 18;
• a hexosaminidase that comprises or consists of SEQ ID NO: 21 , or which is a variant thereof having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity to SEQ ID NO: 21 ;
• a protease selected from: a) a polypeptide that comprises or consists of SEQ ID NO: 24 or SEQ ID NO: 26, or a variant thereof having at least 80%, at least 85%, at least 90% or at least 95% sequence identity to SEQ ID NO: 24 or SEQ ID NO: 26; b) a polypeptide that comprises SEQ ID NO: 24 with the substitutions Y161A, R164S and A188P; c) a polypeptide that comprises SEQ ID NO: 24 with the substitutions S9E, N42R, N74D, V199I, Q200L, Y203W, S253D, N255W and L256E; and d) a polypeptide that comprises SEQ ID NO: 37; and
• at least one enzyme selected from the group consisting of amylases, lipases, mannanases, pectate lyases and cellulases.
In one embodiment, the composition comprises:
• an RNase that comprises or consists of SEQ ID NO: 18;
• a hexosaminidase that comprises or consists of SEQ ID NO: 21 ;
• a protease that comprises SEQ ID NO: 24 with the substitutions Y161A, R164S and A188P, or that comprises SEQ ID NO: 37; and • at least one enzyme selected from the group consisting of amylases, lipases, mannanases, pectate lyases and cellulases; wherein:
o the amylase comprises SEQ ID NO: 30 with the mutations H183*, G184*, I405L, A421 H, A422P and A428T;
o the lipase comprises SEQ ID NO: 31 with the mutations D27R, G38A, D96E, D11 1A, G163K, T231 R, N233R, D254S and P256T; o the mannanase comprises SEQ ID NO: 32;
o the pectate lyase comprises SEQ ID NO: 33; and
o the cellulase comprises SEQ ID NO: 34 or SEQ ID NO: 35.
In one embodiment, the composition comprises:
• an RNase that comprises or consists of SEQ ID NO: 18;
• a hexosaminidase that comprises or consists of SEQ ID NO: 21 ;
• a protease that comprises SEQ ID NO: 24 with the substitutions S9E, N42R, N74D, V199I, Q200L, Y203W, S253D, N255W and L256E; and
• at least one enzyme selected from the group consisting of amylases and cellulases; wherein:
o the amylase comprises SEQ ID NO: 29 with the mutations H 1 *, N54S, V56T, K72R, G109A, F113Q, R116Q, W167F, Q172G, A174S, G182*, D183*, G184T, N195F, V206L, K391A, P473R and G476K; and o the cellulase comprises SEQ ID NO: 34.
In one embodiment, the composition comprises:
• an RNase that comprises or consists of SEQ ID NO: 18, or which is a variant thereof having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity to SEQ ID NO: 18;
• a hexosaminidase that comprises or consists of SEQ ID NO: 22, or which is a variant thereof having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity to SEQ ID NO: 22;
• a protease selected from: a) a polypeptide that comprises or consists of SEQ ID NO: 24 or SEQ ID NO: 26, or a variant thereof having at least 80%, at least 85%, at least 90% or at least 95% sequence identity to SEQ ID NO: 24 or SEQ ID NO: 26; b) a polypeptide that comprises SEQ ID NO: 24 with the substitutions Y161A, R164S and A188P; c) a polypeptide that comprises SEQ ID NO: 24 with the substitutions S9E, N42R, N74D, V199I, Q200L, Y203W, S253D, N255W and L256E; and d) a polypeptide that comprises SEQ ID NO: 37; and • at least one enzyme selected from the group consisting of amylases, lipases, mannanases, pectate lyases and cellulases.
In one embodiment, the composition comprises:
• an RNase that comprises or consists of SEQ ID NO: 18;
• a hexosaminidase that comprises or consists of SEQ ID NO: 22;
• a protease that comprises SEQ ID NO: 24 with the substitutions Y161A, R164S and A188P, or that comprises SEQ ID NO: 37; and
• at least one enzyme selected from the group consisting of amylases, lipases, mannanases, pectate lyases and cellulases; wherein:
o the amylase comprises SEQ ID NO: 30 with the mutations H183*, G184*, I405L, A421 H, A422P and A428T;
o the lipase comprises SEQ ID NO: 31 with the mutations D27R, G38A, D96E, D11 1A, G163K, T231 R, N233R, D254S and P256T; o the mannanase comprises SEQ ID NO: 32;
o the pectate lyase comprises SEQ ID NO: 33; and
o the cellulase comprises SEQ ID NO: 34 or SEQ ID NO: 35.
In one embodiment, the composition comprises:
• an RNase that comprises or consists of SEQ ID NO: 18;
• a hexosaminidase that comprises or consists of SEQ ID NO: 22;
• a protease that comprises SEQ ID NO: 24 with the substitutions S9E, N42R, N74D, V199I, Q200L, Y203W, S253D, N255W and L256E; and
• at least one enzyme selected from the group consisting of amylases and cellulases; wherein:
o the amylase comprises SEQ ID NO: 29 with the mutations H 1 *, N54S, V56T, K72R, G109A, F113Q, R116Q, W167F, Q172G, A174S, G182*, D183*, G184T, N195F, V206L, K391A, P473R and G476K; and o the cellulase comprises SEQ ID NO: 34.
In one embodiment, the composition comprises:
• an RNase that comprises or consists of SEQ ID NO: 18, or which is a variant thereof having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity to SEQ ID NO: 18;
• a hexosaminidase that comprises or consists of SEQ ID NO: 23, or which is a variant thereof having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity to SEQ ID NO: 23; • a protease selected from: a) a polypeptide that comprises or consists of SEQ ID NO: 24 or SEQ ID NO: 26, or a variant thereof having at least 80%, at least 85%, at least 90% or at least 95% sequence identity to SEQ ID NO: 24 or SEQ ID NO: 26; b) a polypeptide that comprises SEQ ID NO: 24 with the substitutions Y161A, R164S and A188P; c) a polypeptide that comprises SEQ ID NO: 24 with the substitutions S9E, N42R, N74D, V199I, Q200L, Y203W, S253D, N255W and L256E; and d) a polypeptide that comprises SEQ ID NO: 37; and
• at least one enzyme selected from the group consisting of amylases, lipases, mannanases, pectate lyases and cellulases.
In one embodiment, the composition comprises:
• an RNase that comprises or consists of SEQ ID NO: 18;
• a hexosaminidase that comprises or consists of SEQ ID NO: 23;
• a protease that comprises SEQ ID NO: 24 with the substitutions Y161A, R164S and A188P, or that comprises SEQ ID NO: 37; and
• at least one enzyme selected from the group consisting of amylases, lipases, mannanases, pectate lyases and cellulases; wherein:
o the amylase comprises SEQ ID NO: 30 with the mutations H183*, G184*, I405L, A421 H, A422P and A428T;
o the lipase comprises SEQ ID NO: 31 with the mutations D27R, G38A, D96E, D11 1A, G163K, T231 R, N233R, D254S and P256T;
o the mannanase comprises SEQ ID NO: 32;
o the pectate lyase comprises SEQ ID NO: 33; and
o the cellulase comprises SEQ ID NO: 34 or SEQ ID NO: 35.
In one embodiment, the composition comprises:
• an RNase that comprises or consists of SEQ ID NO: 18;
• a hexosaminidase that comprises or consists of SEQ ID NO: 23;
• a protease that comprises SEQ ID NO: 24 with the substitutions S9E, N42R, N74D, V199I, Q200L, Y203W, S253D, N255W and L256E; and
• at least one enzyme selected from the group consisting of amylases and cellulases; wherein:
o the amylase comprises SEQ ID NO: 29 with the mutations H 1 *, N54S, V56T, K72R, G109A, F113Q, R116Q, W167F, Q172G, A174S, G182*, D183*, G184T, N195F, V206L, K391A, P473R and G476K; and o the cellulase comprises SEQ ID NO: 34.
In any of the embodiments described above comprising at least an RNase and a hexosaminidase as the cleaning enzymes, the cleaning composition may optionally comprise one or more of any of the other cleaning enzymes described herein. Any of these compositions may thus comprise one or more of a DNase, a Glyco_hydro_114 glucosyl hydrolase, a GH39 glycosyl hydrolase or a GHL13 glycosyl hydrolase.
Cleaning compositions comprising a hexosaminidase and a Giyco hydro 114 polypeptide
One aspect of the invention relates to a cleaning composition comprising at least a hexosaminidase and a Glyco_hydro_114 glycosyl hydrolase as the cleaning enzymes. Exemplary embodiments of this aspect of the invention are described below.
In one embodiment, the composition comprises:
• a hexosaminidase that comprises or consists of SEQ ID NO: 19, or which is a variant thereof having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity to SEQ ID NO: 19;
• a Glyco_hydro_1 14 polypeptide that comprises or consists of SEQ ID NO: 6, or which is a variant thereof having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity to SEQ ID NO: 6;
• a protease selected from: a) a polypeptide that comprises or consists of SEQ ID NO: 24 or SEQ ID NO: 26, or a variant thereof having at least 80%, at least 85%, at least 90% or at least 95% sequence identity to SEQ ID NO: 24 or SEQ ID NO: 26; b) a polypeptide that comprises SEQ ID NO: 24 with the substitutions Y161A, R164S and A188P; c) a polypeptide that comprises SEQ ID NO: 24 with the substitutions S9E, N42R, N74D, V199I, Q200L, Y203W, S253D, N255W and L256E; and d) a polypeptide that comprises SEQ ID NO: 37; and
• at least one enzyme selected from the group consisting of amylases, lipases, mannanases, pectate lyases and cellulases.
In one embodiment, the composition comprises:
• a hexosaminidase that comprises or consists of SEQ ID NO: 19;
• a Glyco_hydro_1 14 polypeptide that comprises or consists of SEQ ID NO: 6;
• a protease that comprises SEQ ID NO: 24 with the substitutions Y161A, R164S and A188P, or that comprises SEQ ID NO: 37; and
• at least one enzyme selected from the group consisting of amylases, lipases, mannanases, pectate lyases and cellulases; wherein:
o the amylase comprises SEQ ID NO: 30 with the mutations H183*, G184*, I405L, A421 H, A422P and A428T; o the lipase comprises SEQ ID NO: 31 with the mutations D27R, G38A, D96E, D11 1A, G163K, T231 R, N233R, D254S and P256T; o the mannanase comprises SEQ ID NO: 32;
o the pectate lyase comprises SEQ ID NO: 33; and
o the cellulase comprises SEQ ID NO: 34 or SEQ ID NO: 35.
In one embodiment, the composition comprises:
• a hexosaminidase that comprises or consists of SEQ ID NO: 19;
• a Glyco_hydro_1 14 polypeptide that comprises or consists of SEQ ID NO: 6;
• a protease that comprises SEQ ID NO: 24 with the substitutions S9E, N42R, N74D, V199I, Q200L, Y203W, S253D, N255W and L256E; and
• at least one enzyme selected from the group consisting of amylases and cellulases; wherein:
o the amylase comprises SEQ ID NO: 29 with the mutations H 1 *, N54S, V56T, K72R, G109A, F113Q, R116Q, W167F, Q172G, A174S, G182*, D183*, G184T, N195F, V206L, K391A, P473R and G476K; and o the cellulase comprises SEQ ID NO: 34.
In one embodiment, the composition comprises:
• a hexosaminidase that comprises or consists of SEQ ID NO: 19, or which is a variant thereof having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity to SEQ ID NO: 19;
• a Glyco_hydro_1 14 polypeptide that comprises or consists of SEQ ID NO: 7, or which is a variant thereof having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity to SEQ ID NO: 7;
• a protease selected from: a) a polypeptide that comprises or consists of SEQ ID NO: 24 or SEQ ID NO: 26, or a variant thereof having at least 80%, at least 85%, at least 90% or at least 95% sequence identity to SEQ ID NO: 24 or SEQ ID NO: 26; b) a polypeptide that comprises SEQ ID NO: 24 with the substitutions Y161A, R164S and A188P; c) a polypeptide that comprises SEQ ID NO: 24 with the substitutions S9E, N42R, N74D, V199I, Q200L, Y203W, S253D, N255W and L256E; and d) a polypeptide that comprises SEQ ID NO: 37; and
• at least one enzyme selected from the group consisting of amylases, lipases, mannanases, pectate lyases and cellulases.
In one embodiment, the composition comprises:
• a hexosaminidase that comprises or consists of SEQ ID NO: 19; • a Glyco_hydro_1 14 polypeptide that comprises or consists of SEQ ID NO: 7;
• a protease that comprises SEQ ID NO: 24 with the substitutions Y161A, R164S and A188P, or that comprises SEQ ID NO: 37; and
• at least one enzyme selected from the group consisting of amylases, lipases, mannanases, pectate lyases and cellulases; wherein:
o the amylase comprises SEQ ID NO: 30 with the mutations H183*, G184*, I405L, A421 H, A422P and A428T;
o the lipase comprises SEQ ID NO: 31 with the mutations D27R, G38A, D96E, D11 1A, G163K, T231 R, N233R, D254S and P256T; o the mannanase comprises SEQ ID NO: 32;
o the pectate lyase comprises SEQ ID NO: 33; and
o the cellulase comprises SEQ ID NO: 34 or SEQ ID NO: 35.
In one embodiment, the composition comprises:
• a hexosaminidase that comprises or consists of SEQ ID NO: 19;
• a Glyco_hydro_1 14 polypeptide that comprises or consists of SEQ ID NO: 7;
• a protease that comprises SEQ ID NO: 24 with the substitutions S9E, N42R, N74D, V199I, Q200L, Y203W, S253D, N255W and L256E; and
• at least one enzyme selected from the group consisting of amylases and cellulases; wherein:
o the amylase comprises SEQ ID NO: 29 with the mutations H 1 *, N54S, V56T, K72R, G109A, F113Q, R116Q, W167F, Q172G, A174S, G182*, D183*, G184T, N195F, V206L, K391A, P473R and G476K; and o the cellulase comprises SEQ ID NO: 34.
In one embodiment, the composition comprises:
• a hexosaminidase that comprises or consists of SEQ ID NO: 19, or which is a variant thereof having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity to SEQ ID NO: 19;
• a Glyco_hydro_1 14 polypeptide that comprises or consists of SEQ ID NO: 8, or which is a variant thereof having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity to SEQ ID NO: 8;
• a protease selected from: a) a polypeptide that comprises or consists of SEQ ID NO: 24 or SEQ ID NO: 26, or a variant thereof having at least 80%, at least 85%, at least 90% or at least 95% sequence identity to SEQ ID NO: 24 or SEQ ID NO: 26; b) a polypeptide that comprises SEQ ID NO: 24 with the substitutions Y161A, R164S and A188P; c) a polypeptide that comprises SEQ ID NO: 24 with the substitutions S9E, N42R, N74D, V199I, Q200L, Y203W, S253D, N255W and L256E; and d) a polypeptide that comprises SEQ ID NO: 37; and
• at least one enzyme selected from the group consisting of amylases, lipases, mannanases, pectate lyases and cellulases.
In one embodiment, the composition comprises:
• a hexosaminidase that comprises or consists of SEQ ID NO: 19;
• a Glyco_hydro_1 14 polypeptide that comprises or consists of SEQ ID NO: 8;
• a protease that comprises SEQ ID NO: 24 with the substitutions Y161A, R164S and A188P, or that comprises SEQ ID NO: 37; and
• at least one enzyme selected from the group consisting of amylases, lipases, mannanases, pectate lyases and cellulases; wherein:
o the amylase comprises SEQ ID NO: 30 with the mutations H183*, G184*, I405L, A421 H, A422P and A428T;
o the lipase comprises SEQ ID NO: 31 with the mutations D27R, G38A, D96E, D11 1A, G163K, T231 R, N233R, D254S and P256T; o the mannanase comprises SEQ ID NO: 32;
o the pectate lyase comprises SEQ ID NO: 33; and
o the cellulase comprises SEQ ID NO: 34 or SEQ ID NO: 35.
In one embodiment, the composition comprises:
• a hexosaminidase that comprises or consists of SEQ ID NO: 19;
• a Glyco_hydro_1 14 polypeptide that comprises or consists of SEQ ID NO: 8;
• a protease that comprises SEQ ID NO: 24 with the substitutions S9E, N42R, N74D, V199I, Q200L, Y203W, S253D, N255W and L256E; and
• at least one enzyme selected from the group consisting of amylases and cellulases; wherein:
o the amylase comprises SEQ ID NO: 29 with the mutations H 1 *, N54S, V56T, K72R, G109A, F113Q, R116Q, W167F, Q172G, A174S, G182*, D183*, G184T, N195F, V206L, K391A, P473R and G476K; and o the cellulase comprises SEQ ID NO: 34.
In one embodiment, the composition comprises:
• a hexosaminidase that comprises or consists of SEQ ID NO: 19, or which is a variant thereof having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity to SEQ ID NO: 19; • a Glyco_hydro_1 14 polypeptide that comprises or consists of SEQ ID NO: 9, or which is a variant thereof having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity to SEQ ID NO: 9;
• a protease selected from: a) a polypeptide that comprises or consists of SEQ ID NO: 24 or SEQ ID NO: 26, or a variant thereof having at least 80%, at least 85%, at least 90% or at least 95% sequence identity to SEQ ID NO: 24 or SEQ ID NO: 26; b) a polypeptide that comprises SEQ ID NO: 24 with the substitutions Y161A, R164S and A188P; c) a polypeptide that comprises SEQ ID NO: 24 with the substitutions S9E, N42R, N74D, V199I, Q200L, Y203W, S253D, N255W and L256E; and d) a polypeptide that comprises SEQ ID NO: 37; and
• at least one enzyme selected from the group consisting of amylases, lipases, mannanases, pectate lyases and cellulases.
In one embodiment, the composition comprises:
• a hexosaminidase that comprises or consists of SEQ ID NO: 19;
• a Glyco_hydro_1 14 polypeptide that comprises or consists of SEQ ID NO: 9;
• a protease that comprises SEQ ID NO: 24 with the substitutions Y161A, R164S and A188P, or that comprises SEQ ID NO: 37; and
• at least one enzyme selected from the group consisting of amylases, lipases, mannanases, pectate lyases and cellulases; wherein:
o the amylase comprises SEQ ID NO: 30 with the mutations H183*, G184*, I405L, A421 H, A422P and A428T;
o the lipase comprises SEQ ID NO: 31 with the mutations D27R, G38A, D96E, D11 1A, G163K, T231 R, N233R, D254S and P256T; o the mannanase comprises SEQ ID NO: 32;
o the pectate lyase comprises SEQ ID NO: 33; and
o the cellulase comprises SEQ ID NO: 34 or SEQ ID NO: 35.
In one embodiment, the composition comprises:
• a hexosaminidase that comprises or consists of SEQ ID NO: 19;
• a Glyco_hydro_1 14 polypeptide that comprises or consists of SEQ ID NO: 9;
• a protease that comprises SEQ ID NO: 24 with the substitutions S9E, N42R, N74D, V199I, Q200L, Y203W, S253D, N255W and L256E; and
• at least one enzyme selected from the group consisting of amylases and cellulases; wherein:
o the amylase comprises SEQ ID NO: 29 with the mutations H 1 *, N54S, V56T, K72R, G109A, F113Q, R116Q, W167F, Q172G, A174S, G182*, D183*, G184T, N195F, V206L, K391A, P473R and G476K; and o the cellulase comprises SEQ ID NO: 34.
In one embodiment, the composition comprises:
• a hexosaminidase that comprises or consists of SEQ ID NO: 20, or which is a variant thereof having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity to SEQ ID NO: 20;
• a Glyco_hydro_1 14 polypeptide that comprises or consists of SEQ ID NO: 6, or which is a variant thereof having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity to SEQ ID NO: 6;
• a protease selected from: a) a polypeptide that comprises or consists of SEQ ID NO: 24 or SEQ ID NO: 26, or a variant thereof having at least 80%, at least 85%, at least 90% or at least 95% sequence identity to SEQ ID NO: 24 or SEQ ID NO: 26; b) a polypeptide that comprises SEQ ID NO: 24 with the substitutions Y161A, R164S and A188P; c) a polypeptide that comprises SEQ ID NO: 24 with the substitutions S9E, N42R, N74D, V199I, Q200L, Y203W, S253D, N255W and L256E; and d) a polypeptide that comprises SEQ ID NO: 37; and
• at least one enzyme selected from the group consisting of amylases, lipases, mannanases, pectate lyases and cellulases.
In one embodiment, the composition comprises:
• a hexosaminidase that comprises or consists of SEQ ID NO: 20;
• a Glyco_hydro_1 14 polypeptide that comprises or consists of SEQ ID NO: 6;
• a protease that comprises SEQ ID NO: 24 with the substitutions Y161A, R164S and A188P, or that comprises SEQ ID NO: 37; and
• at least one enzyme selected from the group consisting of amylases, lipases, mannanases, pectate lyases and cellulases; wherein:
o the amylase comprises SEQ ID NO: 30 with the mutations H183*, G184*, I405L, A421 H, A422P and A428T;
o the lipase comprises SEQ ID NO: 31 with the mutations D27R, G38A, D96E, D11 1A, G163K, T231 R, N233R, D254S and P256T; o the mannanase comprises SEQ ID NO: 32;
o the pectate lyase comprises SEQ ID NO: 33; and
o the cellulase comprises SEQ ID NO: 34 or SEQ ID NO: 35.
In one embodiment, the composition comprises:
• a hexosaminidase that comprises or consists of SEQ ID NO: 20;
• a Glyco_hydro_1 14 polypeptide that comprises or consists of SEQ ID NO: 6; • a protease that comprises SEQ ID NO: 24 with the substitutions S9E, N42R, N74D, V199I, Q200L, Y203W, S253D, N255W and L256E; and
• at least one enzyme selected from the group consisting of amylases and cellulases; wherein:
o the amylase comprises SEQ ID NO: 29 with the mutations H 1 *, N54S, V56T, K72R, G109A, F113Q, R116Q, W167F, Q172G, A174S, G182*, D183*, G184T, N195F, V206L, K391A, P473R and G476K; and o the cellulase comprises SEQ ID NO: 34.
In one embodiment, the composition comprises:
• a hexosaminidase that comprises or consists of SEQ ID NO: 20, or which is a variant thereof having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity to SEQ ID NO: 20;
• a Glyco_hydro_1 14 polypeptide that comprises or consists of SEQ ID NO: 7, or which is a variant thereof having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity to SEQ ID NO: 7;
• a protease selected from: a) a polypeptide that comprises or consists of SEQ ID NO: 24 or SEQ ID NO: 26, or a variant thereof having at least 80%, at least 85%, at least 90% or at least 95% sequence identity to SEQ ID NO: 24 or SEQ ID NO: 26; b) a polypeptide that comprises SEQ ID NO: 24 with the substitutions Y161A, R164S and A188P; c) a polypeptide that comprises SEQ ID NO: 24 with the substitutions S9E, N42R, N74D, V199I, Q200L, Y203W, S253D, N255W and L256E; and d) a polypeptide that comprises SEQ ID NO: 37; and
• at least one enzyme selected from the group consisting of amylases, lipases, mannanases, pectate lyases and cellulases.
In one embodiment, the composition comprises:
• a hexosaminidase that comprises or consists of SEQ ID NO: 20;
• a Glyco_hydro_1 14 polypeptide that comprises or consists of SEQ ID NO: 7;
• a protease that comprises SEQ ID NO: 24 with the substitutions Y161A, R164S and A188P, or that comprises SEQ ID NO: 37; and
• at least one enzyme selected from the group consisting of amylases, lipases, mannanases, pectate lyases and cellulases; wherein:
o the amylase comprises SEQ ID NO: 30 with the mutations H183*, G184*, I405L, A421 H, A422P and A428T; o the lipase comprises SEQ ID NO: 31 with the mutations D27R, G38A, D96E, D11 1A, G163K, T231 R, N233R, D254S and P256T; o the mannanase comprises SEQ ID NO: 32;
o the pectate lyase comprises SEQ ID NO: 33; and
o the cellulase comprises SEQ ID NO: 34 or SEQ ID NO: 35.
In one embodiment, the composition comprises:
• a hexosaminidase that comprises or consists of SEQ ID NO: 20;
• a Glyco_hydro_1 14 polypeptide that comprises or consists of SEQ ID NO: 7;
• a protease that comprises SEQ ID NO: 24 with the substitutions S9E, N42R, N74D, V199I, Q200L, Y203W, S253D, N255W and L256E; and
• at least one enzyme selected from the group consisting of amylases and cellulases; wherein:
o the amylase comprises SEQ ID NO: 29 with the mutations H1 *, N54S, V56T, K72R, G109A, F113Q, R116Q, W167F, Q172G, A174S, G182*, D183*, G184T, N195F, V206L, K391A, P473R and G476K; and o the cellulase comprises SEQ ID NO: 34.
In one embodiment, the composition comprises:
• a hexosaminidase that comprises or consists of SEQ ID NO: 20, or which is a variant thereof having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity to SEQ ID NO: 20;
• a Glyco_hydro_1 14 polypeptide that comprises or consists of SEQ ID NO: 8, or which is a variant thereof having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity to SEQ ID NO: 8;
• a protease selected from: a) a polypeptide that comprises or consists of SEQ ID NO: 24 or SEQ ID NO: 26, or a variant thereof having at least 80%, at least 85%, at least 90% or at least 95% sequence identity to SEQ ID NO: 24 or SEQ ID NO: 26; b) a polypeptide that comprises SEQ ID NO: 24 with the substitutions Y161A, R164S and A188P; c) a polypeptide that comprises SEQ ID NO: 24 with the substitutions S9E, N42R, N74D, V199I, Q200L, Y203W, S253D, N255W and L256E; and d) a polypeptide that comprises SEQ ID NO: 37; and
• at least one enzyme selected from the group consisting of amylases, lipases, mannanases, pectate lyases and cellulases.
In one embodiment, the composition comprises:
• a hexosaminidase that comprises or consists of SEQ ID NO: 20; • a Glyco_hydro_1 14 polypeptide that comprises or consists of SEQ ID NO: 8;
• a protease that comprises SEQ ID NO: 24 with the substitutions Y161A, R164S and A188P, or that comprises SEQ ID NO: 37; and
• at least one enzyme selected from the group consisting of amylases, lipases, mannanases, pectate lyases and cellulases; wherein:
o the amylase comprises SEQ ID NO: 30 with the mutations H183*, G184*, I405L, A421 H, A422P and A428T;
o the lipase comprises SEQ ID NO: 31 with the mutations D27R, G38A, D96E, D11 1A, G163K, T231 R, N233R, D254S and P256T; o the mannanase comprises SEQ ID NO: 32;
o the pectate lyase comprises SEQ ID NO: 33; and
o the cellulase comprises SEQ ID NO: 34 or SEQ ID NO: 35.
In one embodiment, the composition comprises:
• a hexosaminidase that comprises or consists of SEQ ID NO: 20;
• a Glyco_hydro_1 14 polypeptide that comprises or consists of SEQ ID NO: 8;
• a protease that comprises SEQ ID NO: 24 with the substitutions S9E, N42R, N74D, V199I, Q200L, Y203W, S253D, N255W and L256E; and
• at least one enzyme selected from the group consisting of amylases and cellulases; wherein:
o the amylase comprises SEQ ID NO: 29 with the mutations H 1 *, N54S, V56T, K72R, G109A, F113Q, R116Q, W167F, Q172G, A174S, G182*, D183*, G184T, N195F, V206L, K391A, P473R and G476K; and o the cellulase comprises SEQ ID NO: 34.
In one embodiment, the composition comprises:
• a hexosaminidase that comprises or consists of SEQ ID NO: 20, or which is a variant thereof having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity to SEQ ID NO: 20;
• a Glyco_hydro_1 14 polypeptide that comprises or consists of SEQ ID NO: 9, or which is a variant thereof having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity to SEQ ID NO: 9;
• a protease selected from: a) a polypeptide that comprises or consists of SEQ ID NO: 24 or SEQ ID NO: 26, or a variant thereof having at least 80%, at least 85%, at least 90% or at least 95% sequence identity to SEQ ID NO: 24 or SEQ ID NO: 26; b) a polypeptide that comprises SEQ ID NO: 24 with the substitutions Y161A, R164S and A188P; c) a polypeptide that comprises SEQ ID NO: 24 with the substitutions S9E, N42R, N74D, V199I, Q200L, Y203W, S253D, N255W and L256E; and d) a polypeptide that comprises SEQ ID NO: 37; and
• at least one enzyme selected from the group consisting of amylases, lipases, mannanases, pectate lyases and cellulases.
In one embodiment, the composition comprises:
• a hexosaminidase that comprises or consists of SEQ ID NO: 20;
• a Glyco_hydro_114 polypeptide that comprises or consists of SEQ ID NO: 9;
• a protease that comprises SEQ ID NO: 24 with the substitutions Y161A, R164S and A188P, or that comprises SEQ ID NO: 37; and
• at least one enzyme selected from the group consisting of amylases, lipases, mannanases, pectate lyases and cellulases; wherein:
o the amylase comprises SEQ ID NO: 30 with the mutations H183*, G184*, I405L, A421 H, A422P and A428T;
o the lipase comprises SEQ ID NO: 31 with the mutations D27R, G38A, D96E, D11 1A, G163K, T231 R, N233R, D254S and P256T; o the mannanase comprises SEQ ID NO: 32;
o the pectate lyase comprises SEQ ID NO: 33; and
o the cellulase comprises SEQ ID NO: 34 or SEQ ID NO: 35.
In one embodiment, the composition comprises:
• a hexosaminidase that comprises or consists of SEQ ID NO: 20;
• a Glyco_hydro_1 14 polypeptide that comprises or consists of SEQ ID NO: 9;
• a protease that comprises SEQ ID NO: 24 with the substitutions S9E, N42R, N74D, V199I, Q200L, Y203W, S253D, N255W and L256E; and
• at least one enzyme selected from the group consisting of amylases and cellulases; wherein:
o the amylase comprises SEQ ID NO: 29 with the mutations H 1 *, N54S, V56T, K72R, G109A, F113Q, R116Q, W167F, Q172G, A174S, G182*, D183*, G184T, N195F, V206L, K391A, P473R and G476K; and o the cellulase comprises SEQ ID NO: 34.
In one embodiment, the composition comprises:
• a hexosaminidase that comprises or consists of SEQ ID NO: 21 , or which is a variant thereof having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity to SEQ ID NO: 21 ; • a Glyco_hydro_1 14 polypeptide that comprises or consists of SEQ ID NO: 6, or which is a variant thereof having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity to SEQ ID NO: 6;
• a protease selected from: a) a polypeptide that comprises or consists of SEQ ID NO: 24 or SEQ ID NO: 26, or a variant thereof having at least 80%, at least 85%, at least 90% or at least 95% sequence identity to SEQ ID NO: 24 or SEQ ID NO: 26; b) a polypeptide that comprises SEQ ID NO: 24 with the substitutions Y161A, R164S and A188P; c) a polypeptide that comprises SEQ ID NO: 24 with the substitutions S9E, N42R, N74D, V199I, Q200L, Y203W, S253D, N255W and L256E; and d) a polypeptide that comprises SEQ ID NO: 37; and
• at least one enzyme selected from the group consisting of amylases, lipases, mannanases, pectate lyases and cellulases.
In one embodiment, the composition comprises:
• a hexosaminidase that comprises or consists of SEQ ID NO: 21 ;
• a Glyco_hydro_1 14 polypeptide that comprises or consists of SEQ ID NO: 6;
• a protease that comprises SEQ ID NO: 24 with the substitutions Y161A, R164S and A188P, or that comprises SEQ ID NO: 37; and
• at least one enzyme selected from the group consisting of amylases, lipases, mannanases, pectate lyases and cellulases; wherein:
o the amylase comprises SEQ ID NO: 30 with the mutations H183*, G184*, I405L, A421 H, A422P and A428T;
o the lipase comprises SEQ ID NO: 31 with the mutations D27R, G38A, D96E, D11 1A, G163K, T231 R, N233R, D254S and P256T; o the mannanase comprises SEQ ID NO: 32;
o the pectate lyase comprises SEQ ID NO: 33; and
o the cellulase comprises SEQ ID NO: 34 or SEQ ID NO: 35.
In one embodiment, the composition comprises:
• a hexosaminidase that comprises or consists of SEQ ID NO: 21 ;
• a Glyco_hydro_1 14 polypeptide that comprises or consists of SEQ ID NO: 6;
• a protease that comprises SEQ ID NO: 24 with the substitutions S9E, N42R, N74D, V199I, Q200L, Y203W, S253D, N255W and L256E; and
• at least one enzyme selected from the group consisting of amylases and cellulases; wherein:
o the amylase comprises SEQ ID NO: 29 with the mutations H 1 *, N54S, V56T, K72R, G109A, F113Q, R116Q, W167F, Q172G, A174S, G182*, D183*, G184T, N195F, V206L, K391A, P473R and G476K; and o the cellulase comprises SEQ ID NO: 34.
In one embodiment, the composition comprises:
• a hexosaminidase that comprises or consists of SEQ ID NO: 21 , or which is a variant thereof having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity to SEQ ID NO: 21 ;
• a Glyco_hydro_1 14 polypeptide that comprises or consists of SEQ ID NO: 7, or which is a variant thereof having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity to SEQ ID NO: 7;
• a protease selected from: a) a polypeptide that comprises or consists of SEQ ID NO: 24 or SEQ ID NO: 26, or a variant thereof having at least 80%, at least 85%, at least 90% or at least 95% sequence identity to SEQ ID NO: 24 or SEQ ID NO: 26; b) a polypeptide that comprises SEQ ID NO: 24 with the substitutions Y161A, R164S and A188P; c) a polypeptide that comprises SEQ ID NO: 24 with the substitutions S9E, N42R, N74D, V199I, Q200L, Y203W, S253D, N255W and L256E; and d) a polypeptide that comprises SEQ ID NO: 37; and
• at least one enzyme selected from the group consisting of amylases, lipases, mannanases, pectate lyases and cellulases.
In one embodiment, the composition comprises:
• a hexosaminidase that comprises or consists of SEQ ID NO: 21 ;
• a Glyco_hydro_1 14 polypeptide that comprises or consists of SEQ ID NO: 7;
• a protease that comprises SEQ ID NO: 24 with the substitutions Y161A, R164S and A188P, or that comprises SEQ ID NO: 37; and
• at least one enzyme selected from the group consisting of amylases, lipases, mannanases, pectate lyases and cellulases; wherein:
o the amylase comprises SEQ ID NO: 30 with the mutations H183*, G184*, I405L, A421 H, A422P and A428T;
o the lipase comprises SEQ ID NO: 31 with the mutations D27R, G38A, D96E, D11 1A, G163K, T231 R, N233R, D254S and P256T; o the mannanase comprises SEQ ID NO: 32;
o the pectate lyase comprises SEQ ID NO: 33; and
o the cellulase comprises SEQ ID NO: 34 or SEQ ID NO: 35.
In one embodiment, the composition comprises:
• a hexosaminidase that comprises or consists of SEQ ID NO: 21 ;
• a Glyco_hydro_1 14 polypeptide that comprises or consists of SEQ ID NO: 7; • a protease that comprises SEQ ID NO: 24 with the substitutions S9E, N42R, N74D, V199I, Q200L, Y203W, S253D, N255W and L256E; and
• at least one enzyme selected from the group consisting of amylases and cellulases; wherein:
o the amylase comprises SEQ ID NO: 29 with the mutations H 1 *, N54S, V56T, K72R, G109A, F113Q, R116Q, W167F, Q172G, A174S, G182*, D183*, G184T, N195F, V206L, K391A, P473R and G476K; and o the cellulase comprises SEQ ID NO: 34.
In one embodiment, the composition comprises:
• a hexosaminidase that comprises or consists of SEQ ID NO: 21 , or which is a variant thereof having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity to SEQ ID NO: 21 ;
• a Glyco_hydro_1 14 polypeptide that comprises or consists of SEQ ID NO: 8, or which is a variant thereof having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity to SEQ ID NO: 8;
• a protease selected from: a) a polypeptide that comprises or consists of SEQ ID NO: 24 or SEQ ID NO: 26, or a variant thereof having at least 80%, at least 85%, at least 90% or at least 95% sequence identity to SEQ ID NO: 24 or SEQ ID NO: 26; b) a polypeptide that comprises SEQ ID NO: 24 with the substitutions Y161A, R164S and A188P; c) a polypeptide that comprises SEQ ID NO: 24 with the substitutions S9E, N42R, N74D, V199I, Q200L, Y203W, S253D, N255W and L256E; and d) a polypeptide that comprises SEQ ID NO: 37; and
• at least one enzyme selected from the group consisting of amylases, lipases, mannanases, pectate lyases and cellulases.
In one embodiment, the composition comprises:
• a hexosaminidase that comprises or consists of SEQ ID NO: 21 ;
• a Glyco_hydro_1 14 polypeptide that comprises or consists of SEQ ID NO: 8;
• a protease that comprises SEQ ID NO: 24 with the substitutions Y161A, R164S and A188P, or that comprises SEQ ID NO: 37; and
• at least one enzyme selected from the group consisting of amylases, lipases, mannanases, pectate lyases and cellulases; wherein:
o the amylase comprises SEQ ID NO: 30 with the mutations H183*, G184*, I405L, A421 H, A422P and A428T; o the lipase comprises SEQ ID NO: 31 with the mutations D27R, G38A, D96E, D11 1A, G163K, T231 R, N233R, D254S and P256T; o the mannanase comprises SEQ ID NO: 32;
o the pectate lyase comprises SEQ ID NO: 33; and
o the cellulase comprises SEQ ID NO: 34 or SEQ ID NO: 35.
In one embodiment, the composition comprises:
• a hexosaminidase that comprises or consists of SEQ ID NO: 21 ;
• a Glyco_hydro_114 polypeptide that comprises or consists of SEQ ID NO: 8;
• a protease that comprises SEQ ID NO: 24 with the substitutions S9E, N42R, N74D, V199I, Q200L, Y203W, S253D, N255W and L256E; and
• at least one enzyme selected from the group consisting of amylases and cellulases; wherein:
o the amylase comprises SEQ ID NO: 29 with the mutations H 1 *, N54S, V56T, K72R, G109A, F113Q, R116Q, W167F, Q172G, A174S, G182*, D183*, G184T, N195F, V206L, K391A, P473R and G476K; and o the cellulase comprises SEQ ID NO: 34.
In one embodiment, the composition comprises:
• a hexosaminidase that comprises or consists of SEQ ID NO: 21 , or which is a variant thereof having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity to SEQ ID NO: 21 ;
• a Glyco_hydro_1 14 polypeptide that comprises or consists of SEQ ID NO: 9, or which is a variant thereof having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity to SEQ ID NO: 9;
• a protease selected from: a) a polypeptide that comprises or consists of SEQ ID NO: 24 or SEQ ID NO: 26, or a variant thereof having at least 80%, at least 85%, at least 90% or at least 95% sequence identity to SEQ ID NO: 24 or SEQ ID NO: 26; b) a polypeptide that comprises SEQ ID NO: 24 with the substitutions Y161A, R164S and A188P; c) a polypeptide that comprises SEQ ID NO: 24 with the substitutions S9E, N42R, N74D, V199I, Q200L, Y203W, S253D, N255W and L256E; and d) a polypeptide that comprises SEQ ID NO: 37; and
• at least one enzyme selected from the group consisting of amylases, lipases, mannanases, pectate lyases and cellulases.
In one embodiment, the composition comprises:
• a hexosaminidase that comprises or consists of SEQ ID NO: 21 ; • a Glyco_hydro_1 14 polypeptide that comprises or consists of SEQ ID NO: 9;
• a protease that comprises SEQ ID NO: 24 with the substitutions Y161A, R164S and A188P, or that comprises SEQ ID NO: 37; and
• at least one enzyme selected from the group consisting of amylases, lipases, mannanases, pectate lyases and cellulases; wherein:
o the amylase comprises SEQ ID NO: 30 with the mutations H183*, G184*, I405L, A421 H, A422P and A428T;
o the lipase comprises SEQ ID NO: 31 with the mutations D27R, G38A, D96E, D11 1A, G163K, T231 R, N233R, D254S and P256T; o the mannanase comprises SEQ ID NO: 32;
o the pectate lyase comprises SEQ ID NO: 33; and
o the cellulase comprises SEQ ID NO: 34 or SEQ ID NO: 35.
In one embodiment, the composition comprises:
• a hexosaminidase that comprises or consists of SEQ ID NO: 21 ;
• a Glyco_hydro_114 polypeptide that comprises or consists of SEQ ID NO: 9;
• a protease that comprises SEQ ID NO: 24 with the substitutions S9E, N42R, N74D, V199I, Q200L, Y203W, S253D, N255W and L256E; and
• at least one enzyme selected from the group consisting of amylases and cellulases; wherein:
o the amylase comprises SEQ ID NO: 29 with the mutations H 1 *, N54S, V56T, K72R, G109A, F113Q, R116Q, W167F, Q172G, A174S, G182*, D183*, G184T, N195F, V206L, K391A, P473R and G476K; and o the cellulase comprises SEQ ID NO: 34.
In one embodiment, the composition comprises:
• a hexosaminidase that comprises or consists of SEQ ID NO: 22, or which is a variant thereof having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity to SEQ ID NO: 22;
• a Glyco_hydro_1 14 polypeptide that comprises or consists of SEQ ID NO: 6, or which is a variant thereof having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity to SEQ ID NO: 6;
• a protease selected from: a) a polypeptide that comprises or consists of SEQ ID NO: 24 or SEQ ID NO: 26, or a variant thereof having at least 80%, at least 85%, at least 90% or at least 95% sequence identity to SEQ ID NO: 24 or SEQ ID NO: 26; b) a polypeptide that comprises SEQ ID NO: 24 with the substitutions Y161A, R164S and A188P; c) a polypeptide that comprises SEQ ID NO: 24 with the substitutions S9E, N42R, N74D, V199I, Q200L, Y203W, S253D, N255W and L256E; and d) a polypeptide that comprises SEQ ID NO: 37; and
• at least one enzyme selected from the group consisting of amylases, lipases, mannanases, pectate lyases and cellulases.
In one embodiment, the composition comprises:
• a hexosaminidase that comprises or consists of SEQ ID NO: 22;
• a Glyco_hydro_1 14 polypeptide that comprises or consists of SEQ ID NO: 6;
• a protease that comprises SEQ ID NO: 24 with the substitutions Y161A, R164S and A188P, or that comprises SEQ ID NO: 37; and
• at least one enzyme selected from the group consisting of amylases, lipases, mannanases, pectate lyases and cellulases; wherein:
o the amylase comprises SEQ ID NO: 30 with the mutations H183*, G184*, I405L, A421 H, A422P and A428T;
o the lipase comprises SEQ ID NO: 31 with the mutations D27R, G38A, D96E, D11 1A, G163K, T231 R, N233R, D254S and P256T; o the mannanase comprises SEQ ID NO: 32;
o the pectate lyase comprises SEQ ID NO: 33; and
o the cellulase comprises SEQ ID NO: 34 or SEQ ID NO: 35.
In one embodiment, the composition comprises:
• a hexosaminidase that comprises or consists of SEQ ID NO: 22;
• a Glyco_hydro_1 14 polypeptide that comprises or consists of SEQ ID NO: 6;
• a protease that comprises SEQ ID NO: 24 with the substitutions S9E, N42R, N74D, V199I, Q200L, Y203W, S253D, N255W and L256E; and
• at least one enzyme selected from the group consisting of amylases and cellulases; wherein:
o the amylase comprises SEQ ID NO: 29 with the mutations H 1 *, N54S, V56T, K72R, G109A, F113Q, R116Q, W167F, Q172G, A174S, G182*, D183*, G184T, N195F, V206L, K391A, P473R and G476K; and o the cellulase comprises SEQ ID NO: 34.
In one embodiment, the composition comprises:
• a hexosaminidase that comprises or consists of SEQ ID NO: 22, or which is a variant thereof having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity to SEQ ID NO: 22; • a Glyco_hydro_1 14 polypeptide that comprises or consists of SEQ ID NO: 7, or which is a variant thereof having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity to SEQ ID NO: 7;
• a protease selected from: a) a polypeptide that comprises or consists of SEQ ID NO: 24 or SEQ ID NO: 26, or a variant thereof having at least 80%, at least 85%, at least 90% or at least 95% sequence identity to SEQ ID NO: 24 or SEQ ID NO: 26; b) a polypeptide that comprises SEQ ID NO: 24 with the substitutions Y161A, R164S and A188P; c) a polypeptide that comprises SEQ ID NO: 24 with the substitutions S9E, N42R, N74D, V199I, Q200L, Y203W, S253D, N255W and L256E; and d) a polypeptide that comprises SEQ ID NO: 37; and
• at least one enzyme selected from the group consisting of amylases, lipases, mannanases, pectate lyases and cellulases.
In one embodiment, the composition comprises:
• a hexosaminidase that comprises or consists of SEQ ID NO: 22;
• a Glyco_hydro_1 14 polypeptide that comprises or consists of SEQ ID NO: 7;
• a protease that comprises SEQ ID NO: 24 with the substitutions Y161A, R164S and A188P, or that comprises SEQ ID NO: 37; and
• at least one enzyme selected from the group consisting of amylases, lipases, mannanases, pectate lyases and cellulases; wherein:
o the amylase comprises SEQ ID NO: 30 with the mutations H183*, G184*, I405L, A421 H, A422P and A428T;
o the lipase comprises SEQ ID NO: 31 with the mutations D27R, G38A, D96E, D11 1A, G163K, T231 R, N233R, D254S and P256T; o the mannanase comprises SEQ ID NO: 32;
o the pectate lyase comprises SEQ ID NO: 33; and
o the cellulase comprises SEQ ID NO: 34 or SEQ ID NO: 35.
In one embodiment, the composition comprises:
• a hexosaminidase that comprises or consists of SEQ ID NO: 22;
• a Glyco_hydro_1 14 polypeptide that comprises or consists of SEQ ID NO: 7;
• a protease that comprises SEQ ID NO: 24 with the substitutions S9E, N42R, N74D, V199I, Q200L, Y203W, S253D, N255W and L256E; and
• at least one enzyme selected from the group consisting of amylases and cellulases; wherein:
o the amylase comprises SEQ ID NO: 29 with the mutations H 1 *, N54S, V56T, K72R, G109A, F113Q, R116Q, W167F, Q172G, A174S, G182*, D183*, G184T, N195F, V206L, K391A, P473R and G476K; and o the cellulase comprises SEQ ID NO: 34.
In one embodiment, the composition comprises:
• a hexosaminidase that comprises or consists of SEQ ID NO: 22, or which is a variant thereof having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity to SEQ ID NO: 22;
• a Glyco_hydro_1 14 polypeptide that comprises or consists of SEQ ID NO: 8, or which is a variant thereof having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity to SEQ ID NO: 8;
• a protease selected from: a) a polypeptide that comprises or consists of SEQ ID NO: 24 or SEQ ID NO: 26, or a variant thereof having at least 80%, at least 85%, at least 90% or at least 95% sequence identity to SEQ ID NO: 24 or SEQ ID NO: 26; b) a polypeptide that comprises SEQ ID NO: 24 with the substitutions Y161A, R164S and A188P; c) a polypeptide that comprises SEQ ID NO: 24 with the substitutions S9E, N42R, N74D, V199I, Q200L, Y203W, S253D, N255W and L256E; and d) a polypeptide that comprises SEQ ID NO: 37; and
• at least one enzyme selected from the group consisting of amylases, lipases, mannanases, pectate lyases and cellulases.
In one embodiment, the composition comprises:
• a hexosaminidase that comprises or consists of SEQ ID NO: 22;
• a Glyco_hydro_1 14 polypeptide that comprises or consists of SEQ ID NO: 8;
• a protease that comprises SEQ ID NO: 24 with the substitutions Y161A, R164S and A188P, or that comprises SEQ ID NO: 37; and
• at least one enzyme selected from the group consisting of amylases, lipases, mannanases, pectate lyases and cellulases; wherein:
o the amylase comprises SEQ ID NO: 30 with the mutations H183*, G184*, I405L, A421 H, A422P and A428T;
o the lipase comprises SEQ ID NO: 31 with the mutations D27R, G38A, D96E, D11 1A, G163K, T231 R, N233R, D254S and P256T; o the mannanase comprises SEQ ID NO: 32;
o the pectate lyase comprises SEQ ID NO: 33; and
o the cellulase comprises SEQ ID NO: 34 or SEQ ID NO: 35.
In one embodiment, the composition comprises:
• a hexosaminidase that comprises or consists of SEQ ID NO: 22;
• a Glyco_hydro_1 14 polypeptide that comprises or consists of SEQ ID NO: 8; • a protease that comprises SEQ ID NO: 24 with the substitutions S9E, N42R, N74D, V199I, Q200L, Y203W, S253D, N255W and L256E; and
• at least one enzyme selected from the group consisting of amylases and cellulases; wherein:
o the amylase comprises SEQ ID NO: 29 with the mutations H 1 *, N54S, V56T, K72R, G109A, F113Q, R116Q, W167F, Q172G, A174S, G182*, D183*, G184T, N195F, V206L, K391A, P473R and G476K; and o the cellulase comprises SEQ ID NO: 34.
In one embodiment, the composition comprises:
• a hexosaminidase that comprises or consists of SEQ ID NO: 22, or which is a variant thereof having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity to SEQ ID NO: 22;
• a Glyco_hydro_1 14 polypeptide that comprises or consists of SEQ ID NO: 9, or which is a variant thereof having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity to SEQ ID NO: 9;
• a protease selected from: a) a polypeptide that comprises or consists of SEQ ID NO: 24 or SEQ ID NO: 26, or a variant thereof having at least 80%, at least 85%, at least 90% or at least 95% sequence identity to SEQ ID NO: 24 or SEQ ID NO: 26; b) a polypeptide that comprises SEQ ID NO: 24 with the substitutions Y161A, R164S and A188P; c) a polypeptide that comprises SEQ ID NO: 24 with the substitutions S9E, N42R, N74D, V199I, Q200L, Y203W, S253D, N255W and L256E; and d) a polypeptide that comprises SEQ ID NO: 37; and
• at least one enzyme selected from the group consisting of amylases, lipases, mannanases, pectate lyases and cellulases.
In one embodiment, the composition comprises:
• a hexosaminidase that comprises or consists of SEQ ID NO: 22;
• a Glyco_hydro_1 14 polypeptide that comprises or consists of SEQ ID NO: 9;
• a protease that comprises SEQ ID NO: 24 with the substitutions Y161A, R164S and A188P, or that comprises SEQ ID NO: 37; and
• at least one enzyme selected from the group consisting of amylases, lipases, mannanases, pectate lyases and cellulases; wherein:
o the amylase comprises SEQ ID NO: 30 with the mutations H183*, G184*, I405L, A421 H, A422P and A428T; o the lipase comprises SEQ ID NO: 31 with the mutations D27R, G38A, D96E, D11 1A, G163K, T231 R, N233R, D254S and P256T; o the mannanase comprises SEQ ID NO: 32;
o the pectate lyase comprises SEQ ID NO: 33; and
o the cellulase comprises SEQ ID NO: 34 or SEQ ID NO: 35.
In one embodiment, the composition comprises:
• a hexosaminidase that comprises or consists of SEQ ID NO: 22;
• a Glyco_hydro_1 14 polypeptide that comprises or consists of SEQ ID NO: 9;
• a protease that comprises SEQ ID NO: 24 with the substitutions S9E, N42R, N74D, V199I, Q200L, Y203W, S253D, N255W and L256E; and
• at least one enzyme selected from the group consisting of amylases and cellulases; wherein:
o the amylase comprises SEQ ID NO: 29 with the mutations H 1 *, N54S, V56T, K72R, G109A, F113Q, R116Q, W167F, Q172G, A174S, G182*, D183*, G184T, N195F, V206L, K391A, P473R and G476K; and o the cellulase comprises SEQ ID NO: 34.
In one embodiment, the composition comprises:
• a hexosaminidase that comprises or consists of SEQ ID NO: 23, or which is a variant thereof having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity to SEQ ID NO: 23;
• a Glyco_hydro_1 14 polypeptide that comprises or consists of SEQ ID NO: 6, or which is a variant thereof having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity to SEQ ID NO: 6;
• a protease selected from: a) a polypeptide that comprises or consists of SEQ ID NO: 24 or SEQ ID NO: 26, or a variant thereof having at least 80%, at least 85%, at least 90% or at least 95% sequence identity to SEQ ID NO: 24 or SEQ ID NO: 26; b) a polypeptide that comprises SEQ ID NO: 24 with the substitutions Y161A, R164S and A188P; c) a polypeptide that comprises SEQ ID NO: 24 with the substitutions S9E, N42R, N74D, V199I, Q200L, Y203W, S253D, N255W and L256E; and d) a polypeptide that comprises SEQ ID NO: 37; and
• at least one enzyme selected from the group consisting of amylases, lipases, mannanases, pectate lyases and cellulases.
In one embodiment, the composition comprises:
• a hexosaminidase that comprises or consists of SEQ ID NO: 23; • a Glyco_hydro_1 14 polypeptide that comprises or consists of SEQ ID NO: 6;
• a protease that comprises SEQ ID NO: 24 with the substitutions Y161A, R164S and A188P, or that comprises SEQ ID NO: 37; and
• at least one enzyme selected from the group consisting of amylases, lipases, mannanases, pectate lyases and cellulases; wherein:
o the amylase comprises SEQ ID NO: 30 with the mutations H183*, G184*, I405L, A421 H, A422P and A428T;
o the lipase comprises SEQ ID NO: 31 with the mutations D27R, G38A, D96E, D11 1A, G163K, T231 R, N233R, D254S and P256T; o the mannanase comprises SEQ ID NO: 32;
o the pectate lyase comprises SEQ ID NO: 33; and
o the cellulase comprises SEQ ID NO: 34 or SEQ ID NO: 35.
In one embodiment, the composition comprises:
• a hexosaminidase that comprises or consists of SEQ ID NO: 23;
• a Glyco_hydro_1 14 polypeptide that comprises or consists of SEQ ID NO: 6;
• a protease that comprises SEQ ID NO: 24 with the substitutions S9E, N42R, N74D, V199I, Q200L, Y203W, S253D, N255W and L256E; and
• at least one enzyme selected from the group consisting of amylases and cellulases; wherein:
o the amylase comprises SEQ ID NO: 29 with the mutations H 1 *, N54S, V56T, K72R, G109A, F113Q, R116Q, W167F, Q172G, A174S, G182*, D183*, G184T, N195F, V206L, K391A, P473R and G476K; and o the cellulase comprises SEQ ID NO: 34.
In one embodiment, the composition comprises:
• a hexosaminidase that comprises or consists of SEQ ID NO: 23, or which is a variant thereof having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity to SEQ ID NO: 23;
• a Glyco_hydro_1 14 polypeptide that comprises or consists of SEQ ID NO: 7, or which is a variant thereof having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity to SEQ ID NO: 7;
• a protease selected from: a) a polypeptide that comprises or consists of SEQ ID NO: 24 or SEQ ID NO: 26, or a variant thereof having at least 80%, at least 85%, at least 90% or at least 95% sequence identity to SEQ ID NO: 24 or SEQ ID NO: 26; b) a polypeptide that comprises SEQ ID NO: 24 with the substitutions Y161A, R164S and A188P; c) a polypeptide that comprises SEQ ID NO: 24 with the substitutions S9E, N42R, N74D, V199I, Q200L, Y203W, S253D, N255W and L256E; and d) a polypeptide that comprises SEQ ID NO: 37; and
• at least one enzyme selected from the group consisting of amylases, lipases, mannanases, pectate lyases and cellulases.
In one embodiment, the composition comprises:
• a hexosaminidase that comprises or consists of SEQ ID NO: 23;
• a Glyco_hydro_1 14 polypeptide that comprises or consists of SEQ ID NO: 7;
• a protease that comprises SEQ ID NO: 24 with the substitutions Y161A, R164S and A188P, or that comprises SEQ ID NO: 37; and
• at least one enzyme selected from the group consisting of amylases, lipases, mannanases, pectate lyases and cellulases; wherein:
o the amylase comprises SEQ ID NO: 30 with the mutations H183*, G184*, I405L, A421 H, A422P and A428T;
o the lipase comprises SEQ ID NO: 31 with the mutations D27R, G38A, D96E, D11 1A, G163K, T231 R, N233R, D254S and P256T; o the mannanase comprises SEQ ID NO: 32;
o the pectate lyase comprises SEQ ID NO: 33; and
o the cellulase comprises SEQ ID NO: 34 or SEQ ID NO: 35.
In one embodiment, the composition comprises:
• a hexosaminidase that comprises or consists of SEQ ID NO: 23;
• a Glyco_hydro_1 14 polypeptide that comprises or consists of SEQ ID NO: 7;
• a protease that comprises SEQ ID NO: 24 with the substitutions S9E, N42R, N74D, V199I, Q200L, Y203W, S253D, N255W and L256E; and
• at least one enzyme selected from the group consisting of amylases and cellulases; wherein:
o the amylase comprises SEQ ID NO: 29 with the mutations H 1 *, N54S, V56T, K72R, G109A, F113Q, R116Q, W167F, Q172G, A174S, G182*, D183*, G184T, N195F, V206L, K391A, P473R and G476K; and o the cellulase comprises SEQ ID NO: 34.
In one embodiment, the composition comprises:
• a hexosaminidase that comprises or consists of SEQ ID NO: 23, or which is a variant thereof having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity to SEQ ID NO: 23; • a Glyco_hydro_1 14 polypeptide that comprises or consists of SEQ ID NO: 8, or which is a variant thereof having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity to SEQ ID NO: 8;
• a protease selected from: a) a polypeptide that comprises or consists of SEQ ID NO: 24 or SEQ ID NO: 26, or a variant thereof having at least 80%, at least 85%, at least 90% or at least 95% sequence identity to SEQ ID NO: 24 or SEQ ID NO: 26; b) a polypeptide that comprises SEQ ID NO: 24 with the substitutions Y161A, R164S and A188P; c) a polypeptide that comprises SEQ ID NO: 24 with the substitutions S9E, N42R, N74D, V199I, Q200L, Y203W, S253D, N255W and L256E; and d) a polypeptide that comprises SEQ ID NO: 37; and
• at least one enzyme selected from the group consisting of amylases, lipases, mannanases, pectate lyases and cellulases.
In one embodiment, the composition comprises:
• a hexosaminidase that comprises or consists of SEQ ID NO: 23;
• a Glyco_hydro_1 14 polypeptide that comprises or consists of SEQ ID NO: 8;
• a protease that comprises SEQ ID NO: 24 with the substitutions Y161A, R164S and A188P, or that comprises SEQ ID NO: 37; and
• at least one enzyme selected from the group consisting of amylases, lipases, mannanases, pectate lyases and cellulases; wherein:
o the amylase comprises SEQ ID NO: 30 with the mutations H183*, G184*, I405L, A421 H, A422P and A428T;
o the lipase comprises SEQ ID NO: 31 with the mutations D27R, G38A, D96E, D11 1A, G163K, T231 R, N233R, D254S and P256T; o the mannanase comprises SEQ ID NO: 32;
o the pectate lyase comprises SEQ ID NO: 33; and
o the cellulase comprises SEQ ID NO: 34 or SEQ ID NO: 35.
In one embodiment, the composition comprises:
• a hexosaminidase that comprises or consists of SEQ ID NO: 23;
• a Glyco_hydro_1 14 polypeptide that comprises or consists of SEQ ID NO: 8;
• a protease that comprises SEQ ID NO: 24 with the substitutions S9E, N42R, N74D, V199I, Q200L, Y203W, S253D, N255W and L256E; and
• at least one enzyme selected from the group consisting of amylases and cellulases; wherein:
o the amylase comprises SEQ ID NO: 29 with the mutations H 1 *, N54S, V56T, K72R, G109A, F113Q, R116Q, W167F, Q172G, A174S, G182*, D183*, G184T, N195F, V206L, K391A, P473R and G476K; and o the cellulase comprises SEQ ID NO: 34.
In one embodiment, the composition comprises:
• a hexosaminidase that comprises or consists of SEQ ID NO: 23, or which is a variant thereof having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity to SEQ ID NO: 23;
• a Glyco_hydro_1 14 polypeptide that comprises or consists of SEQ ID NO: 9, or which is a variant thereof having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity to SEQ ID NO: 9;
• a protease selected from: a) a polypeptide that comprises or consists of SEQ ID NO: 24 or SEQ ID NO: 26, or a variant thereof having at least 80%, at least 85%, at least 90% or at least 95% sequence identity to SEQ ID NO: 24 or SEQ ID NO: 26; b) a polypeptide that comprises SEQ ID NO: 24 with the substitutions Y161A, R164S and A188P; c) a polypeptide that comprises SEQ ID NO: 24 with the substitutions S9E, N42R, N74D, V199I, Q200L, Y203W, S253D, N255W and L256E; and d) a polypeptide that comprises SEQ ID NO: 37; and
• at least one enzyme selected from the group consisting of amylases, lipases, mannanases, pectate lyases and cellulases.
In one embodiment, the composition comprises:
• a hexosaminidase that comprises or consists of SEQ ID NO: 23;
• a Glyco_hydro_1 14 polypeptide that comprises or consists of SEQ ID NO: 9;
• a protease that comprises SEQ ID NO: 24 with the substitutions Y161A, R164S and A188P, or that comprises SEQ ID NO: 37; and
• at least one enzyme selected from the group consisting of amylases, lipases, mannanases, pectate lyases and cellulases; wherein:
o the amylase comprises SEQ ID NO: 30 with the mutations H183*, G184*, I405L, A421 H, A422P and A428T;
o the lipase comprises SEQ ID NO: 31 with the mutations D27R, G38A, D96E, D11 1A, G163K, T231 R, N233R, D254S and P256T; o the mannanase comprises SEQ ID NO: 32;
o the pectate lyase comprises SEQ ID NO: 33; and
o the cellulase comprises SEQ ID NO: 34 or SEQ ID NO: 35.
In one embodiment, the composition comprises:
• a hexosaminidase that comprises or consists of SEQ ID NO: 23;
• a Glyco_hydro_1 14 polypeptide that comprises or consists of SEQ ID NO: 9; • a protease that comprises SEQ ID NO: 24 with the substitutions S9E, N42R, N74D, V199I, Q200L, Y203W, S253D, N255W and L256E; and
• at least one enzyme selected from the group consisting of amylases and cellulases; wherein:
o the amylase comprises SEQ ID NO: 29 with the mutations H 1 *, N54S, V56T, K72R, G109A, F113Q, R116Q, W167F, Q172G, A174S, G182*, D183*, G184T, N195F, V206L, K391A, P473R and G476K; and o the cellulase comprises SEQ ID NO: 34.
In any of the embodiments described above comprising at least a hexosaminidase and a Glyco_hydro_1 14 glycosyl hydrolase as the cleaning enzymes, the cleaning composition may optionally comprise one or more of any of the other cleaning enzymes described herein. Any of these compositions may thus comprise one or more of a DNase, an RNase, a GH39 glycosyl hydrolase or a GHL13 glycosyl hydrolase.
Cleaning compositions comprising a hexosaminidase and a GH39 polypeptide
One aspect of the invention relates to a cleaning composition comprising at least a hexosaminidase and a GH39 glycosyl hydrolase as the cleaning enzymes. Exemplary embodiments of this aspect of the invention are described below.
In one embodiment, the composition comprises:
• a hexosaminidase that comprises or consists of SEQ ID NO: 19, or which is a variant thereof having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity to SEQ ID NO: 19;
• a GH39 polypeptide that comprises or consists of SEQ ID NO: 10, or which is a variant thereof having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity to SEQ ID NO: 10;
• a protease selected from: a) a polypeptide that comprises or consists of SEQ ID NO: 24 or SEQ ID NO: 26, or a variant thereof having at least 80%, at least 85%, at least 90% or at least 95% sequence identity to SEQ ID NO: 24 or SEQ ID NO: 26; b) a polypeptide that comprises SEQ ID NO: 24 with the substitutions Y161A, R164S and A188P; c) a polypeptide that comprises SEQ ID NO: 24 with the substitutions S9E, N42R, N74D, V199I, Q200L, Y203W, S253D, N255W and L256E; and d) a polypeptide that comprises SEQ ID NO: 37; and • at least one enzyme selected from the group consisting of amylases, lipases, mannanases, pectate lyases and cellulases.
In one embodiment, the composition comprises:
• a hexosaminidase that comprises or consists of SEQ ID NO: 19;
• a GH39 polypeptide that comprises or consists of SEQ ID NO: 10;
• a protease that comprises SEQ ID NO: 24 with the substitutions Y161A, R164S and A188P, or that comprises SEQ ID NO: 37; and
• at least one enzyme selected from the group consisting of amylases, lipases, mannanases, pectate lyases and cellulases; wherein:
o the amylase comprises SEQ ID NO: 30 with the mutations H183*, G184*, I405L, A421 H, A422P and A428T;
o the lipase comprises SEQ ID NO: 31 with the mutations D27R, G38A, D96E, D11 1A, G163K, T231 R, N233R, D254S and P256T; o the mannanase comprises SEQ ID NO: 32;
o the pectate lyase comprises SEQ ID NO: 33; and
o the cellulase comprises SEQ ID NO: 34 or SEQ ID NO: 35.
In one embodiment, the composition comprises:
• a hexosaminidase that comprises or consists of SEQ ID NO: 19;
• a GH39 polypeptide that comprises or consists of SEQ ID NO: 10;
• a protease that comprises SEQ ID NO: 24 with the substitutions S9E, N42R, N74D, V199I, Q200L, Y203W, S253D, N255W and L256E; and
• at least one enzyme selected from the group consisting of amylases and cellulases; wherein:
o the amylase comprises SEQ ID NO: 29 with the mutations H 1 *, N54S, V56T, K72R, G109A, F113Q, R116Q, W167F, Q172G, A174S, G182*, D183*, G184T, N195F, V206L, K391A, P473R and G476K; and o the cellulase comprises SEQ ID NO: 34.
In one embodiment, the composition comprises:
• a hexosaminidase that comprises or consists of SEQ ID NO: 19, or which is a variant thereof having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity to SEQ ID NO: 19;
• a GH39 polypeptide that comprises or consists of SEQ ID NO: 11 , or which is a variant thereof having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity to SEQ ID NO: 1 1 ; • a protease selected from: a) a polypeptide that comprises or consists of SEQ ID NO: 24 or SEQ ID NO: 26, or a variant thereof having at least 80%, at least 85%, at least 90% or at least 95% sequence identity to SEQ ID NO: 24 or SEQ ID NO: 26; b) a polypeptide that comprises SEQ ID NO: 24 with the substitutions Y161A, R164S and A188P; c) a polypeptide that comprises SEQ ID NO: 24 with the substitutions S9E, N42R, N74D, V199I, Q200L, Y203W, S253D, N255W and L256E; and d) a polypeptide that comprises SEQ ID NO: 37; and
• at least one enzyme selected from the group consisting of amylases, lipases, mannanases, pectate lyases and cellulases.
In one embodiment, the composition comprises:
• a hexosaminidase that comprises or consists of SEQ ID NO: 19;
• a GH39 polypeptide that comprises or consists of SEQ ID NO: 11 ;
• a protease that comprises SEQ ID NO: 24 with the substitutions Y161A, R164S and A188P, or that comprises SEQ ID NO: 37; and
• at least one enzyme selected from the group consisting of amylases, lipases, mannanases, pectate lyases and cellulases; wherein:
o the amylase comprises SEQ ID NO: 30 with the mutations H183*, G184*, I405L, A421 H, A422P and A428T;
o the lipase comprises SEQ ID NO: 31 with the mutations D27R, G38A, D96E, D11 1A, G163K, T231 R, N233R, D254S and P256T; o the mannanase comprises SEQ ID NO: 32;
o the pectate lyase comprises SEQ ID NO: 33; and
o the cellulase comprises SEQ ID NO: 34 or SEQ ID NO: 35.
In one embodiment, the composition comprises:
• a hexosaminidase that comprises or consists of SEQ ID NO: 19;
• a GH39 polypeptide that comprises or consists of SEQ ID NO: 1 1 ;
• a protease that comprises SEQ ID NO: 24 with the substitutions S9E, N42R, N74D, V199I, Q200L, Y203W, S253D, N255W and L256E; and
• at least one enzyme selected from the group consisting of amylases and cellulases; wherein:
o the amylase comprises SEQ ID NO: 29 with the mutations H 1 *, N54S, V56T, K72R, G109A, F113Q, R116Q, W167F, Q172G, A174S, G182*, D183*, G184T, N195F, V206L, K391A, P473R and G476K; and o the cellulase comprises SEQ ID NO: 34.
In one embodiment, the composition comprises: • a hexosaminidase that comprises or consists of SEQ ID NO: 19, or which is a variant thereof having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity to SEQ ID NO: 19;
• a GH39 polypeptide that comprises or consists of SEQ ID NO: 12, or which is a variant thereof having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity to SEQ ID NO: 12;
• a protease selected from: a) a polypeptide that comprises or consists of SEQ ID NO: 24 or SEQ ID NO: 26, or a variant thereof having at least 80%, at least 85%, at least 90% or at least 95% sequence identity to SEQ ID NO: 24 or SEQ ID NO: 26; b) a polypeptide that comprises SEQ ID NO: 24 with the substitutions Y161A, R164S and A188P; c) a polypeptide that comprises SEQ ID NO: 24 with the substitutions S9E, N42R, N74D, V199I, Q200L, Y203W, S253D, N255W and L256E; and d) a polypeptide that comprises SEQ ID NO: 37; and
• at least one enzyme selected from the group consisting of amylases, lipases, mannanases, pectate lyases and cellulases.
In one embodiment, the composition comprises:
• a hexosaminidase that comprises or consists of SEQ ID NO: 19;
• a GH39 polypeptide that comprises or consists of SEQ ID NO: 12;
• a protease that comprises SEQ ID NO: 24 with the substitutions Y161A, R164S and A188P, or that comprises SEQ ID NO: 37; and
• at least one enzyme selected from the group consisting of amylases, lipases, mannanases, pectate lyases and cellulases; wherein:
o the amylase comprises SEQ ID NO: 30 with the mutations H183*, G184*, I405L, A421 H, A422P and A428T;
o the lipase comprises SEQ ID NO: 31 with the mutations D27R, G38A, D96E, D11 1A, G163K, T231 R, N233R, D254S and P256T; o the mannanase comprises SEQ ID NO: 32;
o the pectate lyase comprises SEQ ID NO: 33; and
o the cellulase comprises SEQ ID NO: 34 or SEQ ID NO: 35.
In one embodiment, the composition comprises:
• a hexosaminidase that comprises or consists of SEQ ID NO: 19;
• a GH39 polypeptide that comprises or consists of SEQ ID NO: 12;
• a protease that comprises SEQ ID NO: 24 with the substitutions S9E, N42R, N74D, V199I, Q200L, Y203W, S253D, N255W and L256E; and • at least one enzyme selected from the group consisting of amylases and cellulases; wherein:
o the amylase comprises SEQ ID NO: 29 with the mutations H 1 *, N54S, V56T, K72R, G109A, F113Q, R116Q, W167F, Q172G, A174S, G182*, D183*, G184T, N195F, V206L, K391A, P473R and G476K; and o the cellulase comprises SEQ ID NO: 34.
In one embodiment, the composition comprises:
• a hexosaminidase that comprises or consists of SEQ ID NO: 20, or which is a variant thereof having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity to SEQ ID NO: 20;
• a GH39 polypeptide that comprises or consists of SEQ ID NO: 10, or which is a variant thereof having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity to SEQ ID NO: 10;
• a protease selected from: a) a polypeptide that comprises or consists of SEQ ID NO: 24 or SEQ ID NO: 26, or a variant thereof having at least 80%, at least 85%, at least 90% or at least 95% sequence identity to SEQ ID NO: 24 or SEQ ID NO: 26; b) a polypeptide that comprises SEQ ID NO: 24 with the substitutions Y161A, R164S and A188P; c) a polypeptide that comprises SEQ ID NO: 24 with the substitutions S9E, N42R, N74D, V199I, Q200L, Y203W, S253D, N255W and L256E; and d) a polypeptide that comprises SEQ ID NO: 37; and
• at least one enzyme selected from the group consisting of amylases, lipases, mannanases, pectate lyases and cellulases.
In one embodiment, the composition comprises:
• a hexosaminidase that comprises or consists of SEQ ID NO: 20;
• a GH39 polypeptide that comprises or consists of SEQ ID NO: 10;
• a protease that comprises SEQ ID NO: 24 with the substitutions Y161A, R164S and A188P, or that comprises SEQ ID NO: 37; and
• at least one enzyme selected from the group consisting of amylases, lipases, mannanases, pectate lyases and cellulases; wherein:
o the amylase comprises SEQ ID NO: 30 with the mutations H183*, G184*, I405L, A421 H, A422P and A428T;
o the lipase comprises SEQ ID NO: 31 with the mutations D27R, G38A, D96E, D11 1A, G163K, T231 R, N233R, D254S and P256T; o the mannanase comprises SEQ ID NO: 32; o the pectate lyase comprises SEQ ID NO: 33; and
o the cellulase comprises SEQ ID NO: 34 or SEQ ID NO: 35.
In one embodiment, the composition comprises:
• a hexosaminidase that comprises or consists of SEQ ID NO: 20;
• a GH39 polypeptide that comprises or consists of SEQ ID NO: 10;
• a protease that comprises SEQ ID NO: 24 with the substitutions S9E, N42R, N74D, V199I, Q200L, Y203W, S253D, N255W and L256E; and
• at least one enzyme selected from the group consisting of amylases and cellulases; wherein:
o the amylase comprises SEQ ID NO: 29 with the mutations H 1 *, N54S, V56T, K72R, G109A, F113Q, R116Q, W167F, Q172G, A174S, G182*, D183*, G184T, N195F, V206L, K391A, P473R and G476K; and o the cellulase comprises SEQ ID NO: 34.
In one embodiment, the composition comprises:
• a hexosaminidase that comprises or consists of SEQ ID NO: 20, or which is a variant thereof having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity to SEQ ID NO: 20;
• a GH39 polypeptide that comprises or consists of SEQ ID NO: 11 , or which is a variant thereof having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity to SEQ ID NO: 1 1 ;
• a protease selected from: a) a polypeptide that comprises or consists of SEQ ID NO: 24 or SEQ ID NO: 26, or a variant thereof having at least 80%, at least 85%, at least 90% or at least 95% sequence identity to SEQ ID NO: 24 or SEQ ID NO: 26; b) a polypeptide that comprises SEQ ID NO: 24 with the substitutions Y161A, R164S and A188P; c) a polypeptide that comprises SEQ ID NO: 24 with the substitutions S9E, N42R, N74D, V199I, Q200L, Y203W, S253D, N255W and L256E; and d) a polypeptide that comprises SEQ ID NO: 37; and
• at least one enzyme selected from the group consisting of amylases, lipases, mannanases, pectate lyases and cellulases.
In one embodiment, the composition comprises:
• a hexosaminidase that comprises or consists of SEQ ID NO: 20;
• a GH39 polypeptide that comprises or consists of SEQ ID NO: 11 ;
• a protease that comprises SEQ ID NO: 24 with the substitutions Y161A, R164S and A188P, or that comprises SEQ ID NO: 37; and • at least one enzyme selected from the group consisting of amylases, lipases, mannanases, pectate lyases and cellulases; wherein:
o the amylase comprises SEQ ID NO: 30 with the mutations H183*, G184*, I405L, A421 H, A422P and A428T;
o the lipase comprises SEQ ID NO: 31 with the mutations D27R, G38A, D96E, D1 11A, G163K, T231 R, N233R, D254S and P256T; o the mannanase comprises SEQ ID NO: 32;
o the pectate lyase comprises SEQ ID NO: 33; and
o the cellulase comprises SEQ ID NO: 34 or SEQ ID NO: 35.
In one embodiment, the composition comprises:
• a hexosaminidase that comprises or consists of SEQ ID NO: 20;
• a GH39 polypeptide that comprises or consists of SEQ ID NO: 11 ;
• a protease that comprises SEQ ID NO: 24 with the substitutions S9E, N42R, N74D, V199I, Q200L, Y203W, S253D, N255W and L256E; and
• at least one enzyme selected from the group consisting of amylases and cellulases; wherein:
o the amylase comprises SEQ ID NO: 29 with the mutations H 1 *, N54S, V56T, K72R, G109A, F113Q, R116Q, W167F, Q172G, A174S, G182*, D183*, G184T, N195F, V206L, K391A, P473R and G476K; and o the cellulase comprises SEQ ID NO: 34.
In one embodiment, the composition comprises:
• a hexosaminidase that comprises or consists of SEQ ID NO: 20, or which is a variant thereof having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity to SEQ ID NO: 20;
• a GH39 polypeptide that comprises or consists of SEQ ID NO: 12, or which is a variant thereof having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity to SEQ ID NO: 12;
• a protease selected from: a) a polypeptide that comprises or consists of SEQ ID NO: 24 or SEQ ID NO: 26, or a variant thereof having at least 80%, at least 85%, at least 90% or at least 95% sequence identity to SEQ ID NO: 24 or SEQ ID NO: 26; b) a polypeptide that comprises SEQ ID NO: 24 with the substitutions Y161A, R164S and A188P; c) a polypeptide that comprises SEQ ID NO: 24 with the substitutions S9E, N42R, N74D, V199I, Q200L, Y203W, S253D, N255W and L256E; and d) a polypeptide that comprises SEQ ID NO: 37; and • at least one enzyme selected from the group consisting of amylases, lipases, mannanases, pectate lyases and cellulases.
In one embodiment, the composition comprises:
• a hexosaminidase that comprises or consists of SEQ ID NO: 20;
• a GH39 polypeptide that comprises or consists of SEQ ID NO: 12;
• a protease that comprises SEQ ID NO: 24 with the substitutions Y161A, R164S and A188P, or that comprises SEQ ID NO: 37; and
• at least one enzyme selected from the group consisting of amylases, lipases, mannanases, pectate lyases and cellulases; wherein:
o the amylase comprises SEQ ID NO: 30 with the mutations H183*, G184*, I405L, A421 H, A422P and A428T;
o the lipase comprises SEQ ID NO: 31 with the mutations D27R, G38A, D96E, D11 1A, G163K, T231 R, N233R, D254S and P256T; o the mannanase comprises SEQ ID NO: 32;
o the pectate lyase comprises SEQ ID NO: 33; and
o the cellulase comprises SEQ ID NO: 34 or SEQ ID NO: 35.
In one embodiment, the composition comprises:
• a hexosaminidase that comprises or consists of SEQ ID NO: 20;
• a GH39 polypeptide that comprises or consists of SEQ ID NO: 12;
• a protease that comprises SEQ ID NO: 24 with the substitutions S9E, N42R, N74D, V199I, Q200L, Y203W, S253D, N255W and L256E; and
• at least one enzyme selected from the group consisting of amylases and cellulases; wherein:
o the amylase comprises SEQ ID NO: 29 with the mutations H 1 *, N54S, V56T, K72R, G109A, F113Q, R116Q, W167F, Q172G, A174S, G182*, D183*, G184T, N195F, V206L, K391A, P473R and G476K; and o the cellulase comprises SEQ ID NO: 34.
In one embodiment, the composition comprises:
• a hexosaminidase that comprises or consists of SEQ ID NO: 21 , or which is a variant thereof having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity to SEQ ID NO: 21 ;
• a GH39 polypeptide that comprises or consists of SEQ ID NO: 10, or which is a variant thereof having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity to SEQ ID NO: 10; • a protease selected from: a) a polypeptide that comprises or consists of SEQ ID NO: 24 or SEQ ID NO: 26, or a variant thereof having at least 80%, at least 85%, at least 90% or at least 95% sequence identity to SEQ ID NO: 24 or SEQ ID NO: 26; b) a polypeptide that comprises SEQ ID NO: 24 with the substitutions Y161A, R164S and A188P; c) a polypeptide that comprises SEQ ID NO: 24 with the substitutions S9E, N42R, N74D, V199I, Q200L, Y203W, S253D, N255W and L256E; and d) a polypeptide that comprises SEQ ID NO: 37; and
• at least one enzyme selected from the group consisting of amylases, lipases, mannanases, pectate lyases and cellulases.
In one embodiment, the composition comprises:
• a hexosaminidase that comprises or consists of SEQ ID NO: 21 ;
• a GH39 polypeptide that comprises or consists of SEQ ID NO: 10;
• a protease that comprises SEQ ID NO: 24 with the substitutions Y161A, R164S and A188P, or that comprises SEQ ID NO: 37; and
• at least one enzyme selected from the group consisting of amylases, lipases, mannanases, pectate lyases and cellulases; wherein:
o the amylase comprises SEQ ID NO: 30 with the mutations H183*, G184*, I405L, A421 H, A422P and A428T;
o the lipase comprises SEQ ID NO: 31 with the mutations D27R, G38A, D96E, D11 1A, G163K, T231 R, N233R, D254S and P256T; o the mannanase comprises SEQ ID NO: 32;
o the pectate lyase comprises SEQ ID NO: 33; and
o the cellulase comprises SEQ ID NO: 34 or SEQ ID NO: 35.
In one embodiment, the composition comprises:
• a hexosaminidase that comprises or consists of SEQ ID NO: 21 ;
• a GH39 polypeptide that comprises or consists of SEQ ID NO: 10;
• a protease that comprises SEQ ID NO: 24 with the substitutions S9E, N42R, N74D, V199I, Q200L, Y203W, S253D, N255W and L256E; and
• at least one enzyme selected from the group consisting of amylases and cellulases; wherein:
o the amylase comprises SEQ ID NO: 29 with the mutations H 1 *, N54S, V56T, K72R, G109A, F113Q, R116Q, W167F, Q172G, A174S, G182*, D183*, G184T, N195F, V206L, K391A, P473R and G476K; and o the cellulase comprises SEQ ID NO: 34.
In one embodiment, the composition comprises: • a hexosaminidase that comprises or consists of SEQ ID NO: 21 , or which is a variant thereof having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity to SEQ ID NO: 21 ;
• a GH39 polypeptide that comprises or consists of SEQ ID NO: 11 , or which is a variant thereof having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity to SEQ ID NO: 1 1 ;
• a protease selected from: a) a polypeptide that comprises or consists of SEQ ID NO: 24 or SEQ ID NO: 26, or a variant thereof having at least 80%, at least 85%, at least 90% or at least 95% sequence identity to SEQ ID NO: 24 or SEQ ID NO: 26; b) a polypeptide that comprises SEQ ID NO: 24 with the substitutions Y161A, R164S and A188P; c) a polypeptide that comprises SEQ ID NO: 24 with the substitutions S9E, N42R, N74D, V199I, Q200L, Y203W, S253D, N255W and L256E; and d) a polypeptide that comprises SEQ ID NO: 37; and
• at least one enzyme selected from the group consisting of amylases, lipases, mannanases, pectate lyases and cellulases.
In one embodiment, the composition comprises:
• a hexosaminidase that comprises or consists of SEQ ID NO: 21 ;
• a GH39 polypeptide that comprises or consists of SEQ ID NO: 11 ;
• a protease that comprises SEQ ID NO: 24 with the substitutions Y161A, R164S and A188P, or that comprises SEQ ID NO: 37; and
• at least one enzyme selected from the group consisting of amylases, lipases, mannanases, pectate lyases and cellulases; wherein:
o the amylase comprises SEQ ID NO: 30 with the mutations H183*, G184*, I405L, A421 H, A422P and A428T;
o the lipase comprises SEQ ID NO: 31 with the mutations D27R, G38A, D96E, D11 1A, G163K, T231 R, N233R, D254S and P256T; o the mannanase comprises SEQ ID NO: 32;
o the pectate lyase comprises SEQ ID NO: 33; and
o the cellulase comprises SEQ ID NO: 34 or SEQ ID NO: 35.
In one embodiment, the composition comprises:
• a hexosaminidase that comprises or consists of SEQ ID NO: 21 ;
• a GH39 polypeptide that comprises or consists of SEQ ID NO: 11 ;
• a protease that comprises SEQ ID NO: 24 with the substitutions S9E, N42R, N74D, V199I, Q200L, Y203W, S253D, N255W and L256E; and • at least one enzyme selected from the group consisting of amylases and cellulases; wherein:
o the amylase comprises SEQ ID NO: 29 with the mutations H 1 *, N54S, V56T, K72R, G109A, F113Q, R116Q, W167F, Q172G, A174S, G182*, D183*, G184T, N195F, V206L, K391A, P473R and G476K; and o the cellulase comprises SEQ ID NO: 34.
In one embodiment, the composition comprises:
• a hexosaminidase that comprises or consists of SEQ ID NO: 21 , or which is a variant thereof having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity to SEQ ID NO: 21 ;
• a GH39 polypeptide that comprises or consists of SEQ ID NO: 12, or which is a variant thereof having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity to SEQ ID NO: 12;
• a protease selected from: a) a polypeptide that comprises or consists of SEQ ID NO: 24 or SEQ ID NO: 26, or a variant thereof having at least 80%, at least 85%, at least 90% or at least 95% sequence identity to SEQ ID NO: 24 or SEQ ID NO: 26; b) a polypeptide that comprises SEQ ID NO: 24 with the substitutions Y161A, R164S and A188P; c) a polypeptide that comprises SEQ ID NO: 24 with the substitutions S9E, N42R, N74D, V199I, Q200L, Y203W, S253D, N255W and L256E; and d) a polypeptide that comprises SEQ ID NO: 37; and
• at least one enzyme selected from the group consisting of amylases, lipases, mannanases, pectate lyases and cellulases.
In one embodiment, the composition comprises:
• a hexosaminidase that comprises or consists of SEQ ID NO: 21 ;
• a GH39 polypeptide that comprises or consists of SEQ ID NO: 12;
• a protease that comprises SEQ ID NO: 24 with the substitutions Y161A, R164S and A188P, or that comprises SEQ ID NO: 37; and
• at least one enzyme selected from the group consisting of amylases, lipases, mannanases, pectate lyases and cellulases; wherein:
o the amylase comprises SEQ ID NO: 30 with the mutations H183*, G184*, I405L, A421 H, A422P and A428T;
o the lipase comprises SEQ ID NO: 31 with the mutations D27R, G38A, D96E, D11 1A, G163K, T231 R, N233R, D254S and P256T; o the mannanase comprises SEQ ID NO: 32; o the pectate lyase comprises SEQ ID NO: 33; and
o the cellulase comprises SEQ ID NO: 34 or SEQ ID NO: 35.
In one embodiment, the composition comprises:
• a hexosaminidase that comprises or consists of SEQ ID NO: 21 ;
• a GH39 polypeptide that comprises or consists of SEQ ID NO: 12;
• a protease that comprises SEQ ID NO: 24 with the substitutions S9E, N42R, N74D, V199I, Q200L, Y203W, S253D, N255W and L256E; and
• at least one enzyme selected from the group consisting of amylases and cellulases; wherein:
o the amylase comprises SEQ ID NO: 29 with the mutations H 1 *, N54S, V56T, K72R, G109A, F113Q, R116Q, W167F, Q172G, A174S, G182*, D183*, G184T, N195F, V206L, K391A, P473R and G476K; and o the cellulase comprises SEQ ID NO: 34.
In one embodiment, the composition comprises:
• a hexosaminidase that comprises or consists of SEQ ID NO: 22, or which is a variant thereof having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity to SEQ ID NO: 22;
• a GH39 polypeptide that comprises or consists of SEQ ID NO: 10, or which is a variant thereof having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity to SEQ ID NO: 10;
• a protease selected from: a) a polypeptide that comprises or consists of SEQ ID NO: 24 or SEQ ID NO: 26, or a variant thereof having at least 80%, at least 85%, at least 90% or at least 95% sequence identity to SEQ ID NO: 24 or SEQ ID NO: 26; b) a polypeptide that comprises SEQ ID NO: 24 with the substitutions Y161A, R164S and A188P; c) a polypeptide that comprises SEQ ID NO: 24 with the substitutions S9E, N42R, N74D, V199I, Q200L, Y203W, S253D, N255W and L256E; and d) a polypeptide that comprises SEQ ID NO: 37; and
• at least one enzyme selected from the group consisting of amylases, lipases, mannanases, pectate lyases and cellulases.
In one embodiment, the composition comprises:
• a hexosaminidase that comprises or consists of SEQ ID NO: 22;
• a GH39 polypeptide that comprises or consists of SEQ ID NO: 10;
• a protease that comprises SEQ ID NO: 24 with the substitutions Y161A, R164S and A188P, or that comprises SEQ ID NO: 37; and • at least one enzyme selected from the group consisting of amylases, lipases, mannanases, pectate lyases and cellulases; wherein:
o the amylase comprises SEQ ID NO: 30 with the mutations H183*, G184*, I405L, A421 H, A422P and A428T;
o the lipase comprises SEQ ID NO: 31 with the mutations D27R, G38A, D96E, D11 1A, G163K, T231 R, N233R, D254S and P256T; o the mannanase comprises SEQ ID NO: 32;
o the pectate lyase comprises SEQ ID NO: 33; and
o the cellulase comprises SEQ ID NO: 34 or SEQ ID NO: 35.
In one embodiment, the composition comprises:
• a hexosaminidase that comprises or consists of SEQ ID NO: 22;
• a GH39 polypeptide that comprises or consists of SEQ ID NO: 10;
• a protease that comprises SEQ ID NO: 24 with the substitutions S9E, N42R, N74D, V199I, Q200L, Y203W, S253D, N255W and L256E; and
• at least one enzyme selected from the group consisting of amylases and cellulases; wherein:
o the amylase comprises SEQ ID NO: 29 with the mutations H 1 *, N54S, V56T, K72R, G109A, F113Q, R116Q, W167F, Q172G, A174S, G182*, D183*, G184T, N195F, V206L, K391A, P473R and G476K; and o the cellulase comprises SEQ ID NO: 34.
In one embodiment, the composition comprises:
• a hexosaminidase that comprises or consists of SEQ ID NO: 22, or which is a variant thereof having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity to SEQ ID NO: 22;
• a GH39 polypeptide that comprises or consists of SEQ ID NO: 11 , or which is a variant thereof having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity to SEQ ID NO: 1 1 ;
• a protease selected from: a) a polypeptide that comprises or consists of SEQ ID NO: 24 or SEQ ID NO: 26, or a variant thereof having at least 80%, at least 85%, at least 90% or at least 95% sequence identity to SEQ ID NO: 24 or SEQ ID NO: 26; b) a polypeptide that comprises SEQ ID NO: 24 with the substitutions Y161A, R164S and A188P; c) a polypeptide that comprises SEQ ID NO: 24 with the substitutions S9E, N42R, N74D, V199I, Q200L, Y203W, S253D, N255W and L256E; and d) a polypeptide that comprises SEQ ID NO: 37; and • at least one enzyme selected from the group consisting of amylases, lipases, mannanases, pectate lyases and cellulases.
In one embodiment, the composition comprises:
• a hexosaminidase that comprises or consists of SEQ ID NO: 22;
• a GH39 polypeptide that comprises or consists of SEQ ID NO: 11 ;
• a protease that comprises SEQ ID NO: 24 with the substitutions Y161A, R164S and A188P, or that comprises SEQ ID NO: 37; and
• at least one enzyme selected from the group consisting of amylases, lipases, mannanases, pectate lyases and cellulases; wherein:
o the amylase comprises SEQ ID NO: 30 with the mutations H183*, G184*, I405L, A421 H, A422P and A428T;
o the lipase comprises SEQ ID NO: 31 with the mutations D27R, G38A, D96E, D11 1A, G163K, T231 R, N233R, D254S and P256T; o the mannanase comprises SEQ ID NO: 32;
o the pectate lyase comprises SEQ ID NO: 33; and
o the cellulase comprises SEQ ID NO: 34 or SEQ ID NO: 35.
In one embodiment, the composition comprises:
• a hexosaminidase that comprises or consists of SEQ ID NO: 22;
• a GH39 polypeptide that comprises or consists of SEQ ID NO: 1 1 ;
• a protease that comprises SEQ ID NO: 24 with the substitutions S9E, N42R, N74D, V199I, Q200L, Y203W, S253D, N255W and L256E; and
• at least one enzyme selected from the group consisting of amylases and cellulases; wherein:
o the amylase comprises SEQ ID NO: 29 with the mutations H 1 *, N54S, V56T, K72R, G109A, F113Q, R116Q, W167F, Q172G, A174S, G182*, D183*, G184T, N195F, V206L, K391A, P473R and G476K; and o the cellulase comprises SEQ ID NO: 34.
In one embodiment, the composition comprises:
• a hexosaminidase that comprises or consists of SEQ ID NO: 22, or which is a variant thereof having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity to SEQ ID NO: 22;
• a GH39 polypeptide that comprises or consists of SEQ ID NO: 12, or which is a variant thereof having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity to SEQ ID NO: 12; • a protease selected from: a) a polypeptide that comprises or consists of SEQ ID NO: 24 or SEQ ID NO: 26, or a variant thereof having at least 80%, at least 85%, at least 90% or at least 95% sequence identity to SEQ ID NO: 24 or SEQ ID NO: 26; b) a polypeptide that comprises SEQ ID NO: 24 with the substitutions Y161A, R164S and A188P; c) a polypeptide that comprises SEQ ID NO: 24 with the substitutions S9E, N42R, N74D, V199I, Q200L, Y203W, S253D, N255W and L256E; and d) a polypeptide that comprises SEQ ID NO: 37; and
• at least one enzyme selected from the group consisting of amylases, lipases, mannanases, pectate lyases and cellulases.
In one embodiment, the composition comprises:
• a hexosaminidase that comprises or consists of SEQ ID NO: 22;
• a GH39 polypeptide that comprises or consists of SEQ ID NO: 12;
• a protease that comprises SEQ ID NO: 24 with the substitutions Y161A, R164S and A188P, or that comprises SEQ ID NO: 37; and
• at least one enzyme selected from the group consisting of amylases, lipases, mannanases, pectate lyases and cellulases; wherein:
o the amylase comprises SEQ ID NO: 30 with the mutations H183*, G184*, I405L, A421 H, A422P and A428T;
o the lipase comprises SEQ ID NO: 31 with the mutations D27R, G38A, D96E, D11 1A, G163K, T231 R, N233R, D254S and P256T; o the mannanase comprises SEQ ID NO: 32;
o the pectate lyase comprises SEQ ID NO: 33; and
o the cellulase comprises SEQ ID NO: 34 or SEQ ID NO: 35.
In one embodiment, the composition comprises:
• a hexosaminidase that comprises or consists of SEQ ID NO: 22;
• a GH39 polypeptide that comprises or consists of SEQ ID NO: 12;
• a protease that comprises SEQ ID NO: 24 with the substitutions S9E, N42R, N74D, V199I, Q200L, Y203W, S253D, N255W and L256E; and
• at least one enzyme selected from the group consisting of amylases and cellulases; wherein:
o the amylase comprises SEQ ID NO: 29 with the mutations H 1 *, N54S, V56T, K72R, G109A, F113Q, R116Q, W167F, Q172G, A174S, G182*, D183*, G184T, N195F, V206L, K391A, P473R and G476K; and o the cellulase comprises SEQ ID NO: 34.
In one embodiment, the composition comprises: • a hexosaminidase that comprises or consists of SEQ ID NO: 23, or which is a variant thereof having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity to SEQ ID NO: 23;
• a GH39 polypeptide that comprises or consists of SEQ ID NO: 10, or which is a variant thereof having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity to SEQ ID NO: 10;
• a protease selected from: a) a polypeptide that comprises or consists of SEQ ID NO: 24 or SEQ ID NO: 26, or a variant thereof having at least 80%, at least 85%, at least 90% or at least 95% sequence identity to SEQ ID NO: 24 or SEQ ID NO: 26; b) a polypeptide that comprises SEQ ID NO: 24 with the substitutions Y161A, R164S and A188P; c) a polypeptide that comprises SEQ ID NO: 24 with the substitutions S9E, N42R, N74D, V199I, Q200L, Y203W, S253D, N255W and L256E; and d) a polypeptide that comprises SEQ ID NO: 37; and
• at least one enzyme selected from the group consisting of amylases, lipases, mannanases, pectate lyases and cellulases.
In one embodiment, the composition comprises:
• a hexosaminidase that comprises or consists of SEQ ID NO: 23;
• a GH39 polypeptide that comprises or consists of SEQ ID NO: 10;
• a protease that comprises SEQ ID NO: 24 with the substitutions Y161A, R164S and A188P, or that comprises SEQ ID NO: 37; and
• at least one enzyme selected from the group consisting of amylases, lipases, mannanases, pectate lyases and cellulases; wherein:
o the amylase comprises SEQ ID NO: 30 with the mutations H183*, G184*, I405L, A421 H, A422P and A428T;
o the lipase comprises SEQ ID NO: 31 with the mutations D27R, G38A, D96E, D11 1A, G163K, T231 R, N233R, D254S and P256T; o the mannanase comprises SEQ ID NO: 32;
o the pectate lyase comprises SEQ ID NO: 33; and
o the cellulase comprises SEQ ID NO: 34 or SEQ ID NO: 35.
In one embodiment, the composition comprises:
• a hexosaminidase that comprises or consists of SEQ ID NO: 23;
• a GH39 polypeptide that comprises or consists of SEQ ID NO: 10;
• a protease that comprises SEQ ID NO: 24 with the substitutions S9E, N42R, N74D, V199I, Q200L, Y203W, S253D, N255W and L256E; and • at least one enzyme selected from the group consisting of amylases and cellulases; wherein:
o the amylase comprises SEQ ID NO: 29 with the mutations H 1 *, N54S, V56T, K72R, G109A, F113Q, R116Q, W167F, Q172G, A174S, G182*, D183*, G184T, N195F, V206L, K391A, P473R and G476K; and o the cellulase comprises SEQ ID NO: 34.
In one embodiment, the composition comprises:
• a hexosaminidase that comprises or consists of SEQ ID NO: 23, or which is a variant thereof having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity to SEQ ID NO: 23;
• a GH39 polypeptide that comprises or consists of SEQ ID NO: 11 , or which is a variant thereof having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity to SEQ ID NO: 1 1 ;
• a protease selected from: a) a polypeptide that comprises or consists of SEQ ID NO: 24 or SEQ ID NO: 26, or a variant thereof having at least 80%, at least 85%, at least 90% or at least 95% sequence identity to SEQ ID NO: 24 or SEQ ID NO: 26; b) a polypeptide that comprises SEQ ID NO: 24 with the substitutions Y161A, R164S and A188P; c) a polypeptide that comprises SEQ ID NO: 24 with the substitutions S9E, N42R, N74D, V199I, Q200L, Y203W, S253D, N255W and L256E; and d) a polypeptide that comprises SEQ ID NO: 37; and
• at least one enzyme selected from the group consisting of amylases, lipases, mannanases, pectate lyases and cellulases.
In one embodiment, the composition comprises:
• a hexosaminidase that comprises or consists of SEQ ID NO: 23;
• a GH39 polypeptide that comprises or consists of SEQ ID NO: 11 ;
• a protease that comprises SEQ ID NO: 24 with the substitutions Y161A, R164S and A188P, or that comprises SEQ ID NO: 37; and
• at least one enzyme selected from the group consisting of amylases, lipases, mannanases, pectate lyases and cellulases; wherein:
o the amylase comprises SEQ ID NO: 30 with the mutations H183*, G184*, I405L, A421 H, A422P and A428T;
o the lipase comprises SEQ ID NO: 31 with the mutations D27R, G38A, D96E, D11 1A, G163K, T231 R, N233R, D254S and P256T; o the mannanase comprises SEQ ID NO: 32; o the pectate lyase comprises SEQ ID NO: 33; and
o the cellulase comprises SEQ ID NO: 34 or SEQ ID NO: 35.
In one embodiment, the composition comprises:
• a hexosaminidase that comprises or consists of SEQ ID NO: 23;
• a GH39 polypeptide that comprises or consists of SEQ ID NO: 11 ;
• a protease that comprises SEQ ID NO: 24 with the substitutions S9E, N42R, N74D, V199I, Q200L, Y203W, S253D, N255W and L256E; and
• at least one enzyme selected from the group consisting of amylases and cellulases; wherein:
o the amylase comprises SEQ ID NO: 29 with the mutations H 1 *, N54S, V56T, K72R, G109A, F113Q, R116Q, W167F, Q172G, A174S, G182*, D183*, G184T, N195F, V206L, K391A, P473R and G476K; and o the cellulase comprises SEQ ID NO: 34.
In one embodiment, the composition comprises:
• a hexosaminidase that comprises or consists of SEQ ID NO: 23, or which is a variant thereof having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity to SEQ ID NO: 23;
• a GH39 polypeptide that comprises or consists of SEQ ID NO: 12, or which is a variant thereof having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity to SEQ ID NO: 12;
• a protease selected from: a) a polypeptide that comprises or consists of SEQ ID NO: 24 or SEQ ID NO: 26, or a variant thereof having at least 80%, at least 85%, at least 90% or at least 95% sequence identity to SEQ ID NO: 24 or SEQ ID NO: 26; b) a polypeptide that comprises SEQ ID NO: 24 with the substitutions Y161A, R164S and A188P; c) a polypeptide that comprises SEQ ID NO: 24 with the substitutions S9E, N42R, N74D, V199I, Q200L, Y203W, S253D, N255W and L256E; and d) a polypeptide that comprises SEQ ID NO: 37; and
• at least one enzyme selected from the group consisting of amylases, lipases, mannanases, pectate lyases and cellulases.
In one embodiment, the composition comprises:
• a hexosaminidase that comprises or consists of SEQ ID NO: 23;
• a GH39 polypeptide that comprises or consists of SEQ ID NO: 12;
• a protease that comprises SEQ ID NO: 24 with the substitutions Y161A, R164S and A188P, or that comprises SEQ ID NO: 37; and • at least one enzyme selected from the group consisting of amylases, lipases, mannanases, pectate lyases and cellulases; wherein:
o the amylase comprises SEQ ID NO: 30 with the mutations H183*, G184*, I405L, A421 H, A422P and A428T;
o the lipase comprises SEQ ID NO: 31 with the mutations D27R, G38A, D96E, D11 1A, G163K, T231 R, N233R, D254S and P256T;
o the mannanase comprises SEQ ID NO: 32;
o the pectate lyase comprises SEQ ID NO: 33; and
o the cellulase comprises SEQ ID NO: 34 or SEQ ID NO: 35.
In one embodiment, the composition comprises:
• a hexosaminidase that comprises or consists of SEQ ID NO: 23;
• a GH39 polypeptide that comprises or consists of SEQ ID NO: 12;
• a protease that comprises SEQ ID NO: 24 with the substitutions S9E, N42R, N74D, V199I, Q200L, Y203W, S253D, N255W and L256E; and
• at least one enzyme selected from the group consisting of amylases and cellulases; wherein:
o the amylase comprises SEQ ID NO: 29 with the mutations H 1 *, N54S, V56T, K72R, G109A, F113Q, R116Q, W167F, Q172G, A174S, G182*, D183*, G184T, N195F, V206L, K391A, P473R and G476K; and o the cellulase comprises SEQ ID NO: 34.
In any of the embodiments described above comprising at least a hexosaminidase and a GH39 glycosyl hydrolase as the cleaning enzymes, the cleaning composition may optionally comprise one or more of any of the other cleaning enzymes described herein. Any of these compositions may thus comprise one or more of a DNase, an RNase, a Glyco_hydro_114 glucosyl hydrolase or a GHL13 glycosyl hydrolase.
Cleaning compositions comprising a hexosaminidase and a GHL13 polypeptide
One aspect of the invention relates to a cleaning composition comprising at least a hexosaminidase and a GHL13 glycosyl hydrolase as the cleaning enzymes. Exemplary embodiments of this aspect of the invention are described below.
In one embodiment, the composition comprises:
• a hexosaminidase that comprises or consists of SEQ ID NO: 19, or which is a variant thereof having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity to SEQ ID NO: 19; • a GHL13 polypeptide that comprises or consists of SEQ ID NO: 13, or which is a variant thereof having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity to SEQ ID NO: 13;
• a protease selected from: a) a polypeptide that comprises or consists of SEQ ID NO: 24 or SEQ ID NO: 26, or a variant thereof having at least 80%, at least 85%, at least 90% or at least 95% sequence identity to SEQ ID NO: 24 or SEQ ID NO: 26; b) a polypeptide that comprises SEQ ID NO: 24 with the substitutions Y161A, R164S and A188P; c) a polypeptide that comprises SEQ ID NO: 24 with the substitutions S9E, N42R, N74D, V199I, Q200L, Y203W, S253D, N255W and L256E; and d) a polypeptide that comprises SEQ ID NO: 37; and
• at least one enzyme selected from the group consisting of amylases, lipases, mannanases, pectate lyases and cellulases.
In one embodiment, the composition comprises:
• a hexosaminidase that comprises or consists of SEQ ID NO: 19;
• a GHL13 polypeptide that comprises or consists of SEQ ID NO: 13;
• a protease that comprises SEQ ID NO: 24 with the substitutions Y161A, R164S and A188P, or that comprises SEQ ID NO: 37; and
• at least one enzyme selected from the group consisting of amylases, lipases, mannanases, pectate lyases and cellulases; wherein:
o the amylase comprises SEQ ID NO: 30 with the mutations H183*, G184*, I405L, A421 H, A422P and A428T;
o the lipase comprises SEQ ID NO: 31 with the mutations D27R, G38A, D96E, D1 11A, G163K, T231 R, N233R, D254S and P256T; o the mannanase comprises SEQ ID NO: 32;
o the pectate lyase comprises SEQ ID NO: 33; and
o the cellulase comprises SEQ ID NO: 34 or SEQ ID NO: 35.
In one embodiment, the composition comprises:
• a hexosaminidase that comprises or consists of SEQ ID NO: 19;
• a GHL13 polypeptide that comprises or consists of SEQ ID NO: 13;
• a protease that comprises SEQ ID NO: 24 with the substitutions S9E, N42R, N74D, V199I, Q200L, Y203W, S253D, N255W and L256E; and
• at least one enzyme selected from the group consisting of amylases and cellulases; wherein:
o the amylase comprises SEQ ID NO: 29 with the mutations H 1 *, N54S, V56T, K72R, G109A, F113Q, R116Q, W167F, Q172G, A174S, G182*, D183*, G184T, N195F, V206L, K391A, P473R and G476K; and o the cellulase comprises SEQ ID NO: 34.
In one embodiment, the composition comprises:
• a hexosaminidase that comprises or consists of SEQ ID NO: 19, or which is a variant thereof having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity to SEQ ID NO: 19;
• a GHL13 polypeptide that comprises or consists of SEQ ID NO: 14, or which is a variant thereof having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity to SEQ ID NO: 14;
• a protease selected from: a) a polypeptide that comprises or consists of SEQ ID NO: 24 or SEQ ID NO: 26, or a variant thereof having at least 80%, at least 85%, at least 90% or at least 95% sequence identity to SEQ ID NO: 24 or SEQ ID NO: 26; b) a polypeptide that comprises SEQ ID NO: 24 with the substitutions Y161A, R164S and A188P; c) a polypeptide that comprises SEQ ID NO: 24 with the substitutions S9E, N42R, N74D, V199I, Q200L, Y203W, S253D, N255W and L256E; and d) a polypeptide that comprises SEQ ID NO: 37; and
• at least one enzyme selected from the group consisting of amylases, lipases, mannanases, pectate lyases and cellulases.
In one embodiment, the composition comprises:
• a hexosaminidase that comprises or consists of SEQ ID NO: 19;
• a GHL13 polypeptide that comprises or consists of SEQ ID NO: 14;
• a protease that comprises SEQ ID NO: 24 with the substitutions Y161A, R164S and A188P, or that comprises SEQ ID NO: 37; and
• at least one enzyme selected from the group consisting of amylases, lipases, mannanases, pectate lyases and cellulases; wherein:
o the amylase comprises SEQ ID NO: 30 with the mutations H183*, G184*, I405L, A421 H, A422P and A428T;
o the lipase comprises SEQ ID NO: 31 with the mutations D27R, G38A, D96E, D11 1A, G163K, T231 R, N233R, D254S and P256T; o the mannanase comprises SEQ ID NO: 32;
o the pectate lyase comprises SEQ ID NO: 33; and
o the cellulase comprises SEQ ID NO: 34 or SEQ ID NO: 35.
In one embodiment, the composition comprises:
• a hexosaminidase that comprises or consists of SEQ ID NO: 19;
• a GHL13 polypeptide that comprises or consists of SEQ ID NO: 14; • a protease that comprises SEQ ID NO: 24 with the substitutions S9E, N42R, N74D, V199I, Q200L, Y203W, S253D, N255W and L256E; and
• at least one enzyme selected from the group consisting of amylases and cellulases; wherein:
o the amylase comprises SEQ ID NO: 29 with the mutations H 1 *, N54S, V56T, K72R, G109A, F113Q, R116Q, W167F, Q172G, A174S, G182*, D183*, G184T, N195F, V206L, K391A, P473R and G476K; and o the cellulase comprises SEQ ID NO: 34.
In one embodiment, the composition comprises:
• a hexosaminidase that comprises or consists of SEQ ID NO: 19, or which is a variant thereof having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity to SEQ ID NO: 19;
• a GHL13 polypeptide that comprises or consists of SEQ ID NO: 15, or which is a variant thereof having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity to SEQ ID NO: 15;
• a protease selected from: a) a polypeptide that comprises or consists of SEQ ID NO: 24 or SEQ ID NO: 26, or a variant thereof having at least 80%, at least 85%, at least 90% or at least 95% sequence identity to SEQ ID NO: 24 or SEQ ID NO: 26; b) a polypeptide that comprises SEQ ID NO: 24 with the substitutions Y161A, R164S and A188P; c) a polypeptide that comprises SEQ ID NO: 24 with the substitutions S9E, N42R, N74D, V199I, Q200L, Y203W, S253D, N255W and L256E; and d) a polypeptide that comprises SEQ ID NO: 37; and
• at least one enzyme selected from the group consisting of amylases, lipases, mannanases, pectate lyases and cellulases.
In one embodiment, the composition comprises:
• a hexosaminidase that comprises or consists of SEQ ID NO: 19;
• a GHL13 polypeptide that comprises or consists of SEQ ID NO: 15;
• a protease that comprises SEQ ID NO: 24 with the substitutions Y161A, R164S and A188P, or that comprises SEQ ID NO: 37; and
• at least one enzyme selected from the group consisting of amylases, lipases, mannanases, pectate lyases and cellulases; wherein:
o the amylase comprises SEQ ID NO: 30 with the mutations H183*, G184*, I405L, A421 H, A422P and A428T; o the lipase comprises SEQ ID NO: 31 with the mutations D27R, G38A, D96E, D11 1A, G163K, T231 R, N233R, D254S and P256T; o the mannanase comprises SEQ ID NO: 32;
o the pectate lyase comprises SEQ ID NO: 33; and
o the cellulase comprises SEQ ID NO: 34 or SEQ ID NO: 35.
In one embodiment, the composition comprises:
• a hexosaminidase that comprises or consists of SEQ ID NO: 19;
• a GHL13 polypeptide that comprises or consists of SEQ ID NO: 15;
• a protease that comprises SEQ ID NO: 24 with the substitutions S9E, N42R, N74D, V199I, Q200L, Y203W, S253D, N255W and L256E; and
• at least one enzyme selected from the group consisting of amylases and cellulases; wherein:
o the amylase comprises SEQ ID NO: 29 with the mutations H 1 *, N54S, V56T, K72R, G109A, F113Q, R116Q, W167F, Q172G, A174S, G182*, D183*, G184T, N195F, V206L, K391A, P473R and G476K; and o the cellulase comprises SEQ ID NO: 34.
In one embodiment, the composition comprises:
• a hexosaminidase that comprises or consists of SEQ ID NO: 20, or which is a variant thereof having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity to SEQ ID NO: 20;
• a GHL13 polypeptide that comprises or consists of SEQ ID NO: 13, or which is a variant thereof having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity to SEQ ID NO: 13;
• a protease selected from: a) a polypeptide that comprises or consists of SEQ ID NO: 24 or SEQ ID NO: 26, or a variant thereof having at least 80%, at least 85%, at least 90% or at least 95% sequence identity to SEQ ID NO: 24 or SEQ ID NO: 26; b) a polypeptide that comprises SEQ ID NO: 24 with the substitutions Y161A, R164S and A188P; c) a polypeptide that comprises SEQ ID NO: 24 with the substitutions S9E, N42R, N74D, V199I, Q200L, Y203W, S253D, N255W and L256E; and d) a polypeptide that comprises SEQ ID NO: 37; and
• at least one enzyme selected from the group consisting of amylases, lipases, mannanases, pectate lyases and cellulases.
In one embodiment, the composition comprises:
• a hexosaminidase that comprises or consists of SEQ ID NO: 20; • a GHL13 polypeptide that comprises or consists of SEQ ID NO: 13;
• a protease that comprises SEQ ID NO: 24 with the substitutions Y161A, R164S and A188P, or that comprises SEQ ID NO: 37; and
• at least one enzyme selected from the group consisting of amylases, lipases, mannanases, pectate lyases and cellulases; wherein:
o the amylase comprises SEQ ID NO: 30 with the mutations H183*, G184*, I405L, A421 H, A422P and A428T;
o the lipase comprises SEQ ID NO: 31 with the mutations D27R, G38A, D96E, D11 1A, G163K, T231 R, N233R, D254S and P256T; o the mannanase comprises SEQ ID NO: 32;
o the pectate lyase comprises SEQ ID NO: 33; and
o the cellulase comprises SEQ ID NO: 34 or SEQ ID NO: 35.
In one embodiment, the composition comprises:
• a hexosaminidase that comprises or consists of SEQ ID NO: 20;
• a GHL13 polypeptide that comprises or consists of SEQ ID NO: 13;
• a protease that comprises SEQ ID NO: 24 with the substitutions S9E, N42R, N74D, V199I, Q200L, Y203W, S253D, N255W and L256E; and
• at least one enzyme selected from the group consisting of amylases and cellulases; wherein:
o the amylase comprises SEQ ID NO: 29 with the mutations H 1 *, N54S, V56T, K72R, G109A, F113Q, R116Q, W167F, Q172G, A174S, G182*, D183*, G184T, N195F, V206L, K391A, P473R and G476K; and o the cellulase comprises SEQ ID NO: 34.
In one embodiment, the composition comprises:
• a hexosaminidase that comprises or consists of SEQ ID NO: 20, or which is a variant thereof having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity to SEQ ID NO: 20;
• a GHL13 polypeptide that comprises or consists of SEQ ID NO: 14, or which is a variant thereof having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity to SEQ ID NO: 14;
• a protease selected from: a) a polypeptide that comprises or consists of SEQ ID NO: 24 or SEQ ID NO: 26, or a variant thereof having at least 80%, at least 85%, at least 90% or at least 95% sequence identity to SEQ ID NO: 24 or SEQ ID NO: 26; b) a polypeptide that comprises SEQ ID NO: 24 with the substitutions Y161A, R164S and A188P; c) a polypeptide that comprises SEQ ID NO: 24 with the substitutions S9E, N42R, N74D, V199I, Q200L, Y203W, S253D, N255W and L256E; and d) a polypeptide that comprises SEQ ID NO: 37; and
• at least one enzyme selected from the group consisting of amylases, lipases, mannanases, pectate lyases and cellulases.
In one embodiment, the composition comprises:
• a hexosaminidase that comprises or consists of SEQ ID NO: 20;
• a GHL13 polypeptide that comprises or consists of SEQ ID NO: 14;
• a protease that comprises SEQ ID NO: 24 with the substitutions Y161A, R164S and A188P, or that comprises SEQ ID NO: 37; and
• at least one enzyme selected from the group consisting of amylases, lipases, mannanases, pectate lyases and cellulases; wherein:
o the amylase comprises SEQ ID NO: 30 with the mutations H183*, G184*, I405L, A421 H, A422P and A428T;
o the lipase comprises SEQ ID NO: 31 with the mutations D27R, G38A, D96E, D11 1A, G163K, T231 R, N233R, D254S and P256T; o the mannanase comprises SEQ ID NO: 32;
o the pectate lyase comprises SEQ ID NO: 33; and
o the cellulase comprises SEQ ID NO: 34 or SEQ ID NO: 35.
In one embodiment, the composition comprises:
• a hexosaminidase that comprises or consists of SEQ ID NO: 20;
• a GHL13 polypeptide that comprises or consists of SEQ ID NO: 14;
• a protease that comprises SEQ ID NO: 24 with the substitutions S9E, N42R, N74D, V199I, Q200L, Y203W, S253D, N255W and L256E; and
• at least one enzyme selected from the group consisting of amylases and cellulases; wherein:
o the amylase comprises SEQ ID NO: 29 with the mutations H 1 *, N54S, V56T, K72R, G109A, F113Q, R116Q, W167F, Q172G, A174S, G182*, D183*, G184T, N195F, V206L, K391A, P473R and G476K; and o the cellulase comprises SEQ ID NO: 34.
In one embodiment, the composition comprises:
• a hexosaminidase that comprises or consists of SEQ ID NO: 20, or which is a variant thereof having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity to SEQ ID NO: 20; • a GHL13 polypeptide that comprises or consists of SEQ ID NO: 15, or which is a variant thereof having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity to SEQ ID NO: 15;
• a protease selected from: a) a polypeptide that comprises or consists of SEQ ID NO: 24 or SEQ ID NO: 26, or a variant thereof having at least 80%, at least 85%, at least 90% or at least 95% sequence identity to SEQ ID NO: 24 or SEQ ID NO: 26; b) a polypeptide that comprises SEQ ID NO: 24 with the substitutions Y161A, R164S and A188P; c) a polypeptide that comprises SEQ ID NO: 24 with the substitutions S9E, N42R, N74D, V199I, Q200L, Y203W, S253D, N255W and L256E; and d) a polypeptide that comprises SEQ ID NO: 37; and
• at least one enzyme selected from the group consisting of amylases, lipases, mannanases, pectate lyases and cellulases.
In one embodiment, the composition comprises:
• a hexosaminidase that comprises or consists of SEQ ID NO: 20;
• a GHL13 polypeptide that comprises or consists of SEQ ID NO: 15;
• a protease that comprises SEQ ID NO: 24 with the substitutions Y161A, R164S and A188P, or that comprises SEQ ID NO: 37; and
• at least one enzyme selected from the group consisting of amylases, lipases, mannanases, pectate lyases and cellulases; wherein:
o the amylase comprises SEQ ID NO: 30 with the mutations H183*, G184*, I405L, A421 H, A422P and A428T;
o the lipase comprises SEQ ID NO: 31 with the mutations D27R, G38A, D96E, D11 1A, G163K, T231 R, N233R, D254S and P256T; o the mannanase comprises SEQ ID NO: 32;
o the pectate lyase comprises SEQ ID NO: 33; and
o the cellulase comprises SEQ ID NO: 34 or SEQ ID NO: 35.
In one embodiment, the composition comprises:
• a hexosaminidase that comprises or consists of SEQ ID NO: 20;
• a GHL13 polypeptide that comprises or consists of SEQ ID NO: 15;
• a protease that comprises SEQ ID NO: 24 with the substitutions S9E, N42R, N74D, V199I, Q200L, Y203W, S253D, N255W and L256E; and
• at least one enzyme selected from the group consisting of amylases and cellulases; wherein:
o the amylase comprises SEQ ID NO: 29 with the mutations H 1 *, N54S, V56T, K72R, G109A, F113Q, R116Q, W167F, Q172G, A174S, G182*, D183*, G184T, N195F, V206L, K391A, P473R and G476K; and o the cellulase comprises SEQ ID NO: 34.
In one embodiment, the composition comprises:
• a hexosaminidase that comprises or consists of SEQ ID NO: 21 , or which is a variant thereof having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity to SEQ ID NO: 21 ;
• a GHL13 polypeptide that comprises or consists of SEQ ID NO: 13, or which is a variant thereof having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity to SEQ ID NO: 13;
• a protease selected from: a) a polypeptide that comprises or consists of SEQ ID NO: 24 or SEQ ID NO: 26, or a variant thereof having at least 80%, at least 85%, at least 90% or at least 95% sequence identity to SEQ ID NO: 24 or SEQ ID NO: 26; b) a polypeptide that comprises SEQ ID NO: 24 with the substitutions Y161A, R164S and A188P; c) a polypeptide that comprises SEQ ID NO: 24 with the substitutions S9E, N42R, N74D, V199I, Q200L, Y203W, S253D, N255W and L256E; and d) a polypeptide that comprises SEQ ID NO: 37; and
• at least one enzyme selected from the group consisting of amylases, lipases, mannanases, pectate lyases and cellulases.
In one embodiment, the composition comprises:
• a hexosaminidase that comprises or consists of SEQ ID NO: 21 ;
• a GHL13 polypeptide that comprises or consists of SEQ ID NO: 13;
• a protease that comprises SEQ ID NO: 24 with the substitutions Y161A, R164S and A188P, or that comprises SEQ ID NO: 37; and
• at least one enzyme selected from the group consisting of amylases, lipases, mannanases, pectate lyases and cellulases; wherein:
o the amylase comprises SEQ ID NO: 30 with the mutations H183*, G184*, I405L, A421 H, A422P and A428T;
o the lipase comprises SEQ ID NO: 31 with the mutations D27R, G38A, D96E, D11 1A, G163K, T231 R, N233R, D254S and P256T; o the mannanase comprises SEQ ID NO: 32;
o the pectate lyase comprises SEQ ID NO: 33; and
o the cellulase comprises SEQ ID NO: 34 or SEQ ID NO: 35.
In one embodiment, the composition comprises:
• a hexosaminidase that comprises or consists of SEQ ID NO: 21 ;
• a GHL13 polypeptide that comprises or consists of SEQ ID NO: 13; • a protease that comprises SEQ ID NO: 24 with the substitutions S9E, N42R, N74D, V199I, Q200L, Y203W, S253D, N255W and L256E; and
• at least one enzyme selected from the group consisting of amylases and cellulases; wherein:
o the amylase comprises SEQ ID NO: 29 with the mutations H 1 *, N54S, V56T, K72R, G109A, F113Q, R116Q, W167F, Q172G, A174S, G182*, D183*, G184T, N195F, V206L, K391A, P473R and G476K; and o the cellulase comprises SEQ ID NO: 34.
In one embodiment, the composition comprises:
• a hexosaminidase that comprises or consists of SEQ ID NO: 21 , or which is a variant thereof having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity to SEQ ID NO: 21 ;
• a GHL13 polypeptide that comprises or consists of SEQ ID NO: 14, or which is a variant thereof having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity to SEQ ID NO: 14;
• a protease selected from: a) a polypeptide that comprises or consists of SEQ ID NO: 24 or SEQ ID NO: 26, or a variant thereof having at least 80%, at least 85%, at least 90% or at least 95% sequence identity to SEQ ID NO: 24 or SEQ ID NO: 26; b) a polypeptide that comprises SEQ ID NO: 24 with the substitutions Y161A, R164S and A188P; c) a polypeptide that comprises SEQ ID NO: 24 with the substitutions S9E, N42R, N74D, V199I, Q200L, Y203W, S253D, N255W and L256E; and d) a polypeptide that comprises SEQ ID NO: 37; and
• at least one enzyme selected from the group consisting of amylases, lipases, mannanases, pectate lyases and cellulases.
In one embodiment, the composition comprises:
• a hexosaminidase that comprises or consists of SEQ ID NO: 21 ;
• a GHL13 polypeptide that comprises or consists of SEQ ID NO: 14;
• a protease that comprises SEQ ID NO: 24 with the substitutions Y161A, R164S and A188P, or that comprises SEQ ID NO: 37; and
• at least one enzyme selected from the group consisting of amylases, lipases, mannanases, pectate lyases and cellulases; wherein:
o the amylase comprises SEQ ID NO: 30 with the mutations H183*, G184*, I405L, A421 H, A422P and A428T; o the lipase comprises SEQ ID NO: 31 with the mutations D27R, G38A, D96E, D11 1A, G163K, T231 R, N233R, D254S and P256T; o the mannanase comprises SEQ ID NO: 32;
o the pectate lyase comprises SEQ ID NO: 33; and
o the cellulase comprises SEQ ID NO: 34 or SEQ ID NO: 35.
In one embodiment, the composition comprises:
• a hexosaminidase that comprises or consists of SEQ ID NO: 21 ;
• a GHL13 polypeptide that comprises or consists of SEQ ID NO: 14;
• a protease that comprises SEQ ID NO: 24 with the substitutions S9E, N42R, N74D, V199I, Q200L, Y203W, S253D, N255W and L256E; and
• at least one enzyme selected from the group consisting of amylases and cellulases; wherein:
o the amylase comprises SEQ ID NO: 29 with the mutations H 1 *, N54S, V56T, K72R, G109A, F113Q, R116Q, W167F, Q172G, A174S, G182*, D183*, G184T, N195F, V206L, K391A, P473R and G476K; and o the cellulase comprises SEQ ID NO: 34.
In one embodiment, the composition comprises:
• a hexosaminidase that comprises or consists of SEQ ID NO: 21 , or which is a variant thereof having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity to SEQ ID NO: 21 ;
• a GHL13 polypeptide that comprises or consists of SEQ ID NO: 15, or which is a variant thereof having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity to SEQ ID NO: 15;
• a protease selected from: a) a polypeptide that comprises or consists of SEQ ID NO: 24 or SEQ ID NO: 26, or a variant thereof having at least 80%, at least 85%, at least 90% or at least 95% sequence identity to SEQ ID NO: 24 or SEQ ID NO: 26; b) a polypeptide that comprises SEQ ID NO: 24 with the substitutions Y161A, R164S and A188P; c) a polypeptide that comprises SEQ ID NO: 24 with the substitutions S9E, N42R, N74D, V199I, Q200L, Y203W, S253D, N255W and L256E; and d) a polypeptide that comprises SEQ ID NO: 37; and
• at least one enzyme selected from the group consisting of amylases, lipases, mannanases, pectate lyases and cellulases.
In one embodiment, the composition comprises:
• a hexosaminidase that comprises or consists of SEQ ID NO: 21 ; • a GHL13 polypeptide that comprises or consists of SEQ ID NO: 15;
• a protease that comprises SEQ ID NO: 24 with the substitutions Y161A, R164S and A188P, or that comprises SEQ ID NO: 37; and
• at least one enzyme selected from the group consisting of amylases, lipases, mannanases, pectate lyases and cellulases; wherein:
o the amylase comprises SEQ ID NO: 30 with the mutations H183*, G184*, I405L, A421 H, A422P and A428T;
o the lipase comprises SEQ ID NO: 31 with the mutations D27R, G38A, D96E, D1 11A, G163K, T231 R, N233R, D254S and P256T; o the mannanase comprises SEQ ID NO: 32;
o the pectate lyase comprises SEQ ID NO: 33; and
o the cellulase comprises SEQ ID NO: 34 or SEQ ID NO: 35.
In one embodiment, the composition comprises:
• a hexosaminidase that comprises or consists of SEQ ID NO: 21 ;
• a GHL13 polypeptide that comprises or consists of SEQ ID NO: 15;
• a protease that comprises SEQ ID NO: 24 with the substitutions S9E, N42R, N74D, V199I, Q200L, Y203W, S253D, N255W and L256E; and
• at least one enzyme selected from the group consisting of amylases and cellulases; wherein:
o the amylase comprises SEQ ID NO: 29 with the mutations H 1 *, N54S, V56T, K72R, G109A, F113Q, R116Q, W167F, Q172G, A174S, G182*, D183*, G184T, N195F, V206L, K391A, P473R and G476K; and o the cellulase comprises SEQ ID NO: 34.
In one embodiment, the composition comprises:
• a hexosaminidase that comprises or consists of SEQ ID NO: 22, or which is a variant thereof having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity to SEQ ID NO: 22;
• a GHL13 polypeptide that comprises or consists of SEQ ID NO: 13, or which is a variant thereof having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity to SEQ ID NO: 13;
• a protease selected from: a) a polypeptide that comprises or consists of SEQ ID NO: 24 or SEQ ID NO: 26, or a variant thereof having at least 80%, at least 85%, at least 90% or at least 95% sequence identity to SEQ ID NO: 24 or SEQ ID NO: 26; b) a polypeptide that comprises SEQ ID NO: 24 with the substitutions Y161A, R164S and A188P; c) a polypeptide that comprises SEQ ID NO: 24 with the substitutions S9E, N42R, N74D, V199I, Q200L, Y203W, S253D, N255W and L256E; and d) a polypeptide that comprises SEQ ID NO: 37; and
• at least one enzyme selected from the group consisting of amylases, lipases, mannanases, pectate lyases and cellulases.
In one embodiment, the composition comprises:
• a hexosaminidase that comprises or consists of SEQ ID NO: 22;
• a GHL13 polypeptide that comprises or consists of SEQ ID NO: 13;
• a protease that comprises SEQ ID NO: 24 with the substitutions Y161A, R164S and A188P, or that comprises SEQ ID NO: 37; and
• at least one enzyme selected from the group consisting of amylases, lipases, mannanases, pectate lyases and cellulases; wherein:
o the amylase comprises SEQ ID NO: 30 with the mutations H183*, G184*, I405L, A421 H, A422P and A428T;
o the lipase comprises SEQ ID NO: 31 with the mutations D27R, G38A, D96E, D11 1A, G163K, T231 R, N233R, D254S and P256T; o the mannanase comprises SEQ ID NO: 32;
o the pectate lyase comprises SEQ ID NO: 33; and
o the cellulase comprises SEQ ID NO: 34 or SEQ ID NO: 35.
In one embodiment, the composition comprises:
• a hexosaminidase that comprises or consists of SEQ ID NO: 22;
• a GHL13 polypeptide that comprises or consists of SEQ ID NO: 13;
• a protease that comprises SEQ ID NO: 24 with the substitutions S9E, N42R, N74D, V199I, Q200L, Y203W, S253D, N255W and L256E; and
• at least one enzyme selected from the group consisting of amylases and cellulases; wherein:
o the amylase comprises SEQ ID NO: 29 with the mutations H 1 *, N54S, V56T, K72R, G109A, F113Q, R116Q, W167F, Q172G, A174S, G182*, D183*, G184T, N195F, V206L, K391A, P473R and G476K; and o the cellulase comprises SEQ ID NO: 34.
In one embodiment, the composition comprises:
• a hexosaminidase that comprises or consists of SEQ ID NO: 22, or which is a variant thereof having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity to SEQ ID NO: 22; • a GHL13 polypeptide that comprises or consists of SEQ ID NO: 14, or which is a variant thereof having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity to SEQ ID NO: 14;
• a protease selected from: a) a polypeptide that comprises or consists of SEQ ID NO: 24 or SEQ ID NO: 26, or a variant thereof having at least 80%, at least 85%, at least 90% or at least 95% sequence identity to SEQ ID NO: 24 or SEQ ID NO: 26; b) a polypeptide that comprises SEQ ID NO: 24 with the substitutions Y161A, R164S and A188P; c) a polypeptide that comprises SEQ ID NO: 24 with the substitutions S9E, N42R, N74D, V199I, Q200L, Y203W, S253D, N255W and L256E; and d) a polypeptide that comprises SEQ ID NO: 37; and
• at least one enzyme selected from the group consisting of amylases, lipases, mannanases, pectate lyases and cellulases.
In one embodiment, the composition comprises:
• a hexosaminidase that comprises or consists of SEQ ID NO: 22;
• a GHL13 polypeptide that comprises or consists of SEQ ID NO: 14;
• a protease that comprises SEQ ID NO: 24 with the substitutions Y161A, R164S and A188P, or that comprises SEQ ID NO: 37; and
• at least one enzyme selected from the group consisting of amylases, lipases, mannanases, pectate lyases and cellulases; wherein:
o the amylase comprises SEQ ID NO: 30 with the mutations H183*, G184*, I405L, A421 H, A422P and A428T;
o the lipase comprises SEQ ID NO: 31 with the mutations D27R, G38A, D96E, D11 1A, G163K, T231 R, N233R, D254S and P256T; o the mannanase comprises SEQ ID NO: 32;
o the pectate lyase comprises SEQ ID NO: 33; and
o the cellulase comprises SEQ ID NO: 34 or SEQ ID NO: 35.
In one embodiment, the composition comprises:
• a hexosaminidase that comprises or consists of SEQ ID NO: 22;
• a GHL13 polypeptide that comprises or consists of SEQ ID NO: 14;
• a protease that comprises SEQ ID NO: 24 with the substitutions S9E, N42R, N74D, V199I, Q200L, Y203W, S253D, N255W and L256E; and
• at least one enzyme selected from the group consisting of amylases and cellulases; wherein:
o the amylase comprises SEQ ID NO: 29 with the mutations H 1 *, N54S, V56T, K72R, G109A, F113Q, R116Q, W167F, Q172G, A174S, G182*, D183*, G184T, N195F, V206L, K391A, P473R and G476K; and o the cellulase comprises SEQ ID NO: 34.
In one embodiment, the composition comprises:
• a hexosaminidase that comprises or consists of SEQ ID NO: 22, or which is a variant thereof having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity to SEQ ID NO: 22;
• a GHL13 polypeptide that comprises or consists of SEQ ID NO: 15, or which is a variant thereof having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity to SEQ ID NO: 15;
• a protease selected from: a) a polypeptide that comprises or consists of SEQ ID NO: 24 or SEQ ID NO: 26, or a variant thereof having at least 80%, at least 85%, at least 90% or at least 95% sequence identity to SEQ ID NO: 24 or SEQ ID NO: 26; b) a polypeptide that comprises SEQ ID NO: 24 with the substitutions Y161A, R164S and A188P; c) a polypeptide that comprises SEQ ID NO: 24 with the substitutions S9E, N42R, N74D, V199I, Q200L, Y203W, S253D, N255W and L256E; and d) a polypeptide that comprises SEQ ID NO: 37; and
• at least one enzyme selected from the group consisting of amylases, lipases, mannanases, pectate lyases and cellulases.
In one embodiment, the composition comprises:
• a hexosaminidase that comprises or consists of SEQ ID NO: 22;
• a GHL13 polypeptide that comprises or consists of SEQ ID NO: 15;
• a protease that comprises SEQ ID NO: 24 with the substitutions Y161A, R164S and A188P, or that comprises SEQ ID NO: 37; and
• at least one enzyme selected from the group consisting of amylases, lipases, mannanases, pectate lyases and cellulases; wherein:
o the amylase comprises SEQ ID NO: 30 with the mutations H183*, G184*, I405L, A421 H, A422P and A428T;
o the lipase comprises SEQ ID NO: 31 with the mutations D27R, G38A, D96E, D11 1A, G163K, T231 R, N233R, D254S and P256T; o the mannanase comprises SEQ ID NO: 32;
o the pectate lyase comprises SEQ ID NO: 33; and
o the cellulase comprises SEQ ID NO: 34 or SEQ ID NO: 35.
In one embodiment, the composition comprises:
• a hexosaminidase that comprises or consists of SEQ ID NO: 22;
• a GHL13 polypeptide that comprises or consists of SEQ ID NO: 15; • a protease that comprises SEQ ID NO: 24 with the substitutions S9E, N42R, N74D, V199I, Q200L, Y203W, S253D, N255W and L256E; and
• at least one enzyme selected from the group consisting of amylases and cellulases; wherein:
o the amylase comprises SEQ ID NO: 29 with the mutations H 1 *, N54S, V56T, K72R, G109A, F113Q, R116Q, W167F, Q172G, A174S, G182*, D183*, G184T, N195F, V206L, K391A, P473R and G476K; and o the cellulase comprises SEQ ID NO: 34.
In one embodiment, the composition comprises:
• a hexosaminidase that comprises or consists of SEQ ID NO: 23, or which is a variant thereof having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity to SEQ ID NO: 23;
• a GHL13 polypeptide that comprises or consists of SEQ ID NO: 13, or which is a variant thereof having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity to SEQ ID NO: 13;
• a protease selected from: a) a polypeptide that comprises or consists of SEQ ID NO: 24 or SEQ ID NO: 26, or a variant thereof having at least 80%, at least 85%, at least 90% or at least 95% sequence identity to SEQ ID NO: 24 or SEQ ID NO: 26; b) a polypeptide that comprises SEQ ID NO: 24 with the substitutions Y161A, R164S and A188P; c) a polypeptide that comprises SEQ ID NO: 24 with the substitutions S9E, N42R, N74D, V199I, Q200L, Y203W, S253D, N255W and L256E; and d) a polypeptide that comprises SEQ ID NO: 37; and
• at least one enzyme selected from the group consisting of amylases, lipases, mannanases, pectate lyases and cellulases.
In one embodiment, the composition comprises:
• a hexosaminidase that comprises or consists of SEQ ID NO: 23;
• a GHL13 polypeptide that comprises or consists of SEQ ID NO: 13;
• a protease that comprises SEQ ID NO: 24 with the substitutions Y161A, R164S and A188P, or that comprises SEQ ID NO: 37; and
• at least one enzyme selected from the group consisting of amylases, lipases, mannanases, pectate lyases and cellulases; wherein:
o the amylase comprises SEQ ID NO: 30 with the mutations H183*, G184*, I405L, A421 H, A422P and A428T; o the lipase comprises SEQ ID NO: 31 with the mutations D27R, G38A, D96E, D11 1A, G163K, T231 R, N233R, D254S and P256T; o the mannanase comprises SEQ ID NO: 32;
o the pectate lyase comprises SEQ ID NO: 33; and
o the cellulase comprises SEQ ID NO: 34 or SEQ ID NO: 35.
In one embodiment, the composition comprises:
• a hexosaminidase that comprises or consists of SEQ ID NO: 23;
• a GHL13 polypeptide that comprises or consists of SEQ ID NO: 13;
• a protease that comprises SEQ ID NO: 24 with the substitutions S9E, N42R, N74D, V199I, Q200L, Y203W, S253D, N255W and L256E; and
• at least one enzyme selected from the group consisting of amylases and cellulases; wherein:
o the amylase comprises SEQ ID NO: 29 with the mutations H 1 *, N54S, V56T, K72R, G109A, F113Q, R116Q, W167F, Q172G, A174S, G182*, D183*, G184T, N195F, V206L, K391A, P473R and G476K; and o the cellulase comprises SEQ ID NO: 34.
In one embodiment, the composition comprises:
• a hexosaminidase that comprises or consists of SEQ ID NO: 23, or which is a variant thereof having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity to SEQ ID NO: 23;
• a GHL13 polypeptide that comprises or consists of SEQ ID NO: 14, or which is a variant thereof having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity to SEQ ID NO: 14;
• a protease selected from: a) a polypeptide that comprises or consists of SEQ ID NO: 24 or SEQ ID NO: 26, or a variant thereof having at least 80%, at least 85%, at least 90% or at least 95% sequence identity to SEQ ID NO: 24 or SEQ ID NO: 26; b) a polypeptide that comprises SEQ ID NO: 24 with the substitutions Y161A, R164S and A188P; c) a polypeptide that comprises SEQ ID NO: 24 with the substitutions S9E, N42R, N74D, V199I, Q200L, Y203W, S253D, N255W and L256E; and d) a polypeptide that comprises SEQ ID NO: 37; and
• at least one enzyme selected from the group consisting of amylases, lipases, mannanases, pectate lyases and cellulases.
In one embodiment, the composition comprises:
• a hexosaminidase that comprises or consists of SEQ ID NO: 23; • a GHL13 polypeptide that comprises or consists of SEQ ID NO: 14;
• a protease that comprises SEQ ID NO: 24 with the substitutions Y161A, R164S and A188P, or that comprises SEQ ID NO: 37; and
• at least one enzyme selected from the group consisting of amylases, lipases, mannanases, pectate lyases and cellulases; wherein:
o the amylase comprises SEQ ID NO: 30 with the mutations H183*, G184*, I405L, A421 H, A422P and A428T;
o the lipase comprises SEQ ID NO: 31 with the mutations D27R, G38A, D96E, D11 1A, G163K, T231 R, N233R, D254S and P256T; o the mannanase comprises SEQ ID NO: 32;
o the pectate lyase comprises SEQ ID NO: 33; and
o the cellulase comprises SEQ ID NO: 34 or SEQ ID NO: 35.
In one embodiment, the composition comprises:
• a hexosaminidase that comprises or consists of SEQ ID NO: 23;
• a GHL13 polypeptide that comprises or consists of SEQ ID NO: 14;
• a protease that comprises SEQ ID NO: 24 with the substitutions S9E, N42R, N74D, V199I, Q200L, Y203W, S253D, N255W and L256E; and
• at least one enzyme selected from the group consisting of amylases and cellulases; wherein:
o the amylase comprises SEQ ID NO: 29 with the mutations H 1 *, N54S, V56T, K72R, G109A, F113Q, R116Q, W167F, Q172G, A174S, G182*, D183*, G184T, N195F, V206L, K391A, P473R and G476K; and o the cellulase comprises SEQ ID NO: 34.
In one embodiment, the composition comprises:
• a hexosaminidase that comprises or consists of SEQ ID NO: 23, or which is a variant thereof having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity to SEQ ID NO: 23;
• a GHL13 polypeptide that comprises or consists of SEQ ID NO: 15, or which is a variant thereof having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity to SEQ ID NO: 15;
• a protease selected from: a) a polypeptide that comprises or consists of SEQ ID NO: 24 or SEQ ID NO: 26, or a variant thereof having at least 80%, at least 85%, at least 90% or at least 95% sequence identity to SEQ ID NO: 24 or SEQ ID NO: 26; b) a polypeptide that comprises SEQ ID NO: 24 with the substitutions Y161A, R164S and A188P; c) a polypeptide that comprises SEQ ID NO: 24 with the substitutions S9E, N42R, N74D, V199I, Q200L, Y203W, S253D, N255W and L256E; and d) a polypeptide that comprises SEQ ID NO: 37; and
• at least one enzyme selected from the group consisting of amylases, lipases, mannanases, pectate lyases and cellulases.
In one embodiment, the composition comprises:
• a hexosaminidase that comprises or consists of SEQ ID NO: 23;
• a GHL13 polypeptide that comprises or consists of SEQ ID NO: 15;
• a protease that comprises SEQ ID NO: 24 with the substitutions Y161A, R164S and A188P, or that comprises SEQ ID NO: 37; and
• at least one enzyme selected from the group consisting of amylases, lipases, mannanases, pectate lyases and cellulases; wherein:
o the amylase comprises SEQ ID NO: 30 with the mutations H183*, G184*, I405L, A421 H, A422P and A428T;
o the lipase comprises SEQ ID NO: 31 with the mutations D27R, G38A, D96E, D11 1A, G163K, T231 R, N233R, D254S and P256T;
o the mannanase comprises SEQ ID NO: 32;
o the pectate lyase comprises SEQ ID NO: 33; and
o the cellulase comprises SEQ ID NO: 34 or SEQ ID NO: 35.
In one embodiment, the composition comprises:
• a hexosaminidase that comprises or consists of SEQ ID NO: 23;
• a GHL13 polypeptide that comprises or consists of SEQ ID NO: 15;
• a protease that comprises SEQ ID NO: 24 with the substitutions S9E, N42R, N74D, V199I, Q200L, Y203W, S253D, N255W and L256E; and
• at least one enzyme selected from the group consisting of amylases and cellulases; wherein:
o the amylase comprises SEQ ID NO: 29 with the mutations H 1 *, N54S, V56T, K72R, G109A, F113Q, R116Q, W167F, Q172G, A174S, G182*, D183*, G184T, N195F, V206L, K391A, P473R and G476K; and o the cellulase comprises SEQ ID NO: 34.
In any of the embodiments described above comprising at least a hexosaminidase and a GHL13 glycosyl hydrolase as the cleaning enzymes, the cleaning composition may optionally comprise one or more of any of the other cleaning enzymes described herein. Any of these compositions may thus comprise one or more of a DNase, an RNase, a Glyco_hydro_114 glucosyl hydrolase or a GH39 glycosyl hydrolase. Exemplary detergent enzyme combinations
Some exemplary detergent enzyme combinations suitable for use in the cleaning compositions of the invention are listed below:
• a protease comprising SEQ ID NO: 24 with the substitutions S9E, N42R, N74D, V199I, Q200L, Y203W, S253D, N255W and L256E, and an amylase comprising SEQ ID NO: 29 with the mutations H1*, N54S, V56T, K72R, G109A, F113Q, R1 16Q, W167F, Q172G, A174S, G182*, D183*, G184T, N195F, V206L, K391A, P473R and G476K;
• a protease comprising SEQ ID NO: 24 with the substitutions S9E, N42R, N74D, V199I, Q200L, Y203W, S253D, N255W and L256E, and a cellulase comprising SEQ ID NO: 34;
• a protease comprising SEQ ID NO: 24 with the substitutions S9E, N42R, N74D, V199I, Q200L, Y203W, S253D, N255W and L256E, an amylase comprising SEQ ID NO: 29 with the mutations H1*, N54S, V56T, K72R, G109A, F113Q, R116Q, W167F, Q172G, A174S, G182*, D183*, G184T, N195F, V206L, K391A, P473R and G476K, and a cellulase comprising SEQ ID NO: 34;
• a protease comprising SEQ ID NO: 24 with the substitutions Y161A, R164S and A188P, an amylase comprising SEQ ID NO: 30 with the mutations H183*, G184*, I405L, A421 H, A422P and A428T, and a pectate lyase comprising SEQ ID NO: 33;
• a protease comprising SEQ ID NO: 24 with the substitutions Y161A, R164S and A188P, an amylase comprising SEQ ID NO: 30 with the mutations H183*, G184*, I405L, A421 H, A422P and A428T, a pectate lyase comprising SEQ ID NO: 33, a lipase comprising SEQ ID NO: 31 with the mutations D27R, G38A, D96E, D111 A, G163K, T231 R, N233R, D254S and P256, and a mannanase comprising SEQ ID NO: 32;
• a protease comprising SEQ ID NO: 24 with the substitutions Y161A, R164S and A188P, an amylase comprising SEQ ID NO: 30 with the mutations H183*, G184*, I405L, A421 H, A422P and A428T, a pectate lyase comprising SEQ ID NO: 33, a lipase comprising SEQ ID NO: 31 with the mutations D27R, G38A, D96E, D111 A, G163K, T231 R, N233R, D254S and P256, a mannanase comprising SEQ ID NO: 32, a cellulase comprising SEQ ID NO: 34, and a cellulase comprising SEQ ID NO: 35;
• a protease comprising SEQ ID NO: 37, an amylase comprising SEQ ID NO: 30 with the mutations H183*, G184*, I405L, A421 H, A422P and A428T, and a pectate lyase comprising SEQ ID NO: 33; • a protease comprising SEQ ID NO: 37, an amylase comprising SEQ ID NO: 30 with the mutations H183*, G184*, I405L, A421 H, A422P and A428T, a pectate lyase comprising SEQ ID NO: 33, a lipase comprising SEQ ID NO: 31 with the mutations D27R, G38A, D96E, D1 1 1A, G163K, T231 R, N233R, D254S and P256, and a mannanase comprising SEQ ID NO: 32;
• a protease comprising SEQ ID NO: 37, an amylase comprising SEQ ID NO: 30 with the mutations H183*, G184*, I405L, A421 H, A422P and A428T, a pectate lyase comprising SEQ ID NO: 33, a lipase comprising SEQ ID NO: 31 with the mutations D27R, G38A, D96E, D1 1 1A, G163K, T231 R, N233R, D254S and P256, a mannanase comprising SEQ ID NO: 32, a cellulase comprising SEQ ID NO: 34, and a cellulase comprising SEQ ID NO: 35.
Additional cleaning composition components
The cleaning compositions of the invention may be formulated as detergent compositions that comprise, in addition to the at least two cleaning enzymes and at least two detergent enzymes, one or more cleaning components typically used in detergent compositions. The choice of additional components is within the skill of the artisan and includes conventional ingredients, including the exemplary non-limiting components set forth below. Persons skilled in the art will be aware of suitable components depending on e.g. the intended use of the composition, for example for laundry or dishwashing. Although components mentioned below are categorized by general header according to a particular functionality, this is not to be construed as a limitation, as a component may comprise additional functionalities as will be appreciated by the skilled artisan.
Surfactants
The cleaning composition may comprise one or more surfactants, which may be anionic and/or cationic and/or non-ionic and/or semi-polar and/or zwitterionic, or a mixture thereof. In a particular embodiment, the cleaning composition includes a mixture of one or more nonionic surfactants and one or more anionic surfactants. The surfactant(s) is typically present at a level of from about 0.1 % to 60% by weight, such as about 1 % to about 40%, or about 3% to about 20%, or about 3% to about 10%. The surfactant(s) is chosen based on the desired cleaning application, and may include any conventional surfactant(s) known in the art.
When included therein the composition will usually contain from about 1 % to about 40% by weight of an anionic surfactant, such as from about 5% to about 30%, including from about 5% to about 15%, or from about 15% to about 20%, or from about 20% to about 25% of an anionic surfactant. Non-limiting examples of anionic surfactants include sulfates and sulfonates, in particular, linear alkylbenzenesulfonates (LAS), isomers of LAS, branched alkylbenzenesulfonates (BABS), phenylalkanesulfonates, alpha-olefinsulfonates (AOS), olefin sulfonates, alkene sulfonates, alkane-2, 3-diylbis(sulfates), hydroxyalkanesulfonates and disulfonates, alkyl sulfates (AS) such as sodium dodecyl sulfate (SDS), fatty alcohol sulfates (FAS), primary alcohol sulfates (PAS), alcohol ethersulfates (AES or AEOS or FES, also known as alcohol ethoxysulfates or fatty alcohol ether sulfates), secondary alkanesulfonates (SAS), paraffin sulfonates (PS), ester sulfonates, sulfonated fatty acid glycerol esters, alpha-sulfo fatty acid methyl esters (alpha-SFMe or SES) including methyl ester sulfonate (MES), alkyl- or alkenylsuccinic acid, dodecenyl/tetradecenyl succinic acid (DTSA), fatty acid derivatives of amino acids, diesters and monoesters of sulfo-succinic acid or salt of fatty acids (soap), and combinations thereof.
When included therein the composition will usually contain from about 1 % to about 40% by weight of a cationic surfactant, for example from about 0.5% to about 30%, in particular from about 1 % to about 20%, from about 3% to about 10%, such as from about 3% to about 5%, from about 8% to about 12% or from about 10% to about 12%. Non-limiting examples of cationic surfactants include alkyldimethylethanolamine quat (ADMEAQ), cetyltrimethylammonium bromide (CTAB), dimethyldistearylammonium chloride (DSDMAC), and alkylbenzyldimethylammonium, alkyl quaternary ammonium compounds, alkoxylated quaternary ammonium (AQA) compounds, ester quats, and combinations thereof.
When included therein the composition will usually contain from about 0.2% to about 40% by weight of a nonionic surfactant, for example from about 0.5% to about 30%, in particular from about 1 % to about 20%, from about 3% to about 10%, such as from about 3% to about 5%, from about 8% to about 12%, or from about 10% to about 12%. Non-limiting examples of nonionic surfactants include alcohol ethoxylates (AE or AEO), alcohol propoxylates, propoxylated fatty alcohols (PFA), alkoxylated fatty acid alkyl esters, such as ethoxylated and/or propoxylated fatty acid alkyl esters, alkylphenol ethoxylates (APE), nonylphenol ethoxylates (NPE), alkylpolyglycosides (APG), alkoxylated amines, fatty acid monoethanolamides (FAM), fatty acid diethanolamides (FADA), ethoxylated fatty acid monoethanolamides (EFAM), propoxylated fatty acid monoethanolamides (PFAM), polyhydroxyalkyl fatty acid amides, or N- acyl N- alkyl derivatives of glucosamine (glucamides, GA, or fatty acid glucamides, FAGA), as well as products available under the trade names SPAN and TWEEN, and combinations thereof.
The composition may contain a semipolar surfactant. Non-limiting examples of semipolar surfactants include amine oxides (AO) such as alkyldimethylamineoxide, N-( coco alkyl )-N,N- dimethylamine oxide and /V-(tallow-alkyl)-/V,/V-bis(2-hydroxyethyl)amine oxide, and combinations thereof.
The composition may contain a zwitterionic surfactant. Non-limiting examples of zwitterionic surfactants include betaines such as alkyldimethylbetaines, sulfobetaines, and combinations thereof. Hydrotropes
A hydrotrope is a compound that solubilises hydrophobic compounds in aqueous solutions (or oppositely, polar substances in a non-polar environment). Typically, hydrotropes have both a hydrophilic and a hydrophobic character (so-called amphiphilic properties as known from surfactants); however the molecular structure of hydrotropes generally do not favor spontaneous self-aggregation, see e.g. the review by Hodgdon and Kaler (2007), Current Opinion in Colloid & Interface Science 12: 121-128. Hydrotropes do not display a critical concentration above which self-aggregation occurs as found for surfactants and lipids forming miceller, lamellar or other well defined meso-phases. Instead, many hydrotropes show a continuous-type aggregation process where the sizes of aggregates grow as concentration increases. However, many hydrotropes alter the phase behavior, stability, and colloidal properties of systems containing substances of polar and non-polar character, including mixtures of water, oil, surfactants, and polymers. Hydrotropes are classically used across industries from pharma, personal care, food, to technical applications. Use of hydrotropes in cleaning compositions allow for example more concentrated formulations of surfactants (as in the process of compacting liquid detergents by removing water) without inducing undesired phenomena such as phase separation or high viscosity.
The composition may contain 0-10% by weight, for example 0-5% by weight, such as about 0.5 to about 5%, or about 3% to about 5%, of a hydrotrope. Any hydrotrope known in the art for use in detergents may be utilized. Non-limiting examples of hydrotropes include sodium benzenesulfonate, sodium p-toluene sulfonate (STS), sodium xylene sulfonate (SXS), sodium cumene sulfonate (SCS), sodium cymene sulfonate, amine oxides, alcohols and polyglycolethers, sodium hydroxynaphthoate, sodium hydroxynaphthalene sulfonate, sodium ethylhexyl sulfate, and combinations thereof.
Builders and Co-Builders
The cleaning composition may contain about 0-65% by weight, such as about 5% to about 50% of a detergent builder or co-builder, or a mixture thereof. In a dishwashing detergent, the level of builder is typically 40-65%, particularly 50-65%. The builder and/or co-builder may particularly be a chelating agent that forms water-soluble complexes with Ca and Mg. Any builder and/or co-builder known in the art for use in laundry, automatic dishwashing (ADW) or hard surface cleaning detergents may be utilized. Non-limiting examples of builders include zeolites, diphosphates (pyrophosphates), triphosphates such as sodium triphosphate (STP or STPP), carbonates such as sodium carbonate, soluble silicates such as sodium metasilicate, layered silicates (e.g., SKS-6 from Hoechst), ethanolamines such as 2-aminoethan-1-ol (MEA), diethanolamine (DEA, also known as 2,2’-iminodiethan-1 -ol), triethanolamine (TEA, also known as 2,2’,2”-nitrilotriethan-1-ol), and (carboxymethyl)inulin (CMI), and combinations thereof. The cleaning composition may also contain 0-50% by weight, such as about 5% to about 30%, of a detergent co-builder. The cleaning composition may include a co-builder alone, or in combination with a builder, for example a zeolite builder. Non-limiting examples of co-builders include homopolymers of polyacrylates or copolymers thereof, such as poly(acrylic acid) (PAA) or copoly(acrylic acid/maleic acid) (PAA/PMA). Further non-limiting examples include citrate, chelators such as aminocarboxylates, aminopolycarboxylates and phosphonates, and alkyl- or alkenylsuccinic acid. Additional specific examples include 2,2’,2”-nitrilotriacetic acid (NTA), ethylenediaminetetraacetic acid (EDTA), diethylenetriaminepentaacetic acid (DTPA), iminodisuccinic acid (IDS), ethylenediamine-A/./V-disuccinic acid (EDDS), methylglycinediacetic acid (MGDA), glutamic acid-/V,/V-diacetic acid (GLDA), 1-hydroxyethane-1 ,1 -diphosphonic acid (HEDP), ethylenediaminetetra(methylenephosphonic acid) (EDTMPA), diethylenetriaminepentakis (methylenephosphonic acid) (DTMPA or DTPMPA), /V-(2-hydroxyethyl)iminodiacetic acid (EDG), aspartic acid-/V-monoacetic acid (ASMA), aspartic acid-/V,/V-diacetic acid (ASDA), aspartic acid -N- monopropionic acid (ASMP), iminodisuccinic acid (IDA), /V-(2-sulfomethyl)-aspartic acid (SMAS), /V-(2-sulfoethyl)-aspartic acid (SEAS), /V-(2-sulfomethyl)-glutamic acid (SMGL), /V-(2-sulfoethyl)- glutamic acid (SEGL), /V-methyliminodiacetic acid (MIDA), a-alanine-/V,/V-diacetic acid (a-ALDA), serine-/V,/V-diacetic acid (SEDA), isoserine-/V,/V-diacetic acid (ISDA), phenylalanine-/V,/V-diacetic acid (PHDA), anthranilic acid-/V,/V-diacetic acid (ANDA), sulfanilic acid-/V,/V-diacetic acid (SLDA) , taurine-/V,/V-diacetic acid (TUDA) and sulfomethyl-/V,/V-diacetic acid (SMDA), N-( 2- hydroxyethyl)ethylenediamine-/V,/V',/V”-triacetic acid (HEDTA), diethanolglycine (DEG), diethylenetriamine penta(methylenephosphonic acid) (DTPMP), aminotris(methylenephosphonic acid) (ATMP), and combinations and salts thereof. Further exemplary builders and/or co-builders are described in, e.g., WO 2009/102854 and US 5977053
Bleaching Systems
The composition may contain 0-30% by weight, such as about 1 % to about 20%, of a bleaching system. Any bleaching system known in the art for use in laundry/ADW/hard surface cleaning detergents may be utilized. Suitable bleaching system components include bleaching catalysts, photobleaches, bleach activators, sources of hydrogen peroxide such as sodium percarbonate, sodium perborates and hydrogen peroxide— urea (1 :1 ), preformed peracids and mixtures thereof. Suitable preformed peracids include, but are not limited to, peroxycarboxylic acids and salts, diperoxydicarboxylic acids, perimidic acids and salts, peroxymonosulfuric acids and salts, for example, Oxone (R), and mixtures thereof. Non-limiting examples of bleaching systems include peroxide-based bleaching systems, which may comprise, for example, an inorganic salt, including alkali metal salts such as sodium salts of perborate (usually mono- or tetra-hydrate), percarbonate, persulfate, perphosphate, persilicate salts, in combination with a peracid-forming bleach activator. The term bleach activator is meant herein as a compound which reacts with hydrogen peroxide to form a peracid via perhydrolysis. The peracid thus formed constitutes the activated bleach. Suitable bleach activators to be used herein include those belonging to the class of esters, amides, imides or anhydrides. Suitable examples are tetraacetylethylenediamine (TAED), sodium 4-[(3, 5, 5-trimethylhexanoyl)oxy]benzene-1 -sulfonate (ISONOBS), 4-(dodecanoyloxy )benzene-1 -sulfonate (LOBS), 4-(decanoyloxy)benzene-1 - sulfonate, 4-(decanoyloxy)benzoate (DOBS or DOBA), 4-(nonanoyloxy)benzene-1 -sulfonate (NOBS), and/or those disclosed in W098/17767. A particular family of bleach activators of interest was disclosed in EP624154 and particularly preferred in that family is acetyl triethyl citrate (ATC). ATC or a short chain triglyceride like triacetin has the advantage that it is environmentally friendly Furthermore, acetyl triethyl citrate and triacetin have good hydrolytic stability in the product upon storage and are efficient bleach activators. Finally, ATC is multifunctional, as the citrate released in the perhydrolysis reaction may function as a builder. Alternatively, the bleaching system may comprise peroxyacids of, for example, the amide, imide, or sulfone type. The bleaching system may also comprise peracids such as 6-(phthalimido)peroxyhexanoic acid (PAP). The bleaching system may also include a bleach catalyst. In some embodiments the bleach component may be an organic catalyst selected from the group consisting of organic catalysts having the following formulae:
Figure imgf000243_0001
(iii) and mixtures thereof;
wherein each R1 is independently a branched alkyl group containing from 9 to 24 carbons or linear alkyl group containing from 1 1 to 24 carbons, preferably each R1 is independently a branched alkyl group containing from 9 to 18 carbons or linear alkyl group containing from 1 1 to 18 carbons, more preferably each R1 is independently selected from the group consisting of 2-propylheptyl, 2-butyloctyl, 2-pentylnonyl, 2-hexyldecyl, dodecyl, tetradecyl, hexadecyl, octadecyl, isononyl, isodecyl, isotridecyl and isopentadecyl. Other exemplary bleaching systems are described, e.g. in W02007/087258, W02007/087244, W02007/087259, EP1867708 (Vitamin K) and W02007/087242. Suitable photobleaches may for example be sulfonated zinc or aluminium phthalocyanines.
Preferably the bleach component comprises a source of peracid in addition to bleach catalyst, particularly organic bleach catalyst. The source of peracid may be selected from (a) pre-formed peracid; (b) percarbonate, perborate or persulfate salt (hydrogen peroxide source) preferably in combination with a bleach activator; and (c) perhydrolase enzyme and an ester for forming peracid in situ in the presence of water in a textile or hard surface treatment step Polymers
The composition may contain 0-10% by weight, such as 0.5-5%, 2-5%, 0.5-2% or 0.2- 1 % of a polymer. Any polymer known in the art for use in detergents may be utilized. The polymer may function as a co-builder as mentioned above, or may provide antiredeposition, fiber protection, soil release, dye transfer inhibition, grease cleaning and/or anti-foaming properties. Some polymers may have more than one of the above-mentioned properties and/or more than one of the below-mentioned motifs. Exemplary polymers include (carboxymethyl)cellulose (CMC), poly(vinyl alcohol) (PVA), poly(vinylpyrrolidone) (PVP), poly(ethyleneglycol) or poly(ethylene oxide) (PEG), ethoxylated poly(ethyleneimine), carboxymethyl inulin (CMI), and polycarboxylates such as PAA, PAA/PMA, poly-aspartic acid, and lauryl methacrylate/acrylic acid copolymers, hydrophobically modified CMC (HM-CMC) and silicones, copolymers of terephthalic acid and oligomeric glycols, copolymers of poly(ethylene terephthalate) and poly(oxyethene terephthalate) (PET-POET), PVP, poly(vinylimidazole) (PVI), poly(vinylpyridine-/V-oxide) (PVPO or PVPNO) and polyvinylpyrrolidone-vinylimidazole (PVPVI). Further exemplary polymers include sulfonated polycarboxylates, polyethylene oxide and polypropylene oxide (PEO-PPO) and diquaternium ethoxy sulfate. Other exemplary polymers are disclosed in, e.g., WO 2006/130575. Salts of the above-mentioned polymers are also contemplated.
Fabric hueing agents
The cleaning compositions of the present invention may also include fabric hueing agents such as dyes or pigments, which when formulated in cleaning compositions can deposit onto a fabric when said fabric is contacted with a wash liquor comprising said cleaning compositions and thus altering the tint of said fabric through absorption/reflection of visible light. Fluorescent whitening agents emit at least some visible light. In contrast, fabric hueing agents alter the tint of a surface as they absorb at least a portion of the visible light spectrum. Suitable fabric hueing agents include dyes and dye-clay conjugates, and may also include pigments. Suitable dyes include small molecule dyes and polymeric dyes. Suitable small molecule dyes include small molecule dyes selected from the group consisting of dyes falling into the Colour Index (C.l.) classifications of Direct Blue, Direct Red, Direct Violet, Acid Blue, Acid Red, Acid Violet, Basic Blue, Basic Violet and Basic Red, or mixtures thereof, for example as described in W02005/03274, W02005/03275, W02005/03276 and EP1876226 (hereby incorporated by reference). The cleaning composition preferably comprises from about 0.00003 wt% to about 0.2 wt%, from about 0.00008 wt% to about 0.05 wt%, or even from about 0.0001 wt% to about 0.04 wt% fabric hueing agent. The composition may comprise from 0.0001 wt% to 0.2 wt% fabric hueing agent, this may be especially preferred when the composition is in the form of a unit dose pouch. Suitable hueing agents are also disclosed in e.g. WO 2007/087257 and W02007/087243. Adjunct materials
Other optional adjunct materials for use in detergents include anti-corrosion agents, anti- shrink agents, anti-soil redeposition agents, anti-wrinkling agents, bactericides, binders, corrosion inhibitors, disintegrants/disintegration agents, dyes, enzyme stabilizers (including boric acid, borates, CMC, and/or polyols such as propylene glycol), fabric conditioners including clays, fillers/processing aids, fluorescent whitening agents/optical brighteners, foam boosters, foam (suds) regulators, perfumes, soil-suspending agents, softeners, suds suppressors, tarnish inhibitors, and wicking agents, either alone or in combination. Any ingredient known in the art for use in laundry/ADW/hard surface cleaning detergents may be utilized.
Dispersants
The cleaning compositions of the present invention may contain dispersants. In particular powdered detergents may comprise dispersants. Suitable water-soluble organic materials include the homo- or co-polymeric acids or their salts, in which the polycarboxylic acid comprises at least two carboxyl radicals separated from each other by not more than two carbon atoms. Suitable dispersants are for example described in Powdered Detergents, Surfactant science series volume 71 , Marcel Dekker, Inc.
Dye Transfer Inhibiting Agents
The cleaning compositions of the present invention may also include one or more dye transfer inhibiting agents. Suitable polymeric dye transfer inhibiting agents include, but are not limited to, polyvinylpyrrolidone polymers, polyamine N- oxide polymers, copolymers of N- vinylpyrrolidone and /V-vinylimidazole, polyvinyloxazolidones and polyvinylimidazoles or mixtures thereof. When present in a subject composition, the dye transfer inhibiting agents may be present at levels from about 0.0001 % to about 10%, from about 0.01 % to about 5% or even from about 0.1 % to about 3% by weight of the composition.
Fluorescent whitening agent
The cleaning compositions of the present invention may also contain additional components that may tint articles being cleaned, such as a fluorescent whitening agent or optical brighteners. Where present the brightener is preferably at a level of about 0.01 % to about 0.5%. Any fluorescent whitening agent suitable for use in a laundry detergent composition may be used in the composition of the present invention. The most commonly used fluorescent whitening agents are those belonging to the classes of diaminostilbene-sulfonic acid derivatives, diarylpyrazoline derivatives and bisphenyl-distyryl derivatives. Examples of the diaminostilbene- sulfonic acid derivative type of fluorescent whitening agents include the sodium salts of: 4,4'-bis- (2-diethanolamino-4-anilino-s-triazin-6-ylamino) stilbene-2,2'-disulfonate, 4,4'-bis-(2,4-dianilino- s-triazin-6-ylamino) stilbene-2.2'-disulfonate, 4,4'-bis-(2-anilino-4-(/V-methyl-/V-2-hydroxy- ethylamino)-s-triazin-6-ylamino) stilbene-2,2'-disulfonate, 4,4'-bis-(4-phenyl-1 ,2,3-triazol-2- yl)stilbene-2,2'-disulfonate and sodium 5-(2/-/-naphtho[1 ,2-c/][1 ,2,3]triazol-2-yl)-2-[(E)-2- phenylvinyl]benzenesulfonate. Preferred fluorescent whitening agents are Tinopal DMS and Tinopal CBS available from Ciba-Geigy AG, Basel, Switzerland. Tinopal DMS is the disodium salt of 4,4'-bis-(2-morpholino-4-anilino-s-triazin-6-ylamino) stilbene-2,2'-disulfonate. Tinopal CBS is the disodium salt of 2,2'-bis-(phenyl-styryl)-disulfonate. Also preferred are fluorescent whitening agents is the commercially available Parawhite KX, supplied by Paramount Minerals and Chemicals, Mumbai, India. Other fluorescers suitable for use in the invention include the 1 - 3-diaryl pyrazolines and the 7-alkylaminocoumarins.
Suitable fluorescent brightener levels include lower levels of from about 0.01 , from 0.05, from about 0.1 or even from about 0.2 wt % to upper levels of 0.5 or even 0.75 wt%.
Soil release polymers
The cleaning compositions of the present invention may also include one or more soil release polymers which aid the removal of soils from fabrics such as cotton and polyester based fabrics, in particular the removal of hydrophobic soils from polyester based fabrics. The soil release polymers may for example be nonionic or anionic terephthalte based polymers, polyvinyl caprolactam and related copolymers, vinyl graft copolymers, polyester polyamides see for example Chapter 7 in Powdered Detergents, Surfactant science series volume 71 , Marcel Dekker, Inc. Another type of soil release polymers is amphiphilic alkoxylated grease cleaning polymers comprising a core structure and a plurality of alkoxylate groups attached to that core structure. The core structure may comprise a polyalkylenimine structure or a polyalkanolamine structure as described in detail in WO 2009/087523 (hereby incorporated by reference). Furthermore, random graft co-polymers are suitable soil release polymers. Suitable graft co- polymers are described in more detail in WO 2007/138054, WO 2006/108856 and WO 2006/1 13314 (hereby incorporated by reference). Other soil release polymers are substituted polysaccharide structures especially substituted cellulosic structures such as modified cellulose deriviatives such as those described in EP 1867808 or WO 2003/040279 (both are hereby incorporated by reference). Suitable cellulosic polymers include cellulose, cellulose ethers, cellulose esters, cellulose amides and mixtures thereof. Suitable cellulosic polymers include anionically modified cellulose, nonionically modified cellulose, cationically modified cellulose, zwitterionically modified cellulose, and mixtures thereof. Suitable cellulosic polymers include methyl cellulose, carboxy methyl cellulose, ethyl cellulose, hydroxyl ethyl cellulose, hydroxyl propyl methyl cellulose, ester carboxy methyl cellulose, and mixtures thereof. Anti-redeposition agents
The cleaning compositions of the present invention may also include one or more anti- redeposition agents such as carboxymethylcellulose (CMC), polyvinyl alcohol (PVA), polyvinylpyrrolidone (PVP), polyoxyethylene and/or polyethyleneglycol (PEG), homopolymers of acrylic acid, copolymers of acrylic acid and maleic acid, and ethoxylated polyethyleneimines. The cellulose based polymers described under soil release polymers above may also function as anti-redeposition agents.
Rheology Modifiers
The cleaning compositions of the present invention may also include one or more rheology modifiers, structurants or thickeners, as distinct from viscosity reducing agents. The rheology modifiers are selected from the group consisting of non-polymeric crystalline, hydroxy- functional materials, polymeric rheology modifiers which impart shear thinning characteristics to the aqueous liquid matrix of a liquid detergent composition. The rheology and viscosity of the detergent can be modified and adjusted by methods known in the art, for example as shown in EP 2169040.
Other suitable adjunct materials include, but are not limited to, anti-shrink agents, anti- wrinkling agents, bactericides, binders, carriers, dyes, enzyme stabilizers, fabric softeners, fillers, foam regulators, hydrotropes, perfumes, pigments, sod suppressors, solvents, and structurants for liquid detergents and/or structure elasticizing agents.
Formulation of detergent products
The detergent composition of the invention may be in any convenient form, e.g., a bar, a homogenous tablet, a tablet having two or more layers, a pouch having one or more compartments, a regular or compact powder, a granule, a paste, a gel, or a regular, compact or concentrated liquid.
Detergent ingredients can be separated physically from each other by compartments in water dissolvable pouches or in different layers of tablets. Thereby negative storage interaction between components can be avoided. Different dissolution profiles of each of the compartments can also give rise to delayed dissolution of selected components in the wash solution.
Pouches can be configured as single or multiple compartments. They can be of any form, shape and material which is suitable to hold the composition and prevent release of the composition from the pouch prior to water contact. The pouch is made from water-soluble film which encloses an inner volume, which can be divided into compartments. Preferred films are polymeric materials preferably polymers which are formed into a film or sheet. Preferred polymers, copolymers or derivates thereof are selected from polyacrylates, water-soluble acrylate copolymers, methyl cellulose, carboxy methyl cellulose, sodium dextrin, ethyl cellulose, hydroxyethyl cellulose, hydroxypropyl methyl cellulose, dextrin, poly methacrylates, most preferably polyvinyl alcohol copolymers or hydroxypropyl methyl cellulose (HPMC). The amount of polymer in the film, for example PVA, is at least about 60%. Preferred average molecular weights will typically be from about 20,000 to about 150,000. Films can also be of blended compositions comprising hydrolytically degradable and water-soluble polymer blends such as polylactide and polyvinyl alcohol (known under the trade name M8630 as sold by MonoSol LLC, Indiana, USA) plus plasticisers like glycerol, ethylene glycerol, propylene glycol, sorbitol and mixtures thereof. The pouches can comprise a solid laundry cleaning composition or part components and/or a liquid cleaning composition or part components separated by the water-soluble film. The compartment for liquid components can be different in composition than compartments containing solids; see e.g. US2009/001 1970 A1.
A liquid or gel detergent which is not unit dosed may be aqueous, typically containing at least 20% by weight and up to 95% water, such as up to about 70% water, up to about 65% water, up to about 55% water, up to about 45% water, or up to about 35% water. Other types of liquids, including without limitation alkanols, amines, diols, ethers and polyols, may be included in an aqueous liquid or gel. An aqueous liquid or gel detergent may contain from 0-30% organic solvent. A liquid or gel detergent may alternatively be non-aqueous.
Granular detergent formulations
The composition of the invention may be formulated as a granule, for example as a co- granule that combines one or more enzymes. Each enzyme will then be present in more granules securing a more uniform distribution of enzymes in the detergent. This also reduces the physical segregation of different enzymes due to different particle sizes. Methods for producing multi- enzyme co-granulates for the detergent industry are disclosed e.g. in the IP.com disclosure IPCOM000200739D.
Another example of formulation of enzymes by the use of co-granulates are is disclosed in WO 2013/188331 , which discloses a detergent composition comprising (a) a multi-enzyme co- granule; (b) less than 10 wt zeolite (anhydrous basis); and (c) less than 10 wt phosphate salt (anhydrous basis), wherein said enzyme co-granule comprises from 10 to 98 wt% moisture sink component and the composition additionally comprises from 20 to 80 wt% detergent moisture sink component.
Methods and uses
The invention further relates to methods for cleaning and use of the cleaning compositions for cleaning an item such as a textile.
The invention is e.g. directed to methods for using the cleaning compositions in laundry, i.e. cleaning of textile/fabric (e.g. household laundry washing or industrial laundry washing), and in hard surface cleaning (e.g. dishwashing such as automatic dishwashing (ADW), car wash, cleaning of industrial surfaces, and cleaning of washing machines, dishwashers, etc.). One embodiment relates to the use of a cleaning composition of the invention for deep cleaning of an item, wherein the item is a textile or a surface.
One embodiment relates to the use of a cleaning composition of the invention for reduction or removal of biofilm and/or compounds such as RNA or DNA from an item, where the item is e.g. a textile, for example in a laundry process.
One embodiment relates to the use of a cleaning composition of the invention for reduction of redeposition or reduction of malodor, e.g. when the cleaning composition is applied in a laundry process.
One embodiment relates to the use of a cleaning composition of the invention for cleaning an item, for example for preventing, reducing or removing biofilm and/or body secretions such dead cells, sebum or sweat from an item, where the item is e.g. a textile.
One embodiment relates to the use of a cleaning composition of the invention for preventing, reducing or removing stickiness of an item, where the item is e.g. a textile.
One embodiment relates to the use of a cleaning composition of the invention for pretreating stains on an item, where the item is e.g. a textile.
One embodiment relates to the use of a cleaning composition of the invention for preventing, reducing or removing adherence of soil to an item, where the item is e.g. a textile.
One embodiment relates to the use of a cleaning composition of the invention for maintaining or improving whiteness of the item, where the item is e.g. a textile. This is obtained by way of an anti-greying effect provided by the enzymes in the cleaning composition.
In further embodiments, the invention relates to methods for:
(i) preventing, reducing or removing stickiness of an item;
(ii) pretreating stains on an item;
(iii) preventing, reducing or removing redeposition of soil during a wash cycle;
(iv) preventing, reducing or removing adherence of soil to an item;
(v) maintaining or improving whiteness of an item; and/or
(vi) preventing, reducing or removal malodor from an item,
wherein the item is e.g. a textile.
Another embodiment relates to a method for deep cleaning of an item, e.g. a textile, comprising the steps of:
a) contacting the item with a cleaning composition of the invention; and
b) optionally rinsing the item.
The invention further relates to a method of deep cleaning of an item, e.g. a textile, comprising the steps of:
a) contacting the item with a solution comprising a cleaning composition of the invention comprising at least two cleaning enzymes and at least two detergent enzymes and a cleaning component, wherein the cleaning component is selected from 0.1 to 15 wt% of at least one a surfactant; 0.5 to 20 wt% of at least one builder; and 0.01 to 10 wt% of at least one bleach component; and
b) and optionally rinsing the item.
EXAMPLES
The activity of the cleaning enzymes described herein may e.g. be determined using the following assays.
Assay 1 : Determination of DNase activity
DNase activity may be determined on DNase Test Agar with Methyl Green (BD, Franklin Lakes, NJ, USA), which is prepared according to the manual from the supplier. Briefly, 21 g of agar is dissolved in 500 ml water and then autoclaved for 15 min at 121 °C. Autoclaved agar is tempered to 48°C in water bath, and 20 ml of agar is poured into petri dishes with and allowed to solidify by incubation overnight at room temperature. On solidified agar plates, 5 pi of enzyme solutions are added and DNase activity is observed as colorless zones around the spotted enzyme solutions.
Assay 2: Determination of DNase activity
DNase activity may be determined using the DNaseAlert™ Kit (1 1 -02-01 -04, IDT Intergrated DNA Technologies) according to the supplier’s manual. Briefly, 95 mI DNase sample is mixed with 5 mI substrate in a microtiter plate, and fluorescence is immediately measured using a Clariostar microtiter reader from BMG Labtech (536 nm excitation, 556 nm emission).
Assay 3: Determination of RNase activity
RNase activity may be determined by fluorescence using a fluorescence-quenched oligonucleotide probe. This probe emits a signal after nuclease degradation according to the manual from the supplier (RNase alert kit, Integrated DNA Technology, Coralville, Iowa, USA). Briefly, RNase is diluted in water hardness 15°dH to obtain a concentration of 2ppm, and 5mI of the substrate is added to 95mI of the RNase sample. A kinetic curve is measured for 10 min at 22°C using a Clariostar microplate reader (excitation 490nm, emission at 520nm).
Assay 4: Determination of hexosaminidase activity
Hexosaminidase activity may be determined using 4-nitrophenyl N-acetyl-3-D- glucosaminide (Sigma-Aldrich) as substrate. The enzymatic reaction is performed in triplicate in a 96-well flat bottom polystyrene microtiter plate (Thermo Scientific) with the following conditions: 50 mM 2-(N-morpholino)ethanesulfonic acid pH 6 buffer, 1 .5 mg/ml 4-nitrophenyl N-acetyl-3-D- glucosaminide and 20 pg/ml purified enzyme sample in a total reaction volume of 100 mI. Blank samples without polypeptide are run in parallel. The reactions are carried out at 37°C in a Thermomixer comfort (Eppendorf). After 10 minutes of incubation, 5 pi 1 M NaOH is added to each reaction mixture to stop the enzymatic reaction. The absorbance is read at 405 nm using a POLARstar Omega plate reader (BMG LABTECH) to estimate the formation of 4- nitrophenolate ion released due to enzymatic hydrolysis of the 4-nitrophenyl N-acetyl-3-D- glucosaminide substrate.
Assay 5: Determination of hexosaminidase activity
Hexosaminidase activity may be determined using 4-methylumbeliferyl N-acetyl-3-D- glucosaminide (Sigma-Aldrich) as substrate. The enzymatic reaction is performed in triplicate in a 96 well flat bottom polystyrene microtiter plate (Thermo Scientific) with the following conditions: 20 mM 3-morpholinopropane-1 -sulfonic acid pH 7 buffer, 5 mM 4-methylumbeliferyl N-acetyl-b- D-glucosaminide and 20 nM purified enzyme sample in a total reaction volume of 200 mI. Blank samples without enzyme are run in parallel. The reactions are carried out at ambient temperature of 20-25°C. The reaction kinetics are followed immediately after mixing of enzyme and substrate using a SpectraMax M2e plate reader. Excitation wavelength is set to 368 nm and fluorescence emission reading is done at 448 nm. The reaction is followed for 30 min at 60 second intervals. Increase in fluorescence signal is used to estimate the formation of 4-methylumbeliferyl ion released due to enzymatic hydrolysis of the 4-methylumbeliferyl N-acetyl-3-D-glucosaminide substrate.
Assay 6: Determination of Glyco_hydro_114 glycosyl hydrolase activity
The activity of Glyco_hydro_1 14 glycosyl hydrolases may be measured in a pNP-acetate assay as described in Marmont et.al. (2017)“PelA and PelB proteins form a modification and secretion complex essential for Pel polysaccharide-dependent biofilm formation in Pseudomonas aeruginosa", J. Biol.Chem. 292, 1941 1 -19422 or as described by Colvin, K. M., et.al (2013) “PelA deacetylase activity is required for Pel polysaccharide synthesis in Pseudomonas aeruginosa" . J. Bacteriol. 195, 2329-2339.
Assay 7: Determination of GHL13 glycosyl hydrolase activity
Substrate: 1 ,6^-(GlcNAc)4-SPh; N-deacetylation
a) A GHL13 enzyme of the invention is buffer exchanged by ultrafiltration (using a 20 ml_, 50 kDa MW CO filter) into 100 mM HEPES buffer (200 mM NaCI, pH 7.5). Final concentration of PgaB stock solution = 74.8 mM.
b) To 120.3 mI_ PgaB (final reaction cone. 20 mM) is added 18 mI_ NiCI2 solution (stock cone. 2 mM, final reaction cone. 80 mM, in 100 mM HEPES, 200 mM NaCI, pH 7.5) and incubated at room temperature for 1 hour (gently shaking) before use. c) To 225 mI_ of the 1 ,6-3-(GlcNAc)4-SPh solution in a MOPS/DMSO mixture (stock cone. 10 mM, final reaction cone. 5 mM) is added 86.7 mI_ HEPES buffer (100 mM HEPES, 200 mM NaCI, pH 7.5) followed by the 138.3 mI_ PgaB-NiCI2-solution (b). The reaction is shaken (850 rpm) at 37°C overnight. An additional 60 mI_ buffer-exchanged PgaB + 9 mI_ NiCI2 is then added to the reaction (and 20 mI_ PgaB + 3 mI_ NiCI2 to the control 1 ; and 7.7 mI_ buffer to control 2). After 8 hours, the reaction is left at 4°C over a weekend. The degree of N-deacetylation is analyzed by an OPA assay (see below). Before hydrolysis of the 1 ,6-3-(GlcNAc)4-SPh, 4.5 mI_ EDTA (stock cone. 25 mM, final cone. 250 mM) is added and left for 30 min while gently shaking at room temperature.
OPA assay (detection of -NH2 groups after N-deacetylation)
a) A fresh o-phthaldialdehyde (OPA) mixture is prepared by adding 800 mg to 10 mL 95% EtOH, and mixing this with 1 L 0.5 M borate buffer (pH 9.0) containing 2 mL 2- mercaptoethanol.
b) To a 10 pL sample is added 100 pL OPA solution. The mixture is transferred to a 96- well plate and analyzed using a spectrophotometer (ex: 340 nm, em: 455 nm). Glucosamine solutions are used as standards for quantification of N-deacetylation of the 1 ,6-3-(GlcNAc)4- SPh. Labeling and quantification of the free NH2 groups after N-deacetylation is thus obtained by the OPA assay.

Claims

1. A cleaning composition comprising 1 ) at least two cleaning enzymes selected from the group consisting of nucleases, hexosaminidases and glycosyl hydrolases, wherein the nuclease is a DNase or an RNase, and the glycosyl hydrolase is a Glyco_hydro_114, GH39 or GHL13 glycosyl hydrolase; and 2) at least two detergent enzymes selected from the group consisting of proteases, amylases, lipases, mannanases, pectate lyases and cellulases.
2. The cleaning composition of claim 1 , wherein the nuclease is a microbial DNase, preferably obtained from a bacterium or a fungus.
3. The cleaning composition of claim 2, wherein the DNase is a bacterial DNase, e.g. obtained from Bacillus, or a fungal DNase, e.g. obtained from Aspergillus or Trichoderma.
4. The cleaning composition of any of the preceding claims, wherein the DNase is selected from the group consisting of: a) a polypeptide having at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95% or 100% sequence identity to the polypeptide of SEQ ID NO: 1 ; b) a polypeptide having at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95% or 100% sequence identity to the polypeptide of SEQ ID NO: 2; c) a polypeptide having at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95% or 100% sequence identity to the polypeptide of SEQ ID NO: 3; d) a polypeptide having at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95% or 100% sequence identity to the polypeptide of SEQ ID NO: 4; and e) a polypeptide having at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95% or 100% sequence identity to the polypeptide of SEQ ID NO: 5.
5. The cleaning composition of claim 1 , wherein the nuclease is a microbial RNase, preferably obtained from a bacterium or a fungus.
6. The cleaning composition of claim 5, wherein the RNase is selected from the group consisting of: a) a polypeptide having at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95% or 100% sequence identity to the polypeptide of SEQ ID NO: 16; b) a polypeptide having at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95% or 100% sequence identity to the polypeptide of SEQ ID NO: 17; and c) a polypeptide having at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95% or 100% sequence identity to the polypeptide of SEQ ID NO: 18.
7. The cleaning composition of any of the preceding claims, wherein the hexosaminidase is a polypeptide having N-acetylglucosaminidase activity, preferably a b-N- acetylglucosaminidase, more preferably a dispersin.
8. The cleaning composition of claim 7, wherein the hexosaminidase is selected from the group consisting of: a) a polypeptide having at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95% or 100% sequence identity to the polypeptide of SEQ ID NO: 19; b) a polypeptide having at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95% or 100% sequence identity to the polypeptide of SEQ ID NO: 20; c) a polypeptide having at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95% or 100% sequence identity to the polypeptide of SEQ ID NO: 21 ; d) a polypeptide having at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95% or 100% sequence identity to the polypeptide of SEQ ID NO: 22; and e) a polypeptide having at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95% or 100% sequence identity to the polypeptide of SEQ ID NO: 23.
9. The cleaning composition of any of the preceding claims, wherein the glycosyl hydrolase is a Glyco_hydro_114 glycosyl hydrolase, preferably having endo-alpha-1 ,4- polygalactosminidase activity, in particular a PelA enzyme.
10. The cleaning composition of claim 9, wherein the Glyco_hydro_1 14 glycosyl hydrolase is selected from the group consisting of: a) a polypeptide having at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95% or 100% sequence identity to the polypeptide of SEQ ID NO: 6; b) a polypeptide having at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95% or 100% sequence identity to the polypeptide of SEQ ID NO: 7; c) a polypeptide having at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95% or 100% sequence identity to the polypeptide of SEQ ID NO: 8; and d) a polypeptide having at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95% or 100% sequence identity to the polypeptide of SEQ ID NO: 9.
1 1. The cleaning composition of any of the preceding claims, wherein the glycosyl hydrolase is a GH39 glycosyl hydrolase, in particular a PsIG enzyme.
12. The cleaning composition of claim 1 1 , wherein the GH39 glycosyl hydrolase is selected from the group consisting of: a) a polypeptide having at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95% or 100% sequence identity to the polypeptide of SEQ ID NO: 10; b) a polypeptide having at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95% or 100% sequence identity to the polypeptide of SEQ ID NO: 11 ; and c) a polypeptide having at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95% or 100% sequence identity to the polypeptide of SEQ ID NO: 12.
13. The cleaning composition of any of the preceding claims, wherein the glycosyl hydrolase is a GHL13 glycosyl hydrolase having poly-N-acetylglucosaminidase activity, preferably PNAG activity, in particular a PgaB enzyme.
14. The cleaning composition of claim 13, wherein the GHL13 glycosyl hydrolase is selected from the group consisting of: a) a polypeptide having at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95% or 100% sequence identity to the polypeptide of SEQ ID NO: 13; b) a polypeptide having at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95% or 100% sequence identity to the polypeptide of SEQ ID NO: 14; and c) a polypeptide having at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95% or 100% sequence identity to the polypeptide of SEQ ID NO: 15.
15. The cleaning composition of any of claims 1-14, comprising a DNase and a hexosaminidase.
16. The cleaning composition of any of claims 1-14, comprising a DNase and a
Glyco_hydro_114 glycosyl hydrolase.
17. The cleaning composition of any of claims 1 -14, comprising a DNase and a GH39 glycosyl hydrolase.
18. The cleaning composition of any of claims 1-14, comprising a DNase and a GHL13 glycosyl hydrolase.
19. The cleaning composition of any of claims 15-18, further comprising an RNase.
20. The cleaning composition of any of claims 1-14, comprising an RNase and a hexosaminidase.
21. The cleaning composition of any of claims 1-14, comprising an RNase and a Glyco_hydro_114 glycosyl hydrolase.
22. The cleaning composition of any of claims 1-14, comprising an RNase and a GH39 glycosyl hydrolase.
23. The cleaning composition of any of claims 1-14, comprising an RNase and a GHL13 glycosyl hydrolase.
24. The cleaning composition of any of claims 20-23, further comprising a DNase.
25. The cleaning composition of any of claims 1-14, comprising a hexosaminidase and a Glyco_hydro_1 14 glycosyl hydrolase.
26. The cleaning composition of any of claims 1-14, comprising a hexosaminidase and a GH39 glycosyl hydrolase.
27. The cleaning composition of any of claims 1-14, comprising a hexosaminidase and a GHL13 glycosyl hydrolase.
28. The cleaning composition of any of claims 25-27, further comprising a DNase and/or an
RNase.
29. The cleaning composition of any of the preceding claims, comprising a protease and at least one additional enzyme selected from the group consisting of amylases, lipases, mannanases, pectate lyases and cellulases.
30. The cleaning composition of claim 29, comprising a protease and an amylase.
31. The cleaning combination of claim 30, further comprising a lipase, a mannanase, a pectate lyase and/or a cellulase.
32. The cleaning composition of any of the preceding claims, wherein the protease is selected from the group consisting of: a) a polypeptide that comprises SEQ ID NO: 24 with the substitutions Y161 A, R164S and A188P; b) a polypeptide that comprises SEQ ID NO: 24 with the substitutions S9E, N42R, N74D, V199I, Q200L, Y203W, S253D, N255W and L256E; and c) a polypeptide that comprises SEQ ID NO: 26 with the substitutions S27K, N109K, S11 1 E, S171 E, S173P, G174K, S175P, F180Y, G182A, L184F, Q198E, N199K and
T297P.
33. The cleaning composition of any of the preceding claims, wherein the amylase is selected from the group consisting of: a) a polypeptide that comprises SEQ ID NO: 29 with the mutations H 1 *, N54S, V56T, K72R, G109A, F113Q, R1 16Q, W167F, Q172G, A174S, G182*, D183*, G184T, N195F, V206L, K391A, P473R and G476K; b) a polypeptide that comprises SEQ ID NO: 30 with the mutations H183*, G184*, I405L, A421 H, A422P and A428T.
34. The cleaning composition of any of the preceding claims, wherein the lipase is a polypeptide that comprises SEQ ID NO: 31 with the mutations D27R, G38A, D96E, D1 11 A, G163K, T231 R, N233R, D254S and P256T.
35. The cleaning composition of any of the preceding claims, wherein the mannanase is a polypeptide comprising SEQ ID NO: 32.
36. The cleaning composition of any of the preceding claims, wherein the pectate lyase is a polypeptide comprising SEQ ID NO: 33.
37. The cleaning composition of any of the preceding claims, wherein the cellulase is a polypeptide comprising SEQ ID NO: 34 or SEQ ID NO: 35.
38. The cleaning composition of any of the preceding claims, further comprising at least one surfactant and optionally at least one additional cleaning component selected from builders and bleach components.
39. Use of a cleaning composition according to any of claims 1 -38 for cleaning of an item such as a textile.
PCT/EP2019/076825 2018-10-03 2019-10-03 Cleaning compositions WO2020070249A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP18198442 2018-10-03
EP18198442.8 2018-10-03

Publications (1)

Publication Number Publication Date
WO2020070249A1 true WO2020070249A1 (en) 2020-04-09

Family

ID=63762280

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2019/076825 WO2020070249A1 (en) 2018-10-03 2019-10-03 Cleaning compositions

Country Status (1)

Country Link
WO (1) WO2020070249A1 (en)

Cited By (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022063707A1 (en) 2020-09-24 2022-03-31 Unilever Ip Holdings B.V. Composition
WO2022094589A1 (en) 2020-10-29 2022-05-05 The Procter & Gamble Company Cleaning compositions containing alginase enzymes
WO2022106404A1 (en) * 2020-11-18 2022-05-27 Novozymes A/S Combination of proteases
WO2022128368A1 (en) 2020-12-14 2022-06-23 Unilever Ip Holdings B.V. Composition
WO2022128370A1 (en) 2020-12-14 2022-06-23 Unilever Ip Holdings B.V. Composition
WO2022136389A1 (en) 2020-12-23 2022-06-30 Basf Se Amphiphilic alkoxylated polyamines and their uses
WO2022189059A1 (en) 2021-03-09 2022-09-15 Unilever Ip Holdings B.V. Composition
WO2022189521A1 (en) 2021-03-12 2022-09-15 Novozymes A/S Polypeptide variants
EP4060010A2 (en) 2021-03-15 2022-09-21 The Procter & Gamble Company Cleaning compositions containing polypeptide variants
EP4060036A1 (en) 2021-03-15 2022-09-21 Novozymes A/S Polypeptide variants
WO2022194673A1 (en) 2021-03-15 2022-09-22 Novozymes A/S Dnase variants
WO2022228949A1 (en) 2021-04-30 2022-11-03 Unilever Ip Holdings B.V. Composition
WO2022228903A1 (en) 2021-04-30 2022-11-03 Unilever Ip Holdings B.V. Composition
WO2022228951A1 (en) 2021-04-30 2022-11-03 Unilever Ip Holdings B.V. Composition
WO2022228832A1 (en) 2021-04-30 2022-11-03 Unilever Ip Holdings B.V. Composition
WO2022228950A1 (en) 2021-04-30 2022-11-03 Unilever Ip Holdings B.V. Composition
WO2022235720A1 (en) 2021-05-05 2022-11-10 The Procter & Gamble Company Methods for making cleaning compositions and detecting soils
WO2022248108A1 (en) 2021-05-28 2022-12-01 Unilever Ip Holdings B.V. A liquid laundry detergent composition comprising c16 and c18 alcohol ethoxylate surfactant and/or c16 and c18 alkyl ether sulphate
EP4108767A1 (en) 2021-06-22 2022-12-28 The Procter & Gamble Company Cleaning or treatment compositions containing nuclease enzymes
WO2023011892A1 (en) 2021-08-05 2023-02-09 Unilever Ip Holdings B.V. Composition
WO2023012098A1 (en) 2021-08-05 2023-02-09 Unilever Ip Holdings B.V. Method
WO2023012093A1 (en) 2021-08-05 2023-02-09 Unilever Ip Holdings B.V. Method
WO2023051978A1 (en) 2021-09-29 2023-04-06 Unilever Ip Holdings B.V. Composition
WO2023064749A1 (en) 2021-10-14 2023-04-20 The Procter & Gamble Company A fabric and home care product comprising cationic soil release polymer and lipase enzyme
DE102022128399A1 (en) 2021-10-26 2023-04-27 Unilever Global Ip Limited COMPOSITION
WO2023152067A1 (en) 2022-02-14 2023-08-17 Unilever Ip Holdings B.V. A concentrated liquid composition premix
WO2023152092A1 (en) 2022-02-14 2023-08-17 Unilever Ip Holdings B.V. A concentrated liquid composition premix
WO2023165950A1 (en) 2022-03-04 2023-09-07 Novozymes A/S Dnase variants and compositions
EP4273210A1 (en) 2022-05-04 2023-11-08 The Procter & Gamble Company Detergent compositions containing enzymes
EP4273209A1 (en) 2022-05-04 2023-11-08 The Procter & Gamble Company Machine-cleaning compositions containing enzymes
WO2023227331A1 (en) 2022-05-27 2023-11-30 Unilever Ip Holdings B.V. Composition comprising a specific methyl ester ethoxylate surfactant and a lipase
WO2023227421A1 (en) 2022-05-27 2023-11-30 Unilever Ip Holdings B.V. Laundry liquid composition comprising a surfactant, an alkoxylated zwitterionic polyamine polymer, and a fragrance
WO2023227335A1 (en) 2022-05-27 2023-11-30 Unilever Ip Holdings B.V. Liquid composition comprising linear alkyl benzene sulphonate, methyl ester ethoxylate and alkoxylated zwitterionic polyamine polymer
WO2023227332A1 (en) 2022-05-27 2023-11-30 Unilever Ip Holdings B.V. Laundry liquid composition comprising a surfactant, an alkoxylated zwitterionic polyamine polymer and a protease
WO2023227375A1 (en) 2022-05-27 2023-11-30 Unilever Ip Holdings B.V. Laundry liquid composition comprising a surfactant, an aminocarboxylate, an organic acid and a fragrance
WO2023233026A1 (en) 2022-06-03 2023-12-07 Unilever Ip Holdings B.V. Laundry detergent product
WO2023237412A1 (en) 2022-06-09 2023-12-14 Unilever Ip Holdings B.V. A concentrated liquid detergent composition
WO2024017614A1 (en) 2022-07-18 2024-01-25 Unilever Ip Holdings B.V. A concentrated liquid composition
WO2024017623A1 (en) 2022-07-18 2024-01-25 Unilever Ip Holdings B.V. A concentrated liquid composition
EP4321603A1 (en) 2022-08-11 2024-02-14 The Procter & Gamble Company Laundry detergent composition
EP4321604A1 (en) 2022-08-08 2024-02-14 The Procter & Gamble Company A fabric and home care composition comprising surfactant and a polyester
WO2024046757A1 (en) 2022-08-30 2024-03-07 Unilever Ip Holdings B.V. Detergent product
WO2024056278A1 (en) 2022-09-13 2024-03-21 Unilever Ip Holdings B.V. Washing machine and washing method
WO2024056334A1 (en) 2022-09-13 2024-03-21 Unilever Ip Holdings B.V. Washing machine and washing method
WO2024056331A1 (en) 2022-09-13 2024-03-21 Unilever Ip Holdings B.V. Washing machine and washing method
WO2024056333A1 (en) 2022-09-13 2024-03-21 Unilever Ip Holdings B.V. Washing machine and washing method
EP4349944A1 (en) 2022-10-05 2024-04-10 Unilever IP Holdings B.V. Laundry liquid composition
EP4349948A1 (en) 2022-10-05 2024-04-10 Unilever IP Holdings B.V. Laundry liquid composition
EP4349945A1 (en) 2022-10-05 2024-04-10 Unilever IP Holdings B.V. Laundry liquid composition
EP4349946A1 (en) 2022-10-05 2024-04-10 Unilever IP Holdings B.V. Unit dose fabric treatment product
EP4349943A1 (en) 2022-10-05 2024-04-10 Unilever IP Holdings B.V. Laundry liquid composition
EP4349947A1 (en) 2022-10-05 2024-04-10 Unilever IP Holdings B.V. Laundry liquid composition
EP4349942A1 (en) 2022-10-05 2024-04-10 Unilever IP Holdings B.V. Laundry liquid composition

Citations (152)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1296839A (en) 1969-05-29 1972-11-22
US4435307A (en) 1980-04-30 1984-03-06 Novo Industri A/S Detergent cellulase
EP0218272A1 (en) 1985-08-09 1987-04-15 Gist-Brocades N.V. Novel lipolytic enzymes and their use in detergent compositions
EP0258068A2 (en) 1986-08-29 1988-03-02 Novo Nordisk A/S Enzymatic detergent additive
EP0305216A1 (en) 1987-08-28 1989-03-01 Novo Nordisk A/S Recombinant Humicola lipase and process for the production of recombinant humicola lipases
WO1989006279A1 (en) 1988-01-07 1989-07-13 Novo-Nordisk A/S Mutated subtilisin genes
EP0331376A2 (en) 1988-02-28 1989-09-06 Amano Pharmaceutical Co., Ltd. Recombinant DNA, bacterium of the genus pseudomonas containing it, and process for preparing lipase by using it
WO1989009259A1 (en) 1988-03-24 1989-10-05 Novo-Nordisk A/S A cellulase preparation
JPH02238885A (en) 1989-03-13 1990-09-21 Oji Paper Co Ltd Phenol oxidase gene recombination dna, microorganism transformed with same recombinant dna, culture mixture thereof and production of phenol oxidase
EP0407225A1 (en) 1989-07-07 1991-01-09 Unilever Plc Enzymes and enzymatic detergent compositions
WO1992001046A1 (en) 1990-07-06 1992-01-23 Valtion Teknillinen Tutkimuskeskus Laccase production by recombinant organisms
WO1992005249A1 (en) 1990-09-13 1992-04-02 Novo Nordisk A/S Lipase variants
EP0495257A1 (en) 1991-01-16 1992-07-22 The Procter & Gamble Company Compact detergent compositions with high activity cellulase
WO1992019729A1 (en) 1991-05-01 1992-11-12 Novo Nordisk A/S Stabilized enzymes and detergent compositions
WO1992021760A1 (en) 1991-05-29 1992-12-10 Cognis, Inc. Mutant proteolytic enzymes from bacillus
EP0531372A1 (en) 1990-05-09 1993-03-17 Novo Nordisk As A cellulase preparation comprising an endoglucanase enzyme.
EP0531315A1 (en) 1990-05-09 1993-03-17 Novo Nordisk As An enzyme capable of degrading cellulose or hemicellulose.
WO1993018140A1 (en) 1992-03-04 1993-09-16 Novo Nordisk A/S Novel proteases
WO1993024618A1 (en) 1992-06-01 1993-12-09 Novo Nordisk A/S Peroxidase variants with improved hydrogen peroxide stability
WO1994001541A1 (en) 1992-07-06 1994-01-20 Novo Nordisk A/S C. antarctica lipase and lipase variants
WO1994002597A1 (en) 1992-07-23 1994-02-03 Novo Nordisk A/S MUTANT α-AMYLASE, DETERGENT, DISH WASHING AGENT, AND LIQUEFACTION AGENT
WO1994007998A1 (en) 1992-10-06 1994-04-14 Novo Nordisk A/S Cellulase variants
WO1994018314A1 (en) 1993-02-11 1994-08-18 Genencor International, Inc. Oxidatively stable alpha-amylase
US5352604A (en) 1989-08-25 1994-10-04 Henkel Research Corporation Alkaline proteolytic enzyme and method of production
WO1994025578A1 (en) 1993-04-27 1994-11-10 Gist-Brocades N.V. New lipase variants for use in detergent applications
WO1994025583A1 (en) 1993-05-05 1994-11-10 Novo Nordisk A/S A recombinant trypsin-like protease
EP0624154A1 (en) 1991-12-13 1994-11-17 The Procter & Gamble Company Acylated citrate esters as peracid precursors
WO1995006720A1 (en) 1993-08-30 1995-03-09 Showa Denko K.K. Novel lipase, microorganism producing the lipase, process for producing the lipase, and use of the lipase
WO1995010603A1 (en) 1993-10-08 1995-04-20 Novo Nordisk A/S Amylase variants
WO1995010602A1 (en) 1993-10-13 1995-04-20 Novo Nordisk A/S H2o2-stable peroxidase variants
WO1995014783A1 (en) 1993-11-24 1995-06-01 Showa Denko K.K. Lipase gene and variant lipase
WO1995022615A1 (en) 1994-02-22 1995-08-24 Novo Nordisk A/S A method of preparing a variant of a lipolytic enzyme
WO1995023221A1 (en) 1994-02-24 1995-08-31 Cognis, Inc. Improved enzymes and detergents containing them
WO1995024471A1 (en) 1994-03-08 1995-09-14 Novo Nordisk A/S Novel alkaline cellulases
WO1995030744A2 (en) 1994-05-04 1995-11-16 Genencor International Inc. Lipases with improved surfactant resistance
WO1995033836A1 (en) 1994-06-03 1995-12-14 Novo Nordisk Biotech, Inc. Phosphonyldipeptides useful in the treatment of cardiovascular diseases
WO1995035381A1 (en) 1994-06-20 1995-12-28 Unilever N.V. Modified pseudomonas lipases and their use
WO1996000292A1 (en) 1994-06-23 1996-01-04 Unilever N.V. Modified pseudomonas lipases and their use
WO1996011262A1 (en) 1994-10-06 1996-04-18 Novo Nordisk A/S An enzyme and enzyme preparation with endoglucanase activity
WO1996012012A1 (en) 1994-10-14 1996-04-25 Solvay S.A. Lipase, microorganism producing same, method for preparing said lipase and uses thereof
WO1996013580A1 (en) 1994-10-26 1996-05-09 Novo Nordisk A/S An enzyme with lipolytic activity
WO1996023873A1 (en) 1995-02-03 1996-08-08 Novo Nordisk A/S Amylase variants
WO1996027002A1 (en) 1995-02-27 1996-09-06 Novo Nordisk A/S Novel lipase gene and process for the production of lipase with the use of the same
WO1996029397A1 (en) 1995-03-17 1996-09-26 Novo Nordisk A/S Novel endoglucanases
WO1996034946A1 (en) 1995-05-05 1996-11-07 Novo Nordisk A/S Protease variants and compositions
WO1997004079A1 (en) 1995-07-14 1997-02-06 Novo Nordisk A/S A modified enzyme with lipolytic activity
WO1997007202A1 (en) 1995-08-11 1997-02-27 Novo Nordisk A/S Novel lipolytic enzymes
WO1997008325A2 (en) 1995-08-25 1997-03-06 Novo Nordisk Biotech, Inc. Purified coprinus laccases and nucleic acids encoding same
US5648263A (en) 1988-03-24 1997-07-15 Novo Nordisk A/S Methods for reducing the harshness of a cotton-containing fabric
WO1997043424A1 (en) 1996-05-14 1997-11-20 Genencor International, Inc. MODIFIED α-AMYLASES HAVING ALTERED CALCIUM BINDING PROPERTIES
WO1998008940A1 (en) 1996-08-26 1998-03-05 Novo Nordisk A/S A novel endoglucanase
WO1998012307A1 (en) 1996-09-17 1998-03-26 Novo Nordisk A/S Cellulase variants
WO1998015257A1 (en) 1996-10-08 1998-04-16 Novo Nordisk A/S Diaminobenzoic acid derivatives as dye precursors
WO1998017767A1 (en) 1996-10-18 1998-04-30 The Procter & Gamble Company Detergent compositions
WO1998020115A1 (en) 1996-11-04 1998-05-14 Novo Nordisk A/S Subtilase variants and compositions
WO1998020116A1 (en) 1996-11-04 1998-05-14 Novo Nordisk A/S Subtilase variants and compositions
WO1999001544A1 (en) 1997-07-04 1999-01-14 Novo Nordisk A/S FAMILY 6 ENDO-1,4-β-GLUCANASE VARIANTS AND CLEANING COMPOSIT IONS CONTAINING THEM
WO1999011768A1 (en) 1997-08-29 1999-03-11 Novo Nordisk A/S Protease variants and compositions
WO1999019467A1 (en) 1997-10-13 1999-04-22 Novo Nordisk A/S α-AMYLASE MUTANTS
US5977053A (en) 1995-07-31 1999-11-02 Bayer Ag Detergents and cleaners containing iminodisuccinates
WO1999064619A2 (en) 1998-06-10 1999-12-16 Novozymes A/S Novel mannanases
WO2000034450A1 (en) 1998-12-04 2000-06-15 Novozymes A/S Cutinase variants
WO2000060063A1 (en) 1999-03-31 2000-10-12 Novozymes A/S Lipase variant
WO2001016285A2 (en) 1999-08-31 2001-03-08 Novozymes A/S Novel proteases and variants thereof
WO2001044452A1 (en) 1999-12-15 2001-06-21 Novozymes A/S Subtilase variants having an improved wash performance on egg stains
WO2001062903A1 (en) 2000-02-24 2001-08-30 Novozymes A/S Family 44 xyloglucanases
WO2001066712A2 (en) 2000-03-08 2001-09-13 Novozymes A/S Variants with altered properties
WO2001092502A1 (en) 2000-06-02 2001-12-06 Novozymes A/S Cutinase variants
WO2002010355A2 (en) 2000-08-01 2002-02-07 Novozymes A/S Alpha-amylase mutants with altered stability
WO2002016547A2 (en) 2000-08-21 2002-02-28 Novozymes A/S Subtilase enzymes
WO2002092741A2 (en) 2001-05-14 2002-11-21 Novozymes A/S 0etergent compositions comprising bacillus subtilis pectate lyases
WO2002099091A2 (en) 2001-06-06 2002-12-12 Novozymes A/S Endo-beta-1,4-glucanase from bacillus
WO2003006602A2 (en) 2001-07-12 2003-01-23 Novozymes A/S Subtilase variants
WO2003040279A1 (en) 2001-11-09 2003-05-15 Unilever Plc Polymers for laundry applications
WO2003095638A1 (en) 2002-05-14 2003-11-20 Novozymes A/S Pectate lyase variants
WO2004003186A2 (en) 2002-06-26 2004-01-08 Novozymes A/S Subtilases and subtilase variants having altered immunogenicity
WO2004041979A2 (en) 2002-11-06 2004-05-21 Novozymes A/S Subtilase variants
WO2005003275A1 (en) 2003-06-18 2005-01-13 Unilever Plc Laundry treatment compositions
WO2005003276A1 (en) 2003-06-18 2005-01-13 Unilever Plc Laundry treatment compositions
WO2005003274A1 (en) 2003-06-18 2005-01-13 Unilever Plc Laundry treatment compositions
WO2005040372A1 (en) 2003-10-23 2005-05-06 Novozymes A/S Protease with improved stability in detergents
WO2005052161A2 (en) 2003-11-19 2005-06-09 Genencor International, Inc. Serine proteases, nucleic acids encoding serine enzymes and vectors and host cells incorporating same
WO2005056782A2 (en) 2003-12-03 2005-06-23 Genencor International, Inc. Perhydrolase
WO2006066594A2 (en) 2004-12-23 2006-06-29 Novozymes A/S Alpha-amylase variants
WO2006108856A2 (en) 2005-04-15 2006-10-19 Basf Aktiengesellschaft Amphiphilic water-soluble alkoxylated polyalkylenimines with an internal polyethylene oxide block and an external polypropylene oxide block
WO2006113314A1 (en) 2005-04-15 2006-10-26 The Procter & Gamble Company Liquid laundry detergent compositions with modified polyethyleneimine polymers and lipase enzyme
WO2006130575A2 (en) 2005-05-31 2006-12-07 The Procter & Gamble Company Polymer-containing detergent compositions and their use
WO2007006305A1 (en) 2005-07-08 2007-01-18 Novozymes A/S Subtilase variants
WO2007044993A2 (en) 2005-10-12 2007-04-19 Genencor International, Inc. Use and production of storage-stable neutral metalloprotease
WO2007087244A2 (en) 2006-01-23 2007-08-02 The Procter & Gamble Company Detergent compositions
WO2007087508A2 (en) 2006-01-23 2007-08-02 Novozymes A/S Lipase variants
WO2007087242A2 (en) 2006-01-23 2007-08-02 The Procter & Gamble Company A composition comprising a lipase and a bleach catalyst
WO2007087259A2 (en) 2006-01-23 2007-08-02 The Procter & Gamble Company Enzyme and photobleach containing compositions
WO2007087257A2 (en) 2006-01-23 2007-08-02 The Procter & Gamble Company Enzyme and fabric hueing agent containing compositions
WO2007087258A2 (en) 2006-01-23 2007-08-02 The Procter & Gamble Company A composition comprising a lipase and a bleach catalyst
WO2007087243A2 (en) 2006-01-23 2007-08-02 The Procter & Gamble Company Detergent compositions
US7262042B2 (en) 2001-12-20 2007-08-28 Henkel Kommanditgesellschaft Auf Aktien (Henkel Kgaa) Alkaline protease from Bacillus gibsonii (DSM 14393) and washing and cleaning products comprising said alkaline protease
WO2007138054A1 (en) 2006-05-31 2007-12-06 The Procter & Gamble Company Cleaning compositions with amphiphilic graft polymers based on polyalkylene oxides and vinyl esters
EP1867708A1 (en) 2006-06-16 2007-12-19 The Procter and Gamble Company Detergent Compositions
EP1867808A1 (en) 2006-06-06 2007-12-19 Brose Schliesssysteme GmbH & Co. KG Motor vehicle lock
EP1876226A1 (en) 2006-07-07 2008-01-09 The Procter and Gamble Company Detergent compositions
WO2008153815A2 (en) 2007-05-30 2008-12-18 Danisco Us, Inc., Genencor Division Variants of an alpha-amylase with improved production levels in fermentation processes
US20090011970A1 (en) 2007-07-02 2009-01-08 Marc Francois Theophile Evers Laundry multi-compartment pouch composition
WO2009021867A2 (en) 2007-08-10 2009-02-19 Henkel Ag & Co. Kgaa Agents containing proteases
WO2009061380A2 (en) 2007-11-05 2009-05-14 Danisco Us Inc., Genencor Division VARIANTS OF BACILLUS sp. TS-23 ALPHA-AMYLASE WITH ALTERED PROPERTIES
WO2009067279A1 (en) 2007-11-21 2009-05-28 E.I. Du Pont De Nemours And Company Production of peracids using an enzyme having perhydrolysis activity
WO2009087523A2 (en) 2008-01-04 2009-07-16 The Procter & Gamble Company A laundry detergent composition comprising glycosyl hydrolase
WO2009102854A1 (en) 2008-02-15 2009-08-20 The Procter & Gamble Company Cleaning compositions
WO2009109500A1 (en) 2008-02-29 2009-09-11 Novozymes A/S Polypeptides having lipase activity and polynucleotides encoding same
EP2169040A1 (en) 2008-09-30 2010-03-31 The Procter and Gamble Company Liquid detergent compositions exhibiting two or multicolor effect
WO2010065455A2 (en) 2008-12-01 2010-06-10 Danisco Us Inc. Enzymes with lipase activity
WO2010100028A2 (en) 2009-03-06 2010-09-10 Huntsman Advanced Materials (Switzerland) Gmbh Enzymatic textile bleach-whitening methods
WO2010104675A1 (en) 2009-03-10 2010-09-16 Danisco Us Inc. Bacillus megaterium strain dsm90-related alpha-amylases, and methods of use, thereof
WO2010111143A2 (en) 2009-03-23 2010-09-30 Danisco Us Inc. Cal a-related acyltransferases and methods of use, thereof
WO2011036264A1 (en) 2009-09-25 2011-03-31 Novozymes A/S Use of protease variants
WO2011036263A1 (en) 2009-09-25 2011-03-31 Novozymes A/S Subtilase variants
WO2011084599A1 (en) 2009-12-21 2011-07-14 Danisco Us Inc. Detergent compositions containing bacillus subtilis lipase and methods of use thereof
WO2011084417A1 (en) 2009-12-21 2011-07-14 Danisco Us Inc. Detergent compositions containing geobacillus stearothermophilus lipase and methods of use thereof
WO2011084412A1 (en) 2009-12-21 2011-07-14 Danisco Us Inc. Detergent compositions containing thermobifida fusca lipase and methods of use thereof
WO2011098531A1 (en) 2010-02-10 2011-08-18 Novozymes A/S Variants and compositions comprising variants with high stability in presence of a chelating agent
WO2011150157A2 (en) 2010-05-28 2011-12-01 Danisco Us Inc. Detergent compositions containing streptomyces griseus lipase and methods of use thereof
WO2012137147A1 (en) 2011-04-08 2012-10-11 Danisco Us, Inc. Compositions
WO2013001087A2 (en) 2011-06-30 2013-01-03 Novozymes A/S Method for screening alpha-amylases
WO2013001078A1 (en) 2011-06-30 2013-01-03 Novozymes A/S Alpha-amylase variants
WO2013184577A1 (en) 2012-06-08 2013-12-12 Danisco Us Inc. Alpha-amylase variants derived from the alpha amylase of cytophaga sp.amylase|(cspamy2).
WO2013188331A1 (en) 2012-06-11 2013-12-19 The Procter & Gamble Company Detergent composition
WO2014207227A1 (en) 2013-06-27 2014-12-31 Novozymes A/S Subtilase variants and polynucleotides encoding same
WO2015014790A2 (en) 2013-07-29 2015-02-05 Novozymes A/S Protease variants and polynucleotides encoding same
WO2016087617A1 (en) 2014-12-04 2016-06-09 Novozymes A/S Subtilase variants and polynucleotides encoding same
WO2016097354A1 (en) 2014-12-19 2016-06-23 Novozymes A/S Protease variants and polynucleotides encoding same
WO2016097350A1 (en) 2014-12-19 2016-06-23 Novozymes A/S Protease variants and polynucleotides encoding same
WO2016097357A1 (en) 2014-12-19 2016-06-23 Novozymes A/S Protease variants and polynucleotides encoding same
WO2016097352A1 (en) 2014-12-19 2016-06-23 Novozymes A/S Protease variants and polynucleotides encoding same
WO2016135351A1 (en) * 2015-06-30 2016-09-01 Novozymes A/S Laundry detergent composition, method for washing and use of composition
WO2017060475A2 (en) 2015-10-07 2017-04-13 Novozymes A/S Polypeptides
WO2017186943A1 (en) 2016-04-29 2017-11-02 Novozymes A/S Detergent compositions and uses thereof
WO2017186937A1 (en) 2016-04-29 2017-11-02 Novozymes A/S Detergent compositions and uses thereof
WO2017186936A1 (en) 2016-04-29 2017-11-02 Novozymes A/S Detergent compositions and uses thereof
WO2017207770A1 (en) * 2016-06-03 2017-12-07 Novozymes A/S Cleaning compositions comprising enzymes
WO2018011276A1 (en) * 2016-07-13 2018-01-18 The Procter & Gamble Company Bacillus cibi dnase variants and uses thereof
WO2018102478A1 (en) * 2016-12-02 2018-06-07 The Procter & Gamble Company Cleaning compositions including enzymes
WO2018102479A1 (en) * 2016-12-02 2018-06-07 The Procter & Gamble Company Cleaning compositions including enzymes
US20180155802A1 (en) * 2016-12-02 2018-06-07 The Procter & Gamble Company Cleaning compositions including enzymes
WO2018178061A1 (en) 2017-03-31 2018-10-04 Novozymes A/S Polypeptides having rnase activity
WO2018184873A1 (en) 2017-04-06 2018-10-11 Novozymes A/S Detergent compositions and uses thereof
WO2018185150A1 (en) 2017-04-04 2018-10-11 Novozymes A/S Polypeptides
WO2018185285A1 (en) 2017-04-06 2018-10-11 Novozymes A/S Cleaning compositions and uses thereof
WO2018185152A1 (en) 2017-04-04 2018-10-11 Novozymes A/S Polypeptide compositions and uses thereof
WO2018185280A1 (en) * 2017-04-06 2018-10-11 Novozymes A/S Cleaning compositions and uses thereof
WO2018185267A1 (en) * 2017-04-06 2018-10-11 Novozymes A/S Cleaning compositions and uses thereof
WO2018185269A1 (en) * 2017-04-06 2018-10-11 Novozymes A/S Cleaning compositions and uses thereof
WO2018185181A1 (en) 2017-04-04 2018-10-11 Novozymes A/S Glycosyl hydrolases

Patent Citations (161)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1296839A (en) 1969-05-29 1972-11-22
US4435307A (en) 1980-04-30 1984-03-06 Novo Industri A/S Detergent cellulase
EP0218272A1 (en) 1985-08-09 1987-04-15 Gist-Brocades N.V. Novel lipolytic enzymes and their use in detergent compositions
EP0258068A2 (en) 1986-08-29 1988-03-02 Novo Nordisk A/S Enzymatic detergent additive
EP0305216A1 (en) 1987-08-28 1989-03-01 Novo Nordisk A/S Recombinant Humicola lipase and process for the production of recombinant humicola lipases
WO1989006279A1 (en) 1988-01-07 1989-07-13 Novo-Nordisk A/S Mutated subtilisin genes
EP0331376A2 (en) 1988-02-28 1989-09-06 Amano Pharmaceutical Co., Ltd. Recombinant DNA, bacterium of the genus pseudomonas containing it, and process for preparing lipase by using it
US5691178A (en) 1988-03-22 1997-11-25 Novo Nordisk A/S Fungal cellulase composition containing alkaline CMC-endoglucanase and essentially no cellobiohydrolase
WO1989009259A1 (en) 1988-03-24 1989-10-05 Novo-Nordisk A/S A cellulase preparation
US5648263A (en) 1988-03-24 1997-07-15 Novo Nordisk A/S Methods for reducing the harshness of a cotton-containing fabric
US5776757A (en) 1988-03-24 1998-07-07 Novo Nordisk A/S Fungal cellulase composition containing alkaline CMC-endoglucanase and essentially no cellobiohydrolase and method of making thereof
JPH02238885A (en) 1989-03-13 1990-09-21 Oji Paper Co Ltd Phenol oxidase gene recombination dna, microorganism transformed with same recombinant dna, culture mixture thereof and production of phenol oxidase
EP0407225A1 (en) 1989-07-07 1991-01-09 Unilever Plc Enzymes and enzymatic detergent compositions
US5352604A (en) 1989-08-25 1994-10-04 Henkel Research Corporation Alkaline proteolytic enzyme and method of production
EP0531315A1 (en) 1990-05-09 1993-03-17 Novo Nordisk As An enzyme capable of degrading cellulose or hemicellulose.
US5457046A (en) 1990-05-09 1995-10-10 Novo Nordisk A/S Enzyme capable of degrading cellullose or hemicellulose
US5763254A (en) 1990-05-09 1998-06-09 Novo Nordisk A/S Enzyme capable of degrading cellulose or hemicellulose
EP0531372A1 (en) 1990-05-09 1993-03-17 Novo Nordisk As A cellulase preparation comprising an endoglucanase enzyme.
US5686593A (en) 1990-05-09 1997-11-11 Novo Nordisk A/S Enzyme capable of degrading cellulose or hemicellulose
WO1992001046A1 (en) 1990-07-06 1992-01-23 Valtion Teknillinen Tutkimuskeskus Laccase production by recombinant organisms
WO1992005249A1 (en) 1990-09-13 1992-04-02 Novo Nordisk A/S Lipase variants
EP0495257A1 (en) 1991-01-16 1992-07-22 The Procter & Gamble Company Compact detergent compositions with high activity cellulase
WO1992019729A1 (en) 1991-05-01 1992-11-12 Novo Nordisk A/S Stabilized enzymes and detergent compositions
WO1992021760A1 (en) 1991-05-29 1992-12-10 Cognis, Inc. Mutant proteolytic enzymes from bacillus
EP0624154A1 (en) 1991-12-13 1994-11-17 The Procter & Gamble Company Acylated citrate esters as peracid precursors
WO1993018140A1 (en) 1992-03-04 1993-09-16 Novo Nordisk A/S Novel proteases
WO1993024618A1 (en) 1992-06-01 1993-12-09 Novo Nordisk A/S Peroxidase variants with improved hydrogen peroxide stability
WO1994001541A1 (en) 1992-07-06 1994-01-20 Novo Nordisk A/S C. antarctica lipase and lipase variants
WO1994002597A1 (en) 1992-07-23 1994-02-03 Novo Nordisk A/S MUTANT α-AMYLASE, DETERGENT, DISH WASHING AGENT, AND LIQUEFACTION AGENT
WO1994007998A1 (en) 1992-10-06 1994-04-14 Novo Nordisk A/S Cellulase variants
WO1994018314A1 (en) 1993-02-11 1994-08-18 Genencor International, Inc. Oxidatively stable alpha-amylase
WO1994025578A1 (en) 1993-04-27 1994-11-10 Gist-Brocades N.V. New lipase variants for use in detergent applications
WO1994025583A1 (en) 1993-05-05 1994-11-10 Novo Nordisk A/S A recombinant trypsin-like protease
WO1995006720A1 (en) 1993-08-30 1995-03-09 Showa Denko K.K. Novel lipase, microorganism producing the lipase, process for producing the lipase, and use of the lipase
WO1995010603A1 (en) 1993-10-08 1995-04-20 Novo Nordisk A/S Amylase variants
WO1995010602A1 (en) 1993-10-13 1995-04-20 Novo Nordisk A/S H2o2-stable peroxidase variants
WO1995014783A1 (en) 1993-11-24 1995-06-01 Showa Denko K.K. Lipase gene and variant lipase
WO1995022615A1 (en) 1994-02-22 1995-08-24 Novo Nordisk A/S A method of preparing a variant of a lipolytic enzyme
WO1995023221A1 (en) 1994-02-24 1995-08-31 Cognis, Inc. Improved enzymes and detergents containing them
EP1921148A2 (en) 1994-02-24 2008-05-14 Henkel Kommanditgesellschaft auf Aktien Improved enzymes and detergents containing them
EP1921147A2 (en) 1994-02-24 2008-05-14 Henkel Kommanditgesellschaft auf Aktien Improved enzymes and detergents containing them
WO1995024471A1 (en) 1994-03-08 1995-09-14 Novo Nordisk A/S Novel alkaline cellulases
WO1995030744A2 (en) 1994-05-04 1995-11-16 Genencor International Inc. Lipases with improved surfactant resistance
WO1995033836A1 (en) 1994-06-03 1995-12-14 Novo Nordisk Biotech, Inc. Phosphonyldipeptides useful in the treatment of cardiovascular diseases
WO1995035381A1 (en) 1994-06-20 1995-12-28 Unilever N.V. Modified pseudomonas lipases and their use
WO1996000292A1 (en) 1994-06-23 1996-01-04 Unilever N.V. Modified pseudomonas lipases and their use
WO1996011262A1 (en) 1994-10-06 1996-04-18 Novo Nordisk A/S An enzyme and enzyme preparation with endoglucanase activity
WO1996012012A1 (en) 1994-10-14 1996-04-25 Solvay S.A. Lipase, microorganism producing same, method for preparing said lipase and uses thereof
WO1996013580A1 (en) 1994-10-26 1996-05-09 Novo Nordisk A/S An enzyme with lipolytic activity
WO1996023873A1 (en) 1995-02-03 1996-08-08 Novo Nordisk A/S Amylase variants
WO1996027002A1 (en) 1995-02-27 1996-09-06 Novo Nordisk A/S Novel lipase gene and process for the production of lipase with the use of the same
WO1996029397A1 (en) 1995-03-17 1996-09-26 Novo Nordisk A/S Novel endoglucanases
WO1996034946A1 (en) 1995-05-05 1996-11-07 Novo Nordisk A/S Protease variants and compositions
WO1997004079A1 (en) 1995-07-14 1997-02-06 Novo Nordisk A/S A modified enzyme with lipolytic activity
US5977053A (en) 1995-07-31 1999-11-02 Bayer Ag Detergents and cleaners containing iminodisuccinates
WO1997007202A1 (en) 1995-08-11 1997-02-27 Novo Nordisk A/S Novel lipolytic enzymes
WO1997008325A2 (en) 1995-08-25 1997-03-06 Novo Nordisk Biotech, Inc. Purified coprinus laccases and nucleic acids encoding same
WO1997043424A1 (en) 1996-05-14 1997-11-20 Genencor International, Inc. MODIFIED α-AMYLASES HAVING ALTERED CALCIUM BINDING PROPERTIES
WO1998008940A1 (en) 1996-08-26 1998-03-05 Novo Nordisk A/S A novel endoglucanase
WO1998012307A1 (en) 1996-09-17 1998-03-26 Novo Nordisk A/S Cellulase variants
WO1998015257A1 (en) 1996-10-08 1998-04-16 Novo Nordisk A/S Diaminobenzoic acid derivatives as dye precursors
WO1998017767A1 (en) 1996-10-18 1998-04-30 The Procter & Gamble Company Detergent compositions
WO1998020115A1 (en) 1996-11-04 1998-05-14 Novo Nordisk A/S Subtilase variants and compositions
WO1998020116A1 (en) 1996-11-04 1998-05-14 Novo Nordisk A/S Subtilase variants and compositions
WO1999001544A1 (en) 1997-07-04 1999-01-14 Novo Nordisk A/S FAMILY 6 ENDO-1,4-β-GLUCANASE VARIANTS AND CLEANING COMPOSIT IONS CONTAINING THEM
WO1999011768A1 (en) 1997-08-29 1999-03-11 Novo Nordisk A/S Protease variants and compositions
WO1999019467A1 (en) 1997-10-13 1999-04-22 Novo Nordisk A/S α-AMYLASE MUTANTS
WO1999064619A2 (en) 1998-06-10 1999-12-16 Novozymes A/S Novel mannanases
WO2000034450A1 (en) 1998-12-04 2000-06-15 Novozymes A/S Cutinase variants
WO2000060063A1 (en) 1999-03-31 2000-10-12 Novozymes A/S Lipase variant
WO2001016285A2 (en) 1999-08-31 2001-03-08 Novozymes A/S Novel proteases and variants thereof
WO2001044452A1 (en) 1999-12-15 2001-06-21 Novozymes A/S Subtilase variants having an improved wash performance on egg stains
WO2001062903A1 (en) 2000-02-24 2001-08-30 Novozymes A/S Family 44 xyloglucanases
WO2001066712A2 (en) 2000-03-08 2001-09-13 Novozymes A/S Variants with altered properties
WO2001092502A1 (en) 2000-06-02 2001-12-06 Novozymes A/S Cutinase variants
WO2002010355A2 (en) 2000-08-01 2002-02-07 Novozymes A/S Alpha-amylase mutants with altered stability
WO2002016547A2 (en) 2000-08-21 2002-02-28 Novozymes A/S Subtilase enzymes
WO2002092741A2 (en) 2001-05-14 2002-11-21 Novozymes A/S 0etergent compositions comprising bacillus subtilis pectate lyases
WO2002099091A2 (en) 2001-06-06 2002-12-12 Novozymes A/S Endo-beta-1,4-glucanase from bacillus
WO2003006602A2 (en) 2001-07-12 2003-01-23 Novozymes A/S Subtilase variants
WO2003040279A1 (en) 2001-11-09 2003-05-15 Unilever Plc Polymers for laundry applications
US7262042B2 (en) 2001-12-20 2007-08-28 Henkel Kommanditgesellschaft Auf Aktien (Henkel Kgaa) Alkaline protease from Bacillus gibsonii (DSM 14393) and washing and cleaning products comprising said alkaline protease
WO2003095638A1 (en) 2002-05-14 2003-11-20 Novozymes A/S Pectate lyase variants
WO2004003186A2 (en) 2002-06-26 2004-01-08 Novozymes A/S Subtilases and subtilase variants having altered immunogenicity
WO2004041979A2 (en) 2002-11-06 2004-05-21 Novozymes A/S Subtilase variants
WO2005003274A1 (en) 2003-06-18 2005-01-13 Unilever Plc Laundry treatment compositions
WO2005003276A1 (en) 2003-06-18 2005-01-13 Unilever Plc Laundry treatment compositions
WO2005003275A1 (en) 2003-06-18 2005-01-13 Unilever Plc Laundry treatment compositions
WO2005040372A1 (en) 2003-10-23 2005-05-06 Novozymes A/S Protease with improved stability in detergents
WO2005052161A2 (en) 2003-11-19 2005-06-09 Genencor International, Inc. Serine proteases, nucleic acids encoding serine enzymes and vectors and host cells incorporating same
WO2005052146A2 (en) 2003-11-19 2005-06-09 Genencor International, Inc. Serine proteases, nucleic acids encoding serine enzymes and vectors and host cells incorporating same
WO2005056782A2 (en) 2003-12-03 2005-06-23 Genencor International, Inc. Perhydrolase
WO2006066594A2 (en) 2004-12-23 2006-06-29 Novozymes A/S Alpha-amylase variants
WO2006108856A2 (en) 2005-04-15 2006-10-19 Basf Aktiengesellschaft Amphiphilic water-soluble alkoxylated polyalkylenimines with an internal polyethylene oxide block and an external polypropylene oxide block
WO2006113314A1 (en) 2005-04-15 2006-10-26 The Procter & Gamble Company Liquid laundry detergent compositions with modified polyethyleneimine polymers and lipase enzyme
WO2006130575A2 (en) 2005-05-31 2006-12-07 The Procter & Gamble Company Polymer-containing detergent compositions and their use
WO2007006305A1 (en) 2005-07-08 2007-01-18 Novozymes A/S Subtilase variants
WO2007044993A2 (en) 2005-10-12 2007-04-19 Genencor International, Inc. Use and production of storage-stable neutral metalloprotease
WO2007087244A2 (en) 2006-01-23 2007-08-02 The Procter & Gamble Company Detergent compositions
WO2007087508A2 (en) 2006-01-23 2007-08-02 Novozymes A/S Lipase variants
WO2007087242A2 (en) 2006-01-23 2007-08-02 The Procter & Gamble Company A composition comprising a lipase and a bleach catalyst
WO2007087259A2 (en) 2006-01-23 2007-08-02 The Procter & Gamble Company Enzyme and photobleach containing compositions
WO2007087257A2 (en) 2006-01-23 2007-08-02 The Procter & Gamble Company Enzyme and fabric hueing agent containing compositions
WO2007087258A2 (en) 2006-01-23 2007-08-02 The Procter & Gamble Company A composition comprising a lipase and a bleach catalyst
WO2007087243A2 (en) 2006-01-23 2007-08-02 The Procter & Gamble Company Detergent compositions
WO2007138054A1 (en) 2006-05-31 2007-12-06 The Procter & Gamble Company Cleaning compositions with amphiphilic graft polymers based on polyalkylene oxides and vinyl esters
EP1867808A1 (en) 2006-06-06 2007-12-19 Brose Schliesssysteme GmbH & Co. KG Motor vehicle lock
EP1867708A1 (en) 2006-06-16 2007-12-19 The Procter and Gamble Company Detergent Compositions
EP1876226A1 (en) 2006-07-07 2008-01-09 The Procter and Gamble Company Detergent compositions
WO2008153815A2 (en) 2007-05-30 2008-12-18 Danisco Us, Inc., Genencor Division Variants of an alpha-amylase with improved production levels in fermentation processes
US20090011970A1 (en) 2007-07-02 2009-01-08 Marc Francois Theophile Evers Laundry multi-compartment pouch composition
WO2009021867A2 (en) 2007-08-10 2009-02-19 Henkel Ag & Co. Kgaa Agents containing proteases
WO2009061380A2 (en) 2007-11-05 2009-05-14 Danisco Us Inc., Genencor Division VARIANTS OF BACILLUS sp. TS-23 ALPHA-AMYLASE WITH ALTERED PROPERTIES
WO2009067279A1 (en) 2007-11-21 2009-05-28 E.I. Du Pont De Nemours And Company Production of peracids using an enzyme having perhydrolysis activity
WO2009087523A2 (en) 2008-01-04 2009-07-16 The Procter & Gamble Company A laundry detergent composition comprising glycosyl hydrolase
WO2009102854A1 (en) 2008-02-15 2009-08-20 The Procter & Gamble Company Cleaning compositions
WO2009109500A1 (en) 2008-02-29 2009-09-11 Novozymes A/S Polypeptides having lipase activity and polynucleotides encoding same
EP2169040A1 (en) 2008-09-30 2010-03-31 The Procter and Gamble Company Liquid detergent compositions exhibiting two or multicolor effect
WO2010065455A2 (en) 2008-12-01 2010-06-10 Danisco Us Inc. Enzymes with lipase activity
WO2010100028A2 (en) 2009-03-06 2010-09-10 Huntsman Advanced Materials (Switzerland) Gmbh Enzymatic textile bleach-whitening methods
WO2010104675A1 (en) 2009-03-10 2010-09-16 Danisco Us Inc. Bacillus megaterium strain dsm90-related alpha-amylases, and methods of use, thereof
WO2010111143A2 (en) 2009-03-23 2010-09-30 Danisco Us Inc. Cal a-related acyltransferases and methods of use, thereof
WO2011036264A1 (en) 2009-09-25 2011-03-31 Novozymes A/S Use of protease variants
WO2011036263A1 (en) 2009-09-25 2011-03-31 Novozymes A/S Subtilase variants
WO2011084599A1 (en) 2009-12-21 2011-07-14 Danisco Us Inc. Detergent compositions containing bacillus subtilis lipase and methods of use thereof
WO2011084417A1 (en) 2009-12-21 2011-07-14 Danisco Us Inc. Detergent compositions containing geobacillus stearothermophilus lipase and methods of use thereof
WO2011084412A1 (en) 2009-12-21 2011-07-14 Danisco Us Inc. Detergent compositions containing thermobifida fusca lipase and methods of use thereof
WO2011098531A1 (en) 2010-02-10 2011-08-18 Novozymes A/S Variants and compositions comprising variants with high stability in presence of a chelating agent
WO2011150157A2 (en) 2010-05-28 2011-12-01 Danisco Us Inc. Detergent compositions containing streptomyces griseus lipase and methods of use thereof
WO2012137147A1 (en) 2011-04-08 2012-10-11 Danisco Us, Inc. Compositions
WO2013001087A2 (en) 2011-06-30 2013-01-03 Novozymes A/S Method for screening alpha-amylases
WO2013001078A1 (en) 2011-06-30 2013-01-03 Novozymes A/S Alpha-amylase variants
WO2013184577A1 (en) 2012-06-08 2013-12-12 Danisco Us Inc. Alpha-amylase variants derived from the alpha amylase of cytophaga sp.amylase|(cspamy2).
WO2013188331A1 (en) 2012-06-11 2013-12-19 The Procter & Gamble Company Detergent composition
WO2014207227A1 (en) 2013-06-27 2014-12-31 Novozymes A/S Subtilase variants and polynucleotides encoding same
WO2015014790A2 (en) 2013-07-29 2015-02-05 Novozymes A/S Protease variants and polynucleotides encoding same
WO2016087617A1 (en) 2014-12-04 2016-06-09 Novozymes A/S Subtilase variants and polynucleotides encoding same
WO2016097354A1 (en) 2014-12-19 2016-06-23 Novozymes A/S Protease variants and polynucleotides encoding same
WO2016097350A1 (en) 2014-12-19 2016-06-23 Novozymes A/S Protease variants and polynucleotides encoding same
WO2016097357A1 (en) 2014-12-19 2016-06-23 Novozymes A/S Protease variants and polynucleotides encoding same
WO2016097352A1 (en) 2014-12-19 2016-06-23 Novozymes A/S Protease variants and polynucleotides encoding same
WO2016135351A1 (en) * 2015-06-30 2016-09-01 Novozymes A/S Laundry detergent composition, method for washing and use of composition
WO2017060475A2 (en) 2015-10-07 2017-04-13 Novozymes A/S Polypeptides
WO2017059802A1 (en) 2015-10-07 2017-04-13 Novozymes A/S Polypeptides
WO2017186943A1 (en) 2016-04-29 2017-11-02 Novozymes A/S Detergent compositions and uses thereof
WO2017186937A1 (en) 2016-04-29 2017-11-02 Novozymes A/S Detergent compositions and uses thereof
WO2017186936A1 (en) 2016-04-29 2017-11-02 Novozymes A/S Detergent compositions and uses thereof
WO2017207770A1 (en) * 2016-06-03 2017-12-07 Novozymes A/S Cleaning compositions comprising enzymes
WO2018011276A1 (en) * 2016-07-13 2018-01-18 The Procter & Gamble Company Bacillus cibi dnase variants and uses thereof
WO2018102479A1 (en) * 2016-12-02 2018-06-07 The Procter & Gamble Company Cleaning compositions including enzymes
WO2018102478A1 (en) * 2016-12-02 2018-06-07 The Procter & Gamble Company Cleaning compositions including enzymes
US20180155802A1 (en) * 2016-12-02 2018-06-07 The Procter & Gamble Company Cleaning compositions including enzymes
WO2018178061A1 (en) 2017-03-31 2018-10-04 Novozymes A/S Polypeptides having rnase activity
WO2018185150A1 (en) 2017-04-04 2018-10-11 Novozymes A/S Polypeptides
WO2018185152A1 (en) 2017-04-04 2018-10-11 Novozymes A/S Polypeptide compositions and uses thereof
WO2018185181A1 (en) 2017-04-04 2018-10-11 Novozymes A/S Glycosyl hydrolases
WO2018184873A1 (en) 2017-04-06 2018-10-11 Novozymes A/S Detergent compositions and uses thereof
WO2018185285A1 (en) 2017-04-06 2018-10-11 Novozymes A/S Cleaning compositions and uses thereof
WO2018185280A1 (en) * 2017-04-06 2018-10-11 Novozymes A/S Cleaning compositions and uses thereof
WO2018185267A1 (en) * 2017-04-06 2018-10-11 Novozymes A/S Cleaning compositions and uses thereof
WO2018185269A1 (en) * 2017-04-06 2018-10-11 Novozymes A/S Cleaning compositions and uses thereof

Non-Patent Citations (18)

* Cited by examiner, † Cited by third party
Title
"UniProt", Database accession no. PF00545
ANONYMOUS: "Glycoside Hydrolase Family 39 - CAZypedia", 20 August 2016 (2016-08-20), XP055416497, Retrieved from the Internet <URL:https://web.archive.org/web/20160820030330/https://www.cazypedia.org/index.php/Glycoside_Hydrolase_Family_39> [retrieved on 20171017] *
COLVIN, K. M.: "PelA deacetylase activity is required for Pel polysaccharide synthesis in Pseudomonas aeruginosa", J. BACTERIOL., vol. 195, 2013, pages 2329 - 2339
EDGAR, NUCLEIC ACIDS RESEARCH, vol. 32, no. 5, 2004, pages 1792 - 1797
FINN, NUCLEIC ACIDS RESEARCH, vol. 44, 2016, pages D279 - D285
HENRISSAT ET AL.: "Conserved catalytic machinery and the prediction of a common fold for several families of glycosyl hydrolases", PROC. NATL. ACAD. SCI. U.S.A., vol. 92, no. 15, 1995, pages 7090 - 7094, XP055063839, doi:10.1073/pnas.92.15.7090
HODGDONKALER, CURRENT OPINION IN COLLOID & INTERFACE SCIENCE, vol. 12, 2007, pages 121 - 128
JENNINGS ET AL., PNAS, vol. 112, no. 36, September 2015 (2015-09-01), pages 11353 - 11358
KIM ET AL., BIOSCI. BIOTECH. BIOCHEM., vol. 58, 1994, pages 947 - 949
LETUNICBORK, BIOINFORMATICS, vol. 23, no. 1, 2007, pages 127 - 128
M.A. MACHNICKA ET AL.: "Phylogenomics and sequence-structure-function relationships in the GmrSD family of Type IV restriction enzymes", BMC BIOINFORMATICS, vol. 16, 2015, pages 336
MARMONT ET AL., J BIOL CHEM., vol. 292, no. 47, 24 November 2017 (2017-11-24), pages 19411 - 19422
MARMONT: "PelA and PelB proteins form a modification and secretion complex essential for Pel polysaccharide-dependent biofilm formation in Pseudomonas aeruginosa", J. BIOL.CHEM., vol. 292, 2017, pages 19411 - 19422
NASSER ET AL., FEBS, vol. 335, 1993, pages 319 - 326
NEEDLEMANWUNSCH, J. MOL. BIOL., vol. 48, 1970, pages 443 - 453
PRICE ET AL., PLOS ONE, vol. 5, no. 3, 2010
R.D. FINN: "The Pfam protein families database: towards a more sustainable future", NUCLEIC ACIDS RESEARCH, vol. 44, 2016, pages D279 - D285, Retrieved from the Internet <URL:http://pfam.xfam.org>
RICE ET AL.: "EMBOSS: The European Molecular Biology Open Software Suite", TRENDS GENET, vol. 16, 2000, pages 276 - 277, XP004200114, doi:10.1016/S0168-9525(00)02024-2

Cited By (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022063707A1 (en) 2020-09-24 2022-03-31 Unilever Ip Holdings B.V. Composition
WO2022094589A1 (en) 2020-10-29 2022-05-05 The Procter & Gamble Company Cleaning compositions containing alginase enzymes
WO2022094164A1 (en) 2020-10-29 2022-05-05 The Procter & Gamble Company Cleaning composition comprising alginate lyase enzymes
WO2022094588A1 (en) 2020-10-29 2022-05-05 The Procter & Gamble Company Cleaning compositions containing alginate lyase enzymes
WO2022094590A1 (en) 2020-10-29 2022-05-05 The Procter & Gamble Company Cleaning compositions containing alginate lyase enzymes
WO2022094163A1 (en) 2020-10-29 2022-05-05 The Procter & Gamble Company Cleaning composition comprising alginate lyase enzymes
WO2022106404A1 (en) * 2020-11-18 2022-05-27 Novozymes A/S Combination of proteases
WO2022128368A1 (en) 2020-12-14 2022-06-23 Unilever Ip Holdings B.V. Composition
WO2022128370A1 (en) 2020-12-14 2022-06-23 Unilever Ip Holdings B.V. Composition
WO2022136389A1 (en) 2020-12-23 2022-06-30 Basf Se Amphiphilic alkoxylated polyamines and their uses
WO2022189059A1 (en) 2021-03-09 2022-09-15 Unilever Ip Holdings B.V. Composition
WO2022189521A1 (en) 2021-03-12 2022-09-15 Novozymes A/S Polypeptide variants
EP4060010A2 (en) 2021-03-15 2022-09-21 The Procter & Gamble Company Cleaning compositions containing polypeptide variants
EP4060036A1 (en) 2021-03-15 2022-09-21 Novozymes A/S Polypeptide variants
WO2022194668A1 (en) 2021-03-15 2022-09-22 Novozymes A/S Polypeptide variants
WO2022197512A1 (en) 2021-03-15 2022-09-22 The Procter & Gamble Company Cleaning compositions containing polypeptide variants
WO2022194673A1 (en) 2021-03-15 2022-09-22 Novozymes A/S Dnase variants
WO2022228949A1 (en) 2021-04-30 2022-11-03 Unilever Ip Holdings B.V. Composition
WO2022228903A1 (en) 2021-04-30 2022-11-03 Unilever Ip Holdings B.V. Composition
WO2022228951A1 (en) 2021-04-30 2022-11-03 Unilever Ip Holdings B.V. Composition
WO2022228832A1 (en) 2021-04-30 2022-11-03 Unilever Ip Holdings B.V. Composition
WO2022228950A1 (en) 2021-04-30 2022-11-03 Unilever Ip Holdings B.V. Composition
WO2022235720A1 (en) 2021-05-05 2022-11-10 The Procter & Gamble Company Methods for making cleaning compositions and detecting soils
EP4095223A1 (en) 2021-05-05 2022-11-30 The Procter & Gamble Company Methods for making cleaning compositions and for detecting soils
WO2022248108A1 (en) 2021-05-28 2022-12-01 Unilever Ip Holdings B.V. A liquid laundry detergent composition comprising c16 and c18 alcohol ethoxylate surfactant and/or c16 and c18 alkyl ether sulphate
EP4108767A1 (en) 2021-06-22 2022-12-28 The Procter & Gamble Company Cleaning or treatment compositions containing nuclease enzymes
WO2022272255A1 (en) 2021-06-22 2022-12-29 The Procter & Gamble Company Cleaning or treatment compositions containing nuclease enzymes
WO2023011892A1 (en) 2021-08-05 2023-02-09 Unilever Ip Holdings B.V. Composition
WO2023012098A1 (en) 2021-08-05 2023-02-09 Unilever Ip Holdings B.V. Method
WO2023012093A1 (en) 2021-08-05 2023-02-09 Unilever Ip Holdings B.V. Method
WO2023051978A1 (en) 2021-09-29 2023-04-06 Unilever Ip Holdings B.V. Composition
WO2023064749A1 (en) 2021-10-14 2023-04-20 The Procter & Gamble Company A fabric and home care product comprising cationic soil release polymer and lipase enzyme
DE102022128399A1 (en) 2021-10-26 2023-04-27 Unilever Global Ip Limited COMPOSITION
EP4174156A1 (en) 2021-10-26 2023-05-03 Unilever IP Holdings B.V. Composition
WO2023072507A1 (en) 2021-10-26 2023-05-04 Unilever Ip Holdings B.V. Composition
WO2023152067A1 (en) 2022-02-14 2023-08-17 Unilever Ip Holdings B.V. A concentrated liquid composition premix
WO2023152092A1 (en) 2022-02-14 2023-08-17 Unilever Ip Holdings B.V. A concentrated liquid composition premix
WO2023165950A1 (en) 2022-03-04 2023-09-07 Novozymes A/S Dnase variants and compositions
EP4273210A1 (en) 2022-05-04 2023-11-08 The Procter & Gamble Company Detergent compositions containing enzymes
EP4273209A1 (en) 2022-05-04 2023-11-08 The Procter & Gamble Company Machine-cleaning compositions containing enzymes
WO2023215679A1 (en) 2022-05-04 2023-11-09 The Procter & Gamble Company Detergent compositions containing enzymes
WO2023215680A1 (en) 2022-05-04 2023-11-09 The Procter & Gamble Company Machine-cleaning compositions containing enzymes
WO2023227331A1 (en) 2022-05-27 2023-11-30 Unilever Ip Holdings B.V. Composition comprising a specific methyl ester ethoxylate surfactant and a lipase
WO2023227421A1 (en) 2022-05-27 2023-11-30 Unilever Ip Holdings B.V. Laundry liquid composition comprising a surfactant, an alkoxylated zwitterionic polyamine polymer, and a fragrance
WO2023227335A1 (en) 2022-05-27 2023-11-30 Unilever Ip Holdings B.V. Liquid composition comprising linear alkyl benzene sulphonate, methyl ester ethoxylate and alkoxylated zwitterionic polyamine polymer
WO2023227332A1 (en) 2022-05-27 2023-11-30 Unilever Ip Holdings B.V. Laundry liquid composition comprising a surfactant, an alkoxylated zwitterionic polyamine polymer and a protease
WO2023227375A1 (en) 2022-05-27 2023-11-30 Unilever Ip Holdings B.V. Laundry liquid composition comprising a surfactant, an aminocarboxylate, an organic acid and a fragrance
WO2023233026A1 (en) 2022-06-03 2023-12-07 Unilever Ip Holdings B.V. Laundry detergent product
WO2023233025A1 (en) 2022-06-03 2023-12-07 Unilever Ip Holdings B.V. Liquid detergent product
WO2023237412A1 (en) 2022-06-09 2023-12-14 Unilever Ip Holdings B.V. A concentrated liquid detergent composition
WO2024017614A1 (en) 2022-07-18 2024-01-25 Unilever Ip Holdings B.V. A concentrated liquid composition
WO2024017623A1 (en) 2022-07-18 2024-01-25 Unilever Ip Holdings B.V. A concentrated liquid composition
EP4321604A1 (en) 2022-08-08 2024-02-14 The Procter & Gamble Company A fabric and home care composition comprising surfactant and a polyester
WO2024036126A1 (en) 2022-08-08 2024-02-15 The Procter & Gamble Company A fabric and home care composition comprising surfactant and a polyester
EP4321603A1 (en) 2022-08-11 2024-02-14 The Procter & Gamble Company Laundry detergent composition
WO2024046757A1 (en) 2022-08-30 2024-03-07 Unilever Ip Holdings B.V. Detergent product
WO2024046743A1 (en) 2022-08-30 2024-03-07 Unilever Ip Holdings B.V. Detergent product
WO2024046756A1 (en) 2022-08-30 2024-03-07 Unilever Ip Holdings B.V. Detergent product
WO2024056278A1 (en) 2022-09-13 2024-03-21 Unilever Ip Holdings B.V. Washing machine and washing method
WO2024056334A1 (en) 2022-09-13 2024-03-21 Unilever Ip Holdings B.V. Washing machine and washing method
WO2024056331A1 (en) 2022-09-13 2024-03-21 Unilever Ip Holdings B.V. Washing machine and washing method
WO2024056333A1 (en) 2022-09-13 2024-03-21 Unilever Ip Holdings B.V. Washing machine and washing method
WO2024056332A1 (en) 2022-09-13 2024-03-21 Unilever Ip Holdings B.V. Washing machine and washing method
EP4349944A1 (en) 2022-10-05 2024-04-10 Unilever IP Holdings B.V. Laundry liquid composition
EP4349948A1 (en) 2022-10-05 2024-04-10 Unilever IP Holdings B.V. Laundry liquid composition
EP4349945A1 (en) 2022-10-05 2024-04-10 Unilever IP Holdings B.V. Laundry liquid composition
EP4349946A1 (en) 2022-10-05 2024-04-10 Unilever IP Holdings B.V. Unit dose fabric treatment product
EP4349943A1 (en) 2022-10-05 2024-04-10 Unilever IP Holdings B.V. Laundry liquid composition
EP4349947A1 (en) 2022-10-05 2024-04-10 Unilever IP Holdings B.V. Laundry liquid composition
EP4349942A1 (en) 2022-10-05 2024-04-10 Unilever IP Holdings B.V. Laundry liquid composition

Similar Documents

Publication Publication Date Title
WO2020070249A1 (en) Cleaning compositions
US11739287B2 (en) Cleaning compositions and uses thereof
US11499121B2 (en) Detergent compositions and uses thereof
EP3704219B1 (en) Polypeptides and compositions comprising such polypeptides
US20200032171A1 (en) Laundry Method, Use of Polypeptide and Detergent Composition
WO2020070063A2 (en) Detergent compositions and uses thereof
WO2018185285A1 (en) Cleaning compositions and uses thereof
EP3478811A1 (en) Cleaning compositions and uses thereof
WO2020002604A1 (en) Detergent compositions and uses thereof
WO2018185269A1 (en) Cleaning compositions and uses thereof
WO2018185280A1 (en) Cleaning compositions and uses thereof
US20210301223A1 (en) Cleaning compositions and uses thereof
WO2020002608A1 (en) Detergent compositions and uses thereof
WO2020008024A1 (en) Cleaning compositions and uses thereof
US20210017473A1 (en) Laundry Method, Use of Polypeptide and Detergent Composition
WO2020008043A1 (en) Cleaning compositions and uses thereof
WO2018184818A1 (en) Cleaning compositions and uses thereof
WO2023194204A1 (en) Hexosaminidase variants and compositions
CN114616312A (en) Detergent composition
DK201700251A1 (en) Cleaning compositions and uses thereof

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 19779905

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 19779905

Country of ref document: EP

Kind code of ref document: A1